<SEC-DOCUMENT>0000950170-25-071996.txt : 20250515
<SEC-HEADER>0000950170-25-071996.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515074151
ACCESSION NUMBER:		0000950170-25-071996
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40881
		FILM NUMBER:		25948744

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		(617) 221-9059

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pyxs-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-15T07:21:22.5670+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pyxs="http://pyxisoncology.com/20250331" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a26e425e-3944-4a16-a6e2-cb252d7eeff7" name="dei:CurrentFiscalYearEndDate" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">--12-31</ix:nonNumeric><ix:nonNumeric id="F_80c67580-8bb2-49f5-a6e5-90496bccc23d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">Q1</ix:nonNumeric><ix:nonNumeric id="F_55a25125-49a7-44c4-af71-84be795231a1" name="dei:AmendmentFlag" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_29449aad-d243-4379-853d-8e8039b4a2d0" name="dei:EntityCentralIndexKey" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">0001782223</ix:nonNumeric><ix:nonFraction id="F_82180ae2-8643-4fd7-839f-aadb21d1791b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8f68cae7-637c-41f3-b2fe-4981768cebf9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b1a92c6c-dbc2-4b80-aa53-67ac009de2f0" name="us-gaap:PreferredStockValue" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4046ec04-3cd5-4350-b87e-ffcc0d09653e" name="us-gaap:PreferredStockValue" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_40e1fafa-fcae-43cf-bb09-058d3cf2faa5" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_18387c80-8f46-4fb9-a403-2e1db91eb8aa" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">http://fasb.org/us-gaap/2024#NetIncomeLoss</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pyxs-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="C_80d25345-2134-4fdf-8b7a-dc5dcc526082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80ea7a33-ca44-4b1a-9d84-3b098b016750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81dccbcc-0e5d-42f2-a90b-5d7a220cc416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_824b7ea1-2dee-4608-a3e0-704fe74262da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_837677d7-498f-48bb-95c8-9faa16b30f62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88407054-4ac6-407e-bd60-882ac0345a83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89abcaed-dbf0-4b59-a0d5-c994ebb137d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:MabwellAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bcaa3a4-f396-49d4-9a7c-9a2c953ca07d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c771a10-e6fd-417a-b90f-987505443224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d18d1ea-08eb-44d4-af0c-63d65768614d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90baed6e-d409-47ed-8fce-1c10ef7e5899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9785fcb7-9dea-48db-b586-d63e6e45e9ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97ecf8f3-9e3b-4ebb-bbff-1d5047205f7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ac06ca8-b7a6-46a3-8c25-6237c2d2084e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b6f4f8e-a104-4456-901f-a188c4f57515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c3347c8-7c90-48dd-9028-f27b924409e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cae4734-8e55-4f7a-9b85-7922cacc7b3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9dce6431-1c01-4d1f-a411-889976d95f6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e825b7d-73d0-4c61-872f-ab5440ba67fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eedb432-f4a9-43b3-ba2d-11719dfe1ba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0ea1ad7-9313-4e2a-bd73-2726a836f60b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:SimcereLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a41389f4-c186-43d0-9794-403390ddc786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5dc214b-639f-4fb3-8b7c-2568718e0614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:SaleOfRoyaltyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6cf378c-872f-4a4d-8695-c15519d97e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acc32560-f36b-4aae-bb63-26d88b5e0289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3932593-36a9-4778-8638-9db8cecfbe4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4d6bc39-6741-4f87-ba31-c08c44f3521e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b53bcca6-85b4-46ee-be42-becc61d48b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbca090c-3069-4f5a-8956-acdcd6237047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbf42254-df44-4f1b-9c73-8807bc61e7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc5c6809-e7d5-4c1f-a9d6-81bcb2d63dcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd63dfaf-0acf-4759-9e38-63e3f7d254fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd8b966a-b09c-4ecf-99e4-4af048f4ca8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf458c23-24e3-416a-b060-7beb4e11b9d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-26</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c06d934d-2ece-4e58-aff2-9571ee296c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:DepreciationAndAmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c59ed3d1-dcfa-490f-9209-32cb9b6920ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5ab9c1f-a895-4812-ad9e-35f1af6217e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdf070fa-6052-434b-970a-be0e009d0f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf0a40a2-d12e-452a-8754-687353eafcbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d20dc9b5-8895-44ad-af21-3cb92effe49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d297973c-6ba2-4ed6-8a31-917d0510d880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d48085d6-bea7-4f85-a614-7273694f7fc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8f2f73e-7aca-4a71-8f6a-4c1b3ac7de0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da865c67-24d1-400e-a077-12e7011b7389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df592aff-6947-440e-aa39-c1fea2a3aa9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7c0ee51-b9d9-4edc-98ee-3e53a89d2eef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb99ab08-0e63-41ea-bc44-35b639d19208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec093f95-5fcd-47b1-952e-ed9e123d523d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec1ee2ec-2bfc-4df3-8172-db225ac82cb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed227005-05eb-4b2e-b46b-86ab51890c85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f759528e-20d8-4601-852a-3782e7215f4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:SimcereLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcbfab1e-0b3b-450f-9242-753a06599476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe614f09-8f0b-41ae-9225-979a71f0c648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0090356c-a2e4-4923-b76e-2b67349147d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02c3f376-cf08-485b-be5c-ffdbc197e303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_044f61dc-d55f-47ed-bf0d-a9b02b506528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06f49316-3dfe-4d13-b37e-04d9737a5946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_088e0ae4-1139-4dc9-a66c-b53dac8ce75b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0964fba2-c28f-4b10-aca6-474fe77b4e30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b635d7f-a221-440b-8651-5dc1b8df141e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c364169-e051-40a7-a92d-d1015992ee48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c8f0bca-3bcd-4650-a38f-74cace0f746e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10a1478c-a269-4056-ab01-10627d5bbfdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_150aa5b2-9b4d-462c-adf9-5645140d7e33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1659b880-a5b1-4e72-804b-476a70f006ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_186c4ea3-09e7-46f6-8773-3f7d43d03df6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_189a9dd8-c9d5-41ca-b297-364c9a96704a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18c2f871-fdac-46c2-8c4b-4a534962e9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19b0546a-3406-4376-b2bf-06e6e947abae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19d61487-1275-421e-96ed-c8df7b8a1263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d4aedb6-5a72-4040-a006-c27215f1acae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e12a232-a571-45f6-9670-3ee553d3dba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25fe5748-df27-4969-8126-fe2fae43fe71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27edf172-17df-4f47-b122-520ad30120e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27fbe99f-b243-407d-805e-643897908e7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_290608d1-a120-4e94-a552-45ef09566ea1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2967ce11-ebdd-4b1d-826e-9763f4ccb671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b13fbbe-afbd-4ba7-8372-4ec974d6de0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d47bb13-07cb-4ad3-9049-3c989f5e965b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dc476af-db9c-4877-bce2-5597b5ff0528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e03161b-ec31-4f96-ba1e-2d45184ac84f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e0c1cd2-1b21-4b47-bbed-f7f5df307193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33284524-71cb-4060-be6e-5f4b5bb7ea1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_347129ce-fb5c-4096-80fe-ffcae8c2d8cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3478df5d-ec35-4824-83ab-aaf0f4b41638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3899226d-7062-4ed7-98a2-86b74edb9890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38f8afe4-2256-4b92-a723-49f29459a24f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:RoyaltyRevenuesAndSaleOfRoyaltyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40a96fb2-dbbb-44c6-a5a1-b2efcc758b42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:ApexigenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47a74493-ee6e-4c87-8e18-0799e2bce42e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac8c464-a9ee-4f4c-9cbd-ba23e9e145ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4acf36bb-505b-45ee-99cd-5d1d91b303d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b4f6feb-cd93-4d71-b40e-b295d4cf5442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pyxs:ApexigenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d7cc448-0612-40c7-9727-ba960bd2bcad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5032b180-a6c9-4ff7-8f03-2d4bd35aeef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductCandidatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51fc16e6-9e11-4e1d-9846-6d3d5c32f0b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5254b7a9-eb08-4cba-9a41-271a24160c2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54406d8b-7256-474a-b20f-863ecd5c0745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_565d2f6f-3e93-4e23-8ba1-a266d622097c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57742700-4cba-41b8-9f39-b740f3f99b64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:RoyaltyRevenuesAndSaleOfRoyaltyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ba8496a-b732-4e27-8494-8cc671bac84a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:DepreciationAndAmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d1a4394-6692-49e3-a78c-53add9ce8cdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5da75939-3069-4ae8-9442-f8b70f506330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e3e027d-5bca-4423-870c-4ca85780f63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6027eb9f-48b8-4d75-8321-038710d6afd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_610571ac-f3e0-4db3-951b-cc88505cd8c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61d130af-cc4f-4a22-b82e-c45279feb48c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63a6cb3b-0f48-4d6e-abd8-d1208ebf1187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63ba58e4-c1b8-480d-a574-db0f42fe8744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64ad9aed-64e7-4300-99be-13fdf0483d74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_668a1b98-824d-41d1-8593-7b9e8f0d78b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_678c9317-3c78-4a7a-bf89-db2215e97bda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68b75572-7f9e-4d54-be03-9c22d10c8355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1b9939-fd67-4211-8cf2-48609643426e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductCandidatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fc6795c-50db-425e-91fd-5a73256a6dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70a309a0-7032-4844-baa7-96b76069261c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74975660-2e58-4083-b25a-adbe25ac8127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77b5c4a5-315a-49dc-a7f5-2446f1b77e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7afe6a9e-11e5-428d-b499-c4c37cf4f4fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:ToraySublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e808a75-bd9f-4f76-9117-82cd0f5be7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f2bf259-5d8f-4d8c-a46e-c559de6ac9a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pyxs:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_919eb334-f6d5-488e-b6a4-883e2e2b54ae" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_50f475fe-5818-4777-9b17-da883f47b671" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3825054-684d-4b50-bda0-823c939b41eb" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5c2db27-63e3-4ce8-8341-03a838a0716f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_9ca34646-0d13-45cc-8954-5844971bc5f8" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f152e14-7c66-4403-beda-d645932f71e7" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40881</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2793e371-ce17-40a4-af88-14e7b13f0074" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyxis Oncology, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_956826d8-808d-4039-a422-6ce76c954d0e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b7473420-1fed-4592-8109-0f167451df87" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83-1160910</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_20405245-7517-4a03-b3b3-c6da5617b984" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">321 Harrison Avenue</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2.25pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_5f71b9fc-c999-4256-835f-ff6fc5fd75f3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_75bcf2f1-dd71-494e-8817-8f4e642940ca" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e27fcedf-dc02-4a77-a0d5-5de7742c749e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02118</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad82d445-dddf-4a94-ae88-c495fad9152c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9efd3aa3-f9ef-4a1f-b5fe-b1f98df5e379" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">453-3596</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6ed3a3ff-d6f0-41d3-ac0f-14b192ca0e9f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ef4e754d-5cba-43f3-b5a3-ef36ccbc3930" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PYXS</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_af3a92ea-a67f-4645-a807-d791838b1f9c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7b64659-2aab-4e9e-9146-47cf2d0224db" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4cb0a8d-fa1f-408d-b91a-fd4abea238b4" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.364%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:56.131%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:20.404%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.06%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e9675749-0556-47f2-bcaa-1516b3adec5f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a7f42600-038f-412d-afaa-5bcdf726f85f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cc0da0c5-1f01-48e8-98b7-f752b70d5c62" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfa4ee56-7679-4ad5-bb69-45f24681954d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;    No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81e07264-96d4-41b8-89f5-c48092f9075a" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of May 14, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aa0b68a-de3d-45f1-a021-778d1503bbd9" contextRef="C_bbf42254-df44-4f1b-9c73-8807bc61e7ce" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,947,665</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.1%;box-sizing:content-box;"/>
     <td style="width:82.82%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#summary_rf"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Summary Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#sse"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#socf"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_rf"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="summary_rf"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RY RISK FACTORS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	You should consider carefully the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to &#8220;Pyxis Oncology,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this section titled &#8220;Summary Risk Factors&#8221; refer to Pyxis Oncology, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage oncology company with a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses over at least the next several years and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily dependent on the success of our product candidate, micvotabart pelidotin, which is in the early stages of clinical development. If our product candidate is not successful in clinical trials or does not receive regulatory approval or licensure or is not successfully commercialized, our business will be materially and adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate may fail in development or suffer delays that materially and adversely affect its commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidate or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt its clinical development, delay or prevent its regulatory licensure, limit its commercial potential or result in significant negative consequences.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical entities, and our operating results will suffer if we fail to compete effectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidate.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory licensure and approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are unable to obtain marketing licensure or approval for our product candidate, our business will be substantially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to manufacture our product candidate. Any failure by a third party manufacturer to produce acceptable raw materials or product candidate for us or to obtain authorization from the FDA or comparable foreign regulatory authorities relating thereto may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect our intellectual property in and to our product candidates, we may not be able to compete effectively in our markets.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidate or we could lose certain rights to grant sublicenses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our Pfizer license agreement or any of the other agreements under which we acquired, or will acquire, intellectual property rights covering our product candidate, we could lose the ability to continue the development and commercialization of the related product candidate(s).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, operations and financial condition.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of any of our existing or future CROs, manufacturers, other contractors, consultants, or collaborators, may be compromised, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I&#8212;FINANCIAL </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INFORMATION</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Financial Statements.</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GY, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:60.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:17.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d534628-5646-4884-8435-680f3732141f" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,759</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42ad59c8-6da8-4bfa-bb5c-e149045dc96d" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,473</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities, short-term</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7c2981d-8a61-45fb-96c0-1426eba93010" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,673</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a835e633-03b6-41d4-8b60-623f56bb58eb" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,458</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b105eeeb-b55e-4f10-b590-2ff04a1fdf5d" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04ec80d7-7964-465d-882d-95ffdaf38e66" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e461d880-d4c1-4b15-a6c4-abeaa373ed36" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,967</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a17dc9b-7220-4f39-b82b-2946f22b61f0" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_992da8fa-5da5-4042-8293-efb49dd1e8ff" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,871</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9f64ee9-472d-43e1-ae95-4e7559d289a1" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,440</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34bc78f4-1f2d-4cdb-b66a-10f8e535fedf" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,403</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0e5bdda-32f7-4a3a-afa1-b37d68414ba1" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,899</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36a7a0e4-325f-4b9b-bb51-0feb8ac5912d" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,544</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67b0b10f-f909-4029-a0b8-4843ef9b95cd" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_255c5bb8-f31b-4ccf-836f-672d607de18c" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,049</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c662764-ec25-403b-a93f-9c0e74324298" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,242</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ecee1f9-eace-435b-a3cd-a03323436905" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0de4a1-32c1-489c-8acf-0d4c7308af68" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,181</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b98f0abc-c4e5-49ee-9b98-d5617ec390c3" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,846</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77533ec-6c55-4a95-9df8-a71a20574a32" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ece6a40-171f-4435-8466-5b5271643752" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,076</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ed889b9-ec23-475b-9cf9-ba6d6e53b6f6" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,371</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62d2c543-179d-42fb-bc0c-763c24df7ffd" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca37efec-9214-4e29-9efc-e10187ae22d1" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3393e507-9d22-4626-8cac-62b49c177a47" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,430</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_218c83de-ca07-4a8a-80d9-de8685bb99ca" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,680</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d364e7d5-b0ba-457a-9501-a3567da94b5f" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b1f9f2-49e7-4d50-aaff-bbe72bbbf57c" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,650</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_498c4505-383f-4446-9ad3-729b2750f31c" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e906c15f-3e86-4986-813c-5b4a4bb50d60" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba6cb02f-38b8-4679-bc8e-fef7c9ec565c" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,764</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae1f880c-2998-4952-901f-1edc08679ee0" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,430</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_82180ae2-8643-4fd7-839f-aadb21d1791b;"><span style="-sec-ix-hidden:F_8f68cae7-637c-41f3-b2fe-4981768cebf9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, par value $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead71e52-c841-4aec-b2ef-ae5f8de894b6" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9667d7b5-6071-412f-bfe0-6de3565804fd" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6cc3adf-13bb-4cf2-a9d4-bc32d0c31222" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_25fbc405-755d-461d-adce-7ce8f370044d" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5de2ae45-3d4f-4d3e-8efe-2ed4221a7069" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f193cddd-d787-437c-9400-2a127cef5a57" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6ccc5b60-2bf8-4a0d-b5c8-263973fbd89e" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_45523530-4922-4d9d-a904-323a0efcd037" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b1a92c6c-dbc2-4b80-aa53-67ac009de2f0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4046ec04-3cd5-4350-b87e-ffcc0d09653e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3e6b8f6-2c4e-416a-9683-5883c2230f49" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e630c97f-bfda-4868-8d1e-df19bac4e098" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5b16776-3a72-4846-b771-9a1d46578b78" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_83e4bb76-5c97-4b47-a56f-901de3e40e6b" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">190,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efa81bd8-cbbb-4833-ac33-c14aaed6f10d" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_410788a7-1378-46c2-bb68-6a2bd77b3834" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,631,376</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75da5f15-d545-41ab-9fc2-2375965db40f" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a6d106cc-560f-4ed5-8000-fb83982176b7" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,967,814</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12aa39ba-c0f5-468d-be79-4510a7a9c0e8" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34fb1706-fa3e-49ac-9ebb-b5df486e8331" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bd2816c-a2b3-4d8b-8719-964e74a105ad" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">487,706</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7714e5f9-4636-4ba4-8f4d-4300422a782f" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">484,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_841dd3c7-bb6f-45c6-98fc-50509cff33d3" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_505ba08a-a50f-4fab-bc33-701ce2d8f7c5" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a877ff9a-2021-4207-8a37-1b28398f5bef" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">384,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12424634-7251-4250-b980-509163a92667" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">363,556</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_888f76a7-9089-44ad-bc4d-25ad8f02b02f" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_693ed0dd-a527-4200-a996-f91f94e005ed" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,751</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d32026e-aba8-43fc-ad7a-7fb89bc61495" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3c5f7e5-3735-4a4e-b0b6-d6f3f5ca7b18" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,181</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:60.868%;box-sizing:content-box;"/>
     <td style="width:1.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.096999999999998%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.157%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa86b21d-3786-4f75-98ea-75782c0377ea" contextRef="C_2e0c1cd2-1b21-4b47-bbed-f7f5df307193" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,146</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale of royalty rights</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4297952a-0186-4115-98a7-e1104252a2af" contextRef="C_a5dc214b-639f-4fb3-8b7c-2568718e0614" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30eb0429-0ff0-44eb-8d86-850f81f1b382" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,146</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Costs and operating expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6938749a-10b7-4b24-915c-cda36ef022ee" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_713135df-8ece-4450-af8c-7a988272ba4d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,044</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf1df99-5e94-42bd-b75e-54f7f6caec16" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,029</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e6c1f1-3aa5-487b-9dbe-1313081c8356" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,870</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddbb548e-9aa5-4a2f-bc5f-b779559e3a9b" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,247</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total costs and operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a73e057-6189-4a49-bfc4-5faf7abe2b36" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:CostsAndOperatingExpensesTotal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,914</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea32e04a-0d23-44cc-88c9-df5d3aa3b434" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:CostsAndOperatingExpensesTotal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,751</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_045f3b6e-e323-42ed-87c3-ef7ea78c4814" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28fa5319-eac8-4199-af6f-2419e8dbaa1b" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,605</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and investment income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e5f3d6c-003a-4459-933a-8041ca9fca14" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74049cbd-960d-4fe4-8e5a-f7dfc5421b02" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sublease income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0682c8b4-6e69-4c39-940a-d18d46382dce" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">515</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c316f53-78ab-4aae-b3c4-73de6d7016d1" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_102411e8-ad19-49cf-9322-92c0c2dbbf88" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35b5fd0-fd9a-4234-90e2-65dd50601588" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,349</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fea8274-25a6-4373-9442-b2c27fd91d8f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_959e1cb2-4e42-47b7-ade4-bac7b1958dbc" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share - basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5363a8f5-a0fb-4c81-b755-75a2858b712b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_03b6d12f-fdf8-4648-b7a8-82b2a60dea0d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62f0a93a-9b57-4116-9a2d-ae7691610b73" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5155d6c4-628a-494a-938d-78f58c2e3b1e" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.06</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock outstanding - basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08bd7c79-cd46-4949-8552-9d7406fac424" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2191922a-d948-40d6-8b6f-1629b7a80e19" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,048,948</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_178d925c-a38b-4dcc-ba97-fa148f2f0639" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_267956e3-9c12-411b-afa2-21f49f6fa25b" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">51,289,284</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b922ecb-2c44-466f-bf6d-85eb4e4c7a8b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bfa32fa-64eb-4b91-a82f-0da2d43badb8" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af1b43b9-7770-46ed-93d9-ad84516e7ba6" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b41a0fb-93f6-480d-81f9-9124194d9456" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_333f8242-c93e-451d-abd5-3d410e3dc6f0" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,279</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca78208-3eff-4666-b308-11574308b4cc" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,379</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.3in;z-index:2;min-height:0.05in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="sse"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49.78%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:4.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Loss) Income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc2b7173-fa93-4758-8ca7-873166b44106" contextRef="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,967,814</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eeb34d9-31c1-45b8-925d-f81f1c9658a6" contextRef="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aa411a6-4d92-4a3b-b43d-78628a1b7fdb" contextRef="C_a6cf378c-872f-4a4d-8695-c15519d97e1d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">484,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42fdc434-ad92-4521-9895-acd470c7cbf9" contextRef="C_06f49316-3dfe-4d13-b37e-04d9737a5946" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63fc028e-bd8d-4507-9f6f-edbfbd33c1f2" contextRef="C_80d25345-2134-4fdf-8b7a-dc5dcc526082" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">363,556</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b89b4f0-2732-4730-83ec-93491eb58315" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,751</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e486d116-e751-4f18-850d-8b3bdc30e67f" contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0" name="pyxs:ExerciseOfPre-FundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,611,215</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63dba521-a127-4325-bbf7-83c975108b5f" contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0" name="pyxs:ExerciseOfPre-FundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2d19092-7741-417e-99fe-dc3db79d58cc" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:ExerciseOfPre-FundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of restricted common stock, net of tax withholdings</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28f013ab-cbf5-4b42-85c9-21c8db8a4ed8" contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,728</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_767afd1b-b9c1-4a13-87b1-8cc20d4b1556" contextRef="C_0964fba2-c28f-4b10-aca6-474fe77b4e30" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc18980-d907-4712-b3ef-221da1e20a0d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan (ESPP)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42121ed8-8dd3-4a82-b208-5e5208823805" contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,619</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_762e3cc4-a369-4a9d-9df9-6aade6b26fe1" contextRef="C_0964fba2-c28f-4b10-aca6-474fe77b4e30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c81cde43-3957-4eef-be44-ca00f130e92c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2da76f21-c8e2-4f64-81b7-7a9922385727" contextRef="C_27edf172-17df-4f47-b122-520ad30120e0" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba866c89-e183-4a48-bbb4-5621cfb4b22c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24971b87-4a83-4b0b-ac99-2f1d62de5a83" contextRef="C_33284524-71cb-4060-be6e-5f4b5bb7ea1b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6165e690-ba49-48b1-8353-28d9fd203793" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a98b0736-952a-40eb-ab7a-fcac0bb3dc7b" contextRef="C_0c364169-e051-40a7-a92d-d1015992ee48" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,631,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_398da536-4f1e-490a-a42e-61abede1425a" contextRef="C_0c364169-e051-40a7-a92d-d1015992ee48" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dc471dd-7455-4473-82ab-b95652dbc677" contextRef="C_fe614f09-8f0b-41ae-9225-979a71f0c648" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">487,706</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e78065d0-237e-444c-baf6-8b374bf9563f" contextRef="C_b4d6bc39-6741-4f87-ba31-c08c44f3521e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14b759f1-6678-4959-955c-31d9f5217425" contextRef="C_5254b7a9-eb08-4cba-9a41-271a24160c2d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">384,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94917acf-5c95-46a8-9a03-e3776ed39f0a" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Loss) Income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7c94256-c9fe-44ff-b164-bfbb1473885e" contextRef="C_b3932593-36a9-4778-8638-9db8cecfbe4e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,754,853</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcf9b75d-c76e-41c4-96ab-142df94ef271" contextRef="C_b3932593-36a9-4778-8638-9db8cecfbe4e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_457aebe1-07e0-4259-8a5b-07d3b2ec98aa" contextRef="C_64ad9aed-64e7-4300-99be-13fdf0483d74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411,821</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56377afd-0aa5-4914-8af6-6c2290ea3c48" contextRef="C_10a1478c-a269-4056-ab01-10627d5bbfdc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6484dea-2e85-42ec-9b88-2963334f29dd" contextRef="C_cf0a40a2-d12e-452a-8754-687353eafcbf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">286,225</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_959768f3-83f0-4beb-9fc2-5cb46f025629" contextRef="C_70a309a0-7032-4844-baa7-96b76069261c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in private placement, net of offering costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9545a8ad-68b7-4965-bf99-cebd8d7dd8de" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="pyxs:IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,849,371</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c04dba8-a130-4459-8700-2fba72898fb5" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d34a39a3-5eb9-4a36-86c5-636ff9b2d74e" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,163</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c18ee2e-a38f-45d7-9d12-a8506fef4091" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a882db8-de60-4768-a8ee-58fa428644e8" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="pyxs:IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,600,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ec0489-0d98-4f95-a5d7-5d260394d5cc" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b933aaa6-2fd1-4519-b4f1-bf8e471f44d4" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,586</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5955663-630c-4474-863c-c1baae3ec23e" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants in private placement, net of offering costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94164628-ec4f-43d2-9a04-6ddb6a1c6346" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0adf6de-0174-4287-bcc2-4d104f1b6a02" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of restricted common stock, net of tax withholdings</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1628123a-01de-433e-b0f7-19d3b1e4c863" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,497,921</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_755960e9-99a9-4578-8f9e-b030f645dc5e" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee2c6fec-3c89-4115-b804-a38c5527707c" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44edfb31-389f-409d-8f05-ee1a24744741" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cfd3630-ba5f-449d-a1a5-228eccb06e84" contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,981</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48559947-4ad0-4622-bc6e-dd5e00633cdd" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2961843f-99e3-44a3-9e3f-647c0288adfe" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30bf45c1-ceba-479b-ba58-99a1f457fba7" contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99443c53-435e-41d4-8c65-5413c0523395" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3bf106-ddd3-4539-8cc1-dc38ddd59007" contextRef="C_68b75572-7f9e-4d54-be03-9c22d10c8355" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_162485fc-572f-47a8-b3a5-0512f10a71ac" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b69ccbe-5456-4155-9ab6-58609f126855" contextRef="C_610571ac-f3e0-4db3-951b-cc88505cd8c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7797d3d-4e0c-4d8d-ad54-9f95d82eefd9" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f164a1d5-ead3-4994-abce-6cd96fcc01f0" contextRef="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,803,126</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f81cc628-a2e2-4dc2-9e6d-379ef6e1519e" contextRef="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e8688b9-7726-4b3c-bb6e-37c6b2ce3979" contextRef="C_54406d8b-7256-474a-b20f-863ecd5c0745" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a500dff-7b6e-4a08-8ae9-e0a72f72ea2f" contextRef="C_2e03161b-ec31-4f96-ba1e-2d45184ac84f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b718cb25-6ff5-4e35-8e06-8df290c12d3b" contextRef="C_c5ab9c1f-a895-4812-ad9e-35f1af6217e1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc167666-5a16-44e4-a2a7-410c84d74ea8" contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184,156</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.07in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="socf"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments of Cash Flows (In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.96%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b241c64b-0628-4e33-9a43-78f51eb27704" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3cadfe-4774-425f-8260-a7079cb54670" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db09f815-52c6-424c-b4cd-9140be2a0b64" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfee8321-45e0-4bb0-b216-a68d761d0315" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ddf106d-7f8c-4c3a-9a4d-3b3a1df004fb" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ae49bb-4404-49ec-90ae-65c54ffdd57f" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e056ae39-7e53-41fd-88a0-2233aa9682ed" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3570f6a1-75d9-4551-ad96-37996d244c02" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c5ad98d-93a0-4fa3-9fb2-f90f1c77fae1" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_257e5968-3356-4542-b197-1cff2d5076d9" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,288</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df6c0e4a-7578-4df2-99ed-8367ed11777a" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32fba8b0-c193-48cd-a7b1-5f97fa5bd061" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">930</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1af43cf4-6bd7-44fd-8435-b80d93754337" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,046</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a46ae99d-aad0-4e3c-bcbc-f2203f390ffc" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,013</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cc98d8d-1bda-49b2-a69b-d724b6bcb4af" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,365</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfab11e1-82f4-4d9e-94d0-0eeefffcfc2b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,315</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7ced05-692d-4166-ae98-1a8e57a16974" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10e9431a-b96c-412f-ba24-ae1daa2d270d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eae169a-b7ab-4e5e-b41d-0c506f973aca" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67da2b34-1330-4300-b33b-8de1643faab2" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,660</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de24db5b-7d2d-4c07-8e61-2f8813e41271" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,535</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47171c76-b2e0-43f4-a358-ecc6266fecbd" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,710</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redemption of marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1249d671-82f3-40d7-8963-26f9069e11fd" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:RedemptionOfMarketableDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a65138-2c88-4a4f-8cb8-20d0e2431230" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:RedemptionOfMarketableDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,532</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable debt securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89846476-fe54-45e3-bee4-af1e6236ce0c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5270e0-e029-47bb-a09b-f3653858e872" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,793</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_950d48f2-6194-40e6-84dc-0cea46f59699" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ab73fe-77bb-4683-a10a-26f7f3499fc4" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,821</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dde87236-c11c-4807-aab9-cd8f62cb5037" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,498</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_249264bd-6a5a-4a16-9c47-a0247fa5d2ed" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf454984-4dc6-4ac6-b96a-50616a99bca5" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,872</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock pursuant to ATM program, net of offering costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c219da51-495b-40d0-8f92-20e85d061011" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="pyxs:ProceedsFromStockIssuedUnderAtmNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax withholding payments related to net settlement of restricted common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c698a52e-efb8-4a86-a978-12eb1e81429e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60c50b47-519d-40fd-a665-b34388744d7b" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380d1b83-0910-4ca0-8c56-7a8c720762ba" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aabf1f41-c5ab-4947-bb3e-2799d7801293" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,511</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4f9dd3-0800-4cb8-915a-b74f5bd86793" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4cd90f2-725a-4c3d-aa49-b0d4b7f3ca37" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aea171e3-8b46-4498-b681-a9532b3cf89f" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,945</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_413a2d5f-b9da-4246-a9f8-074553328fa1" contextRef="C_70a309a0-7032-4844-baa7-96b76069261c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,136</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a409cc90-1d28-495b-b395-1c2eca52f58d" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b66d9a4c-e596-4e74-98f8-3153cc9e5655" contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,439</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e5be57-71ec-44d7-8560-32d5fdec44e1" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,759</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_839130ac-1894-4756-ba44-f29b15c134c9" contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,967</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53a61e6a-3f3b-4e69-8f55-dfd9085584c6" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_096dc4b1-65b6-4cc3-bad6-141f855ab811" contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9104b223-d6e2-442d-a4b2-9db25b81ceda" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd963eb7-b0b4-40a1-bb14-79a7173178ff" contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,439</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLOGY, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Condensed Consolidate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28aca06a-3a7d-4ed8-801f-392421ee01c2" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58d3ff14-87a8-4781-9c8f-cb531fb2a98e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:NatureOfBusinessPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with a specific focus on head and neck squamous cell carcinoma (HNSCC) tumors.</span></p></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:nonNumeric id="F_276e4bf2-a8b9-4bcc-8770-41b319a2c522" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_276e4bf2-a8b9-4bcc-8770-41b319a2c522_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14e9f0fb-941f-4257-a003-1aff6ea28c35" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s fiscal year ends on December 31 and its first three fiscal quarters end on March 31, June 30 and September 30. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the three months ended March 31, 2025 are not necessarily indicative of those expected for the year ending December 31, 2025 or for any future period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 18, 2025 (Fiscal 2024 10-K).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2aa17f1d-0472-45f1-ac78-8f54d6806d68" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:LiquidityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a13f8ccd-e7a2-4790-8f96-b1b01b6c4201" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">384.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The C</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ompany has incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8656e2-ee42-4eed-be49-0a3ef479e1fe" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">21.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d6cc82f-bc26-4975-a4b6-5531c6c99323" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not generated any revenues from product sales to date and does not anticipate generating any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently expects that its existing cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9faad99-d89b-4b9b-9ee1-e6bc315688d3" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2025 will fund its operating expenses and capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_276e4bf2-a8b9-4bcc-8770-41b319a2c522_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f71ca36-c7a6-4426-91bd-25366c559b24" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, marketable debt securities, fair value of intangible assets and research and development costs, including clinical trial accruals. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2aac487-879f-4739-935d-0704bcc0702d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to early clinical stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third party service providers such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collabo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ration or supply agreements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70455f4d-fb41-46f9-ac51-06bbc3bdfb53" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Con</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">centration of Credit Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents, restricted cash and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash primarily in money market funds and highly liquid United States (U.S.) Treasury securities. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no significant changes to the Company&#8217;s significant accounting policies disclosed in &#8220;Note 2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies&#8221; of the Company&#8217;s Fiscal 2024 10-K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7c5527f-cf01-4a58-b65e-cfeb320f8b4d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures. The amendment requires (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendment requires disaggregated disclosure of (i) certain costs and expenses, (ii) certain already required disclosures must be included in the same disclosure as the new disaggregation requirements and (iii) a qualitative description of the amounts not separately disaggregated. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d8e2f00-b98b-4b2c-9a2f-94b903c587b3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b46831b-d2bf-43d7-aa60-09c0da1d250a" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.586%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.723%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41312c2f-7f24-4ec6-8212-e2f7f4caf03e" contextRef="C_25fe5748-df27-4969-8126-fe2fae43fe71" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,242</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fd66e30-764c-478e-bdd7-40a18540d6cc" contextRef="C_d48085d6-bea7-4f85-a614-7273694f7fc3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,242</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecae893d-05da-48d1-ac31-a0eedb179936" contextRef="C_bbca090c-3069-4f5a-8956-acdcd6237047" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d33412-da34-466f-9b45-8b16c47f9be5" contextRef="C_8c771a10-e6fd-417a-b90f-987505443224" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d648af-f7ea-44cd-8f7a-d3c025cf4289" contextRef="C_47a74493-ee6e-4c87-8e18-0799e2bce42e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a7dd369-6769-4874-bb6a-6ac327a38f02" contextRef="C_ec1ee2ec-2bfc-4df3-8172-db225ac82cb8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85ceeee2-d88d-48ad-9919-b7af25e7807f" contextRef="C_90baed6e-d409-47ed-8fce-1c10ef7e5899" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_649c1561-a6e2-4804-8803-cf44ef6608a1" contextRef="C_df592aff-6947-440e-aa39-c1fea2a3aa9f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5689062a-aac4-4414-84f8-dfc9f56deda4" contextRef="C_51fc16e6-9e11-4e1d-9846-6d3d5c32f0b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,458</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbf747ee-a6b4-4e04-ad29-813c1aaad1ae" contextRef="C_189a9dd8-c9d5-41ca-b297-364c9a96704a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,458</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6883ad28-919f-45c2-8ae6-8baf4ed10adf" contextRef="C_2d47bb13-07cb-4ad3-9049-3c989f5e965b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,949</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9458bb1e-0f32-470d-8b50-82d19a17a4d0" contextRef="C_8d18d1ea-08eb-44d4-af0c-63d65768614d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,949</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents represent deposits in a short-term money market fund quoted in an active market and are classified as Level 1 assets. Marketable debt securities include investments in United States Treasury securities and are classified as Level 1 assets as they are valued using quoted prices in active markets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a2e4af5-9922-4023-8751-d3c4f357eabf" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Marketable Debt Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9834cc27-21cd-491a-a921-fa8032f06bc3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable debt securities, all of which were classified as available-for-sale, consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:28.446%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.763%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.562000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.383000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.403%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_071d1d2d-d06e-4857-a9d4-0239ffca47a1" contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,624</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8567d34-a9d5-40fe-9f7b-a14a590b39dd" contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e07af3f-1983-4592-b0b3-e3dd182f5aa7" contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c847836-51f6-4a5f-81d3-2d2b1bdeec58" contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00982888-e946-4583-8cbe-17ef85af9b9a" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,624</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23b674dd-066d-487c-bc94-c35fedd94f2f" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c393ff8f-a8fe-4e20-9b74-d48d05409199" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceb653ab-954d-4e37-9ced-d2add18f6d70" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f3eb36d-25d6-4bf3-92b1-0c1ac222196c" contextRef="C_a41389f4-c186-43d0-9794-403390ddc786" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,288</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7af2ea60-af64-4b2d-aed0-ebb274a692a7" contextRef="C_a41389f4-c186-43d0-9794-403390ddc786" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_922ecba4-7326-4e4b-b80b-686baa18eee2" contextRef="C_a41389f4-c186-43d0-9794-403390ddc786" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,458</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc2c3a6-94cf-457d-9411-05568743467d" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,288</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1142024-284c-403f-a342-0588f193dd4e" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_800bafc7-a396-4810-a75b-b1a382ecaf6d" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,458</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the remaining contractual terms of the U.S. Treasury securities were less than 12 months.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not recognized any allowances for credit losses or impairments in relation to its marketable securities as these securities are comprised of high credit quality, investment grade securities that the Company does not intend or expect to be required to sell prior to their anticipated recovery, and the decline in fair value of these securities is attributable to factors other than credit losses.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18db2034-dc6c-4cb7-8bf9-7dfd7e2e3ff4" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and investment income consists of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.991%;box-sizing:content-box;"/>
         <td style="width:2.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.823999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.823999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e962e1d3-7c3d-4e3b-9f98-a2c45320aa24" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f03627ca-5847-4560-bf5f-4254001d575d" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042f2084-8a11-4ad7-bae6-b3a5cdc9710e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95956429-9dac-4b2f-97e6-f4d744a04e48" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,288</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total interest and investment income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_935b58a0-213d-4423-b9cc-4fe971c533fa" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4c0cc4-d985-420e-b816-2eab198bdd25" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,550</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_633f879f-abfd-4536-892d-74a4616b7260" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Segment disclosure</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d62568e2-aa77-4d7b-880c-71b29743c159" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eff11b0-e574-4b17-b4a5-ae999582e7c6" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to the development of clinical and preclinical product candidates focused on addressing unmet medical needs in patients with solid tumors with a specific focus on HNSCC tumors. The Company&#8217;s chief operating decision maker (CODM) is the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_40e1fafa-fcae-43cf-bb09-058d3cf2faa5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the single segment are the same as those described in the Company&#8217;s significant accounting policies disclosed in &#8220;Note 2 &#8211; Basis of Presentation and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies&#8221; of the Company&#8217;s Fiscal 2024 10-K. The CODM assesses performance for the segment based on net loss, which is reported on the condensed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_18387c80-8f46-4fb9-a403-2e1db91eb8aa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the product candidate through all stages of development and clinical trials and, ultimately, seek regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As such, the CODM uses cash forecast models in deciding how allocate resources. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_631756e5-d4e4-41eb-8d81-78753f852943" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes segment net loss, including significant expenses for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.3%;box-sizing:content-box;"/>
         <td style="width:1.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Royalty revenue and sale of royalty rights</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ea9f04-769d-41ed-9e95-fd1448a6f252" contextRef="C_38f8afe4-2256-4b92-a723-49f29459a24f" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_008f3d62-2f0e-468f-bb3c-74886d363547" contextRef="C_57742700-4cba-41b8-9f39-b740f3f99b64" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_614cdb46-8d92-475f-ae40-ee91d120d24d" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af61aaf8-0501-4060-afbc-e548309a67ab" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product candidates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a2ceb53-d4d1-4412-9a6c-8b0c4d45f05d" contextRef="C_6d1b9939-fd67-4211-8cf2-48609643426e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3319c881-77fd-495a-8a71-609db9c1dd14" contextRef="C_5032b180-a6c9-4ff7-8f03-2d4bd35aeef6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,974</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product manufacturing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c6d138-3e56-4cc0-b51a-6513f93891b6" contextRef="C_150aa5b2-9b4d-462c-adf9-5645140d7e33" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,384</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cccc7b32-2b33-4c97-bfc7-3919148e8749" contextRef="C_7e808a75-bd9f-4f76-9117-82cd0f5be7ca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,563</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c923affb-e570-4c6d-a31a-c3eab3c9e93e" contextRef="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,739</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91a1cab4-e687-49e2-971d-b5b5d2c931b7" contextRef="C_9dce6431-1c01-4d1f-a411-889976d95f6a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,504</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c438a7-8c6f-4977-a823-974284b3c1d8" contextRef="C_1e12a232-a571-45f6-9670-3ee553d3dba3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b211396-9969-4ec9-aa83-77c66df1cb30" contextRef="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">678</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_236c9424-e023-4315-9bdc-39d9c9888fef" contextRef="C_c06d934d-2ece-4e58-aff2-9571ee296c3f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c637e1-6d14-4c60-a1df-c92552e94d49" contextRef="C_5ba8496a-b732-4e27-8494-8cc671bac84a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (i)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68eea835-d0ae-43a3-a5db-839ff48d87d0" contextRef="C_80ea7a33-ca44-4b1a-9d84-3b098b016750" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3bdf2c0-420d-47fe-b921-53b2cd1e0dba" contextRef="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,995</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba0cc46b-8ba8-42ff-a656-48de9e8f2a92" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,044</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b473f73-bcc1-4e2b-ade6-722cb88153ba" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,029</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe256dc-b6bc-40d2-8e7b-a1ae4f772638" contextRef="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3654a86d-1ad6-4c8d-92d1-7577ad621e8b" contextRef="C_9dce6431-1c01-4d1f-a411-889976d95f6a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,918</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5e7870c-0e7c-4385-9088-fb0dbe749e4c" contextRef="C_1e12a232-a571-45f6-9670-3ee553d3dba3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,509</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a027b66-afec-442a-9f14-17ba764aba13" contextRef="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,643</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d9c90f-e6a4-40d9-8a73-0c7ce41622c7" contextRef="C_9cae4734-8e55-4f7a-9b85-7922cacc7b3e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb9bf7ae-fe09-4c22-84cf-24211b5f44d3" contextRef="C_2967ce11-ebdd-4b1d-826e-9763f4ccb671" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,080</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (ii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12eb3a19-56ed-45bb-bcc4-78e43ce2212d" contextRef="C_80ea7a33-ca44-4b1a-9d84-3b098b016750" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4181f35f-78ef-4941-bf4e-98d542eac641" contextRef="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,606</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b13f8e24-d3a7-4499-a24b-ba62b7b79219" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,870</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5a9e764-cf3f-4703-8c60-fa14b092bc38" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,247</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d742b61-9db6-4980-b51c-0133eba2a573" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="pyxs:CostsAndOperatingExpensesTotal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,914</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2739259a-0ca7-4991-883c-832abf86d01d" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="pyxs:CostsAndOperatingExpensesTotal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,751</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment income (iii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89cf541d-996b-4e65-8c2f-7c43a84e23de" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,756</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48fd381f-259b-4b6d-af6d-72a27e10d70a" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,349</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bee292ae-fec0-4a5e-8b1a-b5d013942930" contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f01cd46c-bef8-47d8-acef-6630fb7564e9" contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of profit or loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments and reconciling items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed43711-744b-4f32-8a18-65759efc820b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,158</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20dd5430-0c42-4052-aaee-266a4d3f6368" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,256</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development segment items include facilities expenses, lab services, professional services and technology costs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment income for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00dbc6de-14d8-47b4-b0c2-cff74c1088c8" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f9d4130-9ed8-436f-b8f7-00c066674653" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest and investment income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51c59098-0422-4693-b21e-71cbf4bd2c6b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b8d8b1-61db-4492-bfef-c3f688696652" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of sublease income, respectively.</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_85018afc-cddb-4596-8220-04c87977eeea" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:LicensingAgreementsTextBlock" escape="true" continuedAt="F_85018afc-cddb-4596-8220-04c87977eeea_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Licensing Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The University of Chicago Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, the Company entered into a license agreement (the &#8220;University License Agreement&#8221;), as well as a sponsored research agreement, with the University of Chicago (the &#8220;University&#8221;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_694fde81-6e33-41cd-8adf-44d58570ea5a" contextRef="C_5d1a4394-6692-49e3-a78c-53add9ce8cdb" name="pyxs:CommonStockIssuedToUniversity" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,919</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in 2020.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the University License Agreement, the Company is obligated to pay potential development and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the University License Agreement as of  March 31, 2025 and 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00a6f56b-887f-4fd7-96e4-179f2314203e" contextRef="C_9785fcb7-9dea-48db-b586-d63e6e45e9ce" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_296eb025-24bf-4618-92cd-c08ffbad9d30" contextRef="C_63ba58e4-c1b8-480d-a574-db0f42fe8744" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer Inc. Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, the Company entered into a license agreement (as amended, the &#8220;Pfizer License Agreement&#8221;) with Pfizer Inc. (&#8220;Pfizer&#8221;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. The Company&#8217;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. The initial licensed targets include CD123 and Extradomain-B Fibronectin (&#8220;EDB+FN&#8221;) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94ae6472-502c-4508-ae87-0edfb369d96f" contextRef="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec" name="pyxs:PaymentForLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the license fee, consisting of an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5627afd9-8d53-4901-a044-c709fc6d3fb3" contextRef="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a47b622-6f23-4422-a08f-a606c7efbe3e" contextRef="C_2dc476af-db9c-4877-bce2-5597b5ff0528" name="pyxs:IssuanceOfConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,152,145</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series B convertible preferred stock, which was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1729a777-3db7-45ee-adc8-1af59bbfd483" contextRef="C_74975660-2e58-4083-b25a-adbe25ac8127" name="pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,911,015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock upon the initial public offering (&#8220;IPO&#8221;) in October 2021, with a value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02b5cb00-4d07-44ab-ba0c-5f56bc84203c" contextRef="C_ed227005-05eb-4b2e-b46b-86ab51890c85" name="pyxs:ConvertiblePreferredStockSharesIssuedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Pfizer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2022, the Company entered into an amended and restated license agreement (the &#8220;A&amp;R License Agreement&#8221;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#8217;s Flexible Antibody Conjugation Technology Flexible Antibody Conjugation Technology (&#8220;FACT&#8221;) Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. In accordance with the terms of the A&amp;R License Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47f58a9d-5928-4308-998c-7c6764237cd9" contextRef="C_63a6cb3b-0f48-4d6e-abd8-d1208ebf1187" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,229,654</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to Pfizer in October 2022, paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7653ed4-9d8a-44fd-8673-2f9b3c10c6bc" contextRef="C_290608d1-a120-4e94-a552-45ef09566ea1" name="pyxs:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Pfizer in January 2023 and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f40d83c-c1cb-48fb-aeb5-c5f1fdb07937" contextRef="C_1659b880-a5b1-4e72-804b-476a70f006ea" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,811,594</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to Pfizer in March 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, pursuant to the A&amp;R License Agreement, the Company is obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the A&amp;R License Agreement as of March 31, 2025 and 2024, and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5048b976-f893-4c6e-91bb-8c9c9a3262c3" contextRef="C_837677d7-498f-48bb-95c8-9faa16b30f62" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_56fea162-42e4-4ecb-b049-e584158cc6d7" contextRef="C_81dccbcc-0e5d-42f2-a90b-5d7a220cc416" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span></p><h2 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></h2><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 28, 2022, the Company entered into a license agreement (the &#8220;Biosion License Agreement&#8221;) with Biosion USA, Inc. (&#8220;Biosion&#8221;), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacturing and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7962d5c-c93d-4c6d-9df8-8d930b6f4dea" contextRef="C_acc32560-f36b-4aae-bb63-26d88b5e0289" name="pyxs:UpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in March 2022. Further, the Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products and sublicensing revenues at varying rates. In December 2024, the Company paused the clinical development of PYX-106. The Company assessed the milestone and royalty events involving the Biosion License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55ae0cf8-158d-4c22-9dc8-f5fc1a5eba07" contextRef="C_0090356c-a2e4-4923-b76e-2b67349147d5" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c1293264-3a9e-4c6a-85df-e3246fa6e100" contextRef="C_97ecf8f3-9e3b-4ebb-bbff-1d5047205f7f" name="pyxs:MilestoneAndRoyaltiesIncurred" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired Out-Licensing Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the Company completed the acquisition of Apexigen, Inc. ("Apexigen") and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assumed all out-licensing agreements of Apexigen upon the Merger.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Simcere License and Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2008, Epitomics, Inc. (&#8220;Epitomics&#8221;) (Apexigen&#8217;s predecessor) and Jiangsu Simcere Pharmaceutical R&amp;D Co., Ltd. (&#8220;Simcere&#8221;) entered into a license and collaboration agreement (the &#8220;Simcere Agreement&#8221;) for the development and commercialization of suvemcitug (BD0801) for oncology in China.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_85018afc-cddb-4596-8220-04c87977eeea_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simcere is obligated to pay the Company milestone payments for achievement of certain clinical development milestones and low to high single-digit percentage royalties on net sales of suvemcitug in China until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_864434b8-2b69-4cb5-9118-9c7d8a928882" contextRef="C_f759528e-20d8-4601-852a-3782e7215f4d" name="pyxs:RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of suvemcitug. The Company assessed the milestone and royalty events involving Simcere as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00d0194a-0405-4884-bd05-451780049384" contextRef="C_a0ea1ad7-9313-4e2a-bd73-2726a836f60b" name="pyxs:MilestoneAndRoyaltiesReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">T-Mab/Mabwell Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2008, Epitomics and Jiangsu T-Mab Biotechnology Ltd., Co. (&#8220;T-Mab&#8221;) entered into a license, co-development and contract manufacture agreement (the &#8220;T-Mab Agreement&#8221;) for the development and commercialization of therapeutic candidates, each directed to a specified target for specified fields, including VEGF for the treatment of ocular diseases, in China. Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) acquired T-Mab in 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, Mabwell was granted an exclusive, royalty-bearing, perpetual license (without the right to sublicense) to rights in certain intellectual property to develop and commercialize such therapeutic candidates. Mabwell is obligated to pay the Company a mid-single-digit percentage royalty on net sales of such therapeutic candidates in China. The Company assessed the milestone and royalty events involving Mabwell as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b4282d-5bd4-43ec-9bc1-90cdd8c8be2d" contextRef="C_89abcaed-dbf0-4b59-a0d5-c994ebb137d6" name="pyxs:MilestoneAndRoyaltiesReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Toray Sublicense Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2012, Epitomics and Toray Industries, Inc. (&#8220;Toray&#8221;), entered into a non-exclusive sublicense agreement (the &#8220;Toray Agreement&#8221;) under which Epitomics granted Toray a non-exclusive, worldwide sublicense, with the right to grant further sublicenses, to develop and commercialize drug product candidates that Toray developed using antibodies created using Apexigen&#8217;s antibody-discovery platform (the &#8220;APXiMAB Platform&#8221;) that target certain molecules to use in the development of its drug product candidates. Under the Toray Agreement, Toray paid an upfront fee, and agreed to pay certain development- and regulatory-related milestone payments and a low single-digit percentage royalty on net sales of licensed products and sublicense revenues by Toray or its affiliates.  The Company assessed the milestone and royalty events involving Toray as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7102fd4f-40fa-44e2-90ed-10b8691e5429" contextRef="C_7afe6a9e-11e5-428d-b499-c4c37cf4f4fc" name="pyxs:MilestoneAndRoyaltiesReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_02ad6792-469b-4959-940a-ce875f9a181e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shelf Registration Statement and ATM Offering Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2022, the Company filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc8e1dc9-0448-4ec4-bd4c-dacb4d8b941f" contextRef="C_9eedb432-f4a9-43b3-ba2d-11719dfe1ba0" name="pyxs:MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On November 14, 2022, the registration statement was declared effective by the SEC. The registration statement includes an ATM offering program for the sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a9a932-feb7-4df5-aa7e-0dc9bdf915a2" contextRef="C_678c9317-3c78-4a7a-bf89-db2215e97bda" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0715e9e0-74a4-4abf-884d-ce618a7641da" contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0" name="pyxs:SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t sell any shares of common stock under the ATM offering program. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, the Company h</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ad $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eecc006-832a-424b-b712-7c126b105850" contextRef="C_3899226d-7062-4ed7-98a2-86b74edb9890" name="pyxs:SaleOfStockRemainingCapacityAvailableUnderProgram" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of remaining capacity available under the ATM facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22f2d7fa-a011-4259-addd-b6c9d728e842" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_07ba01b0-6f0b-47b1-ba4e-92cff3a14bae" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fb6ae36a-7fe0-4e32-af40-93241b3d4299" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f2418b11-7718-464c-a6bd-683cd547f23c" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued and outstanding shares of preferred stock as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3367b3bf-3398-4922-a05b-d4559d77ad1e" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote in respect of each share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reserved Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0479d537-d4d2-4c82-b234-fe70dde5c5f4" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_0479d537-d4d2-4c82-b234-fe70dde5c5f4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0479d537-d4d2-4c82-b234-fe70dde5c5f4_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:23.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:24.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_667ace86-b30e-4e79-9c32-32da68901d47" contextRef="C_565d2f6f-3e93-4e23-8ba1-a266d622097c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,228,168</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_471cd3ef-5876-4d07-981f-a8c887a83f4c" contextRef="C_8bcaa3a4-f396-49d4-9a7c-9a2c953ca07d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,711,075</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c77e975-3278-4d9f-b607-5848ee0b6931" contextRef="C_da865c67-24d1-400e-a077-12e7011b7389" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,421,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a44e085c-5ef8-4c1e-9ac0-d0c59b19974e" contextRef="C_77b5c4a5-315a-49dc-a7f5-2446f1b77e18" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,463,601</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00410a12-c40b-4724-92ba-056a07ab5b68" contextRef="C_824b7ea1-2dee-4608-a3e0-704fe74262da" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,382,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9b62cd4-ffe1-41fa-a72f-466e1ac90372" contextRef="C_044f61dc-d55f-47ed-bf0d-a9b02b506528" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,295,342</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-Funded Warrant Shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e46562-c639-4a4a-94c6-bc9ccfd6cfb0" contextRef="C_ec093f95-5fcd-47b1-952e-ed9e123d523d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,611,215</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da1a95fa-b474-4cb2-9366-8619f444f01d" contextRef="C_d20dc9b5-8895-44ad-af21-3cb92effe49e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,003,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2d6530a-d5ee-4637-9ef8-745588d703d8" contextRef="C_5da75939-3069-4ae8-9442-f8b70f506330" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,003,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40db6a84-44ec-4507-ba79-739a9168aef2" contextRef="C_19d61487-1275-421e-96ed-c8df7b8a1263" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">653,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dff32e-f65a-4755-bc4f-1915401eb6f7" contextRef="C_3478df5d-ec35-4824-83ab-aaf0f4b41638" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">573,316</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee16aefc-cf6c-4a38-8734-39ebcd3dd41e" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,689,919</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a775fec-55fc-432c-9811-9b3a39ba300d" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">19,657,740</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cfb4a96-74a9-4de7-a7ce-27046219e0a7" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:CommonStockWarrantTextBlock" escape="true" continuedAt="F_7cfb4a96-74a9-4de7-a7ce-27046219e0a7_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Apexigen Replacement Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the Merger, each outstanding warrant issued by Apexigen was assumed and converted into a warrant to acquire the Company&#8217;s common stock, on substantially similar terms and conditions as were applicable under such Apexigen warrant agreements. The Company replaced approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcba07ee-ed35-4f02-b618-d77822b71aee" contextRef="C_4b4f6feb-cd93-4d71-b40e-b295d4cf5442" name="pyxs:ReplacementOfWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,815,613</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Apexigen warrants with approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d40835bf-e931-411d-9dec-c389540da301" contextRef="C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a" name="pyxs:ReplacementOfWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,003,191</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pyxis Oncology warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14295e66-d85c-4d5e-b24b-3a19b9a8b78c" contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">344,259</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_751df738-765b-491f-b993-657920577321" contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_636daa47-16fb-40b1-929b-4eba6a0c04fc" contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,212</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d493ff7-6bff-4664-872c-7c9e326a93c7" contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e213bad7-6dac-43c6-bae9-8eb1286fd1a0" contextRef="C_27fbe99f-b243-407d-805e-643897908e7c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">641,720</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d6f4779-7dbf-4c3c-bb07-b42edeb8b6dd" contextRef="C_27fbe99f-b243-407d-805e-643897908e7c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">66.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each of the warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fc62a11-2d35-4b3f-bf3b-a6e5606c5bdb" contextRef="C_d8f2f73e-7aca-4a71-8f6a-4c1b3ac7de0d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">66.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share will expire on the fifth anniversary of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efa64eb7-220f-481c-9878-20c934e9f16e" contextRef="C_27fbe99f-b243-407d-805e-643897908e7c" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 29, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier upon redemption or liquidation. Each of the warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da80a861-01e2-48a2-8db5-87970a9e7f50" contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37969291-8280-48f3-9cbe-e59aca703477" contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52372c30-e9bf-4183-a3a2-ec9b1ca557f4" contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="F_73e49186-d144-4aad-b475-992a6f849bb7" contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 30, 2028</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier upon redemption or liquidation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company received gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e71a41f3-f672-4be6-8e7e-711d0bc88404" contextRef="C_bf458c23-24e3-416a-b060-7beb4e11b9d0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million via private placement with certain institutional and accredited investors by issuing (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88e0d9d-e1cd-47a1-bc09-dc28090885e5" contextRef="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,849,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_564cde6a-5968-47ec-be21-dccb4112d666" contextRef="C_88407054-4ac6-407e-bd60-882ac0345a83" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9609a530-0339-400d-ad44-fb0a247802b0" contextRef="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and (ii) pre-funded warrants (&#8216;Pre-Funded Warrant&#8217;) to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82201f5b-f8b0-40ac-bf65-506381d814d0" contextRef="C_18c2f871-fdac-46c2-8c4b-4a534962e9f8" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,611,215</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217; common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31c4da06-cf50-4b7d-8333-3e92d8a6dca6" contextRef="C_0c8f0bca-3bcd-4650-a38f-74cace0f746e" name="pyxs:PrefundedWarrantsIssuedPricePerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">4.779</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_7cfb4a96-74a9-4de7-a7ce-27046219e0a7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the pre-funded warrant holder exercised their right to convert the Pre-Funded Warrants to common stock and accordingly, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddf16be-1625-476f-9af9-02c70bf713d0" contextRef="C_bc5c6809-e7d5-4c1f-a9d6-81bcb2d63dcd" name="pyxs:PreFundedWarrantsIssuedDuringPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,611,215</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to the warrant holder.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_901b211c-3fc1-415a-aba2-d2d602a08c7f" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_901b211c-3fc1-415a-aba2-d2d602a08c7f_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants stock-based incentive awards pursuant to the 2021 Equity and Incentive Plan (the &#8216;2021 Plan&#8217;), 2019 Equity Incentive Plan (the &#8216;2019 Plan&#8217;), Apexigen Equity Incentive Plans (the &#8216;Apexigen Plan&#8217;) and the 2022 Equity Inducement Plan (the &#8216;2022 Inducement Plan&#8217;). As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c6338e-6586-4845-a3b5-c220482cb708" contextRef="C_b53bcca6-85b4-46ee-be42-becc61d48b23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,072,703</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5683581-dac1-4bcd-8167-0ac41130660a" contextRef="C_c59ed3d1-dcfa-490f-9209-32cb9b6920ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">132,435</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bede5f5-5e3b-47e8-8f71-ef95eb5ea4e2" contextRef="C_40a96fb2-dbbb-44c6-a5a1-b2efcc758b42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">764,154</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0872dc92-dc7f-48a3-bff7-aec1f9e5cb3c" contextRef="C_fcbfab1e-0b3b-450f-9242-753a06599476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">413,537</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the 2021 Plan, 2019 Plan, Apexigen Plan and 2022 Inducement Plan, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_69c68630-2296-4453-b7a1-16329e9d989c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.200000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ebb6338-c9dd-4b05-bf34-9e6f94f56313" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,711,075</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5265a503-06a9-47ce-8e59-2380ec79c99c" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_10714c8e-bed0-4682-b419-42da9649cded" contextRef="C_eb99ab08-0e63-41ea-bc44-35b639d19208" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5224e73c-bca0-45fc-a616-b1d568e9fcaa" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_780c0e93-e63d-4ffb-8ffc-bc718430adf3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,104,372</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c37b5717-607e-44ff-9856-deeb23356079" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_984068ff-beff-4f77-b3d1-ddc4871a9e42" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">587,279</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3f4d3f-0637-4fa5-b070-606f29cf387a" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73ce622-4953-4f1e-8705-0bbf5b94dd44" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,228,168</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1e9288-98a7-40dd-852e-1a5c7c73bc77" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.16</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_29a69e71-f328-4493-af9c-0f1f6e0cc78a" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea86d72f-d4e2-4656-a4d4-a55cc6ffd8b2" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercisable March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8a8f018-b8c5-4054-9f2c-0249fa865bff" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,379,232</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7961af5b-c794-41bd-a333-64e386db1af5" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8a1fef11-361e-4e30-bea1-74cfe0c65622" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf22de3e-9efb-41fc-a75c-9480c12bb90b" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#8217;s common stock o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61602945-0a0e-4189-b643-8c81189c190d" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="pyxs:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r share as of March 31, 2025. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdbee86c-77ea-4cd6-afca-dc3b8518f0d3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c66c621-252b-4c37-9c7f-be9611609475" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_650df13c-4872-4cfa-a20c-0b213c6c6bd7" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options were exercised during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an aggregate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_911b63eb-0497-46c5-896d-a0aea8aff795" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of gross unrecognized stock-based compensation expense as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10d8adcf-c5bb-4868-9fa2-455e7366fd0a" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.94</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a2f12ee-3ab5-4797-be87-966edacf13f2" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d82f20b-32d7-4e02-910a-7079833ecc33" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively, and was calculated using the following key input assumptions in the Black-Scholes option-pricing model:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_e799a3ba-3cf4-418c-89f2-c0306ed5d3e9" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.569%;box-sizing:content-box;"/>
         <td style="width:22.076%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:22.076%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b046986-938a-4858-866b-7b98c64be04d" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">93.920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41b19c66-488b-47f2-a968-b5ebcd1f5b49" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">99.910</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e251b728-7607-4e4d-8026-7b0851407173" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">99.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_851f3c48-1ca2-4567-b694-8891f8c9a24d" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">102.27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2740dea-f054-45f8-97c8-c78bf0abc7e5" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">3.960</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0125b84b-7bc4-4952-950a-609a56b1c3ee" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">4.450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d6dbcda-e38d-41e8-b541-d16a5b774785" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e027856-7557-431e-8601-abd99533c341" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_188c03f5-28e3-478a-9a1b-9d43bdebb780" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74fa6589-1835-4a0e-89de-1c952cf8267a" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_47bddac4-a3c5-4b6d-9d67-9111b824f2bb" contextRef="C_9b6f4f8e-a104-4456-901f-a188c4f57515" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_410ce99c-d2f6-4e22-84a8-66114feef5c8" contextRef="C_bd8b966a-b09c-4ecf-99e4-4af048f4ca8a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_61e296a1-aceb-44a9-9620-521dacbb61f0" contextRef="C_668a1b98-824d-41d1-8593-7b9e8f0d78b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_b3d267fe-438c-47c3-aab6-3190600b2b38" contextRef="C_19b0546a-3406-4376-b2bf-06e6e947abae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_901b211c-3fc1-415a-aba2-d2d602a08c7f_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a4d8d3a-18c0-41ff-8fc7-d6bb0b475189" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock units activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b232a63-9709-4743-b8f4-5f46dfbd935f" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,533,650</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de4fe867-5c27-4c0e-a690-9d5af383f74e" contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6d83514-ff73-438c-9686-da4b69ef4524" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,804</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03259449-2071-4257-93d5-21290948d7fd" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.18</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and settled</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b9d8fe-578b-463e-8878-ee24c92029d9" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">30,892</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60a07a97-3899-43cf-879f-36eb3e4f4d45" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.73</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb048427-93e9-455f-a767-147bad79de92" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,421,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28d88699-f2c8-4f89-b409-94995d0a617e" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efada5f0-6733-4e25-b4bf-210267137194" contextRef="C_da865c67-24d1-400e-a077-12e7011b7389" name="pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">361,263</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs which are vested but not settled at  March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfce2efa-7245-4298-8671-a7bc9411684d" contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,728</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock from the settlement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aae43ba-2435-4c46-9e5a-cae5fc9a530d" contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,892</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted common units, with the remaining shares withheld for taxes. The Company has an aggregate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a6850ef-198a-4d47-a1f2-e09eefd186bf" contextRef="C_da865c67-24d1-400e-a077-12e7011b7389" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">5.04</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of gross unrecognized restricted stock-based compensation expense as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6de3de73-c3db-4af0-b4bd-c89665e6f677" contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03ef56e1-7f14-41b6-89d4-95acfb27afb5" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the total stock-based compensation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.368%;box-sizing:content-box;"/>
         <td style="width:1.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.276999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.276999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a28f99d-6a29-40ca-a2fc-3c80bd98cb5a" contextRef="C_d297973c-6ba2-4ed6-8a31-917d0510d880" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,509</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52f9e4c3-e8f7-4e5e-af8c-5e501f50ae7c" contextRef="C_4d7cc448-0612-40c7-9727-ba960bd2bcad" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b2a5278-1047-4cc5-975d-12f074a2054f" contextRef="C_6fc6795c-50db-425e-91fd-5a73256a6dfc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ee893c7-8fbc-4630-a1cd-c960f0ec2a5c" contextRef="C_088e0ae4-1139-4dc9-a66c-b53dac8ce75b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">678</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_148daaa4-8f72-4670-b574-56fea47aa111" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9131ad9-3aa7-46ca-9456-437cc0d7c6c9" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,320</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the 2021 ESPP in force. The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0744c2e7-4587-4d2b-a71e-31ac6e0f2d77" contextRef="C_9c3347c8-7c90-48dd-9028-f27b924409e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,619</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the 2021 ESPP during the three months ended March 31, 2025. The company did not issue any shares during the three months ended March 31, 2024. As of March 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae9351ff-53f0-427d-a9d8-dc1e11bf5919" contextRef="C_9e825b7d-73d0-4c61-872f-ab5440ba67fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">653,777</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are available for issuance under the 2021 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7a5b322-5d86-4028-a59c-b11e11ff5142" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Operating L</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its office and facilities in Boston, Massachusetts under a non-cancellable operating lease agreement that continues through December 31, 2032. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa9432c1-0783-4d86-ac98-4369663b20bf" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0e3fde-33ab-4efe-b29e-ffdb1d974886" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively, which is included in operating cash flows within the accompanying unaudited condensed consolidated statements of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_dc19ee83-3bc8-4556-bc13-e86db6bde817" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The component of operating lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.34%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006b0c7c-0846-47f6-a75c-5e2f6d045827" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">672</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89fa099b-6ea3-4219-a8b2-c0149f65285a" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">663</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81b422a3-157f-4a50-9292-1a42df69e37c" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bb47fae-a509-4313-b338-e8b9c1a8ce3a" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1148b1-f223-460a-92b5-044e92c46dd9" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc536b8-e238-4f10-b7fc-98f9cb1a4284" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company subleases approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc280d88-407f-4e4c-9a6a-2dc60da48669" contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">17,729</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The Company remains jointly and severally liable under the head lease and accounts for the sublease as an operating lease. The lease term commenced on March 24, 2023 and is expected to end in March 2026. The Company recognized sublease income of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a78009a-214d-4a4d-ae3f-0622928635b8" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5065d81-d10d-4af1-9519-829542cc33d1" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_64a3e4f0-851a-4548-a36a-21b63fefc356" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_64a3e4f0-851a-4548-a36a-21b63fefc356_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s effective tax rate from continuing operations was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a2cc4c6-321b-44d7-b43c-3aa63cebcf68" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc0172a2-4f17-4bd9-9f2f-a4a5bab95552" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f053d39c-054d-45ca-9c08-a5c72c2d26a1" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_655e9779-eb83-4753-89d3-0941f5614f1d" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded a federal income tax provision for the three months ended March 31, 2025 and 2024. The Company recorded a nominal state and local income tax provision for the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company assesses the realizability of the deferred tax assets at each reporting date. The Company continues to maintain a full valuation allowance for its U.S. federal and state deferred tax assets, which significantly consists of net operating losses and tax credits. If</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_64a3e4f0-851a-4548-a36a-21b63fefc356_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial changes in the entity&#8217;s ownership occur, there may be an annual limitation on the amount of the carryforwards that can be utilized. The Company will continue to assess the need for a valuation allowance on its deferred tax assets.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b50f2cd4-44f7-4d9f-9b49-92ba058fbf41" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss per Common Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf384460-e0fe-4ae5-ae46-2783b6a4ad7b" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_bf384460-e0fe-4ae5-ae46-2783b6a4ad7b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:23.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:24.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024*</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cfd4810-8b28-4663-b856-5c12b80c2b70" contextRef="C_6027eb9f-48b8-4d75-8321-038710d6afd6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,228,168</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1d8664d-050f-4246-bfa5-47f505e0d65a" contextRef="C_4ac8c464-a9ee-4f4c-9cbd-ba23e9e145ef" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,892,951</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd48a018-ad53-48e9-bda9-621b91f19a91" contextRef="C_bd63dfaf-0acf-4759-9e38-63e3f7d254fe" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,421,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57026c0c-953d-45c8-a725-c876a37453f2" contextRef="C_7f2bf259-5d8f-4d8c-a46e-c559de6ac9a7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,110,597</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11126c9-e372-48a4-95bc-3774a69095a2" contextRef="C_e7c0ee51-b9d9-4edc-98ee-3e53a89d2eef" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,382,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6bfe8a-cb5a-4c4d-8467-e5d8c171d2e4" contextRef="C_2b13fbbe-afbd-4ba7-8372-4ec974d6de0c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,649,038</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2c5c620-7a3a-40fb-866b-5aa740a60863" contextRef="C_cdf070fa-6052-434b-970a-be0e009d0f61" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,003,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385bced4-797a-454b-b689-8e36d249b45d" contextRef="C_9ac06ca8-b7a6-46a3-8c25-6237c2d2084e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,003,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f9f12b-d707-4b10-a375-c6e6509e954e" contextRef="C_4acf36bb-505b-45ee-99cd-5d1d91b303d4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">653,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cca1161-2c9a-4966-9786-1b4ea21837b7" contextRef="C_186c4ea3-09e7-46f6-8773-3f7d43d03df6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">675,485</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9beeda0a-f17a-415f-a86d-aa80e77056d7" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,689,919</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b96c0d7-aa06-42fc-8570-d7aeafabe65c" contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,331,262</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span><ix:continuation id="F_bf384460-e0fe-4ae5-ae46-2783b6a4ad7b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Pre-Funded Warrant Shares of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5691690c-0ccf-47bf-8700-6f82933e7f07" contextRef="C_347129ce-fb5c-4096-80fe-ffcae8c2d8cb" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,611,215</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6d142dd-9b5c-4bf1-beba-1c2a2abe5141" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Commit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our (1) unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and (2) consolidated financial statements and related notes and management&#8217;s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2024, included in our Fiscal 2024 10-K. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;Pyxis Oncology,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Pyxis Oncology, Inc. and its subsidiaries.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are often identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;to be,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled &#8220;Risk Factors&#8221; set forth in Part II, Item 1A. of this Quarterly Report on Form 10-Q and in our other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyxis Oncology is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate, micvotabart pelidotin, formerly referred to as PYX-201, is an investigational novel antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM). The tumor ECM is a complex network of fibrous proteins and molecules with unique composition that play an important role in cell development and tumor growth and in some instances, in supporting metastasis. The fibronectin strands within the ECM give the tumor shape and support the clustering of tumor cells.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fibronectin is a key component of the ECM and its downstream signaling pathways regulate cell adhesion, migration, differentiation and wound healing. EDB+FN is an alternatively spliced form of fibronectin. EDB+FN regulates blood vessel morphogenesis, which provides the tumor access to nutrition and oxygen, and provides a means to remove waste and a pathway for cells to metastasize. EDB+FN is a compelling target for cancer therapeutics as the physiological expression of EDB+FN is very low in healthy adult tissues, yet it is found to be highly expressed in a large variety of solid tumor tissues. EDB+FN is also found to be expressed during embryogenesis.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By targeting EDB+FN, our goal is to destabilize the barrier that protects, feeds, and provides structure to the tumor, in addition to killing tumor cells directly while sparing healthy cells.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ADC, micvotabart pelidotin, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload. Micvotabart pelidotin is designed to optimize linker stability to enable delivery of the next generation auristatin payload that can be cleaved and released in the ECM and penetrate through the tumor cell membrane to kill tumor cells directly without the need for cell surface antigen-mediated internalization of the ADC. Unlike conventional ADCs which bind to the tumor cell surface antigens, micvotabart pelidotin is designed to deliver the auristatin payload to the extracellular environment and release the free payload to kill tumor cells as well as activated fibroblasts and vascular endothelial cells that support tumor growth. We believe the free payload kills the tumor cells through a combination of bystander effect directly killing highly proliferative cells and through stimulation of the local immune cells.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted a Phase 1 dose escalation (Part 1) study, referred to as PYX-201-101 to evaluate micvotabart pelidotin monotherapy in patients with advanced solid tumors predicted to express EDB+FN. A total of 80 patients were dosed across nine solid tumor types during the PYX-201-101 (Part 1) study. In November 2024, we announced positive preliminary data from Part 1 of our Phase 1 dose escalation study of PYX-201-101 with a data cut-off date of October 4, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients were observed to show the strongest tumor regression response during this Part 1 phase of the study. Among the six efficacy evaluable patients with R/M HNSCC at the therapeutically active dose response range of 3.6 mg/kg &#8211; 5.4 mg/kg IV Q3W, the study achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria including one confirmed complete response (cCR) and two confirmed partial responses (cPRs) and yielded a disease control rate (DCR) of 100%. These six heavily pre-treated patients with R/M HNSCC had either HPV-positive (HPV+) or HPV-negative (HPV-) tumors and a median of four prior lines of systemic therapy in the advanced disease setting.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we observed evidence of tumor regression across all nine solid tumor types that were enrolled in the Phase 1 Part 1 dose escalation study, dose responses were most pronounced in six solid tumor types of interest, including R/M HNSCC, hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, locally advanced / metastatic non-small cell lung cancer (NSCLC), ovarian cancer, sarcoma and triple negative breast cancer (TNBC), at the therapeutically active dose response range of 3.6 mg/kg &#8211; 5.4 mg/kg IV Q3W. Micvotabart pelidotin achieved a 26% ORR (n=31) in patients with these six solid tumor types dosed at 3.6 mg/kg &#8211; 5.4 mg/kg IV Q3W.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Preclinical Data</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently, we presented new preclinical data at the 2025 American Association for Cancer Research (AACR), Annual Meeting in Chicago. We observed broad anti-tumor activity for micvotabart pelidotin across ten solid tumor indications in PDX models, attributed to EDB+FN target expression, proteolytic activity for micvotabart pelidotin linker cleavage and tumor responsiveness to the optimized cytotoxic Auristatin0101 payload. The preclinical data is summarized below:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45% of models demonstrated strong to very strong tumor growth inhibition (TGI%) activity (70%&lt;TGI&lt;90% or TGI&gt;90% respectively), with only 25% of models showing no response (TGI&lt;25%).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PDX models with very strong activity (TGI&gt;90%) were found across nine out of ten solid tumor indications.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete responses to micvotabart pelidotin (tumor volume reached 0mm</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for at least two consecutive measurements) were found across several tumor indications, consistent with previous analysis.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">micvotabart pelidotin was observed to be well-tolerated (3mg/kg, Q4Dx4). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also performed differential gene expression analysis, which enabled us to identify gene signatures linked to anti-tumor activity consistent with our extracellular ADC hypothesis. We observed that enzyme and tumor stroma gene signatures were the gene sets with the greatest number of differentially expressed genes. Further, the preclinical data shows upregulation of certain proteases that may contribute to increased linker cleavage and subsequent increased anti-tumor activity for micvotabart pelidotin, supporting our extracellular hypothesis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also conducted preclinical studies combining a mouse analog of micvotabart pelidotin with anti-PD-1 therapy. The combination of a mouse analog of micvotabart pelidotin with anti-PD-1 therapy inhibited EMT6 tumor growth and improved survival compared to either treatment alone, suggesting potential benefit for combination therapy to deepen anti-tumor responses in solid tumors. The preclinical studies combining a mouse analog of micvotabart pelidotin with anti-PD-1 therapy is summarized below:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monotherapy of mouse analog of micvotabart pelidotin inhibited dose-dependent tumor outgrowth of EDB+FN expressing EMT6 tumors and was well-tolerated at 6 mg/kg.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mouse analog of micvotabart pelidotin boosted the immune response by activating dendritic cells and increasing CD45+ immune cell infiltration, including PD-1+ T cells, into tumors, transforming EMT6 tumors into immune-infiltrated, "hot" tumors.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant TGI observed with mouse analog of micvotabart pelidotin (TGI=94%) and anti-PD-1 therapy (TGI=54%) as monotherapies.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The combination of the mouse analog of MICVO and anti-PD-1 therapy resulted in TGI of 91% and complete response was seen in 9/15 animals &#8211; greater tumor regression and clearance than either treatment alone.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mouse analog of micvotabart pelidotin in combination with anti-PD1 therapy induced lasting immunological memory, enhancing tumor clearance and protecting against tumor recurrence in rechallenged mice.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical data indicated micvotabart pelidotin alone may be eliciting immune responses in previously unresponsive tumors, as observed with the infiltration of T cells into the tumor, representing potential for micvotabart pelidotin to drive immunogenic cell death. Together, these preclinical data further support the three-pronged mechanism of action of micvotabart pelidotin driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the totality of our preliminary clinical and preclinical data supports further development of both micvotabart pelidotin monotherapy expansion and combination therapy trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Clinical Pipeline</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to micvotabart pelidotin for the monotherapy treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the strength of the HNSCC signal that emerged in the Part 1 dose escalation study of PYX-201-101, we have decided to prioritize our resources to focus the next stage of development on characterizing the R/M HNSCC efficacy signal.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our clinical pipeline:</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img33342731_0.jpg" alt="img33342731_0.jpg" style="width:665px;height:366px;"/></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In early January 2025, we initiated the dose expansion phase (Part 2) of the PYX-201-101 monotherapy study with a prioritized focus to confirm the preliminary efficacy signals in R/M HNSCC seen in Part 1. Currently, we are enrolling and dosing patients for two monotherapy R/M HNSCC expansion cohorts. The Part 2 dose expansion phase includes the following two R/M HNSCC cohorts across sites in the United States (US), European Union (EU) and other countries:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">micvotabart pelidotin monotherapy for second line (2L) and third line (3L) R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy. We expect to enroll approximately 20 patients in this expansion cohort at the 5.4 mg/kg IV Q3W dose, a pharmacologically active dose identified during Part 1 of this trial where we have seen clinically meaningful anti-tumor activity with manageable safety. We anticipate having preliminary data in the second half of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">micvotabart pelidotin monotherapy for 2L and 3L R/M HNSCC patients who have received prior epidermal growth factor receptor (EGFR) directed therapy and prior PD-(L)1 inhibitor therapy. We expect to enroll approximately 20 patients in this expansion cohort also at the 5.4 mg/kg IV Q3W dose and anticipate having preliminary data in the first half of 2026.</span></div></div><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning to hold a discussion with the FDA to align on our approach for finding the optimal monotherapy dose, as required under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ject Optimus and expect the dose optimization phase to commence in 2026.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced a Clinical Trial Collaboration and Supply Agreement with Merck &amp; Co, Inc. or Merck (known as MSD outside of the US and Canada), for a Pyxis Oncology-sponsored study of micvotabart pelidotin in combination with Merck&#8217;s anti-PD-(L)1 therapy, KEYTRUDA&#174; (pembrolizumab).</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In early January 2025, we initiated the Phase 1/2 combination study with KEYTRUDA&#174; now called PYX-201-102 and are actively recruiting patients in this study. PYX-201-102 is a Phase 1/2 open label, global, multicenter dose escalation and dose expansion study to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluate the safety, tolerability, PK, PD and preliminary efficacy of micvotabart pelidotin in combination with pembrolizumab in patients with advanced solid tumors. Patients with histologically or cytologically confirmed advanced solid tumors, including 1L R/M HNSCC, 2L+ R/M HNSCC, cervical cancer, gastric cancer, HR+/HER2- breast cancer, sarcoma and locally advanced or metastatic TNBC, are eligible to enroll.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We initiated Part 1 dose escalation phase of PYX-201-102 covering multiple tumor types with an aim to identify the Recommended Phase 2 Dose (RP2D) of micvotabart pelidotin in combination with pembrolizumab. Currently, we are enrolling and dosing patients to clear the three doses that will be tested in combination with pembrolizumab. During Part 1 dose escalation, we anticipate testing a fixed dose of pembrolizumab in combination with 3 different doses of micvotabart pelidotin ranging from 3.6 mg/kg &#8211; 5.4 mg/kg IV Q3W. Pembrolizumab (standard dose at 200 mg IV) will be given with escalating doses of micvotabart pelidotin with a starting dose of 3.6 mg/kg IV every 3 weeks (Q3W). Upon clearance of the initial dose level of 3.6 mg/kg IV Q3W by the Dose Escalation and Steering Committee (DESC), and depending on observed safety data, we may escalate to 4.4 mg/kg IV Q3W of micvotabart pelidotin with 200 mg IV of pembrolizumab, with a potential of dosing at 5.4 mg/kg IV Q3W of micvotabart pelidotin with 200 mg IV of pembrolizumab. We aim to select a dose of micvotabart pelidotin in combination with pembrolizumab by mid-year 2025, which will guide our discussion with the FDA about potential RP2D for further combination study.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently to the Part 1 dose escalation and assuming each dose clears the escalation step, the Phase 1/2 combination study will evaluate micvotabart pelidotin and pembrolizumab in patients with 1L and 2L+ R/M HNSCC. We expect to enroll approximately 20 patients, which will be enrolled for each dose in their respective backfill cohort upon clearance of the dose by the DESC. Pembrolizumab (standard dose at 200 mg IV) will be given with escalating doses of micvotabart pelidotin with a starting dose of 3.6 mg/kg IV every 3 weeks, followed by dose of 4.4 mg/kg IV Q3W, if DESC clears it and then a dose of 5.4 mg/kg IV Q3W, if DESC clears it. We anticipate having preliminary data on at least a subset of these R/M HNSCC patients in the second half of 2025. Timing of data availability from the full recruitment and dosing of R/M HNSCC patients is dependent on the timing of activation of additional clinical trial sites and patient enrollment. Further guidance on anticipated timing of the full preliminary data readout will be provided in mid-year of 2025.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have focused substantially all of our resources on conducting research and development activities, undertaking preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital, establishing and maintaining our intellectual property portfolio and identifying potential product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. We have incurred significant operating losses since our inception. We reported net losses of $21.2 million and $3.3 million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $384.7 million, net equity of $103.1 million, and cash, cash equivalents and short-term investments of $105.4 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We expect that our expenses and capital expenditures will increase substantially in connection with our ongoing activities. Our operations to date have been financed primarily through sales of convertible preferred stock and sale of equity securities and additional funding may be necessary to fund future clinical and preclinical activities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Our Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenues from product sales and do not expect to generate any revenues from product sales in the foreseeable future. We record revenues from research and development agreements, including amounts related to upfront receipt for license fees, royalties, milestones and other contingent receipts and fees for research and development services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate product revenues will depend upon our ability to successfully develop, obtain regulatory approval and commercialize our product candidate. Due to the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict the amount, timing or whether we will be able to obtain product revenues.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of our cost of revenues are expenses directly attributable to revenues. During the three months ended March 31, 2025, the Company has not incurred any costs with respect to revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred for our research activities, including our discovery efforts and research work to support clinical development, and the development of our programs. Research and development expenses are separated into program-specific costs and unallocated costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Program-specific costs include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">direct third party costs, which include expenses incurred under agreements with contract research organizations (CROs), and the cost of consultants who assist with the development of our product candidate on a program-specific basis, investigator grants, sponsored research, and any other third party expenses directly attributable to the development of the product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with contract development and manufacturing organizations (CDMOs) to the extent they can be allocated to a specific program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">license fees and milestone payments related to the acquisition and retention of certain licensed technology and intellectual property rights for a specific product candidate; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with preclinical activities that are directly attributable to the development of the product candidate.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unallocated costs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses for research and development personnel, including salaries, bonus, payroll taxes, related benefits, severance and other staff-related expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock-based compensation expenses for employees engaged in research and development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities and other costs, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, laboratory supplies, third party cost for discovery research and the cost of consultants who assist with our research and development and costs related to contract manufacturing, but are not allocated to a specific program.</span></div></div><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our research and development expenses will increase substantially in connection with our ongoing and planned preclinical and clinical development activities in the near term and in the future. The successful development of our product candidate is highly uncertain. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidate and we may never succeed in obtaining regulatory approval for any of our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, and severance for our personnel in executive, legal, finance and accounting, human resources and other administrative functions. General and administrative expenses also include professional fees for auditing, tax, and legal services, as well as insurance, board of director compensation, consulting, other administrative expenses and facility costs not otherwise included in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net primarily consists of interest earned on our invested cash and cash equivalent balances, accretion of discounts associated with our marketable debt securities and sublease income under our sublease.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended March 31, 2025 and 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.42%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,146</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,146</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale of royalty rights</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,146</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,146</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Costs and operating expenses</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(475</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,044</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,015</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,247</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,377</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total costs and operating expenses</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,914</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,751</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,163</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,914</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,605</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17,309</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and investment income</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(309</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sublease income</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">515</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">799</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(284</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,756</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,349</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(593</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(21,158</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(3,256</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(17,902</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues for the quarter ended March 31, 2025, were $0, compared to $16.1 million for the quarter ended March 31, 2024. In March 2024, we entered into the settlement agreement with Novartis, pursuant to which we transferred our rights to future royalties on the net sales of Beovu&#174; to Novartis for a one-time amount of $8.0 million. Novartis also agreed to forgo its right to reclaim royalties previously paid of $8.1 million to us and Apexigen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Costs and Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended March 31, 2025 and 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.42%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Program-specific costs:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Micvotabart pelidotin</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,098</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,357</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,741</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PYX-106</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">936</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,989</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,053</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other program costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total program costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8,530</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,537</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Unallocated costs:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses including stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,861</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,182</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,679</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,653</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,310</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">343</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,044</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,015</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $4.0 million, from $13.0 million for the three months ended March 31, 2024 to $17.0 million for the three months ended March 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Micvotabart Pelidotin program-specific research and development costs increased by $2.7 million, primarily due to a $1.1 million increase in contract manufacturing costs due to the timing of manufacturing runs for micvotabart pelidotin, $0.8 million increase in clinical trial related expenses related to our dose expansion phase (Part 2) of the PYX-201-101 monotherapy study and trial set up costs related to combination study, PYX-201-102, and $0.4 million increase in preclinical and translation work to support clinical development work of micvotabart pelidotin .</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYX-106 program-specific research and development costs decreased by $1.0 million as we paused the clinical development of PYX-106-101 in December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unallocated research and development increased by $2.0 million from $6.5 million for the three months ended March 31, 2024 to $8.5 million for the three months ended March 31, 2025. This increase was primarily due to severance cost of $1 million due to the reduction in workforce announced in March 2025 and increase in stock based compensation by $0.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our general and administrative expenses for the three months ended March 31, 2025 and 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.42%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses including stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,561</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,561</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consultant fees</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities, insurance and other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,606</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8,247</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(2,377</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses decreased by $2.4 million, from $8.3 million for the three months ended March 31, 2024 to $5.9 million for the three months ended March 31, 2025. The decrease was primarily related to decrease in stock-based compensation by $1.2 million, decrease in professional and consultant fees and lower corporate insurance cost.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net for the three months ended March 31, 2025 and 2024 was $1.8 million and $2.3 million, respectively. The decrease was primarily due to a decrease in interest and investment income as compared to the previous quarter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had cash, cash equivalents and short-term investments of $105.4 million as of March 31, 2025. For the three months ended March 31, 2025 and 2024, we had net losses of $21.2 million and  $3.3 million, respectively. As of March 31, 2025, we had an accumulated deficit of $384.7 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2022, we filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units up to an aggregate of $250.0 million. On November 14, 2022, the registration statement was declared effective by the SEC. The registration statement includes an at-the-market, or ATM, offering program for the sale of up to $125.0 million of shares of our common stock. As of March 31, 2025, we had $106.2 million of remaining capacity available under the ATM facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance clinical trials for our product candidate in development. The timing and amount of our funding requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with monotherapy and combination therapy clinical trials for micvotabart pelidotin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manufacture of drug products and drug substance for micvotabart pelidotin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and progress of our other preclinical and clinical development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress of the development efforts of parties with whom we have entered, or may in the future enter into, in-licensing, collaborations and research and development agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing licensure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of maintaining, expanding and protecting our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of regulatory licenses; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insurance, legal and other regulatory compliance expenses to operate as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, we can generate substantial product revenues, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidate, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidate that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding our cash flows for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:21.299999999999997%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.78%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:21.299999999999997%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,535</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,710</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,821</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,498</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,511</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(6,714</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">18,303</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, net cash used in operating activities was $22.5 million, which consisted of our net loss of $21.2 million and a net change in our operating assets and liabilities of $4.6 million, partially offset by non-cash charges of $3.2 million. The non-cash charges of $3.2 million was primarily due to $3.6 million of stock-based compensation, $0.6 million of depreciation and amortization expenses, offset by $1.2 million related to accretion of discounts on marketable debt securities. The net change in our operating assets and liabilities was primarily due to decrease in accounts payable by $2.0 million, accrued expenses and other current liabilities by $1.3 million and reduction in prepaid expenses by $0.9 million primarily related to the timing of vendor payments and services performed related to our ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2024, net cash used in operating activities was $20.7 million, which consisted of our net loss of $3.3 million and a net change in our operating assets and liabilities of $21.8 million, partially offset by non-cash charges of $4.3 million. The non-cash charges of $4.3 million was primarily due to $4.3 million of stock-based compensation, $1.1 million of depreciation and amortization expense, offset by $1.3 million of accretion of discounts on marketable debt securities. The net change in our operating assets and liabilities was primarily due to an increase in accounts receivable of $8.0 million and a decrease in deferred revenues of $7.7 million related to the Settlement Agreement with Novartis, and reductions in prepaid expenses and other current assets and accounts payable driven primarily by the timing of payments and services performed related to our ongoing clinical trials.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, net cash provided by investing activities was $15.8 million, which consisted primarily of redemption of marketable debt securities of $67.2 million, partially offset by purchase of marketable debt securities of $51.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2024, net cash used in investing activities was $18.5 million, which consisted primarily of purchases of marketable debt securities of $92.8 million and purchases of property and equipment of $0.2 million, partially offset by redemption of marketable debt securities of $74.5 million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, there were no major financing activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2024, net cash provided by financing activities was $57.5 million, which consists primarily of net proceeds of $46.9 million from the Private Placement which closed in February 2024 and net proceeds of $10.6 million from our ATM program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Outlook</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, we had approximately $105.4 million in cash, cash equivalents and short-term investments. We believe that our cash, cash equivalents and short-term investments as of March 31, 2025, will be sufficient to fund our operations into the second half of 2026. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, we could utilize our available capital resources sooner than we expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating lease obligation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease an office and laboratory space in Boston, Massachusetts with lease payments that continue through December 31, 2032, and have scheduled rent increases each year of 3%. Additionally, we sublease 17,729 square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The remaining contractual fixed lease payments, net of sublease payments and tenant improvement allowance, over the term of the lease aggregate to $26.4 million. The operating lease obligation is discussed in Note 10. Leases to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into licensing and related agreements in the normal course of business. In accordance with these agreements, we are obligated to pay, among other items, future contingent payments, royalties, and sublicensing revenues in the future, as applicable. We have not included potential future payments due under these licensing and collaboration agreements in contractual obligations because the payment obligations under the agreements are contingent upon future events. Refer to Note 6. Licensing Agreements, to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we enter into contracts in the normal course of business with CDMOs, CROs, and other third parties for preclinical work and clinical development related work. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the contractual obligations above as the amount and timing of such payments are not known.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not have during the years presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our unaudited condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no significant changes to our critical accounting policies and estimates as compared to those described in &#8220;Note 2 &#8211; Summary of Significant Accounting Policies&#8221; to our audited financial statements set forth in our Fiscal 2024 10-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For information with respect to recently issued accounting standards and the impact of these standards on our consolidated financial statements, refer to Note 2. Summary of Significant Accounting Policies to our unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jumpstart Our Business Startups Act</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; to take advantage of an extended transition period to comply with new or revised accounting standards. We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenues were less than $100 million during the most recently completed fiscal year. We may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenues, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_quantitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company&#8221;, we are not required to provide the information required by this item in this report.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_controls"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls and Procedures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. L</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">egal Proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business. We are not currently a party to any material legal proceedings, and are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_rf"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Form 10-Q, including our financial statements and related notes appearing in this Form 10-Q. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your investment. This Form 10-Q also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage oncology company with a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses over at least the next several years and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage oncology company with a limited operating history. Since our inception, we have incurred significant operating losses. We reported net losses of  $21.2 million and $3.3 million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $384.7 million. To date, we have not generated any revenues from product sales and have financed our operations primarily through equity offerings. As such, we expect that it will be several years, if ever, before we have a product candidate ready for regulatory licensure and commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing licensure for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including, without limitation, procuring clinical- and commercial-scale manufacturing, successfully completing preclinical studies and clinical trials of our product candidate, establishing arrangements with third parties for the conduct of our clinical trials, obtaining marketing licensure for our product candidate, manufacturing, marketing and selling any products for which we may obtain marketing licensure, discovering or obtaining rights to additional product candidates, identifying collaborators to develop product candidates we identify or additional uses of existing product candidate and successfully completing development of product candidate for our collaboration partners.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop, conduct clinical trials and seek regulatory approvals for micvotabart pelidotin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scale up external manufacturing capabilities for later stage trials and to commercialize our products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand, maintain and protect our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ultimately establish a sales, marketing and distribution infrastructure for which we may obtain marketing licensure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, regulatory, scientific, operational, financial and management information personnel; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to operate as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other comparable regulatory authorities to perform trials in addition to those that we currently expect to perform, or if we experience any delays in establishing appropriate manufacturing arrangements for completing our clinical trials or the clinical development of our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause investors to lose all or part of their investment.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to generate revenues from the sale or out-licensing of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing and planned activities, particularly as we continue our clinical trials for micvotabart pelidotin. We currently expect that our existing cash, cash equivalents and short-term investments of $105.4 million as of March 31, 2025, will fund our projected operating expenses and capital requirements into the second half of 2026. Even if our product candidate is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other comparable regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our estimate as to how long we expect to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, including market volatility resulting from global economic developments, political unrest, high inflation and other factors, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use our cash and cash equivalents for development and regulatory activities relating to our product candidate, and other general corporate purposes. Advancing the development of our product candidate will require a significant amount of capital. Our cash and cash equivalents will not be sufficient to fund our product candidate through regulatory licensure. Because the length of time and activities associated with successful research and development of any individual product candidate are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing licensure and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost associated with dose escalation and dose expansion mono and combo clinical trials for our product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manufacture of drug products and drug substance for our product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and progress of our other preclinical and clinical development activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for our product candidate for which we receive marketing licensure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in prosecuting, maintaining, enforcing and expanding patent and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of regulatory licenses; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insurance, legal and other regulatory compliance expenses to operate as a public company.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We will be required to seek additional funding in the future and our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. For example, market volatility resulting from global economic developments, political unrest, high inflation and other factors could adversely impact our ability to access capital as and when needed. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development of our Product Candidate</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing and product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the clinical testing and the development and commercialization of our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidate, we or our collaborators must conduct extensive trials to demonstrate the safety and efficacy of the product candidate. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the timing and outcome. A failure of one or more clinical trials can occur at any stage of the process. We may experience numerous unforeseen events during, or as a result of, clinical trials, which could delay or prevent our ability to receive marketing licensure or commercialize our product candidate, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching, or the failure to reach, a consensus with regulators on clinical trial design;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidate or other materials necessary to conduct clinical trials of our product candidate may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidate to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching, or the failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of regulators or institutional review boards to authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well studied and for which the natural history and course of the disease is poorly understood; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the selection of certain clinical endpoints that may require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidate may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may fail during screening or drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or the failure to recruit suitable patients to participate in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidate may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may have to suspend or terminate clinical trials of our product candidate for various reasons, including a finding that the participants are being exposed to unacceptable safety risks or that the benefit-risk ratio is negative;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the third parties with whom we contract may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement from regulators or institutional review boards that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or unacceptable safety risks;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidate may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product candidate development and discovery programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidate may be greater than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with the class of our product candidate or after an inspection of our clinical trial operations, trial sites or manufacturing facilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements for approving our product candidate, or such requirements may not be as we anticipate; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so.</span></div></div><p style="text-indent:4.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may modify or enhance clinical trial requirements which may affect enrollment and retention of patients. In August 2023, the FDA published a guidance document, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Informed Consent, Guidance for Institutional Review Boards (IRBs), Clinical Investigators, and Sponsors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which supersedes past guidance and finalizes draft guidance on informed consent. FDA&#8217;s new guidance presents evolving requirements for informed consent which may affect recruitment and retention of patients in clinical trials. Effects on recruitment and retention of patients may hinder or delay a clinical trial, which may increase costs and delay clinical programs. Further, in December 2023, the FDA published a final rule, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Institutional Review Board Waiver or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alteration of Consent for Minimal Risk Clinical Investigations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which allows exceptions from informed consent requirements when a clinical investigation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of human subjects.</span></p><p style="text-indent:4.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidate beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidate or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing licensure for our product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing licensure at all; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain licensure for indications or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain licensure with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to perform additional clinical trials to support marketing licensure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have regulatory authorities withdraw or suspend their license, or impose restrictions on distribution of the product candidate in the form of a modified REMS;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements or changes in the way the product is administered; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fail to receive approval of any companion diagnostics that may be required by the FDA or comparable foreign regulatory authorities in connection with approval of our therapeutic product candidate; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have our product removed from the market after obtaining marketing licensure. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.715%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the FDA launched </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Project Optimus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative and as described in a 2023 draft guidance &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optimizing the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; the FDA will likely request sponsors of oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates to conduct dose optimization studies pre-approval. The FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.715%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing licensure. We do not know whether any of our preclinical studies or clinical trials will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidate, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidate, which may harm our business, results of operations, financial condition and prospects.</span></p><p style="text-indent:4.715%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.715%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, cancer therapies sometimes are characterized as first line, second line or third line. The FDA often approves or licenses new oncology therapies initially only for third line or later use, meaning for use after two or more other treatments have failed. When cancer is detected early enough, first line therapy, usually hormone therapy, surgery, radiation therapy, immunotherapy or a combination of these, is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sometimes adequate to cure the cancer or prolong life without a cure. Second line and third line therapies are administered to patients when prior therapy is not effective. Our clinical trials are, and any future clinical trials will be, with patients with difficult to treat cancer. We expect that we would initially seek regulatory licensure for use of this product candidate in appropriate treatment settings. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek licensure potentially as a first line therapy, but any product candidate we develop, even if approved for second line or third line therapy, may not be approved for first line therapy and, prior to seeking and/or receiving any licensures for first line therapy, we may have to conduct additional clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily dependent on the success of our product candidate, micvotabart pelidotin, which is in the early stages of clinical development. If micvotabart pelidotin is not successful in clinical trials or does not receive regulatory approval or licensure or is not successfully commercialized, our business will be materially and adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have invested a significant portion of our efforts and financial resources in the development of micvotabart pelidotin. Our future success is substantially dependent on our ability to successfully initiate and complete clinical development for, obtain regulatory licensure for, and successfully commercialize micvotabart pelidotin, which may never occur. We currently have no products that are approved or licensed for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to the clinical development, management of clinical and manufacturing activities, regulatory licensure, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts related to micvotabart pelidotin before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if micvotabart pelidotin receives regulatory licensure, such product will be able to successfully compete against therapies and technologies offered by other companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, testing, manufacturing, labeling, licensure, sale, packaging, marketing, and distribution of biological products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market micvotabart pelidotin in the U.S. until we receive licensure of a BLA or NDA from the FDA for such product candidate, as appropriate. Further, we are not permitted to market micvotabart pelidotin in any foreign countries until we receive the requisite licensure or approvals from such countries. We have not submitted a BLA or NDA to the FDA or comparable applications to any other comparable regulatory authorities for micvotabart pelidotin. We will not be in a position to do so for several years, if ever. If we are unable to obtain the necessary regulatory licensure or approvals for micvotabart pelidotin, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenues to continue our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate may fail in development or suffer delays that materially and adversely affect its commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidate or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to achieve and sustain profitability depends on obtaining regulatory licensure for and successfully commercializing our product candidate, either alone or with third parties. Before obtaining regulatory licensure for the commercial distribution of our product candidate, we or an existing or future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety, purity and potency in humans of our product candidate. We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory licensure of, or our ability to commercialize, a product candidate, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive results from preclinical studies or clinical trials leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product-related side effects experienced by participants in our clinical trials or by individuals using therapeutic biological products similar to our product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions imposed by the FDA, the EMA or other comparable authorities regarding the scope or design of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in enrolling patients in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">high drop-out rates of patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater than anticipated clinical trial costs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">poor effectiveness of our product candidate during clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable FDA or other comparable regulatory agency inspection and review of a clinical trial site; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our third party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">varying interpretations of data by the FDA, the EMA and other comparable foreign regulatory authorities; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">landscape changes around market access and pricing policies that may impact reimbursement and product sales.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the foregoing circumstances occur, we could experience significant delays or an inability to successfully commercialize our product candidate, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no experience as a company completing a clinical trial or submitting a BLA or NDA and may be unable to successfully do so for micvotabart pelidotin.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conduct of a clinical trial is a long, expensive, complicated and highly regulated process. Although certain of our employees have conducted successful clinical trials and made regulatory submissions in the past across many therapeutic areas while employed at other companies, we, as a company, have not completed any clinical trials, or submitted a BLA or NDA, and as a result may require more time and incur greater costs than we anticipate. Failure to commence or complete, or delays in, our clinical trials or planned regulatory submissions would prevent us from, or delay us in, obtaining regulatory approval of and commercializing micvotabart pelidotin, which would adversely impact our financial performance. Large-scale clinical trials would require significant additional financial and management resources and heavier reliance on third party clinical research organizations (CROs) and consultants. Relying on third party CROs and consultants may cause us to encounter delays or other operational issues that are outside of our control. Although our third parties are required to comply with good laboratory practice (GLP) and good clinical practice (GCP) for any studies or trials we plan to submit to a regulatory authority, and have historically complied, relying on third parties in the conduct of our preclinical studies or clinical trials exposes us to a risk that they may not adequately comply with GLP or GCP in the future We may be unable to identify and contract with sufficient investigators, CROs and consultants on terms that are acceptable to us on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to submit INDs to commence additional clinical trials on the timelines we expect and, even if we are able to, the FDA may not permit us to proceed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may submit additional INDs in the future. We may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing us to commence clinical trials or that, once begun, issues will not arise that lead to the suspension or termination of our clinical trials. Additionally, even if the applicable regulatory authorities agree with the design and implementation of the clinical trials set forth in our INDs, we cannot guarantee that those regulatory authorities will not change their requirements in the future, or that circumstances will not arise under which FDA or other regulatory authorities may place our clinical trials on partial or full clinical hold. These considerations apply to the INDs described above and also to new clinical trials we may submit as amendments to existing INDs or as part of new INDs in the future. Any failure to submit INDs on the timelines we expect or to obtain authorization to proceed with our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and potency of our product candidate, which would prevent or delay development, regulatory approval or licensure and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory licensure for the commercial sale of our product candidate we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidate is safe, pure, and potent, as required under a BLA. Preclinical and clinical testing is expensive and can take many years to complete and the outcome of these activities is inherently uncertain. Failure can occur at any time during the preclinical studies and clinical trial processes and, because our product candidate is in an early stage of development, there is a high risk of failure. In addition, any failures or adverse outcomes in preclinical or clinical testing seen by other developers of similar product candidates could materially impact the success of our program. We may never succeed in developing marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that the results of preclinical studies and early clinical trials of our product candidate may not be predictive of the results of later-stage clinical trials. Although our product candidate may demonstrate promising results in preclinical studies and early clinical trials, it may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and, therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, purity, and potency profile despite having progressed successfully through preclinical studies and/or initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety, purity and potency in large-scale pivotal clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency, insufficient durability of potency or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved or licensed for commercialization. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical studies or clinical trials we conduct may contradict, undermine or otherwise not replicate or advance the results of the research programs and preclinical studies that were completed prior to our in-licensing or acquisition of product candidates, which may materially and adversely affect our business, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our PYX-201-101 Phase 1 clinical trial is an open label study, where both the patient and investigator know whether the patient is receiving the investigational product candidate. Most typically, open label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open label clinical trials are aware when they are receiving treatment. In addition, open label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. For instance, the FDA may also not consider open label clinical trials to be adequate and well controlled trials sufficient to support BLA licensure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, purity, and potency necessary to obtain regulatory licensure to market our product candidate. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, purity, and potency of our product candidate, if we do not meet the clinical endpoints with statistical and clinically meaningful significance or if there are safety concerns associated with our product candidate, we may be prevented or delayed in obtaining marketing licensure for the product candidate. In some instances, there can be significant variability in safety, purity, and potency results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. If that were to occur, or if other developers of similar products were to find an unacceptable severity or prevalence of side effects with their candidates, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure of our product candidate for any or all targeted indications. Product-related side effects could also affect patient recruitment or the ability of enrolled patients to complete an ongoing trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our product candidate could cause undesirable side effects in clinical trials related to on-target toxicity. If an unacceptable safety profile is observed or if our product candidate has characteristics that are unexpected, we may need to abandon its development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes to the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. For example, in November 2024, we announced preliminary data from our Phase 1 clinical trial of micvotabart pelidotin. Preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or top-line data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data should be viewed with caution until the final data is available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failures or setbacks involving the FACT Platform or the APXiMAB Platform, including adverse events, could have a detrimental impact on our research pipeline and future success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business depends not only on our ability to successfully develop, obtain regulatory licensure for, and commercialize our product candidate, but to continue to generate new product candidates through our FACT Platform and APXiMAB Platform (the Platforms). Any failures or setbacks involving the Platforms, including adverse events, could have a detrimental impact on our research pipeline and future success. For example, we may uncover a previously unknown risk associated with the Platforms or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining regulatory approval, necessitate additional clinical testing or result in the failure to obtain regulatory licensure. If the Platforms or any of their respective components that are used in our product candidate are not safe, we would be required to abandon or redesign other product candidates we develop via the Platforms, which could have a material adverse effect on our business, financial condition, results of operations and prospects. If we cannot validate our technology platform by successfully commercializing product candidates, we may not be able to obtain product, licensing or collaboration revenue in future periods, which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are parties to and may in the future enter into additional agreements with third parties under which those parties have or will be granted a license to develop product candidates discovered using our APXiMAB Platform. If any such programs are not successful or if disputes arise related to such programs, we may not realize the full commercial benefits from such programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our APXiMAB Platform has enabled the discovery of several product candidates with potential utility in multiple therapeutic areas and has resulted in several programs that have been licensed to third parties, including larger global biopharmaceutical companies and mid-sized regional or China-focused companies. Such arrangements generally allow the licensing parties to control the amount and timing of resources that they dedicate to the development or potential commercialization of any product candidates they develop from the technology we have licensed to them, subject to any territorial or field of use restrictions in the license. Apexigen typically negotiated milestone payments and royalty fees from the licensees that will require various levels of success with their product candidate development program in order for us to generate revenue from them. Our ability to generate revenue from these licensing arrangements will depend on our counterparties&#8217; abilities to successfully develop and commercialize the product candidates they are developing. We cannot predict the success of any licensing program that we enter into or whether such program will lead to any meaningful milestone or royalty revenue to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects. Our spending on current and future research, product candidates and discovery programs for specific targets or indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market may not be receptive to micvotabart pelidotin because it is based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of this product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if regulatory licensure is obtained for our product candidate, we may not gain sufficient market acceptance among physicians, patients, healthcare payors and others in the medical community. Micvotabart pelidotin is based on the FACT Platform. Our future success depends on the successful development of this novel therapeutic approach. Additionally, the regulatory licensure process for a novel product candidate such as ours can be more expensive and take longer than for other, better-known or extensively-studied product candidates. No regulatory authority has granted licensure for any therapeutic using the FACT Platform. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development. Any development problems we experience in the future related to our program may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Advancing our products creates significant challenges for us, including educating medical personnel regarding the potential potency and safety benefits, as well as the challenges, of incorporating our product candidate, if approved, into treatment regimens and establishing the sales and marketing capabilities to gain market acceptance, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors may prevent us from commercializing our product candidate we may develop on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market acceptance of our product candidate will depend on, among other factors:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our receipt of any marketing and commercialization licensures; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any licensures and the countries in which licensures are obtained; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety, purity, and potency of our product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with our product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the limitations or warnings contained in any labeling approved by the FDA, or other comparable foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative convenience and ease of administration of our product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to accept any new methods of administration; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of our physician education programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of adequate government and third party payor reimbursement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing of our products, particularly as compared to alternative treatments; and </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of alternative effective treatments for the disease indications our product candidate is intended to treat and the relative risks, benefits and costs of those treatments. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts. Our product candidate, micvotabart pelidotin, is in the early stages of clinical development. The results of preclinical studies and early stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early stage clinical trials that are continuing may not be predictive of the results of the later stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed on in later stage clinical trials. In particular, the small number of patients in our Phase 1 clinical trial may make the result of this trial less predictive of the outcome of later clinical trials. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain marketing licensure of their products. Our clinical trials may not ultimately be successful or support further clinical development of micvotabart pelidotin. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators experience delays or difficulties in the enrollment of patients in our clinical trials, these clinical trials could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to continue clinical trials for our product candidate if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials, as required by the FDA or other comparable foreign regulatory authorities. Our ability to identify sites who will enroll eligible patients for clinical trials may turn out to be limited or we may be slower in enrolling these trials than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidate and, as a result, patients who would otherwise be eligible for our clinical trials may instead elect to enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment in clinical trials is also affected by other factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility criteria for the trial in question; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the competing clinical trials or approved therapies which present an attractive alternative to patients and their physicians; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the burden on patients due to the scope and invasiveness of required procedures under clinical trial protocols, some of which may be inconvenient and/or uncomfortable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that a high number of patients fail during screening or enrolled patients will drop out or die before completion of the trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients failing to complete a clinical trial or returning for post-treatment follow-up; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture the requisite materials for a patient and clinical trial. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our or our collaborators inability to timely enroll a sufficient number of patients for our clinical trials, based on the above factors or others, could result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidate, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt its clinical development, delay or prevent its regulatory licensure, limit its commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by our product candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory licensure or approval by the FDA or other regulatory authorities. As is the case with oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny licensure or approval of our product candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidate may only be uncovered with a significantly larger number of patients exposed to the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that our product candidate receives regulatory licensure or approval and we or others later identify undesirable side effects, any of the following adverse events could occur, which could result in significant negative consequences:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their licensure or approval of the product or seize the product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall the product or change the way the product is administered to patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings and may be associated with payments from collaborators. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones may vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our revenue may be lower than expected, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face significant competition from other oncology-focused biotechnology and pharmaceutical entities, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of therapeutic biological products is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidate. Competitive therapeutic treatments include those that have already been approved or licensed and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly evolving technologies, intense competition and strong defense of intellectual property and proprietary technologies. Any product candidate that we successfully commercialize may be competitive with currently marketed therapies and any new therapies commercialized in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several companies that are developing cancer immunotherapies and ADCs. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent and the patient pool available for participation in clinical trials which could negatively impact our ability to execute our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will partially depend on our ability to develop and protect therapeutics that are more safe, pure, and potent than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidate is licensed, it will compete with a range of therapeutic treatments that are either in development or currently marketed. Many companies are active across various stages of development in the oncology subsector and are marketing and developing products that employ similar ADC and immunotherapy approaches. As of February 2025, there were approximately 650 ADCs in clinical or preclinical development worldwide, of which the vast majority are being developed for the treatment of various cancer indications. Additionally, there are several large and small companies working on various immunotherapy approaches for treatment of cancer. Multiple companies are also involved in the development of ADC therapeutics and immunotherapies, including, but not limited to, AbbVie Inc., Abcure, Inc., ADC Therapeutics SA, Alligator Bioscience AB, Astellas Pharma, Inc., AstraZeneca plc, Celldex Therapeutics, Inc., Daiichi Sankyo Company, Ltd., Eucure Biopharma, a subsidiary of Biocytogen, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, plc, Lyvgen Biopharma, Nextcure, Inc., Pfizer, Philogen S.p.A., Merck Sharpe Dohme (MSD) and Rakuten Medical, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face competition on specific targets, including the target of our micvotabart pelidotin candidate, EDB+FN, from Philogen S.p.A. as well as other emerging agents in key indications of interest including R/M HNSCC. Merus&#8217;s EGFR and LGR5 targeting biclonic, petosemtamab, and Bicara&#8217;s EGFR/TGF-beta targeting bifunctional, ficerafusp alfa (BCA101), are notable competitors that are targeting patient populations of interest to micvotabart pelidotin and pose a potentially significant threat to our clinical development strategy.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other competitors may also include agents targeting specific segments such as HPV+ HNSCC, namely Hookipa&#8217;s and PDS Biotech&#8217;s vaccines and agents such as Nanobiotix&#8217;s radioenhancer that may be used earlier in the treatment sequence. Furthermore, there are also some ADCs such as Sacituzumab govitecan, Gilead&#8217;s TROP-2 ADC and Pfizer&#8217;s Nectin-4 targeting ADC, enfortamab vedotin that are in clinical development in HNSCC and have shown preliminary clinical efficacy in early stage trials. Additional competitive dynamic changes may be observed with clinical development updates in the other lines of HNSCC treatment, including the recent positive data from pembrolizumab in the Keynote-689 trial suggests a potential upcoming paradigm shift in treating perioperative patients. The potential implementation of using IO in the earlier disease settings could impact patient segmentation and treatment choices in the R/M setting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have significantly greater scientific, research and development capabilities, as well as greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. Competitive products may make any products we develop obsolete owing to treatment paradigm shifts or noncompetitive, reducing the addressable market before we recover the expense of developing and commercializing our product candidate. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our ability to successfully compete will depend on, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop and protect therapeutics that are more effective and safer than competing products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to innovate with rapidly evolving technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and scope of regulatory licenses for these products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the price of our product candidate and whether coverage and adequate levels of reimbursement are available under health insurance plans; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to utilize any abbreviated licensure pathways; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time we are granted market exclusivity for any product candidate we may develop that is licensed as a biological product under a Biologics License Application (BLA).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such failure could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to be exposed to significant product liability risks inherent in the development, testing and manufacturing of our product candidate and products, if approved. Product liability claims could delay or prevent completion of product candidate development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our third party manufacturer&#8217;s processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidate may be used or suspension or withdrawal of licenses. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. In addition, we may be subject to liability based on the actions of our existing or future collaborators in connection with their development of products using the FACT Platform or the APXiMAB Platform. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Licensure or Approval and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory licensure and approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are unable to obtain marketing licensure or approval for our product candidate, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval or licensure by the FDA and other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval and licensure policies, regulations or the type and amount of clinical data necessary to gain approval or licensure may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval or licensure for any product candidate, and it is possible that our existing product candidate, or any product candidates we may seek to develop in the future, will never obtain marketing approval or licensure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate could fail to receive marketing licensure in the U.S. for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may disagree with the design or implementation of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA that the product candidate is safe, pure, and potent; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials may not meet the level of statistical significance required by the FDA for licensure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data collected from clinical trials of our product candidate may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain marketing licensure in the U.S.; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the licensure policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for licensure. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This lengthy licensure process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory licensure to market our product candidate, which would significantly harm our business, results of operations, financial condition and prospects. The FDA has substantial discretion in the licensure process and determining when or whether regulatory licensure will be obtained for our product candidate. Even if we believe the preliminary data collected from clinical trials of our product candidate is promising, such data may not be sufficient to support licensure by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we were to obtain licensure, regulatory authorities may approve our product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant a license contingent on the performance of costly post-marketing clinical trials, or may approve or license a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive regulatory licensure of our product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidate is licensed or approved by regulatory authorities, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, track and trace, serialization, post-market adverse event reporting, and submission of safety, purity, potency, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and foreign regulatory authorities will continue to monitor closely the safety profile of any product even after approval. If the FDA or foreign regulatory authorities become aware of new safety information after approval of a product candidate, they may require labeling changes or establishment of a Risk Evaluation and Mitigation Strategies (REMS), if not already established in pre-approval, or similar strategy, impose significant restrictions on its indicated uses or marketing, or impose ongoing requirements for potentially costly postapproval studies or post-market surveillance.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.542%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.185%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and comparable foreign regulatory authorities may conduct periodic inspections for compliance with regulatory requirements and standards. Later discovery of previously unknown problems with our product candidate, may result in consequences including, among other things:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions and warnings on the labeling of a product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to relationships with any potential collaborators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable press coverage and damage to our reputation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA and comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of licenses; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidate; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and any collaborators, must comply with requirements concerning advertising and promotion for our product candidate for which we or they obtain marketing licensure. Promotional communications with respect to prescription biological products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we, and any collaborators, will not be able to promote any products we develop for indications or uses for which the biological product is not licensed. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we decide to seek additional Breakthrough Therapy Designation and/or Fast Track Designation by the FDA, even if granted for any of our product candidate, may not lead to a faster development or regulatory review or licensure process and it does not increase the likelihood that our product candidate will receive marketing licensure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.559%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional Breakthrough Therapy Designation and/or Fast Track Designation for our product candidate. For example, in February 2025, the FDA granted Fast Track Designation for use of micvotabart pelidotin in the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. The FDA may withdraw the Fast Track Designation if the clinical development program no longer meets the criteria for Fast Track Designation. There is no assurance that the FDA will grant these designations to any of our current or future product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the drug or biological products may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, increased interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as Breakthrough Therapies by the FDA may also be eligible for other expedited approval programs, including Accelerated Approval and Priority Review, if they meet regulatory requirements for those other programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing applications submitted by sponsors of products in Fast Track development may qualify for Priority Review under the policies and procedures offered by the FDA, but the Fast Track Designation does not assure any such qualification. The FDA may withdraw any Fast Track Designation at any time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In any event, the receipt of a Breakthrough Therapy Designation and/or Fast Track Designation for a product candidate may not result in a faster development process, review or licensure compared to standard review and do not assure ultimate licensure by the FDA. In addition, even if our product candidate qualifies as a Breakthrough Therapy, the FDA may later decide that the product no longer meets the conditions for qualification. Additionally, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may withdraw any Fast Track Designation at any time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we decide to seek Orphan Drug Designation for any of our current or future product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Orphan Drug Designation for one or more of our current or future product candidates. For example, in May 2023, the FDA granted Orphan Drug Designation for micvotabart pelidotin in pancreatic cancer. Also, the FDA granted Orphan Drug Designation for PYX-107 in the treatment of soft tissue carcinoma, esophageal and GEJ cancers. Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S. when there is no reasonable expectation that the cost of developing and making available the drug in the U.S. will be recovered from sales in the U.S. for that drug or biological product. In the U.S., Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants Orphan Drug Designation, the identity of the drug or biological product and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and licensure process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has Orphan Drug Designation subsequently receives the first FDA approval or licensure for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug or biological product for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. As a result, even if our product candidate receives orphan exclusivity, the FDA can still approve or license other drugs or biological products that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Orphan Drug Designation for our product candidate in additional orphan indications in which there is a medically plausible basis for the use of this product candidate. Even if we obtain Orphan Drug Designation, exclusive marketing rights in the U.S. may be limited if we seek licensure for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek Orphan Drug Designation for other product candidates, we may never receive these designations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Congress is also considering updates to the orphan drug provisions of the Federal Food, Drug, and Cosmetic Act (FDCA) in response to a 2021 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerated approval by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidate will receive marketing licensure. If not granted, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate. Even if we receive accelerated approval, if our confirmatory post-marketing trial does not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to seek accelerated approval of micvotabart pelidotin and may seek approval of future product candidates through the FDA&#8217;s Accelerated Approval Program. For any licensure to market a biological product, we must provide the FDA and comparable foreign regulatory authorities with clinical data that adequately demonstrate the safety, purity, and potency of the product for the indication applied for in the NDA or BLA or other respective regulatory filings. The Accelerated Approval Program is one of several approaches used by the FDA to make prescription drugs or biological products more rapidly available for the treatment of serious or life-threatening diseases. Section 506(c) of the FDCA provides that the FDA may grant accelerated approval to &#8220;a product for a serious or life-threatening condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.&#8221; Licensure through the Accelerated Approval Program is subject, however, to the requirement that a sponsor perform adequate and well controlled post-marketing clinical trials to verify and describe the drug&#8217;s clinical benefit, where there is uncertainty as to the relationship of the surrogate endpoint to the clinical benefit, or of the observed clinical endpoint to ultimate outcome. Typically, clinical benefit is verified when post-marketing clinical trials show that the biological products provide a clinically meaningful positive therapeutic effect, that is, an effect on how a patient feels, functions, or survives. If required, these confirmatory trials must be underway prior to accelerated approval, pursuant to the Food and Drug Omnibus Reform Act of 2022 (FDORA) enacted in 2022 and under FDA&#8217;s draft guidance on &#8220;Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway&#8221; made available in January 2025. If such confirmatory post-marketing trials fail to confirm the product&#8217;s clinical profile or risks and benefits, the FDA may withdraw accelerated approval of the product.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has broad discretion with regard to licensure through the Accelerated Approval Program and even if we believe that the Accelerated Approval Program is appropriate for one of our products, we cannot assure you that the FDA will ultimately agree. The FDA may also change its policies with respect over accelerated approval over time. For example, in March 2023, the FDA announced the availability of draft guidance on &#8220;Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics,&#8221; in which the Agency outlined, and invited public comment on, its &#8220;preferred approach&#8221; of randomized controlled trials, including those that provide for longer term follow-up that could fulfill a post-marketing requirement to verify clinical benefit. The draft guidance, while not finalized, included statements where the FDA acknowledged that historically, single-arm trial designs and response endpoints have most commonly been used in oncology, but noted that such trials have limitations. Furthermore, even if we do obtain licensure through the Accelerated Approval Program, we may not experience a faster development process, review, or licensure compared to conventional FDA procedures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the FDA reviews a BLA seeking accelerated approval, there can be no assurance that licensure will be granted on a timely basis, or at all. The FDA may disagree that the design of, or results from, our studies support accelerated approval. Additionally, the FDA could require us to conduct further studies or trials prior to granting licensure of any type, including by determining that licensure through the Accelerated Approval Program is not appropriate and that our clinical trials may not be used to support licensure through the conventional pathway. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or licensure might not be granted because our submission is deemed incomplete by the FDA. There also can be no assurance that after subsequent FDA feedback we will continue to pursue licensure through the Accelerated Approval Program. A failure to obtain licensure through the Accelerated Approval Program could result in a longer time period to obtain licensure of our products, could increase the cost of our products&#8217; development, could delay our ability to commercialize our products and could significantly harm our financial position and competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive licensure for one of our products through the Accelerated Approval Program, we will be subject to rigorous post-marketing requirements, including the completion of one or more confirmatory post-marketing trials as the FDA may require, to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. These requirements could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or licensure process. Further, receiving accelerated approval does not provide assurance of ultimate full FDA licensure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required confirmatory post-marketing trial with due diligence, our confirmatory post-marketing trial does not confirm the predicted clinical benefit, other evidence shows that the product is not safe, pure, or potent under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading. Further description of the expedited withdrawal process was released by the FDA in the recent draft guidance "Expedited Program for Serious Conditions &#8211; Accelerated Approval of Drugs and Biologics" made available in December 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, Congress is considering potential changes to the Accelerated Approval Program that could impact our ability to obtain accelerated approval, or increase the burdens associated with post-marketing requirements in the event we do obtain accelerated approval. In particular, the FDA must specify certain conditions for required postapproval studies for products that receive accelerated approval, which may include enrollment targets and milestones, including the target date for study completion, by the time the drug is approved. The FDA may also require postapproval studies to be underway at the time of accelerated approval or within a specified time period following accelerated approval for such drugs, and must explain any instances where it does not require such studies. FDA&#8217;s January 2025 draft guidance on "Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway", while not finalized, suggests that FDA generally intends to consider a confirmatory trial to be "underway" prior to accelerated approval if (1) the trial has a target completion date that is consistent with diligent and timely conduct of the trial, considering the nature of the trial&#8217;s design and objectives, (2) the sponsor&#8217;s progress and plans for postapproval conduct of the trial provide sufficient assurance to expect timely completion of the trial, and (3) enrollment of the confirmatory trial has been initiated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay in obtaining, or inability to obtain, licensure through the Accelerated Approval Program, or any issues in maintaining approval granted under the Accelerated Approval Program, would delay or prevent commercialization of our products, and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If foreign regulatory authorities approve biosimilar versions of our product candidate that receive marketing approval, or such authorities do not grant our product candidate appropriate periods of data or market exclusivity before approving generic versions of our product candidate, the sales of our product candidate could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU and the UK, innovative medicinal products are authorized based on a full marketing authorization application and conditional authorization (as opposed to an application for marketing authorization that relies on data in the marketing authorization dossier for another, previously approved medicinal product). Applications for marketing authorization for innovative medicinal products must contain, inter alia, the results of pharmaceutical tests, preclinical tests and clinical trials conducted with the medicinal product for which marketing authorization is sought.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A marketing authorization can be obtained via the centralized procedure or the national procedure. The centralized procedure results in a single marketing authorization, issued by the European Commission (based on the opinion of the EMA), which is valid across the entire European Economic Area (EEA) which comprises the EU, Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are (i) derived from biotechnology processes, such as genetic engineering; (ii) contain a new active substance indicated for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases; (iii) designated orphan medicines; and (iv) advanced-therapy medicines, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. The centralized procedure would be mandatory for the product candidate we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an applicant for a marketing authorization submits a full dossier containing its own pharmaceutical, preclinical tests and clinical trials data, and where the application does not fall within the &#8216;global marketing authorization&#8217; of an existing medicinal product, reference product candidates may receive eight years of data exclusivity and an additional two years of market exclusivity, upon grant of the marketing authorization. If granted, during the data exclusivity period, applicants for approval of biosimilars cannot rely on data contained in the marketing authorization dossier submitted for the already authorized, or reference product candidate, to support their application. The market exclusivity period prevents a successful biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial marketing authorization of the reference product in the EU, but a biosimilar marketing authorization application can be submitted during this time. The overall 10-year market exclusivity period can further be extended by one more year if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, even if a compound is considered to be a new active substance and the innovator is able to gain the period of data and market exclusivity, provided that no other intellectual property or regulatory exclusivities apply, another unrelated company could also apply for a marketing authorization and market another competing medicinal product for the same therapeutic indication if such company obtained its own marketing authorization based on a separate marketing authorization application based on a full self-standing scientific data package supporting the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical testing or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological products. There are currently no such guidelines for complex biological products such as gene or cell therapy medicinal products, and so in the short term it is unlikely that biosimilars of those products will be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the criteria for designating an &#8220;orphan medicinal product&#8221; are similar in principle to those in the U.S. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. The application for Orphan Drug Designation must be submitted before the marketing authorization application. Orphan Drug Designations entitle a party to financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to 10 years of market exclusivity. During the 10-year market exclusivity period, the EMA cannot accept another marketing authorization application, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar medicinal product. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="text-indent:4.777%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.481%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.777%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.481%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for Orphan Drug Designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. At any time, a marketing authorization may be granted to a similar product for the same indication if:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product has given his consent to the second applicant; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the UK has left the EU, its regulatory legal framework provides for similar periods of protection (namely regulatory data exclusivity, marketing protection and market exclusivity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition that our product candidate may face from biosimilar versions of our product candidate could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in the product candidate. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in this product candidate may be substantially limited if our product candidate, if and when approved, are not afforded the appropriate period of non-patent exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidate outside the U.S. and the sales of our product candidate could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market and sell our product candidate in other jurisdictions, we must obtain separate marketing approvals for those jurisdictions and comply with their numerous and varying regulatory requirements. We may not obtain foreign regulatory approvals on a timely basis, or at all. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the U.S., product reimbursement approvals must be secured before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidate in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country. Our failure to obtain approval of our product candidate by foreign regulatory authorities may negatively impact the commercial prospects of such product candidate and our business prospects could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to obtain required regulatory clearances or approvals for any companion diagnostic tests that we may pursue may prevent or delay approval of our product candidate. Moreover, the commercial success of a product candidate that requires a companion diagnostic will be tied to the receipt of any required regulatory clearances or approvals and the continued availability of such tests.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to identify patient subsets within a disease category that may derive selective and meaningful benefit from the product candidate we are developing. Through collaborations or license agreements, companion diagnostics may help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidate, if approved. In connection with the clinical development of our product candidate for certain indications, we may work with collaborators to develop or obtain access to companion diagnostic tests to identify appropriate patients for our product candidate. We may rely on third parties for the development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. The FDA and foreign regulatory authorities regulate companion diagnostics as medical devices that will likely be subject to clinical trials in conjunction with the clinical trials for product candidates, and which will require separate regulatory clearance or approval prior to commercialization. This process could include additional meetings with health authorities, such as a pre-submission meeting and the requirement to submit an investigational device exemption (IDE). In the case of a companion diagnostic that is designated as &#8220;significant risk device,&#8221; approval of an IDE by the FDA and an IRB is required before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate. We or our third party collaborators may fail to obtain the required regulatory clearances or approvals, which could prevent or delay approval of our product candidate. In addition, the commercial success of our product candidate that requires a companion diagnostic will be tied to and dependent upon the receipt of required regulatory clearances or approvals and the continued ability of such third parties to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our relationships with customers, physicians and third party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians and third party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing licensure. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers, drug wholesalers/distributors, pharmacy benefit managers, and third party payors subject us to various federal and state fraud and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, develop, sell, market and distribute our product candidate, if we obtain marketing licensure. In particular, the research of our product candidate, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties; damages; fines; disgorgement; imprisonment; exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid; additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws; contractual damages; reputational harm; and/or the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we commercialize our product candidate, it or any other product candidates that we develop, may become subject to unfavorable pricing regulations or third party coverage or reimbursement practices, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory licensure. Our ability to successfully commercialize our product candidate will depend, in part, on the extent to which coverage and adequate reimbursement for any products for which we obtain marketing authorization will be available from third party payors, including government health care programs, managed care providers, private health insurers, health maintenance organizations and other organizations. In the U.S., no uniform policy for coverage and reimbursement for pharmaceutical products exists among third party payors. Third party payors decide which medications they will pay for and establish reimbursement levels; therefore, coverage and reimbursement for our product candidate for which we may obtain marketing authorization could differ significantly from payor to payor. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Payors consider a number of factors when determining whether to cover a new product, including, for example, whether the product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Third party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication if they are granted Accelerated Approval. Failure to obtain or maintain coverage and adequate reimbursement for our product candidate, if approved, could limit our ability to market the products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Limitation on coverage and reimbursement may impact the demand for, or the price of, and our ability to successfully commercialize any product candidate that we develop. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, increasing efforts by third party payors in the U.S. and abroad to cap or reduce healthcare costs may cause payor organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidate. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable marketing authorizations or approvals. Additionally, we may also need to provide permissible discounts to purchasers, private health plans or government healthcare programs. Our product candidate may nonetheless not be considered medically necessary or cost-effective. If third party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after marketing authorization or approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third party payors in connection with the potential sale of our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations that govern marketing approvals, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. In some countries, the pricing for a drug must be approved before the drug may be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. There can be no assurance that any country will allow reimbursement and pricing arrangements for our product candidate that are sufficient to recoup our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing licensure or approval of and commercialize our product candidate and may affect the prices we may set.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect results of our future operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Inflation Reduction Act (IRA), which was signed into law on August 16, 2022, allows Medicare to: beginning in 2026, establish a &#8220;maximum fair price&#8221; for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services (CMS); and, beginning in 2023, penalize drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companies that raise prices for products covered under Medicare Parts B and D faster than inflation, among other reforms. It is unclear how future regulatory actions to implement the IRA, as well as the outcome of pending litigation against the IRA, may affect our products and future profitability. See Part I, Item 1, Government Regulation &#8211; Healthcare and Data Privacy Regulation &#8211; Healthcare Reform of Annual Report on Form 10-K (Fiscal 2024 10-K) for additional detail on recent healthcare reform efforts that could affect our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that federal and state governments will pay for healthcare items and services. This could result in reduced demand for any product candidate we develop or could result in additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the U.S., reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the U.S. can have a significant impact on the profitability of a given market, and further uncertainty is introduced if and when these laws change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the U.S. or any other jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we, or these third parties, are not able to maintain regulatory compliance, our product candidate may lose any regulatory licensure or approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, agency leadership, and resulting regulatory updates and changes in policy priorities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act (APA) &#8220;must exercise their independent judgment&#8221; and &#8220;may not defer to an agency interpretation of the law simply because a statute is ambiguous.&#8221; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by the Department of Health and Human Services (HHS), CMS, FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation and judicial scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, federal agency priorities, leadership, policies, rulemaking, communications, spending, and staffing may be significantly impacted by election cycles, including, for example, the current presidential administration&#8217;s commitment to significantly reduce government spending through cuts to federal healthcare programs and reductions in the workforces of key government agencies, such as HHS, FDA and CMS. Efforts by the current administration to limit federal agency budgets or personnel may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidate or obtain regulatory approval for our product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these changes, or a combination of such changes may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, operations, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share, or collectively, process, personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third party data, business plans, transactions, clinical trial data and financial information or collectively, sensitive data. Any failure or perceived failure by us to comply with federal, state or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). Most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 (HIPPA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH). We are not currently acting as a covered entity (health plans, health care clearinghouses and certain health care providers) or business associate (individuals or entities that create, receive, maintain or transmit individually identifiable health information in connection with providing a service for or on behalf of a covered entity, as well as their covered subcontractors) under HIPAA and therefore are not directly regulated under HIPAA. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has disclosed individually identifiable health information in a manner that is not authorized or permitted under HIPAA. In addition, in the future, we may maintain sensitive personal information, including health-related information, that we receive throughout the clinical trial process, in the course of our research collaborations and/or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement these types of programs. As a result, we may be subject to data privacy and security laws protection such information, including state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past few years, numerous U.S. states have enacted health-specific or comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. For example, Washington&#8217;s My Health My Data Act regulates consumer health data, which includes personal information identifies a consumer&#8217;s past, present, or future physical or mental health. However, the My Health My Data Act provides exemptions for personal data used or shared in research, including data subject to 45 C.F.R. Parts 46, 50, and 56. Another example, the California Consumer Privacy Act of 2018 (CCPA), as amended by the California Privacy Rights Act of 2020 (CPRA), collectively CCPA, creates individual data privacy rights for consumers and operational requirements for companies, including placing increased privacy and security obligations on entities handling certain personal information of consumers or households; imposes additional data protection obligations on covered businesses, including additional consumer rights processes; limitations on data uses; new audit requirements for higher risk data; and opt outs for certain uses of sensitive data. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, private right of action for data breaches, and created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement and litigation. Similar laws have been adopted or proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. While these laws generally include exemptions for health-related data such as clinical trial data, they add layers of complexity to compliance in the U.S. market and could increase our compliance costs and adversely affect our business. In the event we are subject to or affected by HIPAA, the CCPA, or other privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the FTC and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information and in particular health information. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5 of the FTC Act. The FTC has also been active with respect to enforcement of its Health Breach Notification Rule and in scrutinizing the use and disclosure of sensitive personal information. The FTC finalized changes to the Health Breach Notification Rule in April 2024. Additionally, the FTC published an advance notice of proposed rulemaking in 2022 on commercial surveillance and data security, and may implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (1) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive in the coming years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union General Data Protection Regulation (EU GDPR) and the United Kingdom&#8217;s GDPR (UK GDPR), collectively GDPR, impose strict requirements for the processing of personal data. The GDPR imposes a number of compliance obligations including accountability and transparency requirements, requirements to process personal data lawfully, obligations to consider data protection as any new products or services are developed and designed, obligations to implement appropriate technical and organizational security measures to safeguard personal data and to report certain personal data breaches, obligations to comply with data protection rights of data subjects and additional requirements around the processing of special categories of personal data, including health and genetic data. The GDPR have restrictions on transfers of personal data from their jurisdiction to other jurisdictions. Companies may be subject to robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million (under the EU GDPR) or &#163;17.5 million (under the UK GDPR) or up to 4% of the annual global turnover of the preceding year for the noncompliant company, whichever is greater.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our third party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We cannot eliminate the risk of contamination or injury from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and/or liabilities under applicable laws and regulations. We generally contract with third parties for the disposal of these materials and wastes and cannot eliminate the risk of accidental contamination or injury. Upon an event of this nature, we may be held liable for any resulting damages and such liability could exceed our resources and federal, state or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Environmental laws and regulations are complex, change frequently and have tended to become more stringent and we may incur substantial costs to comply. Current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, anti-corruption laws and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to various federal, state, and foreign government export and import laws and regulations, anti-bribery and anti-money laundering laws in the U.S. and countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We may also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of these activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical and medical device industries are subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.</span></p><p style="text-indent:4.548%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act (APA) &#8220;must exercise their independent judgment&#8221; and &#8220;may not defer to an agency interpretation of the law simply because a statute is ambiguous.&#8221; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by HHS, CMS, FDA and other agencies with significant oversight of the biopharmaceutical and medical device industries. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation and judicial scrutiny.</span></p><p style="text-indent:4.548%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, federal agency priorities, leadership, policies, rulemaking, communications, spending, and staffing may be significantly impacted by election cycles. For example, the current presidential administration&#8217;s commitment to significantly reduce government spending through cuts to federal healthcare programs and reductions in the workforces of key government agencies, such as HHS, FDA, and CMS. Efforts by the current administration to limit federal agency budgets or personnel may result in reductions to agency budgets, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidate or obtain regulatory approval for our product candidate.</span></p><p style="text-indent:4.548%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to attract and retain qualified senior management and key scientific and medical personnel, our business may be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon members of our senior management, including Lara Sullivan, M.D., our President, Chief Executive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officer and Chief Medical Officer, and Pamela Connealy, our Chief Financial Officer and Chief Operating Officer, as well as our senior scientists, senior medical personnel and other members of our senior management team. The loss of one or more of our executive officers, senior scientists, senior medical personnel and other members of our senior management team could delay or prevent the successful development of our product pipeline, the initiation and completion of our clinical trials or the commercialization of our product candidate or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees, consultants and collaborators may engage in misconduct or other improper activities, including insider trading and non-compliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, consultants, distributors, and collaborators may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates the regulations of the FDA, U.S. regulators and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of conduct applicable to all of our employees, officers, directors, including consultants, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no marketing, sales, or distribution infrastructure and both establishing this infrastructure or outsourcing this function to a third party carries substantial risks to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no marketing, sales, or distribution capabilities because our product candidate is still in clinical development. If our product candidate completes clinical development and is approved, we intend to either establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidate in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborators&#8217; business strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of any of our existing or future CROs, manufacturers, other contractors, consultants, or collaborators, may be compromised, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we collect, process, and store proprietary, confidential, and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our information technology systems and infrastructure, and those of our current and any future CROs, manufacturers, other contractors, consultants, existing or future collaborators and other third party service providers are vulnerable to damage from various methods, including cybersecurity attacks, breaches, errors, malfeasance, or other technological failures, which can include, among other things, computer viruses, unauthorized access attempts, including third parties gaining access to systems using stolen or inferred credentials, ransomware attacks, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Furthermore, because the techniques used to obtain unauthorized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security breaches, there can be no assurance that our security measures or those of our service providers, partners and other third parties, will be effective in protecting against all security breaches and material adverse effects on our business that may arise from such breaches. The recovery systems, security protocols, network protection mechanisms and other security measures that we (and our third parties) have integrated into our platform, systems, networks and physical facilities, which are designed to protect against, detect and minimize security breaches, may not be adequate to prevent or detect service interruption, system failure or data loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development program and our business operations including without limitation, disruptions of our drug development programs, delays in our regulatory approval efforts, regulatory investigations or enforcement actions, litigation, indemnity obligations, negative publicity, and financial loss and significant liabilities. In addition, system failures could cause the loss, theft, exposure, or unauthorized access or use of valuable clinical trial data as a result of accidents, errors or malfeasance by our employees, independent contractors or others working with us or on our behalf or otherwise disrupt our clinical activities and be expensive and time-consuming to remedy. Some of the federal, state and foreign government legal requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed, ongoing or future clinical trials involving our product candidate could result in delays in our regulatory licensure efforts and significantly increase our costs to recover or reproduce the lost data. Any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in various stages of development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We may be required to expend resources; modify our business activities and practices; or modify our operations, including our development program activities; or information technology in an effort to comply with applicable data protection laws, privacy policies and data protection obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidate could be delayed and we could be subject to significant fines or penalties for any noncompliance with certain state, federal or international privacy and security laws.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach, may not cover all claims made against us and could have high deductibles. Defending a suit, regardless of its merit, could be costly and divert management attention. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek regulatory approval or licensure of our product candidate outside of the United States. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals or licenses, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing trade, manufacturing, development and investment in the countries where we currently conduct our business could adversely affect our business, reputation, financial condition and results of operations. Changes or proposed changes in U.S. or other countries&#8217; trade policies may result in restrictions and economic disincentives on international trade. The U.S. government has recently imposed, or is currently considering imposing, tariffs on certain trade partners, including China. Tariffs, economic sanctions and other changes in U.S. trade policy have in the past and could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the future trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing retaliatory measures on certain U.S. goods. Further, any emerging protectionist or nationalist trends (whether regulatory- or consumer-driven) either in the United States or in other countries could affect the trade environment. Our business, like many other corporations, would be impacted by changes to the trade policies of the United States and foreign countries (including governmental action related to tariffs, international trade agreements, or economic sanctions). Such changes have the potential to adversely impact the U.S. economy or certain sectors thereof, the global economy, and our industry, and as a result, could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, the SEC and other government agencies could hinder their ability to perform normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government funding, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the U.S. Securities and Exchange Commission (SEC), and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidate or we could lose certain rights to grant sublicenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to license agreements with Pfizer, Biosion, and the University of Chicago, pursuant to which we in-license patents and technology for certain of our product candidate, pursuant to which we may license patents and technology for future product candidates. Our current license agreements and our collaboration agreement impose, and any future license agreements or collaboration agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future. If any of these collaborations, strategic alliances or licensing arrangements are not successful, we may not be able to capitalize on the market potential of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our current or future product candidates. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate strategic partners, and the negotiation process for these sorts of transactions is time-consuming, complex and expensive. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidate because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidate as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. Additionally, our existing partners may decide to acquire or partner with other companies developing oncology therapeutics, which may have an adverse impact on our business prospects, financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we enter into additional collaboration agreements and strategic partnerships or license our product candidate, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business prospects, financial condition and results of operations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies the entry into the transaction in the first place. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidate could delay the development and commercialization of our product candidate in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to manufacture our product candidate. Any failure by a third party manufacturer to produce acceptable raw materials or product candidate for us or to obtain authorization from the FDA or comparable foreign regulatory authorities relating thereto may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory licensure or approvals or commercialize approved products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to manufacture or distribute preclinical, clinical or commercial quantities of drug substance or drug product, including our existing product candidate. We rely on third party contract manufacturers to manufacture our preclinical and clinical trial product supplies. We expect to continue to rely on third party manufacturers if we receive regulatory licensure for our product candidate. We do not have complete control over the ability of our third party manufacturers to maintain adequate manufacturing capacity and capabilities to serve our needs, including quality control, quality assurance and qualified personnel. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices, whether as a result of inflationary pressures or otherwise.</span></p><p style="text-indent:4.832%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.593%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.832%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.593%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, any replacement of any of our manufacturers could require significant effort and expense because there may be a limited number of qualified replacements and could take a significant amount of time to complete.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as Current Good Manufacturing Practice (cGMP). In the event that any of our manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidate may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidate. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop our product candidate in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely on third party manufacturers if we receive regulatory licensure for our product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for our product candidate, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidate successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP or similar foreign requirements could adversely affect our business in a number of ways, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate or continue clinical trials of the product candidate under development; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory licenses, for the product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of the cooperation of an existing or future collaborator; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting third party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidate; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize a product candidate, and an inability to meet commercial demands for such products. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to establish agreements with third party CDMOs, or to do so on acceptable terms. Even if we are able to establish agreements with CDMOs, reliance on them entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the CDMO for regulatory, compliance and quality assurance; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing agreement by the CDMO; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the CDMO at a time that is costly or inconvenient for us. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have only limited technology transfer agreements in place with respect to our product candidate, and these arrangements do not extend to commercial supply and, in some instances, to clinical supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to our product candidate and other materials. If we receive marketing licensure for our product candidate, we will need to establish an agreement for commercial manufacture with a third party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CDMOs we retain may not be able to comply with cGMP regulations or comparable foreign regulatory requirements. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of license, license revocation, seizures or recalls of our product candidate or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The facilities used by our contract manufacturers to manufacture our product candidate must be approved by the FDA or the EU Member States in coordination with the EMA pursuant to inspections that will be conducted after we submit our BLA to the FDA or our marketing authorization application to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing. Third party manufacturers may not be able to comply with cGMP regulations or comparable foreign regulatory requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory bodies, they will not be able to secure and/or maintain marketing licensure for their manufacturing facilities. In addition, we do not have complete control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EU Member States and the EMA or other comparable regulatory authorities do not approve these facilities for the manufacture of our product candidate or if they withdraw any such licensure in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing licensure for or market our product candidate, if approved or licensed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of licensure, license revocation, seizures or recalls of products or our product candidate, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidate and harm our business and results of operations. Our product candidate and any products that we may develop may compete with other product candidates and products for access to suitable manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing licensure. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current CDMOs cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidate, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidate or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing licensure on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A portion of our manufacturing of our product candidate takes place in China, through third party manufacturers. A significant disruption in the operation of those manufacturers could materially adversely affect our business, financial condition and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently contract manufacturing operations to third parties, and large quantities of our product candidate is manufactured by these third parties globally, including in China. Any disruption in production or inability of our manufacturers to produce adequate quantities to meet our needs could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidate. Foreign and certain Chinese biotechnology companies and CDMOs, may become subject to U.S. legislation, including the legislation pending in Congress called the BIOSECURE Act. The Act could impose trade restrictions, sanctions, and other regulatory requirements by the U.S. government, which could restrict or even prohibit our ability to work with such entities. If we are restricted or prohibited from working with our current CDMOs, we may incur added costs or reduction of the supply of material available to us, delays in the procurement or supply of such material or adverse effects on our ability to manufacture our product candidate. Any of these matters could materially and adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any recall of the manufacturing lots or similar action regarding our product candidate used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, supply chain disruptions and delays may also occur as a result of any new tariff policies or trade restrictions, which could also negatively impact third party manufacturing. For example, on April 2, 2025, the United States government announced a baseline 10% tariff on all foreign goods, with goods imported from specified nations, including China and those in the European Union, taxed at higher rates. Any of these matters could materially and adversely affect our business and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CDMOs may be unable to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay or prevent us from developing our product candidate and commercializing approved products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to conduct clinical trials of our product candidate, we will need to manufacture it in large quantities. Quality issues may arise during scale-up activities. Our reliance on a limited number of CDMOs, the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required licensure, or commercialization of our product candidate, cause us to incur higher costs and prevent us from commercializing our product candidate successfully. Furthermore, if our CDMOs fail to deliver the required commercial quality and quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement CDMOs capable of production in a timely manner at a substantially equivalent cost, then testing and clinical trials of our product candidate may be delayed or infeasible, and regulatory licensure or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of our product candidate requires the timely delivery of sufficient amounts of raw and intermediate materials. We work closely with our suppliers to ensure the continuity of supply but cannot guarantee these efforts will always be successful. Further, while efforts are made to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. While we believe that alternative sources of supply exist where we rely on sole supplier relationships, there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidate in a timely or cost-effective manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for completing such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will rely on third party CROs to conduct clinical trials for our biological product candidate. We currently do not plan to conduct any clinical trials independently. Agreements with these CROs might terminate for a variety of reasons, including for their failure to perform. Entry into alternative arrangements, if necessary, could significantly delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on these CROs for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these CROs do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing licenses for our product candidate and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect our intellectual property in and to our product candidate, we may not be able to compete effectively in our markets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, proprietary know-how, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidate and discovery programs. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property rights in the U.S. and other countries. We and or licensors have filed patent applications in the U.S. and abroad directed to our product candidate in an effort to establish intellectual property positions for their compositions of matter as well as uses in the treatment of diseases. Our intellectual property includes patents and patent applications that we own, as well as those we in-license, including in-licensed patents that we manage directly and those that remain managed by our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidate in every country or territory in which we may sell our products, if approved. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we cannot be sure that any of our pending patent applications will issue, or that if issued, will be in a form advantageous to us. The United States Patent and Trademark Office (USPTO), international patent offices, or judicial bodies may deny, or significantly narrow claims made under our patent applications and our patents may be successfully challenged, may be designed around, or may otherwise be of insufficient scope to provide us with protection for our commercial products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may be subject to a third party submission of prior art to the USPTO, or other patent offices, in our pending patent applications. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing. In addition to the above, patent prosecution is a lengthy process, during which the scope of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims initially submitted for examination by the USPTO may be significantly narrowed or may not issue at all. The claims of our issued patents or patent applications when issued may not cover our current or future product candidates, or even if such patents provide coverage, the coverage obtained may not provide any competitive advantage. The patent applications that we own, or in-license, may fail to result in issued patents with claims that cover our current or future product candidates in the U.S. or in other foreign countries, or we may be required to disclaim all or a portion of the remaining patent term to secure issuance. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of current and future product candidates. Further, if we encounter delays in regulatory licensure or approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we own or have in-licensed with respect to our product candidate and discovery programs fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future product candidates, it could dissuade companies from collaborating with us to develop and commercialize product candidates and future drugs and threaten our ability to commercialize future drugs. Any such outcome could have a negative effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our intellectual property rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Furthermore, other parties may have developed or may develop technologies that may be related to, or competitive with, our technologies, and such parties may have filed, or may file, patent applications, or may have received, or may receive, patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents, and that we may rely upon to establish exclusivity for our products in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. It is also possible that in our evaluation of third party intellectual property, we failed to identify relevant patents or applications. We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current and future products. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patent rights may be challenged in the courts or patent offices in the U.S. and abroad. For example, we may become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding, or in litigation, could reduce the scope of our patent claims, result in our patent rights being held invalid, in whole or in part, or unenforceable, or limit the duration of the patent protection of our technology and products, and allow third parties to commercialize our technology or products and compete directly with us without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or any future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, patents have a limited lifespan. In the U.S. and internationally, a patent generally expires 20 years after the earliest filing date of a non-provisional patent application. Various extensions may or may not be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic and/or biosimilar versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent rights may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours. We may also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Even if our patent rights are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned patent rights by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates, but that has a different composition that falls outside the scope of our patent protection. If the protection provided by our patent rights with respect to our product candidate is not sufficiently broad to impede such competition, or if the breadth, strength or term (including any extensions or adjustments) of protection provided by our patent rights with respect to our product candidate or any future product candidates is successfully challenged, our ability to successfully commercialize our product candidate could be negatively affected, which would harm our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on a combination of in-house employees, reputable law firms, service providers, and our licensors to pay these fees and to help us comply with these requirements. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as, or similar to, our product candidate, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we fail to apply for, or are unsuccessful in our application for, applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings against us or our licensors or collaborators alleging that we or our licensors or collaborators are infringing their intellectual property rights or to challenge the validity or scope of our intellectual property rights, including in oppositions, interferences, reexaminations, inter partes reviews, derivation or other similar proceedings before the U.S. or other domestic or foreign jurisdictions. These proceedings can be expensive and time-consuming and adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators can.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An unfavorable outcome could require us or our licensors or collaborators to cease using the related technology or developing or commercializing our product candidate, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees. A finding of infringement could prevent us from commercializing our product candidate or force us to cease some of our business operations, which could materially harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees, consultants or advisors were previously, or are currently, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals have used or disclosed confidential information or intellectual property, including trade secrets, or other proprietary information of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents, or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our Pfizer license agreement or any of the other agreements under which we acquired, or will acquire, intellectual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property rights covering our product candidate, we could lose the ability to continue the development and commercialization of the related product candidates(s).</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we may enter into additional such agreements in the future. In particular, the rights to the intellectual property covering micvotabart pelidotin are in-licensed from Pfizer. If we fail to meet our obligations under any of our in-license agreements, including the amended and restated license agreement with Pfizer, dated October 6, 2022, as further amended, then the licensor may terminate the license agreement. If one of our material in-license agreements is terminated, we will lose the right to continue to develop and commercialize the product candidate(s) covered by such in-license agreement. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under our in-license agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in such proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counter claims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent, withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available or weakening the rights of patent owners in certain circumstances or situations. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties, or limit the enforceability of patents against third parties, including government agencies or government contractors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as the U.S. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims, or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Additionally, some foreign countries do not protect intellectual property rights to the same extent as the federal laws of the U.S. and we may encounter problem protecting and defending our intellectual properties rights in such countries, which could negatively affect our business. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties, or limit the enforceability of patents against third parties, including government agencies or government contractors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidate, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive, time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we rely on third parties to help us discover, develop, manufacture or commercialize our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. are sometimes less willing to protect trade secrets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price is volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price is highly volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price they purchased their common stock. The market price for our common stock may be influenced by many factors, including the other risks described in this section of the Quarterly Report on Form 10-Q titled &#8220;Risk Factors&#8221; and the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of our preclinical studies, IND submissions and clinical trials, of our product candidate, or those of our competitors or our existing or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory actions with respect to our products, product candidate, preclinical studies, clinical trials, manufacturing process or sales and marketing terms or that of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to raise additional capital and the terms on which we raise it, including announcement and expectation of additional financing efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">speculation in the press or investment community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the concentrated ownership of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting principles; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions, including, but not limited to, terrorist acts, acts of war, periods of widespread civil unrest, natural disasters, public health emergencies and other calamities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise additional capital in the future. To the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be dilution to our existing investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. We may choose to raise additional capital through the issuance of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market. If no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our product candidate, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, bank failures, increases in inflation rates and uncertainty about economic stability. Any such volatility and disruptions may have adverse consequences for us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Inflation can adversely affect us by increasing our costs, including personnel costs. Any significant increases in inflation and related increases in interest rates could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of  May 14, 2025, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, beneficially own approximately 38.3% of our outstanding common stock. As a result, these stockholders, if acting together, have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with interests of our other stockholders. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to us may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering (IPO), (b) in which we have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700 million as of the prior June 30th and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An emerging growth company may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exemptions from the requirement to hold a nonbinding advisory vote on executive compensation and to obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have elected to take advantage of certain reduced disclosure obligations and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our investors may be different from the information you might receive from other public reporting companies that are not emerging growth companies in which you hold equity interests. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourself of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; and will continue to be a smaller reporting company as long as (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law would make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in the amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on actions by our stockholders by written consent; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that directors may only be removed &#8220;for cause&#8221; and only with 66 2/3% voting stock of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that only the board of directors may change the number of directors and fill vacancies on the board; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">division of our board of directors into three classes, serving staggered terms of three years each; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has and will be required to devote substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we have incurred and, particularly after we are no longer an emerging growth company or a smaller reporting company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or to incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors or our board committees or as executive officers. These rules and regulations are also often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a public company, we incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company or a smaller reporting company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or detect all errors and all fraud.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the U.S Securities and Exchange Commission. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. In addition, securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are without merit, defending against these claims could result in substantial costs and divert management time and resources. We may be a target for securities and shareholder lawsuits in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5) any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section 115 of the Delaware General Corporation Law. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated bylaws further provide that the federal district courts of the U.S. will be the exclusive forum to the fullest extent permitted by law, for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation and amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated bylaws described above.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to use net operating loss carryforwards and other tax attributes may be subject to limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. Unused losses will carry forward to offset future taxable income, if any, subject to certain limitations (including the limitations described below) until such unused losses expire. As of December 31, 2024, our federal and state net operating losses (NOLs) in the U.S. were $63.1 million ($300.7 million before tax) and $15.1 million ($229.6 million before tax), respectively. The federal NOL carryforwards in the U.S. after tax year 2017 can be carried forward indefinitely but may be subject to annual usage limitations to the extent certain substantial changes our ownership occur. The federal NOL and the state NOL carryforwards of the Company will begin to expire in 2033 and 2035, respectively. In addition, the federal and state credit carryovers of the Company will begin to expire in 2030. These loss and credit carryforwards are subject to review and possible adjustment by the relevant taxing authorities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our NOL and credit carryforwards are subject to review and possible adjustment by the IRS, and state tax authorities. Under Section 382 of the Internal Revenue Code of 1986, as amended, our federal NOL and credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company, which generally occurs if one or more stockholders, or groups of stockholders, who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. In addition, we may experience ownership changes in the future due to subsequent shifts in our stock, some of which are outside of our control. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Proceeds from Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our initial public offering of common stock, or the IPO, was effected through a Registration Statement on Form S-1 (File No. 333-259627) that was declared effective by the U.S. Securities and Exchange Commission (SEC) on October 7, 2021. We issued and sold in aggregate 10,500,000 shares of common stock, at a public offering price of $16.00 per share, for net proceeds of $152.3 million after deducting underwriting discounts, commissions and other offering costs of $15.7 million. BofA Securities, Inc., Jefferies LLC, Credit Suisse Securities (USA) LLC, William Blair &amp; Company, L.L.C. and LifeSci Capital LLC acted as underwriters for the offering. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our planned use of the net proceeds from the IPO as described in our final prospectus filed with the SEC on October 8, 2021 has changed due to the re-prioritizations of our pipeline contemplated in connection with our reorganization announced in November 2023 and our portfolio prioritization announced in December 2024. As a result, we currently expect to use our cash and cash equivalents, which include the net proceeds from our IPO, to advance the clinical development of micvotabart pelidotin, as well as for general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Defaults Up</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on Senior Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safety Disclo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_other"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nformation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c5c6533-cdac-4758-bdaf-09a23f583036" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_8bb09e40-1dc3-4aa6-b893-e64f6c517dcf" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_fd2c7b21-38ce-4b1b-b872-c14d503d4f76" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_cb037122-fe58-44e3-b806-da9b639546a3" contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5.96%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:56.42%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:14%;box-sizing:content-box;"/>
     <td style="width:3.62%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed Herewith</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pyxs-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement and General Release of Ken Kobayashi</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pyxs-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pyxs-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pyxs-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pyxs-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*  The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"/>
     <td style="width:5.04%;box-sizing:content-box;"/>
     <td style="width:3.04%;box-sizing:content-box;"/>
     <td style="width:46.46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pyxis Oncology, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;/s/ Lara Sullivan</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lara Sullivan, M.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chief Medical Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Pamela Connealy</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pamela Connealy</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pyxs-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                                                                                                     Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPARATION AGREEMENT AND GENERAL RELEASE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS SEPARATION AGREEMENT AND GENERAL RELEASE </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made and entered into as of March 18, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PYXIS ONCOLOGY, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, having an address at 321 Harrison Avenue, 11</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Floor, Suite 1, Boston MA 02118 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pyxis</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Ken Kobayashi, residing at 15957 Avenida Calma, Rancho Santa Fe, CA 92091 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parties desire to set forth in this Agreement the terms upon which they have mutually agreed to an orderly termination of Employee&#x2019;s employment with Pyxis;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in consideration of the mutual agreements and other consideration contained in this Agreement, the parties agree as follows:</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance and Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In accordance with the terms of the executive employment agreement between Pyxis and Employee, dated November 21, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which is attached hereto and incorporated herein as Attachment A, Pyxis agrees to pay Employee the severance benefits set forth in Section 4(b)(i) of the Employment Agreement in accordance with the terms thereof.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In consideration for the payments made pursuant to Section 1 above, Employee, on behalf of Employee, Employee&#x2019;s heirs, executors, administrators, successors and assigns, hereby releases, acquits and forever discharges Pyxis and any and all of its current or former subsidiaries and other affiliated entities and benefit plans, as well as its and/or their officers, directors, representatives, attorneys, agents, servants, employees, stockholders, successors, predecessors and affiliates, each in their respective capacities from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys&#x2019; fees, damages, indemnities and obligations of every kind and nature, in law, in equity or otherwise, known or unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, acts or conduct at any time as of or prior to the Effective Date, including, but not limited to: all such claims under California&#x2019;s Fair Employment and Housing Act; all such claims or demands arising from Employee&#x2019;s employment or the termination of Employee&#x2019;s employment; all such claims and demands related to salary, bonuses, commissions, stock, stock options (except as provided in Section 4 of the Employment Agreement), expense reimbursements, or any form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the Federal Civil Rights Acts of 1964, as amended, the Age Discrimination in Employment Act of 1967, as amended; statutory wage and hour claims under Massachusetts or California law (including but not limited to claims for violation of the Massachusetts Wage Act); claims under any law or legal principle of similar effect in any other relevant jurisdiction; contract claims; tort claims; or claims of wrongful discharge, discrimination, fraud, defamation, and emotional distress.  Employee further agrees not to sue or otherwise institute or cause to be instituted or in any way voluntarily participate in the prosecution of any complaints or charges against any persons or entities released herein in any federal, state or other court, administrative agency or other forum concerning any claims released herein.  Notwithstanding the foregoing, this release by Employee excludes (i) any rights to payment under Section 4(b)(i) of the Employment Agreement, (ii) any rights to vested accrued benefits and compensation under the Company&#x2019;s applicable plans and arrangements (including with respect to equity awards), (iii) any right to indemnification by the Company or its affiliates and (iv) any right to coverage under applicable directors&#x2019; and officers&#x2019; or other third party liability insurance policies.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded from this Agreement are any claims which by law cannot be waived in a private agreement 		between an employer and employee, including claims by Employee for workers&#x2019; compensation benefits or 		unemployment insurance benefits. This Release does not prohibit Employee from filing a charge with the 		Equal Employment Opportunity Commission (the &#x201c;EEOC&#x201d;) or equivalent state agency in Employee&#x2019;s state 		or participating in an EEOC or state agency investigation. Employee agrees to waive his right to monetary 		or other recovery should any claim be pursued with the EEOC, state agency, or any other federal, state or 		local administrative agency on his behalf arising out of or related to his employment with and/or separation 		from Pyxis, if this waiver is allowed by applicable law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release of Unknown Claims</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Employee acknowledges that the general release above is intended to include claims that Employee does not know or suspect to exist at the time of Employee&#x2019;s execution of this Agreement, regardless of whether the knowledge of such claims would have affected Employee&#x2019;s decision to execute this Agreement. Thus, Employee hereby waives any rights Employee may have under California Civil Code Section 1542 which states:</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:5.833%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee agrees and acknowledges that the non-solicitation restrictions set forth in the Proprietary Information, Inventions and Non-Solicitation Agreement between Pyxis and Employee, dated November 21, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proprietary Information, Inventions and Non-Solicitation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), remain in full force and effect until the one-year anniversary of the date of Employee&#x2019;s termination (i.e., until March 18, 2026).  Employee further agrees that Employee&#x2019;s other post-employment restrictions and obligations set forth in the Proprietary Information, Inventions, and Non-Solicitation Agreement remain valid and binding and Employee agrees to comply with such obligations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The parties covenant and agree that for a one-year period following the Effective Date, each shall refrain from making any defamatory, derogatory or other unfavorable statements regarding the other or, in the case of Employee, Pyxis&#x2019;s business, officers, directors, employees and agents.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except for his own attorney, his tax advisor and his immediate family, Employee agrees that the existence and the terms of this Agreement shall be confidential, and that he, his attorney, his tax advisor and his immediate family will not disclose any information concerning the terms of this Agreement to anyone, including but not limited to past, present or future employees of Pyxis.  In addition, Employee is party to and bound by the provisions of the Proprietary Information, Inventions and Non-Solicitation Agreement, including with respect to confidentiality. </font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding Paragraphs 4 and 5, nothing in this Agreement prevents Employee from discussing or 		disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any 		other conduct that Employee has reason to believe is unlawful.</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Admission</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee understands and agrees that nothing contained in this Agreement is to be considered an admission by Pyxis of any wrongdoing under any federal, state or local statute, regulation, public policy, tort law, contract law, common law.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that he has read and understands this Agreement and executes it knowingly, voluntarily and without coercion.  Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that he is being advised herein in writing to consult with an attorney prior to executing this Agreement, that he has consulted with an attorney, and he has been given a period of at least 21 days within which to consider and execute this Agreement, unless he voluntarily chooses to execute this Agreement before the end of the 21 day period by executing the attached Election to Execute Prior to Expiration of 21 Day Consideration Period.  Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understands that he has 7 days following his execution of this Agreement to revoke his execution of this Agreement.  The Effective Date of this Agreement shall be the 8th day after it is executed and has not been revoked.  For any revocation to be effective, written notice of revocation must be delivered to Pyxis Oncology, attention: Pam Connealy, CFO &amp; COO at pconnealy@pyxisoncology.com, no later than 5:00 p.m. ET on the 7th calendar day after Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">signs this Agreement.  If Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revokes this Agreement, it shall not be effective or enforceable and he shall not receive the benefits described herein.  No payments shall be made under the terms of this Agreement until the 7-day revocation period described in this paragraph has expired without revocation by Employee.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may not be modified in any way except in a written agreement signed by both Employee and an authorized representative of Pyxis.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts without giving effect to its conflict of law provisions.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement constitutes the entire agreement and understanding between the parties relating to Employee&#x2019;s separation from Pyxis.  Employee acknowledges and agrees that in executing this Agreement, Employee has not relied on any promises or representations other than those set forth in this Agreement.  For the avoidance of doubt, this Agreement does not alter, amend or otherwise change the rights or obligations of Employee or Pyxis in respect of grants of any stock options or other equity compensation, which such rights or obligations are set forth in the applicable plan and grant documents.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS THEREOF, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee and Pyxis, after carefully reading the provisions of this Agreement, herein declare that they understand such provisions and willingly accept and agree thereto by executing this Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pyxis Oncology, Inc.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sincerely,</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Ken Kobayashi</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Lara Sullivan</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ken Kobayashi</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lara S. Sullivan M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President &amp; Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELECTION TO EXECUTE PRIOR TO EXPIRATION<br>OF 21 DAY CONSIDERATION PERIOD</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Ken Kobayashi, understand that I have at least 21 days within which to consider and execute the foregoing Separation Agreement and General Release.  However, after having an opportunity consult counsel, I have freely and voluntarily elected to execute the Separation Agreement and General Release before the 21-day period has expired.</font></p><p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:13.333%;text-indent:38.461%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                       </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:29.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By : </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Ken Kobayashi</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ken Kobayashi</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="margin-left:13.333%;text-indent:38.461%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">               </font></p><p style="margin-left:13.333%;text-indent:38.461%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                     </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>pyxs-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Lara Sullivan, M.D., certify that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Pyxis Oncology, Inc.;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;/s/ Lara Sullivan</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lara Sullivan, M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chief Medical Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>pyxs-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Pamela Connealy, certify that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Pyxis Oncology, Inc.;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;/s/ Pamela Connealy</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pamela Connealy</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>pyxs-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Lara Sullivan</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lara Sullivan, M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chief Medical Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>pyxs-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;/s/ Pamela Connealy</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pamela Connealy</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Chief Operating Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img33342731_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33342731_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" <:#.0# 2(  A$! Q$!_\0
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M$/BA_P! OPU_X#S_ /R17R]5BE]0PW\AA_JCD?\ T#1_'_,^E_\ AX;\3O\
MH$^&?_ >?_Y(JS;?\%!OB1,DI_LSPYF/_IVG_P#DBOE^I8IO*\VE]0H?RF/^
MJ&2?\^/Q/I.7_@HI\2XI?+_L_P -Y_Z])_\ Y(I?^'A_Q0_Z!?AO_P !)_\
MY(KYKBM/-JK=?Z)6?U'#_P H?ZHY+_T#Q_'_ #/I[_AXC\3/^@?X:_\  .?_
M .2*/^'B/Q,_Z!_AK_P#G_\ DBOEZBG]1P_\H?ZHY+_T#Q_'_,^H/^'AWQ*_
MZ!OAG_P#N/\ Y(H_X>&_$K_H&^&?_ .X_P#DBOE^BCZE0_E#_5#)/^?'XGU!
M_P /#?B5_P! WPS_ . =Q_\ )%'_  \,^)O_ $"?#7_@)<?_ "17R_3XO]91
M]2H?RA_JADG_ #X_$^H?^'@_Q._Z!/AG_P !Y_\ Y(J/_AX9\3?^@3X:_P#
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M#1_[<[C_ .2*^68OWU'^IH^HX?\ E(_U5R;_ )\?B?4__#Q/XD_] SPS_P"
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M_6SN/_DBE_X>*_$G_H%^&/\ P#N/_DFOEB+_ %5)1]2H?RA_JQE'_/D^K/\
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M *NDI_4</_*'^K>4_P#/G\3ZIE_X*.?$Z),_V/X8_P# .X_^2:/^'COQ._Z
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M?^4C_5W*O^?/XGU=_P /(OB=_P! ;PO_ . =Q_\ )-'_  \B^)W_ $!O"_\
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M</\ RB^H8?\ E/KK_AYO\3O^@)X2_P# .Y_^2:D_X>9?$[?C^Q/"7_@'<_\
MR37R!%#'_P!-*O6MI'=W,7ET?4</_*/ZCA_Y3ZQB_P""F_Q.EN/*_L7PG_X!
MW/\ \DTRY_X*:?%*&Y\O^P_"/E^OV.Y_^2:^0[K3_LESYE58O,N]2\NCZCA_
MY3#ZGA_Y3[%B_P""G/Q.F_U>B>$O_ .Y_P#DFB7_ (*<?%*+_F">$O\ P#N?
M_DFOD2_B_L^HK6;[71]1P_\ *'U/#_RGUQ_P\_\ BD/]9H?A'_P#N?\ Y)I)
M/^"HGQ2'_,#\(_\ @'<__)-?']U_SSI?LE'U'#_RF?U.A_*?7?\ P]$^*O\
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MW_Y)KXPBFJ6+]]_K*/[/PW\I',?8W_#UCXI_] /P;_X!7O\ \DT?\/5OBO\
M] +P7_X WO\ \DU\7_9(_-_Y:5++:1^5_P M*U_L["_R!S'V-_P]6^+QD^3P
M[X+,?J;&]_\ DFC_ (>M_%K_ *%[P9_X!7O_ ,DU\:6NH_9(_LW_ #SJ.Z\R
M7_GG1_9^%_D,+L^SQ_P55^+PC\V3P[X-\K_KSN?_ ))J.U_X*N?%N:7RY/#W
M@P?2RO?_ ))KXO\ WDL7E_NZEO[3R;FV_P"O:G_9^%_D(YV??7@7_@IMX[UV
M\\K7-,\+6D7F/S:V5P?W8CSWN:YS6/\ @JI\3;.^\NST;P?+;^7G,MC>9_\
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M)H/_  5M^+Y^YX=\$'_MRO?_ ))KX8M8O-J]%:>5+1_9V%_D*^L5.Y]NR_\
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M/;5.Y]SVO_!5WXK7<<N-"\&>9'V^Q7O_ ,DU7NO^"L?Q;B_U?A[P8?K97O\
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MIX=\&'ZV-[_\DU\3_P!H^=6E8:=_:-9?4,-_*=$<34EU/KZQ_P""LGQDO/\
MF6O! _[<KW_Y)I+G_@K/\8X+AXO^$:\$''_3E>__ "37QI?S?V?5&6*2[_TG
M]WY4E'U##?RE>WJ=S[:C_P""MWQ6/70?!?\ X WO_P DU(/^"L?Q?ED_=^'O
M!!C]?L5[_P#)-?%?V2RAL?,_TCS:-+\R6*7[/_J_^FM'U##?RA[>IW/M"3_@
MK)\8!)C_ (1WP1_X!7O_ ,DU'_P]N^+_ )OE_P#".^!__ *]_P#DFOBZZ\S[
M3_RSJS+-'#'^\\RCZAAOY2_;5.Y]J2_\%8OBW#%%(_AWP8!)Z6-[_P#)-,B_
MX*R?%N7_ )EWP7_X!7O_ ,DU\52ZA;3>5')YE68H;;R_,C\RCZAAOY0]M/N?
M:$O_  5=^+T7_,N>"_\ P"O?_DFE_P"'KWQ;_P"A=\&?^ 5[_P#)-?&<5WY5
M177F1?\ /.CZAAOY0]M/N?:'_#USXQ_]"QX+_P# &]_^2:B_X>Q_%_\ Z%[P
M1_X!7O\ \DU\0_VM+_TSHENY)8_^6='U##?RA[:?<^V?^'M'QB_Z%SP/_P"
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M:5.Y]%T5VG_"D_B%_P!$_P#$_P#X)[C_ .-T?\*3^(7_ $3_ ,3_ /@GN/\
MXW7L>UI_S(_O[^U\N_Z":?\ X$CAY*DBF\FNT_X4G\0O^B?^)_\ P3W'_P ;
MH_X4G\0O^B?^)_\ P3W'_P ;H]K3_F0?VOEW_033_P# D<7+-YU%=I_PI/XA
M?]$_\3_^">X_^-T?\*3^(7_1/_$__@GN/_C='M:?\R#^U\N_Z":?_@2.+HKM
M/^%)_$+_ *)_XG_\$]Q_\;H_X4G\0O\ HG_B?_P3W'_QNCVM/^9!_:^7?]!-
M/_P)'%T5VG_"D_B%_P!$_P#$_P#X)[C_ .-T?\*3^(7_ $3_ ,3_ /@GN/\
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M7_0@^*/_  3W'_QNCVL/YD1+,L%+_E]'[T<3YT=)YM=M_P *.^(/_0A>)_\
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MZ942PQ_]-*[/_A2'Q(\S_DG_ (H_\$]Q_P#&ZED^"/Q'/_,@>*#_ -P>X_\
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M3_T3_P 4_P#@FN/_ (W4>UA_,C+^T\'_ ,_5]YPW_+6I98I):[>/X%_$@=?
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M9Y7^M_U55OB-]BT^^\NS^T?ZR7_6U>M?@S\5K2*2.W^'WBV+_N!7'_QNI?\
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M_8"N/_C='M:?\R(^LT/YU]YP\LW[KRX__(M$4ODQ_O*[[_A07Q*_Z)SXJ_\
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M7UFC_.OO.!BN_)HE_?5VLOP!^)Y_YISXN_\ !#<?_&ZEB^ /Q/\ ^B<^+O\
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MO_!#<?\ QJCVM/\ F7WA[2'\R^\\R_U,O[RMB+3I)H_^6==;_P ,\_%#S/\
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M_5_\O_\ VUKK)?@)\789?]'^&_B_R_\ L W/_P :JO%^SQ\699?,D^&_B_\
M\$-S_P#&J/;4_P"9?>7[6E_,<CXCTF2TTV+_ )Z^95&*TDM/]9_Y"KT#4_@5
M\6;R+RQ\,_&?_A.W/_QNB7]G[XJRR?\ ),_&?_@AN?\ XU1[:G_,OO,O:TOY
MCSN7]S+5FZEDEMHO+\NNV_X9Y^*GF?\ ),_&?_@AN/\ XW6D/V?_ (GQ6>/^
M%:>+L^G]@W'_ ,:H]M3_ )E]YS^UCW/+K6TN9OWDGE^56O\ 9/.MO,C_ /(M
M=C_PH3XJ?9I!_P *S\9Y\O\ Z -Q_P#&JCB_9Z^+ MY!_P *X\79]/[!N/\
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M[,X2*&YFMI?+\NBZ\R6.+S/+_=Q^57K%_P#L[_%&'3?W?PR\7RR_],M!N?\
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MUU^S3\6)I(S_ ,*O\98'_4!O?_C=4HOV:?B[%<2)_P *O\9>2>__  CM[_\
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MQ</3X5^-C_W+M[_\;J/_ (9O^+L2;Q\*_&Q/I_PCM[_\:J?K%+^9?>'L*O\
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M;4OYU]X>RJ_RGGU_]F\K]YYE1VOF31^7;^7_ -M:])F_9M^+LO\ S2KQN/\
MN7+W_P"-5L:#^S;\58?]9\+O&<7_ ' ;W_XU1[:E_.OO#V57^4\B\G_GI_K:
ME\JO5]3_ &;?BJ1)Y7PN\9D?]@&]_P#C58<?[-WQB'7X5>-Q_P!RY>__ !JC
MVU+^=?>'LJO\IY_:S1W<GE_O*O2Q?9/^//\ \BUW?_#-/Q8A_P!7\*O&_P#X
M3M[_ /&J6+]G/XO?]$J\;_\ A.7O_P :H]M2_G7WD^PJ_P IYU?RV\TGVG]Y
MYM6?W<ME%<R>9^\KNY/V:?BR>GPK\;G_ +EV]_\ C5$O[-_Q=,4<?_"J_&Y
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M?[O_ %E>E1?LN_%GS;:3_A5WC/C_ *@-[_\ &JLVW[-OQ9AO8R?A=XSQZ_\
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MO_QJCVU+^9?>5R2['FMA]F\R7S/,_P"V52_V3YTOF22?]<Z] B_9M^+7E_\
M)+O&?_A.7O\ \:J72_V>/B[+>Q&3X7>-XHH_^>OAR]_^-4>VI?S+[PY)=CSJ
M*:]AE^S1_9_^VM4;KS);GRY/+\W_ *95[#<_LY_%7[1F/X7>,\?]@&]_^-5D
M1?LV_%X:EYG_  J[QGY7_8N7O_QJCVU+^9?>')+L<'%%'%^ZJ+[)+IW[RO3O
M^&;?BSYG_)+O&?\ X(;W_P"-5+?_ +.7Q:FCQ'\+O&>?^P#>_P#QJCVU+^9?
M>')+L>61:C]KE_>?ZK_IE45A^]N?W=>@6W[-7Q<7K\*_&P^OAV]_^-5;TO\
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M ,*O\9^4?^I=O?\ XU1[:E_.OO+Y)=CCM4TFVAE_Y:46$4<-S%_K/]97=_\
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M8KAXOV;_ (NQ22R_\*O\9>9(?,_Y%V]Z_P#?NCVU/^9?>'++L<!+Y</^C?\
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M_P BGXHQ2L.R&?+_ )%'R_Y%/Q1BBP60SY?\BCY?\BGXHQ18+(9\O^11\O\
MD4_%&*+!9#/E_P BCY?\BGXHQ18+(9\O^11Q_D4_%&*+!9#,?YQ1C_.*?BC%
M+E\QV789C_.*,?YQ3\48HY?,++L-XHXIV*,4["LAF/\ .*,?YQ3\48I<OF.R
M[#./\BCY?\BGXHQ3L*R&?+_D4?+_ )%/Q1BBP60SY?\ (HX_R*?BC%%@LAFV
MC;3\48I<J'9=AFVC;3\48HY4%EV&;:-M/Q1BCE06789MHVT_%&*.5!9=AFVC
M;3\48HY4%EV&;:-M/Q1BCE06789MHVT_%&*.5!9=AFVC;3\48HY4%EV(_+'K
M1Y8]:EHHL3RKL1>6/6CRQZU+118.5=B+RQZT>6/6I:*+!RKL1[!ZT;!ZBI**
MH.6/8CV#U%&P>M244!RQ[$?RT?+_ )%/Q1BE8=D,^7_(H^7_ "*?BC%%@LAG
MR_Y%'R_Y%/Q1BBP60SY?\BCY?\BGXHQ18+(9\O\ D4?+_D4_%&*+!9#/E_R*
M/E_R*?BC%%@LAGR_Y%'R_P"13\48HL%D,^7_ "*/E_R*?BC%%@LAGR_Y%'R_
MY%/Q1BBP60SY?\BCY?\ (I^*,46"R&?+_D4?+_D4_%&*+!9#/E_R*/E_R*?B
MC%%@LAGR_P"11\M/Q1BBP60S8/6C8/6I**8N6/8BV>]&SWJ6BIMYARKL1;/>
MC9[U+11;S#E78CQ[T8_SBGXHQ1R^;*LNPS'^<48I^*,4<OF%EV&;!ZT;!ZBI
M**HGECV(MGO1L]ZEHJ;>8<J[$7ECUH\L>M2T46#E78CV#UHV#U%2450<L>Q'
ML'J*-@]14E% <L>Q'L'J*-@]14E% <L>Q'L'J*-@]:DHH#ECV(_EHX_R*?BC
M%*P[(9MHVT_%&*7*AV789MHVT_%&*.5!9=AFVC;3\48HY4%EV&;:-M/Q1BCE
M06789MHP/6GXHQ1RH++L,X_R*./\BGXHQ56%9#./\BCC_(I^*,4!9#./\BCC
M_(I^*,4!9#./\BCC_(I^*,4!9#-OO1M]Z?BC%*P<J&<?Y%%/Q118+(6BBBF,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BDX(I!BBXAU%)Q1Q0 M%)Q1D4!<6BFJ0>E+0%Q:***!A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !129H- A:*:I!Z4M 7%HHHH&%%(2!1D$>M KBT4G%'% "T4G!I,#WH
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M%5<D=13:7@"@!:*0D>M&010%Q:***!A1110 4444 %%)P12#%%Q#J*;2\ 4
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M[;$J+V/=QU3V.'<NIY#_ ,-_?'?_ *'O_P I-E_\C4?\-_?'C_H?/_*39?\
MR-7S]Y,GE2R^7^ZC_=>;3*^U>"PMM((^,6,Q-]9']"HY I:1?NCZ4M?GI^A+
M8***0]*!GY_?M[?M._$SX._&#2M#\&^)#HNF3Z#%>R1BRM[@F4W%Q&3^\BDQ
M]R.O'O@[^VU\:?%?Q=\#Z+JGC(W6FZEKEE87,8TJSA,D4EQ'%)@B/(ZGIS6C
M_P %2O\ DX+0?^Q9MO\ TIO:^?\ ]G;_ )+_ /#+_L9]-_\ 2F*OKL/AZ+P?
MM''4^.Q&(JK%\BEH?NB.@I:0=!2U\B?8(\._:^\?^(/A;^SYXJ\3>&+T:9K-
MG]B%O<^7'+Y7F7D4<G[N3]V?W<AZ^OL*_-X?M^_'<=/'?_E)LO\ Y&K]!_\
M@H!_R:9X[_[<?_2ZWK\=*^HRJA2K4&ZD;L^4S.O5I5U[.5C]IOV0O'WB'XI_
ML]^%/$WB>]_M/6;W[:+BZ\N.+S/+O98XSY<?[L?NXQT_QH_:]\?>(?A9^SWX
MK\3^&+W^S-9LOL0M[KRXY?+\R]BCD/ER?NS^[D/7U^E8G[ ?_)I'@/Z7W_I=
M<4?M^?\ )I'CSZ6/_I=;UXG*OK7)TYK?B>WSOZKS?W;GY[G]OSX[G_F>_P#R
MDV7_ ,C5]L_L*?M277QS\.ZCH/BJ\CN/&NEG[2TRQQQ?;;8G_6".+Y!Y9(C_
M ._?<U^4==C\(_B7JOP@^(.D^+M$E/VW3Y/,EB!Q'<1?\M8Y/^NE?4XC+Z52
MERP5F?,8/'U8U.>;NC]Y:*Y/X<>/M+^)G@O2/$^BS&?3=4MQ<1,2,J#CY/YU
MU?:OBW%Q=F?:QFI*Z/S,_:Y_:[^+7PQ_:(\6>&O#7BK^R]$LOL7V:T&G64@3
MS+:*20F22/S#^\DKL?V"?VG?B7\9/C!JFA^,O$AUK3(-"EO8X_L=O;D2BXMX
M\_NXH\_?DKYP_;Z_Y.U\=_2R_P#2&VKT#_@EK_R<#K__ &+-Q_Z56M?42P])
M9?[3EU/E8XBK+'\E]#]4 >:X'XN_&/PQ\#O"4WB#Q3>_9;48CAAB&^6XD_YY
MQIW-=\?NFOR!_;_^*UY\1/C_ *MI >0:/X9_XEMM#_TU_P"6LO\ W\_]%1UX
M>!PWUBIR7T/=QF*^K0YK7.E^)O\ P4I^)/BN\GC\+167A#2QS&8HH[FYV?[<
MDN8Q_P!^Z\1U3]IWXO:O)YEQ\2/$\7_7KJLEM_Z+I/V?/@+KO[0GC<^']%D2
MUABC^TWM_<C,=O'7W;I'_!+'X>Q6")JWBGQ/J%X/ORVDEO;1G_MD8I!^M?15
M9X/"/V;C[W8^<IPQN)7M(2]WN?&&A?ME?&?PS<^9;_$#5+K_ *97_E7/_HRO
MIGX&_P#!3>2YU*UTKXFZ7#!;O^Z&O:6F1'_UUB[_ /;/G_IG57XT_P#!,AM
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M/ KCOB9_P35\3>._B/XM\26WC+2;2UUG5;C4HX9;:3S(O,EDDQG_ +:5[/\
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MM)?$#43()$CU:2RCQ_SSMO\ 1O\ VG7+E=&%>N_:*Z1U9G6G1H+V;LV>T?\
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M+'^KD(_>)^$@(_"O"S'"0P]3FI[,]S+\7+$0Y:FYW=%%%>2>R%%%% !1110
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MQ_T/8_\ !39?_(U>AC\NJXJOS4UH>?@,?3PE'EJ,_9#\31^-?C>?V_?CN?\
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M4?\ [5K(_P""5?@D77C#QMXOE3'V.SBTRV]_,D\V7_T5&?\ MI7BO[>WC?\
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M\>?2Q_\ 2ZWH_8#_ .32/ ?TOO\ TNN*/V_/^32/'GTL?_2ZWKY3_F-_[?\
MU/J/^8/_ +</QTJQ=6ESI\GEW$<D4OEQR>5+_P \I(O,BJO7W!^TQ^SHNO\
M[,/PO^)VAVZKJ>E>%=*@UB&$8\ZU^SQ;)?\ MD3S_P!,_P#KF*^SJUXTIPC+
M[1\A3HNI&4H]"K_P3C_:+'A#Q:_PWURYQI&N2^9I4LO_ "[WO>+_ +:_^C/^
MNE?I^3P:_GNM9I+2YBN;>22*6.3S8Y8O^6=?LI^Q_P#'V+]H#X4V=_=/&/$6
MEG[%JT(_YZ@<2?23&?KOKY[-L-R3]M'9GT&58GGC[*6Y^=?[?7_)VOCOZ6/_
M *0VU>@?\$M?^3@=?_[%FX_]*K6O/_V^_P#D[;QY]++_ -(;:O0/^"6O_)P.
MO_\ 8LW'_I5:UZ4_^18CS:?_ ",C]4#]TU^(/[6'AZY\-?M(_$2RO$D2636;
MF^C([QW,GFQ_^C:_;YC@@U\??MP_L?W'QLL8/%OA*-!XQL(O+DMR=@O[?J5S
MCB0=J\#+*T*-?WW9'O9G1G5H^XKGQ%^R#^T9;_LZ?$6ZU#4]/DO=%U6V^Q7A
MM>9(CYO^MC'<5^I7PZ_:1^&GQ/BB&@>,M,N;J08%C<3?9KG_ +]28D_2OQ,U
MG0]1\/:E<Z=JEE<:7J=M)Y4EK=1^5+'5*OI,5E]+%R]I&7O=SYW"X^KA(\DH
M^[V/Z$P!@C(.:^-?%'_!,SP'XJ\3ZWK,OB'7+)M1O9;TVMIY0BM_,E\PI%^[
MZ5^?7@#]H+XD?"^2(>&?&>IV-K%_RZFX\VV_[]2_NZ^K?@[_ ,%/M6L[VWL_
MB+HUO?V4IV?VSI*%)(O^ND7\?_D.O&> Q.#=Z+N>PL?A\7I6C8^FO@%^Q9X-
M_9Y\87/B;PYJVNWM]<6<MC(FISV\D8CDDCD.!'%'WB2O?;^]MM-L;B[N95B@
M@C,DDA_@3_(K,\&>--&^(7AZRU[P]?P:GI%Y'YD-S"<AA7/_ !]N9+#X%_$2
MXA;9+!X<U&5#Z$6TA%>/-SJ3M4>I[$(TZ<+T]C\4_B?X\O/B9\0_$'BN_P"+
MG5;V2Y_ZYQ?\LHJ^F?\ @FQ\(++QS\5=3\4W\ N+7PO!"]O',/\ E\E/[N3_
M +9B*4?C7Q[7Z7?\$K;../X7^,;S_EI-K:0G_MG#'_\ '*^RQTW2PMHGQV!@
MJV*]X^YAR.*0@T^BOA'%,^Z6AX-^UK^SXG[17PR;1+*6UL=?L[B*ZT^_N5S'
M"<@2=/6//XA*^>?!O_!*C2( C^*O'%W>L5.^WTBUCM\'M^\D\S/_ '[%??\
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M_P#CUU6RAO8E/\'F1@[/PS7X.ZIIUSI.I7.G7D?V6^MI)+:2+_GG+'7Z>?\
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MHO[C[3G_ +^>;7Z*?!']F'X ZCX'L+S0M"T?Q=;-!'YFI73?:))7"@GS$/\
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M95][Z#H-GX9T/3-'T^,0V6FVT5K;1_\ /.-$\M!^0%?!'_!6;[_PM_W=6_\
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M$?AC6O"FI?V=KFE:AHU]'_RZW]M);2_]^Y*\^.4<S^/]X=RS;^Y^[/VPT?\
M9K^%OAYD:R^'OAE&C'^LETJ*63\)'!/ZUZ+I^G6VD6D=K:6\5M;QC"101B-$
M'T%?E=^R#^VMKWPN\2:;X:\7:M)J?@JXD^S"6_E\R33_ /II')_SS_Z9_E7Z
ML0SI-$DD;;XWZ.*\7%T:]&7+49[&"JT*T>:DBQ1117">D%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ)'H5E'I/F 8Q)'YLD@_!Y)!^%1DZ;Q"Y=C3-W;#^]N<Y^Q%KT^@_M/^ W@
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MGA;5M0D?RA9VDUSO/1-B$U^!-&1_;EW%G6\%V/TY_P""5I_XM)XM_P"P\?\
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M_;>T.30_VI/'<3_\O%Q%<Q_]M(HI*RRUQGBZDH_:V\C;,%..%C&6EOQ/1/\
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M&OP_\.>);#QKIT1UC3K;4OLMS8R(4$L8D\L2 YQSZ5X=\<_V9O&W[/=[;?\
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M?_2F*OM\*VL$IKH?"XGWL7*/<^]A_P $K/ !'_(W>)/SMO\ XU1_PZK\ ?\
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MP-14<3[Q^O%%- XI<5\,?<ZE.[N[;3;>2XN)X[>WB'[R263RT3\:L%A)'\A
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MO:I_U[2_^@&OP KCR3_EX=N;_P#+L_2[_@E7IB1?#?QKJ'\<^JI;'_MG$/\
MXY7W&#M&37Q1_P $K?\ DD7BW_L/?^VT5?;1ZFO&S#7%3;Z'L8#3#12ZGYH?
M\%6;/R/'O@BY$?\ K=*EC\W_ *YRY_\ :M?+O[.__)?OAE_V,^F_^E,=?6G_
M  5=_P"1C^'?_7O>_P#HR*ODS]G;_DO_ ,,O^QGTW_TIBKZ;"7^H,^;Q:7UW
M4_=!>@^E?E?_ ,%2_P#DX/0O^Q9MO_2F]K]4$^Z/I7Y7_P#!4O\ Y.#T+_L6
M;;_TIO:\#+/]Y1[F9?[L>7?L0?\ )U/P^_Z^)?\ TFEK]?/'6KMX?\&>(M2C
M?RY;+3KBZ1SV,<9-?D'^Q!_R=3\/O^OB7_TFEK]@?&&D-K_A77M-0XDO;&XM
M4/O)&173FW^\F&4_[O,_ NOT[_X)9Z1%%\&/%.HX!NKC7OLSY_N1V\./UDDK
M\R)89(I/+D_=2QU^D7_!*KQ9;2> O&WAGS8Q<6>HQZCY0_YYRQ^4/_2:O5S2
M+^K(\O*FEB6?=O!Z&LC4?#VEZM<6UQ>:?:7-U;Y-O+<01R/'_N''%:X&.E>)
M_M#?M/\ A;]F[_A'V\2V6H7[:N\JQ0Z6(I)(_+QESYLD?'[P5\=2C*4[4SZ^
M;BH?O#VM8P.E+]:^;/!?[>?P;\9WMG8P^([C3;V>1(8K;4+&6-I'/N@*?K6Q
M^V3\9KCX&_!#5=7TMPFMWDJ:=I\X Q%+)O/F?\ C21OPK=8>K[2--K5G/[>C
M[.52+T1I_&']K+X;?!.5[/Q!KXDU91_R#-.C^TW0X[@<)_VT(KYB\;?\%6;9
M1+#X4\"2RC_EG=:S>"//_;*/_P".5^>MU=W.HW,MS<2275S))YLDLLGFRR2U
M^@7P,_X)GZ=JGAG3==^(>L:A%?7<<5R='TW9#]GXSY;R8.ZO<J8+!X2G?$-L
M\.&,Q>+J?N+(\3\=?\%"_C#XPB>*TU6S\,VK@#RM'MO+D_[^2>9)7S+7[.^&
M?V1?@Y\+[-[ZT\%:=<RVJ&3[5J2_;)0/K*37XQ5Z675</5?)1CR^9Y^.I8B'
MOUGS'ZF?\$M?^3??$'_8SW/_ *36M>@?M^_\FE>/?^W'_P!+K>O/O^"6G_)
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MHKQ9RE4ES29[4(1IQY8H_&[]OW_D[?QY]+'_ -(;:NP_X)B?\G(77_8 N?\
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M))(X[:YSYDG^L_Y:>IZU^>=>O@ITZE-RIQLCR<7"I3FE4=S^A1/NK]*_*_\
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M_P!-/XXO_'_K7VMI^I6NKV,%Y9W$=U93QB2.XB?S(Y$]<U_/[_J?]97Z;?\
M!+[XE7WBOX9^(_"FHW#7)\-W4?V?S1REO<>81'^$D4M>=F.!ITH>UI:+L>CE
MV-J5)>RJ:ON?;E%%(:^</I1:*:.#4%Q<1V\;R2.J1I]]WXHUZ";4=65-8UFQ
M\/:?<ZAJ%Q%96-K&9)[FX?RXXT'<GI7Y4?M@_MH:C\:[^Z\+^&9)+#P/ X!^
M8QR:C_TTD_Z9?],^]3_ML_M=S_&?Q#<^$O#%Y)%X%LI"))H_^8I)'SYG_7+_
M )Y_3S*^</ 'P_UWXG^*[/PUX=T][W5KR3RXXX^D0_YZR_\ 3*OJLOP4*4?;
M5ON/E,=C)UY>QH:^91\*>%=9\=>(K+0M!T]]2U:\D\NWMH^!)7Z]_LC_ ++.
MG?LX^$7:>2._\5:G'&=2O8Q^[4C_ )91>D8-6OV8_P!E/P]^SEX=)C\O5/%%
MY'_Q,-7D3EO^F<?_ #SC'I7O .WK7GYCF+Q+]G3V._ Y?&@O:SW%'7\*_/+_
M (*S??\ A;_NZM_[95^AH(/(K\\?^"LO^N^%_P#NZK_[95S9;?ZW!]CIS%VP
MLEW/SZK].$_X)7> &&?^$M\2#\;;_P"-5^8]?T))]T?2O<S7$5L.X\DK7/$R
MO#TL0I<\=CXF_P"'5O@#_H;?$GYVW_QJN4^)_P#P3=\#> _AIXN\36OB;Q!<
MW.C:3>ZE%%*;;RY)8XI)/^>7^Q7Z#=J\Y_:/_P"3?_B9_P!BQJ7_ *2RUXE/
M'XGFMSGM2P.'C&_*?AC7ZE_\$LO^2!:__P!C/<_^DUM7Y:5^I?\ P2R_Y(%K
M_P#V,]S_ .DUM7T.:_[LCY[+/]Y/LND)Q3<@CVKX8_;N_;"D\"17'P\\$7@B
M\23QG^T]4BD_X\HO^><?_34_^0Z^3H4I8B?+ ^MKUXX>/-(J_MH_MR'PG<7_
M ("^'5ZAUG/EZKKD9S]@_P"F47_34_\ /3I'CUR8_P X?WDLG_/662B*&2[N
M8HXXY)9))/*CBB_Y:5^F'[&?[#]O\/H;'QQX]M1/XHP);+2I1F+3\_\ +1_6
M7_T7_+ZV]'+:>FK/D_WV85-=C._87_8ND\&26/Q'\=6PCUTQB32]&FC_ ./$
M'_EK+_TU]O\ EG7W@0"/:E&%'I0".U?)5ZTL1+FD?64*,,/'EB<5\4?A9X;^
M+_A1_#WBFRDU#27D25H8IY(SYB'(YC(KYZN/^":'PDEU2WNUEUV*VCE\QM/6
M]C\J3_8)\OS,?]M*]H^-'[07@CX"6VG7'C#49K!=2\Q+?RK.6X,ACQOXC!_Y
MZ"O&H_\ @I/\*)M5LM.@M]>F-S<)$;DV4<4<6?XW,D@P/PKHH1Q*A^Z3.:O+
M#.I^]9].^&?"FC>"=#MM&T+3K;2-,MDV16MK&$CC'M7E7[5'P3TCXR_"/7K&
MYLH)=9LK.6YTR],0,EO<)^\&/]_&/QKVX$'FL7Q/K=KX:\,ZQJ]T$^RZ;:2W
M4A?^Y'&7/\JXZ<WSWN[G9*"<+61^ U?JG_P3,\<W'B7X%7NAW;-))X>U*6W@
M8]3!)B0?^1/-K\K*_37_ ()7:-<6GPH\6ZI(1]GO=;\J,?\ 7.*/_P".5]?F
MD8_5U?<^1RF4OK#70\@_:D_;!^+OPX^/7BWPYX;\7"PT2PN(XX+7^S;*3R\Q
M1D_O)8_<UY:/V_?CN/\ F>__ "DV7_R-7O?[2'[!WQ'^*GQJ\4^+=&FT-=-U
M2>.6#[5>R1RC$4<9Z1GT->9_\.R/B]_S\^'/_!C+_P#&JRP_]G^Q2G:YKB?K
M_MKQV.0_X;_^/'_0^#_P4V7_ ,C5^QL3;ES7Y1#_ ()D?%\_\O/AS_P8R_\
MQJOU=B7:,5Y68_5^9?5]CT\O^L6_?CQPM?.O[?OS?LE>.SZ?8?\ TNMZ^B1]
MX5\[_M_?\FE>._\ MR_]+K>O,PR:KT[=T>GB?>H3N?CI7[?_ +*__)M_PV_[
M 5I_Z+%?B!7[?_LK_P#)M_PV_P"P%:?^BQ7T^<_PZ9\WD_\ %J'JHZBOC/\
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MWG^_;6:\@=>LAP?H(Z]V_:/^$D/QQ^$/B+PH'CCO[B,26<KC/EW,?SQG]/\
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MP3Z^.5U>;)/"$%A'U^T2ZI9[/RBDS7U%6M@\:HJI*UCY>G1Q>#<O9J]STO\
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M\KW5I)IUS+;7$<D5S')Y4D4O_+.6OT^_9D_X)[Z;\*M8MO%'C6[@\0^([?\
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M##5:F(3@KGZI+]T?2EI , 4M?+GU2V"D/2EHH&?E;_P5*_Y."T'_ +%FV_\
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M7/#NH3Z;JMI)YB7,8X(K[-\*_P#!5/Q)I]BL?B'P+8:O=+'_ ,?5E>R68D_
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M4_Z]I?\ T U^ %?T!ZW:/J.EWENG$DT$D8_$8_K7Y?G_ ();?%8?\S!X._\
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M_P# W7]./,EEKTA /]R2WA(_425Z/^W]_P FE^.OI8_^EUO7$?L5_LM_$?\
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MF+TJ+0YC_@FS^S_?:SXQ/Q1U.W\G1]+22WTKS$P;FX?]W)(/6.--XQ_ST/\
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M@I\$/#W@S6Y+.XU'3?M&^>QE>2)S)<R2\%XXS_RTQR.U>5_MO?LO^+/VD_\
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MX/\ @H_\:EZ:CI _[A\=='_PZV^*W_0P>#O_  +N?_D:C_AUM\5O^A@\'?\
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MYZ#_ ();?%8_\S!X._\  NY_^1J_1[X4>&+SP+\+?!_AR_>&6_TC1[+3KB2
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M.[4M%*R6P:]1I; S2##^QI]%%DU9AK>Z&\T<TZBE8JXT?6G4455B1 *#2T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT-,+$<8S1H-*Y+FEJ"5]J DJ#[G%)')N3@JQ] :=F3UM;_(L44E+2&%%%(:
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M4D<FY."K'T!IV9/6UO\ (L44E+2&%%%% !1110 4444 %%%(: #-+4.X#_\
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M*7*^@1:>P\-2LV*BE;:@SMS[G%)')N7@JQ]!5V>XGJ[)?Y%BBD%+4C"BBB@
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M[DM%0&XC3[SJ/QI1(&7*$,*3370>J5VB:BD%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E!/%,&,YS3"R1(SEN
M*=NPE=Z/<\I_:&^+EO\ !KX:ZCK*O&-0D_T>QCX'F3R=!_-_PK\WC^T%\2V.
M3XVULGU-T]=Y^U=\5[KXQ_%9M+TEWN='TV;['810_P#+Q+_RTD_!\#\*I_M!
M_ E?@MX9^'R2+_I^H6=S]OF]9\1?)]/WGE_2OHL/1ITH1=3=G]+<*9/E^48:
MA0S"">(Q/PIJ]M/Z^9^@?P-\72>-OA#X5U>ZG%Q<W%C%Y\O]^7&R3_Q\&O10
MQ$A'H*^=_P!A+Q NM_L_V5H&^;3+VYLR?^VGF?\ M2OH=G!#%C@+WKPZD>63
MB?@.=898+-,30BMI22^3T)LT9KY&^/G[;UI\/]>N?#WA&QAUS5;1_+N;VX<B
MVBD_N?)RYKQ[0_\ @H)X\M+Y'UK2M+U"R(Q+':1O;R?]LW,A!K6.%J.-WH?2
MX/@G.<;A8XR%-*,OANTF_D>S_MW_ !3UCP)HOAG3]"U>ZTG4+^ZDF::QDV2^
M5''\P_\ 'Q^51_L(>)O%?C+2/$VK>)=<U'5XEN8[2W%]/YAC*1[Y,?7S4KYL
M_:T^,FF_&;Q?H.HZ/*QTZWTN,B)AB2-Y))/,_E%7N'@KQ7JW[/?['OA[Q+I.
MFV=]=W5^UQ=K<;_+$<LDFR3]W[)%^==TJ7)2C%K5GV^+R583AG#8=T4L36GR
MW>Z=WI^"^\^V@11D>M?,?[+7[3FJ_'35M>L-8TZQL+BRCBDMVL?,_>@D^9G?
MZ9C_ #KWSQ1X@L/"F@7^L:G=);:?:6[SS2MT" 9)KRY4G"7+(_'\?E>,RS%O
M!8F%JE[66OS.@R/6C(]:^#?#W[=/COQOXQM]"T#PSI<S7]Q]GLTGW"0 =Y?G
MXKZ)^-/[0&A_ OP[:2ZR_P!OUNYB"P6%F-AF<#YWY^XF><G]:TEAIQ=CU\7P
MQFF#Q%'"2I\U2IJDFF[=WV/:J*_.;5/^"AOCV:Y']FZ/HEI;@8\N9)+B3_OL
M2 ?I7;?"O_@H!-J&O6VF^.=(M+.VGD\O^TM.,B10'UD23G9[YK3ZE5MH>QB.
M \]PU.565&]NB:;^X^XLT9JIYP:%9!]W;NKX>\>_MZ>*/#OCW7=$TC1-+NK.
MPOY+)+FZW_O-DFP]'K&G0G5YN5;'SF3Y%C\]J3I8&'-*.KZ'W9FC-?#?Q/\
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MD^X!_P"AGV4U^:7@;0KG6;/Q=XPO_P!Y;Z+:?:)+J4?ZR\N)/+M__(DGF?\
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M/#]IX@U:XUOQ QN7:TMW-S<D&>3R_,8<)^[\OKBOKO1-:M]>TBQU&V<26]W
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M07HMK6,;$&?GF?!Q&@SRYQTKXQ\6_P#!1+Q-=7KIX;T#3K*UQ\DNI>;<,?\
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MN/[-NY+?S!(_EQ^84Z\H>M?/>C>)/C9XET\76C:K\0=6LC)Y8N+*XO+B,_\
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M)NG*HNA[E/),96R^>9PC>E#=GTYFC-8?BCQ%I_A3P_?:QJ=PEMIUG \\TK=
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M1B/R>/O)_</TKY!_X)SZ]86WBGQCI=Q+'%J%Y;6TEN.GF)&9/,/X>9'7U?\
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MI4$=O;ZAK,D5G;Q#&R.2Y_=QU^K7Q@\2'P=\,O%&L*ZQR6NG3R0_]= AV?\
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MMX/\/Q28\J*XNY1_UT_=Q_\ H$M=O_P3R\.G2_AAJVKR#+:G?9C/_3-$ _\
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MIVNW.W-Q>:E;)<2N^.>9,[:^4?\ @G]X5&M_%K4-6EB_<Z982>6?25Y=@_\
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MC7]WY2>7)B1'_P!O\4KTKX@?L;?![X::3#J'B'QAKVDV<D@@22XGMQO<]/\
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M\)_L^^(8HF$;WD<>GPQCOYC@$?\ ?&_\J^3/V#/#ZZQ\<TU%XLQ:18/.)/\
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M0O&GPZT?5_#,2V^CS6P:W@2+R_*&.$V=L5^9NLZ/\4#K%\([#Q?Y?VF3R_\
M1[BON']AW0+K1_@592W6^,W\\UTL<G54SL _\<!KZ)$*DYVC..N.:X'4C0JR
M35[GY7@\[APKF>+A0IJJF[)R^?DS\6]=BU6UU2Y36X[R/4O^6D=]YGF_^1*Z
MR'2/BF8\1V/B[R_]RXKK?VSCC]I3QKQC)LQ_Y)QU^F_AU1_8.F949\A.W^Q7
MHUL1&-&F[7/UG/N+U@,LP%>%",_:4]8M_#^'^1XG^SSJFI>%/V6;35/$:W<-
MY86VH7-RFI[TF"I//)\^_G[F.M?F]INF:IXS\0I:6-O)?:KJ%QE(S_RTDDK]
M,?VQ/$W_  C/[/\ XF1'"7&HQQV"#U$C@2?^0_,/X5\:_L/>&_[?^/NF7$BA
MTTR"XO')]3'Y0_\ 1M9X:3C&56VYXW!^.E@\MS'/HQ2O*Z7R;M?U=OD8+?LE
M?%Q<9\$7G/\ T\VW_P <I?\ AD?XO$9_X0B\Q_U\VW_QVOU= &!Q0< 5S?7Y
M]D?,OQ+S*UO84_NE_P#)'E?PAT ?"GX%:#IVH1K;2:9I?GWL8_Y9RX,DO_CY
M>OS/^']C)\3/C-HT-P/WFKZS'-<#_KI)YLM?H_\ M3^*4\-? #QE="38]Q9F
MR0_[4Y$0_5Z^*_V%_#Z:O\>K2\==T>DVEQ=*?<_NO_:E=.$;A3J5+'J\'UOJ
MN59GFTE:;V^YO\VD=5^W_P## :!XTTOQA:(/LNKP_9KC'_/Q&./SC_\ 1=6/
M!?QO>?\ 8P\5Z+<S ZGHL1TJ/UDM[B3RHC^L@_[9U]2?M-?#Q?B?\']<TN-$
MEU&)/MEAC'^OCY'Y\I_P,U^5T6HW,5M<VT=S)%;7'^LB_P">E=&%MB:44]T>
M[PK&AQ5DE'"8J5JN'J+EO_+_ )6T/H7]@WPU_;_QRCOVC_=:18SW&?\ II(?
M+_\ 9Y:_2EFW#;[5\8?\$YO#_DZ'XQ\0,@)FN(K-'[_(F]__ $:GY5],ZG\8
M_ >@ZI/IVI^+]"T[48?DEM;C4X(Y(_JA?(KS,8ISK.*6Q^;<=U:F/S^M1@G+
MV:4=-=CO!T%!Z51L[VVU.VBN;6>.YMITWQRQOYB2)ZC\ZNMUKSS\V?ND9;Y2
M-P]\BODKXZ?"#X'W7BF^UGQ=XOGTG6;Q_,DCCOH]P]A&8W/Z5[;\?/&-Q\/?
MA'XD\06(#7UI9D6S'_EG(YV!_P -_P"E?G7^SW\-;;X\_%.72]?UB>*/[/+J
M-Q+YG^D7!\S_ %:&3H_[SKVKTL-1DU*HG:Q^E\(Y5.>'Q&<U<1.E3I=8;O\
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MX@DGN;Z20;!V\O[GZ5^>_P <_P!G_6/@1J]E;:K=6NHV>H>9]DN+<8\SR_\
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M\7?$?7M4\/6DEEI6H78DL[?R_+R?7RZ_4W5M2;X9?!:YO+ED:71=%:0GT>.
M_P"%?F3\ /"Q\9_&7P?I:\J^H1RN/5(_WDG_ *+K[R_;=\1KH'P"U. 2B*;4
MKF"RC/K^\$A_\AQR5MC+SJ4Z;/3XWA3KYCEF24G>*M>^KU:ZGYU^!?!^H_$3
MQKI'AZP_>7NJ7'E^<?\ R++7Z7> ?V4_AYX-\-Q6%QX9T_7;G;F>\U*W2XE=
M\=C)G;7RC_P3^\*C6_BUJ&K2Q?N=,L)/+/I*\NP?^."2OT7;:8QP2.G6LL?7
MGS<D6>)XAY_B7C?[+PM1QIPUMLV_7MY'PQ_P48\1(NH^#?#D'_+&&XO)8_\
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MO_!.;PP+GQ+XO\12QY-M;QV44GKYCF23_P!%Q5]#?M>>)AX6_9_\5%9 DEW
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M[RI+"6;2/W23@"6"2= B!QV<&0 U\'?L>Z!%K_[0OAL2 &&T\R\.?2./$?\
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M92U=O+]3D? GP!\=_%'27U;PUX?.J6"3&$2+=P)\XZ_ZR3WKIC^QE\95&?\
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MLN\7VJ'43';1G_EK/)%'Y8_4#_@%<'^R=\-)OB[\8TU74C]HL=+<ZI=S2_\
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M/_1=?K6B>6FT?PJ!7QM^PS\!]3\,W%UXVUZT:QFNK<6]C:RJ!(L?5W/U-?:
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M^%?H=@48'I73#%3IQY8GVN$XSS/!94\HH\JI][>\KN^]_EL0%]AV =!2;]Q
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M(OA-H&O7'BG3QIFJW]W&?*\^.4>4D?&#'QU>2OIB>>*V21Y'6.-!N=WZ"K!
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M#YO;^3_IK_SS_G7UY\9?AD/B1\)-:\':?)'9B>"-;5L?+&T<B.F1_P  %>I
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M\0M0U+4_"K6UKJ>J27%Q<B_LR4B=_3S.>*_1ZRLH]+LH+>)5CBC3:%K4P*,
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M_!7A_P"QS^SMXP^'OQ%O]>\5:'_9L$5A);VO[^"0AWD3_GFY_@6OM\@'M0%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D/2EHH KK&JQX .">F:?L"C!Z>]24M-MBLK\SW$I:**0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM% #!D=3S4,T:S
M#E1(!V(JS28IWMJA._<JI;B+ B"HG?%3*Q9L#H*DQ13<K[@E9N3U;%HHHJ1A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )FBHPH!]*&.>P/XT-I"OV):*AWM_='
MYT;V_NC\Z5I#T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N
M345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]
MT?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM
M_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(
M-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-
M[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ
M'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.
MBT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/
MSHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R
M:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_N
MC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O
M[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!
MIW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O
M;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0
M[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT
M6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^
M=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N3
M45#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T
M?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_
M='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-
M.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[
M?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'
M>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.B
MT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/S
MHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:
MBH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC
M\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[
MH_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!I
MW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;
M^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[
MV_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6
MD&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=
M&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N34
M5#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?
MG1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_=
M'YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.
MY-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?
MW1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>
MW]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT
M@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SH
MWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:B
MH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\
MZ+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H
M_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW
M)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^
MZ/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V
M_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D
M&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&
M]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345
M#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G
M1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='
MYT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y
M-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W
M1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W
M]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@
MT[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHW
MM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH
M=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z
M+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_
M.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)
MJ*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z
M/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_
MNC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&
MG<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]
MO[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#
MO;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-14.]O[H_.C>W]T?G1
M:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1^=%I!IW)J*AWM_='Y
MT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT6D&G<FHJ'>W]T?G1O;^Z/SHM(-.Y-
M14.]O[H_.C>W]T?G1:0:=R:BH=[?W1^=&]O[H_.BT@T[DU%0[V_NC\Z-[?W1
M^=%I!IW)J*AWM_='YT;V_NC\Z+2#3N345#O;^Z/SHWM_='YT[2#3N2YHS46"
M.6^;V I"2>-A%"LR7*SLR>BD'2EH*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH]V'_$+<H_Y_5/OC_P#(GZC_ /#;'P<_Z&\_^"N\_P#C5'_#;'P<_P"AO/\
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MW*/^?U3[X_\ R)^H_P#PVQ\'/^AO/_@KO/\ XU1_PVQ\'/\ H;S_ ."N\_\
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MH]V'_$+<H_Y_5/OC_P#(GZC_ /#;'P<_Z&\_^"N\_P#C5'_#;'P<_P"AO/\
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MW*/^?U3[X_\ R)^H_P#PVQ\'/^AO/_@KO/\ XU1_PVQ\'/\ H;S_ ."N\_\
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M1 =G^D./M,?_ %SD_P"6G_;3'UK[[^'OQ,T#XI>'+;6] U".\LY!@X/SH_\
M<=.Q]J\FMAJE'='XUGW"N9\/27UN'N2VDMOGV.TS2U&<9IP.!7*?'73V'444
M4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !112&@ S0Q !)Z"H&0NZM7 ?'+XB6WPK^&^N^(
M9 &EMX"88_[\S_)&/S(K2,.9V1O0HSQ-6%&DKN3L?,_[9_[3=QIDUSX"\+7?
MDW$B$ZE?1R<H/^>"?^S^@-?$-3ZEJD^LZA<7]].]Q>7;R7%Q))_RTDDJO7UE
M&C&C&T3^U^'<CH\/X%82A;WOB=M7\PHHHK7E/J9-RT"BBBK)"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BN[^!OP_LOBK\5-#\+W]Q/
M;66HM.LDEL<292WD<?\ HNOL'_AW?X/4;7\2ZZ)",J T6/Q_=URU<1"D[2W/
MC,YXNRO(<0L-CI-2:3T5]W8^ Z*^_'_X)R^%B/\ 1_%6KQG_ *:)')7'>-/^
M">-Q864L_AKQ.U]=1#,=IJ5N%$GL9!S6,,;3E*S/,H^(.05I<L:K7K%H^-**
MN:WHU_X<UB]TS4K-[+4+23R[BWD.9$DKZ=^!_P"Q?:?%WX9Z3XNE\43Z9+?&
M5?LR6F_RS'<21_\ /3_8KHJ5X4X\TF?39EG^793A8XS%5+4Y2Y4TK]_\CY6H
MKK/BIX,C^&_Q"UWPVEW)>1Z9.+<W,L?E[_:N3K6,G./-%'L8:O3Q=*-:C).+
MC&2?J%%%%6= 44446?8-5JUIWT"BBBHY@U>J044454KK9%6;^'\;!1113)U>
MJ04444:]$$4Y_"U]X4444 %%%%*5X[DRERRY9:>?3[PHK[*^'G[ T>N^"M.U
M?Q+K%_I6JW4(E>RCBC'D'^#M]\<<U\D>(]*CT37M2TV.3S8K*YEMO-_ZYR5C
M3K0J2E&+V/G<LXBR[-ZU>CA)\SI^6YF4445N?2!1110 4444 %%%% !1110
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M:&0?]L_+K]!/A5X_M?BGX T?Q+"@@74(0[0EMXC<_(\>?9P1^%?#>B?\$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME3VC<^OX@XHQN ]CA<HP\ISJ[.S:U_KY'Q1=?L@?%W3XQ++X.D7OA+RW<_\
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M ^^>M<Q\%OVZ](\7W5]:>-K>U\,20('BO8Y&DMIO6,''^L]JY_K&(<>:*O\
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M/,B0C%K:'!^< _?/N:^"?"NM?\(WXFTG5-GVDZ?>1W/E_P#/3RY/,KU7XO\
M[6WC3XJ6UQI<<J>']"<8DL[,YE?V>3^,<=!7GUH5JNSL?F_%&7YUFTJ6!RV?
M)AY;OJOU/T[MKRWU+3(KJTECN+:6'=%)&V4=/4?G7XZ^/?\ D>_$W_81N?\
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MKV.1I+:;UCZ?ZSVKY\_:V\6_#GQWXLM=<\"WINM2D_=ZKY5G)'')_P \W_>
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MCV<8NVKZ'ZSGG&E;)\'0A.E?%U%%\O:_<^ F_8X^,"VGV@^$"._E?;[?S/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
MH/[%"%OV;?"ONU[_ .ED]</\8OVV#\(_B5J_A1?!_P#;"Z<(E-RNIB(R%XXY
M/]7Y9_YZ>O:NZ_8HS_PS5X4V]?,O?_2R>OB7]LL!?VD_&@'3=:?^D<=?/4(0
MJXFI&>Q_+V1Y-@<]XKQV'QT'**=1Z.WVSV:\_P""D&I2VY^S^!+>WDZ;WU3S
M!^L<=?.'Q;^.GBOXTZA&^NWB16,!S!IMNA2W0^I)Y->?T5Z]/"TJ<KI'[IEW
M"F3Y14]O@J-I]&W>WWGM7[&G_)RG@O\ W[O_ -([BOL3]O#_ )-ZO/\ K_MO
M_1HKXY_8V7=^TEX+!X^>Z_\ 22XK[&_;Q(/[/E\/XOM]KQ_VUKS,0U]:BET/
MRSBB2_USR_\ [A_^ER_S/@3X1_"K5_C+XP30-'V1.(_-N;F09CMX^T@'K7VA
M8_L5_";X<Z1%J7CC79KB*(9EGU.\2SMO\1_WW7 _\$X]1L8/$_C.S=HQJ%S;
MV[P#N8XY)?,_]&QUZ9^V3\"/%OQ?30;[PN4U%M.\Q)--DN!&)/,P-Z>9\F1[
MT\1-RK<M[(.)<\Q>*XA653Q?U:C'[7P]+_\  W-CX/\ BOX#Z=XXM?#OP^M+
M%]:FC<_:;2SDD_U:=[A\]O<U@_\ !13/_"G]$SU_MN'_ -$7%9'[)?[*?B3X
M9>*W\6>*I+>VO8H)+>UTZ&3S<!SDO))W)QBM[_@H1ILE_P#!O3[E/]5:ZM#(
MX]C'-'_[4KGCRJNM;GQU)8&CQ5A883$2JP35Y2=VW?O8X;_@FL,O\1!_LZ?_
M .W%9'_!1Z9SXJ\&VX_U:6MQ*?\ OL5K_P#!-;_6?$3'7;I__MQ6+_P4<(/C
M/PCC_GPE_P#1@K=-?7>9['UE)K_B(M1O7_\ 8/%OV5)9(OVA/!(3I]L,7_D*
M6ONW]M53_P ,X>,3VS9?^ED5?!W[+//[0G@G_L(G_P!%5]Y_MK'/[-GB_/7=
M9?\ I9%3Q37UBGU+XQER\5Y<O\%__!E_^ ?$G[&G_)R?@S_>N_\ TCN*^Q_V
M[)Y$_9^U%(^DMW;1O]/-%?&W[&PW?M)>"QG'SW7_ *27%?8W[>)!_9\OO[WV
M^UX_[:U.(M]:BM[!Q7RSXRR]2U7+33_\#E_F?FC7[,^#IFN?!FE._P!^2RB8
M_4QBOQFK]E?!G_(D:.!R#IT.?;Y*>8-MJY?BM&,(X.2W=_D?F7^R%;)<_M&^
M#HI_N-+<,,^J6\DG]:_1;XP>'_"WB7P#?Z9XOO(M.\/7$D?VB::[^S)Q*'3]
MX2,?O .]?EI\*_&9^'OQ'\.^) I:.PNXWD1>KQG_ %A_[]U^H7Q#\(:+^T!\
M*+G3(;])+'5[9)+2^A_>!7X>.0?B :G&1E[52EL>5XAT)T<VPN*K2<:;BES)
M7L^K/G]O@;^S,#QXNTDC_L:$_P#CM>Y:!\7?A9X9\.Z?HUGX[\.?9-/MDMXE
M?68'<QHFP9._KP*^)=+_ &&?BA=^)X]-N["VMM.\S]YJ_P!KCDB,?IL/SY_[
M9U[I\6?V1_@_X&\"WVN7CZAH\5A;F4R6^H$F5L?<_>>9_K#@?C15Y9R47.YY
M^:X/*ZM6AAZV93KN7\JYN7R^(YK]@BTL8?B3\23:R12Q1&*.VDC_ .>?FR__
M &NK7_!262[^S> HX]WV0R7OF8_YZ_Z/Y?Z>97CO[%/Q(M? /Q>2TU&X6WL]
M:A%IO<XC23_61_S\OZR"OL_]J#X&2?'7P+!::=-';ZS8R"XLY9.48_QH?J*<
M[4\2I3V/5S2I#)N-,/C<9I3TU_[<Y?SU/RR_U-?L[H5Q)>^%]/DF.V>:V1W^
MI2O@3X7_ +#7C>_\7V1\8V%OI&A6\F^X N4EDN$_YYH8^E?H4FQ;!?*(;:OR
MDBIQE:-5KE=SA\1\ZP&95<-# U%-QWET>Q^*E%%%>^MC^FJ?P1]#L_@S_P E
MA\"_]C!I_P#Z41U^I'Q[_P"2&^/?^P#>_P#I.]?EM\&EW?%_P*OKK^GC_P F
M(Z_47X\J!\#_ !VIZ#0;['O_ *.]>%B[.K"W0_G7Q&DEG>#76R_]*N?EW\&/
M^2P^!/\ L8-/_P#2B.OTT_:9N&M?@-XX>/K_ &5*H_[Y-?F7\%QGXQ>!!Z^(
M-._]*(Z_3']I[_D@/C8'_H'RX_*C%V]M32-N.[3X@R^,NMO_ $L_)NOUC_9E
ME9O@/X,+]?[-B7_QVOR<K]8/V8$"_ +P=WW:='GV^6ML>VXIR/8\4$EEV&OT
ME:WR9\3_  ]@23]N68/]T>)]1'_C]S7U_P#MB2W$?[.'BT6V?-6.W+8Z[/M$
M>_\ 3-?!FO\ BY_ '[3NN:_$F\:?XKN+B2,?\M(OM$GF5^E/B#2='^,_PSO;
M**\2XTK6[+Y)X#G(<?(X/ZUCB$XSA.6R/D^*/:83&Y3F52/[I*G=_P""U_O/
MR"K],?V';B>;X :,93B*&:>&//=!*<5\IM^PU\4#XG&G)861TXR?\A=KR,1^
M7_?V??S_ -LZ^_/A-X$L?A=X%TWPO:2^>FG((W=AC>Y^=W_$OG\:K&UX5(6B
M[GL^(W$.6YAEU##X.K&<[ZVU2^9^=/[9W_)RGC/ZV?\ Z11U^A_P#_Y(3X%_
M[ -E_P"DZ5^=W[9?/[2?C/O\UG_Z1QU^A_P' ?X&> AC(_L&Q'_D!*G%6^KT
M['C<824N'<I?:*7W11^8UO:QW'Q[CMYQF)_$_ER?^!-?IY\:9KB#X+^,I+;<
M;A-#NS%LZ[_L[XQ^-?E3XMU&32?B1KE[;_\ 'S;:M)+'_P!_:_5?X?>,-&^+
MGPZM+^ QW.GZC:[)8V;.W(P\;_J*K%J5H3Z(]#Q HU8_4,;)7C%:_@?D(3GV
MI\MW)+'%')))+%'_ *N+S/\ 5U]*>,OV$/B#IGB.ZMM"2TU;2/- M[J:=(Y/
M+_Z:)CG\*^K_ (:_LX^%/ ?PML=!\2:;I>LM!%)->75];QR1^8>9#^\'"?TK
MKJ8NG**>Y]WFG'N4X>A2Q%*U:4OL_P ORU/S5\"^"=3^(OB?3]!T>#?J%T^Q
M#*/W40_YZR5]N^&_V$_A[X*T4ZGXX\07%ZL47^DM+.EE9I^ Y'_?=>:_LW>)
M?"C?M9ZW-H]I!8:)=6LUMI,<2[(_W9BY'^^D;M_P.OHO]KCX->(/C'\/[&R\
M-3H;RTNQ=?9)9-D=Q[$URXB;<U"]EW/C>)>(L=7S+#8"%1X6C-)RD]&K_EVW
M.8\#>(OV<?!7C'2M(\(6^G7GB&ZG2VM9K>WDO)$D[9N9,_\ H==A^V>XD_9K
M\6LIR,V?;'_+Y%7@O[-O['_B[PW\0=.\3^+[>'1[?39#/;V"7"3R-)COY?R5
M[[^V/I\VI_L\^*TA!5@D$I!_Z9W$;C_T&N::BJ\;2YK'QF.A@\-Q%@UA,4Z_
MO0;G*5U=23W/A3]DQ/,_:'\&+ZW$O_HN6OMK]N(Y_9ZUH_\ 3Q;?^E,=?$'[
M+%REC^T#X,F9_+07<L8'_;*6OT$_:9^'.I_%/X/:MH6B"-]4F>.:".638'*2
M*X&?PK?%7IUTY'V/&=>.'XKP&(J.U.-M?+FN?E)7[*^,W\SP7K8[#3IS_P"0
MC7Y._%/X2Z_\']7M=-\0);I?74'VQ(K63S/+.^1/Y(*_6'QF^/!.L?\ 8.G'
MYQ&C&R4G3<41XCXJEC9Y?B*$E*,N>S7K'_(_+[]ERV@N?C]X,2;_ %8O/-_[
M:>5+Y=??7[7^HW6F_L]>+Y;-0)6ACA)_Z923QI)_XX37YF>"/$\_@CQ;HVOV
MHW3:9>1W#0_\]1')TK]79%\/?'7X9/&DOVS1=<LC'YD3 .!(,?@R?TJ\7=5(
M3DM$7Q^IX3-L#F6(C>E%*]EVES/\#\B*^X/^"<-[=2:?XUM7'^@1S6L\?_76
M02>9_P"@1UY?K7[!GQ+L]:DMM/AL=2T[S,1WS3I%B/\ ZYU]D?L\?!2#X#>
M!ILMQ'<ZA<.;F_NX^$:4CG'HG%7BZ].=+EB[L]+C?B7+,;DBP6$K1J3FUHNG
M4^8O^"B]K;GQGX1N(P/M+VDD4I']S>/+_P#:E?7GP"&/@;X%/IH5D?\ R72O
MSL_:M^*T7Q7^*]]?:>XN=&L$_L^TE'1RG^LD_"23'X5^B7P#X^!W@0#G.A6(
M/M_HZ5R5XRAAX1ENCXCB?#5<%PYEM"ONKNWJ?E3\1))+GXA>*9Y/]8^JW,DG
M_?R6OMC_ ()RNY\#>*DSA$U!&'XQC_"OB/Q[_P CWXF_["-S_P"C9:^W/^"<
M./\ A"?%OK_:,>/^_8KLQ=_J^FY^G<<WCPNK;?N_3[CR3_@H5_R6_3".^@VQ
M_P#(\]?57[&S1?\ #-_A-H$\N/9<8'_;>2OE?_@H9C_A=^EGUT&W_P#2BXKW
M_P#8(UZ+6/@?_9>[#:9?W%NR^F\^;_[5KFJ7EA8KL?!YW1=3@G+ZL=D]?E<^
M&_CG,\OQG\<[D\M_[:N\'U&^2NB_9O\ CO-\!_&LM_-#)>:-J,8@N[:+F0$'
M/F1BF?M6:0-"_: \:6HZ/>"X_P"_D44G_M2N[_8^^%WP]^+-UJ^D^*8'NM>M
MW^T06_VN2-)H/7"$<<_^1*]"4E*A=['ZIBZ^$7"\*V-@YT'3AMOY_<?:O@CX
M[?#CXEP^7HWB#3[N60?/:7#".7\8Y.?TJAXX_9B^&?CR)VO_  U9VMQ)P;C3
M4%O)^<>*^>OV@/V';VXN[+4/AO80"WCA,=QI#S>7\_\ STCD?O6O^RM\"_BS
MX \:6]]XDO9-&\-Q)+&^DRW_ -I\X](\1Q_NX_[_ !SS7DN%-+GA/Y'X8\#@
M,-A/[4RC,7"7\C?O_@__ &T\1_::_9B?X'/9ZOI%Y/J/A^[D$&+E,R0.>B.>
MXKP6+S(I8I(_];_RS\JOT#_X* >-]-L/AC8^'A)'-JNI7B3Q1YY2.,Y,GX8K
MX6^'NCOXB\=^'-,A.'N]0M[<_222O5PU2<J'-,_;^$LXQ&-X?6)S'WFG):KH
MEN?J_P#&/RS\'_%AGV^6='N=^_ICR&S7Y!5^J_[5/B&+PW\!/%<LC^6MQ9-9
M(?>;$0_]#K\J*PR]7@VSY'PMH2^IXFI;1R3^[_APHHHKUS]U"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ]J_8T;;^TIX+/^W=C_P D[BOT,^-OQ('PC^&&K^*%L3J1L/) MQ,(
M_,,DJ)]\\#[]?GC^QL W[27@L'IYEU_Z27%?;?[:G_)MGB[=P=UG_P"ED5>!
MC+/%01_-_'&&I8CBO!8>LKQFJ:EYWF[_ )GB1_X*22GK\/8B?7^VS_\ (]<7
MX[_;[\9>*-/>TT'3;/PSYHP9O,^T7$?O'_\ 7CKY=HKTU@Z*E=(_5,/P+P]A
M:GM*>&5_-R?ZDMU=R7=S+<W$DDMS))YLDLO_ "TK]/\ ]B,Y_9N\+#_II>?^
MED]?EW7ZA?L4(#^S9X4)!),EX./^OR>N7,.54TCY/Q/C&GDU&$=(^TT^Z9\*
M?M5R27'[07C9G?S,7@B'_?J*O:?^"<LT@\6>+US^Z6TMS_X\U>(?M2?\G!^-
M?^P@/_15>V_\$Y<?\)GXMS_SXQ?^AFG._P!3\SNSV37!2M_SZIKY][&W_P %
M)SF?X>'_ &-0_P#;>O-OV>?V0;[XOZ3'XAUJ^DTG0)'VVPMX\7%P,^O_ "SC
M]J]$_P""D (N/A^#UV7^1_X#U]%_LQZGI^I_ WP>U@T95-,@MG,73S(QY<GY
M.'KE53DPMDCX.&>8S*>#<)]4T<FTW:]O>D_U/(=8^"_[-_P99$\17D$]_&,^
M3J6H/-<'_MWC/\HZ]R^"GBWP7XP\'++X#MXK/0K>>2!(;:S^S1AQUPG%?%/Q
M._8T^)FI?$?6KFQM8-6TS4KN2ZBU.2[C0+YG:2-\OQ[5]E_L]_"<?!KX;V7A
MY[M+R]1WGGE1<(9'.37/6C!T])7/FN(88-Y;2K3S"6(JRZ.5TO5=#X#_ &SC
M_P 9*>,,]VL__2..OHWX _MJ^'-4\/Z7H7C.Z71M6M8TMWOYVQ;W?& XDZ(_
M7@UX%^UY8PZ5^U%J\^J(\NG7$MG<R1P_ZR2+[/'&_P#Z+DKZ@L_V0?A-XG\"
MF;PW:!GU.RS:ZP+R2Y5?,'R2!#)L/Y5W3=/V-.,T?=9SBLJGP[EE/-(R^%*,
MHK2.B6I['<Z3X&^+.F![FTT7Q-9MTD*1SK^#<@UXA\2_V#/!GB"UGNO#$MQX
M:U$C,:*WFV['WC?(KYT'['/QD\-:\(]'L0-G^JU.RU)(H_\ T9YM?>?POTG7
MO"'PMTNR\9:LFI:Q:6Q^UZC*^/4DE^,[4.-YZXS7)4E*@U["=_4^(Q49\-*E
M7R;,_:*7V4]5ZJ[_ $/SW_9?\/7&C_M1^&M(U6W$%Y8WMY%/'GA)$MY/_C=?
MH)\8= \+^)?A_J&F^+KR+3_#]Q)']IEFN_LR9$H=/WA(Q\X'>OSIU/XM067[
M2]QX^M%\W3X]6$ZLO'F6^/*R/^V=?HA\0O"&C_'WX2W6E0W\<NGZO:I+9WT1
M\P*^ \<@_$ UIBU)5(S?0]OCF%?^T,!C\5>$912;6MGU9\_GX&_LS _\C=I)
M'_8T)_\ ':]RT'XN_"WPUX<T_1K/QWX<^R:?;);Q+)K,#N8T38,G?["OB32_
MV&?BA>>)H].N["VMM.\S,FK_ &N.2(Q^FP_/G_MG7NOQ9_9'^#_@;P+?:Y>/
MJ&CQ6%N93);Z@296Q]S]YYG^L.!^-.KRU)*+G<QS;"975JT,/7S*==R_E7-R
M^7Q'POXBBM[7Q'J\=G)')91W,D=O)%_SS\VLVBBO>1_3U"/LXI7N%%%%%WW+
MJ>\FGMY'Z\_ 7_DAG@7_ + %E_Z3I7Y0^._^1Y\2_P#81N?_ $9+7ZM? 9?+
M^!W@0YX_L&R)_P# =*_*;Q[_ ,CUXE_["5S_ .C9:\; O][4L?@'ANT\RS!?
MUO+_ #,.BBBO:/Z!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!]/?\$]&Q\;M4'][P_*/_(\%>D_\%(1_Q)/
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MPV2Y9FU)6<$XM]W>Z*7[1GB&+X<_ 3Q+/:XMMEA]@MR.B-(/*C_5Q7'_ +"
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M>&VDWQBWG3'\Y/\ R%7Z'?$SP)I'QX^%]WHPNU2"_1)[6[C&_P J08>.0?B
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M:A\&A]-2PM+!X:6'P<5"/V;+;_,^NO!GP0_:%^!4<S>&I-/U"RD_>-91W2/
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ML@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXY!Z2?\ +20>PK9UG]M7X@^(=#O-(U2UT.\L[N"2WN(FM)#YD<@Q_P ]/2O
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M .U_]LZ\THJY4H3C&,EL>I/*,#4PL<'.DG!?9:]WY+H?7$?_  49\5I:;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBBE9"Y4]VWZA1111JM@2M&,5T_$****8PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@84444#NN:["BBBHY5T)6DI3LKOR"BBBK ****CE74:;CM:_
MFKA1111RCYF]&%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?MS!_P >
M\?\ NBOQ&K]N8/\ CWC_ -T5\_F&U,_GGQ7^+!?]O_\ MA+1117CGX %%%%
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M']*_1G/S5^8?_!5#_DKWA+_L _\ MS)7I9=&^(2.G"YQB<AG_:&#=IP/E_\
MX3>R_P">=Q1_PF]E_P \[BN(HK[3V4.QZO\ Q%SB7^:'_@)V_P#PF]E_SSN*
M/^$WLO\ GG<5Q%%'LH=@_P"(N<2_S0_\!_X)V_\ PF]E_P \[BC_ (3>R_YY
MW%<111[*'8/^(N<2_P T/_ ?^"=O_P )O9?\\[BC_A-[+_GG<5Q%%'LH=@_X
MBYQ+_-#_ ,!_X)V__";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_\  ?\
M@G;_ /";V7_/.XH_X3>R_P">=Q7$44>RAV#_ (BYQ+_-#_P'_@G;_P#";V7_
M #SN*/\ A-[+_GG<5Q%%'LH=@_XBYQ+_ #0_\!_X)V__  F]E_SSN*/^$WLO
M^>=Q7$44>RAV#_B+G$O\T/\ P'_@G;_\)O9?\\[BC_A-[+_GG<5Q%%'LH=@_
MXBYQ+_-#_P !_P""=O\ \)O9?\\[BC_A-[+_ )YW%<111[*'8/\ B+G$O\T/
M_ ?^"=O_ ,)O9?\ /.XH_P"$WLO^>=Q7$44>RAV#_B+G$O\ -#_P'_@G;_\
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M=O\ \)O9?\\[BC_A-[+_ )YW%<111[*'8/\ B+G$O\T/_ ?^"=O_ ,)O9?\
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M8/\ B+G$O\T/_ ?^"=O_ ,)O9?\ /.XH_P"$WLO^>=Q7$44>RAV#_B+G$O\
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MT/\ P'_@G;_\)O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#_P !_P""=O\
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M%%'LH=@_XBYQ+_-#_P !_P""=O\ \)O9?\\[BC_A-[+_ )YW%<111[*'8/\
MB+G$O\T/_ ?^"=O_ ,)O9?\ /.XH_P"$WLO^>=Q7$44>RAV#_B+G$O\ -#_P
M'_@G;_\ ";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_P# ?^"=O_PF]E_S
MSN*/^$WLO^>=Q7$44>RAV#_B+G$O\T/_  '_ ()V_P#PF]E_SSN*/^$WLO\
MGG<5Q%%'LH=@_P"(N<2_S0_\!_X)V_\ PF]E_P \[BC_ (3>R_YYW%<111[*
M'8/^(N<2_P T/_ ?^"=O_P )O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#_
M ,!_X)V__";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_\  ?\ @G;_ /";
MV7_/.XH_X3>R_P">=Q7$44>RAV#_ (BYQ+_-#_P'_@G;_P#";V7_ #SN*/\
MA-[+_GG<5Q%%'LH=@_XBYQ+_ #0_\!_X)V__  F]E_SSN*/^$WLO^>=Q7$44
M>RAV#_B+G$O\T/\ P'_@G;_\)O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#
M_P !_P""=O\ \)O9?\\[BC_A-[+_ )YW%<111[*'8/\ B+G$O\T/_ ?^"=O_
M ,)O9?\ /.XH_P"$WLO^>=Q7$44>RAV#_B+G$O\ -#_P'_@G;_\ ";V7_/.X
MH_X3>R_YYW%<111[*'8/^(N<2_S0_P# ?^"=O_PF]E_SSN*/^$WLO^>=Q7$4
M4>RAV#_B+G$O\T/_  '_ ()V_P#PF]E_SSN*/^$WLO\ GG<5Q%%'LH=@_P"(
MN<2_S0_\!_X)V_\ PF]E_P \[BC_ (3>R_YYW%<111[*'8/^(N<2_P T/_ ?
M^"=O_P )O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#_ ,!_X)V__";V7_/.
MXH_X3>R_YYW%<111[*'8/^(N<2_S0_\  ?\ @G;_ /";V7_/.XH_X3>R_P">
M=Q7$44>RAV#_ (BYQ+_-#_P'_@G;_P#";V7_ #SN*/\ A-[+_GG<5Q%%'LH=
M@_XBYQ+_ #0_\!_X)V__  F]E_SSN*/^$WLO^>=Q7$44>RAV#_B+G$O\T/\
MP'_@G;_\)O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#_P !_P""=O\ \)O9
M?\\[BC_A-[+_ )YW%<111[*'8/\ B+G$O\T/_ ?^"=O_ ,)O9?\ /.XH_P"$
MWLO^>=Q7$44>RAV#_B+G$O\ -#_P'_@G;_\ ";V7_/.XH_X3>R_YYW%<111[
M*'8/^(N<2_S0_P# ?^"=O_PF]E_SSN*/^$WLO^>=Q7$44>RAV#_B+G$O\T/_
M  '_ ()V_P#PF]E_SSN*/^$WLO\ GG<5Q%%'LH=@_P"(N<2_S0_\!_X)V_\
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M_B+G$O\ -#_P'_@G;_\ ";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_P#
M?^"=O_PF]E_SSN*/^$WLO^>=Q7$44>RAV#_B+G$O\T/_  '_ ()V_P#PF]E_
MSSN*/^$WLO\ GG<5Q%%'LH=@_P"(N<2_S0_\!_X)V_\ PF]E_P \[BC_ (3>
MR_YYW%<111[*'8/^(N<2_P T/_ ?^"=O_P )O9?\\[BC_A-[+_GG<5Q%%'LH
M=@_XBYQ+_-#_ ,!_X)V__";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_\
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MT/\ P'_@G;_\)O9?\\[BC_A-[+_GG<5Q%%'LH=@_XBYQ+_-#_P !_P""=O\
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M%%'LH=@_XBYQ+_-#_P !_P""=O\ \)O9?\\[BC_A-[+_ )YW%<111[*'8/\
MB+G$O\T/_ ?^"=O_ ,)O9?\ /.XH_P"$WLO^>=Q7$44>RAV#_B+G$O\ -#_P
M'_@G;_\ ";V7_/.XH_X3>R_YYW%<111[*'8/^(N<2_S0_P# ?^"=O_PF]E_S
MSN*/^$WLO^>=Q7$44>RAV#_B+G$O\T/_  '_ ()V_P#PF]E_SSN*/^$WLO\
MGG<5Q%%'LH=@_P"(N<2_S0_\!.\M?%EE=W,5O''<>;)7[I(5CA5>?E^7\J_
M/0?^0Y;?]=:_?R#_ %:?[H_E7S.;1Y73+Q_$V/XGP&'Q&82NX.<?P@R<=*6B
MBOGSYX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** &?Q&OS#_X*H?\E>\)?]@'_P!N9*_3
MS^(U^8?_  50_P"2O>$O^P#_ .W,E>KEO^\Q/+S#_<ZA\44445]L?$!1110
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M1A1111R]PYNP4445)044457+?8GF[A1111RMQN@YDI684445)04444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9//O/$<DFS#R&^CY_\ (5?%'["?@3_A._VF?"_F1^9:Z,)=7E/IY?\ JO\
MR)Y=?K3_ ,);#_PL;_A%H]OFII7]I2>P,OEQ_P#HN3\JZ\TQ-2$U"D[=SDRO
M#PJ1E*HMC\D_VU/@CX>^ 'Q3TWP]X8:[>QN-%BOI/MTWG2&3[1<1Y'_?N.O
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M7GRTY??H<M;!UZ$>:HONU/#Z*L6&GW.HWUM96=M)=7-S)Y4<44?FRR25]E>
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MC_MI7Q77[]:WIVD^*;34="OHH;VWN;;RKNTD&0\,F],'V.)!7XM_M+? ^\^
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M='S6$M+$13V9ZE^VO^Q[X$_9^^%>F^(O#$FK37MSK4=E)]NN8Y(Q']FN9/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!DG_+*HZD_Y95'0*844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_15>,_M'_L"Z=\"_A[J?C.W\?&XM;/RXX;&ZT[9)*\DH_=^:)<=_^>=>R_\
M!*7_ ))WXX/_ %%H_P#T71B/9?4/W'P7(P_M?K_[[XSY7_;Z.?VM?'?TLO\
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MW?OBOF:OUE_X*&:7XUU_X(G3/"NCR:II\MQ]IU@6YS+';1#S(\1]_P!X ?\
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MJ7]K>7_RT>*2*.//YQ#_ +^5G"4O[.:@];FLU'Z^O:(X;]N_]K+QIH_Q4O\
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MJO\ PC]E+ZQ1_O/_ $6;:O(?^"6?CH6'Q#\5^%99!Y6J:?'>QY_YZ6\A&/\
MOW*/^_5?HKK%YIO@G0->\0311P6T$,NI7LD8Y<1Q#+G_ +9QC\J\[$R="I4I
MK[1Z&%BL13A4_E/G;X,>-_\ A./VU/C(8I/,MM&TVRTF+V\N0^9_Y$\ROEC_
M (*D_P#)P.@_]BS;?^E-[7:_\$Q-<N?$/Q9^)VK7DOF7%[;Q74O_ %TDN9:X
MW_@J;_R<%H'_ &+-M_Z4WM=.&@J>-4$<U>3JX-S9\<U]"?L"?\G;> _I>_\
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M\4OV>/\ A OVU?AU\0-%M_*\/^(-5_TY(H_^/>]\J3G_ +:__':V/^"I/_)
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MEDNYRW_!/I(!^R?X,\L)N$EZ9<?\]/MLW_UJ_-']JC?_ ,-'?$G?T_MJY_\
M1E?;/_!,'XGV>L?#S6? =RR1ZCHUX;VW3(^>VD(XQ_TSD_22.O(O^"A/[.&O
M:7\4KOX@Z'I-QJ>@:Q'')>RVT7F?8KF,>7^\_P"F<F16N&DJ..DI:)F5>+Q.
M!BZ>K1\645W?PC^"?BKXU^)[;1_#&E7%T))/*N;_ ,K_ $:RC_YZ225^DOQX
M_9G^"G@GX(:AK6N>%K.-O#NDK%#?6R_9KFXECC$</F&/'FO))Y8_>9Y(]*]K
M$8ZGAIJ._H>-AL#4KPYOST/E[_@EY% /V@]8+^7YG_".7.S_ '_M-MFO7?\
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MZQVT9-?/E=N#N\,K[G)BK?67;8****ZCD"BBBF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!8BBD^Q2R?\LHY(HJKU=B_Y ES_P!?,7_M6J5
M2U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH&=1\,?"N
MH^.OB%HFAZ9'')J.H7'EVYED\NOWH0_*%QVQ7XF_L@_\G,_#S_L*1_RK]M!W
M^E?)YO*]2,>Q]GE5:4L+[%_9DW]]O\AXZ4M%%> >N%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #3UK\T?^"JO_)0O!/_ &"Y?_1M?I<>M?FC_P %5?\ DH7@G_L%R_\
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MX8ZKX?\ $.E:_?W]UK$FHI)IEO;O'Y<D5O&.9)8\<Q^E?.OQY^(&G?$_XO\
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M&^$?A!/!7CF*Z_LNS>1]/U2VC\SR8GS*\4J#D8)_G7AO[7_C71?B+^T7XO\
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M_85CK]M>PKX_-W%U[)W/K,GYO8MM6N.HHHKPSZ **** "BBB@ HHHH ****
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MS_HFO@__ ,$%M_\ &J[VBCVL^[#V,.R."_X9[^%G_1-?!_\ X(+;_P"-4?\
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M""V_^-4?\,]_"S_HFO@__P $%M_\:KO:*/:S[L/8P[(X+_AGOX6?]$U\'_\
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MS_HFO@__ ,$%M_\ &J[VBCVL^[#V,.R."_X9[^%G_1-?!_\ X(+;_P"-4?\
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M_P :KO:*/:S[L/8P[(X+_AGOX6?]$U\'_P#@@MO_ (U1_P ,]_"S_HFO@_\
M\$%M_P#&J[VBCVL^[#V,.R."_P"&>_A9_P!$U\'_ /@@MO\ XU1_PSW\+/\
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M_P :H_X9[^%G_1-?!_\ X(+;_P"-5WM%'M9]V'L8=D<%_P ,]_"S_HFO@_\
M\$%M_P#&J/\ AGOX6?\ 1-?!_P#X(+;_ .-5WM%'M9]V'L8=D<%_PSW\+/\
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M&>_A9_T37P?_ .""V_\ C5=[11[6?=A[&'9'!?\ #/?PL_Z)KX/_ /!!;?\
MQJC_ (9[^%G_ $37P?\ ^""V_P#C5=[11[6?=A[&'9'!?\,]_"S_ *)KX/\
M_!!;?_&J/^&>_A9_T37P?_X(+;_XU7>T4>UGW8>QAV1P7_#/?PL_Z)KX/_\
M!!;?_&J/^&>_A9_T37P?_P"""V_^-5WM%'M9]V'L8=D<%_PSW\+/^B:^#_\
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MS_HFO@__ ,$%M_\ &J[VBCVL^[#V,.R."_X9[^%G_1-?!_\ X(+;_P"-4?\
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M !1110 4444 %%%% &%X6_Y?O^NE;M87A;_E^_ZZ5NT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &%KO_(2L?\ KI6[6%KO_(2L?^NE;M !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A77
M_(T6W_7.MVL*Z_Y&BV_ZYUNT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!9L?^/B*MJL6Q_P"/B*MJ@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "LG5/];%6M63JG^MBH I4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4-:_P"01<TN@_\ ((M:36O^01<TN@_\@BUH O4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%X6_P"7
M[_KI6[6%X6_Y?O\ KI6[0 444477<+,****BY=D%%%%%V%D%%%%7J1H%%%%
M!1110 4444 %%%% !1111J%F%%%% !1110 44446D%XA1110 444472W86;V
M04444 %%%%%TMV%F]D%%%% !1110 444470684444 %%%%&G+>X6?-:P4445
M,6WNBI)+8****HD**** "BBBHN79!1115W1%GV"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****+I;L+-[(**** "BBB@
MHHHHN@LPHHHH ****+H+,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM=
M_P"0E8_]=*W:PM=_Y"5C_P!=*W: "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH H:U_R"+FET'_D$6M)K7_((N:70?\ D$6M
M %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>SGN>E3J*K'VD-CE/#?Q3\(>+-?OM!T3Q%I>J:Q9^;]IL+6Y\R6+RY?+D_\
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MP_$_3:N4\$?%/P?\1Y;F/POXCTO7I;+_ (^?L%SYOEURW[,OQ7E^-'P9\/\
MB>[:,:G)');7HB[7,9\L_G_K/^VE?)/_  2U_P"0_P#$+_KVLO\ T9+7-]5D
MHU)2=N4Z?K<7*G&*OS'Z%445F2^)])BO?L4FK6<5]_SZ_:8_-KDC%RV1V2DH
M[LTZ**\6_;*\3:KX/_9K\9:KHFHSZ9J4<=M'%=6TGERQ>9<Q1R?^0Y*J%-U)
M1BNI-2HJ<92?0]DBFCE_U<D<OE_NOW584OQ(\)Q>*?\ A&9/$^CQ>)?^@-_:
M,?V[_5^9_JO]9_JZ\9_8 EDN_P!F;0Y9)))99+V]EDEE_P"6G^DRU=OOV3[*
M[_:8_P"%Q_\ "1W$5UYL<G]E_9OW7[NV^S?ZSS*UE2C"I*G)[>1E&M*=.-2*
MW\SWNBBH;J\MM/MI;BXECM8X_P#62RR5S13G\*.F34/B:)J*J6&I66K6WVFS
MN+>YMO\ GK:R>;%5NG*+A\6A,9J?P:A1114I/9HIM;IA12$],<TM3?WI1L]"
MK>[&5UJ%%4+K7-.T^YBM[C4;>UN;G_5Q2R>7+)5^KDG&/,TR8M2ERIH**H?V
MYIO]I_V;_:-G]N_Y]?M,?F_]^JOTI>YK)!%J>D6@HHHH&5=5U>RT.QN;W4+R
MWL;&WC\R2ZNI/*BCKQR/]M+X+RZO_9W_  GEG]I_YZ_9KGRO^_GE>77SE_P4
MO\<:L=6\&>"X[R33_#][']NN?^FDGF^7^\_ZYUZGXV_8J^$5K\&=2BL])CM)
M;+3I+JW\1&XEEE\R.+S/,D/_ #SKU:>&ITZ<9UW\7;4\FIB:E6I*%!;=]#ZA
ML-1MM1LHKVSN8[JVN(_,CEBD\V*2.IJ^*_\ @F)XRU76_ /BKPY>222Z;HUS
M;2V7F_\ +/[1YOFQ?^0_,_[:U]J5PXBDZ%:5)[+J=^'JJO1]HM^P5E^)/$^B
M^#M,_M'7]6T[1;+S/*^U7]Q';1?]_)*U*^8/^"C'_)M]S_V%K:IHP]K4C3[E
M5I^RIRJ=CV+_ (:$^%G_ $4KP?\ ^#^V_P#CM$7QY^&-W)Y<?Q%\)RRR?\LH
MM:MO_CM?&'[-7["G@/XQ?!3P_P",-<U7Q):ZEJ'VGS8M/N;>./\ =W,D7_+2
M+_IG7H]__P $P/AU+;?Z)XG\3VMS_P ]99;:7_VE7H5*6%IRE&4]O(\ZG6Q5
M2,91AOYGV!:W<=W;17-O)'+%)_JI8I/]946LZWIWA[3+G4=4O;?2[&W_ 'DM
MU=2>5%'_ -M*_-+X;:GXN_8J_:;L/!.J:H+_ ,.:I<6T5Q'_ ,NTEM++Y<=S
M%'_RRDCP/_(E?;/[7O/[-7Q!_P"P;_[5K">&Y9QY7>+ZF\,5S1ES*TET.A_X
M:$^%G_12O!__ (/[;_X[4D7QY^&-W)Y=O\1?"<LO_/*+6K;_ ..U\$?L>_L<
M^"_VA?AEJ?B/Q)J.MV%];:M+8Q1:7<QQ1>7Y44G_ "TBE_YZU[7?_P#!,'X=
M2VW^@>)_%%M+_P ];F2VE_\ :4==$Z6$IU)4YSM;R,(5<74IQJ0A>_F?8%K=
MQW=M%<V\D<L4G^JEBD_UE2U^8ET?B+_P3Z^*%C')J,NN^!]1E_U72VO8_P#E
MK^Z_Y9W-?I/X;\167BW0--UK2[G[5INH6\=S;2_\](Y*Y:^']CK%W1U8?$>V
MTDK,U****XSL"N8\4_$?PQX.UO0])US6K.PU/69?LVFVLO\ K;F3_5_^U*\X
M_:$_:O\ !GP"LI;:[N?[8\5>5YEMH5K+^]_[:2?\LXZ_/K2_'7C3XE_M6?#7
MQ-XRBN8KG4=>TFYL8I8_+CCLOMW[KR_^F?\ K:[Z&$E5BY2=CSJN,5.7+%7/
MUSHHHK@/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH PM=_Y"5C_P!=*W:PM=_Y"5C_ -=*W: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#"NO^1HMO^N=;M85U_R-%M_USK=H PO%'CCPYX(MK:X\2>(M
M+T&*X_=QRZI>QVWF?]_*Y_\ X:$^%G_12O!__@_MO_CM?+__  5%_P"1%\#_
M /81N?\ T547PO\ ^"=OP[\<?#/PCXCU#6O$\-]JNDV5]<16MS;>5'))%%+^
M[_T:O5CAZ7L8U9NUSR98BK[:5*"O8^J;#XZ?#74;F.VL_B#X7NKF3_5Q1:U;
M2R_^C:[C_75\8Z[_ ,$P/ DMC)_9'BO7[:^\O]W+?_9KF+S/^V<4=>:?LB^/
MO%?P(_:%N/@SXGO/M6F7-Q)9>49/,CMKGRO-BEC_ .F<O_M6B.&IU(2=*5Y+
MI8'BITY1C5C:Y^C5%%5;K5K*TN;:VN+ZWBN;C_5Q2R?O9*\N*<OA1ZK:CS*3
M6A:HHJAJFN:;I/E?VAJ5O8>9_J_M4OE>91%<_P *"34/B:+]9?B?Q+I/@S1+
MG6M;U&WTO3+?RS+=74OEQ1_\LZTXIO.C\R/]['7@/[>'_)JGCC_MR_\ 2ZVK
M2G3<ZD8/2YG4J*-&56&MNA[/X7\6:+XWT2+5O#^K6^LZ9)_J[JUD\V*2JFF?
M$GPIK7B"YT#3_$^CWVM6WF"YTNUU&.6YC\O_ %GF1_ZRO%?^"?7_ ";#X>_Z
M^;[_ -*9:T/AI^RC9_#CX\>)?B<GB*XOKK69+V4V#V_EQQ?:)/-/[SS*WE3C
M&4XW^$PC4E*-.5OB_ ]]HHJIJ&KV6DVIN=0O+>QMO^>ES+Y4=<D4Y_"CK;4>
M92:T+=%1131W<7F1R1RQ2?\ +6*JM_KFG:3Y7]H:E;V'F?NH_M4OE>919O9,
M+I;M%^N=\4?$/PQX#^S?\)'XCT?PX;CS/LW]J7L=MYGE_P"M\OS*Z'_75X3^
MU!^RW9_M*?\ "-?:/$-QH/\ 8WVG_56_F^9YGE?_ !JM*:A*I[.;M\C.I*<:
M<JD%>WF>[131S1121R>;%)2U5L+3^SK&VMO,\W[/''%5JL4U+:YLD^M@HJA8
M:YINK2RQV>I6=U+'_K(HKF.7RZOTY>Y\2)BU/2+0445EQ>)])N[Z6RM]6LY;
MF/\ Y917,?FTXIRV1,I*&YJ44457)+:VH<\=[Z!156ZU:RM+FVMKB]MXKFX_
MU<4LG[V2K539K=%1:ELT%%%%**<I<MAR:C'F;"BBB@ HHJK8:YINK>;]CO;>
MZ\O_ %GV63S/+IQ3GLA2:ANT<]HWQ2\'^(?%%]X<TOQ'I=_XALO,^TZ7%<^9
M+'Y?[N3]W75U^>G[+'/_  4 ^)__ %\:W_Z75^A==%>@Z+Y5J<^'KJO&4GI8
M**H:IKFFZ5Y?]H:C9V'F?ZO[5<QQ>95J*:.[B\RWDCEB_P">L5<]FHW:9T73
ME9-$M1>='YGE^9'YO^M\JI3P*^"_^";GBO6?&OCKXDZSK^JW>L:C<6UB)+FZ
MD\R3_62UT4J$JM.52/0YJV(A2J1I[W/O2BBJ&J:YINE>7_:&HV=AYG^K^U7,
M<7F5SQ7/\*.F34/B:+]%1131W<7F6\D<L7_/6*I:<HN,K,F,E.-X:A117QI_
MP4/^,VL^&].\._#_ ,,3SVU_X@/FWDUM)Y<HC\SRHX_^VLA_\AUK1I.M4Y$9
MUJJHT^=GT)XG_:*^&/@[4O[.UCQQH=K??ZJ2U^VQR2Q_]=?+_P!775>$O'/A
MSQY9"\\-Z]8:];1_ZR6PN(Y?+KYL^&W_  3L^'&@>%K:/Q59S^)M<DC_ -)N
MS>2V\4<G_3+RJ\!^/WPFO/V(OB7X;\;_  ^U2\_L>\EDC^P74O\ SRYDMY/^
M>D<E=\,/1JR]G"7O'G3Q-:G'VDXVCW/TCU35[+0]-N=1U"YCM;*SCEN;BYF_
MU4<<?^MDK(\&_$CPQ\2+:YN?"^O:?KT5O)Y4DMA<^;Y=<9\5O$5MXL_9=\7Z
M_9_\>NJ^#[V^C_ZYR6,DE?.__!+K_D1?''_81MO_ $57*L.W2E4;VZ'6\2E5
MC22WZGV[6/XM\9:!X#TG^U?$&K6>C:;YGE_:K^7RHO,K8KY?_P""C'_)N%S_
M -A:VK+#TG6J1@W:YM6JJE3E-*]CZ,\,>)=)\9Z);:UHFHV^J:9<>88KJUE\
MR*3_ )9U)K>NZ=X=TR74M3U"STRQB_UES?2^5''_ -M:\0_8/_Y-4\#_ /;[
M_P"EUS7RS#I^K?MV_M-:WIM_JMY9>!-",OE0VQ_U=O'+Y<?E9_Y:2?\ /2MX
M8=2J2A*5N4YZF)<:<9QC>Y]J6'[4/PEU#4C96_Q \/FY_P"FE]'%'_W\KTR*
M:.[CCDCDCEBD_>1RQ5\T:]_P3Q^$6JZ!-96&E7^CWOE_NM3AU&6242?]<Y?W
M=>/?L3^/O$7PI^.GB#X'^(+TW]C')<QV69/]7<Q_O?W?_3.6/S)*TE1I5J<I
MP>QG&O5I5(PJK<^[=;UW3O"^F7.I:OJ%IIFFVW^LN;Z7RHX_^VE<E_PT)\+/
M^BE>#_\ P?VW_P =KQ;_ (*.^)1HG[/0L/,_?:SJMO:_]LH_,E_]I5YU\)O^
M"=O@;QE\+?"NOZ_JWBBUU?5=.BO;F*UN+:.*+S(_,_Y:6U*G3HNG&<W:_D*I
M6KQJ2A!7MYGUE;?'KX8W5Q';V_Q%\)RR2?NXXHM:MOWG_D6NYKY,T?\ X)K?
M#+1-5LM1MM?\5R364D=S%YM[;?\ +/\ [=J^LZPJJG#^'*YU475G'FJ1Y0HH
MHKE.H**** +-C_Q\15M5BV/_ !\15M4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5DZI_K8JUJR=4_P!;%0!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH H:U_P @BYI=!_Y!%K2:U_R"+FET'_D$6M %ZBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ">I\5/^O;5__3E;5]F:U\>O GASX@V/@/4->CM?%5Y)%';V M9?WOF?ZO\
M>>7Y=:8AU*>*4J>MC/#JE/#251VN?%WPT_X*.Z]X#LK7P[\1/"DFJ76G1_9I
M+^*7[-<_N_\ GK%)_P M/^_=?1G@3]NWX0^/)([=]>D\.7TG_++7K;[-_P"1
M?]7_ .1*]9\8_"?P7\1P/^$H\,:7K,G_ #UNK:.26/\ [:5\X_%#_@G#\/\
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MK7_KI^[DD_[9U#^T_P#M=:%^S[IW]G6>S6/&-Q'_ */I?F?N[?\ Z:W%>*_
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MA\2/C%H_AOX)6_B^#2]$O7^RQRW1\OS(O^?:23_EI'_SSC_[95ZS^RG\*?\
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M_BS=?$#7-/.M:Y)Y7EQW_P"\MK?RXO+_ -7_ /'*^2OVH1C]O[X8?]?&B?\
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M=H_^"=%SXVMI-:^(?Q$U34/&=['YDDMK'YD44G_//]Y_K/\ R'7(_M3?O?\
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MHH *R=4_UL5:U9.J?ZV*@"E1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!0UK_ )!%S2Z#_P @BUI-:_Y!%S2Z#_R"+6@"]1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 87A;_ )?O^NE;
MM87A;_E^_P"NE;M 'YS^//\ E)_:_P#86TW_ -(8J_1@\UR=Q\)?!EUXR_X2
MRY\-:9-XE\V.7^U);;_2?,CC\L?O:ZRNO$5UB(QBUM&QR8>@\/*4D]Y7.!^-
M_P (=*^-WPWU+PSJ>(OM$?FV=U_S[W/_ "RDKX1_8X^+VI?LZ_&+6/A3XT_T
M'3;V]^S2"23]U97W_+*3_KG+_P#&J_2RN&\4?!'X?>-];DU;Q!X/T?6=3D_=
M?:KJRCEEK6AB>6C*A-7B]O(QKX9RK1KP=FM_,^9/%)_X71_P41T/3D_>:1X$
MLOM,G_76/]Y_Z-EB_P"_5?:E<IX<^%GA3P;XDU/7]'T6WL-<U7_C]OXO];<U
MU=<U6I[3E25K'51I>SYFW>Y^>F@_\I3)?^OFY_\ 31+7TQ^V;\-_^%F?L]>)
M+>.+S;[3XO[6M_\ KI%_K/\ R'YE>HQ?#?PG%XI_X2:/PQH\7B7_ *#/]G1_
M;O\ 5^7_ *W_ %G^KKH98?-C\N3_ %5;U,5[2I&HE:T;'/3PJA3E3;O>5S\Q
M?V0SK'Q]^.O@)]>Q+IGP]T6,1Y[^7)_HW_;3S)(_^_5?7G[>'_)JGCC_ +<O
M_2ZVKUWPO\/?"G@*6ZE\-^&-'\.2W/\ Q\_V7IL=MYG_ %U\NM/7_#VD^+-)
MN=*UC3;/6=,N/]987]M'+%)_VRDJJN+52M&HHV2Z$T<(Z=&5-RNWU/F__@G/
M_P FWVW_ &%KFOI^LOPWX8T7P=IG]G:!I.G:+9>9YOV6PMX[:+_OW'6I7)6G
M[6I*IW.RC#V5.-/L<#^T'_R03XE?]BQJ7_I-+7S!_P $NO\ D1O''_81MO\
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MT^*6CZA%8Z=)_HTOEYN+,?\ M6/WKZ-U7_@H)\%=/TYKBV\07E_*!Q8VVE7
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MBDE\V.YC_P">G^J_]&U]2^+?^"@WPITG21+X>OM0\6:O)_Q[:?:V4L7FR?\
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MI="\#Z?+Y?FQ<VUE'G][^\_Y:7$E?I;H.AV7AG0['2=/MOLMC9VT5M;11?\
M+../_55:BACM(XH[>..**/\ U<452URU\1[72*LCJP^']CS.3NV%%%%<FO5G
M79<W,D@K\]/VIO\ E(#\,/\ KXT3_P!+J_0NN<U/X;>%-:\06VO:AX8T>^UN
MV\LVVJ76G1RW,?E_ZORY/]9710K>Q=[7.:O1]LK7L='1117,SJ"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?B__ -%!U?\ [^5Y'11]6H_RA]9K?S'KG_#6OQ?_ .B@ZO\ ]_*/^&M?B_\
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M\7_^B@ZO_P!_*/\ AK7XO_\ 10=7_P"_E>1T4?5J/\H?6:W\QZY_PUK\7_\
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M#&CWVMVWEFVU2ZTZ.6YC\O\ U?ER?ZRNCI5JWM8QC:U@HT/92E*^Y^>F@_\
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M,V_F?9O[4LH[GR_,_P!;Y?F4?6U[>->VW0/JC]A*C??J:?AS_D :9_U[Q?\
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MMM=1^;%)_P!LZ7U[]_[91T[%_4?W'L7+7N?.\7_!0CX,2Z)'>R:_>QW/E_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#"UW_ )"5C_UTKS[]K[_DVOX@_P#8
M._\ :M>@Z[_R$K'_ *Z5Y]^U]_R;7\0?^P=_[5KJH?Q*9CB/X50_&JBBBOT
M_.PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ*G!4O@T"BBBH+"BBBBR"["BBB@ HHHHL@NPHHHH ****+(+L**** "BBB@
MHHHHL@NPHHHH **** "BBBBR[!=]PHHHHLNP7?<****+)[H+M;,**** "BBB
M@ HHHH LV/\ Q\15M5BV/_'Q%6U0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M63JG^MBK6K)U3_6Q4 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*&M?\@BYI=!_Y!%K2:U_R"+FET'_ )!%K0!>HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTRR2_P#+7][_ ,M*["N ^ OB34?&'P8\&:]J]R;K4M1TJWNKFZV1Q^9+Y?\
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M:222/_6Q21?\]/\ 6?\ ?JOHWXR?%W1?@CX U+Q7K?F2VUO^[CM8O];<R?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"UW_D)6/_ %TK
MS[]K[_DVOX@_]@[_ -JUZ#KO_(2L?^NE>>_M??\ )MGQ!_[!O_M6NG#_ ,2/
MD<^(;]E*W4_&NBBBOT-19^=N2"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<
MR"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBC
ME8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"B
MBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<
MR"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBCE8<R"BBBE
MJ%PK[U_8O_8HEF>R\>?$/3\1_P"LTG0KF+_R+<Q?^TJL_L4_L5&U:Q^('C^R
M_>_\?.E:%=1?ZKI_I,O_ ,;K[UKYO,,Q_P"7-!_,^DR_+O\ E]77R"BBBOF+
MMZR=SZ>R6D59!1110,**** "BBB@#"NO^1HMO^N=;M85U_R-%M_USK=H ^2/
M^"D/B?6O#/PN\-7&CZMJ&C7,FM>7)+87,D7F?NI?^>=<S_P3^_:;N/%MO+\.
MO%NHR7.NVXDN=)NKJ7S);F+_ ):1>9_STB_S_JZU/^"H'_))?"O_ &&O_;:6
MO#?C7\#+WP)\+?A/\;/!'F6%S'HNDR:C]F_Y=[G[-'Y5S_\ '*^AHTZ53"QI
MR5F^I\[6J5:>*E43NET/T[KX+_X*6>,M>\)^(/ <>AZ]JFC12VU[YGV"]EB\
MS]Y%_P \Z^HOV<_CKIWQ^^'%EKUN(XM2C_T;4; #_CVN?_C=?(__  5)_P"0
M_P##W_KVO?\ T9%7'@H<F+5*HM6=N,GSX1U:;T1^A5%>+?M6?&W5O@=\,K75
M=#TI-8UO4M1CTBRBD/\ JY)8I9/,\O\ Y:?ZO_5U\DW7Q>_;!\.Q+XAU#2]4
METT_O)+670;:6../_II'''YL=8TL).JN:Z1M4QD*34=S]'Z*^%/A]_P4^T[[
M*8O'GA&]M;Z/_EKH/[R*3_ME))^[_P"_E>E?LY?M::C^T;\7]3T_3/#TNC^#
M-/TF23S9?WLDESYL7E>9)_RR_=^;^[J)X2M!2E;8J&+HU)<J9Y=\6/C_ /$K
MXZ_&V]^%/PCU,:+9:=+)%>ZI%+Y<DGE_ZR3S?^6<?_7.I[_]AGXM^']-EU;P
M_P#&S4+KQ+_K/LLLMS;>9_VU\W_VE7TC\(?V9/"'P1\4:OKWA\ZA]NU6/RKG
M[?<>9_RT\S_GG7JEW>VVG64EQ<21VMM;Q^9)++_JHXZZ7BN5J-)'+#"OEYJS
M/DC]C']IWQ#X\\1ZQ\-OB%QXNTOS#'=21^5)+Y?[N6.3_II'76_MF?M*77P)
M\'6-EH9BE\6ZR3%9>9^\^SQY_>2^7_Z+KYU_9?O!\7/V[O$GCC1XW&AV\E[>
MB7_IG)_HT7_?WS/-JU\<I1\0?^"B_A70+OS);'2KG3;;RO\ IGY7VG_VK7;[
M"E]9DY+11YK?H<7MZKPT4MW+E-O0?V-/C1X\T6/Q-XH^+VJ:-XEN(O-BL)9;
MB7[/_P!,I)/-_=_]LZUOV;_CS\0OA_\ &9_@U\6KF2^OI/W>G:I=R&27S/\
MEG^\_P"6D<M?;]?GS_P4BBD\)_%;X:^,+./RK[RY?+E_Z]I8I(O_ $97/AZK
MQ4_9R2.C$45A8>TBV?H-145K+'=VT5S'^]BDC\V.I:\9[GMK8****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +-C
M_P ?$5;58MC_ ,?$5;5 !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.J?ZV*M
M:LG5/];%0!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZ]_R"+J
MC0?^01:TFM?\@BYI=!_Y!%K0!>HJKJFHVVDZ;<WMQ)Y5M;QR2R?]<HZ^?/\
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MS/*_UG_7*2O1ZB47"7+4T*C)5(\]/4****FZ[EV?8**** "BBBBZ"S"BBB@
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MO_+P]BC3HQ_AG@_[<7P3TGXG_""^\0R2P:?K?AJVEO;:^F(C$D7/F6\GU_\
M1F*^/OV:M#N?VK_C7HEEX_UX7VF^'=-C\JPNI/WE[''_ ,LX_P#VK7J?[6_Q
M2U;]HKXM:9\$/ DGFV4=[Y6HW47^JDN(_P#6>;_TSCK._:6_9@N?V9K+PA\2
MOAI+<12Z%Y=MJ,O_ $T_Y^9/^NO^KDKV</:GAXTJDO?D>)7O4Q$JM->XC]$X
MHHH8HHXX_*BC_P!7%%7Y_?LJ^&+;5OV\OBQJ-Q''+_95[JTMM_TSEDOO+_\
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MT_\ &?7OVB-2\-:C;_#'6/"^I:-YL?VF*22Y\SS/*\O_ )91>7Y?_M6OH?\
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M%_JXO^O:I/V\/AGXJ\0? _X>^*]8_P")GXAT*/RM>DM8_P#5_:8H_-E_=_\
M+..2+R_^VE?0'[+_ .T'X?\ C1\.=+":C!%XDM+:*VU'3)),2B2/_EIY?_/.
M3K^-=\>18;EY>9^IYS<_K/,Y67H?)GQ]_:TU[X\_#'4O"-Q\'-4TN6XDCDBO
M_MLDOV:2.7_GG]F_[9_]M*]9^!?B'7M#_8 \5R7D5Q8:GHUEJ5M;?:H_*ECC
M_P!9%_Z,KNOVK/VN-/\ @3H$5GX?N-/U/QM<R1^583?O([>/_EK+*(Y*Z_PC
M%XA^._[.-W'XTTZST;5_$^DW$7V6UBDCBMXY(\1?ZS_OY6<JC=)0E"R]32%+
MEJ^TA*[[GB'_  2_T&UA^%'BG5XXX_[0N=9^Q22?],HK:*2/_P!&R5]@ZUI%
MCXBT6^TK48O.L;RVEMKB+_GI')7P/^P%\6++X1>)/%/PN\:21Z%?27OFVWVK
M]U%]IC_=2Q_^0XZ^OOCE\=/#OP2\#7NM:IJ%O]N^S?\ $NL?,_>WDG_+/$=9
M8RC.6*3I[&V#K0CAW[7<^1_^"8EI_9WC+XEVWF>;]FCMHO\ R++7Z U^?/\
MP2[FDN_%/Q&DDD\V66VLI)/^_DM?H-49@F\39FF6-/#73"BBBO-/3"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"UW_D)6/_ %TJM\1O
M 6G?$WP3J_A35)+BUL=5B^S22VLG[VK.N_\ (2L?^NE;M%VI<R#1QY6?(?\
MP[%^%O\ T'O&'_@;;?\ R-1_P[%^%O\ T'O&'_@;;?\ R-7UY17?]=K_ ,QY
M_P!1H?RGR'_P[%^%O_0>\8?^!MM_\C4?\.Q?A;_T'O&'_@;;?_(U?7E%'UZO
M_,'U&A_*?(?_  [%^%O_ $'O&'_@;;?_ "-1_P .Q?A;_P!![QA_X&VW_P C
M5]>44?7J_P#,'U&A_*?(?_#L7X6_]![QA_X&VW_R-1_P[%^%O_0>\8?^!MM_
M\C5]>44?7J_\P?4:'\I\A_\ #L7X6_\ 0>\8?^!MM_\ (U'_  [%^%O_ $'O
M&'_@;;?_ "-7UY11]>K_ ,P?4:'\I\A_\.Q?A;_T'O&'_@;;?_(U'_#L7X6_
M]![QA_X&VW_R-7UY11]>K_S!]1H?RGR'_P .Q?A;_P!![QA_X&VW_P C4?\
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M7X6_]![QA_X&VW_R-1_P[%^%O_0>\8?^!MM_\C5]>44?7J_\P?4:'\I\A_\
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MKJ3RHHXZ^ ?C5^T!XJ_:]\3_ /"KOA197'_",O)_IM_+^[-S%_STD_YYV_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!0UK_D$7-+H/\ R"+6DUK_ )!%S2Z#_P @
MBUH S/B-_P D[\2_]@FY_P#14M?AK8:?<ZM<RQ6\?FR1QR2_]LXXO,E_]%U^
MY7Q&_P"2=^)?^P3<_P#HJ6OR3_9!\,VWC'X_:'H-Y_Q[:K9:E8R_]M--N8Z^
MERM^SIUJG8^<S2'M*D:=]SZH_P""7_C?[7X;\9^#Y)?^/*YCU*V_[:?NY?\
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M:_53X:^%--^!7P6TC2KJ6*UL?#NE>9>W7_++]W'YES)_W\\R2OS6_80^&?\
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MMXK\+:OHMW''):ZC92V4OF?\\Y(_+K\9OV<];D\,?'GX?:C')Y7EZU;12?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"S8_P#'Q%6U6+8_\?$5;5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %9.J?ZV*M:LG5/];%0!2HHHH **** "BBB@ HHHH ****
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M6TVVO8XY(H[B.*2.*6/RY:_+C]C[]D_6_BQXPTWQ/K^G/:>"+*3[3)+=Q?\
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M%92_9L_\M+G_ )91_P#?ROR=_90\)W'C']HOP%96\?F_9M6BOI?^N5M^\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 86N_P#(2L?^NE;M86N_\A*Q_P"NE;M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!A77_(T6W_7.MVL*Z_Y&BV_ZYUNT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!9L?^/B*MJL6Q_X^(JVJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *R=4_P!;%6M63JG^MBH I4444 %%%% !17.^
M,OB1X8^&]M;7/BC7M/T&*XD\J*6_N?*\RN9L/VD/A;JVHVUE9^//#]U?7$D<
M4<45['^\DDK6-*I+5+0RE6IQT<CTBBBN/\8_%[P7\/KVVLO%'B;2]!N;B/S(
MXK^YCB\R.LXJ4](*YI)QAK-V.PHK@?"_QY^'7C'6[;1=#\::/JFIW'F>7:VM
M['++)_RTJ[XQ^,7@;X>ZG'I_B3Q7I>@W\L7VF.UO[F.*3R_^>G_D.M/8U-K:
MF7MJ6]]#L:*R_#'B;2?&>B6VLZ)J-OJFF7'F&*ZM9?,BD_Y9UIRS1PQ2R22>
M5%'4\DN;E:+YXN/,F+17D'BG]KOX0>$[R6VO_'FG_:8_W<GV#S+[_P!%QR5T
M/@+X\_#[XF7'V;PWXPTO5+[_ )]8Y/*NO^_<G[RM98>K&/.XNW<RCB*4I64D
M=]117F?_  TK\+?M/V;_ (6#X?\ M/F^5Y7VV/\ UM91A*>D%=FLIPAK-V1Z
M911146>W4NZWZ!17G'_#1_PM^V_8O^$]\/\ VGS/*\K[;'YOF5Z/6LJ<H1O/
M1F4:D9ZPU045Q7COXR>!OAF ?$_BS2]'D(XMKFY_>_\ ?O\ UE<7IG[9?P8U
M:X-M;>/-/BE\SRQ]JCDMHO\ OY)'3C1JSC=18O;TE*SDCVFBJFBZ[IWB+3(K
MW2[RWU.RD_U=S:R>;')5NL9*4?B1M%QE\+"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"AK7_ ""+FET'_D$6M)K7_((N:70?^01:T 7J***&VK6=@<5/
ME=M@HHHI<\NM[>@^2/1*X$9HHHK3GERN-R>6/->P4445$G*6['%1C'E2*NJ:
M39:W92V6H65O?VTG^LBNH_-BKF;'X-^ M*O?MMGX'\.6MS_SUATFVBE_]%5V
M%%7&IRQLFS.5/GE=I!111423G+FM<TNJ<>5,*,#THHIQJI:1;^XF5'FUDE]X
M4444B@KD]>^%'@;Q+<22ZSX/\/ZI+)_K);_3;:7_ -&15UE%7&5C.4;]OF9>
M@^&-$\,Q^7H^DZ?I<4G_ "RL+:.+_P!%UJ444G.4OB=QQA&'P*S"BBBIT>Q>
MJW C-%%%7S2U1')!68FT9S2T442E.7+Y!3A#WK+<.E%%%1=O66Y=DM([%"ZT
M/3=0N(KB\TZSN98_]5++'YM7HH?)C\N/]U%2T4Y2E+=L7+%2O%(*,444DY*W
M*QR49?$@HHHH;DK).P24)<KML%5-0TBRU>V\N\L[>YB_YY74?F5;HJE*4%>+
ML^Y$H1GI-7CV(;.RMK.+R[>W2VC_ .>4<=3444.4I*\G=]PC",-(*T>P4445
M)8444477-8+/EN%%%%&NS#3H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &%X6_Y?O^NE;M87A;_E^_ZZ5NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &%KO_(2L?\ KI6[6%KO_(2L?^NE;M !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!A77_(T6W_7.MVL*Z_Y&BV_ZYUNT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS^\_[^U]L5^2_P #/C1HOAG]H+Q?\5_%'[WRX[W4K*UB_P!;<W-S+Y<44?\
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MPEHRDI;!3Q;G*,7&US[AHHHKSST0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH PO"W_+]_P!=*W:PO"W_ "_?]=*W: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#"UW_ )"5C_UTK=K"UW_D)6/_ %TK=H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,*Z_Y&BV_P"N=;M85U_R-%M_USK=H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"S8_\?$5;58MC_Q\15M4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\O\ =Q_]_)/_ $;75?\ !0+X9_\ ""?'FYU:WC\O3?$T?]I1X_YZ_P"JE_\
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M1VT7FUIC'&AAXX>#O8RP*E6Q$J\UN;M%%%?/'T04444 %%%% !1110 4444
M%%%% !1110!0UK_D$7-+H/\ R"+6DUK_ )!%S2Z#_P @BUH X']IOQ9_P@_P
M"\>ZMYGE2QZ3);1R_P#363]U%_Y$DKY3_P""8O@*WN])\<>([RWCNHI+FVTV
MV\V/_GG^\E_]&Q5]A_%OX3Z+\:?!-SX9U^2[BTZXDCDD^PR^5+)Y=1_!OX.^
M'?@7X3D\.>&_M'V&2YENI/M4GFRR22?_ +NO3IXB-+"RC#1L\NIAY5<5&4]D
M=5_PCVD_] FS_P# >.OAG]N_XS^*M/\ BMX>^&^AZ[)X2T.YMK:6]O[63RO,
M\V66/]Y)_P \X_*K[UKQ;]H']E3PA^T2=-N-;DO-+U>R_=1W]A)'YOE_\\Y*
MRPM2FJEZST-<52FZ=J*/BC]J3X#_  [^#'P^MI(_'&J>,?'=Y<1QQQ37L<D<
M<?\ RTD\K_[97NO[-/C'PQ^S5^R#HGB/Q6EQ]AU[4;B246UMYOF22?NX_,_[
M9VU='#_P3I^%T7A(:))+K8N)+B.YDUC[3%]J_=^9B/\ U?E^7^\/;_GG7M&A
M?!#PUI/PEM_AW=V\FO>&K:W^SB'5/+DDEB\SS,'R_+KKJUX>SY(NYQT:$_:<
M\E8^+=4_96^#WQL\)3^//AYXWC\'V,OFR2V&L>7Y5M)_SSD_>>9'_P"1*M?\
M$YOBIXOO_'^M^"[W4Y]<\-0:=)<Q2S2R216<L<D<<?E?],Y!)_JZ],U+_@F7
M\-KO4?M$&M>)+&RD_P"7:&XCD\O_ +:2QU[U\&_@-X/^ VB7.G>$]-DB^T_O
M;F_NI/-N;G_KI)15Q5'V4E=R;"EA*RJ1=N6Q\%_'C4;?XF?M_P"FZ5>21QZ;
M9:EINFR2R_\ /*/][)_Y$\ROTPM;N*[B\RWDCEB_YZQ2U\T_&?\ 8(\(?&/Q
MK?>)X]6U#0=2O?WM[%:^7)%))_STKWKX>^"++X<>!-$\,6$LDMCI5E%;12R_
MZV3R_P#EI6&+JPJT8N#VZ&^#I3I5I<ZWZG15\4?\%0/%GV3P!X1\.QR?O=1U
M*2^DB_Z9QQ>7_P"U:^UZ\1^/'[)/A7]HG6M-U7Q'JVMVDNG6WV:*/2[B..+_
M %G_ $TBDK+"584JL9SZ&V,I3JT91AU+?['GA3_A#?V</ ]E)'^]N;+^TI/^
MWF3S?_:E?*?_  4[\32:MX[\#^%+?][+;V4M]Y47_/2YE\N+_P!%5^@NC:1;
M:'I-CIUG^ZMK.VCMH_\ KG'7BWC_ /9"\%_$OXLV/Q UO4M;EU*RDMY8["*X
MB^S$V_\ RS_U7F?^1*VPV(A#$>WJ&.)P\Y8=4*?WGJ/PY\)VW@+P!X?\.6\<
M<46E645M^Z_Z9Q5^>M]XK\4?M1_M0:WX&UWQ[>^#_"UE<7L5O8VUSY49CMI/
M*\O_ *:2?]=/^FM?I97S1\6?V"/A_P#%CQS?>)Y+W5-!O[V3S;V+2Y(_*EE_
MYZ_O(O\ 65.&KQBYRJ/WGL^Q6)H2DH1IKW5NNY\+?M/?#CP1X)^(FD>%/ &L
MWGB>^\O_ (F-_=7T=S_I,DG[J/\ =_Y_>U[?_P %'_#,OA/PU\(M*@_Y!&E6
M5S8Q^5_RSDCCMO\ XW7NM_\ \$^/A;>7VAWFGRZWH,NDQQ1QBPN8_P#29(Y/
M,\V7S(Y/,DKVSXJ?"7PY\8O"=UX=\3V7VJQD_>1RQ?NY;:3_ )ZQ25W2QD4X
M6>QY]/!RGS<RW/+M ^//P^^$7[-/AO7H]5L+JQLM%MK:VL;:XC\VYN8XO]4(
M_P#GIYE<]JG[5=E\4OV6?B-XSTO1M2T&.SL9=-BDOQ'Y<ES)%Y?[O_O['^=<
MOI?_  3&\!6FK?:;SQ/KE_8_\^O[N/\ \B^57N_C?]G/PKXV^$\?PVB2\\.>
M%8S'Y<6CR1QRCRY/,X\R.2N.I/"1ES0DV=M.&,E'EE%(_.3]G7]D?4?CEX&\
M7>*A>?9K+3H[FVTZUB_UMY>QQ>9%'_UR_>1U]+?\$ROB/_:W@;Q+X,N)/WNE
M7/VVV_ZY2?ZW_P B1_\ D6OISX+?!K0_@9X+7PSH$]W=:?'<27(EOGCDF>23
MK_JXX\_E7$?##]D+PA\'OB7J?C/0-2UN&^O?M,<EA)<Q&V$<DOF^7_JO,_\
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MX7?$SPCJ%K'IU[;_ &;Q/I]Y&'MXI8XR)?\ 5_ZO][_J_P!Y_JZ\=_:#\ ?
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M/_72MVL+7?\ D)6/_72MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 86N_P#(2L?^
MNE;M86N_\A*Q_P"NE;M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!A77_(T6W_7.MVL*Z_Y&BV_
MZYUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9L?
M^/B*MJL6Q_X^(JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\92V'^MDCMK:27_ )YQR7,44M>>_P#!-30+/3O@CJ6JV_ERWVHZM)'<2?\
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M?[=?@3X.^/M7\'ZQI/B.YU+3C'YLFGV]O+'B2..0?ZR7_II7)_\ #SKX7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &%KO\ R$K'_KI6[6%KO_(2L?\ KI6[0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^FD<4G_ )"DKU[_ (*)_P#)RE]_V#;;_P!%5]5>-?@!'\>/V,/A_;6D<?\
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MMO-_Y:7/_+*+_OY7QE_P3M^!@\;^.Y?'FL6_FZ1X=D\NR\W_ %4E[_\ :_\
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M44D$=S<67V*VS_SUN/W?_M2LC]BCP'_P@?[-_A6.2+RKG58_[7N?^VG^J_\
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M7BZE.$]3&5)82G4G!V/GS]DWX(R?M5>.O$OQ.^)4DFL6,=Z(H[4R>7%<W/\
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M!?EJ-,\?,+.5--'Z6?\ #/?PL_Z)KX/_ /!#;?\ QJC_ (9[^%G_ $37P?\
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MM''YDDLLG[J..OS/_:N^(.B_M7?$C2=!^&GA6\U[Q!IQDMO[9B_Y?(O^N?\
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M^"8G_)!O$/\ V,]S_P"DUM7MG[2T4=I^S?\ $&....**/0+F*.*+_KE7B?\
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MQR$?I7WM7!B8U%**EJGU/1PLH-2<=&N@4445YYZ(4444 6;'_CXBK:K%L?\
MCXBK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX"^!_C<VFGQIHO\ ;/\ 9PD%E_IMQ;>5YGE^9_JI(_\ GG'7G_\ PP9\"O\
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MA[W<QJ83&XF/LZLO=[&1^R7\+;WX.? KP_H.J1>5J\GF7M[%_P \Y)/^6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNG>(-*U#1[_^T;F7[+?VTEM+_P!^I*^B:\S%-2Q$FNIZF%3CAXI]#@?V@_\
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MB$,7SQV(IT:D\)R26IC_  '\?6WQ,^$7A7Q%!)')]ITZ,7'_ $SN8_W<L?\
MW\KOZ_-O2-"^/'[#FOWT6D:3+XR\#W$GFXM;:2YM9?\ II^[_>6\G^?WE=7=
M?\%(_&&HVWV+1_A+)#J__++S;V2YC_[]QQ1_^C*PJ8.<W>#3-:>,A&/+--'N
MG[6G[4@_9RLO#T=GIUOK6KZA<R&2PEE\K_1H_P#EK_W\\O\ \B52_:1TG4?C
MG^QS>ZL=&DTO6)--MO$$>F&7S)8_+_>>5_W[\RO!?A!^R_\ $3]H'XEQ?$7X
MS0W%KID<L<O]GWT7E2W,<9_=Q^5_RSC[_P"?,K]"_*C\OR_+_=4JKIX;EY'J
MATHU,2I>T6Y\D_\ !-CQY;ZY\&+[PQYL?V[0=2D_=?\ 3M)^\BE_[^>97UO7
MY[_%']F7XD_LX_$NY\>?!F.XO](E_>2:781^9+;Q_P#/M)%_RTCK2M/^"D7C
M'3K86VL?":0ZM_JS+'>26T?F?]<Y(I/_ $96U7#O%5)5,.^:_?0BEBEA:<:>
M(C:W;4^M_CS\5+?X+?"O7_%4XCFDLX_]"MI?^7BYD_U45<S^RY\>-3_:$\ W
M/B._\.C08K>Y^Q1B*X\V.Y_YZ2?ZNOCS5/#'QU_;E\4V/]N:3+X3\&6<OF1_
M:K:2VMK?_IK'YG[RYD_S^ZK]!?AOX"TKX6>"M)\,Z)&8M-T^+RXQ_P M)/\
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M6?'7@F7POJ6C:?%_8T4.DWMM+<7,GFQX_>R?O/+D\K_5^OTKH_V!OAQ+X"^
M5C<WEM):ZEK-[+?2QRQ_O(O^64?_ *+_ /(E<,8^PI3E?5GH5)?6:L8I:(]V
M\>^.-)^&_A+4O$6N2R1:1IT7FW,L4?FUA_"#XQ>'/C=X3D\2>%Y+B738KB6U
M_P!*C\J7S(__ -Y73>*/#&G>,O#>IZ#JD?VK3-1MI+:YB_Z925^?>B>'/B_^
MPEXOU<:/X>N/'?@+49?,/V2*0Q=?W<G[O_CVD[?\\ZRI0C5IZNS-*LY4JFBN
MC]!/%&AZ;XG\-ZEI6L11W6D7EM+'<Q2_ZKRZ^!_^"7^H7L7C+Q[I-O<_:M#^
MS1R_]M/-_=?^0_,JQXX_:-^-?[2&E2>$?!'PQU#PQ;:A_HU[?_O)?W?_ #S^
MTR111QU]*_LH?LX1?L[^ 9;.XN8K_P 2ZK+]IU&ZB'[O_IG'%_TSCKH5J%"2
MF[M[>1SINK7BX*UM_,^5? ?_ "D_NO\ L+:E_P"D,M?HQ7YD_$?1/BM\.?VO
MO$WQ!\*?#O7-9DM]1N9;*:31KFYM;GS(O+ZQ?]=:[W_AK?\ :D_Z(P/_  E]
M6_\ CM;8FC*NH\K6D;;G/AL3&AS<Z>LKGWS17Q!\/_VH/VC?$GC[PUI.M_"?
M^S-$O=2M[:\OQX=U&/[-;22_O9?,DE_=_NZ^WQS7F5</4I;:GK4<33K;!7YR
M_LW?\I#/&_\ V%M?_P#2F6OT:K\N;K3_ (N_";]I[QOXX\)_#?6]:>;6M2^S
M37&@WLMK+%+<R?O<Q5W8&RA)-VN<&/3<HR2V/U&HKX&_X:V_:D_Z(Q_Y:^K?
M_':/^&MOVI/^B,?^6OJW_P =K/ZG/^;\37Z[3_E_ ^[M:TF/6](OM.N/]5>6
MTMM)_P!M*_./]@KQ#)\'/VB_$OP^\0'[!<ZC'+8_O?\ GYMI/W7_ )#\VOM;
M]G/Q[XT^(7PXBUKQYX<_X1?Q#]IEC^P?8I;;]U_RR_=R?O*\A_:W_8YNOBYJ
M4?CCP1<QV/C>V\KS(Y9/*CO?+_U<GF?\LY*O#24.:A4V?4C$PG/EKP6W0^KZ
M\)O_ -AWX)ZC?7-[<>#/-N;B3S9)?[6O?]9_W]KYDT?]LKXX_ VV_L;XC^"+
MG6/LW[O[??1R6TLO_;S'^ZDJ6_\ ^"AGQ.^(7F:=X ^'4=K?W'[J.6+S=2DC
M_P#(4553PN)I_#(FIBL-4^*)ROQ9^%OAGX1_MO?##0/"FG?V7IO]HZ)<_91<
MR2?O/MW_ $TKZW_;P_Y-4\<?]N7_ *76U>#_  *_8_\ B/XU^)FD?$WXL:K/
M:7EA>VVHQ6CR>;>W$D4OF1B0#]W''7T=^V1X7U3QA^SCXNT;0]/N-4U.Z-EY
M5I:Q^9+*?ML4G]*VJU(JM%<U[&-&G-X>5HVN<3_P3G_Y-OMO^PM<U]/XYKY[
M_84\':]X"^ UMI/B#2KS1M3_ +1N9?LM_'Y4OEU]"5Y^(FG6DD]ST</#]S%M
M;!7P-_P53Z_##_N)?^VU??-?#O\ P4P\'Z[XM/PZ&A:-?ZR;8:B9186TER8A
M_HW_ #SK?+Y*.)YI'/F,7+#<L3[ ^'P\WX>>&O\ L$VW_HJOFG]LS]D^S\8>
M'+KQQX,T[^S/&6E?Z3)'ID?E?VC'_P#'*^F_A]%):>!/#4<D<D4D>FVT4D4O
M_7*MVN:&(G3J\\7H=4\-3J4N1K4^1OV&?VJ)?BMI7_"&>)[DR^*=+MO,MKZ2
M3_D(VW_QR.NY_;P_Y-4\;_\ ;E_Z6VU?,/[4OP&\5_!+XZ:;\1?A?I-Y+:WM
MS]NCBTNVDE^Q7/\ RUB\N/\ Y9R__':^AOVA]4U3XV?L9:Y?:/X<U@:QJ,=E
MG0?L4GVZ.6.^B\V/RO\ 6=I*[I1I^WHUXZ)[KL>?3=1X>M0GTV?<M_\ !/K_
M )-A\/?]?-]_Z4RU]&UX)^PYX:U7PM^SIH>G:UI=WH^I17-SYMK?6\EM)'_I
M,G_+.2O>Z\_%6EB)-=3TL+>.'BGT/E[_ (*)^)]0\,_L[26VGR/$=5U6VTVX
MEB_YY>7))_[2K3_8/^'V@^%/@%H>LZ9;1_VGKT7VG4K_ /Y:R2>;+^[_ .V5
M>H?'/X0Z=\<_AGJ_A34)/LOVC][;77_/M+'_ *J6OA3X=_$3XO?L07>H^%==
M\#W/B/PT+CS(A$9?),G_ #TMKCRO;_5UW4;5<-R0=IGGUDZ6)YYJ\#O_ -NK
M]F:Y@N9OB[X(1[;4['_2=5AM1B4"/_E^B_Z:1_\ +3_OYVKQSX(77B+]K[]J
MGPSK/B?RY8M%MK:YO?*C_=>5;?\ QRY_]&RUV7C/XM?'']L.(^%/#'@VY\,^
M%;D^7>RGS/*D_P"NES)_RS_Z9QUA_$;]E_XB_LCZUH'COP)J-SKL5O%&+V6U
MM_\ 5R?\M8Y(_P#EI;25Z=+VD*7LJLESGF5%3=3VM*+Y#]-Z*PO >K:UK?@W
M2-1\2:3'H.N7-M'+>V$4GF_9I:W:^6>Y]6MC\YO^"HG_ "/_ (,_[!,O_HVO
MML?L]?"W'_)-O!__ ((;;_XU7R)_P4=^''B_QOX[\(W'AOPIKFO6UMITL4LN
MEZ=)<^5^\_Z9U]\C@5ZM:IRT*?*SR*-)2Q%1S1Q^C_!KX>^'[C[1I?@?PYI=
MS'_RUM-*MXI?_15=A117F5)>UTF>O%*G_#21^<W_  5%_P"1_P#!G_8)E_\
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M!ER<:$4UL%%%%>:>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )2;+_XU1_PWE\=?^AY_\I-E_P#&J\"HH^JX?^0/K6(_G/??^&\OCK_T//\
MY2;+_P"-4?\ #>7QU_Z'G_RDV7_QJO J*/JN'_D#ZUB/YSWW_AO+XZ_]#S_Y
M2;+_ .-4?\-Y?'7_ *'G_P I-E_\:KP*BCZKA_Y ^M8C^<]]_P"&\OCK_P!#
MS_Y2;+_XU1_PWE\=?^AY_P#*39?_ !JO J*/JN'_ ) ^M8C^<]]_X;R^.O\
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M^FB6M+_@JG][X8?]Q+_VVJ[I'PY\5Q?\%(I/$S^&-8B\-?:;C_B<G3I18_\
M(-DB_P!;_J_]95__ (*3_#[Q-X\_X5S_ ,(WX=UCQ']F_M+[3_9=E)<^7YGV
M;RO,\NNY5(K%497WC;T.!0E]6K1MM*_J?1OQ@_Y-F\<?]B?>_P#I#+7@W_!+
M_P#Y)+XJ_P"PU_[;15] ?%C3+N^_9W\7:=:V<]QJ5SX8O;6*UCC\R224VT@$
M7E_6O%?^"<_@GQ%X(^&?B:V\2:#JF@W4FK>;'%JEE);2R1>5'_STKA4DL/.+
M>YWM-UXM*UCW7]H/_D@GQ*_[%C4O_2:6OFK_ ()G7EMIWP8\9WMQ+Y5M;ZMY
MLDO_ #SC^S15],?':QGU/X)?$"SL8'O;VYT'48;:VMT\R264VT@$47XU\_?\
M$_/AOK7A_P"#GC/1?%F@ZIH/]HZE+_HNJ64EM+)%);11_P#+2BBX?5I1VN%7
MG>)C-]#R30_B;\9OVT_B'KEGX+\0R>!/".G?ZS[+))$8XI/]5YDL?[R223RZ
M](L?^";EOJTD<GC/XG:YXC/^MDBBC\K_ -&2RUY-X(\/?&3]AKXAZU_9_@^X
M\:^&M5_=R2V%M)+'<1Q_ZN3S8_\ 52?ZW_65ZI??'+X_?'^RDT'P9\,;CX?6
MUY^ZN=>UB67_ $>/_IG))%%_Y#CEKNJJI3E_LS2AWW."$HU8_P"T7YNRT/-?
MV -.LM#_ &L/B#IVG_O=,LM)OK:V_P"N<=];>573?\%5/^:7_P#<2_\ ;:H?
MV3_@1XT^ 7[4M];ZAHNJ77AZ6RN=-_MZ*VD^S2?ZJ2*3_P A5T/_  4F^'WB
M?QX?AU_PC?AW6/$?V?\ M+[3_9=E)<^5YGV;RO,\NG[2G]?C*^B(Y*GU&2Y=
M6?9WAS_D :9_U[Q?^BJY#X^_#:+XN_"'Q-X9\J,75[9?Z'_TSN8_WD7_ )$K
MK]!BDBT33(Y(_*ECMHZOUX*G&%6ZT/H7"52C9ZGP#^QQ^T(?A[^S7\1;+5.+
M[P9YES96LO\ T\_ZJ+_P)_\ 1M=?_P $V?A[+:>#_$OQ!U3S)=2\17OV:WEE
M_P"><?\ K)?^VDG_ **KYO\ VO?AQJ/@/]I#7-!\/^9]F\;_ &:YCM8O^6GV
MFY_U7_@3'7Z<?#3P/9_#?P!H'ABS.;72K**V$G_/3_GK)7M8QQA3O#>9XN"B
MYU/>VB=/576;22[TF^MH_P#6R6TL4=6J*\);GO/5'Y^_\$NM0CT_Q!\2M%N/
MW5])%92^5_USEN8Y?_1D=?H%TKX-^-'P ^('P,^--S\6OA-8/JMA<2R75[I=
MM%YDD9DYDC\K_EI'(?\ GGZ5/=?M@?&CXN:;_P (SX'^%-[H.MW'^C2:Q+YD
ML5O_ --?WD44<?\ VTKV<106*JJLGH>)AZ[PM)TFOF9'[,^HV^J_\% _B5<V
MDGFV\G]K>7+_ -O,5=Y^V?\ M.>*O!?B_1/AG\/2(/$>J",RZA''YD@DDE\N
M.VC_ .FE>??L9?!+QI\*?VH-<CUO1M4.F6^FW-M_;4ME)':W,GFQ?ZJ62NN_
M;6_9V\::M\1-$^*O@"VDU34M.BMOM%A:_O;F.2WE\R*6*/\ Y:5T?N7B8N3N
MD<\?;0PTHQ5KD=A^P;\0?&,45QX_^-&J2W,G^LM;7S+G_P B22_^TZ^<_P!L
M;]G?PS^SO?>$=*\/ZCJ%]<ZA;W-S>RW\D?\ SUB\K_5_]M:^EM&_;6^,&K64
M6G1_ ;5+KQ!)^Z^U?Z3%;?\ ?ORO_:E>+_M ?LV_'/QS'9_$#Q/92Z]XEU.7
M[++H.CQ>9_9UMC,7^KZ_\M/\R5I0G-UN:LTOP,ZT(*BHT4_GJ?IV>E?GI_P2
MV_Y&#X@_]>]E_P"C):^\O!NH7.H^$=#O+NVN+2YN;**62UNO];')Y7^KDK\W
M?!WA/XY_L@_$CQ)'X7\!WGB.QO/]&$L6G7-[;7,<<G[J7]U_JZ\["VY*E-L]
M+$7C.%1+8]T_;._:;\5>#/%^B?#/X>D0^)-5$9EU"./S)/,DE\N.VC_Z:5E6
M'[!OQ!\8Q17/C_XT:I+<R?ZRUM?,N?\ R)++_P"TZQOVH_@7\1?&&K>"/C-X
M4TFX_P"$EBTVQN=1T:*/-U97L?[SS(X_^6O_ #S\O_IG70Z+^VK\8-4LHM.C
M^ ^J76OR?N_M7^DQVW_?ORO_ &I73&$J="/U>VGS.24XU,1+VZ>O;0^:?VQ?
MV>/#/[/%[X2TKP_J.H7USJ%O<W-[+?R1_P#/2+RO]7_VUK]:J_,/X_\ [-OQ
MS\<1V?C_ ,3V4NO>)=3E^RRZ#H\1D_LZV_Y9?ZOK_P M/\R5^D7@S4+G4/".
MB7EW:W%I<W%G'+):W7^MCD\O_5R5ECK.C!IW:-L!S*M)-:,VJ***\8]L\O\
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M !1110 4444 %%%% !1110 4444 %%%% &%X6_Y?O^NE;M87A;_E^_ZZ5NT
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M>;;?VI91W/E_]_*=.4(RYIJYE4C.4>6#L?$W[-^FZK^U)^U#J7QBUC3Y=/\
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M?_1<?_;6OI:OR;_;P^*?_"S?C]?:=9R>;IGAW_B46WE?\M)?^6O_ )$_=_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH PO"W_+]_P!=*W:PO"W_ "_?]=*W: ..UWXR> O"NJW.E:QXY\.:/J4
M_>6%_JUO%+'_ -LY):I_\-"?"S_HI7@__P ']M_\=K\_?C]X)LOB9_P4(O\
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M ):RU5T_5[+5[7[3I]Y;WT7_ #UM9/-J8IS7,D[=QRDH/E;U['/^"/BGX/\
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M689C_P N:#^9])E^7?\ +ZNOD%%%%?,7;UD[GT]DM(JR"BBB@84444 %%%%
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MIUS'?:=%]FD_>?\ +.6/_5_\\Y)*\=_X)T_%@^#OC'<>%+N3RM-\2V_EQ_\
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M.VLK$_\ +*+_ %<?_D/_ %E1E>'JT*GM*RY45F>(I5Z?LZ+NS[R^"%I>S?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU=&C%1J5=F17K2E[.&Y[?XI_X)I6FA:.NH_#_P 9ZO;>*+/,L<U_+'Y<DO\
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M\NL3X@?#+QI^P=XZ\/>(_ ^O:AKWA74;GRI+"7_EI)_SRECC_P!9^[_Y:?\
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M6D[S/SV_X):_\A_XA?\ 7M9?^C):_0JOS^_X)DPQVGC;XGQV_P#JHX[:./\
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MD%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 86N_P#(2L?^NE;M86N_\A*Q_P"NE;M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_>1UO@\8\+&<)*\7^!AB\&L5)3O9G3T445Y][[GH)6E<AELXKKR_/CCE\O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!9L?^/B*MJL6Q_P"/B*MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LG5
M/];%6M63JG^MBH I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-:
M_P"01<TN@_\ ((M:36O^01<TN@_\@BUH O4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &%X6_P"7[_KI6[6%X6_Y
M?O\ KI6[0 4444678+ON%%%%%EV"[[A1110 5Y5X,_9J\%^ OBAKGQ!TN*\_
MX2'59+F2YEEN?,B_TF7S)?W5>JT549.$91AI<B45.493UL%%%%39=2[OH%%%
M%%D]T%VMF%%%% !1110 4444 %%%%%DMD%V]V%%%% !1110 444467-<+ON%
M%%%39]"HM+<****HD****+(+L**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH PM=_P"0E8_]=*W:PM=_Y"5C_P!=*W: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK7_((N:70?^01:TFM?\@B
MYI=!_P"01:T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#"\+?\OW_ %TK=K"\+?\ +]_UTK=H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,+7?\ D)6/_72MVL+7?^0E8_\ 72MV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH PKK_D:+;_ *YUNUA77_(T6W_7.MV@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** +-C_Q\15M5BV/_'Q%6U0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !63JG^MBK6K)U3_6Q4 4J*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *&M?\@BYI=!_Y!%K2:U_R"+FET'_D$6M %ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PO"W
M_+]_UTK=K"\+?\OW_72MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM=_Y"5C_P!=
M*W:PM=_Y"5C_ -=*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#"NO^1HMO^N=;M85U_R-%M_U
MSK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S8_\
M?$5;58MC_P ?$5;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.J?ZV*M:LG
M5/\ 6Q4 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&M?\ ((N:
M70?^01:TFM?\@BYI=!_Y!%K0!>HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,+PM_P OW_72MVL+PM_R_?\ 72MV
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH PM=_Y"5C_ -=*W:PM=_Y"5C_UTK=H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,*Z_Y&BV_ZYUNUA77_ "-%M_USK=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"S8_\ 'Q%6U6+8_P#'Q%6U0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !63JG^MBK6K)U3_6Q4 4J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *&M?\@BYI=!_P"01:TFM?\ ((N:70?^
M01:T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#"\+?\OW_72MVL+PM_R_?]=*W: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#"UW_D)6/_72MVL+7?\ D)6/_72MV@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PKK_ )&B
MV_ZYUNUA77_(T6W_ %SK=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M??ZO[+:ZM;22_P#?KS*["JE&4?B(C.,_A84445)9A>%O^7[_ *Z5NUA>%O\
ME^_ZZ5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &%KO\ R$K'_KI6[6%KO_(2L?\
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MBBB@ HHHH **** ,*Z_Y&BV_ZYUNUA77_(T6W_7.MV@ HHHH] ]0HHHH]0]
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M_P#O*^7O^"?GQ^_X5O\ $/\ X1#6+GRO#_B:7RX_-_U5O>_\LI/^VO\ J_\
MOU71[.EB,)STU[W8YHU*F%Q?)4?N]S[Q_:2^-%M\"?A3J7B-S'+J0/V;3;:3
M_EXN9/\ 5C_VI_VSKY<_9K_:R^,_Q\^)]EH4=MX?BTB/_2=6NHK*3]W;?]_?
M]97A7[9_QRE^./Q=_LW2)9+OP_HTOV+3HXOWOVF7_EI)_P!M*^^/V1_@!'\!
M_A=:V=W''_PDNJ_Z3JTO_33_ )9Q?]L__CE$H4\-A_?7O IU,5B/W;T/C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 86N_P#(2L?^NE>>_M?'_C&SX@?]@W_VK7H6N_\
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MM-:'UN!QZK1]E4>O<]]HHHKQ+IZ)GN6:W04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &%=?\C1;?]<ZW:PKK_D:+;_KG6[0!\Z_MG?M$>(_V=_#
M?AK4?#EGI=_+J-S);2?VI%)+_P L_P#IG)'7@UA^V/\ M+:M96]YI_PABU"R
MGCBDM[JU\,:C+%)'_P ](_WM=-_P5%_Y$7P/_P!A&Y_]%5]/_L^_\D$^&O\
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M&=12E%;&TZ\*3C&3W/L*BOA2/_@H[XD\,ZA;#QG\*;S2M.N?]5-'))')Y?\
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MU[_RUC_[:_ZS_O[7T!_P3Z_:,'CCPC_P@&NWOFZ_HL?^A2RR?\?-EV_[]_\
MHNN#'48XJ'UN"]X[\#6EA9_59_">'?\ !3;_ )+UH?\ V+%M_P"E-S7E_P .
M?V/_ (G?%/P=8^)_#>BV]UI%[YGV:66]CB_U<OE?^TJ]0_X*;?\ )>M#_P"Q
M8MO_ $IN:^F?V(_B1X4\._LQ>#+'5/$VD6%]']M\RUNM2CBEC_TZYKI5>I1P
M=/V4;OS1@Z%.MC*CJRMZ,^._^'?OQH_Z%RT_\&-M_P#':^TOV&?@OXK^"7@'
MQ!I/BRRCL+Z\U+[3'%%<QR_N_+C_ .>=>Q?\+?\  7_0Z>&__!M;?_':T]%\
M>>&/$U]]BT?Q'H^J7/E^;Y5A>QRR_P#D.O(K8FM5I^]&WR/6HX>C3J>[*_S-
MVOR@_;J^ UM\'/BC%JNF1QQ>'_$WF7-M:_\ /O+'_K8_^N?[V/\ [^U^K]?
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MSQ?N'?EDJ:ER27OGY??MX?\ )UGCC_MQ_P#2&VK]./V?/^2"?#7_ +%C3?\
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MZ-]I_LWROM]S';>9_P ?/_/2BFF\M;BKL51VS*TW9'Z(5^6?_!2*&.+]HO\
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M3)'+XCDMHO*DDE\V66.3_GI70^*/VT?@GI-E<Q7'B^SU3]WY?V:PMI+GS/\
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M^W?]NT?[N+_VI)_VUKT91CAO;5(_:V/,A*6,]C3_ )=SZEJ*ZNX[2REN9/\
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MCO@Q\.;"WTE/&?A^UM[*/RH[73)?M/EQ_P#//]W7P)^VS\9_!'Q8^(7A[7O
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M):DXA1J8JG%LQ/\ AA[X]?\ 18__ "K7M>7_ +1G[,WQ2^%GPXEU[Q9\1O\
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MHH **** "BBB@ HHHH *R=4_UL5:U9.J?ZV*@"E1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!0UK_ )!%S2Z#_P @BUI-:_Y!%S2Z#_R"+6@"'Q9I
M4FN^%M7TZV\N*YO;*6VC\W_II'7Q1^S5^PGX]^#GQK\/^,-<U7PY=Z9IWVGS
M(K"YN9)?WEM)'_RUB_Z:U]UT5TT\1.E&4([,Y:F'A5J1J3Z'S9^V=^S%K7[1
M&G>&I/#]YI=CJFE22F234Y9(HI8I/^N<<G_/.LW]C+]DO7OV=M7\2ZKXHO-+
MU"^U&*.VMO[+EDD\N/\ Y:>;YD4?_3.OJ6BK^MU/8^PO[I'U2G[;V]O>/B;]
MJS]BKQQ\<OB]<^*]"U30+:QDMK:V\F^N;B*7]W_USCDKV#XB_!#7_%O[(MM\
M+K.ZL8?$,>E:38_:999/LWF6TMMYA_U?F<^5_P \^]>\T4I8JI*-.-_A".%A
M&527\Q\<_L>?L=>-/V?/B9J7B/Q)J.AW]C<:3)8QQ:7<R2R^9YL4G_+2*+_G
ME7UOK.AV7B+2;[2M4MH[_3;R/[-<6LO^JDCJ_16=6M*M4]I+<UHT8T:?LUL?
MG?\ &3_@FOJMGJ]Q>_#?4;>ZTV7_ )A>J2>7)'_USE_Y:5Y-8?\ !/[XV7=Y
MLD\.6EA%_P _4NJV_E_^0I*_6FBO0CFF(COJ>?+*Z#VT/E3]E3]A_3?@K?Q>
M*/$EY!KWBU(O]&%N,6UG_P!<P?\ 62?]-*^JZ**\^M6G7E>;/1HT84(V@>=_
MM ?"^+XS?"3Q!X4WP1W-[;@64MR/W<5S&?,BKX>\,_\ !,_QY#XBTJ76M9\,
M7&B0W,<E[!9W-QYLMOYF9!%_HU?I+16M#%5,/3]G%F-?"4\14]I)"10QPQ11
MQQ^5''_JXHJ6BBN.[>K.VR6B/FW]IO\ 8IT#X\77]NZ5<1^'/%WE?O+H1>9%
M>_\ 76/_ -J5\7:]_P $]_C1I-S+'9Z+I^LQ?\];#4H__:GE5^L=%>KA\RKX
M>/(M8^9Y.(RVAB)<[TEY'YB^ _\ @FO\1=<U&+_A*+W2_"^F?\M/WGVFY_[9
MQ1_N_P#R)7Z _"#X.>'/@CX.B\.^&[;RK;_6W-U+_K;F7_GK)7<T5S8C%U<1
M'E;L=.'P=*A+FM=A1117&=H48S115*3CL1**EN%%%%26%%%% !1110 4444
M?"G[2G["?CWXQ?&OQ+XOT/5?#EIINH_9O+BO[FYCE_=VT4?_ "RC_P"F=?8G
MPO\ #5QX'^&7A#P[J$D<M]I6DV5C<RVO^JDDCBCC_=UT]%=,\1.I&,)O1'+3
MP\*4I3AU.%^-7PGT[XT?#/5_"FH?NOMD?^CW6/\ CWN/^64E?#_@7_@GY\9_
MAUXPTGQ+HGB;P?;ZCI]Q]HC!O;G!'_/+_CVK]&J*NEBJE*/*GH16PL*LN9GQ
MC^UK^Q]XZ^/_ (\TGQ%I&H^']-CMM&CL;B*^N+G_ %GFRR2>7Y=OS'^\ZUXI
M_P .Q?BE_P!![P?_ .!MS_\ (U?IS173',J\(QC%Z(YY9;0G*4I;L_,7_AV-
M\4O^@]X/_P# VY_^1J]K_9%_8U\:_ ?XJR^)_$&J:!<V,FG2VWE:9<W$LOF2
M21?\](X_^>5?9]%14Q]:K'ED53R^C2ES(*^8OVTOV9O%'[1W_"&?\(WJ&CV/
M]C?;?M']IR21>9YOE>7Y?EQR?\\Z^G:*XJ525&7/!ZG=5I0K1E&:W/!_V.O@
M=K_[/OPRU/P[XDN["^OKC59+Z.33)9)8Q'Y44>/WD<?_ #RKWBBBHG)U*DIO
MJ53BJ=.--= KX4_:I_8O^(/QC^,VK^+- DT>'3;F*VCC^U7,D4O[N+R_^>5?
M==%;T,1/#U.>!A7P\,13Y)G*?"KPS>>#?A=X0T'4/+^W:5HME8W'E?ZKS8XH
MXZD^)?AFY\;_  W\5>'+.2.*YUG2;FQBEE_U4<DD4D5=/16?M/>YC7V?N\I\
M1?LZ?L&^+/@M\9_#_C#5/$6CZA8Z=]I\RUM?,\V3S+:2+_GG_P!-:^W:**JK
M5=:7-,FC15&/+ ^:/VN/V0X_VB!I&K:'>V>C>);+_1I+JZ.8KFV_Z:>75']D
MC]FGX@_LY:KJ=MJGB+1]4\,ZC'YLEI:^9YL=S_STC_=5]2T5<L1.5'V#?ND1
MPT(UO;I>\>-?M+?LU:%^T1X7AMKR7^S-<L_WEGJD<?F>7_TSD_Z9U\%^(O\
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MJR\8:E<6%SJ-['+;1164DG[KRO\ IG7=AJ3G@ZG*KG'BIJ&*IMNQ^EE?+_\
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M+F+_ %?F>9_JX_\ OWY5?.WPF^%'C3]NS5-5\7>._%-]9>%+:]^RV]C:G.)
M/]7;QG]W'Y?F?ZWDU^@NL^ ]!\0^#O\ A%-0TZ.Z\/?9H[;[!+_JO*C_ -5_
MZ*I/ 7P\\.?#/0/[&\,:;'I>FB3S/LL4DDO[S_MI72\9RJ4W\3ZG*L%S.,%\
M*/B?XO?L"R?"CPY<^,_A7XKUR+5]&BDN9+:ZE_TF6./_ %OER1^57NG[$_Q\
MO?CO\,I1K4GF>)=&E^S7TH_Y>/\ GG+_ )_YYUT?[5GQ:TOX1_!OQ!>W<RC4
M=2MI++3K4$>9<2R1^7_Y#SYA^E>,?\$SO =[X>^&?B'Q/>6WE1:[>QQVWF_\
MM(K;_EK_ -_))?\ OU5>TJU,->IN3&G2CB>6&QYAX#/_ !L^N3_U%=2_](9:
M_1FOSG\!_P#*3^Z_["VI?^D,M?HQ48^*7+;K&YK@&WS7Z2L%%%8VO^,M!\)B
MV_MO6M/T;[1_J_M]Q';>9_W\KSHQE)VBCT92C"-Y,S/B9\5/#'PB\.?V]XKU
M+^R]-^T16WVG[-))^\_[9UK^%/%&F^,O#>G:[H]S]JTW4+>.YM[KRY(_,C_[
M:5\E?\%"?'GACQ-\!HK+1_$>CZI<_P!M6TOE6%['+)_JI?\ GG7JG[-WQ2\%
MZ3\!O =E>>+-#M;FVT6VCDBEU**.6/\ =?\ 72NWZO+V/-8X8XA2K<MSW:BL
M_1?$.D^);+[9HVHVFJ6OF>7YMC<QRQ?G'6A7%)<GQ'=%\\>:(4445)04444
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MU=7RN8Y@ZLO94GH?69;EZA'VM5!1117S\4HZVU/HN9[!11102%%%% !1110
M4444 %%%% !1110 4444 %%%% &%=?\ (T6W_7.MVL*Z_P"1HMO^N=;M 'SK
M^V=^SQXC_:(\-^&M.\.7FEV$NG7,ES(=4EDB_P"6?_3..2O8_A=X:N/ _P ,
MO"'AW4)(Y;[2M*LK&YEM?]5))'%''^[KIZ*WE6G*G&GT1A&C"-253JPHHHK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>%O\
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M^U4^/?P^C^%'_!/:^\*)'B73K+3?M _Z>9+ZVDE/_?SS*^?_ -GW6]5_:?\
MCC\)]-U2/S=,\":3%]I\W]YYGV:3]U+_ -M?]&KZY_;P_P"35/''_;E_Z76U
M8.'U>I1P[>JE?U-$_K%.MB.CC;T,#_@G/_R;?;?]A:YKZ?KY?_X)S_\ )N%M
M_P!A:YKZ@KS\8D\1)KJ>I@V_J\4^AP/[0?\ R03XE?\ 8L:E_P"DTM?$?[ 7
MP,\"?%WPGXNN?%_ARWUFYLKV.*WDEDDC\N+RO^F=?;G[0?\ R03XE?\ 8L:E
M_P"DTM?,'_!+K_D1O''_ &$;;_T57;AI2A@ZEM#CQ$55Q5-21[A_PQ=\&/\
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M<G%XI4OW:=CU7X8?"#QM^VSX\B^(?Q,EEL/!$<G^A6$0,?VB+_GE;?\ 3/\
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M_P B4?\ #(?P<_Z)_I?_ )$KU^BCZQ6_F#ZM1_E/(/\ AD/X.?\ 1/\ 2_\
MR)1_PR'\'/\ HG^E_P#D2O7Z*/K%;^8/JU'^4\@_X9#^#G_1/]+_ /(E'_#(
M?P<_Z)_I?_D2O7Z*/K%;^8/JU'^4\@_X9#^#G_1/]+_\B4?\,A_!S_HG^E_^
M1*]?HH^L5OY@^K4?Y3R#_AD/X.?]$_TO_P B4?\ #(?P<_Z)_I?_ )$KU^BC
MZQ6_F#ZM1_E/(/\ AD/X.?\ 1/\ 2_\ R)1_PR'\'/\ HG^E_P#D2O7Z*/K%
M;^8/JU'^4\@_X9#^#G_1/]+_ /(E'_#(?P<_Z)_I?_D2O7Z*/K%;^8/JU'^4
M\@_X9#^#G_1/]+_\B4?\,A_!S_HG^E_^1*]?HH^L5OY@^K4?Y3R#_AD/X.?]
M$_TO_P B4?\ #(?P<_Z)_I?_ )$KU^BCZQ6_F#ZM1_E/(/\ AD/X.?\ 1/\
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MX.?]$_TO_P B4?\ #(?P<_Z)_I?_ )$KU^BCZQ6_F#ZM1_E/(/\ AD/X.?\
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M LV/_'Q%6U6+8_\ 'Q%6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63JG^M
MBK6K)U3_ %L5 %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK7_
M ""+FET'_D$6M)K7_((N:70?^01:T 0^*?$5EX3\-ZOKVH2>58Z=;R7US_UR
MCC\ROQVU34/%W[7'QSCC#^9JVNW)CMX9)/W5E;?_ !N..OTL_;<U"32?V7?'
MES'_ *V2VMK;_OY<Q1_^U*^)/^"<5I'=_M%^9)'^]M])N9(__(4=?0Y?&,,/
M/$I>\CYW&N57$1P\G:+/J_PC_P $\_A-HF@QV6LZ;=^(M2V?/?R7LMOF3_IG
M'')Q7R3^UE^QW<_!C7](N/!EMJ>NZ#JLDD<<(C\V6VN?^>?[NOU3HKAI9C6I
MRO5E?R.ZKEM&I&U*-O,^>OV)+OQXGP=BT/QYHVH:5=:3)]FTZ74X_+EDMO\
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MD1YDKV^BBLZE6I4^)ETZ<:7PA1116=D:W84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:[_R$K'_KI6[6
M%KO_ "$K'_KI6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 85U_P C1;?]<ZW:PKK_ )&BV_ZY
MUNT ?&W_  5 _P"22^%?^PW_ .VTM?-GP'\?>(OV/?B7X?N=;+GP9XNTJRO;
MDQ1_NI+>2/S(Y(_^FD7F5])_\%0/^22^%?\ L-?^VTM;WBO]GRV^/_['/P^T
M^VCBC\2Z=X8TVYTJ[D_YZ_9HOW7_ %SDKZ"C4Y,/&E/X6?.UJ?-B)5:7Q(^I
M;6\MM1L8KFWDCNK:XC\R.6+_ %4D=?GW_P %2?\ D8/A]_U[7O\ Z,BKJ?V
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MX9U[ROM-C%_JHHY)?+N8_P#KG_JI:_1:O@+_ (*GQ1_:?AK<_P#+22/4HO\
MTFKAP-256LXS=[G=CJ4*5)2@K,^_:*H:--)=Z38W,G[V62VCEDJ_7E/<]=;!
M1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!9L?^/B*MJL6Q_P"/B*MJ@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &%KO\ R$K'_KI6[6%KO_(2L?\ KI6[0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 85U_R-%M_
MUSK=K"NO^1HMO^N=;M 'QM_P5 _Y)+X5_P"PU_[;2U]%_L^?\D$^&O\ V+&F
M_P#I-%7A7_!1CP3XB\;_  S\,VOAO0=4UZZCU;S9(M+LI+F6.+RI/^>=>\?
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M_P#IE7SUH^E?&RP^+LGQ%O\ X5:YXB\027,EUY>L>'+V6VCD_P"N<?E_ZO\
MY9U[R/VMOVI/^B,?^6OJW_QVO3]C*A1Y*+7-_-<\OV\*];FK)\O8^^(8?*B\
MN/\ =1U^>OQR8?#_ /X*+^%=?NS]FM=5N=-D\T?\\Y(_LW_M*O3?@5^T5\>?
M'GQ5T/0/&?PS'AOPW<&X-SJ?]@WMMY0CMY)(OWLLGE_ZSRZZ_P#;1_9FN/CM
MX3LM0\/A(?%VC&0VWF/Y8N8S_P LO_C=<&'?L*TE4>\;?\$[\1^_IQE35K2O
M8^CZ_/G_ (*3RR>+/BC\-/!]G)YM]Y<GE1?]-+F6*.+_ -%5I>'?VT/C!X#T
M"+PQXH^$VJ:SXEMX_LT=_+%<Q>9_TUDC\K]Y_P!LJT/V</@#X^^)?QB?XS?%
MFUDL;J/]YIVF7<9CD\S_ )9_N_\ EG''6V'I/"S]I)F.)K+%0]G%'V_:Q1VE
MM%;1_NHHX_*CJ6BBO&>Y[:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"S8_\?$5;58MC_P ?$5;5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9.J?ZV*M:LG5/\ 6Q4 4J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+7?^0E8_P#72MVL+7?^
M0E8_]=*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#"NO^1HMO^N=;M85U_P C1;?]<ZW: "BB
MBB[VN$4HZV"BBBB/N[!+WMPHHHH **** "C%%%.\ELV+EB]T@HHHI\S?Q"Y4
MOAT"BBBEH_BNQZKX;(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"S8_\?$5;58MC_P ?$5;5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9.J?ZV*M:LG5/\ 6Q4 4J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *&M?\ ((N:70?^01:TFM?\@BYI=!_Y!%K0
M!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,+PM_P OW_72MVL+PM_R_?\ 72MV@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH PM=_Y"5C_ -=*W:PM=_Y"5C_UTK=H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,*Z_Y&BV_Z
MYUNUA77_ "-%M_USK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"S8_\ 'Q%6U6+8_P#'Q%6U0 4444 %%%% !1110 4444 %%%%
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M*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X"S__ "11_P -^_$3_H&>&_\
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M'^IF1?\ 0)#\?\SZ5_X;]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%G_\
MDBOFJBCZK2[!_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ$_Z!
MGAO_ ,!9_P#Y(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P" L_\
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MO_P%G_\ DBOFJBCZK2[!_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\
M#?OQ$_Z!GAO_ ,!9_P#Y(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW
M_P" L_\ \D4?\-^_$3_H&>&__ 6?_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_A
MOWXB?] SPW_X"S__ "11_P -^_$3_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_
M $"0_'_,^E?^&_?B)_T#/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH
M^JTNP?ZF9%_T"0_'_,^E?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P#
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M*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X"S__ "11_P -^_$3_H&>&_\
MP%G_ /DBOFJBCZK2[!_J9D7_ $"0_'_,^E?^&_?B)_T#/#?_ ("S_P#R11_P
MW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF9%_T"0_'_,^E?^&_?B)_T#/#?_@+
M/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^:J*/JM+L'^IF1?\ 0)#\?\SZ5_X;
M]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%G_\ DBOFJBCZK2[!_J9D7_0)
M#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ$_Z!GAO_ ,!9_P#Y(KYJHH^J
MTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P" L_\ \D4?\-^_$3_H&>&__ 6?
M_P"2*^:J*/JM+L'^IF1?] D/Q_S/HRQ_;M\?V'F>5I_AX>9_STMI_P#Y(JS_
M ,-^_$3_ *!GAO\ \!9__DBOFJBCZM2[#_U-R+_H$A^/^9]*_P##?OQ$_P"@
M9X;_ / 6?_Y(H_X;]^(G_0,\-_\ @+/_ /)%?-5%'U6EV%_J9D7_ $"0_'_,
M^E?^&_?B)_T#/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF
M9%_T"0_'_,^E?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^
M:J*/JM+L'^IF1?\ 0)#\?\SZ5_X;]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GA
MO_P%G_\ DBOFJBCZK2[!_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\
M#?OQ$_Z!GAO_ ,!9_P#Y(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW
M_P" L_\ \D4?\-^_$3_H&>&__ 6?_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_A
MOWXB?] SPW_X"S__ "11_P -^_$3_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_
M $"0_'_,^E?^&_?B)_T#/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH
M^JTNP?ZF9%_T"0_'_,^E?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P#
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M*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X"S__ "11_P -^_$3_H&>&_\
MP%G_ /DBOFJBCZK2[!_J9D7_ $"0_'_,^E?^&_?B)_T#/#?_ ("S_P#R11_P
MW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF9%_T"0_'_,^E?^&_?B)_T#/#?_@+
M/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^:J*/JM+L'^IF1?\ 0)#\?\SZ5_X;
M]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%G_\ DBOFJBCZK2[!_J9D7_0)
M#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ$_Z!GAO_ ,!9_P#Y(KYJHH^J
MTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P" L_\ \D4?\-^_$3_H&>&__ 6?
M_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X"S__ "11_P -^_$3
M_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_ $"0_'_,^E?^&_?B)_T#/#?_ ("S
M_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF9%_T"0_'_,^E?^&_?B)_
MT#/#?_@+/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^:J*/JM+L'^IF1?\ 0)#\
M?\SZ5_X;]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%G_\ DBOFJBCZK2[!
M_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ$_Z!GAO_ ,!9_P#Y
M(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P" L_\ \D4?\-^_$3_H
M&>&__ 6?_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X"S__ "11
M_P -^_$3_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_ $"0_'_,^E?^&_?B)_T#
M/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF9%_T"0_'_,^E
M?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^:J*/JM+L'^IF
M1?\ 0)#\?\SZ5_X;]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%G_\ DBOF
MJBCZK2[!_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ$_Z!GAO_
M ,!9_P#Y(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P" L_\ \D4?
M\-^_$3_H&>&__ 6?_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_AOWXB?] SPW_X
M"S__ "11_P -^_$3_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_ $"0_'_,^E?^
M&_?B)_T#/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH^JTNP?ZF9%_T
M"0_'_,^E?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P# 6?\ ^2*^:J*/
MJM+L'^IF1?\ 0)#\?\SZ5_X;]^(G_0,\-_\ @+/_ /)%'_#?OQ$_Z!GAO_P%
MG_\ DBOFJBCZK2[!_J9D7_0)#\?\SZ5_X;]^(G_0,\-_^ L__P D4?\ #?OQ
M$_Z!GAO_ ,!9_P#Y(KYJHH^JTNP?ZF9%_P! D/Q_S/I7_AOWXB?] SPW_P"
ML_\ \D4?\-^_$3_H&>&__ 6?_P"2*^:J*/JM+L'^IF1?] D/Q_S/I7_AOWXB
M?] SPW_X"S__ "11_P -^_$3_H&>&_\ P%G_ /DBOFJBCZK2[!_J9D7_ $"0
M_'_,^E?^&_?B)_T#/#?_ ("S_P#R11_PW[\1/^@9X;_\!9__ )(KYJHH^JTN
MP?ZF9%_T"0_'_,^E?^&_?B)_T#/#?_@+/_\ )%'_  W[\1/^@9X;_P# 6?\
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MT#/#?_@+/_\ )%?-5%/ZM3[#_P!3<B_Z!(?C_F?2O_#?OQ$_Z!GAO_P%G_\
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M7'_QNE'P7^(1Z>!?$G_@GN/_ (W6?.ENT>1_;&6O;$1^]'&T5V0^#'Q"(R/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!>C_Y!%S_ -?$?_M2J-7H_P#D$7/_ %\1_P#M2J-9"IA1116HPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]/_9H_Y+UX,_Z_T_E7ZV+T
MK\D_V:/^2]>#/^O]/Y5^MB]*^;Q_\0_F'Q3_ .1G0_Z]H?1117EGXP%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(>E+2'I0!"G4_05\#?\%&O^1[\*?]>$G_ *&*^^4ZGZ"O
M@;_@HU_R/?A3_KPD_P#0Q7H8#_>#]&\//^2AH_\ ;WY'R#1117U!_7X4444
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MKHNHQYT^[TV!)MG!*[%R,UI5Q?LXQDHWN>UG''%#+<+@\72I\\:_G;E_!W_
M_)73=%U#61)]@T^[OO+_ -9]FMY)/+JM+%)%+Y<D?E2QU^@-E^V9\*/ ]_'X
M8TC2;P:/:/\ 9_MUA!%]E_WH\/OD'N!79?M ? _PY\=_AS/K6B6]LVOI9?;-
M+U*VQ^_X\R.-\??C<_SR*GZXU*TXV/*7'E;#XBG#,,%*E3F[*3?XVLOS/S(H
MK[@_X)X^/XY[37O!5ZRM-"_V^SR.L?W)/R_=G_MI7E?[<O@%O"WQE.LPQ^79
M:_"EP#C \R/]W(!]/W3_ / ZVCB>:M*DUML^Y]+A>*?;9[/)*E'E:^&5_B^5
MM.O7H?.=%?;O_!.[X?I'9>(O&=T@S+*-.M9&_N)EG_F@_P"V=>3?MO?$!?&'
MQGNM*M762RT"/[&A4<&7'F2G\?\ 5_\ ;.G'$<U:5)+;J5A^)Y8K/:F34J-U
M35Y2YMMM+6[M+?OV/GNO:/V-XA/^TCX,1NA>[_\ 2.XKQ>O:OV,_^3E?!7^_
M=?\ I'<4\0W[&270]GB2[R;'-.W[N7X1N??WQO\ C1H_P)\,VNLZK8W5]#<7
M:VBQ62J9-_ER2#KC/$9KRC2?^"@OP[U&1([O3-;TS/\ RUEMXY(T^ICD-,_X
M**?\D<\/?]C!#_Z3SU^>->7@\+3J1YF?B?!_!V69]E+Q.*YN?F:NI6V/U1^(
M/PP\$?M*> 8[R 6EX9H/,L-8M5S)'D=0?_9#7YA^*O#FH>#/$.HZ'J2!-0L+
MB2WN(QT(K[F_X)U:W->^ _$VER2;UL;Z-T3_ )YAX^G_ (Y7AO[=6B#3OV@;
MF>./+:C86TQ/OB2/_P!IUMA[PK2I7O8]7@_$U,FSO%</UIN5)*ZOOT_1_@?.
MU6?[/O?LWVG[-<?9O^>OE_NJ_1'X#?LS^$_@YX)A\1^+[6UN?$9A%Y=W-^ T
M=B0,[8\\#R^GF=?>IO\ AN?X5W&O'1@-1%D6\K^U)+)?L>?3[_F?^0ZV^N-R
MM"-SV:W'U6I7G#+,%*M3B[<R;7Z,_-^BOT-_:+_99\.^/_"-UXG\(6EO:^(4
M@^V1_8 H2_7KVXWGC$G6OE7]E?X7V'Q9^+MIINJ()-.LX);^:W;D7"1^7'L/
MT>2,_A733Q$*E.4^Q])E_&.!Q^65LQ5XNE\47NCRW2/#6LZ^,Z9I5_J?E][:
MWDDJ/4_#^HZ+)Y>IZ=>6,G_3U;21U^C_ ,=/VB-._9I.C:1:>#VU.*XM]\20
M.+2")1QLSY9 ^F*I^ _VM?AU\8/#>IVWBB'3_#H0&*XT[6)XI$G3_8_YZ#\*
MXUBY2^&-SY.GQKFM6E_:5/+VZ'=2_2US\WZ*[[XD>'/#EQ\4[C2_AY??VSI=
M]<1Q:>NV0XED_P"6>9/^FE?='@;X/?#W]EKP,-?\1BUN-3MXO-N]5N(A+)OQ
M]R$'IZ ?Y'34Q/)&+MJSZ[..+*&58>C-4I3JU4G&FE:6O?M]Q^;-%?I=X/\
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M=*4NQ\EX<UH83"YCB:C?+'YOKT.2HK]--=\9_"']F;POILL&GP+%,#':0Z5
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M=D!ZXJ(8MN2C.-KGEY7QNL3CXY=F6'="I+:[NG\[(^4:(H?.E\N/_6U]Z_\
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MKYI_;.X_:5\:?[UI_P"D<=>-"A"6*E#HC\#RGAG 8GB?%Y94YO9PBVM?\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'I_[-'_ "7KP9_U_I_*OUL7I7Y)_LT?\EZ\&?\
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MM%T?]FSQ5A@>;/;@]OM<-?F#7GX"ZI-M'Y9X72YLJK02U]IU_P ,5^A]\?\
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M#5,IG@,_HK6DU&3_ )O\NOWD_@.TM_V=?V98)KR$)+I>FO>SPGC?<R$R&/\
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M,3&\.5'ZAQ%AYU\HQ4*:N^627G<^C_\ @I.[B;X?H/N%=0S_ .2]?$U??O\
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M_P#'\5Y7\*_V%=#\ >)K37M8U]_$3V,OVBW@^S?9XP_\)D_>/YF*X_\ ;?\
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MV5X[9?\ !.?0DU[[3<>,;^71-V[^SQ:11R_]_>G_ (Y7I'QX^-'A_P#9X^'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %Z/_D$7/\ U\1_^U*HU9B_Y!-S_P!?,?\
M[4JM4<HJ844458PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M]+_9F_Y+WX+_ .PA'_*OUP7I7Y&?LV_\EU\'?]A"/^5?KFO2OG,?_$/YA\4_
M^1E0_P "'T445Y1^,!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"S%_R";G_KYC_]J56JS%_R";G_ *^8_P#VI5:@5,****!A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z1^S;_R77P=_P!A
M"/\ E7ZYKTK\C/V;?^2Z^#O^PA'_ "K]<UZ5\YC_ .(?S#XI_P#(RH?X$/HH
MHKRC\8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4?VC1#_B)^2=I_\ @/\ P3\Z:*_1;_AA?X9?\^^J?^!E'_#"_P ,O^??5/\
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M/_ RC^T:(?\ $3\D[3_\!_X)^=-%?HM_PPO\,O\ GWU3_P #*/\ AA?X9?\
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M;T/SIHK]%O\ AA?X9?\ /OJG_@91_P ,+_#+_GWU3_P,H_M&B7_Q$[).T_\
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M_:-$/^(GY)VG_P" _P#!/SIHK]%O^&%_AE_S[ZI_X&4?\,+_  R_Y]]4_P#
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MZI_X&4?VC1#_ (B?DG:?_@/_  3\Z:*_1;_AA?X9?\^^J?\ @91_PPO\,O\
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M_P ,+_#+_GWU3_P,H_M&B'_$3\D[3_\  ?\ @GYTT5^BW_#"_P ,O^??5/\
MP,H_X87^&7_/OJG_ (&4?VC1#_B)^2=I_P#@/_!/SIHK]%O^&%_AE_S[ZI_X
M&4?\,+_#+_GWU3_P,H_M&B'_ !$_).T__ ?^"?G317Z+?\,+_#+_ )]]4_\
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M_/OJG_@91_PPO\,O^??5/_ RC^T:(?\ $3\D[3_\!_X)^=-%?HM_PPO\,O\
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M17Z+?\,+_#+_ )]]4_\  RC_ (87^&7_ #[ZI_X&4?VC1#_B)^2=I_\ @/\
MP3\Z:*_1;_AA?X9?\^^J?^!E'_#"_P ,O^??5/\ P,H_M&B'_$3\D[3_ / ?
M^"?G317Z+?\ #"_PR_Y]]4_\#*/^&%_AE_S[ZI_X&4?VC1#_ (B?DG:?_@/_
M  3\Z:*_1;_AA?X9?\^^J?\ @91_PPO\,O\ GWU3_P #*/[1HA_Q$_).T_\
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M4?VC1#_B)^2=I_\ @/\ P3\Z:*_1;_AA?X9?\^^J?^!E'_#"_P ,O^??5/\
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M/_ RC^T:(?\ $3\D[3_\!_X)^=-%?HM_PPO\,O\ GWU3_P #*/\ AA?X9?\
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M #[ZI_X&4?\ #"_PR_Y]]4_\#*/[1HA_Q$_).T__  '_ ()^=-%?HM_PPO\
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MM_PPO\,O^??5/_ RC_AA?X9?\^^J?^!E']HT0_XB?DG:?_@/_!/SIHK]%O\
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M^=-%?HM_PPO\,O\ GWU3_P #*/\ AA?X9?\ /OJG_@91_:-$/^(GY)VG_P"
M_P#!/SIHK]%O^&%_AE_S[ZI_X&4?\,+_  R_Y]]4_P# RC^T:(?\1/R3M/\
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MJQ_PPO\ #+_GWU3_ ,#*7]HT11\3LDCTG_X"?G317Z+?\,+_  R_Y]]4_P#
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MIHK]%O\ AA?X9?\ /OJG_@91_P ,+_#+_GWU3_P,H_M&B'_$3\D[3_\  ?\
M@GYTT5^BW_#"_P ,O^??5/\ P,H_X87^&7_/OJG_ (&4?VC1#_B)^2=I_P#@
M/_!/SIHK]%O^&%_AE_S[ZI_X&4?\,+_#+_GWU3_P,H_M&B'_ !$_).T__ ?^
M"?G317Z+?\,+_#+_ )]]4_\  RC_ (87^&7_ #[ZI_X&4?VC1#_B)^2=I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH PO"W_+]_UTK=K"\+?\OW_72M
MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH PM=_Y"5C_P!=*W:PM=_Y"5C_ -=*W: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#"NO^1HMO^N=;M85U_R-%M_USK=H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KHZYRNCH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?#_ /X*4>/=#U&./Q7IVG^)]-_Y:&*+[-<Q_P#7/_EG_P"0Z]%Y7B.AY_\
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M %4DG_32*O7OA-X@\3_ ;XQVOP@\5ZM)XA\-:U;R77A36;H?Z3'Y?^MMI?\
M/_HS]WI/#<D;IF5/%<\K-6/J&BBBN([S"\+?\OW_ %TK=K"\+?\ +]_UTK=H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,+7?\ D)6/_72MVL+7?^0E8_\ 72MV@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH PKK_D:+;_ *YUNUA77_(T6W_7.MV@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "NCKG*Z.@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "LG5/];%6M63JG^MBH I4444 %%%% 'Q%_P %1?\ D1?
M_P#V$KG_ -%5\&W7A22+X>Z1XF_Y9WFK7NFR_P#3/RXK:3_VYK[R_P""HO\
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MZ/U5_P!H7^R>=]:7U"U_>-W_ ()D_#+^UO'_ (A\<7$?^C:+;?8;;_KYD_\
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M +^?^BJ\=_X)B?\ )>?$/_8L7/\ Z4VU6O\ @IWYH^./A^/_ )=O^$<B\O\
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M'O[Z3[;YEU=:='++)_IUS7S-_P %-O\ DO6A_P#8L6W_ *4W->7_  Y_8_\
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M_*CC\ORO*E\O_EG_ ,M?^_=?1'_!-2\U&Z^ -]'>?\>UOK=S%9?]<O+BD_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#"UW_D)6/_ %TK=K"UW_D)6/\ UTK=H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,*Z_Y&BV_ZYUNUA77_(T6W_7.MV@ HHHH ****+I[,+-;H**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Z.N<KHZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *R=4_UL5:U9.J?ZV*@"E1110 4444 ?$7_!47_D1? __81N
M?_15'[!7A.+Q[^R9\0?#MQ_J]5U:]L?^_EC;5ZG^V=^SOXC_ &B/#?AK3O#E
MYI=A+IUS)<R?VI+)%_RS_P"F<<E:7['7P-U_]GWX9ZGX=\27EA?7UQJLE]')
MIDLDL?E^5%'C]Y''_P \J]N->$<%&%]4>'["?UV4FM&?DCYNHZ))J>F^9):^
M9_HU[%_USE_U7_?R*OT/_89\$?V'^RAXXUZ2/][KWV[R_P#KE'%Y7_HSS:Y#
MXO\ _!.WQQXQ^*/BK7_#^J^&[;2-5O9;ZVBNKFYCEC\S]Y_RSB_YZ5]>^!OA
M;+X)^ ]EX#MWMQ?6^B_899?^6<ES)'^\E_[^5V8W%4ZM!>S>O4X\'AJE&N_:
M+3H?FE^P?_R=9X'_ .W[_P!(;FN]_P""FO\ R7G0_P#L6+;_ -*;FO3OV:OV
M$_'OP<^-?A_QAKFJ^'+K3=.^T^9%87-S)+^\MI(_^6L?_36NE_;"_8Z\:?M!
M_$S3?$?AO4=#L+&WTF.QDBU2YDBE\SS99/\ EG%)_P ]*IXJF\7[2^A"PU6.
M$E3MN=[^Q/I%MK?['7A;3KS_ (]KVWU*VD_ZYR7MS7YM&'7OV<OC?&+B/_B;
M^%=6CD\J7_EY\N3_ -%RQ_\ HVOU<_9G^&.K?!OX*:!X0URXL[G4].-SYLMA
M))+$?,N9)/\ EI_UTKF_VEOV2O#G[1-E%>R2_P!C>*K:/R[;5(H_]9'_ ,\I
M8_\ EI'7)A\5"C7J7U4SKK86=3#T[:.!Z+\,_BQX8^+OANVUGPWJL%]%)'YD
MD1E_>V__ $SDC_Y9U\P_MW_M267AGPG%X,\%^(\>);FYCEO;K1KG][91Q_O?
M]9'_ ,M)/W=?-_B/_@GC\9-$N98]/TG3]>B_YZV&I1Q>9_W\\JNI^'/_  37
M\>ZYJL1\7WFG^&-(/^L\JY^TW4G_ %S\O]W6L,/A*=3VCJ7\K&<\1BYT_9J%
MO.Y[S^P!\3OB9\4M*\07_C#6I-9\/V7E65E)<VT?FR7/_+7]Y_RT\O\ =_\
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M;M)N;J3RXI?,_P!9%YG^?^6E?<GC+XB>'/A[H,NLZ_K-GIFF1Q^89;F7[_\
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MN.3_ )Y5AA*L:6(O)V-\=2E7P]H(Y_\ X)B?\D&\0_\ 8SW/_I-;5]>5X/\
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M6VN?^64M?+?[.O[!WBSX+_&?P]XPU3Q%I&H6.G?:?,M;7S/-D\RVDB_YY_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M86N_\A*Q_P"NE;M86N_\A*Q_ZZ5KW=Y;:=;2W%Q)':VT?^LEEDJ^7L5&+EHM
M^A-16#_PG/AO_H/:9_X&1T?\)SX;_P"@]IG_ (&1T^7R?W'1]3Q7\GY_Y&]1
M6#_PG/AO_H/:9_X&1T?\)SX;_P"@]IG_ (&1T<OD_N#ZGBOY/S_R-ZBL'_A.
M?#?_ $'M,_\  R.C_A.?#?\ T'M,_P# R.CE\G]P?4\5_)^?^1O45@_\)SX;
M_P"@]IG_ (&1T?\ "<^&_P#H/:9_X&1T<OD_N#ZGBOY/S_R-ZBL'_A.?#?\
MT'M,_P# R.C_ (3GPW_T'M,_\#(Z.7R?W!]3Q7\GY_Y&]16#_P )SX;_ .@]
MIG_@9'1_PG/AO_H/:9_X&1T<OD_N#ZGBOY/S_P C>HK!_P"$Y\-_]![3/_ R
M.C_A.?#?_0>TS_P,CHY?)_<'U/%?R?G_ )&]16#_ ,)SX;_Z#VF?^!D='_"<
M^&_^@]IG_@9'1R^3^X/J>*_D_/\ R-ZBL'_A.?#?_0>TS_P,CH_X3GPW_P!!
M[3/_  ,CHY?)_<'U/%?R?G_D;U%8/_"<^&_^@]IG_@9'1_PG/AO_ *#VF?\
M@9'1R^3^X/J>*_D_/_(WJ*P?^$Y\-_\ 0>TS_P #(Z/^$Y\-_P#0>TS_ ,#(
MZ.7R?W!]3Q7\GY_Y&]16#_PG/AO_ *#VF?\ @9'1_P )SX;_ .@]IG_@9'1R
M^3^X/J>*_D_/_(WJ*P?^$Y\-_P#0>TS_ ,#(Z/\ A.?#?_0>TS_P,CHY?)_<
M'U/%?R?G_D;U%8/_  G/AO\ Z#VF?^!D='_"<^&_^@]IG_@9'1R^3^X/J>*_
MD_/_ "-ZBL'_ (3GPW_T'M,_\#(Z/^$Y\-_]![3/_ R.CE\G]P?4\5_)^?\
MD;U%8/\ PG/AO_H/:9_X&1T?\)SX;_Z#VF?^!D='+Y/[@^IXK^3\_P#(WJ*P
M?^$Y\-_]![3/_ R.C_A.?#?_ $'M,_\  R.CE\G]P?4\5_)^?^1O45@_\)SX
M;_Z#VF?^!D='_"<^&_\ H/:9_P"!D='+Y/[@^IXK^3\_\C>HK!_X3GPW_P!!
M[3/_  ,CH_X3GPW_ -![3/\ P,CHY?)_<'U/%?R?G_D;U%8/_"<^&_\ H/:9
M_P"!D='_  G/AO\ Z#VF?^!D='+Y/[@^IXK^3\_\C>HK!_X3GPW_ -![3/\
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M1XBT_0?MGF?9OM]SY7F^7_K?_1E=-%-'-%%)')YL4E?!'_!53_FE_P#W$O\
MVVK[I\.?\@#3/^O>+_T573*CRTXU+[G-3K>TJ5*=OA+]%)+-'%%++))Y4<?_
M "UEJMI>N:=KD7FZ?>V]_'_SUM9/-KFBG*/.D['3)J,N1M7+5%%%*/O_  CE
M[FL@HJA:Z[IMW>R65OJ-G+?1_P"LM8KB/S8ZOT[-?$K"BU/X6B*66.+RO,DC
MB\S]U'577_$.D^$])N=5UC4K/1M,M_\ 67]_<QQ11_\ ;62OAKQ9XLUG5_\
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MJ$FH\R;6A:HI(IHYHHI(Y/-BDI:+-;H=T]F%%%% !1110 5T=<Y71T %%%%
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M56G0G7J%%%% !1111HM@U>X4444 %%%% &%X6_Y?O^NE;M87A;_E^_ZZ5NT
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M^,]0OO$ME;27W^EVT?E7$L?[S_KI'6=^RS_RD ^)_P#U\:W_ .EU??GB/_D
M:G_U[R_^BJVKXF=&2C#0QPN&A5C.4V]#\V?@/XJ^+W[4GABU^%5GXFDT?P_I
M7[W4=>_Y>9+;_EE;?]-/^6G^8JW_ (\?L"6_P<^'5]XS\*>*M0NKW1A]JD2Z
MC\K]W_STCDC_ -76S_P2JZ_$_P#[AO\ [<U]6_M0?\F\?$;_ + MS_Z+JZU>
M=+&>SA9?(FA0A4P?M)W.4_8G^*VH?%WX$V6H:O.]UJVE7,NFW-S*/WESY?ER
MQR_]^Y8Z^,OVD;SQ/9_M[:Z?!AQXJN)+*VTXG_EG))IL<?\ [5KZ-_X)B?\
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M?O?L/^LN;C_KVDC\K]Y5WXI_L&^,?"?C2]\7_!CQ'_99DDDECTO[1)8W-O\
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MUBZU=^QBH2O<^C;;_@F!X9ET23[7XTUB7Q!)'S=11Q_9O,_ZY?ZS_P BU@_
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MJ4HO6P4445YIZ@4444 %='7.5T= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M9.J?ZV*M:LG5/];%0!2HHHH **** / /VJOVJC^S*?#7_%,_\)'_ &U]I_YB
M/V;RO+\O_IG+_P ]:\&'_!54_P#1,?\ RO\ _P!S4?\ !5/_ )I?_P!Q+_VV
MJ']@O]GSX??%CX0ZQJOBSPQ;ZQJ5OKTEM%-++)%^[^S6TG_+.3_IK)7T%*GA
ME@XU9QNV?/5:F(^N2IQE:Q-_P]5/_1,?_*__ /<U>E?L\_MV_P#"_OB9;>%/
M^$'_ +!\RVEN?M7]K?:?]7_TS\J.O0O^&+_@O_T(=G_X$W/_ ,=K?\"_LW_#
M;X9Z_'K/A?PK;Z5J\<<D7VN&23_5_P#?RN6L\$Z>D&F=5%8U5-9IHXW]JK]J
MH_LRGPU_Q3/_  D?]M?:?^8C]F\KR_+_ .F<O_/6O!A_P55/_1,?_*__ /<U
M'_!53_FE_P#W$O\ VVJ#]@O]GOX?_%GX1:QJOBSPQ;ZQJ5OKTEM%-)+)&?+^
MS6TG_+.3_II)772HT(X3VM6)QUJU>6,E3HRV-33/^"I^G37'_$P^'=Q:1_\
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M-%TH:Q_91MLV!N/L_F^9<1Q?ZSRY.\M?(_\ P]5/_1,?_*__ /<U>\_MX?\
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MS7\C]#]/U&VU:RMKVSN8[JVN(_,CEBD\V*2.IJ^?OV+_  +\0/AA\*9?#OQ
MMH[7[-<^;IT1N8[F2.*3K'^[_P"FG_HRO9/''CS0?AQX?NM:\1ZK;Z/IMO\
MZRZNO\_O*\2=*U3DAJ>Y"K>G[2>ANT5\AZ[_ ,%-/AMIU[]FT_1?$&J1_P#/
MU%;1QQ?^1):].^#O[8'PV^--Y%INDZK+IFN2\1Z9J\?E2R?]<O\ EG)6L\'7
MA'F<3..,H2VD>W45C>-/$T'@GPAKGB*^C>6RTJRN;ZYCMN9)(HH_,_=UX=\+
MOV[OAO\ $R[U:W2'6-!@TK39-2NK[78XHXA''+%%_P LY)/WG[V.LH4*E2/-
M%&E3$4Z<K29]%45\?:G_ ,%-/AW::U]FM-!\07VG1C_C_BCCC\S_ *Y1RRU[
M%_PUA\,1\+X_'DGB:,:'))Y7E_\ +S]I_P">7E_\]*UE@Z\-7$RCC*$MI'K]
M%?'5K_P4Y^'4NK_9KCPYX@M;'_EG=>7'_P"BO-KZM\&^,M%^(7ANQU[P_J,>
MJ:1>Q^;;7459U,/5HZU(V1K3Q%*MI3E=GRS\>/V_3\$_BIKO@L>!!K/]E?9_
M]/\ [5^S>9YEM')_JOLTG_/2OJ_PWJW_  D/A_3=5\OROMMM'<^5_P \_,BK
M\F/V[_\ DZOQQ_VX_P#I#;5]O:Q^V5\-O@OX9\/Z5JNHWFJ:O;:=;?:-/T:/
MS98OW4?,G[SRZ]6O@G]7@Z$=6>/0QB6(DJ\MCZ8HKPSX0?MB?#;XU:I%I.E:
ME<:9KL@_=Z9J\?DRR?\ 7+_EG)7N=>/.E4HRY:JL>W3K4ZT;TG<**\C^,G[4
MWP[^!S?8]>U<2ZP1YHTRQB\VY_\ M?\ VTKQO2_^"G/PZN[WR[S0?$EA;?\
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MBN-3BTJVEN9+6U_ULD<?_/*CPM_R_?\ 72MV6&.6*6.2/S8I/]9%+30F>/\
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MS_65ZW43A.G*TD73G"I&\6%%%%24%%%% !1110 4444 %%%% !1110 4444
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MO_D/S:_2KPOX,T#P1926?AO1=/T&QDD\R2UTNRCMHI)/^>O[NJW_  KWPO\
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M(?\ L9[G_P!)K:OJZ6(=++XJU[>1\E5PZJYA4UM\SY7_ +#_ &K/^>OQ/_\
M V]_^.U]1_L'Z=\6[35_%_\ PLR3Q9]F^S6WV+_A([FYE_YZ^;Y?F5]@YHKR
M*^,<Z>E.QZ]'!*E4_B7/@?\ X*J?\TP_[B7_ +;5WG_!,3_D@WB'_L9[G_TF
MMJX/_@JI_P TP_[B7_MM7>?\$Q/^2#^(?^QGN?\ TFMJ[)KFR_4Y(/ES"I8^
MO*_'']L>TCM/VF?'L<?_ #^Q2_\ ?R**OUU\6>,]&\!Z)<ZKX@U2ST73;?\
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MU/\ L^_ 7]G>?X9:;J'C_P 9:!?^)-4M_M$MK+XBCM?[.\T9\ORXY?\ 6?\
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MH **** "BBB@ HHHH **** ,+PM_R_?]=*W:PO"W_+]_UTK=H ^$_P#@I7X
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MOA)KUQXN^%/@S6KN3S;[4=%LKV7_ *ZR6T<E?F'^Q=\#+?X_>.K[2=?DN/\
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M.5Q487QFVAUUY6P>^I>U_6]5\,_\$X[6]TB22*^_X1BQC\V+_6QQR2Q1R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBG$<08A4X/EHQ^&-[_?W"BBBN0^#"BBB@ HHHH **** "BBB@ HHHH ****
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M_P#'G3Y?,M_!\EK+_P!,M:LHO_;FOURHI8?'U<-&48]2L1@:6(E&3Z'Y+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#"UW_D)6/_ %TK.^+'@^X\>_#C7?#UO<);7.H6
MWEQRR#_5UHZ[_P A*Q_ZZ5NU<9<LN8WI5IT*E.I2=G&2?W'PE_P[T\2?]#1I
MO_@-)_C2_P##O3Q)_P!#3IO_ (#2?XU]V45U_7*W<_0/^(@Y_P#\_OP/A/\
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M,OV;RI?^6GF?\]/*KRK]C[]J3QAXR^(&K?#;XEHG_"2V4<GV>Y^S>5(9(_\
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M%]F\S_MI_JZZOJU51NXLY/K-)[-'O=%%%<_*^IT<R>J"BBBI+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *&M?\@BYI=!_P"01:TFM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:[_
M ,A*Q_ZZ5NUA:[_R$K'_ *Z5NT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%=?\C1;?]<ZW:PK
MK_D:+;_KG6[0!\#_ /!53_FF'_<2_P#;:OMOP/I5MHG@W0].LK:.UL;:RMHH
MXHO^6<?EU\2?\%5/^:8?]Q+_ -MJ^Z?#G_( TW_KWB_]%UZ6(B_JE/EW/-HR
M4L94YMC\^?VK])MK_P#;Q^'UE/%YMK>W&B1W/_33_2?+K]%/7TK\]?VIO^4@
M/PP_Z^-$_P#2ZOT+IXN[IT?(C"-*I7\_P/ST\-Q1Q?\ !4>2./\ =?Z;<_\
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MZ%^V5\=O#_PL^$/B'1A?V\GB76K*6RLK"*3][^\C\OS/^F?[LUY[_P $O_\
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MV/F?O+*7_EK7Q]^VQ\0;?]H/XJ>#?A9X'N(]8N;:ZE%Q<VH$D0N)./\ 6?\
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M $B2/R_L$MM'Y5?$_P ._P!J'QA\,OVI-<\(_%KQ%<SZ'YDEE;274444=O\
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MO^QGMO\ TFN:^3?V3/V6[+]I3_A*?M'B*XT+^QOLW^IMO,\SS/-_^-5]9?\
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M9L=+LI;FVN(_,_UO_M2.6OLS]M>3XGW_ (#T_1?AGI-_<IJ$DO\ :E]I<O\
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MB3[-'^[C_P"6G[N/_IE7S?\ $'P;XB_9M^,-UI*:CY6MZ%<1R6^IVW[KS?\
MEI%)793P%&I*4%/5>1PSQ]:G&,IPT?F?M?16%\/O$/\ PF/@3PUKTGE_\373
MK:^_=?\ 32+S*W:\*4>67*>_&7-'F"BBBH+"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,+PM_R_?]=*W:PO"W_+]_UTK=H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,+7?^0E8_]=*W:PM=_P"0E8_]=*W: "BBB@ HHHH **** "BBB@ HHHH
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MDKW2O*Q"A[;EI+0]7#N?L>:L]0HHHKF.H**** "BBB@ HHHH **** "BBB@
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M74Q>(G1DXPM<Q/"&H?M6?M,:0-8TK7Y-!\/W'[N*ZCECTV/_ +9^7^]KYO\
MVA_AEKWPG^)%SH/BC6O[>US[-'<W-_YDDGF>9_TTEKVKX)?\% -:^%'PTL?"
M$GA6#7I+(>5IUR+[[-Y<?_/.2/ROWE>/?M _\+ UOQ1;>,_'^G2:7?>)8_M-
MM%+'Y?E6T?[N+]W_ ,LZ]7"\]/$:I)'DU^2K0TNV?H#X\_Y1XVO_ &)6F_\
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MIG5Y(_\ EI964O\ Y"K](?V??^2"?#3_ +%C3?\ TFBK\X_^"B?_ "<I??\
M8-MO_15<F!<5BI2D]&=>.4I86$;7:/T<_9]_Y()\-/\ L6--_P#2:*N^K@?V
M??\ D@GPT_[%C3?_ $FBKOJ\:K+W^8]BAK#E84445F;!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &%X6_Y?O^NE;M87A;_E^_ZZ5NT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &%KO_ "$K'_KI6[6%KO\ R$K'_KI6[0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M85U_R-%M_P!<ZW:PKK_D:+;_ *YUNT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M45<IRE&S9G&$8RND@HHHJ-5L::/<**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"UW_D
M)6/_ %TK=K"UW_D)6/\ UTK=H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,*Z_Y&BV_ZYUNUA77
M_(T6W_7.MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "NCK BB\V6*M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]U%YUM)'5BB
M@#G**NWUIY4GF?\ +.J5 !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#6
MO^01<TN@_P#((M:36O\ D$7-+H/_ ""+6@"]1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 87A;_E^_ZZ5NUA>%O^
M7[_KI6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 86N_\ (2L?^NE;M86N_P#(2L?^
MNE;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!A77_(T6W_ %SK=K"NO^1HMO\ KG6[0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%211>;)Y<= %G3(<R;_
M .Y6M45O%Y,03TJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_P!G7-']G7-
M%:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/\ 9US1_9US
M0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_ &=<T?V=
M<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_P!G7-']
MG7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/\ 9US1
M_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_ &=<
MT?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_P!G
M7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/\
M9US1_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!6HJS_
M &=<T?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L_V=<T?V=<T 5J*L
M_P!G7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:BK/]G7-']G7- %:B
MK/\ 9US1_9US0!6HJS_9US1_9US0!6HJS_9US1_9US0!S.N_\A*Q_P"NE;M4
M-:T6\EO;(QQ^:!UK8_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZ
MYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH YFZ_Y&BV_ZYUNU0NM%O#XD
MMI1'^Z'_ "UK8_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_L
MZYH K459_LZYH_LZYH K459_LZYH_LZYH K459_LZYH_LZYH K45=_LJ7_IG
M4L6DQ_\ +23S: *,44DTO[NM:UM?LT7J]2QQ"(?)4E !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !112-R#WH -P/<49'K7Q/\<_B
MG\=?"_Q8UO3O".CZK<>'X#!]A>UT4W,>#!&9/WFP_P#+3S*\^NOVA/VD]*M;
MF[N=+U6WM(4W2W,WA[9&B?W_ /5_I7?'!SE&Z9]WA>#\7BZ5.I"M2O-)VY]=
M>FVY^C-&1ZU^:6A?M6?'GQ4]RFBRW&MO;\2'3]&2Y$?_ '[CK9/QU_:<88_L
M/7C_ -RS_P#:ZIX&I'=G97X%S#"S]G7K4HR[<_\ P#]%,CUH!!Z'-<+\+M3U
MC5_AOX?OO$43V^NS644MY'+!Y+K+M_> Q_P<]J^??V1?VD/%WQF\::OI/B"+
M3H[:SL?M,?V*$IF3>GK(>.37)[)\LI+H?*4<GQ->CB<13LX4+<S];_Y'UY1F
MH0^]3M_(TWYAR0JU@GW/!;L[-%FDS30?6F/GLF::\QZO8FHJ)2>^*>2>PS1H
M]@>@ZBBB@8F:6F ^V*8Q/8BAV6XDTR7-&:A(W#YAGW!I3A5 QD&EZ@W;5[$N
M:,U")%ESMY/H:%!') 44[H;T=K$V:*8X!ZC-'"KSP*FXO78?FC-1%BO<#\*3
M)/<&G=!=]B;(]:,U7&YNH5OI3G81J,\>PIZ=!)\VB6I-FC(]:KJ^U">K<9%?
M)G[3?[3'B[X3?%G1O#F@QZ<=.N+&WN)/M4!DD\R6XDCXQ(.,1UM"FZCM$]7+
M<MQ.:XCZOAU>6OX'UWFC-5U<R1JR8.1GFG D?>P*POK8\MNSM8FS1FH"Q*[B
M,GT_&OD;QA^T=XTTG]K&'X?0368\/2:C9VWE&V_>['BCDD/F?]M*VA3<SU<N
MRZMFDJD:#7N1<W=VT7;N_(^P:*B4=N@%(2V3T(],UGH>4M2:DS42D]R*>3Z#
M-+1[ VEN/HJ,/ZBD9AV(H>FXE)/8EI,U&"1U  I"PSP,FF-M+<ES1FO!OBS^
MT[I/PV^(&C>#8;.?4M9O[BVBD0'RXH(I7QYAD_.O<PH<[NQ JI0<5=G;7P=?
M#4Z=6K&RFKQ\R:EKY!\9?M&^,]%_:U@^'UM/:?\ "/2:C9VWE&V_>[)(HY)#
MYG_;2OK?<=ZKC .:;A8Z,;EU; 1I2J-/VD>96=]//L_(FHS4.\L/E(;ZT!BO
MWL"LKH\F^MK$]%0LQ7IR*7?M3)&*-2GHKLDS1FHCD>@HP2>@-%T*_D344S'O
M2YQ5"N+FC(]:A;:=QZ9'6O"_BS^TYHWPW\>:1X-AL9]1U[4+FWB<+^[B@BD?
M'F%ZJ$'/8[L)@\1CZGLL/'FEN_)=SWK-&:C4@@'KQ37V*G)(&:G0XF[:]";-
M+5;S&+J5 *GJ:^9OVROCQXL^"K>$O^$:FMH?[4%YY[7%OYG^K\KR\?C)5PIN
M<N5'I9;@*N:8JGA*+7-/:[LOFSZAS17,>!=7GU[P;H.H7B@7%YI]O=28_OO&
M"?YUT>%0 <\U$DUL<%2+I3<9;(DS1D>M0J0P('/L:;\RGH%%*ZZD-VW6I8R/
M6C(/>O,/CYXVO_AK\(_$'B/2O)_M*TC1XOM*EH\F1%YQ[&N2_9"^,&M_&;P#
MJ6K:]%:)=VVI26J?8U*IY?EQ2 \_]=*V]F^7F/6CEF(G@9Y@E[D9<OS/?:**
M0]*Q/*%I,U\@^,/VC_&NB_M90?#ZVGM/^$?DU"SMO*-M^]V/%')(?,_[:5]:
MR,3*JE,@]_2M94Y1L>MC\KKY?&C*HT_:1YU9]'W[/R+.:,U"^3R &H#%0,X7
M-971X]];)$]%)UI:"A*6H\=#GFF$D-\J_4T[!OL345#M<GD!A065, G'TJ4[
MB3OLB;-&148 V$8.,TT*!T&/J:+]@UW6Q-FC(]:A4AE('/L:;AE/ 513NNHF
M[;K4L9I:@4 #"@XIQ8D_+@BGIT&FFR2BJQ;+!5.&'.VO#K[]J'2%^.FG_#73
M;*>[OY;E[>[O)/W<=O\ NO,^3(_>=NE5"$JE^7H=V$P6(QO/["#ER+F?DNY[
MW29J-FPI(&<=:;&V\\+BH2;5V<5F]439HJ-B O(XIBLW\*X'J:JPE=Z]"Q29
MJ-G"]3C\*874X^934K78>O8GR*-P'<50U"YCM+1YWX6,9(-?!7BG]KWXG?%#
MQG<:-\-;!H[-#_HYM;/S[B2/_GI)YF(XQ]:Z:6'E5U/HLHR'&YS[2>'24*>L
MI-V2/T$R/6C-?/\ ^RQK?Q/UK2-;E^)B3+<1O&EEY]I%;R8Y\S_5]ON5[SO)
MC!9>3VK*4.65CR,9AI8/$2PTFG)=5JOO+%)32"13">S8_.L]%N<?2Y-29J-2
M>Y&*<3[9H5GL#:6X^BBD- PS1D5#YB@X!Q[$4;"#E5 /K2N@>FZ)Z2F'D>M!
MPJ\\4[Z7%^1)142DYYQ3R3V&:-'L#=A<TM-XQG-,)!Z8-&BW EHJ%2>^!3\\
M<?G1H]@>@[-%5_F/0*U.+[ -WY"CT$G=V2)Z*C8 CIFA0%'3%3<?Y#\T9'K4
M6-W) /O2<MD'##TIW07\B;(HJ LIV#!(/0UQGQ4^*.D?";PC/X@U@RFSC8)Y
M=O'YCNYZ(!6D8.3LC:A2J8FI&E25Y2V7<[K(]:,CUKS'X(?%(?&?P!:^)18_
MV6D]Q/&EN9-^5CD,>3^5>(_M:_M)^+?@MXUTO2?#L6FO;W5C]HD^VP%_WF]_
M20>@JU2;ERGL83),;C,<\NIQ7M5>ZOMR[GU[14%O(9(E8C&0#3R3CBL7=2L>
M':SLQ^:*2HG9L_=S3MV$M=B>BD'2EI %)FD;CH*A8MGH/SHTZAJ6*3-1JP'4
M@4[@CUHT>PKCLBC-5MA9NO[LC&*-C*_7]WC&*-.XKOMUM_P2S2U$.O( _&G,
MP Y.*/0:N.S1D5$ )!GAJ-I)P0"*>@7[IDN:,U">>P8>H-*5#@9!%"UW'YO8
MES1FH1(LH.T9([&A01R0%%('H[6)LT4QP#U&:3A5YX%3<6V^Q)FBHT(93C@4
MHP![5=A<U]5L/S1FHCPAROX9I/X.%_"C38=^G4FHJ$'<, [O8T9*]PM3=!=]
MB;-+49 ZYI<Y'%58&TAV1ZT5$5W=0#3694&"=OL!2NA^B+%)FFJ?6F/GLF:%
MYBU>Q-142D]\4\D]AFC1[ W8=1302>M,8D'@"BZ6X+4D) ZG%&X8ZBO*?VDO
M'^I?#+X-Z[XCTL0?VC;&W2(SJ7CS)<1Q\X_WZP_V4_B=JWQB^%<FMZZ;87JZ
MA+;#[*A5/+CV8//U-:^S]SG/6_LS$?V?_:5OW7/R7\[7/<Z*0< 4M9'E!29K
M,U?5;+0=-GOK^XCM;*W0O)/(^Q$7ZU\7?$']O35=1UF32/AKH/\ :+;Q&EY=
MQR2O<'_IE!&,FMJ=*578]W*LDQN<R:PL+I;MNR7S/N3-%?GW+\2OVK)(_P"T
MO[.U>*SQN^SG1;?_ -%^7YM;WPN_;SU2RUU-&^).E+9Q[_+?4;:-XWMS_P!-
M8B#71]3J.-XV9]%+@K,94JE7"SIUN3=4Y<S^2LKGW-D49'K658ZE;:EI\5W9
MO'<VDT7F1/&V4=:^6/!?[2?BW7_VJY/A_<1:<-!2^O+9?+@/VC8D4DD?S^9C
M/R>E<\:4I<WD?+X+*L5F"KSHQTHQ<I7T:2\CZ]I,UY3^TC\0=6^&7P9UWQ+H
MKQQZE:M;+$94WIF2XCCY'_ ZPOV3_B?KOQ:^%\VO^(G@EU#[?); VT?E@1C9
MCC\:GD]WF)CEU66!EF%UR*7+OK?T[>9[GFC-5MA9LY_=D8Q1L97Z_N\8Q6>G
M<\B[[=;?\$LTM1#KR /QI78*I/3 H]!J^P_-&:^/_A?^TAXS\5?M1ZEX'OYK
M/^P8=1U"VCACMOWGEPF3RR9/^ 5];N[;#\N>,_7FM94W%V/5S++JV5SA"NT^
M:*EH[Z/]?(LY%&1ZU"06'(#4 %>P6L;H\J_D39HR*B &P\&D"@=!CZFB_8-=
MUL39HR/6H5(92!S[&FX93P HIW743=MUJ6"<49![UX7^U3\6]8^$/PW75]#%
MK)>M?Q6_^DH73RWWD]/]T5O?LW_$/4?B?\']"\1:J(/[2NS<+-]G4I'^[N)(
M^,^R5M[-\O,>O++,1' QS"W[MRY?G:YZM1D>M1H0X/&*\O\ VA-?\5^&?A;J
MU[X+MI[CQ!"UN;:.WM?M$C#SX_,Q'W_=[ZSA'F=C@PU*6)JQI0:][2[/5,T9
MK\Z_^%[_ +3A'_($UW_PF?\ [76%KO[6WQP\+7<=KK=Q)I5Y(GF1VUYI26\G
MEC_EI^\C_2N^.!J2V9^B4N \PK3]G2K4I/LIW_0_3&C(]:_.Q?C[^TS<1!TT
M76I8G]/#1'_LE>J?LT_$SXS>*?B'-9^.-+U*UT3[&\BR76B&TC\W]W_RT*?[
MW>HEA)P6K/,QW">*P%"5:I6IOEZ*=W^1]?YI:A'//!]*0.2<%@?:N&Z/A[OL
M39HS7RY^V7\=_%GP5E\*)X;EMH1J0O//:XM_-_U8C\O]9*]]\":M/X@\&:!J
M=V MW=Z=;W,G^^\8)_G6LH<L>8]:OEM;#X.ECIM<M3FM9Z^[W70Z;-&:@4[Q
M@'=[&E&4]%%9770\B[ZK4GI,@=ZA=LJ<=>M>(_M4_%?5OA!\-$UG0Q;/?RWT
M5NWVE"R"-]_I_NBM(PY]$=V"PE7'XBGAJ"O*3L>Z @]#FBO*?V;?'FH?$GX-
MZ!XDU7R?[0N_M"2"W4K'F.XDCXS[)7J(!*D>M*4>65C/$4)X6O/#U-XMQ^YV
M)<CUHS5<0XVDGG&*XWXE?%'0/@_X7FUK7[Q;6TC'EQ1IS)/)_<1.YH4>;1&=
M&E4KU%2I1;DW9):W.[I,CUKX#U3]M;XH_$G59K/X>>%3'"G3R[.2\N5_W\?N
MQ^=9U_\ %W]J#P9;2:EK%EJ,UG&,R"YTJ#9&/^V4>:Z_JDU\32/OX\$9@O=K
MU:=.?\LII2^X_0ZDS7RM^SS^VC8?$_4D\/\ B>VBT/7IOW=M+'+FWNI.\8_N
M2>QKZAA=6R5Y7^]ZURU*<Z<K21\AF668O*L0\-BX<LE]WR?4L9'K1FJ^&8\A
M6%.<A5 /'L*SNNAY*=]EJ34;@.XJ,CMZ=*\T^/OC.^^'?PB\1>)=+\G^T;2-
M&C%PI:/)D1#G'M3BN:7*=.'P]3%5J="DM9M+[ST_(]:-PSC(S7@7[(WQAUSX
MS^ =0U77HK1+NVU.2T3[&I5/+\N*0=?^NE>>_$O]I3Q9X3_:?TSP/:1::=$F
MU#3[64R0_O?+G\L2?\M/^FGI6ZH3=24.Q[D,AQE3%UL%%+GI*3?_ &[N?7]%
M-4[E!]:C=F!^[FL+'SF^Q-FC-1&11_LTW=NZ%30M=A.ZZ$^11FO*_P!H[X@Z
MC\+_ (-:[XET@0C4K5K=(A<J7CS)<1Q\X]GK _94^*NM?&'X9MK6N"U%V-0E
MM\VJ%(]B;/7ZFM/9MPYT>M#+,14R^6917[M2Y;^=KGNE)FHU)[D8IQ/H,UEH
M]CR6TA]%,SQS3223Q@T:+<%J2TF:C# 'J!3N"*-'L%QV:,CUJL5.X\_N\8Q0
M$._K^ZQC%&G<5WVZV_X)9S2U74'/1:>7"XR2?I3TZ G?9,EI,U&I/<BE)]!F
MEH]AMI#\CUHR/6O*?C?\<-%^!?AZ#4=6@FNC<.(K:W@0DRR8Z?[-=#\-/%[>
M/O 6B>(YH$M7U2SBN3;1R;_+W@'K6G(^7F.Z6!Q4,+'&3A:G)V3[OL=KFBOD
M+]J3]HWQC\*?C%HGAW09K2+3KJPMIY#-;^8?,DN)(_\ V2OK*"5I(U+#&4!/
MUIRIN,5+N;XO+JV#P]#$U&N6K>UGKIW70MYHS4"R+*/E&3Z&E4$<D!161Y;T
M=FB;-%,< ]1FC 5>>!4W%Z[#\T9J(Y'H*,$GH#3N@OY$U%,Q[TH..*H5QU)F
MD/J:08Q2'=#LT9'K7P[\>?VS_%7@GXHZYH'A*'3+O3M),<<\UU;R29D_C'$@
M_C_=U]*_ CXEI\6?A=HOB0;$O)H]EY#'TCN%XD7\P:Z)T)TXQE+K^!]+C^'L
MPR[!TL?7A^[J6L_7OV/3J*0=!0:YSYL,CUHS41 ;T-(6"<9"_2E=!Z(GI,U&
M3QQU'44FY0I)XIZ"OI?H2T9J, ,0<9]P:;A=_<FGH%TMR;(]:,U$</T :D 9
M>@"TKH3=NA/11104)D>M&:A*EOX0U'*>BTKH5_(FHR*:#3'4'MG\:+W#T)<T
M9J$MO^[@GWHW!!EL#Z47UL/K:Q-FC(]:AW!^AW?6@ +Z"B^M@]43T4TG I,Y
MZ"JL3S#LT9'K4" $$*<CT-)@K_"%_&E==0O;=:EFBHT.>V*1R1TQ^)HT&G?8
MDR#WHS5>,",$[=GU-2*RE3SGBDVD"OL]R3(]:,YKEO&/B[3_  )X4OM>U)VB
MTVPB,L[*I8A>_%</\ OCA;_'+3=:U2RL)-.TZQO?LD'FM\\B>5&_F..WWJUY
M'R\R.ZG@<34P\L7R_NXZ-]GV/8J**0UF<09HS4('S E?UIP7YB2:%YAZDF:6
MH.IRPY]0:D.>W6G83NMQV:,CUJ%OO<KTYS7S%^V/\>/%GP4D\)_\(U+:Q#5!
M>&<W-OYHS&(]F/3F2JA3E.5CTLMP%;-,7#!4&N>>UW9?-]#ZCR#1D&N-\)>)
M&N/AUI7B#4F$9DTR.]N7V]/W6]_ZUP'P*_:.T[XY>)_$EEH^GS6VEZ5'!)'<
M7!P\_F>8/N'E/]7WZT^1^];H..78J=.M6A&\*7Q/M=V7WGN.:,@]ZXSXI^([
MCP;\._$^OVBQM>:=IEQ=P"7_ %?F)&[C/XBO'?V/?CCXB^-6E^))?$4=C%+I
M\END7V)"O^LWYSD^PIQIN5-U.Q=++,16P53,(K]W!I-_XMCZ5S1FJZ,W=0E2
M-@J,G/N*QNGL>59K3J2T4@H-, S1N'J*\J_:.^(>I?"[X0:YXDTGR/[2M#;K
M ;E2\>9+B.,Y'_ S7R;\+_VX/&&K_$/0K#Q#!I T:\NX[6=[>"2.1/,.P/S(
M>]=5/#RJQYHGU65\,YCF^#JXW"PO"&GSM>Q^@^:6H059$;/!'%/SWKF:/E+]
M.H[(]11FOE[]KG]HW4_@P^@:?X=CM9=4OC+<3?:U+A(D ST_S\E/_8Y^/WB;
MXXR>+%\01649TP69MS9Q%/\ 6"3S,Y/K'6_L)JG[1GU+X;S".5_VO*/[K_@V
M1]/9I:9GGIBF,3V(KGVW/ETTR7-&:@+'^)<CVIYVE!Q3L#TU>Q)FC-1%QV(I
M,OV(J;H3;70GI*8,CK2,0>F#3=EN).Y)D>M&:A10#G;C\:=*0L3-Z FG8:OL
MR3(]:*^0OV2OVDO%OQG\::QI7B*+38[>UL?M$?V&$I^\WH.\A]37UJCF0 G@
MY.*UJ4W3=I'JYGEN)RG$/#8E6DK?B6,T9J L?XER*>=I0<<5E8\MZ:O8EHI!
M2T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I#T-+2'I0! L8   ![9(KS[X]A5^"7CX! ,
M:#>GI_TP>O01V^E<'\?O^2)>/O\ L WW_I.]:T_XBU.K .V*I);*:_ ^4/\
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M46&5TZT'F7!R/[@^Y]7P*\QTG_@H'\.-0OA!=VVN:7$!C[3=6J-&?^_4CO\
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MN;6/RA_WQ(7_ $KQS]D7X'6WQKL9?$?BZ:76=-T7_B5Z?I\[YB4#$A)'?_6
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M%G[4?@#P=X9TK7;_ %%PNJVZ7=I9QH7N)$(!_P!7_#7G7_!1-\_!_P /CO\
MV_ ?_)>XKA_V1/V;M"^(/@Y/&GC"$ZR9R;>PMKEMT<4<?[L\>OR>7_VSK2%*
M'LN>1>!R?*GDL<TS*;7++EY4OB]'T/0-%_X*!_#G5+PV]Y::QH\?_/S<VJ21
M_G%))7TCX>\16'BC28-3TV\@OK"=-\=Q;2!XW!]"*^;OVC/V7_ ][\+O$&L:
M)H-EHNK:/9R7<#:=#Y6\QH7V.D>,@XZ>]<__ ,$ZO$DVH>%/%FB23"6WT^[C
MFMX_^>8E,G'_ )#HJ4H3IRJ4]+#Q>5Y3B\GJ9ME3<7"2BXRUWZW/K+7O$-AX
M9TF?4=2NX+*Q@0O)<7#A(T'N37S[XB_;N^&>@R2);R7^NE.K6%H?_:A05S'[
M97@+XE?$_4=&T;PSH[7GANW3S)VBNHT#7!/\:%P2$0?CYGM7IW@']E;X<>!/
M#]M;W'AK3M<O(T'GWFI6R7$KOZY?.VIIPI4X\U77T.3"8+)<+@:>*S&3JU*F
MT(-:>KZ?<<YX1_;I^&_B2Z6UNYKS0F<?*^J0A$/_  -'<?K7MVN>+K+1/">H
M^(9&\S3K&SDOY7@_>%XXXRY*>O XKY/_ &Q?V>/!GA_X;7GBW0='AT74[.2
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MKK6D1_\ /S=6L<D?YQ225YS^R-^S?HOQ!\(P^,_%\!UK[03!8VUTVZ.**/\
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MM=@MR8_,D1)$_>?20?K7IFJZM::/:S75]=1VEI"ADDGF<)&B#U-? /Q&._\
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M $KW#X?_ !0\,?$[25U'PWJ]KJ,"X#A'_>(?1T/*'ZURNI?LT_#;4=#;2O\
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MC_5^WF9/_?!K1_9O_9(\*Z'X-TW6/%.D0:UKE_;)<2PW\8DCA209\L1_ZO\
M2E3IPA352KU(P>3X#"Y;'-<XNU-M0C'[276_3[CHO ?[:GP\\=:G%8R37.B7
M4_R11:I$$20^TB.\?ZU]#I(LL:LI^4U\D?M,_LCZ1K/@V;6? WAU++Q!:,DO
MV#3HQ&EV@/\ JR@XYKKO@MXJ\3_#+]G74;_XBZ?/:7GAR.;RO/<&2X@2,&/\
M?X/PJ:D*<U>D9X_+,LQ6$IX[)I6<I*/LY6Y]>OFCTCXG?''P?\(+-)/$>K16
MTLO^KMHAOGD^B 9->/VW_!0+X<37YMY+/7K:+&!=2VL?E_\ HS?^E>#?L\?"
MV7]J#XD>(_%_C>XDO=/@=)9X]^SSY'&8X\=4CCC[>]?86I?LT_"[4M'>P?P3
MI,4/EX\Z"R2*?\)$ >M.2C2?++4]+&9=P_D<XX',>>I7^URM)1]-[_@=AX'^
M)/A_XBZ+'JF@:E!J%I(,B2%\[>,X?^Z?K3/B-X_TKX8^%;OQ#K1D73K0Q^:8
MX][KOD$8X^KBO@O2Q-^R7^TY!ID%V\GAF_FC1C(<[[1\C+G^_')W[A/>OJO]
MM(@_LV>+B.0PLCG_ +?(:F5#EE%=SS<5P_0H9GA:5-N5'$2BHMJVC:7X7-"?
M]J;X>P>!+3Q?=:N]KIER[I;12Q?O[AT[1Q]2>#7GUG_P4(^'ESJ+0R:9KUM;
M'_EZDMXQ'^?F5XA^QY\!+'XO"\UCQ0&U+1-*D^Q6FG,^83)_K)"1W_UG_C]?
M3WC[]DOP!XL\+7%EIV@:?HM\(#]FO;.U$<B/C@OT\S_@>:UJ4Z,)<MSVL;EG
M#.39A4P&*<YW=KIV4?EUMU_I'J_@KQOH?Q!\/VVL:!?0ZCI\XS%-$V0:^2/V
MXOC9X?U'1]4^'<:79URQN8)I,Q$0?ZL2?ZSZ.*YK_@G9XENX?''B;P_+)BWN
M+(WGD?W9(WCC/_HRO3OV[O!NA6_PNO=?BT+3(]<DO;9'U/[%']H?GIY@&_\
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M/^U+X!\=Z9J]]:ZG)I]GHZ1R7<^H1^0B!^1R:X#4/^"@/PZT[4UMH;/7M4A
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M;7$@_>2R?]<__:<E8QH7K2IWT1X^#X:>(SBME]2?+&ES.<K;*/6WF>Y>(?\
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MY+^Y?!?/'[O/]Q,X KX]^.B_V]^V?/;73H(Y-<TZ$+*/W?EXMHZ_3*(!4C]
M*]6LY4:,5%[GZKQ%.64Y%@,NPSY55CSSMN]K:_/\$&S+9X ]".E?-W[7_P
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MJ%W'YL5O:6YE)C\P)GCW-3?%OX_>$_@XFD#Q,]S&=3\TVZV]OYO^K\O?]/\
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MK^%1=3P:CI@F>ZDGB\N!/+/S_O#Z9KS]?V_OAL=;DL?)UE+/'.I&S_<_EO\
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MX72J6\[<J_0]@_X**M_Q:?0!_P!1Z$_^0+BO1?V084@_9Z\(^6OE;X9-J_\
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M.UTJX%P\G'^QE4_'%?"OAWQI?^(OVF?#_BS7+26SDU37+>[\MSDQQR/Y4?\
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M?_(==.%BY1FD?<<$X.IF%+,</2^)TG:Y^K.T-)NW<=,8KY(_X*'SQ#X7>'8
M!YHUM"I_V?L]Q_\ 8UZEHG[6?PNUO1H]2_X2JTLG:/+6MZWE7">QC/-?(WQP
M^)-_^UC\3- \+^#;25M,M))$@<Q9W^8,27$AZI& ,>]+#TI0G>:LC'A;(\?2
MS:&+Q5)TZ=#64I+EM]^Y]1?LW:Q#X*_99\/ZQK<ZI9Z?83WC2MVB#R29_P"^
M,5X+J?[6OQ7^,>O3Z?\ #+0S86T9ZB%)K@H?XY'<^7'].:]\^/OP[DL/V5-8
M\(Z(CR#3M-M4BCC/[QXX)(W<#ZI'BOG_ /8;^,?A#P)I6O:%XDOH-'O;JYCN
M+>[NALBE^01[ _J,5TTU&2E4Y;^1Z^54,+B,)C\]IX;V]55;1A:^CUNUU_X!
ML6OP3_:7\;1*VL^,?[%AD'SPB^\L_P#DO7BUIX#N_AU^U9X=\.W>H'6+NQU[
M3))[YH^7WF.0_P#H=?;WCC]K/X;^!]-FF3Q'9:Y<+'F.UTJX%P\G'^Q\J?CB
MOA7PYXTO_$7[3/A_Q9KEI+9R:IKEO=^7(<F..1_*C_[9^76M"=:TKQW/I^&L
M3F^+H8R=:@J5%TY:1BHMM]KW;L?7?_!0%O\ BRUL.W]JP'_QR2NE_8D'E_LY
M>&')P&>\ _\  R>N;_;_ ./@?:C_ *BL'_H#UTW[$GS?LX^%?]F2]_\ 2N>N
M&3_V:Y^?XC3@ZER[^VM_Y+N>\@[LXK\\="!/_!0LCO\ VQ<?^DLE?H2$P^[T
M K\W/&?B.W^%7[;M_K>K[X;*WU/SW\N/@1R18\P_]_*G"?:Y>IKP/&4Y8VC#
M64J$DEYL_2@D+SUI=W'-<%\,OB_X7^+FGW5WX9U3^T(+63R97\B2/9)CI\X%
M=Q+\S?-M*^]<LH.+M(_.*]"KA9RI58\LET>AXG^V89O^&<?%WD?ZTK;X_P"_
M\=>?_P#!.J&/_A4>O28S)_;;Y]?^/>WKW[XG^"Q\0O >N>'97,(U"TD@$@ZH
MQ&$?\#S^%?!W[/'Q:O/V8_B!K/@_QI:RVNGW4VV=GCPMK+_STS_'')V/M7=1
M?M<.Z<=V?I.2TGFO#6)RW#:UE/GMU:M:R/T?CR!MZL.IKX5_X*1+$-7\"F/
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ME<XH8[/:V4XO&5XTZ-*6CO!1<UVBNIPG_!0UIC\8M&R?]&&B1"+_ *Z>?/\
M_:Z_073V1;2W$/$/E#&/I7R9^WS\*+WQ3X>TGQCIL$ES)I0DBO(8^/W#CF3_
M +9X/_?9K:_9T_:P\(ZWX$TW2/%.M6VB:]86R02G4I D<Z1C'F"3[GY&HJ1=
M6A%15['%C\/4S;AG 5L!!S5!24DE=IMWO8^HC$JH2Q(&<\\5XG^V+/-_PSCX
MM>V*^9L@Z'/R?:(_,_3->9?M5_M0>$W^&VH^&/#&KP:YJ^K)]D=[)]Z6\$G$
MC&0>U3?LZ? :[U']F;7M+UV62WO?%22R11W!S]GC\O$ _#'F?C6%.BZ:]I+3
MR/(P&3SRRE0SK'-T[58KE:M)I6;>_P"A\^?L^_!OXH?$#PM?W_@+Q@GARQCN
MS;SP?VG<6P>3RHSYFR./C[]>K']E[]HV0E6^*)./[WB*_P ?^BZX7]G;XL7_
M .S%\0M:\)^-K::QL;J79-F/S/L\G\$@/\<9&1GM7V3=?M,?#"RT_P#M!_'&
MDF+'^JCNHY)/^^ =_P"E==>=9U+Q5S[KB/,<YH9@Y8*A"K3E\$E2C*_SMJSY
M,UO]B#XN>*[]9]:\5Z1JEQ&OEQRZAJ=W<R(G_ XZ^C?VQ;=[;]EWQ/%/)O:,
M60:3U_TRWS7SE8?%[QU^T)^T-%'X)U75=$\/B2./9')L2"SC_P!;))&<IYG)
M_..OI']M)O\ C&KQ4&;+YL\D>OVN*E4<^>G=GE9A5S*GFF58?,9QYE*$E%))
MPO*+LU\CEO\ @GY&D7P7O,)MWZK.?_'(Z^GI4)C8 X4KBOF/]@!-_P %+I?7
M59__ $".OIQP0']EKAQ%O:Z'P_$]O[=Q3AMS.Q^>?["S;?VC_$?_ &"[G_TK
M@KZ _;X_Y(+<_P#80M_YUX!^PKG_ (:/\28&?^)5<_\ I7!7T-^W382WGP#U
M&5(_EMKNW>3']PRB/_VI7=5:^LJ1^@YNVN,,*ZEM/9WU\D3_ +#;9_9]T-?^
MF]U_Z4R5\[_\%$_^2I>'_P#L$?\ M22NQ_9$_:.\$>$?AKI?A#6M2DTW6$O)
M(HU>%Y%F,DN8\.@(.?,%<7_P4.9'^)_A]D.0VD$Y_P"VDE727+B>9G3E6$KX
M3C.K*M3<8R]IRNWQ:/8_0B- 567/5:^"/VYO!USX"^*N@?$#25$,EV\9>4?P
MW$',9_%-O_?JOO>*,-;1J3CY1C\J\=_:J^&;?$CX.ZU96Z+)J5G$;ZTR/^6D
M?) ^J;T_X'7#0GR5#\YX8S+^S,VA.I_#DN67G%G&_M'_ !QAA_9DBUG39/+N
M/%=I';VK'^ 2QYD_*/S*9^PG\.F\(_".36IX@E[K\PG'8B!/DC_ X>3_ +:5
M\6^'-2U?XNP?#[X;0O)LM;V2."4=X[B3S))?^V7[ROU9T'1+7PYI5GIMH@AM
M+2"."&(=%1!@?IBMZ\51@X)ZL^NXEPT.'<I650?OUI2G/_!%VA^&ILCH*#T-
M+2-]TXZXKRS\E1\D_M&?M@W/P\\3S>#O"&E)J?B2/RX[BZD)>.)Y#Q''&.9)
M/;WKA;71?VKO'T;23W\F@VLO*"66WM/_ $7^\KS'6+Y/@S^V3?ZMXG@?['%K
MMSJ!(C\P?9[CS)(Y/_(A_P"_5?<P_:2^&)MA<?\ "=:.%QG!NTW_ /?&=WZ5
MZRM1C:E&_J?M.-HQR#!8197@(5I58*<IN+G[SZ)75CX>_:(^!/C?X=^$=/\
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M6ZR:6_H;-M\$OVF/&T:G6O&/]BQ/]^$7WEG_ ,EZ\6M? =W\.OVK/#OAV[U
MZQ=V&O:9)/?-'R^\QR'_ -#K[>\<?M9_#?P/ILTR>([/7+A8\QVNE7 N'DX_
MV,JGXXKX5\.>-+_Q%^TSX?\ %FN6DMG)JFN6]WY<AR8XY'\J/_MGY=;4)UK2
MO'<^CX9Q.;XNAC)UJ"I473EI&*BVWVO=NQ]?_P#!0'_DA\&.G]KV_P#Z+DKI
MOV)O^3;/"G^_>_\ I9/7+_M_G'P.M5_ZBL'_ * ]=+^Q)\W[.'A7VDO?_2N>
MN"7^Z_,^!Q'_ "1M-?\ 3_\ ]ML>^T44AK@/S@;Z_2OSB_X*%_\ );]-_P"P
M#;_^E%Q7Z-%.%'I7YQ_\%!FW_&S3#_U K?\ ]*;BN_!6574_1> )<N>1;VY9
M+[T?H7H'_("TW_KWC_\ 1=:-Q_J'_P!TUGZ%_P @+3/^O>/_ - K1GYMY/\
M=/\ *N/[1\#5_BM^9^=_["[!?VC_ !'GOI=R/_)N"OT-"^6!_='6OSP_8;./
MVC/$I_ZA5S_Z5P5^B:C)/N*[<9;VET?=\>6_MEM?RI?@?$'_  4I_P!=\//]
MW4/_ &WKZ9\*:W9>%/@9HNLZA.+:PT[0X+BXE/01I ":^9?^"D^1+\/ >N-0
M/_I-_A7IWQ0T*^\2_L93V&G1M+,-!L)PB?\ +2.,PR./Q2,UIRIT::N>K6H0
MQ.0Y/1J22C*I--]DZEK_ ':GC=_^UI\6OC-XBGT_X6Z$UE;Q$8VP1SW'E_\
M/21Y#Y<?T.:THO@M^TUXYYUWQDVC1O\ ZR+[=Y7ZV]8G[#/QD\)^ M/UO0_$
M-]!H]Y=7"3P7=S^[BDS&(P@D/!(Q^M?1OC?]K3X<>"-,GG3Q'::W<+'^[M=+
MN!<O)QQPF53\<5I4YZ<^2G!>IZN;RQ.4XYY=E670Y8_#-P<F_-N]G]Q\2VO@
M&\^&O[6'ASPY=Z@=:O+#7M+EFOFC_P!9O\N0_P#HROJS]O\ 0_\ "E+=\_*=
M5@&/^ 25\B^'_&FI:]^TSX>\6Z[:36<VJ:U;W@CDZQQR/Y47_;/RZ^N?V^Q_
MQ8ZW;;C?J\#'GOL>MIIJK3/7SE8B.?9-4Q37,XQ4FMM']E'7?L2?\FU^%/\
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M4OTN?H46/)/3C'M7YU>/H&F_;ZB%@XRNN6&\#T\NWW_IYE?5?C?]JKX=>"M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5PE64)/L[?@> >!OV.OAKX-OH;U=&;6+A%/E/J\AG"'_ '#\@_*N@\<?LU^
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M7M)\W-<X'CL6\1];]K+VG\U]>WY:&/H^E6NA:99Z?8QB*RMHXX(8A_ B<#]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMTMW?RVV/I6S\1Z7J5N\]GJ%O=QIPSP2B0*?PKEYOC?X BU#["_C/P^EX?\
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M#GQ;\$;2V\%W^K2:MX1N9_MVF2&/YED0.LJG'^K_ -:*^Y?V/R&_9V\(*?\
MGC)_Z.DK6K!0PR2=SZ'.\'3P7"U&%&HIPE6NI6MI;:Q[92,<*3[4@ZU3U*Y^
MS:?<S#YMD9;]*\Q(_)8+G=CX#_:W^+NM_%?XF1_##PY*_P!AAO8[22&$?\?5
MV>?WG_3./J?>OH/X._LB^"OAUHEHVJZ5;>(M=,8-Q>WT?F1F3_81\XKY0_8O
MLO\ A+/VCX]4OB+BZ@AN]1DSVDD/EG])#7Z8KSCZFO3Q+E17LX.WF?K?%F+K
M9%3H9%@9<D%%2FXZ.;?\QPFN?"#P7XJTZ6SU/PQI-S;R#DFSCS_WUBO@KX\?
M##4OV6?BSI.N>%+F>+3[A_M&GRN?]7)_RTMY/^>@]/\ KK7Z9\8]!5*XL;6[
MDCDG@CE>'YT>1/N5ST<3.G*\]4?*9'Q/B<FJM5&YTI?%!O27WW,#X=^+1X[\
M&:-KB0O:F_M8YS!)]Z-R/G0_0Y%;UY>VVFVSSW-Q%;P1C+O+($1!^-9WBG7X
M/"/AO5-7G!6UT^VDNGVC^!$)/\J_/?P3X9\7?MM?$34[[7=<EL-"L#O>"(B2
M.#S!^[CCC/MD^94TZ7M-6[&.4Y/2S;VV,J551H4]V]7KT2TN?=@^-G@0WGV3
M_A,_#PN?^>/]JP>9^6_-=99:A:ZI LUO/'<0.,H\<GF(XKY(U7_@G?X6:R9+
M'Q/K-O<X^5[D1R1Y_P!P(A_\?KR?X$^(?$_[/O[1B?#_ %&[DN-,GO/L%S;$
M8CD\P?N[B/\ \A@_4UNL-"<6XRV/8I<.Y;F6&K3RO%\]6G'FY'%IM>NI^BMU
M<Q6EN]Q<.D,4:EWD?H@JK8^(--U.VDGLM0M[N*/[[P2B0*?PKDOCY)M^!OCW
M'0Z#?#_R7>OSI^ GA[Q?\6[*Z^'6@7ATK1)ISJ&KW(Z^7^[CP.SY_P">=10P
MRJQE)NUCSLFR".9X.KCJM7V<*<HINU]^O3;MU/T:?XX> 4U V+^,_#T5Y_SP
M;58!)^6_-=E;7D-ZBR12I(C?=9.:^.-:_P""=NA)H$HTWQ-J/]KB/"23K&T#
M'WBQBN._8B\?:_X1^*>H?#G5I)IK-_M$8MY'!-I<1D&09]_WE/V$)1E*$KV.
MZKP_EV)P5;%Y7B74=+5Q<>73O>Y^@60 <G%<]XB\:Z#X8@\S5]:L-*B_OWMU
M'$/_ !\UX1^V5\;]1^$O@JUL-#86NL:U))%'='_EC&@S)(/]H93BO(?@_P#L
M2I\1_#=IXH\;>(-3BN-6C^V);VQ!EV2#,;.\GF$G'-13HQ<>:;L<&!R3#?4?
M[1S/$*E%Z127,Y?BK'V/H'Q,\)^)I?L^D>)M&U23_GG8:A%*1_WP:ZY9%900
M00?0U^?WQI_8AM_A_P"$=0\4^%]:OI_[-C^TM9WA3S/+CYD=)$ (..:]>_8<
M^*.K?$#X>ZC8:Q,U[?:)<I&ES+_K7BD&8R_OP_Y54Z$%3YXRN:8[(<-_9KS/
M+L0JD(R46FN5J_WGU)D <G KD/$/Q0\)>%KH66K>*-&TFX[1WNHQ1/\ DYKY
M\_;9_: U'X<6%GX7\.7)LM8U*,O<7L?,EO;Y_P"6?_31^<?[AKAOA=^P7'XE
M\/1ZIXZUC4[/5+Q!.+6T$9D@)_OR21R9?GK2AA[14ZCM<TPG#V&IY>LSS6O[
M*$_@2CS.7G:ZLCV7]L34K36/V9O$MU:7$%S;RM:&.2!Q(C_Z7%TQUK'_ ."?
MBX^"5PW_ %%YQ_XY'7S=\?/@MXG_ &>/#UWI]CJ\^J^"-?E2*9)HQF*X2021
MER/XSY?^L]O:OH[_ ()^-_Q9:X7_ *BL_P#Z!'714IJ&&LG<^FQN!I8+A&:P
MM7VD'6NG:SM;9H^G9)4B&7? ]^*XS4_C#X'T6?R=0\7:%82?\\[G5((S^1>O
MB_X[>./%GQ^^.K?#/P]?R66BV]S+9F/?Y<<CQ_ZUW_YZ 8?BO0[#_@G7X3&G
MJESXFUN6] ^9X4@CBS[(8W/_ (_6"HTU&\Y6/G9</9=@*%">:8ODJ55=1C%R
M:CW;NM?(^K-'\2:;K\ GTW4;748CTDM)TD'YBM9FR#CD^U?F-\3/AWXF_8Z^
M(.BZCHFN//;WH\VVG"A/-\O_ %D<D8_UG_+/_OY7Z+^$-<A\1>'-+U2.$Q+J
M%O'<[,_WTW_UJ:M!4TG%WN<.?9%#+J-#&8.NJU"K>TEHU;R/E/\ ;>\)7O@[
M6?#7Q5T!3;ZC87$=M/(@Z8.]'/\ Y$C_ .VM?37PK\>6?Q.\ Z)XCL (UO8!
M(\?>.3^-/P?(_"LC]H;PM'XV^"_C#2F :22P>2+':6/]Y'_X^@KY_P#^"=7B
MS[;X6\4^&FEVO87<=W$GI'+V_P#(>?\ @=7)>TP[D]T>JX?VKPTJ\_XF&DHW
M[PEW]&?9PZ4M)2UP'YV%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %(:6B@"'<2?Q%?$/_  4BOF2/P'9CA)FNYS_VS, _]GK[@)^;'8U\<_\
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MTC'YDU^=_P 4M:7]J#]H[3K7P[;R2V$NRP2YV;!);Q_O9)P?^VL@KMP[E/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/
M2EHH A/#+7FGQ^^'B?%3X6Z[H@ ^U2P%[8GM.GSQG_OI17J%(R@J01P:TA/E
MES'1AJ]3"UZ=>F[.+N?&_P#P3Z\;;O#_ (C\%W9,5[ILXNXHI6_>>6YV2#'^
MQ)&?^_@K[!D7S$9/52*^*_C!X%UCX!?M!:3\3_"^G7%[H6IW'EZG:646_P O
MS/\ 6<>DA_>?]=/K7V3IEY'J=A!<P_-!,GF(P/7-=.(:<N>)]3Q,J>)Q$<TP
M[7LZWO><7UC_ ,$^?_V<?V3IO@-XGU'69/$ZZVUU:_9O*6Q^SB,>9O\ ^>CU
M]#7UA#?6LEM.BRQR*59''WJN@48K"=64Y<S/ QN98K,L1];Q<^:IWV_(^4?
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M0;+<1"/9O]/K7O.!1BM)8B4H\O0Z\;Q+F>.H2PM:I^[?+HDDO=V/-/C-\&-
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MLIN\CRLPS/%YK6^L8N?-/[E;LET/G[]GC]ENS^ ^LZKJ46O7&K?VA!]G\J:
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M<3B*N+K2Q%9WG)W;/F?X#?LF/\&OB%J7BN7Q.FJR7UM+"MH+#R/+WR1N3O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2'D&EHH I.B1E5!\L>@%6,<Y![5)@'M2U7,^HE%)\RW>X@I
M:**D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M9AU*S.H)9FY@^W
M-'YOV;S0)-G]_9UZ^U/N]2M; +]KN(;4/T\V0)G\Z+[>9-WKY&A14$4J31;X
MSO4^E,N;N&RC\R>1(HQ_&[8%-)MV$Y):]"U15..]MI+<7,<Z&#'^L#_)4EM=
MPW<8DAD22,_QH>*+,?,BQ169JNM:?HEH;G4+V"QMQ_RUN)1&GYFGZ=JMEJUJ
M+FPO(+R!O^6MO*)$/XBEK:]@OK8T**H2:A;0W*6TMQ''/)]R/>-Y_"KP.:;3
M0*28M%4[G4+6TV>=/'#O^YYCXS5G(I6?8=UW'T5S]GXRT+4KTV5IK%A=7H&3
M;PW,<C_D#FMP'>N13:E%7:)C.,G9,DHHHI%A13>*.*5T+4=13&R:"-RXI*5W
M8;NE=#Z*8!M&*,;A3NKV%K:X^BD)Q61J?B32]!\O^TM4M+#S/N?:YTBW_3.*
MI)LER4=S8HJ+_61_(:D..]3=%:BT4REI<R#4=13,GTHR?[M59BYD/HIIZ4#D
M4KZ7*U'44SM[T?SHNK7%J/HJE->6UH\<<\R1R2?)&)'Y>K@((IZ]0NMD+111
M0,**S;G6["SD\JXNX(I?[DD@!I;;6].NI/*@O()91_!'(#0KRV1+:CNS1HJC
M=ZA:V:!KFYBMQZRR!*M@]:F[UT'=/9CZ*IWEW;V,/F7-Q%;Q=WED\L4P:O92
MW!MTNH7N/^>:R#-79]">9+<OT4S.!52._MI[A[:.XCDGC^_&'^<?A4QO)715
MTG9EZBFKC-03SQ11N\C[$3JY-&K^$+I?$6:*JVMW#=1B2&1)4/1T.15C&>:J
MS6Y/,GL.HJE;7=M=J_D3)+L^3]V^<5</-+5;E73V%HJJES$9_(WKYN-VSOBK
M&.*;5G82ES*Z'4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,SS7S7^T[\*_%?Q%^
M)'P3U;P]IAU'3_#WB:+4=4?[1%']EM_,MSOP[YDXCDXCY]O7Z7HITVZ;N14A
M[2/*?+_[9GP?\8^/K/PCXD^&\*R>-_#M]((LRQ1?Z/+&1*/,D]Q'6H/@??\
MA?\ 8UO?AQHEDMSXA;PY+:_9?-2+S+V6,O)\_3_6R'FOHNEK=5I**CV,/J\.
M:3[GS1X"^%7BO0OV)+KP%>Z:(_%LGAK4=.&GBXB;%Q+]H$2>8'\O_EHG.<?T
MT_V;/@Y>:#^ROI'P\\?Z4+:YEMKZUU&R,R2#RY;FXD \R/@_NY!7T'BC%3*M
M-JR?6XU0@I7\K'Q/X.\,_M _LJH_ACPUX?L_BOX$C=VTZ4WL=I=V:]HB#SC_
M +^5'KWPF^,W[6FO:3;_ !+T6S^'OPYT^<7$FCVU_P";=7T@Z9:/G'/_ $SZ
MU]MG% Q6_P!<E?GLN;N8?4X_#]GL4[6SATZUCMH(HX;>!!''''QL3_(KXG_:
M8_9@^(GBCXO:K)X'ME'A+QW:V5OXGN1<(IMY(KB/,HBDDR?W<4?^K&?]9W-?
M<U%84JLJ4N9'35HQJQLS(T;0[+0-&LM+L(1;V5G;QVT$0Z)'&,(/R%?./QI_
M9S\6Z;\4X?BW\']1M+#Q:8O)U72+_/V758_<]C7U%WZ?K0.O3]:B,YQ=QRA%
MH^2I/C!^T[K=J;"P^#.FZ)J,A\O^U+[5XI;:+_;\L29-=I^S/^SE<?"2XUGQ
M1XIU8>)?B)XBE\[5=4VD1J!_RSB'IG^G]P5]!84=J.*UE76J@K7,8T'[O.[V
M$!W<^E?(?[<OP'\=?$X^&M<^'MG]M\0V<-[I5[&ES';>99W,7ED9DD X_>8_
MZZ&OKW@48!K.E5]C/GB:5:7MH<DCY=_:"_9ZU;6/V9O#7A+P5"EUXH\)RZ;<
M:45DCAWS6Y$;OYDG X,C^YQ5OX0_L\:KH/[)FI> -5<:7XJU^ROO[0N3*)3'
M>W/F?-))'_K,90$U],T5K[>?)R,CZM#GYT?$7P)\9_%GX%?#VR^'$WP0U36-
M6TN62*#5+"ZB2PN-\AD\R23M_K.?I6W^S1\,OBCX4_:/\>^*?'>FVQA\2Z;'
M=&_T^026\=QYD>+89_>?NX\1@GC]U7U^$ I<^G%.6)?O:;D0PJ7+?H?(6E:%
M\?/@#X@U^P\/Z"GQ>\)7][+?V5QJ.M);WUGOY\J22XD^8?A71?L^_!GQM%\8
M_%OQ@^(5OINC^(=<LH].MM#TR0RQVUN/*_UDG>3_ $>/IQ7TYBEI.O)Q:[EQ
MPT8RYB,_?KYU^!_PC\2^"?V@_C+XIU:SCBT3Q/<6TNG2I<))Y@C\S.8^QY'6
MOHVC%90FX*274WG!3E%]CY*\9?!_XE_"#XT:Y\2/A-:6/B:P\2>6-;\*W]R+
M8O*/^6T<K\#_ .V25FZM\*/BU^T]XL\.O\4-&TWP#X$T.^CU'^P+:_2^N-1E
M':22/@ >W_/2OL8@'K0 !TK=8N5KZ<W<Y/JD;V^SV/FKQ]\*_%6O_MF_#3QS
M9Z;YWA;1=*NK2]OS/$/+E>*Y"?NR_F'F2/G%=G^U'X*UCXC_  %\7^'?#EG]
MOUJ_MTBMK?SHXO,(E1_OR< <5['BC K+VCO%]C?V*Y9Q_F.$^"OA^^\+?!SP
M+H>J0"WU33="L;.YBW[]DL=O'&XS]0:\Q_8C^%WB;X1_ ZV\.^+-._LS5([^
MXF-L)XY?W;G(YCXKZ*I,4O:.S7<I4TG%]CY8^%'P+UZV^-GQYO/%.B^3X2\8
MF&WMIC<Q2+>Q;98Y?DC<R1_ZS^.N8\!>$?CW^S)9W7@WPUX3T_XI^#8I9)-)
MNIM6CL;JWC<Y\J3S.N*^SZ*T5>5]=3+ZM&UD?.OP)^&_Q+F^(.O?$#XFZQ]D
MO-0MQ;6/A+2[R22QL8@?^6G_ "SDD]ZI?LY_"KQ7X$^-GQR\0:[I9L-)\2ZM
M;7.ES_:(I3<Q1O<D\1OF/B2/A\=37TO28J75;OIN5&@H\NNQ\T_M-_"OQ7\1
M?B5\%-6\/:8=1T_P]XFBU'5'^T11FUM_,MSOP[Y?B-^(^?ZM_;O\.BZ^",OB
MBRN4L-;\&ZC;:[IMS(./-CD\O9^/F?GLKZ6&!G'-?,/Q<_9O^(7QK\?+;^)/
M'MK_ ,*GCNXK[_A'+2S\NXE,?_+*24#.,]]_X5I1J>]%RT2,JM/W9*.MS9_8
MA^'=QX$^!6F7VIQD^(?$LLFO:E+)]^224_NR?^V0CKZ%)^6HH(8[:-(XT2.-
M/D1$Z"K%<]27M)N9TTZ?)#D/ES0OA%XNL_VY?$/Q!ETG9X2N]!2PAU+[1$?,
MEV6W_++?YF!Y<G.*^H.YI]%.<W4Y;]!0IJGS6ZC1S7S5^VU\*O%?Q;^'OAG2
MO"VF?VI?67B:VU&XC-Q%$([>..X!?,C@9R\?%?2]%*G-TI<T1SIJI'ED-7!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%\*>.KSQ/X5TO7;J#Q)+%%)J%M'+(D?E1\4H0I3C*2OH7.I5A*,9=3ZRT/\
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MJE/V;L%&K[6-S'\1^*-)\':-<ZOK>H6^F:;;#,]U=2;(XQ[DUP!_:H^$6?\
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MP9TKP]J_[:VI:Q\([2WLO .G:*;+7KK1XMFFW-[GB./CR^/W7^K_ .>4E?<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M59OLQ0@1CS8Y?I%'Q7*?%[]GOXY_'N'1-<UZ\\.:-?Z/>QW6G>&;&24QQ_\
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M5^QGJ'PCDOM'_P"$DG241W44\GV,$W(EQO\ *W_CY=<]&JNKZG36HOHCT_\
M9V\/:9'^S3\/].-LD=G>^&;(21$_?\VV$D@_$R/7D7_!-#3+>R_9T>\2-/M%
M]K5S)/(!_K#^[3/Z5]$?"OPQ>>!_A;X/\.7[PRW^CZ/9:=<20#$;R11)&Y0=
M<94X_"N!_9*^"^N? ;X/Q>%->FT^ZU&*\N+KSM,EDDB/F'/62.,_I1[3W)1O
MN5[/WHRML?-^A:A=^'_'O[9UQI,OV6YM].DN8@G6.7RKD^;2_LHW/QR\-_ [
M0$\">"_!U[X?NEEN8[Z^O9([BXD,G63]YU_Y9_\ ;.O>OA=^S_JWA'XP_%[Q
M)K3:;?:!XU,(M[2%W>01CS/,$@*#KYF.,UQ7AS]G#XR_ RXU'2_A)XO\.7/@
MJXGDN+?2O%L4AELI#U$<D4?(^M=;KP<>4Y/83YN:Q7^"OPQ^*]M^U-?_ ! \
M5:3X?T.VU/2C::G8Z1J1F,C 1B.7RS_UR09K[$[5\]_ G]G/5?!7CG7/B)X]
M\0IXK\?:O&+;[3#%Y5O9VPZ11"OH3&5KBKSYY7.W#04(VL?&?AS_ )2:>*_^
MQ8C_ /1=M7V4.I/M7QW\5?V;_C%<_M&ZM\3?AQXA\-:*+VQCL$.IO*\HC\N(
M2?)]GD3DQ<5:_P"$"_;%_P"B@> O^_+_ /R%6M6,:BC:6R1STI3IN7N[E'X[
M_P#*03X*?]@V;^5S7V0.@^E?*7[1O[.WQ.\??&KPGX^^'FLZ#I%_H6G_ &>.
M367DQYIDDSB,12?\LY3UJF/ ?[8O_10/ 7_?A_\ Y"IU%"<(VEL53YX2E+EW
M,7]L"3_A$_VGO@+XTU M%H2WQL;BZS^ZMI/,Q^\_[^9_[9U]H@?=],5Y+XW^
M"4/QK^!UAX-^($\=SJS6=LUUJ-CQY6HQQC?<1>G[S?@>AKQK2/AO^U1\-=//
MA[1/%WA#Q9HL">59:AKL<HNHXQ_SU(_^V5#Y:T(Q<K6+]ZC.4XQO<]T\:?'K
MPMX!^('A/P=J=U.VM^)9=EC!:VYD&=XC'F'^ <G_ +]R>E>F;LC-?,WP1_98
MU?PU\1;GXE_$SQ)'XQ\?RQF&WE6#%KIT>.D6?YX3Z5J?M$^)OB!X:^(7PI;P
MKK]CIVA:GKUOIVJZ5*D<ES>H\GF2"/?$2$\J*3D21_C6;I1YN2#^9<*D^7VE
M16\CZ([5\N?M'_$+P+X)^*G@UKCP??>//BNL<LFA:9I\LGF1QX?]Z^#L _UO
M_+-S^[)_Y9@CZBQ\IKY@^//P0\>2_&OPU\8/AO\ V9?^(-,LO[-O-&U1S%'<
MPXD^Y)V_UIHH-*5Y!B$Y1M$\._:X\=?&+QQ\"]=?Q/\ #/3/ OA=&MI99+O5
MX[J^\S[2/+\KR^G;/F1_W_:OMSX3&1OA5X.DF'[TZ/9;_KY,=?+_ ,8?@Y\=
M_P!IKP1<Z;XF_P"$<\$V4 %Q;:)87$MR]]<<X%Q+T2/KP*^JOAQH]]HW@+PY
MIVJ&,ZC9:=;6]QY3[T\U(PCX/?D&NC$23HI1W.7#1<:^NQQG[3OP>@^.?P@U
M;PQ-JD>C/))'<P7TO^KBDC.09/;K7SWX@^('QT^&/@V^TKXK?"S1_B/X,M[<
MPWFHZ+<C,MO&,F22,CGC_IE'T]J^D_V@/@EIWQZ^&U[X5O[F2PDDECN;.^B3
M?);7,9S'+^%>*7_PH_:9U[PQ)X.U3QWX,31)X397&LP6MP^IR6Y&PGF,1>8<
MT8>:45%LK$TY.7,D<)^U[XE\-^._V)_">J^"K1+#PW>:K;Q65KL\H0_\?$6S
M';$O%?:_BZYCL/"6MW$G$4=C/(_X1FO%?&/[)6@Z[^S/9_"2PU%K.&P2*2SU
M*:,2'[5YAD,LB9Y\QWDR/]LUR>G_  =_:!\6Z%#X0\>>./#EOX/*?9+ZZT"*
M0ZIJ%OC:4WRQ^7'Y@X..>:F3A)))[%0C4@Y-J]SR;P</^-56MG_KY_\ 3E7U
MW^SWH%EX:^!7@6RTY8X[ Z)9R_NN%>22,222?\#=R?QKRW0OV5]?TO\ 8\U#
MX1OJVG3:U.LH2^"R?9N;GS1D=:QO#7P._:%^&?AJU\)>#?'WAF;PY%;0Q0W.
MM6TK7NFG)$D<.(R)(^OE^9SZUK4G&HFE*WO7,J=.4'=Q^S8XCX#_  _M/&&N
M?M5_#;[0-/\ #-QJVRW:+ CLY))+D$CZ>7%_W[K1\-S_ +0_P!\&VN@7/@O0
M_BMX(L;86\4ND7'EW,EMR!D'_6#R_2-\U[#X&_9'\,>%?@IK_P /[^]GUF;Q
M())-8UB8C[3=7!/^LS_L$#'TKA/#OPB_:;\"^';7PEH'COP7=:!9QFWL]5U2
MVN/[3CM^!$#&(_*S&,?E3]M%WU)]A/L=%\-O'?@KXB?LA^+[_P !Z(GAO1XM
M*U&WN-)CB$7V>Y-MYD@P/^N@YKY<\67D\/\ P3=^$=EY@BT_4?$TEM>_]<OM
M5]+_ .TZ^Q?AM^S@GPG_ &?O$'@/3=2_M+5M9MKV6YU*Y^1+B]N(O++X&=B<
M)P,]*Q/ 7[*2']D_3OA!XXEM;B2);GS+_3'\P)))<RRQRQ>8G7]YW'K13K4X
M2OTYKESI5)JR_EL>[2^%],E\.'06LX/[%-O]B^PE/W?V?9L\O'ICCZ5\>?LC
M6L6G_L6_$NTMY/.MXY];2.7^^/LXKJ-,^#?[1<>B1^"+KXE^'4\*)%]B&NV]
MO*-7^S#C.TQ^6)/+[^974_!/]F[6?A)^SUXK^'-QJ%A>WVJG4?LUU'O\M/M$
M?EQ^9\G;OQ6,9*,7%RO=EN#F[QC8\=^&6M?#K0/^">?A*X^*%K)J7AK[1>1I
MIUK))%)<S_;KGRXX_+>,YX/>NX;XN?&SQOX>>R\,_ VU\-Z%+"8/MGBC5HXX
MX[<QX_X]AY<@':LW5_V-?$>I_LD^$OAM)J^FVOC'PY?OJ5M=Q[Y+&23[1<2!
M,>7DCRY<?ZO.1TKH)]._:1^)VAGPOK>G^%_ MG=1_9[_ ,0V5VUU<R1$8D^S
MQ#B.3K][@5T<T')RONSE]G/EC'EV.#_8V\S_ (8-\<;_ +OE:SL^GV?_ /77
MJ'_!//2+2P_99\*7$$"127LEY<3NI_UDGVF6,-_WQ''^55_@#^SYXJ^&G[.G
MBKX>ZQ<:=_:-XVH16,\<YD39<1;(S)^['\><\?X5Z)^R_P#"[5_@K\$/#O@S
M6Y+.XU'3?M'F3V,KR1.9+F27@O'&?^6F.G:LJ]2+<N5[LWH4I>[S+8\4\"+_
M ,*%_;9\9>&97,/ASQ_9?V]9EW&R.YC\R27Z?\O)/MY=:'[&T+_$_P"('Q2^
M-%XF8M=U$:1HWF=4LK<_U_=_]^ZRO^"D>@)<^!?".K:=.UMXLBU4Z;IR0G][
M<1W,4D<D2#U.4/X5](?!;X>6OPK^%OAOPC;&,_V591P2/'_RTEQF1_QD+FG.
M=J/,]Y?H*G"]:45LCNB./PKXX_8_TV'5OVCOVC-<U$K/KUOKPL4ED&9([+S;
MCR@/8B)!_P!LZ^R2.#7S'\2/V;/%]A\6+CXF_"+Q)I_A[Q%J,7E:KIVM1R2V
M%[Z2$1\YKFHRM&44[7.NO!2<9-7L<K_P4HL(+'X/^&?$5L?L>O:5XCMSI]Y'
M_K8V,<AX/MY:2?\ ;(4[XV%S^V_\!3(NV3[)=[_^_<O'YUK67[,_Q&^*?C_0
M_$/QL\3Z1J6G:!<?:=-T#PS&_P!D>;M)-YL>37;_ !$^ NJ^+OVB?AW\0[74
M+2#3O#<,L5S;3!_-E,@D&8\<?\M.]=$*BBE%N^YRSHRE+FC&Q[H> *^1_P!M
M;GXM?LW_ /8YQ?\ I1;5]=XX%> _M#? W7?BQXU^$^LZ3=V$-KX2UZ/5;V*_
M>2.2:(21R$1>6A_>?NN^!S7-0:C4NSLQ"YJ7*C@M$_XLK^W7J]DY^SZ#\2M)
M^VQ?O/W?VZV_UG7OCS#_ -M:X32R_P 1/A#^TM\7[@>;'XFMK[3M)X_YAMM$
M8HS_ -M/_9*]L_:Y^ .N_'CPUH'_  B=_::1XIT*]-Q;7M[*\<:QO&1+&=D<
MAY_=]NU;,OP)ET[]EJ]^%VBR6L5\V@R:7'</\L3W#QGS)>.F9"YKK52$8*=]
M3BE2G*?L[:'P[X@.L:K\*OV3]!T^SL[Y+BYO98+#4)?*M;VYCO8O*CD_S_RT
MKZ;\4W/[2WC/POJVAZEX!\"MIVHV<MK<?\3&3_5O&0?^6GN:N-^QPWB']FCP
MEX"U[5(K#Q7X;+W.GZ[ILDCQVUSYDDFX<1DIR!@XZ?G4U'X1_M.>,?#\OA;7
M/'G@S3]%N(_(N=9TRWN#J;Q^P\N.,'Z5I*M"2232L8QH36DE<XO7/ /BKX:?
M\$ZO$_AWQ7):R7]@A-O]ENOM,9MOMD<D?[SOU>OI+]F'2;/1?V>?AK;VUO':
MK+X>LKED3H))(DDD_-Y"?QKD?%7[-"6O[+.I?"/P9);V[RVT<,5WJ1\L/)YL
M<DDLOEIU..P_E7JGPJ\,WG@;X6^#_#E^\,U_H^CV6G7$EN,1M)%$D;E!UQD'
M'X5R5:JY>6_4[:5!N7,T?-'[!44>L>(_C-X@O\3>);KQ1+;W+S?ZR.,<B/\
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M2 $O''\_[OGKUJS+\&];;]JX_$X7%C_PCY\-_P!C^1YDGVKS/-\WIY>SR_\
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MN5T".Y^WZ'=>3<G]W;?N\_K7Z$D<&OG+2O@?XBT_]LK6OB@[6G_"-WNC"QC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 44@JAJ6I6^D6DMY>3QVMG!'YDEQ/((XT'N32CJ!H45\C>#/VSXOB
MU^U'IG@7PG';W7@\6US]HU21#OO)8TD/[K_IGD#FOK;N?>MJM.5%I2ZF%*M&
MMS<O0?11161N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 (*X?XK_"?P]\9O"R^'?$UO+=:4;B.X>WCD,?F%#Q
MGVKN:*4?= ^+=5\+Z5X._P""AOPTT;1=/ATW2[3P7*EO:VL?EQ1#S+W@5]GC
MJ?:OD?QO_P I*? /_8ER?^C+VOK?NU=->3FHN3V1Q8:,8N?*B2BD'2EKG.T*
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pyxs-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-15T07:21:24.1061+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://pyxisoncology.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:pyxs="http://pyxisoncology.com/20250331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995475 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities" id="DisclosureMarketableDebtSecurities">
        <link:definition>995485 - Disclosure - Marketable Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1" id="DisclosureSegmentDisclosure1">
        <link:definition>995495 - Disclosure - Segment Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements" id="Role_DisclosureLicensingAgreements">
        <link:definition>995505 - Disclosure - Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995515 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants" id="DisclosureCommonStockWarrants">
        <link:definition>995525 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995535 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>995545 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1" id="DisclosureNetLossPerCommonShare1">
        <link:definition>995565 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995575 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>995585 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995605 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables" id="DisclosureMarketableDebtSecuritiesTables">
        <link:definition>995615 - Disclosure - Marketable Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables" id="DisclosureSegmentDisclosureTables">
        <link:definition>995625 - Disclosure - Segment Disclosure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995635 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995645 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>995655 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>995665 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>995695 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails" id="DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails">
        <link:definition>995715 - Disclosure - Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails" id="DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails">
        <link:definition>995725 - Disclosure - Marketable Debt Securities - Interest and Investment Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" id="DisclosureSegmentDisclosureAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Segment Disclosure - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails" id="DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails">
        <link:definition>995745 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails" id="DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails">
        <link:definition>995755 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" id="DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
        <link:definition>995785 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" id="DisclosureCommonStockWarrantsAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Common Stock Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995815 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" id="DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
        <link:definition>995825 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
        <link:definition>995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails">
        <link:definition>995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails">
        <link:definition>995855 - Disclosure - Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>995875 - Disclosure - Operating Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995895 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet" id="DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet">
        <link:definition>995905 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="pyxs-20250331.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails" xlink:href="pyxs-20250331.xsd#DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails" xlink:href="pyxs-20250331.xsd#DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails" xlink:href="pyxs-20250331.xsd#DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:href="pyxs-20250331.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="pyxs-20250331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pyxs-20250331.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails" xlink:href="pyxs-20250331.xsd#DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pyxs-20250331.xsd#DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet" xlink:href="pyxs-20250331.xsd#DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pyxs-20250331.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="pyxs-20250331.xsd#DisclosureDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pyxs-20250331.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="pyxs-20250331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities" xlink:href="pyxs-20250331.xsd#DisclosureMarketableDebtSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1" xlink:href="pyxs-20250331.xsd#DisclosureSegmentDisclosure1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:href="pyxs-20250331.xsd#Role_DisclosureLicensingAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity" xlink:href="pyxs-20250331.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants" xlink:href="pyxs-20250331.xsd#DisclosureCommonStockWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="pyxs-20250331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases" xlink:href="pyxs-20250331.xsd#DisclosureOperatingLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pyxs-20250331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:href="pyxs-20250331.xsd#DisclosureNetLossPerCommonShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="pyxs-20250331.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="pyxs-20250331.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pyxs-20250331.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="pyxs-20250331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables" xlink:href="pyxs-20250331.xsd#DisclosureMarketableDebtSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables" xlink:href="pyxs-20250331.xsd#DisclosureSegmentDisclosureTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="pyxs-20250331.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="pyxs-20250331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables" xlink:href="pyxs-20250331.xsd#DisclosureOperatingLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="pyxs-20250331.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails" xlink:href="pyxs-20250331.xsd#DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="pyxs-20250331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="pyxs-20250331.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantTextBlock" xlink:label="pyxs_CommonStockWarrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesReceivable" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AverageSalePricePerShare" xlink:label="pyxs_AverageSalePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrantsValue" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenEquityIncentivePlanMember" xlink:label="pyxs_ApexigenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionOfMarketableDebtSecurities" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOfWarrants" xlink:label="pyxs_ReplacementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionNoticePeriod" xlink:label="pyxs_RedemptionNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockBasedCompensationMember" xlink:label="pyxs_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromStockIssuedUnderAtmNet" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantsMember" xlink:label="pyxs_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpenseRecognized" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AtTheMarketOfferingProgramMember" xlink:label="pyxs_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RestrictedCashFairValueDisclosure" xlink:label="pyxs_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductCandidatesMember" xlink:label="pyxs_ClinicalProductCandidatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ToraySublicenseAgreementMember" xlink:label="pyxs_ToraySublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SimcereLicenseAgreementMember" xlink:label="pyxs_SimcereLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesReservedForFutureIssuanceMember" xlink:label="pyxs_SharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementWarrantsMember" xlink:label="pyxs_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EsbatechAgreementMember" xlink:label="pyxs_EsbatechAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PyxisOncologyMember" xlink:label="pyxs_PyxisOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOptionsMember" xlink:label="pyxs_ReplacementOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenReplacementWarrantsMember" xlink:label="pyxs_ApexigenReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OtherMember" xlink:label="pyxs_OtherMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfRoyaltyRightsMember" xlink:label="pyxs_SaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesAbstract" xlink:label="pyxs_CostsAndOperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantThreeMember" xlink:label="pyxs_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantOneMember" xlink:label="pyxs_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrants" xlink:label="pyxs_ExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpense" xlink:label="pyxs_IncrementalStockBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProfessionalAndConsultantFeesMember" xlink:label="pyxs_ProfessionalAndConsultantFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantTwoMember" xlink:label="pyxs_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantRedemptionConditionMinimumSharePrice" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_InvestmentInJointVenturePolicyTextBlock" xlink:label="pyxs_InvestmentInJointVenturePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" xlink:label="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DepreciationAndAmortizationMember" xlink:label="pyxs_DepreciationAndAmortizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RightOfUseAssetsNonCurrent" xlink:label="pyxs_RightOfUseAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock" xlink:label="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SalesAgentsCommissionPercentage" xlink:label="pyxs_SalesAgentsCommissionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantLiabilityPolicyTextBlock" xlink:label="pyxs_WarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MabwellAgreementMember" xlink:label="pyxs_MabwellAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductManufacturingMember" xlink:label="pyxs_ClinicalProductManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IntangibleAssetsNetPolicyTextBlock" xlink:label="pyxs_IntangibleAssetsNetPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementRestrictedStockUnitsMember" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares issued upon conversion of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Shares Issued Upon Conversion of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common shares issued upon conversion of preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions paid to the placement agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development, Contract to Perform for Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesTotal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs and operating expenses, total.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesTotal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Operating Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesTotal_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized (loss) gain on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net unrealized loss on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating and Reporting Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone and royalties receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone And Royalties Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone and royalties receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock, net of tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease agreement, square feet space area in building</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provisional purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisional purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone and royalties payments received post acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone And Royalties Payments Received Post Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone and royalties payments received post acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Level 3 Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AverageSalePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Average sale price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AverageSalePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average Sale Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AverageSalePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average sale price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares, warrants, and replacement stock options and restricted stock units issued for acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Warrants, And Replacement Stock Options And Restricted Stock Units Isued For Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, warrants, and replacement stock options and restricted stock units ("RSUs") issued for acquisition of Apexigen, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but unsettled in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested but Unsettled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested but unsettled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan ("ESPP")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consecutive trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Consecutive Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant rr right redemption of warrants or rights threshold consecutive trading days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act, deferred tax asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act, Deferred Tax Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options two thousand twenty two, two thousand twenty one and two thousand nineteen plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Two Thousand Twenty Two, Two Thousand Twenty One and Two Thousand Nineteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options 2022 Plan, 2021 Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise of pre-funded warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of pre-funded warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Vested and Unsettled Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-vested And Unsettled Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested and unsettled restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Apexigen Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Apexigen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Apexigen Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at March 31,2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related expenses excluding stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Related Expenses Excluding Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel related expenses excluding stock based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability statement of financial position extensible enumeration not disclosed flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prefunded warrants issued price per warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrants Issued Price Per Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Effects on Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount payable related to licensed products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Apexigen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Apexigen, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Apexigen, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Apexigen, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment for which derivative liability recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment for Which Derivative Liability Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment for which derivative liability recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued to university.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued To University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockIssuedToUniversity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued to university</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redemption of marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption Of Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption of marketable debt securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Nonrecurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Replacement of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Replacement Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Replacement of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issuable upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares reserved and autorized for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PfizerLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redemption notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RedemptionNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-Funded Warrant Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in private placement, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Private Placement, Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in private placement, net of offering costs (See Note 7) (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in private placement, net of offering costs (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in the fair value of derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested and unsettled restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in exercise price of relevant option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UniversityLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of option to purchase restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Issued Under ATM, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from stock issued under atm, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to ATM program, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock shares issued value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Expense related to the Life Science Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Replacement Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction expenses incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Replacement RSU Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Replacement in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, replacement in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated cost to purchase licensed products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Cost To Purchase Licensed Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated cost to purchase licensed products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Consolidated net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock-based compensation expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Stock-Based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental stock-based compensation expense recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan ("ESPP") (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicensingAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of Business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RestrictedCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards relating to prior tax years before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Relating to Prior Tax Years Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards relating to prior tax years before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductCandidatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Product Candidates [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductCandidatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical product candidates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductCandidatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical product candidates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ToraySublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Toray Sublicense Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ToraySublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Toray Sublicense Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ToraySublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Toray sublicense agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired in acquisition of Apexigen, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TemporaryEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities Classified as Available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liability offset to research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Offset to Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability offset to research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SimcereLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simcere License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SimcereLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simcere License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SimcereLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simcere license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved for Future Issuance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesReservedForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock, net of tax withholdings (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of restricted common stock, net of tax withholdings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting of Restricted Common Stock, Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Replacement Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Replacement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Replacement warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EsbatechAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Esbatech Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EsbatechAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESBATech Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_EsbatechAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Esbatech agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Awards and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense weighted average amortized period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Federal Income Tax Expense (Benefit), Continuing Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Replacement RSU Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Replacement in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, replacement in period, weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PyxisOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pyxis Oncology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PyxisOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pyxis Oncology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PyxisOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pyxis oncology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential development and commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development and Commercial Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development and commercial milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock under ESPP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum value of stock and debt instruments authorized to issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Value of Stock and Debt Instruments Authorized to Issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum value of stock and debt instruments authorized to issue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LegoChem license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lego Chem License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LegoChemLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LegoChem License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Replacement Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Replacement Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Replacement Options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Apexigen Replacement Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Apexigen Replacement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Apexigen Replacement Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax withholding payments related to net settlement of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquisition date fair value of replacement awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of consideration transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and investment income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and investment income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification and Accretion of Convertible Preferred Stock [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, short-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in private placement value, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Private Placement Value, Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in private placement, net of offering costs (See Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Apexigen Two Thousand and Twenty Two Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Apexigen Two Thousand and Twenty Two Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Royalty Rights [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Royalty Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Royalty Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate%</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective income tax rate%</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs and Operating Expenses [Abstract].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_CostsAndOperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Costs and operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted common stock, net of tax withholdings (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted common units issued, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202108Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2021-08</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202108Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2021-08 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options available for issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Available For Issuance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Available for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current income tax expenses (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares are included in the computation of basic and diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units ('RSU')</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded warrants issued during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Issued During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested and settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested and Settled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested and settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable debt securities, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RelatedPartyTransactionOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Investment Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Nonoperating Income, by Component [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncrementalStockBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental stock-based compensation expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on reserves for unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant-date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProfessionalAndConsultantFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional and Consultant Fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProfessionalAndConsultantFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Professional and consultant fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProfessionalAndConsultantFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consultant fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days common stock issued from effective date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Common Stock Issued From Effective Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days common stock issued from effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and Uncertainties [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties on reserves for unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock remaining capacity available under program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Remaining Capacity Available Under Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining capacity available under program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discount, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards and Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent payments to receive over sublease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax withholding payments related to net settlement of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common stock, net of tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Finance lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Finance lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares pursuant to at-the-market program, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Shares Pursuant To At-The-Market Program, Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14) (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuanceExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Redemption Condition Minimum Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant redemption condition minimum share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period for licensed products upon first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period For Licensed Products Upon First Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period for licensed products upon first commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (Expense) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InvestmentInJointVenturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Joint Venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InvestmentInJointVenturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment in Joint Venture [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_InvestmentInJointVenturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment in Joint Venture [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Revenues and Sale of Royalty Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty revenues and sale of royalty rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Revenues and Sale of Royalty Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty revenue and sale of royalty rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two equity inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TwoThousandTwentyTwoEquityInducementPlan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Equity Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period for licensed products upon after first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period For Licensed Products Upon After First Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period for licensed products upon after first commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Replacement Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Replacement Options in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangements by share-based payment award, options, replacement options in period, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit carryovers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DepreciationAndAmortizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DepreciationAndAmortizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation And Amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_DepreciationAndAmortizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for normal approval.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum obligation to pay future contingent milestone payments for normal approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to be repurchased under a stock repurchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Number of Shares Authorized to be Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MaximumPercentageofOwnershipInterest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Ownership Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of ownership interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted common stock, net of tax withholdings, (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted common units, net of tax withholdings, (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments for first four licensed products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting commission and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable debt securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issuable under exercise of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Common Shares Issuable Under Exercise of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of common shares issuable under exercise of options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biosion License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biosion license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_BiosionLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biosion License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options 2022 Plan, 2022 EIP, 2020 EIP, 2021 Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Two Thousand Twenty Two Plan Two Thousand Twenty Two EIP Two Thousand Twenty EIP Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options two thousand twenty two plan two thousand twenty two eip two thousand twenty eip two thousand twenty one plan and two thousand nineteen plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RightOfUseAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RightOfUseAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use Assets Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_RightOfUseAssetsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets non-current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OptionUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option upfront payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value vesting of restricted common stock, net of tax withholdings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting of Restricted Common Stock, Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock, net of tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants in private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre-funded Warrants In Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the ATM program, net of commission (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under ATM offering program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued pursuant to at-the-market ("ATM") program, net of commission</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued pursuant to at-the-market ("ATM") program, net of commission.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of Intangible Assets [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards relating to prior tax years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Relating to Prior Tax Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards relating to prior tax years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock pursuant to at-the-market program value, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock pursuant to at-the-market program Value, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value $0.001 per share; 190,000,000 shares authorized; 61,631,376 and 59,967,814 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options Vested and Settled in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Outstanding, Vested and settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone and royalties required</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone and royalties incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone and Royalties Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SalesAgentsCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales agents commission rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SalesAgentsCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agents Commission Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SalesAgentsCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agents commission percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities Classified as Available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of pre-funded warrants in private placement, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Pre-Funded Warrants In Private Placement, Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of pre-funded warrants in private placement, net of offering costs (See Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants in private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants redemption exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right redemption price of warrants or rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extra milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ExtraMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extra milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual royalty fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual royalty fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MinimumAnnualRoyaltyFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stocks.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stocks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Replacement Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Replacement In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options replacement in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U S Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative liability related to extra milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MabwellAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mabwell Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MabwellAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mabwell Agreement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_MabwellAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mabwell agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Product Manufacturing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical product manufacturing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClinicalProductManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical product manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IntangibleAssetsNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IntangibleAssetsNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_IntangibleAssetsNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible Assets Net [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Replacement RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Replacement Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Replacement Restricted Stock Units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options 2022 Inducement Plan, 2022 Plan, 2020 Plan, 2021 Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options Two Thousand Twent Two Inducement Plan Two Thousand Twenty Two Plan Two Thousand Twenty Plan Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options Two Thousand Twent Two Inducement Plan Two Thousand Twenty Two Plan Two Thousand Twenty Plan Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Redemption of Warrants or Rights Threshold Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right redemption of warrants or rights threshold trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in deferred tax assets valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CommonStockWarrantTextBlock" xlink:to="pyxs_CommonStockWarrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="pyxs_CostsAndOperatingExpensesTotal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestoneAndRoyaltiesReceivable" xlink:to="pyxs_MilestoneAndRoyaltiesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" xlink:to="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AverageSalePricePerShare" xlink:to="pyxs_AverageSalePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" xlink:to="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfFinanceLease" xlink:to="pyxs_NumberOfFinanceLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExerciseOfPre-FundedWarrantsValue" xlink:to="pyxs_ExerciseOfPre-FundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:to="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ApexigenEquityIncentivePlanMember" xlink:to="pyxs_ApexigenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" xlink:to="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LiquidityPolicyTextBlock" xlink:to="pyxs_LiquidityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TaxCreditCarryforwardExpirationYear" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:to="pyxs_PrefundedWarrantsIssuedPricePerWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ApexigenIncMember" xlink:to="pyxs_ApexigenIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CommonStockIssuedToUniversity" xlink:to="pyxs_CommonStockIssuedToUniversity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RedemptionOfMarketableDebtSecurities" xlink:to="pyxs_RedemptionOfMarketableDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ReplacementOfWarrants" xlink:to="pyxs_ReplacementOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PfizerLicenseAgreementMember" xlink:to="pyxs_PfizerLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RedemptionNoticePeriod" xlink:to="pyxs_RedemptionNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PreFundedWarrantsMember" xlink:to="pyxs_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockBasedCompensationMember" xlink:to="pyxs_StockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UniversityLicenseAgreementMember" xlink:to="pyxs_UniversityLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromStockIssuedUnderAtmNet" xlink:to="pyxs_ProceedsFromStockIssuedUnderAtmNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CommonStockWarrantsMember" xlink:to="pyxs_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IncrementalStockBasedCompensationExpenseRecognized" xlink:to="pyxs_IncrementalStockBasedCompensationExpenseRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AtTheMarketOfferingProgramMember" xlink:to="pyxs_AtTheMarketOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicensingAgreementsTextBlock" xlink:to="pyxs_LicensingAgreementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NatureOfBusinessPolicyTextBlock" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RestrictedCashFairValueDisclosure" xlink:to="pyxs_RestrictedCashFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClinicalProductCandidatesMember" xlink:to="pyxs_ClinicalProductCandidatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ToraySublicenseAgreementMember" xlink:to="pyxs_ToraySublicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceOfCommonStock" xlink:to="pyxs_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TemporaryEquityIssuanceCosts" xlink:to="pyxs_TemporaryEquityIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SimcereLicenseAgreementMember" xlink:to="pyxs_SimcereLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SharesReservedForFutureIssuanceMember" xlink:to="pyxs_SharesReservedForFutureIssuanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:to="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ReplacementWarrantsMember" xlink:to="pyxs_ReplacementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_EsbatechAgreementMember" xlink:to="pyxs_EsbatechAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PyxisOncologyMember" xlink:to="pyxs_PyxisOncologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" xlink:to="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LegoChemLicenseAgreementMember" xlink:to="pyxs_LegoChemLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_InitialPublicOfferingPolicyTextBlock" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ReplacementOptionsMember" xlink:to="pyxs_ReplacementOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ApexigenReplacementWarrantsMember" xlink:to="pyxs_ApexigenReplacementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OtherMember" xlink:to="pyxs_OtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsExpirationYear" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" xlink:to="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SaleOfRoyaltyRightsMember" xlink:to="pyxs_SaleOfRoyaltyRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="pyxs_CostsAndOperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202108Member" xlink:to="us-gaap_AccountingStandardsUpdate202108Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsAvailableForIssuanceMember" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_WarrantThreeMember" xlink:to="pyxs_WarrantThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:to="pyxs_PreFundedWarrantsIssuedDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontPayments" xlink:to="pyxs_UpfrontPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicenseAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_WarrantOneMember" xlink:to="pyxs_WarrantOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UpfrontFee" xlink:to="pyxs_UpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RelatedPartyTransactionOwnership" xlink:to="pyxs_RelatedPartyTransactionOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExerciseOfPre-FundedWarrants" xlink:to="pyxs_ExerciseOfPre-FundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IncrementalStockBasedCompensationExpense" xlink:to="pyxs_IncrementalStockBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProfessionalAndConsultantFeesMember" xlink:to="pyxs_ProfessionalAndConsultantFeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" xlink:to="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnvestedRestrictedStockAwardsMember" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_WarrantTwoMember" xlink:to="pyxs_WarrantTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IncreaseDecreaseInFinanceLeaseLiability" xlink:to="pyxs_IncreaseDecreaseInFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" xlink:to="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockIssuanceExpenses" xlink:to="pyxs_StockIssuanceExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_WarrantRedemptionConditionMinimumSharePrice" xlink:to="pyxs_WarrantRedemptionConditionMinimumSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_UnderwritingDiscountsAndCommissions" xlink:to="pyxs_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseMember" xlink:to="us-gaap_NonoperatingIncomeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_InvestmentInJointVenturePolicyTextBlock" xlink:to="pyxs_InvestmentInJointVenturePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" xlink:to="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" xlink:to="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DepreciationAndAmortizationMember" xlink:to="pyxs_DepreciationAndAmortizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumPercentageOfOwnershipInterest" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMilestonePayments" xlink:to="pyxs_AggregateMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_FairValueOfCommonStockPerShare" xlink:to="pyxs_FairValueOfCommonStockPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_BiosionLicenseAgreementMember" xlink:to="pyxs_BiosionLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_RightOfUseAssetsNonCurrent" xlink:to="pyxs_RightOfUseAssetsNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OptionUpfrontPayment" xlink:to="pyxs_OptionUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:to="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsBeforeTax" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" xlink:to="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock" xlink:to="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" xlink:to="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MilestoneAndRoyaltiesIncurred" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SalesAgentsCommissionPercentage" xlink:to="pyxs_SalesAgentsCommissionPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_PaymentForLicenseFee" xlink:to="pyxs_PaymentForLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" xlink:to="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ExtraMilestonePayment" xlink:to="pyxs_ExtraMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_WarrantLiabilityPolicyTextBlock" xlink:to="pyxs_WarrantLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MinimumAnnualRoyaltyFees" xlink:to="pyxs_MinimumAnnualRoyaltyFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_SeriesBConvertiblePreferredStocksMember" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_MabwellAgreementMember" xlink:to="pyxs_MabwellAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClinicalProductManufacturingMember" xlink:to="pyxs_ClinicalProductManufacturingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_IntangibleAssetsNetPolicyTextBlock" xlink:to="pyxs_IntangibleAssetsNetPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ReplacementRestrictedStockUnitsMember" xlink:to="pyxs_ReplacementRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:to="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RightOfUseAssetsNonCurrent" xlink:label="pyxs_RightOfUseAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="pyxs_RightOfUseAssetsNonCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesAbstract" xlink:label="pyxs_CostsAndOperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfRoyaltyRightsMember" xlink:label="pyxs_SaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_CostsAndOperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pyxs_SaleOfRoyaltyRightsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="pyxs_CostsAndOperatingExpensesTotal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrantsValue" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrants" xlink:label="pyxs_ExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_ExerciseOfPre-FundedWarrantsValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_ExerciseOfPre-FundedWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionOfMarketableDebtSecurities" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromStockIssuedUnderAtmNet" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pyxs_RedemptionOfMarketableDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromStockIssuedUnderAtmNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pyxs_IncreaseDecreaseInFinanceLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LicensingAgreementsTextBlock" xlink:label="pyxs_LicensingAgreementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="pyxs_LicensingAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantTextBlock" xlink:label="pyxs_CommonStockWarrantTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pyxs_CommonStockWarrantTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NatureOfBusinessPolicyTextBlock" xlink:label="pyxs_NatureOfBusinessPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_InitialPublicOfferingPolicyTextBlock" xlink:label="pyxs_InitialPublicOfferingPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LiquidityPolicyTextBlock" xlink:label="pyxs_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RisksAndUncertaintiesPolicyTextBlock" xlink:label="pyxs_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IntangibleAssetsNetPolicyTextBlock" xlink:label="pyxs_IntangibleAssetsNetPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock" xlink:label="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_InvestmentInJointVenturePolicyTextBlock" xlink:label="pyxs_InvestmentInJointVenturePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantLiabilityPolicyTextBlock" xlink:label="pyxs_WarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" xlink:label="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_NatureOfBusinessPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_InitialPublicOfferingPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_LiquidityPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RisksAndUncertaintiesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_IntangibleAssetsNetPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_InvestmentInJointVenturePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_WarrantLiabilityPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202108Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RestrictedCashFairValueDisclosure" xlink:label="pyxs_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="pyxs_RestrictedCashFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TransactionTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesAbstract" xlink:label="pyxs_CostsAndOperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductCandidatesMember" xlink:label="pyxs_ClinicalProductCandidatesMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductManufacturingMember" xlink:label="pyxs_ClinicalProductManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockBasedCompensationMember" xlink:label="pyxs_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DepreciationAndAmortizationMember" xlink:label="pyxs_DepreciationAndAmortizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProfessionalAndConsultantFeesMember" xlink:label="pyxs_ProfessionalAndConsultantFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OtherMember" xlink:label="pyxs_OtherMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ClinicalProductCandidatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="pyxs_CostsAndOperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ClinicalProductManufacturingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_StockBasedCompensationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="pyxs_CostsAndOperatingExpensesTotal" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_DepreciationAndAmortizationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ProfessionalAndConsultantFeesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_OtherMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LicenseAgreementsAbstract" xlink:label="pyxs_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EsbatechAgreementMember" xlink:label="pyxs_EsbatechAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SimcereLicenseAgreementMember" xlink:label="pyxs_SimcereLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MabwellAgreementMember" xlink:label="pyxs_MabwellAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ToraySublicenseAgreementMember" xlink:label="pyxs_ToraySublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesReceivable" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_EsbatechAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_CommonStockIssuedToUniversity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontFee" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_SimcereLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_MabwellAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_ToraySublicenseAgreementMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesReceivable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_OtherLiabilities" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OptionUpfrontPayment" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AtTheMarketOfferingProgramMember" xlink:label="pyxs_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SalesAgentsCommissionPercentage" xlink:label="pyxs_SalesAgentsCommissionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AverageSalePricePerShare" xlink:label="pyxs_AverageSalePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_AtTheMarketOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_PrefundedWarrantsIssuedPricePerWarrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_StockIssuanceExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_PreFundedWarrantsIssuedDuringPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SalesAgentsCommissionPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_AverageSalePricePerShare" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfCommonStock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenReplacementWarrantsMember" xlink:label="pyxs_ApexigenReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesReservedForFutureIssuanceMember" xlink:label="pyxs_SharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantsMember" xlink:label="pyxs_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_ApexigenReplacementWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_SharesReservedForFutureIssuanceMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_CommonStockWarrantsMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantOneMember" xlink:label="pyxs_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOfWarrants" xlink:label="pyxs_ReplacementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantTwoMember" xlink:label="pyxs_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PyxisOncologyMember" xlink:label="pyxs_PyxisOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantThreeMember" xlink:label="pyxs_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementWarrantsMember" xlink:label="pyxs_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantRedemptionConditionMinimumSharePrice" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionNoticePeriod" xlink:label="pyxs_RedemptionNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ReplacementOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_PyxisOncologyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementWarrantsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_PreFundedWarrantsIssuedDuringPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_PrefundedWarrantsIssuedPricePerWarrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_WarrantRedemptionConditionMinimumSharePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_RedemptionNoticePeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpense" xlink:label="pyxs_IncrementalStockBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpenseRecognized" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOptionsMember" xlink:label="pyxs_ReplacementOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementRestrictedStockUnitsMember" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenEquityIncentivePlanMember" xlink:label="pyxs_ApexigenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_IncrementalStockBasedCompensationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_IncrementalStockBasedCompensationExpenseRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementOptionsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_FairValueOfCommonStockPerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementRestrictedStockUnitsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_ApexigenEquityIncentivePlanMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" xlink:label="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenReplacementWarrantsMember" xlink:label="pyxs_ApexigenReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesReservedForFutureIssuanceMember" xlink:label="pyxs_SharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantsMember" xlink:label="pyxs_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_ApexigenReplacementWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_SharesReservedForFutureIssuanceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_CommonStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionOwnership" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_UpfrontPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesAbstract" xlink:label="pyxs_CostsAndOperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfRoyaltyRightsMember" xlink:label="pyxs_SaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_CostsAndOperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pyxs_SaleOfRoyaltyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="pyxs_CostsAndOperatingExpensesTotal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrantsValue" xlink:label="pyxs_ExerciseOfPre-FundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExerciseOfPre-FundedWarrants" xlink:label="pyxs_ExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" xlink:label="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" xlink:label="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_ExerciseOfPre-FundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_ExerciseOfPre-FundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TemporaryEquityIssuanceCosts" xlink:label="pyxs_TemporaryEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pyxs_TemporaryEquityIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" xlink:label="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionOfMarketableDebtSecurities" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromStockIssuedUnderAtmNet" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pyxs_RedemptionOfMarketableDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromStockIssuedUnderAtmNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pyxs_IncreaseDecreaseInFinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfFinanceLease" xlink:label="pyxs_NumberOfFinanceLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202108Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pyxs_NumberOfFinanceLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RestrictedCashFairValueDisclosure" xlink:label="pyxs_RestrictedCashFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="pyxs_RestrictedCashFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" xlink:label="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesAbstract" xlink:label="pyxs_CostsAndOperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductCandidatesMember" xlink:label="pyxs_ClinicalProductCandidatesMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClinicalProductManufacturingMember" xlink:label="pyxs_ClinicalProductManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" xlink:label="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockBasedCompensationMember" xlink:label="pyxs_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DepreciationAndAmortizationMember" xlink:label="pyxs_DepreciationAndAmortizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProfessionalAndConsultantFeesMember" xlink:label="pyxs_ProfessionalAndConsultantFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OtherMember" xlink:label="pyxs_OtherMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_CostsAndOperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ClinicalProductCandidatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="pyxs_CostsAndOperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ClinicalProductManufacturingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_StockBasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="pyxs_CostsAndOperatingExpensesTotal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_DepreciationAndAmortizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_ProfessionalAndConsultantFeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pyxs_OtherMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SeriesBConvertiblePreferredStocksMember" xlink:label="pyxs_SeriesBConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EsbatechAgreementMember" xlink:label="pyxs_EsbatechAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockIssuedToUniversity" xlink:label="pyxs_CommonStockIssuedToUniversity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PfizerLicenseAgreementMember" xlink:label="pyxs_PfizerLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontFee" xlink:label="pyxs_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="us-gaap_NonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_LegoChemLicenseAgreementMember" xlink:label="pyxs_LegoChemLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_BiosionLicenseAgreementMember" xlink:label="pyxs_BiosionLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" xlink:label="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SimcereLicenseAgreementMember" xlink:label="pyxs_SimcereLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_EstimatedCostToPurchaseLicensedProducts" xlink:label="pyxs_EstimatedCostToPurchaseLicensedProducts"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MabwellAgreementMember" xlink:label="pyxs_MabwellAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ToraySublicenseAgreementMember" xlink:label="pyxs_ToraySublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" xlink:label="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PaymentForLicenseFee" xlink:label="pyxs_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumPercentageOfOwnershipInterest" xlink:label="pyxs_MaximumPercentageOfOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" xlink:label="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PotentialDevelopmentAndCommercialMilestonePayment" xlink:label="pyxs_PotentialDevelopmentAndCommercialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MinimumAnnualRoyaltyFees" xlink:label="pyxs_MinimumAnnualRoyaltyFees"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" xlink:label="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesIncurred" xlink:label="pyxs_MilestoneAndRoyaltiesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MilestoneAndRoyaltiesReceivable" xlink:label="pyxs_MilestoneAndRoyaltiesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IssuanceOfConvertiblePreferredStockShares" xlink:label="pyxs_IssuanceOfConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ConvertiblePreferredStockSharesIssuedValue" xlink:label="pyxs_ConvertiblePreferredStockSharesIssuedValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AggregateMilestonePayments" xlink:label="pyxs_AggregateMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" xlink:label="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OptionUpfrontPayment" xlink:label="pyxs_OptionUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePayment" xlink:label="pyxs_ExtraMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" xlink:label="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" xlink:label="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pyxs_SeriesBConvertiblePreferredStocksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_EsbatechAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_CommonStockIssuedToUniversity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_PfizerLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_NonoperatingIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_LegoChemLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_BiosionLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_SimcereLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_EstimatedCostToPurchaseLicensedProducts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_MabwellAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pyxs_ToraySublicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PaymentForLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MaximumPercentageOfOwnershipInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MinimumAnnualRoyaltyFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_MilestoneAndRoyaltiesReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_IssuanceOfConvertiblePreferredStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ConvertiblePreferredStockSharesIssuedValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_AggregateMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_OtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_OptionUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AtTheMarketOfferingProgramMember" xlink:label="pyxs_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" xlink:label="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="pyxs_GrossProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnderwritingDiscountsAndCommissions" xlink:label="pyxs_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockIssuanceExpenses" xlink:label="pyxs_StockIssuanceExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" xlink:label="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SalesAgentsCommissionPercentage" xlink:label="pyxs_SalesAgentsCommissionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" xlink:label="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_AverageSalePricePerShare" xlink:label="pyxs_AverageSalePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pyxs_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_AtTheMarketOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_PrefundedWarrantsIssuedPricePerWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_StockIssuanceExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_PreFundedWarrantsIssuedDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SalesAgentsCommissionPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_AverageSalePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="pyxs_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForCommissions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:label="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenReplacementWarrantsMember" xlink:label="pyxs_ApexigenReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesReservedForFutureIssuanceMember" xlink:label="pyxs_SharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantsMember" xlink:label="pyxs_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_ApexigenReplacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_SharesReservedForFutureIssuanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantOneMember" xlink:label="pyxs_WarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementWarrantsMember" xlink:label="pyxs_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOfWarrants" xlink:label="pyxs_ReplacementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantTwoMember" xlink:label="pyxs_WarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PyxisOncologyMember" xlink:label="pyxs_PyxisOncologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantThreeMember" xlink:label="pyxs_WarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsIssuedDuringPeriod" xlink:label="pyxs_PreFundedWarrantsIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PrefundedWarrantsIssuedPricePerWarrant" xlink:label="pyxs_PrefundedWarrantsIssuedPricePerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_WarrantRedemptionConditionMinimumSharePrice" xlink:label="pyxs_WarrantRedemptionConditionMinimumSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionNoticePeriod" xlink:label="pyxs_RedemptionNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ReplacementOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_PyxisOncologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pyxs_WarrantThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_PreFundedWarrantsIssuedDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_PrefundedWarrantsIssuedPricePerWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_WarrantRedemptionConditionMinimumSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_RedemptionNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwothousandtwentytwoequityinducementplanMember" xlink:label="pyxs_TwothousandtwentytwoequityinducementplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenIncMember" xlink:label="pyxs_ApexigenIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="pyxs_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementOptionsMember" xlink:label="pyxs_ReplacementOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" xlink:label="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ReplacementRestrictedStockUnitsMember" xlink:label="pyxs_ReplacementRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpense" xlink:label="pyxs_IncrementalStockBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncrementalStockBasedCompensationExpenseRecognized" xlink:label="pyxs_IncrementalStockBasedCompensationExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_FairValueOfCommonStockPerShare" xlink:label="pyxs_FairValueOfCommonStockPerShare"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" xlink:label="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenEquityIncentivePlanMember" xlink:label="pyxs_ApexigenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" xlink:label="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwothousandtwentytwoequityinducementplanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pyxs_ApexigenIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pyxs_ReplacementRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_IncrementalStockBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_IncrementalStockBasedCompensationExpenseRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_FairValueOfCommonStockPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pyxs_ApexigenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" xlink:label="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" xlink:label="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_OperatingLossCarryforwardsExpirationYear" xlink:label="pyxs_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCreditCarryforwardExpirationYear" xlink:label="pyxs_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_TaxCutsAndJobsActDeferredTaxAsset" xlink:label="pyxs_TaxCutsAndJobsActDeferredTaxAsset"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pyxs_TaxCutsAndJobsActDeferredTaxAsset" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ApexigenReplacementWarrantsMember" xlink:label="pyxs_ApexigenReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UnvestedRestrictedStockAwardsMember" xlink:label="pyxs_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" xlink:label="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_SharesReservedForFutureIssuanceMember" xlink:label="pyxs_SharesReservedForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CommonStockWarrantsMember" xlink:label="pyxs_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_StockOptionsAvailableForIssuanceMember" xlink:label="pyxs_StockOptionsAvailableForIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_ApexigenReplacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_SharesReservedForFutureIssuanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pyxs_StockOptionsAvailableForIssuanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_PreFundedWarrantsMember" xlink:label="pyxs_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pyxs_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UniversityLicenseAgreementMember" xlink:label="pyxs_UniversityLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RelatedPartyTransactionOwnership" xlink:label="pyxs_RelatedPartyTransactionOwnership"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_UpfrontPayments" xlink:label="pyxs_UpfrontPayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pyxs_UniversityLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_RelatedPartyTransactionOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pyxs_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="pyxs_RightOfUseAssetsNonCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RightOfUseAssetsNonCurrent" xlink:label="pyxs_RightOfUseAssetsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_CostOfRevenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="pyxs_CostsAndOperatingExpensesTotal" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_SubleaseIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pyxs_ProceedsFromStockIssuedUnderAtmNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pyxs_RedemptionOfMarketableDebtSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pyxs_IncreaseDecreaseInFinanceLeaseLiability" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="13" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromStockIssuedUnderAtmNet" xlink:label="pyxs_ProceedsFromStockIssuedUnderAtmNet"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_RedemptionOfMarketableDebtSecurities" xlink:label="pyxs_RedemptionOfMarketableDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" xlink:label="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_IncreaseDecreaseInFinanceLeaseLiability" xlink:label="pyxs_IncreaseDecreaseInFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_CostOfRevenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="pyxs_CostsAndOperatingExpensesTotal" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="pyxs_CostsAndOperatingExpensesTotal" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="pyxs-20250331.xsd#pyxs_CostsAndOperatingExpensesTotal" xlink:label="pyxs_CostsAndOperatingExpensesTotal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_PyxisOncologyMember" name="PyxisOncologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" name="IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" name="StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ReplacementOptionsMember" name="ReplacementOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ClinicalProductManufacturingMember" name="ClinicalProductManufacturingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_CommonStockIssuedToUniversity" name="CommonStockIssuedToUniversity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_WarrantTwoMember" name="WarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_NumberOfFinanceLease" name="NumberOfFinanceLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ReplacementWarrantsMember" name="ReplacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_OptionUpfrontPayment" name="OptionUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_BiosionLicenseAgreementMember" name="BiosionLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_MabwellAgreementMember" name="MabwellAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" name="AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" name="MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate" name="NumberOfDaysCommonStockIssuedFromEffectiveDate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RedemptionOfMarketableDebtSecurities" name="RedemptionOfMarketableDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_StockIssuanceExpenses" name="StockIssuanceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_CostsAndOperatingExpensesAbstract" name="CostsAndOperatingExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_WarrantThreeMember" name="WarrantThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AverageSalePricePerShare" name="AverageSalePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_PrefundedWarrantsIssuedPricePerWarrant" name="PrefundedWarrantsIssuedPricePerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MaximumPercentageOfOwnershipInterest" name="MaximumPercentageOfOwnershipInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_WarrantRedemptionConditionMinimumSharePrice" name="WarrantRedemptionConditionMinimumSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" name="SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_IncrementalStockBasedCompensationExpense" name="IncrementalStockBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" name="MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_EsbatechAgreementMember" name="EsbatechAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" name="MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" name="RoyaltyRevenuesAndSaleOfRoyaltyRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ExtraMilestonePayment" name="ExtraMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_StockBasedCompensationMember" name="StockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" name="DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ApexigenEquityIncentivePlanMember" name="ApexigenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ToraySublicenseAgreementMember" name="ToraySublicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AggregateMilestonePayments" name="AggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_IssuanceOfConvertiblePreferredStockShares" name="IssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_PaymentForLicenseFee" name="PaymentForLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsBeforeTax" name="OperatingLossCarryforwardsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_PreFundedWarrantsIssuedDuringPeriod" name="PreFundedWarrantsIssuedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ReplacementRestrictedStockUnitsMember" name="ReplacementRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember" name="NonVestedAndUnsettledRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IncreaseDecreaseInFinanceLeaseLiability" name="IncreaseDecreaseInFinanceLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ExerciseOfPre-FundedWarrants" name="ExerciseOfPre-FundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MilestoneAndRoyaltiesIncurred" name="MilestoneAndRoyaltiesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_FairValueOfCommonStockPerShare" name="FairValueOfCommonStockPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_NatureOfBusinessPolicyTextBlock" name="NatureOfBusinessPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" name="ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" type="enum2:enumerationSetItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" enum2:domain="us-gaap:LiabilitiesAbstract" enum2:headUsable="false" enum2:linkrole="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <xsd:element id="pyxs_SharesReservedForFutureIssuanceMember" name="SharesReservedForFutureIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_CommonStockWarrantTextBlock" name="CommonStockWarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" name="ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_AtTheMarketOfferingProgramMember" name="AtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" name="RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ProfessionalAndConsultantFeesMember" name="ProfessionalAndConsultantFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" name="StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_MinimumAnnualRoyaltyFees" name="MinimumAnnualRoyaltyFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_PfizerLicenseAgreementMember" name="PfizerLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ProceedsFromStockIssuedUnderAtmNet" name="ProceedsFromStockIssuedUnderAtmNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" name="IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" name="StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" name="StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IncrementalStockBasedCompensationExpenseRecognized" name="IncrementalStockBasedCompensationExpenseRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable" name="ScheduleOfCommonStockReservedForFutureIssuanceTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_DepreciationAndAmortizationMember" name="DepreciationAndAmortizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" name="RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ExerciseOfPre-FundedWarrantsValue" name="ExerciseOfPre-FundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_SimcereLicenseAgreementMember" name="SimcereLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ConvertiblePreferredStockSharesIssuedValue" name="ConvertiblePreferredStockSharesIssuedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram" name="SaleOfStockRemainingCapacityAvailableUnderProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears" name="OperatingLossCarryforwardsRelatingToPriorTaxYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LicensingAgreementsTextBlock" name="LicensingAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ApexigenIncMember" name="ApexigenIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_EstimatedCostToPurchaseLicensedProducts" name="EstimatedCostToPurchaseLicensedProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock" name="ImpairmentOfIntangibleAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TaxCutsAndJobsActDeferredTaxAsset" name="TaxCutsAndJobsActDeferredTaxAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_RedemptionNoticePeriod" name="RedemptionNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_InvestmentInJointVenturePolicyTextBlock" name="InvestmentInJointVenturePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_IntangibleAssetsNetPolicyTextBlock" name="IntangibleAssetsNetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock" name="NumberOfCommonSharesIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_CostsAndOperatingExpensesTotal" name="CostsAndOperatingExpensesTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" name="SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SaleOfRoyaltyRightsMember" name="SaleOfRoyaltyRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" name="IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ReplacementOfWarrants" name="ReplacementOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ClinicalProductCandidatesMember" name="ClinicalProductCandidatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" name="IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_RightOfUseAssetsNonCurrent" name="RightOfUseAssetsNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp" name="ProceedsFromIssuanceOfCommonStockUnderEspp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" name="OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_SeriesBConvertiblePreferredStocksMember" name="SeriesBConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" name="StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_SalesAgentsCommissionPercentage" name="SalesAgentsCommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_MilestoneAndRoyaltiesReceivable" name="MilestoneAndRoyaltiesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_TwothousandtwentytwoequityinducementplanMember" name="TwothousandtwentytwoequityinducementplanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_RestrictedCashFairValueDisclosure" name="RestrictedCashFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" name="ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_RelatedPartyTransactionOwnership" name="RelatedPartyTransactionOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_LegoChemLicenseAgreementMember" name="LegoChemLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_StockOptionsAvailableForIssuanceMember" name="StockOptionsAvailableForIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" name="IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_GrossProceedsFromIssuanceInitialPublicOffering" name="GrossProceedsFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember" name="PersonnelRelatedExpensesExcludingStockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_UniversityLicenseAgreementMember" name="UniversityLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_WarrantOneMember" name="WarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_ApexigenReplacementWarrantsMember" name="ApexigenReplacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" name="ScheduleOfCommonStockReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pyxs_PotentialDevelopmentAndCommercialMilestonePayment" name="PotentialDevelopmentAndCommercialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pyxs_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pyxis Oncology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1160910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Harrison Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">453-3596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PYXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,947,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,759<span></span>
</td>
<td class="nump">$ 19,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable debt securities, short-term</a></td>
<td class="nump">92,673<span></span>
</td>
<td class="nump">107,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">111,871<span></span>
</td>
<td class="nump">132,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,403<span></span>
</td>
<td class="nump">9,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">12,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">135,867<span></span>
</td>
<td class="nump">157,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,076<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,430<span></span>
</td>
<td class="nump">17,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">18,254<span></span>
</td>
<td class="nump">18,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, net of current portion</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">32,764<span></span>
</td>
<td class="nump">36,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 190,000,000 shares authorized; 61,631,376 and 59,967,814 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">487,706<span></span>
</td>
<td class="nump">484,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(384,714)<span></span>
</td>
<td class="num">(363,556)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">103,103<span></span>
</td>
<td class="nump">120,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 135,867<span></span>
</td>
<td class="nump">$ 157,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">61,631,376<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">61,631,376<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,044<span></span>
</td>
<td class="nump">13,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesTotal', window );">Total costs and operating expenses</a></td>
<td class="nump">22,914<span></span>
</td>
<td class="nump">21,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,914)<span></span>
</td>
<td class="num">(5,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest and investment income</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,158)<span></span>
</td>
<td class="num">$ (3,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">61,048,948<span></span>
</td>
<td class="nump">51,289,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">61,048,948<span></span>
</td>
<td class="nump">51,289,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable debt securities</a></td>
<td class="num">$ (121)<span></span>
</td>
<td class="num">$ (123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (21,279)<span></span>
</td>
<td class="num">(3,379)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pyxs_SaleOfRoyaltyRightsMember', window );">Sale of Royalty Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CostsAndOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs and Operating Expenses [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CostsAndOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CostsAndOperatingExpensesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs and operating expenses, total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CostsAndOperatingExpensesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pyxs_SaleOfRoyaltyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pyxs_SaleOfRoyaltyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 125,704<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 411,821<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="num">$ (286,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,754,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts', window );">Issuance of common stock in private placement, net of offering costs</a></td>
<td class="nump">39,172<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">39,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts', window );">Issuance of common stock in private placement, net of offering costs (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,849,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts', window );">Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)</a></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">10,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts', window );">Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14) (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts', window );">Issuance of pre-funded warrants in private placement, net of offering costs</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Issuance of restricted common stock, net of tax withholdings</a></td>
<td class="num">(196)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of restricted common stock, net of tax withholdings, (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable debt securities</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,256)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">184,156<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">473,638<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(289,481)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,803,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">120,751<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">484,077<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(363,556)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ExerciseOfPre-FundedWarrantsValue', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ExerciseOfPre-FundedWarrants', window );">Exercise of pre-funded warrants (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Issuance of restricted common stock, net of tax withholdings</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of restricted common stock, net of tax withholdings, (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan ("ESPP") (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss on marketable debt securities</a></td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,158)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 103,103<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 487,706<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (384,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,631,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExerciseOfPre-FundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExerciseOfPre-FundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ExerciseOfPre-FundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ExerciseOfPre-FundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in private placement, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in private placement value, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to at-the-market program value, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares pursuant to at-the-market program, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of pre-funded warrants in private placement, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (21,158)<span></span>
</td>
<td class="num">$ (3,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,631<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on marketable debt securities</a></td>
<td class="num">(1,157)<span></span>
</td>
<td class="num">(1,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(930)<span></span>
</td>
<td class="num">(2,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,315)<span></span>
</td>
<td class="num">(2,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,535)<span></span>
</td>
<td class="num">(20,710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RedemptionOfMarketableDebtSecurities', window );">Redemption of marketable debt securities</a></td>
<td class="nump">67,173<span></span>
</td>
<td class="nump">74,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable debt securities</a></td>
<td class="num">(51,352)<span></span>
</td>
<td class="num">(92,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">15,821<span></span>
</td>
<td class="num">(18,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement', window );">Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">46,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ProceedsFromStockIssuedUnderAtmNet', window );">Proceeds from issuance of common stock pursuant to ATM program, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments related to net settlement of restricted common stock</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(6,714)<span></span>
</td>
<td class="nump">18,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">20,945<span></span>
</td>
<td class="nump">11,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">14,231<span></span>
</td>
<td class="nump">29,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,759<span></span>
</td>
<td class="nump">27,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 14,231<span></span>
</td>
<td class="nump">$ 29,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants in private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ProceedsFromStockIssuedUnderAtmNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from stock issued under atm, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ProceedsFromStockIssuedUnderAtmNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RedemptionOfMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RedemptionOfMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (21,158)<span></span>
</td>
<td class="num">$ (3,256)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with a specific focus on head and neck squamous cell carcinoma (HNSCC) tumors.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s fiscal year ends on December 31 and its first three fiscal quarters end on March 31, June 30 and September 30. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the three months ended March 31, 2025 are not necessarily indicative of those expected for the year ending December 31, 2025 or for any future period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 18, 2025 (Fiscal 2024 10-K).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">384.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The C</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ompany has incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not generated any revenues from product sales to date and does not anticipate generating any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently expects that its existing cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2025 will fund its operating expenses and capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, marketable debt securities, fair value of intangible assets and research and development costs, including clinical trial accruals. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to early clinical stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third party service providers such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collabo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ration or supply agreements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Con</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">centration of Credit Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents, restricted cash and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash primarily in money market funds and highly liquid United States (U.S.) Treasury securities. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no significant changes to the Company&#8217;s significant accounting policies disclosed in &#8220;Note 2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies&#8221; of the Company&#8217;s Fiscal 2024 10-K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures. The amendment requires (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendment requires disaggregated disclosure of (i) certain costs and expenses, (ii) certain already required disclosures must be included in the same disclosure as the new disaggregation requirements and (iii) a qualitative description of the amounts not separately disaggregated. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.586%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.723%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">116,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">116,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents represent deposits in a short-term money market fund quoted in an active market and are classified as Level 1 assets. Marketable debt securities include investments in United States Treasury securities and are classified as Level 1 assets as they are valued using quoted prices in active markets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Debt Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Marketable Debt Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable debt securities, all of which were classified as available-for-sale, consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:28.446%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.562000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92,624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">107,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the remaining contractual terms of the U.S. Treasury securities were less than 12 months.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not recognized any allowances for credit losses or impairments in relation to its marketable securities as these securities are comprised of high credit quality, investment grade securities that the Company does not intend or expect to be required to sell prior to their anticipated recovery, and the decline in fair value of these securities is attributable to factors other than credit losses.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and investment income consists of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.991%;box-sizing:content-box;"></td>
         <td style="width:2.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.823999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.823999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total interest and investment income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Disclosure</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Segment disclosure</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to the development of clinical and preclinical product candidates focused on addressing unmet medical needs in patients with solid tumors with a specific focus on HNSCC tumors. The Company&#8217;s chief operating decision maker (CODM) is the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_40e1fafa-fcae-43cf-bb09-058d3cf2faa5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the single segment are the same as those described in the Company&#8217;s significant accounting policies disclosed in &#8220;Note 2 &#8211; Basis of Presentation and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies&#8221; of the Company&#8217;s Fiscal 2024 10-K. The CODM assesses performance for the segment based on net loss, which is reported on the condensed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_18387c80-8f46-4fb9-a403-2e1db91eb8aa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the product candidate through all stages of development and clinical trials and, ultimately, seek regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As such, the CODM uses cash forecast models in deciding how allocate resources. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#8217;s compensation, along with cash forecast models.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes segment net loss, including significant expenses for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.3%;box-sizing:content-box;"></td>
         <td style="width:1.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Royalty revenue and sale of royalty rights</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product candidates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product manufacturing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (i)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,044</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,643</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (ii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment income (iii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,756</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,349</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,158</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,256</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of profit or loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments and reconciling items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,158</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development segment items include facilities expenses, lab services, professional services and technology costs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment income for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest and investment income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of sublease income, respectively.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LicensingAgreementsTextBlock', window );">Licensing Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Licensing Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The University of Chicago Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, the Company entered into a license agreement (the &#8220;University License Agreement&#8221;), as well as a sponsored research agreement, with the University of Chicago (the &#8220;University&#8221;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,919</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in 2020.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the University License Agreement, the Company is obligated to pay potential development and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the University License Agreement as of  March 31, 2025 and 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer Inc. Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, the Company entered into a license agreement (as amended, the &#8220;Pfizer License Agreement&#8221;) with Pfizer Inc. (&#8220;Pfizer&#8221;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. The Company&#8217;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. The initial licensed targets include CD123 and Extradomain-B Fibronectin (&#8220;EDB+FN&#8221;) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the license fee, consisting of an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,152,145</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series B convertible preferred stock, which was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock upon the initial public offering (&#8220;IPO&#8221;) in October 2021, with a value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Pfizer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2022, the Company entered into an amended and restated license agreement (the &#8220;A&amp;R License Agreement&#8221;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#8217;s Flexible Antibody Conjugation Technology Flexible Antibody Conjugation Technology (&#8220;FACT&#8221;) Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. In accordance with the terms of the A&amp;R License Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,229,654</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to Pfizer in October 2022, paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Pfizer in January 2023 and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,811,594</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to Pfizer in March 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, pursuant to the A&amp;R License Agreement, the Company is obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the A&amp;R License Agreement as of March 31, 2025 and 2024, and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span></p><h2 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Biosion USA, Inc.</span></h2><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 28, 2022, the Company entered into a license agreement (the &#8220;Biosion License Agreement&#8221;) with Biosion USA, Inc. (&#8220;Biosion&#8221;), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacturing and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in March 2022. Further, the Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products and sublicensing revenues at varying rates. In December 2024, the Company paused the clinical development of PYX-106. The Company assessed the milestone and royalty events involving the Biosion License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were required.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired Out-Licensing Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the Company completed the acquisition of Apexigen, Inc. ("Apexigen") and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assumed all out-licensing agreements of Apexigen upon the Merger.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Simcere License and Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2008, Epitomics, Inc. (&#8220;Epitomics&#8221;) (Apexigen&#8217;s predecessor) and Jiangsu Simcere Pharmaceutical R&amp;D Co., Ltd. (&#8220;Simcere&#8221;) entered into a license and collaboration agreement (the &#8220;Simcere Agreement&#8221;) for the development and commercialization of suvemcitug (BD0801) for oncology in China.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simcere is obligated to pay the Company milestone payments for achievement of certain clinical development milestones and low to high single-digit percentage royalties on net sales of suvemcitug in China until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of suvemcitug. The Company assessed the milestone and royalty events involving Simcere as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">T-Mab/Mabwell Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2008, Epitomics and Jiangsu T-Mab Biotechnology Ltd., Co. (&#8220;T-Mab&#8221;) entered into a license, co-development and contract manufacture agreement (the &#8220;T-Mab Agreement&#8221;) for the development and commercialization of therapeutic candidates, each directed to a specified target for specified fields, including VEGF for the treatment of ocular diseases, in China. Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) acquired T-Mab in 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, Mabwell was granted an exclusive, royalty-bearing, perpetual license (without the right to sublicense) to rights in certain intellectual property to develop and commercialize such therapeutic candidates. Mabwell is obligated to pay the Company a mid-single-digit percentage royalty on net sales of such therapeutic candidates in China. The Company assessed the milestone and royalty events involving Mabwell as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Toray Sublicense Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2012, Epitomics and Toray Industries, Inc. (&#8220;Toray&#8221;), entered into a non-exclusive sublicense agreement (the &#8220;Toray Agreement&#8221;) under which Epitomics granted Toray a non-exclusive, worldwide sublicense, with the right to grant further sublicenses, to develop and commercialize drug product candidates that Toray developed using antibodies created using Apexigen&#8217;s antibody-discovery platform (the &#8220;APXiMAB Platform&#8221;) that target certain molecules to use in the development of its drug product candidates. Under the Toray Agreement, Toray paid an upfront fee, and agreed to pay certain development- and regulatory-related milestone payments and a low single-digit percentage royalty on net sales of licensed products and sublicense revenues by Toray or its affiliates.  The Company assessed the milestone and royalty events involving Toray as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such amounts were receivable.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LicensingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LicensingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shelf Registration Statement and ATM Offering Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2022, the Company filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On November 14, 2022, the registration statement was declared effective by the SEC. The registration statement includes an ATM offering program for the sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t sell any shares of common stock under the ATM offering program. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025, the Company h</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ad $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of remaining capacity available under the ATM facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued and outstanding shares of preferred stock as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Each holder of outstanding shares of common stock shall be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote in respect of each share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reserved Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:23.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:24.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,463,601</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,382,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,295,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-Funded Warrant Shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573,316</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,689,919</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19,657,740</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CommonStockWarrantTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Apexigen Replacement Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the Merger, each outstanding warrant issued by Apexigen was assumed and converted into a warrant to acquire the Company&#8217;s common stock, on substantially similar terms and conditions as were applicable under such Apexigen warrant agreements. The Company replaced approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,815,613</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Apexigen warrants with approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pyxis Oncology warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344,259</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,212</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">641,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each of the warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share will expire on the fifth anniversary of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 29, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier upon redemption or liquidation. Each of the warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 30, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or earlier upon redemption or liquidation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company received gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million via private placement with certain institutional and accredited investors by issuing (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,849,371</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and (ii) pre-funded warrants (&#8216;Pre-Funded Warrant&#8217;) to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217; common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.779</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the pre-funded warrant holder exercised their right to convert the Pre-Funded Warrants to common stock and accordingly, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to the warrant holder.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CommonStockWarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CommonStockWarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company grants stock-based incentive awards pursuant to the 2021 Equity and Incentive Plan (the &#8216;2021 Plan&#8217;), 2019 Equity Incentive Plan (the &#8216;2019 Plan&#8217;), Apexigen Equity Incentive Plans (the &#8216;Apexigen Plan&#8217;) and the 2022 Equity Inducement Plan (the &#8216;2022 Inducement Plan&#8217;). As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,072,703</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,435</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764,154</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413,537</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the 2021 Plan, 2019 Plan, Apexigen Plan and 2022 Inducement Plan, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.200000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,104,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587,279</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercisable March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,379,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#8217;s common stock o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r share as of March 31, 2025. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock options were exercised during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an aggregate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of gross unrecognized stock-based compensation expense as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.94</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively, and was calculated using the following key input assumptions in the Black-Scholes option-pricing model:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.569%;box-sizing:content-box;"></td>
         <td style="width:22.076%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:22.076%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.920</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.910</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.960</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.450</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.06</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock units activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,533,650</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,804</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and settled</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,892</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361,263</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs which are vested but not settled at  March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,728</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock from the settlement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,892</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restricted common units, with the remaining shares withheld for taxes. The Company has an aggregate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.04</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of gross unrecognized restricted stock-based compensation expense as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, remaining to be amortized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the total stock-based compensation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.368%;box-sizing:content-box;"></td>
         <td style="width:1.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.276999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.276999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan (&#8220;2021 ESPP&#8221;)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the 2021 ESPP in force. The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,619</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the 2021 ESPP during the three months ended March 31, 2025. The company did not issue any shares during the three months ended March 31, 2024. As of March 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,777</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are available for issuance under the 2021 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Operating L</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases its office and facilities in Boston, Massachusetts under a non-cancellable operating lease agreement that continues through December 31, 2032. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively, which is included in operating cash flows within the accompanying unaudited condensed consolidated statements of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The component of operating lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">727</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company subleases approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,729</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The Company remains jointly and severally liable under the head lease and accounts for the sublease as an operating lease. The lease term commenced on March 24, 2023 and is expected to end in March 2026. The Company recognized sublease income of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s effective tax rate from continuing operations was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded a federal income tax provision for the three months ended March 31, 2025 and 2024. The Company recorded a nominal state and local income tax provision for the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company assesses the realizability of the deferred tax assets at each reporting date. The Company continues to maintain a full valuation allowance for its U.S. federal and state deferred tax assets, which significantly consists of net operating losses and tax credits. If</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial changes in the entity&#8217;s ownership occur, there may be an annual limitation on the amount of the carryforwards that can be utilized. The Company will continue to assess the need for a valuation allowance on its deferred tax assets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss per Common Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:23.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:24.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024*</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,892,951</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,110,597</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,382,829</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,649,038</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">675,485</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,689,919</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,331,262</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Pre-Funded Warrant Shares of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Commit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyxis Oncology, Inc. (the &#8220;Company&#8221;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with a specific focus on head and neck squamous cell carcinoma (HNSCC) tumors.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s fiscal year ends on December 31 and its first three fiscal quarters end on March 31, June 30 and September 30. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the three months ended March 31, 2025 are not necessarily indicative of those expected for the year ending December 31, 2025 or for any future period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 18, 2025 (Fiscal 2024 10-K).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">384.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The C</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ompany has incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2025 and 2024, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not generated any revenues from product sales to date and does not anticipate generating any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently expects that its existing cash, cash equivalents and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2025 will fund its operating expenses and capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, marketable debt securities, fair value of intangible assets and research and development costs, including clinical trial accruals. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual results could differ from those estimates and there may be changes to management&#8217;s estimates in future periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to early clinical stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third party service providers such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collabo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ration or supply agreements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risks</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Con</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">centration of Credit Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents, restricted cash and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash primarily in money market funds and highly liquid United States (U.S.) Treasury securities. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures. The amendment requires (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendment requires disaggregated disclosure of (i) certain costs and expenses, (ii) certain already required disclosures must be included in the same disclosure as the new disaggregation requirements and (iii) a qualitative description of the amounts not separately disaggregated. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of Business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instruments Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the financial instruments carried at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.586%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.723%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">116,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">116,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Marketable Securities Classified as Available-for-sale</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable debt securities, all of which were classified as available-for-sale, consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:28.446%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.763%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.562000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.383000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92,624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized <br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized <br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate <br/>Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">107,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">107,458</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock', window );">Interest and Investment Income</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and investment income consists of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.991%;box-sizing:content-box;"></td>
         <td style="width:2.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.823999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.823999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total interest and investment income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Significant Expense related to the Life Science Segment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes segment net loss, including significant expenses for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.3%;box-sizing:content-box;"></td>
         <td style="width:1.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Royalty revenue and sale of royalty rights</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product candidates</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,974</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical product manufacturing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,504</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (i)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,044</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,643</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional and consultant fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (ii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total costs and operating expenses</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment income (iii)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,756</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,349</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,158</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,256</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of profit or loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments and reconciling items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,158</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development segment items include facilities expenses, lab services, professional services and technology costs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment income for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest and investment income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of sublease income, respectively.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Issuance</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock for issuance:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:23.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:24.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,463,601</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,382,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,295,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-Funded Warrant Shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573,316</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,689,919</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19,657,740</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 (in thousands, except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.200000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Remaining Contractual<br/>Term (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,711,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,104,372</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587,279</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercisable March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,379,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value Assumptions</a></td>
<td class="text">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.569%;box-sizing:content-box;"></td>
         <td style="width:22.076%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:22.076%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.920</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.910</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.960</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.450</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.06</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Awards and Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock units activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,533,650</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,804</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and settled</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,892</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding at March 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361,263</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs which are vested but not settled at  March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Total Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the total stock-based compensation expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.368%;box-sizing:content-box;"></td>
         <td style="width:1.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.276999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.276999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The component of operating lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">727</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:23.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:24.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024*</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,228,168</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,892,951</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units outstanding</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421,954</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,110,597</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future issuance</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,382,829</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,649,038</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Apexigen replacement warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,003,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">675,485</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,689,919</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,331,262</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Pre-Funded Warrant Shares of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,611,215</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (384,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (363,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">21,158<span></span>
</td>
<td class="nump">$ 3,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 105,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 92,673<span></span>
</td>
<td class="nump">$ 107,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">92,673<span></span>
</td>
<td class="nump">107,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">100,915<span></span>
</td>
<td class="nump">116,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,242<span></span>
</td>
<td class="nump">9,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">92,673<span></span>
</td>
<td class="nump">107,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">100,915<span></span>
</td>
<td class="nump">116,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,242<span></span>
</td>
<td class="nump">9,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | U S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 92,673<span></span>
</td>
<td class="nump">$ 107,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable debt securities, Amortized Cost</a></td>
<td class="nump">$ 92,624<span></span>
</td>
<td class="nump">$ 107,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable debt securities, Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable debt securities, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities, Aggregate Fair Value</a></td>
<td class="nump">92,673<span></span>
</td>
<td class="nump">107,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable debt securities, Amortized Cost</a></td>
<td class="nump">92,624<span></span>
</td>
<td class="nump">107,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable debt securities, Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable debt securities, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities, Aggregate Fair Value</a></td>
<td class="nump">$ 92,673<span></span>
</td>
<td class="nump">$ 107,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities - Interest and Investment Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of discount, net</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Total interest and investment income</a></td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">Net Income (Loss)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesAbstract', window );"><strong>Costs and operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 17,044<span></span>
</td>
<td class="nump">13,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesTotal', window );">Total costs and operating expenses</a></td>
<td class="nump">22,914<span></span>
</td>
<td class="nump">21,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other segment income</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,158)<span></span>
</td>
<td class="num">(3,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract', window );"><strong>Reconciliation of profit or loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">(21,158)<span></span>
</td>
<td class="num">(3,256)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesAbstract', window );"><strong>Costs and operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">17,044<span></span>
</td>
<td class="nump">13,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CostsAndOperatingExpensesTotal', window );">Total costs and operating expenses</a></td>
<td class="nump">22,914<span></span>
</td>
<td class="nump">21,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other segment income</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,158)<span></span>
</td>
<td class="num">(3,256)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember', window );">Royalty revenue and sale of royalty rights | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductCandidatesMember', window );">Clinical product candidates | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">3,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductManufacturingMember', window );">Clinical product manufacturing | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember', window );">Personnel-related expenses excluding stock-based compensation | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,739<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_StockBasedCompensationMember', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">2,509<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_DepreciationAndAmortizationMember', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_ProfessionalAndConsultantFeesMember', window );">Professional and consultant fees | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pyxs_OtherMember', window );">Other | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CostsAndOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs and Operating Expenses [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CostsAndOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CostsAndOperatingExpensesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs and operating expenses, total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CostsAndOperatingExpensesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_ClinicalProductManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_DepreciationAndAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_DepreciationAndAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_ProfessionalAndConsultantFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_ProfessionalAndConsultantFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pyxs_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pyxs_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest and investment income</a></td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,044,000<span></span>
</td>
<td class="nump">$ 13,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,631,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PaymentForLicenseFee', window );">Payment for license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,594<span></span>
</td>
<td class="nump">2,229,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock', window );">Number of common shares issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember', window );">Pfizer License Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of convertible preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,152,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ConvertiblePreferredStockSharesIssuedValue', window );">Issuance of convertible preferred stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember', window );">Biosion License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember', window );">Biosion License Agreement | Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_UpfrontFee', window );">Upfront fee</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_SimcereLicenseAgreementMember', window );">Simcere License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale', window );">Royalty obligation period for licensed products upon after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesReceivable', window );">Milestone and royalties receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_MabwellAgreementMember', window );">Mabwell Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesReceivable', window );">Milestone and royalties receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=pyxs_ToraySublicenseAgreementMember', window );">Toray Sublicense Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesReceivable', window );">Milestone and royalties receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember', window );">University License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_CommonStockIssuedToUniversity', window );">Common stock issued to university</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MilestoneAndRoyaltiesIncurred', window );">Milestone and royalties required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_CommonStockIssuedToUniversity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued to university.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_CommonStockIssuedToUniversity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ConvertiblePreferredStockSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ConvertiblePreferredStockSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_IssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_IssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MilestoneAndRoyaltiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone and royalties incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MilestoneAndRoyaltiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MilestoneAndRoyaltiesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone and royalties receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MilestoneAndRoyaltiesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PaymentForLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PaymentForLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period for licensed products upon after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_SimcereLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_SimcereLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_MabwellAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_MabwellAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pyxs_ToraySublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pyxs_ToraySublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,631,376<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,631,376<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue', window );">Maximum value of stock and debt instruments authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram', window );">Remaining capacity available under program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_AtTheMarketOfferingProgramMember', window );">ATM Offering Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PrefundedWarrantsIssuedPricePerWarrant', window );">Purchase price per warrant</a></td>
<td class="nump">$ 4.779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission', window );">Common stock issued under ATM offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock public offering price per share</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,849,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PreFundedWarrantsIssuedDuringPeriod', window );">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of stock and debt instruments authorized to issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PreFundedWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-Funded warrants issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PreFundedWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PrefundedWarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants issued price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PrefundedWarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock remaining capacity available under program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to at-the-market ("ATM") program, net of commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">21,689,919<span></span>
</td>
<td class="nump">19,657,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">12,228,168<span></span>
</td>
<td class="nump">9,711,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,421,954<span></span>
</td>
<td class="nump">2,463,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pyxs_SharesReservedForFutureIssuanceMember', window );">Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,382,829<span></span>
</td>
<td class="nump">4,295,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember', window );">Pre-Funded Warrant Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember', window );">Apexigen Replacement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,003,191<span></span>
</td>
<td class="nump">1,003,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">653,777<span></span>
</td>
<td class="nump">573,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pyxs_SharesReservedForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pyxs_SharesReservedForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 23, 2023</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ReplacementOfWarrants', window );">Replacement of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,631,376<span></span>
</td>
<td class="nump">59,967,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pyxs_ApexigenIncMember', window );">Apexigen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ReplacementOfWarrants', window );">Replacement of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,815,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PrefundedWarrantsIssuedPricePerWarrant', window );">Purchase price per warrant</a></td>
<td class="nump">$ 4.779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantOneMember', window );">Warrant One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants outstanding expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantTwoMember', window );">Warrant Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants outstanding expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantThreeMember', window );">Warrant Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants outstanding expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 29,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_PreFundedWarrantsIssuedDuringPeriod', window );">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Pre-Funded Warrants issued to purchase aggregate number of shares of common stock</a></td>
<td class="nump">8,849,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PreFundedWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-Funded warrants issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PreFundedWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_PrefundedWarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants issued price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_PrefundedWarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ReplacementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Replacement of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ReplacementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pyxs_ApexigenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pyxs_ApexigenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pyxs_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pyxs_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pyxs_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pyxs_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_FairValueOfCommonStockPerShare', window );">Fair value of common stock per share</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units ('RSU')</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense weighted average amortized period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Gross unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 5,040,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of restricted common units, net of tax withholdings, (Shares)</a></td>
<td class="nump">22,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common units issued, gross</a></td>
<td class="nump">30,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember', window );">2022 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">413,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">4,072,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">132,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">653,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="nump">29,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pyxs_ApexigenEquityIncentivePlanMember', window );">Apexigen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">764,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_FairValueOfCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_FairValueOfCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwothousandtwentytwoequityinducementplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pyxs_ApexigenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pyxs_ApexigenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning Balance</a></td>
<td class="nump">9,711,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,104,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(587,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending Balance</a></td>
<td class="nump">12,228,168<span></span>
</td>
<td class="nump">9,711,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at March 31, 2025</a></td>
<td class="nump">4,379,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">4.16<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at March 31, 2025</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at March 31,2025</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">93.92%<span></span>
</td>
<td class="nump">99.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">99.91%<span></span>
</td>
<td class="nump">102.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, Beginning Balance | shares</a></td>
<td class="nump">2,533,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(80,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod', window );">Number of Shares, Vested and settled | shares</a></td>
<td class="num">(30,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, Ending Balance | shares</a></td>
<td class="nump">2,421,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Forfeited | $ / shares</a></td>
<td class="nump">3.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Vested and settled | $ / shares</a></td>
<td class="nump">3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">$ 3.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units ('RSU')</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod', window );">Number of Shares, Vested but unsettled</a></td>
<td class="nump">361,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but unsettled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pyxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,631<span></span>
</td>
<td class="nump">$ 4,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,509<span></span>
</td>
<td class="nump">3,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,122<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Sublease agreement, square feet space area in building | ft&#178;</a></td>
<td class="nump">17,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">21,689,919<span></span>
</td>
<td class="nump">13,331,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember', window );">Apexigen Replacement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">1,003,191<span></span>
</td>
<td class="nump">1,003,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">12,228,168<span></span>
</td>
<td class="nump">6,892,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">2,421,954<span></span>
</td>
<td class="nump">3,110,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_SharesReservedForFutureIssuanceMember', window );">Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">5,382,829<span></span>
</td>
<td class="nump">1,649,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders</a></td>
<td class="nump">653,777<span></span>
</td>
<td class="nump">675,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_ApexigenReplacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_SharesReservedForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pyxs_SharesReservedForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares are included in the computation of basic and diluted net loss per common share</a></td>
<td class="nump">1,611,215<span></span>
</td>
<td class="nump">1,611,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pyxs_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #<]KUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #<]KUKSGD],\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( #<]KUHR D"WY@4  , ?   8
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M!@:TZ^Y5O]\;=C:'C)V#-5+S@B!;.DZ(9^:$?+FTW%LN3X^S1=E.=7B^MOW
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M44<UZF@4]5=I6'8"P*@?,4+BB'0@.L0\ZOO8#3*N0<9'0@OLJLQS%5*[I[;
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M3\)JF.&["B@;@-=74IKWB3T.V[>?^7]02P,$%     @ -SVO6OG,QFHF!0
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M]@><;OOG!1XIY[3IWVX(%C=J<H#X?DTI_WX@'T$X/@5S]U]02P,$%     @
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MH'*T ,_IE6/S@0YH?Y]S^1]02P,$%     @ -SVO6@E%[137 P  4@D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULG5;=C^(V$'_GKQCEJE,K4?(!
M[,(N( %[JU;J2JMC]_I0]<$D$V)M8F=M9SG^^XZ=$-@><->^Q/9\_.;#,^-,
MME*]Z S1P-<B%WKJ9<:4-[ZOXPP+IGNR1$&<5*J"&3JJC:]+A2QQ2D7N1T%P
MY1>,"V\V<;1'-9O(RN1<X*,"714%4[L%YG([]4)O3_C,-YFQ!'\V*=D&5VB>
MRT=%)[]%27B!0G,I0&$Z]>;AS6)@Y9W %XY;?;0'&\E:RA=[^#V9>H%U"'.,
MC45@M+SA$O/< I$;KPVFUYJTBL?[/?J]BYUB63.-2YG_R1.33;V1!PFFK,K-
M9[G]#9MXAA8OEKEV7]C6LOV!!W&EC2P:9?*@X*)>V=<F#T<*H^",0M0H1,[O
MVI#S\HX9-ILHN05EI0G-;ERH3IN<X\)>RLHHXG+2,[-[QA5\87F%\(!,5PHI
MXT9/?$/@5L2/&Z!%#12= >K#@Q0FT_!)))B\U_?)J=:S:._9(KH(^,!4#_IA
M%Z(@&E[ Z[>1]AU>__N1WG$=Y](&J^&O^5H;1<7Q]ZF8:\C!:4C;,#>Z9#%.
M/>H(C>H-O=G'#^%5<'O!X4'K\. 2^G^YFHM I]WL]^", 7C*$%*94[]RL0'#
MUCGER6D* \8RN6 BYBP'+BAY5:T6,Z4X)L ,I!;YS2';SJ/NC2MB$AIU$-?
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MMAG]]*"R L1/):6K.5@#[6_4[!]02P,$%     @ -SVO6EX^28,4!   RPD
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M.ZV+04*V?CK4&V^6\;J>&8_+/RX+O+;8!@:<SXWQVTTPL'N_3?X!4$L#!!0
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MDVA^G!"U9/VRY7!Q3.Y9SN%H:[94?J;NZ- X0(E2;F\5#ETG8!W%ZWAP #R
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MQIVOH\"G7AQ>'+7]JUA0,8 ]X@*X2J-%4]FE.B=-<T 8Q?A;+@%E1'\,'!E
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M%%J YV.-&:%\0PJJW]M<_ =02P,$%     @ -SVO6K70_'?4!   (@L  !D
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M8<UZ8>_5Z2..\>2.KU3"^%\X#;99'$#9&ZO:$4P*6BZ'?_8TYN$%H'@+D(Z
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MRQ4-]JBL )TOI#0/']9 ]Z_"Y#]02P,$%     @ -SVO6EA7SZ]Y @  B 4
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M >C^C>@W5K5^+A^4I2GOES4]JZB= 7VO%-VD8>,"C _UYC]02P,$%     @
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MG8V<@4-26-(RUP]B>P.UG]#P)2)7]I=LZUK/(4FIM"AJ,"HH&*_^Z6N=0PN
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M-M"4B<N2QCHZ%J#[PMIPV+"![H]"]@=02P,$%     @ -SVO6N4&)_![!P
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MV'+P+HMHU&P_EH'7T:/[Z"^05?!CD+\!&+X&R$.^P9]E_^;$X@ZNDX$+/?Q
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MTYU:A<B!41#,T'A^U'C^AWZ\^B1:U^8LBK--F\I6:%^5D3!__NHO^-46(7)
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ML,Q!'";[O\%+?2$. DSGC0"K#K". \9O!-AU@'UN@%,'..=F:5P'C,\-<.L
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M0Q8V#;)&64"44!Q3W?%>>U[W NVS9#J.ITD:[@_UA <MXEX;^J=V0EDF84O
M:/2!&$S7P5V NO9=L]%(/>BG)3UZ8%P"[6^UQM? ->+PC&9_ %!+ P04
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MHY&H=<$XW$BBZK*D\G$*A5B-'=]9+]RR+-=FP8U&%<U@#OJNNI$X<SN4A)7
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M7[\:Y@T86![(]&=KC>\V7B%/UP&VIT]5"#93O!*QF>)K#8A_W8"1)/[=QO(
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=FY;L) %(7A5T%^ (:[F"R"5&G21KR
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MLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_H*>?4$L! A0#%     @
M-SVO6D;'34B5    S0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  W/:]:\YY/3/(    K @  $0
M@ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  W/:]:F5R<(Q &
M  "<)P  $P              @ 'D 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( #<]KUHR D"WY@4  , ?   8              " @24(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  W/:]:PR*I7.T%
M   _&   &               @(%!#@  >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L! A0#%     @ -SVO6H(<DS2Q @  "0D  !@              ("!
M9!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #<]KUKY
MS,9J)@4  &D6   8              " @4L7  !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"% ,4    "  W/:]:M CPX'P'   1,P  &
M    @(&G'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M-SVO6EV$CCX(!P  *!\  !@              ("!620  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #<]KUIM=S:N2P(  *(%   8
M          " @9<K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  W/:]:$ZV'ZT0"  "*!@  &               @($8+@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ -SVO6A0&^RD# P  ;P8
M !@              ("!DC   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( #<]KUK;BE,Z[ P  *LC   9              " @<LS  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ -SVO6@E%[137
M P  4@D  !D              ("![D   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  W/:]:7CY)@Q0$  #+"0  &0
M@('\1   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #<]
MKUHC2!74? <  $L2   9              " @4=)  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ -SVO6CDEU$_\"@  >R,  !D
M         ("!^E   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  W/:]:M=#\=]0$   B"P  &0              @($M7   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( #<]KUIOJC[5FP0  &T+
M   9              " @3AA  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ -SVO6OEU8A$J!P  .A,  !D              ("!"F8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  W/:]:-&+9
M-PH$   ="0  &0              @(%K;0  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( #<]KUJ!*^85<0,  !,(   9
M  " @:QQ  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M-SVO6@9C9NR% P  B <  !D              ("!5'4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  W/:]:B'%%^<(#  !C"   &0
M            @($0>0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( #<]KUH6M%--V T  /<F   9              " @0E]  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ -SVO6DL?D(Q! P
MM@<  !D              ("!&(L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  W/:]::^$454L#  !P"   &0              @(&0
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #<]KUK6
M?N)JNP0  "\+   9              " @1*2  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ -SVO6N6D9:$2 P  808  !D
M     ("!!)<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #<]KUJL$]*%+00  -H9   9              "
M@2>I  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ -SVO
M6IOK#: R P  Z0P  !D              ("!BZT  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  W/:]:AA_+5[X"   O!P  &0
M        @('TL   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( #<]KUI!"K'*3@,  #0(   9              " @>FS  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ -SVO6N4&)_![!P  3#(
M !D              ("!;K<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  W/:]:7M'X'+ "  ":!@  &0              @($@OP
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( #<]KUH\'CV>
MC H  -20   9              " @0?"  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ -SVO6E_L6,,""   !DX  !D
M ("!RLP  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  W
M/:]:/-:AO1$$  "G%@  &0              @($#U0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #<]KUIT9J'(D @  -]D   9
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M970T-"YX;6Q02P$"% ,4    "  W/:]:JZU=GE8"  !2!0  &0
M    @(&#\P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M #<]KUH'S>@0,0,  .(+   9              " @1#V  !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ -SVO6B7N.K7" @  4 <  !D
M             ("!>/D  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    "  W/:]:I*^E29<"  #H!@  &0              @(%Q_   >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( #<]KUJUS;T2=0(
M $@&   9              " @3__  !X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ -SVO6H<M GI9!   NA8  !D              ("!
MZP$! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  W/:]:
MQ>BMD:T"  #O!@  &0              @(%[!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #<]KUHUVMVW+0,  .X2   -
M      "  5\) 0!X;"]S='EL97,N>&UL4$L! A0#%     @ -SVO6I>*NQS
M    $P(   L              ( !MPP! %]R96QS+RYR96QS4$L! A0#%
M  @ -SVO6O,UI]Y(!   1B(   \              ( !H T! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( #<]KUJAE^J4R0$  * >   :
M  "  142 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M #<]KUHHM&@3PP$  (D>   3              "  184 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     [ #L %!    H6 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Marketable Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities</Role>
      <ShortName>Marketable Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Segment Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1</Role>
      <ShortName>Segment Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements</Role>
      <ShortName>Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Marketable Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables</Role>
      <ShortName>Marketable Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Segment Disclosure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables</Role>
      <ShortName>Segment Disclosure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails</Role>
      <ShortName>Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Marketable Debt Securities - Interest and Investment Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails</Role>
      <ShortName>Marketable Debt Securities - Interest and Investment Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Segment Disclosure - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails</Role>
      <ShortName>Segment Disclosure - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails</Role>
      <ShortName>Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails</Role>
      <ShortName>Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995765 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common Stock Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails</Role>
      <ShortName>Common Stock Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Operating Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pyxs-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet</Role>
      <ShortName>Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="pyxs-20250331.htm">pyxs-20250331.htm</File>
    <File>pyxs-20250331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img33342731_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="414">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pyxs-20250331.htm": {
   "nsprefix": "pyxs",
   "nsuri": "http://pyxisoncology.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "pyxs-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "pyxs-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 195,
   "keyCustom": 37,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 29,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 6
   },
   "contextCount": 137,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 630,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 414,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02c3f376-cf08-485b-be5c-ffdbc197e303",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_70a309a0-7032-4844-baa7-96b76069261c",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_70a309a0-7032-4844-baa7-96b76069261c",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995475 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities",
     "longName": "995485 - Disclosure - Marketable Debt Securities",
     "shortName": "Marketable Debt Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1",
     "longName": "995495 - Disclosure - Segment Disclosure",
     "shortName": "Segment Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements",
     "longName": "995505 - Disclosure - Licensing Agreements",
     "shortName": "Licensing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995515 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants",
     "longName": "995525 - Disclosure - Common Stock Warrants",
     "shortName": "Common Stock Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:CommonStockWarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:CommonStockWarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995535 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases",
     "longName": "995545 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1",
     "longName": "995565 - Disclosure - Net Loss per Common Share",
     "shortName": "Net Loss per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995575 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:NatureOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995605 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables",
     "longName": "995615 - Disclosure - Marketable Debt Securities (Tables)",
     "shortName": "Marketable Debt Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables",
     "longName": "995625 - Disclosure - Segment Disclosure (Tables)",
     "shortName": "Segment Disclosure (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995635 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995645 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables",
     "longName": "995655 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "longName": "995665 - Disclosure - Net Loss per Common Share (Tables)",
     "shortName": "Net Loss per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "pyxs:LiquidityPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
     "longName": "995695 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Instruments Carried at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec1ee2ec-2bfc-4df3-8172-db225ac82cb8",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails",
     "longName": "995715 - Disclosure - Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details)",
     "shortName": "Marketable Debt Securities - Summary of Marketable Securities Classified as Available-for-sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails",
     "longName": "995725 - Disclosure - Marketable Debt Securities - Interest and Investment Income (Details)",
     "shortName": "Marketable Debt Securities - Interest and Investment Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Segment Disclosure - Additional Information (Details)",
     "shortName": "Segment Disclosure - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
     "longName": "995745 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details)",
     "shortName": "Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails",
     "longName": "995755 - Disclosure - Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details)",
     "shortName": "Segment Disclosure - Summary of Significant Expenses Related to The Life Science Segment (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "longName": "995765 - Disclosure - License Agreements - Additional Information (Details)",
     "shortName": "License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f457fd30-0a38-4eba-9ed6-486f8bf622ec",
      "name": "pyxs:PaymentForLicenseFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "pyxs:LicensingAgreementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
     "longName": "995785 - Disclosure - Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Common Stock Warrants - Additional Information (Details)",
     "shortName": "Common Stock Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a",
      "name": "pyxs:ReplacementOfWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "pyxs:CommonStockWarrantTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a",
      "name": "pyxs:ReplacementOfWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "pyxs:CommonStockWarrantTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "pyxs:FairValueOfCommonStockPerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "pyxs:FairValueOfCommonStockPerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995815 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_02c3f376-cf08-485b-be5c-ffdbc197e303",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
     "longName": "995825 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Estimated Fair Value Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
     "longName": "995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_02c3f376-cf08-485b-be5c-ffdbc197e303",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02c3f376-cf08-485b-be5c-ffdbc197e303",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
     "longName": "995845 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_da865c67-24d1-400e-a077-12e7011b7389",
      "name": "pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da865c67-24d1-400e-a077-12e7011b7389",
      "name": "pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails",
     "longName": "995855 - Disclosure - Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Total Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Operating Leases - Additional Information (Details)",
     "shortName": "Operating Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b635d7f-a221-440b-8651-5dc1b8df141e",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
     "longName": "995875 - Disclosure - Operating Leases - Components of Lease Expense (Details)",
     "shortName": "Operating Leases - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995895 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12af53c6-9378-49ea-91fd-c3d3ea22941c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
     "longName": "995905 - Disclosure - Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details)",
     "shortName": "Net Loss per Common Share - Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_18c2f871-fdac-46c2-8c4b-4a534962e9f8",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "pyxs:CommonStockWarrantTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202108Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202108Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2021-08",
        "label": "Accounting Standards Update 2021-08 [Member]",
        "documentation": "Accounting Standards Update 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r735"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount on marketable debt securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r61",
      "r125",
      "r531",
      "r563",
      "r567"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12",
      "r20",
      "r423",
      "r426",
      "r496",
      "r558",
      "r559",
      "r846",
      "r847",
      "r848",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r735",
      "r990"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r855",
      "r856",
      "r857",
      "r858",
      "r926",
      "r991"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r160",
      "r161",
      "r162",
      "r163",
      "r174",
      "r220",
      "r221",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r262",
      "r263",
      "r266",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r463",
      "r464",
      "r475",
      "r476",
      "r477",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r514",
      "r515",
      "r516",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r316"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval",
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval.",
        "terseLabel": "Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval",
        "documentation": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval.",
        "terseLabel": "Aggregate maximum obligation to pay future contingent milestone payments for normal approval"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_AggregateMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "AggregateMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate milestone payments for first four licensed products",
        "label": "Aggregate Milestone Payments",
        "documentation": "Aggregate milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770",
      "r780",
      "r812"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r773",
      "r783",
      "r815"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r808",
      "r816",
      "r820",
      "r828"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r357"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive effect excluded from computation of diluted net loss per share attributable to common stockholders",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "pyxs_ApexigenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ApexigenEquityIncentivePlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apexigen Equity Incentive Plan.",
        "label": "Apexigen Equity Incentive Plan [Member]",
        "terseLabel": "Apexigen Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ApexigenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ApexigenIncMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Apexigen",
        "terseLabel": "Apexigen, Inc.",
        "label": "Apexigen, Inc. [Member]",
        "documentation": "Apexigen, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ApexigenReplacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ApexigenReplacementWarrantsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apexigen Replacement Warrants.",
        "label": "Apexigen Replacement Warrants [Member]",
        "verboseLabel": "Apexigen Replacement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ApexigenTwoThousandAndTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Equity Incentive Plan",
        "label": "Apexigen Two Thousand and Twenty Two Equity Incentive Plan [Member]",
        "documentation": "Apexigen Two Thousand and Twenty Two Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease agreement, square feet space area in building",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r121",
      "r150",
      "r189",
      "r198",
      "r209",
      "r213",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r411",
      "r415",
      "r466",
      "r525",
      "r625",
      "r704",
      "r705",
      "r735",
      "r751",
      "r887",
      "r888",
      "r944"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r127",
      "r150",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r411",
      "r415",
      "r466",
      "r735",
      "r887",
      "r888",
      "r944"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r726"
     ]
    },
    "pyxs_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Offering Program",
        "label": "At The Market Offering Program [Member]",
        "documentation": "At the market offering program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities, Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketable debt securities, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable debt securities, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r253",
      "r524"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities, Aggregate Fair Value",
        "verboseLabel": "Marketable debt securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r253",
      "r442",
      "r518",
      "r726",
      "r730",
      "r866",
      "r929",
      "r930",
      "r931"
     ]
    },
    "pyxs_AverageSalePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "AverageSalePricePerShare",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average sale price per share.",
        "label": "Average Sale Price Per Share",
        "terseLabel": "Average sale price per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and summary of significant accounting policies.",
        "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_BiosionLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "BiosionLicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biosion License Agreement",
        "documentation": "Biosion license agreement.",
        "terseLabel": "Biosion License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r401",
      "r718",
      "r719"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r401",
      "r718",
      "r719"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase price",
        "totalLabel": "Provisional purchase price",
        "terseLabel": "Provisional purchase price",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r11"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisition date fair value of replacement awards",
        "terseLabel": "Fair value of consideration transferred",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r74",
      "r75"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired in acquisition of Apexigen, Inc.",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r120",
      "r692"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash Equivalents",
        "verboseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r71",
      "r148"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r71",
      "r148"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r71"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r116",
      "r159",
      "r220",
      "r241",
      "r242",
      "r243",
      "r249",
      "r250",
      "r262",
      "r266",
      "r384",
      "r392",
      "r393",
      "r402",
      "r403",
      "r405",
      "r418",
      "r419",
      "r430",
      "r431",
      "r463",
      "r464",
      "r476",
      "r491",
      "r492",
      "r514",
      "r515",
      "r556",
      "r557"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r116",
      "r220",
      "r241",
      "r242",
      "r243",
      "r249",
      "r250",
      "r251",
      "r262",
      "r266",
      "r384",
      "r392",
      "r393",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r417",
      "r418",
      "r419",
      "r420",
      "r430",
      "r431",
      "r432",
      "r435",
      "r463",
      "r464",
      "r476",
      "r491",
      "r492",
      "r514",
      "r515",
      "r556",
      "r557",
      "r841"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r173",
      "r246"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r150",
      "r178",
      "r179",
      "r181",
      "r183",
      "r191",
      "r192",
      "r239",
      "r274",
      "r277",
      "r278",
      "r279",
      "r283",
      "r284",
      "r287",
      "r288",
      "r290",
      "r293",
      "r299",
      "r466",
      "r574",
      "r575",
      "r576",
      "r577",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r613",
      "r634",
      "r656",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r839",
      "r852",
      "r859"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of shares are included in the computation of basic and diluted net loss per common share",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "label": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Consecutive Trading Days",
        "documentation": "Class of warrant rr right redemption of warrants or rights threshold consecutive trading days."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading days",
        "label": "Class of Warrant or Right Redemption of Warrants or Rights Threshold Trading Days",
        "documentation": "Class of warrant or right redemption of warrants or rights threshold trading days"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants redemption exercise price per share",
        "label": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights",
        "documentation": "Class of warrant or right redemption price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classification and Accretion of Convertible Preferred Stock",
        "label": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]",
        "documentation": "Classification and Accretion of Convertible Preferred Stock [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClinicalProductCandidatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClinicalProductCandidatesMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Product Candidates [Member]",
        "documentation": "Clinical product candidates.",
        "terseLabel": "Clinical product candidates"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ClinicalProductManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ClinicalProductManufacturingMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Product Manufacturing [Member]",
        "documentation": "Clinical product manufacturing.",
        "terseLabel": "Clinical product manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91",
      "r528",
      "r612"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r268",
      "r269",
      "r685",
      "r882",
      "r884"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r686"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuable upon conversion",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Number of common shares reserved and autorized for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "pyxs_CommonStockIssuedToUniversity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "CommonStockIssuedToUniversity",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued to university.",
        "label": "Common Stock Issued To University",
        "terseLabel": "Common stock issued to university"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r855",
      "r856",
      "r858",
      "r926",
      "r987",
      "r991"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r613"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Pre-Funded Warrants issued to purchase aggregate number of shares of common stock",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r613",
      "r631",
      "r991",
      "r992"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued, value",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "terseLabel": "Common stock, par value $0.001 per share; 190,000,000 shares authorized; 61,631,376 and 59,967,814 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r530",
      "r735"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, authorized (in shares)",
        "verboseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "pyxs_CommonStockWarrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "CommonStockWarrantTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrant [Text Block]",
        "documentation": "Common stock warrant.",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r134",
      "r141",
      "r520",
      "r540",
      "r541"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r101"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r840"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r155",
      "r189",
      "r200",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r704",
      "r705",
      "r887",
      "r888"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r155",
      "r189",
      "r200",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r704",
      "r705",
      "r887",
      "r888"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r290",
      "r745",
      "r746",
      "r747",
      "r748"
     ]
    },
    "pyxs_ConvertiblePreferredStockSharesIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ConvertiblePreferredStockSharesIssuedValue",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock shares issued value.",
        "label": "Convertible Preferred Stock Shares Issued Value",
        "terseLabel": "Issuance of convertible preferred stock value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost of Revenue, Total",
        "label": "Cost of revenues",
        "terseLabel": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r150",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r466",
      "r704",
      "r887"
     ]
    },
    "pyxs_CostsAndOperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "CostsAndOperatingExpensesAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs and Operating Expenses [Abstract].",
        "label": "Costs and Operating Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:",
        "verboseLabel": "Costs and operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_CostsAndOperatingExpensesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "CostsAndOperatingExpensesTotal",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs and operating expenses, total.",
        "label": "Costs and Operating Expenses, Total",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Marketable Securities Classified as Available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting commission and issuance costs",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r106",
      "r854"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: valuation allowance",
        "negatedLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance",
        "label": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "pyxs_DepreciationAndAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "DepreciationAndAmortizationMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation And Amortization [Member]",
        "documentation": "Depreciation And Amortization.",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r189",
      "r202",
      "r213",
      "r704",
      "r705"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability",
        "label": "Derivative Liability",
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Derivative liability related to extra milestone payment",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r442",
      "r443",
      "r456",
      "r465",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r626",
      "r628",
      "r629",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r694",
      "r929",
      "r930",
      "r931",
      "r988"
     ]
    },
    "pyxs_DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "DerivativeLiabilityOffsetToResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability offset to research and development expenses.",
        "label": "Derivative Liability Offset to Research and Development Expenses",
        "terseLabel": "Derivative liability offset to research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability statement of financial position extensible enumeration not disclosed flag.",
        "label": "Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r318",
      "r349",
      "r350",
      "r352",
      "r721"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r176",
      "r178",
      "r181",
      "r182",
      "r183",
      "r188",
      "r399",
      "r409",
      "r439",
      "r440",
      "r521",
      "r542",
      "r697"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r178",
      "r181",
      "r182",
      "r183",
      "r188",
      "r399",
      "r409",
      "r439",
      "r440",
      "r521",
      "r542",
      "r697"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r185"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r184",
      "r186",
      "r187"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effective tax rate",
        "totalLabel": "Effective income tax rate%",
        "label": "Effective income tax rate%",
        "terseLabel": "Effective tax rate from continuing operations",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r723"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense weighted average amortized period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Gross unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Gross unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "Stock Options Outstanding",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options Outstanding",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r113",
      "r136",
      "r137",
      "r138",
      "r156",
      "r157",
      "r158",
      "r161",
      "r168",
      "r170",
      "r172",
      "r190",
      "r245",
      "r252",
      "r263",
      "r301",
      "r382",
      "r383",
      "r395",
      "r396",
      "r397",
      "r400",
      "r408",
      "r409",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r438",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r479",
      "r496",
      "r539",
      "r558",
      "r559",
      "r560",
      "r584",
      "r656"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770",
      "r780",
      "r812"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "pyxs_EsbatechAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "EsbatechAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Esbatech Agreement",
        "label": "ESBATech Agreement [Member]",
        "documentation": "Esbatech agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_EstimatedCostToPurchaseLicensedProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "EstimatedCostToPurchaseLicensedProducts",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated cost to purchase licensed products.",
        "label": "Estimated Cost To Purchase Licensed Products",
        "terseLabel": "Estimated cost to purchase licensed products"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "pyxs_ExerciseOfPre-FundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ExerciseOfPre-FundedWarrants",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants (Shares)",
        "label": "Exercise of pre-funded warrants",
        "documentation": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ExerciseOfPre-FundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ExerciseOfPre-FundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "label": "Exercise of pre-funded warrants, Value",
        "documentation": "Exercise of pre-funded warrants, Value"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ExtraMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ExtraMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extra milestone payment",
        "label": "Extra Milestone Payment",
        "documentation": "Extra milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ExtraMilestonePaymentForWhichDerivativeLiabilityRecognized",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extra milestone payment for which derivative liability recognized",
        "label": "Extra Milestone Payment for Which Derivative Liability Recognized",
        "documentation": "Extra milestone payment for which derivative liability recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r456",
      "r726"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r456",
      "r726"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Instruments Carried at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r927",
      "r928",
      "r933"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r457",
      "r728"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r457",
      "r728"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r455",
      "r456",
      "r458",
      "r506",
      "r507",
      "r508",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r726",
      "r730"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r446",
      "r726",
      "r930",
      "r935"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r517",
      "r726",
      "r731"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r306",
      "r311",
      "r443",
      "r456",
      "r506",
      "r715",
      "r716",
      "r717",
      "r726"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r306",
      "r311",
      "r443",
      "r444",
      "r456",
      "r507",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r726"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r443",
      "r444",
      "r445",
      "r446",
      "r456",
      "r508",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r726",
      "r730"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r457"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Level 3 Fair Value Measurements",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r452",
      "r457"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r446",
      "r726",
      "r930",
      "r935"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Changes in the fair value of derivative liability",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r934"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r455",
      "r456",
      "r458",
      "r506",
      "r507",
      "r508",
      "r711",
      "r712",
      "r715",
      "r716",
      "r717",
      "r726",
      "r730"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r446",
      "r726",
      "r930"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r935"
     ]
    },
    "pyxs_FairValueOfCommonStockPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "FairValueOfCommonStockPerShare",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock per share.",
        "label": "Fair Value Of Common Stock Per Share",
        "terseLabel": "Fair value of common stock per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Federal Income Tax Expense (Benefit), Continuing Operations, Total",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal income tax provision",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r365",
      "r366"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, payments",
        "label": "Finance Lease, Liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r489"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease liabilities, net of current portion",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r816"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r816"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r816"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r816"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r816"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "Total general and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r636"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "pyxs_GrossProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "GrossProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance of initial public offering",
        "label": "Gross Proceeds from Issuance Initial Public Offering",
        "documentation": "Gross proceeds from issuance initial public offering.",
        "verboseLabel": "Gross proceeds from issuance of initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from sale of shares",
        "label": "Gross Proceeds from Issuance of Common Stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentEffectsOnEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentEffectsOnEarningsPerShareTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Effects on Earnings Per Share [Table]",
        "documentation": "Disclosure of information about the effects of asset impairment charge on per share or per unit basis."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ImpairmentOfIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ImpairmentOfIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Intangible Assets",
        "label": "Impairment of Intangible Assets [Policy Text Block]",
        "documentation": "Impairment of Intangible Assets [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r77",
      "r727"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r448",
      "r452",
      "r457",
      "r553",
      "r555",
      "r641",
      "r689",
      "r729",
      "r958"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r267",
      "r448",
      "r452",
      "r457",
      "r553",
      "r555",
      "r641",
      "r689",
      "r729",
      "r958"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r367",
      "r368",
      "r373",
      "r379",
      "r723",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r367",
      "r368",
      "r373",
      "r379",
      "r723",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r362",
      "r367",
      "r370",
      "r371",
      "r372",
      "r374",
      "r378",
      "r387",
      "r389",
      "r390",
      "r391",
      "r579",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax expenses (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r171",
      "r172",
      "r189",
      "r203",
      "r213",
      "r365",
      "r367",
      "r388",
      "r544",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r363",
      "r364",
      "r374",
      "r375",
      "r377",
      "r381",
      "r573"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in deferred tax assets valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r723",
      "r923"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r850"
     ]
    },
    "pyxs_IncreaseDecreaseInFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IncreaseDecreaseInFinanceLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease liabilities",
        "label": "Increase Decrease In Finance lease Liability",
        "documentation": "Increase Decrease In Finance lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r850"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "pyxs_IncrementalStockBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IncrementalStockBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock-based compensation expense",
        "label": "Incremental Stock-Based Compensation Expense",
        "documentation": "Incremental stock-based compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IncrementalStockBasedCompensationExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IncrementalStockBasedCompensationExpenseRecognized",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock-based compensation expense recognized",
        "label": "Incremental Stock-Based Compensation Expense Recognized",
        "documentation": "Incremental stock-based compensation expense recognized."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r808",
      "r816",
      "r820",
      "r828"
     ]
    },
    "pyxs_InitialPublicOfferingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering.",
        "label": "Initial Public Offering Policy [Text Block]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r832"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r832"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r832"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r880",
      "r881"
     ]
    },
    "pyxs_IntangibleAssetsNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IntangibleAssetsNetPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets Net [Policy Text Block]",
        "documentation": "Intangible Assets Net [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_InvestmentInJointVenturePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "InvestmentInJointVenturePolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Joint Venture",
        "label": "Investment in Joint Venture [Policy Text Block]",
        "documentation": "Investment in Joint Venture [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails": {
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r201",
      "r213",
      "r704",
      "r849"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and investment income",
        "totalLabel": "Total interest and investment income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r69"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails": {
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesInterestAndInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of discount, net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r569",
      "r570",
      "r571",
      "r572",
      "r666",
      "r667"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in private placement, net of offering costs.",
        "label": "Issuance Of Common Stock In Private Placement, Net Of Offering Costs",
        "verboseLabel": "Issuance of common stock in private placement, net of offering costs (See Note 7) (Shares)",
        "terseLabel": "Issuance of common stock in private placement, net of offering costs (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in private placement value, net of offering costs.",
        "label": "Issuance Of Common Stock In Private Placement Value, Net Of Offering Costs",
        "verboseLabel": "Issuance of common stock in private placement, net of offering costs (See Note 7)",
        "terseLabel": "Issuance of common stock in private placement, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock pursuant to at-the-market program value, net of offering costs.",
        "label": "Issuance of common stock pursuant to at-the-market program Value, net of offering costs",
        "verboseLabel": "Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock shares pursuant to at-the-market program, net of offering costs.",
        "label": "Issuance Of Common Stock Shares Pursuant To At-The-Market Program, Net Of Offering Costs",
        "verboseLabel": "Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14) (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfConvertiblePreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfConvertiblePreferredStockShares",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible preferred stock shares.",
        "label": "Issuance Of Convertible Preferred Stock Shares",
        "terseLabel": "Issuance of Series B convertible preferred stock, Shares",
        "verboseLabel": "Issuance of convertible preferred stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of pre-funded warrants in private placement, net of offering costs.",
        "label": "Issuance Of Pre-Funded Warrants In Private Placement, Net Of Offering Costs",
        "verboseLabel": "Issuance of pre-funded warrants in private placement, net of offering costs (See Note 8)",
        "terseLabel": "Issuance of pre-funded warrants in private placement, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r734"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_LegoChemLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "LegoChemLicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LegoChem license agreement.",
        "label": "Lego Chem License Agreement [Member]",
        "terseLabel": "LegoChem License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, term",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r150",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r412",
      "r415",
      "r416",
      "r466",
      "r611",
      "r698",
      "r751",
      "r887",
      "r944",
      "r945"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r92",
      "r533",
      "r735",
      "r853",
      "r879",
      "r936"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r119",
      "r150",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r412",
      "r415",
      "r416",
      "r466",
      "r735",
      "r887",
      "r944",
      "r945"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r927"
     ]
    },
    "pyxs_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_LicensingAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "LicensingAgreementsTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureLicensingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreements.",
        "label": "Licensing Agreements [Text Block]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MabwellAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MabwellAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mabwell Agreement",
        "label": "Mabwell Agreement [member]",
        "documentation": "Mabwell agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities, short-term",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Debt Securities",
        "terseLabel": "Summary of Marketable Securities Classified as Available-for-sale",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized (loss) gain on marketable debt securities",
        "verboseLabel": "Net unrealized loss on marketable debt securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r313",
      "r358",
      "r446",
      "r511",
      "r552",
      "r554",
      "r568",
      "r603",
      "r604",
      "r665",
      "r668",
      "r669",
      "r670",
      "r678",
      "r687",
      "r688",
      "r710",
      "r713",
      "r720",
      "r730",
      "r731",
      "r732",
      "r733",
      "r737",
      "r889",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "pyxs_MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MaximumNumberOfCommonSharesIssuableUnderExerciseOfOptions",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of common shares issuable under exercise of options",
        "label": "Maximum Number of Common Shares Issuable Under Exercise of Options",
        "documentation": "Maximum number of common shares issuable under exercise of options."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MaximumPercentageOfOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MaximumPercentageOfOwnershipInterest",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MaximumPercentageofOwnershipInterest",
        "label": "Maximum Percentage Of Ownership Interest",
        "terseLabel": "Maximum percentage of ownership interest"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum value of stock and debt instruments authorized to issue",
        "label": "Maximum Value of Stock and Debt Instruments Authorized to Issue",
        "documentation": "Maximum value of stock and debt instruments authorized to issue."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "pyxs_MilestoneAndRoyaltiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MilestoneAndRoyaltiesIncurred",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone and royalties required",
        "documentation": "Milestone and royalties incurred.",
        "label": "Milestone and Royalties Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MilestoneAndRoyaltiesPaymentsReceivedPostAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone and royalties payments received post acquisition",
        "label": "Milestone And Royalties Payments Received Post Acquisition",
        "documentation": "Milestone and royalties payments received post acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MilestoneAndRoyaltiesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MilestoneAndRoyaltiesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone and royalties receivable",
        "label": "Milestone And Royalties Receivable",
        "documentation": "Milestone and royalties receivable."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_MinimumAnnualRoyaltyFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "MinimumAnnualRoyaltyFees",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual royalty fees.",
        "terseLabel": "Minimum annual royalty fees",
        "label": "Minimum Annual Royalty Fees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r313",
      "r358",
      "r446",
      "r511",
      "r552",
      "r554",
      "r568",
      "r603",
      "r604",
      "r665",
      "r668",
      "r669",
      "r670",
      "r678",
      "r687",
      "r688",
      "r710",
      "r713",
      "r720",
      "r730",
      "r731",
      "r732",
      "r737",
      "r889",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "pyxs_NatureOfBusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "NatureOfBusinessPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business.",
        "label": "Nature Of Business Policy [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r73",
      "r93",
      "r117",
      "r130",
      "r133",
      "r138",
      "r150",
      "r160",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r180",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r399",
      "r409",
      "r440",
      "r466",
      "r538",
      "r633",
      "r654",
      "r655",
      "r749",
      "r887"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r774",
      "r784",
      "r808",
      "r816"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "pyxs_NonVestedAndUnsettledRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "NonVestedAndUnsettledRestrictedStockUnitsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Vested and Unsettled Restricted Stock Units",
        "label": "Non-vested And Unsettled Restricted Stock Units [Member]",
        "documentation": "Non-vested and unsettled restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other segment income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (Expense) Income",
        "documentation": "Primary financial statement caption encompassing nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "NumberOfCommonSharesIssuedUponConversionOfPreferredStock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issued upon conversion of preferred stock",
        "label": "Number of Common Shares Issued Upon Conversion of Preferred Stock",
        "documentation": "Number of common shares issued upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_NumberOfDaysCommonStockIssuedFromEffectiveDate": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "NumberOfDaysCommonStockIssuedFromEffectiveDate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days common stock issued from effective date.",
        "label": "Number of Days Common Stock Issued From Effective Date",
        "terseLabel": "Number of days common stock issued from effective date"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_NumberOfFinanceLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "NumberOfFinanceLease",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of finance lease",
        "documentation": "Number of finance lease.",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating and Reporting Segment",
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r861"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r708",
      "r861"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction expenses incurred",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r699",
      "r860",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r734"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash lease expense",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "verboseLabel": "Non-cash lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, current portion",
        "terseLabel": "Current portion of Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "totalLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r488"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforward",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "pyxs_OperatingLossCarryforwardsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OperatingLossCarryforwardsBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards before tax",
        "label": "Operating Loss Carryforwards Before Tax",
        "documentation": "Operating loss carryforwards before tax."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OperatingLossCarryforwardsRelatingToPriorTaxYears",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards relating to prior tax years",
        "label": "Operating Loss Carryforwards Relating to Prior Tax Years",
        "documentation": "Operating loss carryforwards relating to prior tax years."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OperatingLossCarryforwardsRelatingToPriorTaxYearsBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards relating to prior tax years before tax",
        "label": "Operating Loss Carryforwards Relating to Prior Tax Years Before Tax",
        "documentation": "Operating loss carryforwards relating to prior tax years before tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r704",
      "r705"
     ]
    },
    "pyxs_OptionUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OptionUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Upfront Payment",
        "label": "Option Upfront Payment",
        "terseLabel": "Stock option upfront payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r17",
      "r131",
      "r134",
      "r140",
      "r168",
      "r467",
      "r468",
      "r473",
      "r519",
      "r539",
      "r846",
      "r847"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount payable related to licensed products",
        "label": "Other Liabilities",
        "totalLabel": "Other Liabilities, Total",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r526",
      "r607",
      "r608",
      "r751",
      "r955",
      "r989"
     ]
    },
    "pyxs_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "OtherMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other [Member]",
        "documentation": "Other."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r772",
      "r782",
      "r814"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r775",
      "r785",
      "r817"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r775",
      "r785",
      "r817"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "pyxs_PaymentForLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PaymentForLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for license fee",
        "label": "Payment for License Fee",
        "documentation": "Payment for license fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions paid to the placement agent",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Tax withholding payments related to net settlement of restricted common stock",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable debt securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r143",
      "r223"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "pyxs_PersonnelRelatedExpensesExcludingStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PersonnelRelatedExpensesExcludingStockBasedCompensationMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related expenses excluding stock-based compensation",
        "label": "Personnel Related Expenses Excluding Stock Based Compensation [Member]",
        "documentation": "Personnel related expenses excluding stock based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_PfizerLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PfizerLicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer license agreement.",
        "label": "Pfizer License Agreement [Member]",
        "terseLabel": "Pfizer License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "pyxs_PotentialDevelopmentAndCommercialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PotentialDevelopmentAndCommercialMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and commercial milestones",
        "label": "Potential Development and Commercial Milestone Payment",
        "documentation": "Potential development and commercial milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_PreFundedWarrantsIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PreFundedWarrantsIssuedDuringPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded warrants issued during period.",
        "label": "Pre-Funded Warrants Issued During Period",
        "terseLabel": "Pre-Funded Warrants issued to purchase aggregate number of shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants.",
        "verboseLabel": "Pre-Funded Warrant Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r613"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r613",
      "r631",
      "r991",
      "r992"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "terseLabel": "Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r529",
      "r735"
     ]
    },
    "pyxs_PrefundedWarrantsIssuedPricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PrefundedWarrantsIssuedPricePerWarrant",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants issued price per warrant.",
        "label": "Prefunded Warrants Issued Price Per Warrant",
        "terseLabel": "Purchase price per warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r254",
      "r255",
      "r693"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Funding",
        "label": "Private Placement [Member]",
        "verboseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock in initial public offering, net of issuance costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from issuance initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pyxs_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants in private placement.",
        "label": "Proceeds From Issuance Of Common Stock And Pre-funded Warrants In Private Placement",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ProceedsFromIssuanceOfCommonStockUnderEspp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEspp",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under ESPP",
        "label": "Proceeds From Issuance Of Common Stock Under ESPP",
        "documentation": "Proceeds from issuance of common stock under ESPP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pyxs_ProceedsFromStockIssuedUnderAtmNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ProceedsFromStockIssuedUnderAtmNet",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Stock Issued Under ATM, Net",
        "documentation": "Proceeds from stock issued under atm, net.",
        "terseLabel": "Proceeds from issuance of common stock pursuant to ATM program, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r513",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r691",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r885",
      "r886",
      "r892",
      "r957",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r513",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r691",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r885",
      "r886",
      "r892",
      "r957",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "pyxs_ProfessionalAndConsultantFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ProfessionalAndConsultantFeesMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional and Consultant Fees [Member]",
        "documentation": "Professional and consultant fees.",
        "terseLabel": "Professional and consultant fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Consolidated net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r130",
      "r133",
      "r145",
      "r150",
      "r160",
      "r168",
      "r171",
      "r172",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r399",
      "r409",
      "r410",
      "r413",
      "r414",
      "r440",
      "r466",
      "r522",
      "r537",
      "r583",
      "r633",
      "r654",
      "r655",
      "r724",
      "r725",
      "r750",
      "r848",
      "r887"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r490",
      "r523",
      "r536",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r102",
      "r105",
      "r535"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "pyxs_PyxisOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "PyxisOncologyMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pyxis Oncology",
        "label": "Pyxis Oncology [Member]",
        "documentation": "Pyxis oncology."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r305",
      "r313",
      "r344",
      "r345",
      "r346",
      "r358",
      "r446",
      "r509",
      "r510",
      "r511",
      "r552",
      "r554",
      "r568",
      "r603",
      "r604",
      "r665",
      "r668",
      "r669",
      "r670",
      "r678",
      "r687",
      "r688",
      "r710",
      "r713",
      "r720",
      "r730",
      "r731",
      "r732",
      "r733",
      "r737",
      "r743",
      "r883",
      "r889",
      "r930",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r305",
      "r313",
      "r344",
      "r345",
      "r346",
      "r358",
      "r446",
      "r509",
      "r510",
      "r511",
      "r552",
      "r554",
      "r568",
      "r603",
      "r604",
      "r665",
      "r668",
      "r669",
      "r670",
      "r678",
      "r687",
      "r688",
      "r710",
      "r713",
      "r720",
      "r730",
      "r731",
      "r732",
      "r733",
      "r737",
      "r743",
      "r883",
      "r889",
      "r930",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "pyxs_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "documentation": "Recently issued accounting pronouncements not yet adopted policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]",
        "terseLabel": "Reconciliation of profit or loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Significant Expense related to the Life Science Segment",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "pyxs_RedemptionNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RedemptionNoticePeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption notice period",
        "label": "Redemption Notice Period",
        "documentation": "Redemption notice period."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_RedemptionOfMarketableDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RedemptionOfMarketableDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of marketable debt securities",
        "label": "Redemption Of Marketable Debt Securities",
        "documentation": "Redemption of marketable debt securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r312",
      "r500",
      "r501",
      "r527",
      "r534",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r630",
      "r632",
      "r664"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r500",
      "r501",
      "r502",
      "r503",
      "r527",
      "r534",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r630",
      "r632",
      "r664"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r637",
      "r638",
      "r641"
     ]
    },
    "pyxs_RelatedPartyTransactionOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RelatedPartyTransactionOwnership",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Ownership",
        "label": "Related Party Transaction Ownership",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r312",
      "r500",
      "r501",
      "r527",
      "r534",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r630",
      "r632",
      "r664",
      "r943"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r501",
      "r504",
      "r580",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r661",
      "r663"
     ]
    },
    "pyxs_ReplacementOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ReplacementOfWarrants",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Replacement of warrants",
        "label": "Replacement Of Warrants",
        "documentation": "Replacement of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ReplacementOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ReplacementOptionsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Replacement Options",
        "label": "Replacement Options [Member]",
        "documentation": "Replacement Options."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ReplacementRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ReplacementRestrictedStockUnitsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Replacement RSUs",
        "label": "Replacement Restricted Stock Units [Member]",
        "documentation": "Replacement Restricted Stock Units."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ReplacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ReplacementWarrantsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Replacement Warrants",
        "label": "Replacement Warrants [Member]",
        "documentation": "Replacement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r922"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r922"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r922"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "pyxs_CostsAndOperatingExpensesTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "verboseLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r689",
      "r704",
      "r952"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768",
      "r778",
      "r810"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r776",
      "r786",
      "r818"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r851",
      "r953",
      "r956"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r851"
     ]
    },
    "pyxs_RestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash Fair Value Disclosure",
        "documentation": "Restricted cash fair value disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested and unsettled restricted stock units",
        "label": "Restricted Stock",
        "verboseLabel": "Restricted Stock Awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of restricted common stock, net of tax withholdings, (Shares)",
        "verboseLabel": "Issuance of restricted common units, net of tax withholdings, (Shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units ('RSU')",
        "verboseLabel": "Restricted Stock Units Outstanding",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax withholding payments related to net settlement of restricted common stock",
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Issuance of restricted common stock, net of tax withholdings",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r81",
      "r532",
      "r562",
      "r567",
      "r578",
      "r614",
      "r735"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r156",
      "r157",
      "r158",
      "r161",
      "r168",
      "r170",
      "r172",
      "r245",
      "r252",
      "r263",
      "r382",
      "r383",
      "r395",
      "r396",
      "r397",
      "r400",
      "r408",
      "r409",
      "r421",
      "r424",
      "r425",
      "r428",
      "r438",
      "r476",
      "r479",
      "r558",
      "r560",
      "r584",
      "r991"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r690",
      "r695"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r139",
      "r150",
      "r189",
      "r199",
      "r200",
      "r207",
      "r213",
      "r216",
      "r218",
      "r219",
      "r239",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r466",
      "r522",
      "r704",
      "r887"
     ]
    },
    "pyxs_RightOfUseAssetsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RightOfUseAssetsNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset",
        "label": "Right-of-use Assets Non-current",
        "documentation": "Right-of-use assets non-current."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "documentation": "Risks and Uncertainties [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalty Revenues",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation period for licensed products upon after first commercial sale",
        "label": "Royalty Obligation Period For Licensed Products Upon After First Commercial Sale",
        "documentation": "Royalty obligation period for licensed products upon after first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation period for licensed products upon first commercial sale",
        "label": "Royalty Obligation Period For Licensed Products Upon First Commercial Sale",
        "documentation": "Royalty obligation period for licensed products upon first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_RoyaltyRevenuesAndSaleOfRoyaltyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "RoyaltyRevenuesAndSaleOfRoyaltyRightsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Revenues and Sale of Royalty Rights [Member]",
        "documentation": "Royalty revenues and sale of royalty rights.",
        "terseLabel": "Royalty Revenues and Sale of Royalty Rights",
        "verboseLabel": "Royalty revenue and sale of royalty rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "pyxs_SaleOfRoyaltyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SaleOfRoyaltyRightsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Royalty Rights [Member].",
        "label": "Sale of Royalty Rights [Member]",
        "terseLabel": "Sale of Royalty Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SaleOfStockRemainingCapacityAvailableUnderProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SaleOfStockRemainingCapacityAvailableUnderProgram",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock remaining capacity available under program.",
        "label": "Sale Of Stock Remaining Capacity Available Under Program",
        "terseLabel": "Remaining capacity available under program"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SalesAgentsCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SalesAgentsCommissionPercentage",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agents commission rate",
        "label": "Sales Agents Commission Percentage",
        "documentation": "Sales agents commission percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ]
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Reserved for Issuance",
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Total Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r236",
      "r237",
      "r238",
      "r239",
      "r466"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r150",
      "r236",
      "r237",
      "r238",
      "r239",
      "r466"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and Investment Income",
        "label": "Schedule of Other Nonoperating Income, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r922"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Awards and Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r703",
      "r709"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosure1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Disclosure",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r189",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r204",
      "r205",
      "r206",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r700",
      "r701",
      "r702",
      "r704",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r206",
      "r213"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r206",
      "r213"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SeriesBConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SeriesBConvertiblePreferredStocksMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stocks.",
        "label": "Series B Convertible Preferred Stocks [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Cancelled",
        "negatedLabel": "Number of Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of restricted stock units granted",
        "label": "Number of Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of option to purchase restricted common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares, Outstanding, Ending Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding, Ending Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Replacement RSU Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Replacement in Period",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, replacement in period."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Replacement RSU Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Replacement in Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, replacement in period, weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Vested and settled",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and settled in period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested and Settled in Period",
        "negatedLabel": "Number of Shares, Vested and settled"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options vested and settled in period, weighted average grant date fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options Vested and Settled in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Outstanding, Vested and settled"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but unsettled in period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested but Unsettled in Period",
        "terseLabel": "Number of Shares, Vested but unsettled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable at March 31, 2025",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at March 31, 2025",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted",
        "verboseLabel": "Weighted-average grant-date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Number of Options, Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Options, Outstanding, Ending Balance",
        "terseLabel": "Number of options to purchase common stock",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324"
     ]
    },
    "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Replacement Options",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Replacement In Period",
        "documentation": "Share based compensation arrangement by share based payment award options replacement in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock outstanding percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options, Replacement Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfTotalStockbasedCompensationExpenseDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "pyxs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReplacementOptionsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Replacement Options",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Replacement Options in Period, Weighted Average Exercise Price",
        "documentation": "Share-based compensation arrangements by share-based payment award, options, replacement options in period, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r322",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r353",
      "r354",
      "r355",
      "r356"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatedFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at March 31,2025",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase price per share",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock public offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued pursuant to the ATM program, net of commission (shares)",
        "verboseLabel": "Common stock issued under ATM offering program",
        "label": "Shares issued pursuant to at-the-market (\"ATM\") program, net of commission",
        "documentation": "Shares issued pursuant to at-the-market (\"ATM\") program, net of commission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SharesReservedForFutureIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SharesReservedForFutureIssuanceMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for Future Issuance",
        "label": "Shares Reserved for Future Issuance [Member]",
        "documentation": "Shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SharesWarrantsAndReplacementStockOptionsAndRestrictedStockUnitsIsuedForAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, warrants, and replacement stock options and restricted stock units issued for acquisition.",
        "label": "Shares, Warrants, And Replacement Stock Options And Restricted Stock Units Isued For Acquisition",
        "terseLabel": "Shares, warrants, and replacement stock options and restricted stock units (\"RSUs\") issued for acquisition of Apexigen, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_SimcereLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "SimcereLicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simcere License Agreement",
        "label": "Simcere License Agreement [Member]",
        "documentation": "Simcere license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r150",
      "r178",
      "r179",
      "r181",
      "r183",
      "r191",
      "r192",
      "r239",
      "r274",
      "r277",
      "r278",
      "r279",
      "r283",
      "r284",
      "r287",
      "r288",
      "r290",
      "r293",
      "r299",
      "r466",
      "r574",
      "r575",
      "r576",
      "r577",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r613",
      "r634",
      "r656",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r839",
      "r852",
      "r859"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r58",
      "r59",
      "r113",
      "r136",
      "r137",
      "r138",
      "r156",
      "r157",
      "r158",
      "r161",
      "r168",
      "r170",
      "r172",
      "r190",
      "r245",
      "r252",
      "r263",
      "r301",
      "r382",
      "r383",
      "r395",
      "r396",
      "r397",
      "r400",
      "r408",
      "r409",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r438",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r479",
      "r496",
      "r539",
      "r558",
      "r559",
      "r560",
      "r584",
      "r656"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r190",
      "r479",
      "r513",
      "r569",
      "r595",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r635",
      "r636",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r656",
      "r744"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r190",
      "r222",
      "r479",
      "r513",
      "r569",
      "r595",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632",
      "r635",
      "r636",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r656",
      "r744"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r771",
      "r781",
      "r813"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock based compensation.",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_StockIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockIssuanceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance expenses",
        "label": "Stock Issuance Expenses",
        "documentation": "Stock issuance expenses.",
        "verboseLabel": "Stock issuance expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (\"ESPP\") (Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (Shares)",
        "verboseLabel": "Stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81",
      "r574",
      "r656",
      "r680"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Vesting of restricted common stock, net of tax withholdings (Shares)",
        "terseLabel": "Restricted common units issued, gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r81"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Stock options exercised (Shares)",
        "negatedLabel": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81",
      "r328"
     ]
    },
    "pyxs_StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedCommonStockNetOfTaxWithholdings",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock, net of tax withholdings (Shares)",
        "documentation": "Stock issued during period shares vesting of restricted common stock, net of tax withholdings.",
        "label": "Stock Issued During Period Shares Vesting of Restricted Common Stock, Net of Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (\"ESPP\")",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81",
      "r584",
      "r656",
      "r680",
      "r750"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock, net of tax withholdings",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r81"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercised",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r58",
      "r59",
      "r81"
     ]
    },
    "pyxs_StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedCommonStockNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value vesting of restricted common stock, net of tax withholdings.",
        "label": "Stock Issued During Period Value Vesting of Restricted Common Stock, Net of Tax Withholdings",
        "terseLabel": "Vesting of restricted common stock, net of tax withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in exercise price of relevant option",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "pyxs_StockOptionsAvailableForIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockOptionsAvailableForIssuanceMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options available for issuance.",
        "label": "Stock Options Available For Issuance [Member]",
        "terseLabel": "Stock Options Available for Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockOptionsTwoThousandTwentTwoInducementPlanTwoThousandTwentyTwoPlanTwoThousandTwentyPlanTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options 2022 Inducement Plan, 2022 Plan, 2020 Plan, 2021 Plan and 2019 Plan",
        "label": "Stock options Two Thousand Twent Two Inducement Plan Two Thousand Twenty Two Plan Two Thousand Twenty Plan Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]",
        "documentation": "Stock options Two Thousand Twent Two Inducement Plan Two Thousand Twenty Two Plan Two Thousand Twenty Plan Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockOptionsTwoThousandTwentyTwoPlanTwoThousandTwentyTwoEipTwoThousandTwentyEipTwoThousandTwentyOnePlanAndTwoThousandNineteenPlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options 2022 Plan, 2022 EIP, 2020 EIP, 2021 Plan and 2019 Plan",
        "label": "Stock Options Two Thousand Twenty Two Plan Two Thousand Twenty Two EIP Two Thousand Twenty EIP Two Thousand Twenty One Plan And Two Thousand Nineteen Plan [Member]",
        "documentation": "Stock options two thousand twenty two plan two thousand twenty two eip two thousand twenty eip two thousand twenty one plan and two thousand nineteen plan."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "StockOptionsTwoThousandTwentyTwoTwoThousandTwentyOneAndTwoThousandNineteenPlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options two thousand twenty two, two thousand twenty one and two thousand nineteen plan.",
        "label": "Stock Options Two Thousand Twenty Two, Two Thousand Twenty One and Two Thousand Nineteen Plan [Member]",
        "terseLabel": "Stock Options 2022 Plan, 2021 Plan and 2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized to be repurchased under a stock repurchase plan",
        "label": "Stock Repurchase Program Number of Shares Authorized to be Repurchased"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r76",
      "r615",
      "r631",
      "r657",
      "r658",
      "r735",
      "r751",
      "r853",
      "r879",
      "r936",
      "r991"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r149",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r429",
      "r659",
      "r662",
      "r684"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Reverse Stock Split",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r660"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureSegmentDisclosureSummaryOfSignificantExpensesRelatedToTheLifeScienceSegmentParentheticalDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sublease income",
        "label": "Sublease Income",
        "terseLabel": "Base rent payments to receive over sublease term",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r734"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r505"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r505"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersParenthet",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForIssuanceDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit carryovers",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "pyxs_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit carryovers expiration year",
        "documentation": "Tax credit carryforward expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_TaxCutsAndJobsActDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TaxCutsAndJobsActDeferredTaxAsset",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cuts and jobs act, deferred tax asset.",
        "label": "Tax Cuts and Jobs Act, Deferred Tax Asset",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_TemporaryEquityIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TemporaryEquityIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issuance costs.",
        "label": "Temporary Equity Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "pyxs_ToraySublicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "ToraySublicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toray Sublicense Agreement",
        "label": "Toray Sublicense Agreement [Member]",
        "documentation": "Toray sublicense agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionDomain",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "pyxs_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_TwothousandtwentytwoequityinducementplanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "TwothousandtwentytwoequityinducementplanMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two equity inducement plan.",
        "label": "TwoThousandTwentyTwoEquityInducementPlan [Member]",
        "terseLabel": "2022 Equity Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r160",
      "r161",
      "r162",
      "r163",
      "r174",
      "r220",
      "r221",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r262",
      "r263",
      "r266",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r463",
      "r464",
      "r475",
      "r476",
      "r477",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r514",
      "r515",
      "r516",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsCarriedAtFairValueOnRecurringBasisDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureMarketableDebtSecuritiesSummaryOfMarketableSecuritiesClassifiedAsAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U S Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r715",
      "r717",
      "r726",
      "r954"
     ]
    },
    "pyxs_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions",
        "label": "Underwriting discounts and commissions",
        "documentation": "Underwriting discounts and commissions.",
        "verboseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "pyxs_UniversityLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "UniversityLicenseAgreementMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University license agreement.",
        "label": "University License Agreement [Member]",
        "terseLabel": "University License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties on reserves for unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on reserves for unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "pyxs_UnvestedRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "UnvestedRestrictedStockAwardsMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock Awards and Units",
        "documentation": "Unvested restricted stock awards.",
        "label": "Unvested Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_UpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "UpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront fee",
        "label": "Upfront Fee",
        "documentation": "Upfront fee."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "UpfrontPayments",
     "crdr": "credit",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r99",
      "r100",
      "r103",
      "r104"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r734"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "pyxs_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant Liability [Policy Text Block]",
        "documentation": "Warrant liability policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant One",
        "label": "Warrant One [Member]",
        "documentation": "Warrant One."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_WarrantRedemptionConditionMinimumSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale price per share",
        "label": "Warrant Redemption Condition Minimum Share Price",
        "documentation": "Warrant redemption condition minimum share price"
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Three",
        "label": "Warrant Three [Member]",
        "documentation": "Warrant three."
       }
      }
     },
     "auth_ref": []
    },
    "pyxs_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pyxisoncology.com/20250331",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Two [Member]",
        "terseLabel": "Warrant Two",
        "label": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants outstanding expire date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r183"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pyxisoncology.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r183"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0000950170-25-071996-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-071996-xbrl.zip
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M[H#J-().7*UG(4)">0-KN$S'8V[>%>B2VMRQNFL:AM$)0<[?-K.V]RQ%9SE
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MTG!6S2::<>RLC?=[Q>2JG/H1ZC%Y(R!=4=!OX)(.IC&=TG9ZW%;/7V+H&ND
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ME#:ML;8&I)% 2IYK(%<.D)$S@=-:LPDF#R?;L9=.;*+UG9T.,O5<@ 1":L^
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MI7-XIU:()_-!#/37%L*(ALS(Q/#RXL$2745?'J';T$!0O*%T$$?2MU3>$[F
MZ'_XE?1% F>RO;O 7]W!U-O>-QU'MN]H>D8/ACJU7.Q%S^4%?6"WOK,F8DK5
MM;%.:F'IX+&OX-AL<CL<.\B=K^EY9#M=CL>SH[6I6]@8'._#\W*/4;-0[ZL'
M[CD'S3C.UY!BZ"^!YW.000J'AG\./B\J[>^&LZS[+GBX)YYJ'(3M:!,U^K[\
M*!,$QEA? WWH9LJ'V4HN&33_4NM'^^2LG"C'",J=ZAK<8#>4+[M")0]<T=OK
MX5H+D0\_&*HVR#^N:Q)DG=5D*[MXNO;JGI:?+KPNF6F8<%<QZ^]<_4>M6\I0
M-\+UK/T-VO]B3->Y2U5>'@[W\DK!IU0H@>'FEK.U'W4XT@6TDQHMEO,JA6&Y
M^GEMMR<TD@:%+;15D_4HOG=0U2Y,BN:\IV\ROT."TK<4)OKA+D1V<$@#%I8[
M);T_8MIS#:-EO<--]-F0^:X[#H9'C4_8/%4Y:.^&92]BH+EJY'T4>@'G5V&O
MM7NI08<K!;)>\1GO'9ADNHR-M6D-Z2-7A4EKGM/!&!B)!'U.T !:6O2<<"J=
MSVF;J[U3%B)GYE$F^7)_J"/ZTOTJ-8"PX!?>3U P"VK&,AUH!E^8_;=491W;
MZ&H71=U=00^3)M4P16P6U:4(C)*BF&^\D;Y,$T,:XK+N@/!:J UV RV1K#%*
MPUB/-20=^O):%+,J*94J!0/,8U!GM0[/=Z;F.5#"@KSQ^L_.;5]A 7AX]9'3
M>Y,%!D$_G?;MDNVEO]9F5):[JBE8E)N<)0@/M-Z/^Q3M#6CPM&^D>C'JK0NZ
MJJ91[ID=1AIATE?O>#XPBP1<T#"\8S#R@I=+&&F8*%W?&,G"TTD+FU**TV\D
M#E %"\]P9TM6OO^!E6$_6W0!HEYBD9:"/X[B1&S@]Z7;S3I\\T"[8=Y?: 1I
M [%"'VE-L_?AJ\8\LCFD8:RF/QM--$9'5MP!G7I85SL/%$ZDM,C;^7I?QY7R
M;5%]@M8/MY@JSP[>GOU%+NK88]1_Z)DDNU:V*2#\&\_@<\W>$S!/Y/U- 7&T
MJ% $I73JP"C^WJNX07DX5IWVH=B;>X=<S'M*CT,"(L2XL#-3B4-5U-^I7WU
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MDIT?_1]F$3/DD]I#ZF7,\&UQ+[UH,7R]JC;?(-S:;6(LFTE<<YK2)<7>N,W
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MF071O,'>XV-!!I5QQ0UT]!Z@6G&1AK^*KD%Q^>I1G$?\BE\P3-)9$/N9/-1
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M0&5+M$ 5,L:+ZQ%Z 3&('_SBO4G?SQB"%B^27-I)F)_&P@&NOR>8^E3/16
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MO.^"2%,X?!(ZI(-*O1K)/I/=OP+H]Y/PNE#FJ2*"G%3*_I)04^SWU7S5_)3
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MCPQ:JW0<QUF0A$?PGNY'ID0N%L0&BE/!0S2D;\\H#, 8PM[!N?T.YY)MFW
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MFJ[@GECNIO!4XP(2H$O=+PNUW4(0UU[T^Q4-: B=Q;@!^?AP-;%1U$7,)VU
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M+/J95NLLM"EL]3[>N6U/DV+8TXF<FX12Y;A-PCESC"!++;;^%ZUCI!4ZDGN
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MC3F4MM;"NV ^OHQ[L?08Y9$UX63<4=2@D#NIB<S!F4) WR3JY/V#[ E-8 T
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M!T=,9MK0#]LAW&1PE)4B_L$:!"4RA##\5+X3MVJ3G#H#,>XD;B?/FB]>(2"
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MS!%51UYEM;MVJ6PBP#WN0IBB&%K4U&%."#,MR%_K(4&7GTQ&K_U>)H3QI%>
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M!6-6./8M)6)V('Z(Z,S<O3Q'(T2".@D6"M;E<50>\@I\Z>2ZNFM,!Q0*ROV
M3\0>X#F\)**)\M17*\BQZ8>#B^M!+]T=G=6)2RKK7'LI'O &UX8SE"?=%I6T
MA&PKIW9ET\T22IWQJ6!GK)Y9F?VJ>B[]_[Z10_JO?1S<<?O_O;/S55^^_MT+
M2):7_"?]:(B"B=)'%<6;J/^C'"_L]?_QST%Z\*UHCYHX(>Q1*A>#KJ*6Q,.9
M%-(^4:\"5PMH9#?SF:UU<'-!5OV9^33GI!<$.B.DL:M+C\%@O*]-;(_3:U7
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M9\\ML^*.QVPB-I/K*\Z]>LA1,EW!%J*E[5M#'>\%$_F2-BVKN1QXPX3<5=E
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MYX[RP(7LMS6V+=?DOYT(^>.Q.SGYI-"4"1A?X/W3E$F8?/'+/I(H%NQG\J7
MN5CHNPRQ_[F?(?1J0HR/JY'F?Q%Z-3D3RO$\*'TNU-/>@ (8I$7P!3\*&"%T
M!1[T,*2 ?BSWIY72B,Q_,&=(2@3VNQ6\PNPS@-#SD?5=9G,^SZ17+GH]4CJV
MQA>@&'K+X3F;KW&4/OMK;>1!(U+,;,Q)H:,/LYUF#<7;\]P]@[P.9+P_M!G/
MT1:NN\Z@9I7#SEC.J;]:;%5=\V\)I"X$C4W76'*U,(;E\7IU$HE:BR*^Z$B
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M'^&YI^_D'XR1V>&47'@E_,P1GI&+T(UVC?]*#91D&ZPTG>>7V7N"QRYUC8P
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MMR4:BIH?" .#L<N7:DINX*41HR\ES\P&G"?52UMO+QH'-*?M$I]#XT%1#!'
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MZK"+DD6/#8ZR?,IM<S;)?3V;M1+6*MX1+]C/E4A!4&_\*3--9I:99O[)K1Y
MK.E!=GAQ%X"HN2Z!$2IE1$D']'^&DCR%?6,E1>**JIRX_V@KTF;#N/+5Y,I4
M6Z1(O*G0:9O1=8V.9TG;L)\)9!,2:HF80\'--?&]"@_@SG=WY:KJ61%YQ_C=
MPBAM"X/LS%ME"7'IW=<VT(3)L(7DGS5/-@,;_?>"MDV6PF&M],QQ\^S3!@>C
MT8VVNX,S.\!2FP?> V]<]E7? ^U?0>WP5:_G;7Y>L>H>GC-TT,ET0]AC;<<
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M&1RR-+TAM?ES^O09NV7A$M8-F9=[(#9%1 3XI!>&]7?T3B7?RU2+DN?OE],
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M#< C*SMK/I6W@K JN <RBKJ&6@.W84U.?N9-]/P!30SU7=+P$^)X1\^'.!M
MR;$DJ?#,#TG04 6\PM#/5M'5HX!$2D[T!,!#[UNV9%N-6! 8%0#*Y6_QZ )
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MU%S_OG7,'NC"39=H"O""!SMZ:?(Y]04TW?X+I+,#0[Z;09IVW$-[H*P8\#@
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M =[>,KO:C:B-SE-[H'R8__36'HB)OO0+0?'^;*]*P0BYAKN549 ?,+%^(K.
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M*%P15*D](]#FU'.C_U&<,.UX8M'V!);&(3,I^AHKE4GRG@EECF!T.0Z'.-6
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M9VT5'!6*])/,7L"'G\5\I'XPAEZ<_I4/ON(T%#LPL >ZT,3YGW;^9V6JV/=
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MCYW9T>$+.?[MZ*0LA-69W+N[@_F(.A!H*1J).TF!PVL^6%B,WF^::Z7O>)3
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MA6$:5:QD[;)+JQ?[5YY?9!]K+)97)1"0EF?'HFOD/[?>O-PHM?Y\K)DQ@$0
M:]$Q;3SZ A6+$:R7!!4ID4CT8?=#%LTWI20B&SP-)P2W4B*^T>:EIIXUU'NW
MK$E6OYF&/6E G%:.R&.[@TR82_0RBN53.A>12"1/!<E6AM;=Y6E#*?\>D4O@
MPUY=LT@U!B_3G:)80=#57F1:AS]Q$ATK5Y1-]?@,K_U+:ITWJX;E@IRM7/]H
M=5K4*W+%K]WTYB+701!:O]+S#NU1 6A6,Q1"F)-C7_11^AZPH1YSUU^A:RAU
MYRJQ?SH-"#GPM(?\=TBOWVC/OS*N8UFZ86.C(;1R)K0N;"F%F,0'DLW:P'
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M**#-58;G.@UVK8J,1T@U-,=O@17Q3T\M5S<QWMP=<U-A##O5T1Q\Q?D/IY9
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M?(E)6^3M-G-?2&X)*:?#9LR;L<U1FR_5"_GZG!$#RO!C?\)L6M32?XI%'$C
MAB7F:6R5][\;!OM%K1.1@CC\"IM(/67^1,1N!RW.]!AC7P@]T6]/\=S9+FIX
MB+.O=(J(DGCHCW!8:3.@@)G\][LU0BS@_WC86:>[@"9R2#1E(#-._(7E]XDO
M:.?=S9IHE>?SBI4BF5N3N8,X4 3H?JFRW +HCW3;GYBXBNC"'?^ "T@T5DQ%
M\W/7-:.1PASN$*"=1U3@O \5ZM$E PWJ(8^*.R\5_ CT?^^M]<'=-#/+UW^%
M"?JXE/K6_WV#^A -$J[^^\>P'=W4FM4"M4!>J(2"2CR:=3) N-2G[0$!V-!$
MX^6BU']-P/$<0,,<J[(A $47!=>DC@KM#!5_Z9$\6)U4%=ND5;25/O8:(5DN
M0'<JC,:2Y (4O1M<_9S8AG/3$K5<MO9JAOWS_C?X\4 _0>C=^#-F%H=';J[5
MWX@-AGXDQFO S =<W"?;O"?A"P5Z*HWCT$&A>R.;Y0VDVY#MI@ .X.CN-8';
M'>9VA0E'OF=5N@_O>\@4%L]4!^^"'E1?_X%.P? Q_-;RI>AP@J/!KKF9=F>S
M62;.N4J9O;7-;C+&KQ+=[:H8=]B3(K1N_+O44-CJWU7_527W;DNLS-OJ? _]
MQ@'T=-UXMGIY-_ :^HS;^'7KSB?%'J/T/.KH88A>=5&E',&FDW5T$1*#FL3<
M#5>H<!:]X+Z:1?87.;NS*BY'! IRH? !QBPH?&VQ]:AY=5U/KV+QRNQM#N!5
MR8 %ZEZ0FH&PX?D5V_E&(\^Y%J56Y*<PB5H1NO8BGLFON%]WAX1Q_VQ7]^'M
M)^PH9CB-/=W;SQ;8HW7[Q0/);Z!B$U#G$K6ZA?B3^3^KYD2SI(R(FA);("W+
M@NN^.O!S*[:^,OFB?&>TDD="FN$J?,0>DMPB^O6(OG>H$Q<7&A-[3R"]V55I
MH,B9(L_\E30JA)Z'ACJ1=6EQ:K]\2-E;AT:;G^HAZ0K$[XGYJ_"LX5&LIMY-
MYI-)/:70&D:$G:G1-FSH?5CPXUXQ_^ZW:>QJL"7$#-;! 0@S3<M"$>9TN'A^
MNE#,WL:9A#BW>%DA0)Q6U,IS#L!6EB;WLS0Z\;I/Z:'$GY#5#]VR>&HI8XBE
M,-:&@C "Z=BN9AOF-1SD[>JDS]DW!/N$/.FE^SV9-3)ZV)W1>NRS98H//DKG
M[I=0E,5D9:6OTH @Q6NW5[)'1 8&5ID*XP#:Y#[2#QAN&\BS>M>]\H5&52/5
MV5/FR4K*]GG_3\C*=($#2$ S_<@S'?-7)A0J2$I!H@\PH16('VW_]#FS ?K.
MBAZ/C7L"5F_CG[:3Y^35')0396O_+V25M_#[^H]]]%OV%=@\3):\BM@?Y#,:
M46U)T-5CVU_?\@UA[[KDV_YYJ%*I$SNSM2-7&KA]W(,\'R9):XY>>GERB9;$
MHQV)%T!,>"F,M)\_.^16:FQ1ZU[CVS.[5T=6Z@#.;$/@?--VH:,=9NS>IE!B
M*K7+Q3"*G7TAH$V+\=6;7E%NM[XX>GU"HP9+GK2Z_J2(4-2@4XZ_TK.4GB[F
M(K]<5]<$5W5KDZ*C.8#C !&W"G\47<@DAJT=IE/S9?T$^.9]#N#AR DS-Z;*
MGQHW+PT[C*"$VIA\87TJ6(D!!MOR_0#B4W5ZF1M^7Y_H>I"=0N1O=MW4TDLJ
M8_7,-16CXV#2[/ELU%MH4)E'N%YTR;JU^LMWD^O>L2?N&>J6;>I>6X_(D\%%
MU#YH3E55-LB-#N\K/C5JDZWSL$.JQS5P;:*K(_T)'3H87OC5J0?UU&$.?"7^
M\K^*J^2R8TM ?R=3AD5H.E2)+-O58,^LS_^)N\H!>#U_ +*5NV.8;2SA>X97
MWDDF0T*[SSARD[G81)^F\#E-+6>/=<U+7IIW<-,6=;0@TI<(=XB[<A[>0+%?
M_F&4DXC#[2\6[%X<?SBM!W&V?%LLN!XAO31JNB86BN  KH4%'28W;Z6=C3 H
M<*\+O9RGR?*>+8-,ZUF)(G\R'^<_JS[[Y!;WMZ[M-1X(B0(I8.O8FKP'$?0W
M(%); <21W2G(5O4[2X_?[0X)W]SI#WU_]T23OPY"S".K+PRSXR*9W"+WNWBJ
M-O672'0,:..K=?/-YWU?CHHWVQQ__C 2*1F-Z-^MO&E;?^FIS>LDF<-BOY_T
M6.H>O10=ZMPU+_)3]5R$Q4^<G :FD3W8DHH?N 3*!'ZT1%\/GQH.UXC34P_-
M! O9J9=1>*RKE</^)?01=@C<<_61K(#/\'9R .0/L)\2USU^>)3KM-QYMY>L
MT\OE4#I]C!:J%;F9[KT@&ZWP\)E(Q-U@XOSS/KBM7,U<0:Q963TLUE(@9M%7
MM'W\L%;6(IA>B+>A/8?!E;K]$K'GT9(:3E(4A;>Q;-N--\;<?WN^);>)F Z@
M?HDE'N/[;7=X_QFAQ647]") 8!R^.PJBMNJ';W?A8\+A74H K_#CS(LF-?8_
M?)8E/[K-,!K ]WC5#H+(]EU"$F?H=8L*%O,VB!_CSKLJ?X8^IX(5P<Q8$XEA
M/G-KZZH,">$04=>G61WGOTQ];NNQGY\3I((<U<[45HUM*;I$IA1%3+/D=IRM
MZ%.4HYU.4MC\GJXVR7?S3C]\-BOV-?\4%B";D^\04[&&'( G@@]QDGF6DL=T
MD:I ]1YS&I;=ZEDG8/5 +OASJ'=L/;K%#4O!R<Q+3J;<#_S#+PL?!F6</JTZ
M9RR7#SFR0*9#&T2S"9ZEW:(RZ*\V7%S78$"(V0%4[#M)]LPZ/TF2FD!O)>\^
MV:G4,2YC%8 FGVX@UWAV4[%/9+/G+VO4OK_W*7+M)'J8ZZ2G>F""%(TXJ!K*
MHT$P/*, U?5"R=?G*2C#98=9.Z\+;0+=Q"5Y6/^Q%?M8>M2Y3LVWM^XDUHM5
MSQO+*3GREG, [HBD%U!?\MEPW'>%H)/ 35IP7\"RD1:"YCVIOO-K&R+-]4:Z
M3*6P0NB=R?V$SE"%?=.?/AC\@:?(E;_ /2CF7VV5J2NW.N7?26VG.3F&1NPD
MA@,1_A*78G@T.A?)V6,)H[C<_#I*2+N>6%L:>%+'OL"S.=&AM6ZE^)BR;),A
M-'YC(5_[2V=*VY)?'U:>NV%QQ["UB,3I<,':'O:1'DC)/##_XJ>U L>0DWR:
MH$WKNA=;N9+2XWL!;1*H]']N?:R3E;73F:R?=X*_KN< PKP7E&82"/BX0$1\
ML-;Y:,(Y2X.&VO^2;6/R0J3;:&%2"YL;.\?0;1IO0J+2M^"GF9FL8J@9!W *
MT0.^O&[?F5)2*)W[#WQ8&_Y'-5N]0@U;F^WI<@#G=W!/F9-^%R4\OBO@Y@+'
M*"[-[O$PE0UK?R?/P^'D[?(B#L FR#LD3.JE%8*$2#9D0_2N< !XUCVL01L/
M/1AT@BE#KGS_T%NM-?':LY3.: UC#@"1YO@[&Q\!VP%]BU\+[<YKXG6^V//$
MTZ;4/-_1[$NK> .3-Q[[KS?XW6$L8M\>*["N)^NC//DM+!@W/G8 ENMM[\SS
MCV7=!,YD$D'OF+)$UIG[Y)76B"+58*!G$X/OK3)/VE$.0!\YU#9MR/>Y^1^E
MP;%BF UL@BTM(4?G  A-QY!--8T,?@AU2$F) S (J_V/BG:LK_@WU'&4X"29
M<:U5X+(^)-UGK']P3^\5ZYV>[D:;#,4:O0CG7Z?98:8N)+3JV:\=[7U[)P7$
MO7/)(@R796>XK_?.T>_ADVBR*2$OH]#?EWI8&1O!3O/2)++MN+<'-@BK,B6T
M:F*D9=])I@V,X7Y BEZQZ,S6!<3WZN['R[FNXEFK_FQ#0Z6>GYT+4UL;9=US
MC,A)]U4PZ13C+GV Z4)YJ*64H":N;5:#$4RQMQ^23 8IT5YR $M&&WOWOUG;
MA,.C5.W-# C>972?:\:5OJ+05./__*0.5[ WVP0]&T"7]%3I+X4Y@$@95'F/
MV@\.H 3FGJ/$'D=/?1G7OW1XQ"HQT1-W<IVXJ2@J5_RF_5&\Q2-,7@.[3KKX
M<_P.HN=[?%SOT2B$I1,?98-:\5/O)/]8V[!B WH@ASCV.:T?A\2'Z![W-O^P
MKJTO3C][0DZE\C^ZEF] Y,5MVT+)<9M5 1J37Y*@VI#O(N+VVL>/ ]!9;LB_
M?VCL5$-6HBY Q$.S^SOR%48K]B)F:#L5V^4N,O.VH-6<PEWA2E34U_3ARJX7
M>B%O"^0?EJ(N0ZU3?:"(*H\BRW0>7$8C[YO3#Z>RH.%TKC6>TA/QUI-NB-$N
MRS$B[DB^7Y0P?'\%6 'M6 #3KPN0!B<+91-49\Z8Z<T/#R3+G>, /)H:02^O
M=R*&O$OR3DT@5(/U<A07!_K5.H8%WJ(&+R.#EL)'LIGK%!XF/T]/M4.AIY9>
M>O':T&T1Q\[=/EAE]9%#FY_8&A[270[@3*>7B'D9J@-%?]-UK.2.])P8)?]8
MW)R!N>9^A>S;LLL!>[IG.Z)JH.B3E(\?%:U:LX/UW@\*5P()-EU*O%!9\EYS
MSSO%Z+JOYU(^+:_ ?L3-(DWH'5UX\B,\_YQ3<ZC?O:HQG]L[IE\.TII X+EQ
MBP[SRIX3EAUA^4$AT:@MFF__-NCNSA^N-<3=!ZZ^@3YS#8_M%%%,+[5-872X
MN#2\AP$QZ%JV(-/R9YM"Z+US(0\^]'K?ZDP!7;K'&NGY]\:3 BW_E8@S:HL#
M/3+Q9?&Q6WB<^>_M  /O+I G/HD&/*ISQK/LEUU[1$10<$:*_DLC\/Y+8R0S
MUNG4 GZ&_61TOVR;WU,0Z_'64 +I6I)U-JV?,;ABF/9NC&6CB^G[&NHYCE"6
M.]IAF^\<E:%]#IR='=Q$4_?TWDUXS"56KZ'Z&4QC[Z+?DQD+?J9A"ZGW\+;'
M7L'2]_TV9RA4$((+I!CU4I17-O2-=LM3Y,!=K+:4P=X=+\N.H8LK6BI._(/*
MT&O=A']:<];S#G]1F2/9B8MW-V^</\T!A-K<ILP[&@=DVWVCR,8'8GGHL%V[
MB6W)L;V9.P-IPS<(MS<@@M![W$7$>)V+D,9&!5Z7;$"P'+?*=C%(:I^>):5B
M[6>Z&>)S[\[9'IW<PK<HF.-,L.E*)%$?%D0/89_F(]KKWKN-]A1Q92&9M?9W
MYN>Y7Q1II!_90AXF^*90;+ZK.UT9>6KL&7)96VIQI*4PN?.Q):]%;AB.%I&G
MB3V[8BOEK/-$=VI"&XTA_98ZO[^[VH/%$3NPQTM$GCS2:R)<RVGK.9OO\((#
MF#+F_:O-Z\^T[FCFW]D;@2+@V-1?',"QR=TF)K/=;N2[5069+6MMWSX]Z6V@
M1M[S$8;J#!IP7<3A[92-)W6FO_<JM%:VW&:.7=1)AN5R $G0;88V;+(9TIUG
M;B;TJ(K]?2KCZK7OKGC^CDDNNE4'"4RS)_1D(6>8QRA!DUR*@:I5]X#C/KZ+
M92>6LQ(+K567BX=E;/64>#]:?OOW6;_F'70K\F2H)!'2"9& 6HX$[E-\T6?#
M\TO%W.;E4#O$N"7T""0A7S[M&_X,QK2BYTHR8=@LWXCK%_+?J-1P , N6"2[
M4T*,C:>S2ART_,R4YPEDO@TVEYQ[V8QS]7-L'+9*[_CL4SDVS0;S9@#F!F:A
M'/<76JN+$..--<=CT)U/=="\QR^7.?4/X3-0@_ :PR[>=Q*:].E%DOIN5W8K
M-=<EU?O=<E. 6%51Q#?F#_1HZ-!?&7OHX6&Z+"1Z"$7A[=3:[3ZFY8L4;^8
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MC+5*7,#+Y<#/M-9:3Y'U<B'-*FOFZ"-<E<MX\AMT[*R=1[R9>R<?*D<BC^_
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MP"M*].]\!_9W@)."&(8;\*-HJ(;KXF]51D[K/4VGY;J3^6 %T'*6J!3XT//
M!E257;J)TWL9HY]<\5&^ZOL$Q!!EN@7]8]GL49CLA-ZU]3:AG_LMK;(&HS+J
MU:*G=$IE4T"3/&GUP+]JH&?(P]17;VAW&^LR.S-$7/?'_YF3*4#>U-B02CE
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M5#9L6QQ].??39<H4A3YR^XWX[QY>L#<9>=>G>D\?7"X%;FH[UU=]1/9;'T1
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M4%&NI2;!;;)0U[9WE6U.:8_@B\!JY;H.T6DO/7CI^>U"$ZMP0W8;1U5AR>&
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MURYQN>1EMZLLTT'Q=[-:O08$2M"*)3LNX!@7$+V*\Z=V2Y FK'IV)>CN+A>
MGW28]O?I/QO2J]28?AS%!:!^;^W:?U^F+J=I2(047*.U)I[;_3 \IQ+KDT+=
M:<UT_Z>*35J1*$HP_&_%]\V3I_*7C(M1H93^PT/.4)$'R*-*+":";TEL-6@6
M33<".T\?O_+V3$F?Z3 >)A=.X@)^.RF.5^^'Y!4_H;O?*:?@WFOT7.:S(A=Y
M.%:C%C@';V0S+,,1?>#*:[$\O5]=YQ>Q=5$%#E$3GWD_&89^H<"Q,=XDS2V[
M1R0\_J$KNU'[M#3C9EK/[,S<X@6V,A=@0"2,!3G$M"&!<,_\<6V7QM$Y,9DJ
M*L.9ES/#@T!A#V66&/.0K76R_ZN\?HUYI!6K@\@38B2FXCQRE N8%5UO7X\<
M"GP=.]_OF$C6J?S#!23#F%Q O['BIL)V&L4[2X4N2(R]T*8NYYL%=P52Q<7O
MBG !YX@-.OT?Y"5L<Q =;>+=R@=$DYR.^CVRN\ZJM4^9+* "5W6_X7_ D?W/
MX_TR]?N"WD*8(6!V 33O.!>@"G%C);"S&B_8LN3IQ=GN.W?)>?'RE>-WU,,2
MO[+:$+FN6=K_^I!EE"RZ+,KJ^E)!3;Z)*LE\)>Y77DK]L%<23*=J"40%%,&$
M8S[)GTHT^?MW=/"&W >@36!9]2W!&DP8^*7*6#3!BJD2CA4LNCMU>]IE0-.6
M7[7:^9+$7>T.S7Y.,XV^WOIG&7&>*A:Y96]T^T-P0N_8ME]B-T\%?F2@)V2!
MF6],C\]"LFR "K9A5"N[S!?TU(M(GV+K;:=S?UU.Q;W^$%P820_=Z.(<!1;9
M=/ 6^83KZ=_Q[.1.T]3CL*T$8S#3/DAA]=),D*E@2+Q;]>GX'N7<?#N(9 >0
M<DY(D"T&E4,,Z5]$BK#@5+O>-\G50J/XO1%Y/&+==$Z%?D/O]SY(P35-\[L6
M2JQ5]3]5\^("E,YH=3 :W4=*<N^'E#)3A"T*WLY*G3B<T;#DMK45Q!J>> .N
M\&P!OT>HFTH;$4_77DB2+GIH]!(W=LE#YF[7)P@)^6LXDZ5)+V""X$=*:\O^
MQ=[<KH^24Y$?2"9XO28QTTDQ:T<96G@'N4&$%OQU.O,.<S7T\: YI#J@7;;B
M0U<9N$T-J<-44QD]-L,%M""/]_R@AXQNG2JK5H,$Y4_>-5^9_XI?,C8/%Y>_
ML'6=:GU?4K;IGU\+G]/*,LV"/UV#IB'?47%D21+J..LN_6M0B;]-GZG2-7^2
M\!D/+$8-PG!5H&$:],^X82B$;?.^+4ET4A$(M//+>&7^C CX,Z:G7G(?"2UM
M.SKR*_F U0"\/LB%"YA'IRJLD3#_8L;5H1%-T^6YO>F>D6G4F7XE?!YU;]3-
MG<'!R)A*G8<#NPY7FV]>*3P?.^;;,#GMN#'\JU%P ''>?_@N92MB7<7'%'6E
M&TF[4KEK/P,<M9R=#F%I2H<3WGN3?1=?.6,'BON(EG!?-6</^%>>M^ "*-7;
MPVW%!A;)*A-+R<(!SGW6<B.";*:PY=\6V &/CE]%L,'%GH[3\.%(ZS6%E2[%
ME@%8GH!'N>=P=3PC@.G(NH.4AKL-DL\E<N33%%BFY&S@QB!XB N8@[!%H4Z(
M+BY@?\5T."^L-)9*-#8]A99/&L&"8)?WG1=;[")\<Q9E+%)?3)F"8QJ5WJ]W
MI[RJ]7_.$PKH)6'+%:TPEED>'=VBXUOP%";=$SZP__E'F:,R7N:1Z7F&=U('
MVWW<G1@GH"'-73MF;J3!I5H*DKQ"(=RA:,7 P45+IPM<V96BA+&S[_:?2U '
MKI_0Y=#J!>D*P/ =+J#9D2AFEA.<U2N['BJ'[M6A8<8-B#T1K81H1==<.R.O
M7)?7DOYKYQ-5L6&<#18/0W1V<=L2E)E_.0>L>COFNPKL[.Q_[DR7<P'/17.M
MM6=E_0IURZ/I16('G^83T;@'*U/#=;A@#7TS=J6^_ 2=1#JTD!!',OD74!XB
MO[2 WBKC LA@IK/#)%.-GCVSWNRYS[IR/=+;!6L0 $0'@XI @XE89T[M9AL\
MF[I^+]V0/DER48E)]G ("D4Q%N6RGB,9)TQV=PS9[Q!2[F.&)=F>1+!0CZ>7
ML(ZIZ&#CT/UI6DNNW>*1!_/W\;XP=GK(+.N$B-CU_CS-H"9[G.4&2&'[]R#K
M -'SU-^QQ1#/EPHUV#BK+8,G^U_<[4:8=]"-%=A,S ^PHX<KW)"I[5I0X)$@
MR5<3J@Q^)W<%3*CT+REG7D<0&L]0Y?$1E9@HB;;DPJ/O74J4OT!5. <]MH]N
M-P3=^A=Q$-'9*(MJW@V=<HVX7^ONSLBU/HZ!929XWM#NSG1/JR#.? T.%DSM
M*:VQ<S /[Z!TYN2193LNM8^!U3?F;DT+(RXQ'K#R'(; ?O.^8F)@=AG.?I,L
M3# KW]_7)^DCY''X_ZKH'\KY3]'_8'(@G,:ST_:@\KU)7'EQ!2JN1Q1JJR-+
M<C:.RUB;V%QL']M*,9IVI!'P8Q_00@BEE91KT(9$BR%I#QPYYW,TSL(Y#3\[
M_%8A_OV530_0[^!X60+-AM7!3@%I@QY0%YNOS6NU>?IMC_)OH79X(<5LV?Y-
MU:5#9X!11T\6!TE8OUN6@QMS 1]W.(^_*YEFG;(TR(N[5'0'K/Q[9OC*P\8Z
M-S+N6RVC:6;Z_^W<18P6.9Q20^W5YHJ3<8\:@2Q9"KX%>M0HVV7WN07E2%7/
MN9N-CBC<.8[ZFONLYXAL"VX<*BWRC^H+/5E( DR%K?DQ -DQC\%R5/S#Z :S
MJ&@?Y-7;VX'>M)8L6H"S,P<<;=69Z".J72^%.+L@NK+@K58G[";TP7=MUXKU
MC7K[I#M:N#+=[/*ID"DNP"I!45N6]/R-'6=-AYF^O42=:#Q*-\BEOVE_$4VR
M35PEKVQ['^@!_T#XT("K/;-?B>BX*:'22W7:KSA#<[M-&Z@A5>A-GN6[ZS&G
MY7 HO;@,'R!C1-$_WU2\7'WYWP]U0&A:>YQBE%KW(;. T]4K'HU,*;]570H$
M0G]'M.4"A%>2HP)R7>]H%WO,G8E=T^' >#EDLNN^G4^W_$;'S_)%>BJ4A>BR
M+[>[%]JBKWA^:']_HT%_42IZ T=7P$1ZQU,VH'_"_M9A;;(G.PY(2:.D7#!T
MQHLZY+@Y<3XB3%_,GOY*\G/.T%9-3YWME>S \2RYQ"46,-;K<:915%D#*JR'
M>J;D:?O13U*?LN42*I/JT?PL$<JX?SVQ.MS;2RRM6B*\%KF[N!!0AIS382.J
M(N_$;_R!1;/&V:&@Z^Q*:H?F@=..?5=D2#W@C;Z]EFJRL?MFWM-.=/$=G5?F
MY;*MW9;5/9=F5?S[XV+*@P_9S<'B%.?V#I6):D.UF(G=B41IF>.F]MY[D@S0
M@R1,T6MC@(PJ- M,^0<CC'1A_?/OIM7<?B4MR(8_62Z!1[-Q=]"93\-BDNQ%
M"5DS((6A\F4QRP_!.S20Z2RA"2G.LK;%4TKB-&__5(WZ51.GE^4,IO5!;MI'
ML%31[?=(G)/5!'88&4R?#S9E\KGZZDO3=<;"AO\Q@!5.=<&BGDMV*JPQN  <
M!&J";#;,C8*Q\UQ1NZMHDKU/J8^CQ1#N-UM0E\3J%XS#A#?_"2MH&]4ZHY6'
M5F5DYB+:P:*VEJ4Q#RC9-J/&,.#8<UOFK8?G-A/1S3@SK99L%YI&=ZF1IU#'
M:B&*4WE[2K;,->%4?95K^H^H?1@P.Y?U3Z,879(D?5/^2-=3^3KDL#%?,MA2
MM.MAL0DM.J&2T%-^;UVZE9ZA>>6YX^G)I*3T>GO![F.I+^BQU!/&LL1UZ"#X
MDC+/CY*3F$(Y-H8Y2U5#K]_^O"EQ'M6,NX)S I] B< #*&5=J N]1-..\K_Q
M#!X!SQE((W(FI\9&FZY4:PG9CI_MND<[>'/=7GO'3QS_==M!GNBX573A,*KE
M4!_;EUGD[#_=.L0Y2?&M+)Z0_CDRVO4&\N5N!R>)(4_)NQ/L1_0,6ST[NSCH
M00+OT!J_LLO!KAY:;1)>_L!FK=(IZ_KU@77R/$/\@OHI9XZ-<Z,VL1S\9#JT
MWQUQ"2F]?)ICD?J=7ZGHM!U0C927R@4 [H,E?AQ;WG2ZY*,7=^:KLMCLA(-S
MC%U9<8[YGP;RCMV6"OTB.#+=F&Z>[4+MV%BV_,OCGV&-6 +G VV%9VD.P]6H
M1JUWUZ9;;.2'2I*SK-"K'3N@SET@YZ@DT:*!GCC+/GK]8"BDOZ=E'WM)#L_I
MA_0VA/[G).^!/H30E%M9'7^E+N/Y/A3E' V_+%.9IVETK#MIM-'Z<Z/XK#AQ
MR7KPQ_92PW:U(ZF)J0XWEY7]-58J4W_("R&11OC%44=QA->/&1<8O> "EB0,
M5Q-L3?16M@]O/"SO_Q*P6/?^F$N[_=2-Z&^XJTAW@@0=B8>*KV'@.DMZE97?
M;(P#SG2;FV0]54%CUO9:">X#1:_7:WK&_Z7@Q1S]XRKO'584[#(9[S?3W  ;
MZHOZM]RBYK44 RTIW::>V3TO):8.QG31WFN;999"4^MZ4=0;*V+-NH)B#*1K
M(D^[&-5@:I!/)_>O&-%%G92&Z#VL#?LK;WP>]?X"4W^Y_XT_FIB9K;T2Y_YN
M(/9HF9G#XKP_:$U*,94X>ROM1WK9&P9#G>II'_.X<E#9W#:.IF?*L3$*7@C
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MDC/M,3&Z-]9UAX?-NSZM[.U%XHD,])BR2"D=2/SK@]I%N*(&D<1:L,&>X,[
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M7][5/. 6?F7C!GCK[KW)?=UB6JG!@Z=[SBB" Q\^E.O"+6WHX=C1WX 4".:
M91'\UF #!/3@[^(9Y[O/D/,D"'L8NHG18WT'W03=H3+:RWA80_FX_1."JO]V
M4RM91E9TED0L+*5(0,6MZFA?K>=2.(#,/?>O"!RV_$@Z]:!%6H>1REO+/-D<
M&[2[(EU^I/47N4ZPO^DU;5TGBF$(EZ0>^33%$H%0UHH0,A7QEAH3Y^3J@B/<
MF9N02VSA!>)!ILHD/\U\6E6^<^/+&PBJ9R=A (ZFT;5GN-SDI+'$94FGY!_
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M16VF&O4;Q0YFKW, 'H1%? O^\"A,\V>.Y(!)'J_VN[>7+M.11I27A@A'N.P
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M(\M2L1)ZJ]"+-.,I$5SQF1TGL/' -I&?CM,%/QYZUV"%7/Z8-(\9]+SR,>!
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M];-*-9/IO2"D\)QHO$&.3K7:V@19J%AXPTAFW\FCSL)U:.\*EYN4^Y%EI#-
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MD#)TD%E'BV  F:849.2:=']%T'  ]TE9QW9^.P+5V!E(O+[A\@)J9+F%>"8
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M92-/-PC^Z%CE#E9B?(NN[=R,4JW 9O_<__&O5Q\W 7T!CBOJF6KS<[[9R6R
MJZI*:H>M&6H:D4CG1YPB0^JSR0I;89Z=RZU59'>1[X$9RF =1CL;L#@:12C#
M/8,&J:PU1Q[5JB310C=M!#M9H=?28<-BL:WB5S;;G&$& *Y;DC^_)EQ\D;=B
MF$2^K.*'IW)@"Z2YN=7<@$BQ@(P3M/Y/M+#?'0U0LD!P@?1J9M2B%6BP/$)[
MW&Q]!MM+O_4D2$SM&[_=$S; $VE2JI 78!O4*'P;]LY5J\97LL7]>6TF\/A+
MUQ:(DTR0)0H/XQ*YZ1R9GOV<#7 JJEE\$N<)61W$]CPTBGW] XPZ&EH0A!4V
M%+4N1ANO[U"H=K1>4H/-AWFJ3^W3FY=SIN@3FZ\Y&9S)#YGE)'(XP;N*6N ]
M'"#2L,7QHP&SO[DX>5%O_4?JKI^HX<%V%NT\J]9J%YHSR:7K6Z4DPHQ;D8<8
M1[I87#1[YQ_>SV4N,V?&EC%+TN*KNMBCS&_(0[YTHD!$B;.:^F=-K\_FEN_%
M$U8N,J>C$'6OEXL&__S97547LW5!K'D0KUNP5 ^B6;T1E5^W'$.0+9@CI< W
MN*-FA@-NQ/(!:>F9RLJH*VIU@ZUHS,Z,L-?*HU?X*(%L@PBCL [C%XGR:A%/
MI0M53QGS6XQ[^-A?W6?\NHY0*\#,80,<>4(A_&!IF*N05I*[5Q;^P)F!%ZV^
MT:<%T1)1N"7QF-K5W5U*V5?7,Z6=TK9ONK_[502QK+=*::/(!(D>2)G"U0./
M^7K/B$7M=!P?O *\#?IE'[OIOXVFEM,$R/*$G*90!2FNAHGGW077ILK"'ONY
M Y6CLYBC,3QK03#/2:.@><D<R_N)LH,)Y$/R('RK7*;C ^OA&J2$#TL;S6I'
MG7C.$F2(=MVP><!3O%B4%3/6**Q;9O:^<D9I#785X<!, %]"W*4U$0R\I>3Z
MG+>V*JU"JF[3WS3"R8,?NI!>.P)A-]&WS83O$:_H5Y;M#X4/(57*['2QS@\9
MG?VCC"U:#OV"+V5J,.*Y B98QD?AS>NV*/6;:\N#WKB--E2G#C,OBC2Q'$Z&
M$=Q##XQ?+*WL2=!NVRDKAJ1<X00M^AHM&I:CQ/?(46FV;&=3WQ+?;43F4LC4
M&)*\W3$P-[/%=!^EL '!P*,EL-?I1\J[/)V2"&]]=.4]Q-=]/-:2:7)XJAZM
MB. .O)WK6LM/5XCZ])69=S^6?F<<)JTLWI;JEP1YBTR:]+\/$#D$.OS$\<33
MS6?;#&PHY=CG O\-AW:5'[JM#S4$#[][Z2F8+W..!H&2YX(51(Z:!CV_09\_
MQMLX=EBAFY!0F3%JLX,!<<=F*_6]+K9D=+;SB+(:V0!>M:-?SZT=OZNPI&1/
M>53Y_8.FA^!F#&2-CC>G( [25LA7"4?=8(:#[H3PN$!7HS8XBU<7]N6/:-S!
M_1_WD[!WE!;#O3PVKXJ*/8TCI.F9S#V '$OUTF[#%?LL)]J1GMXN7!H\DN>;
M85Y_]A0T\9EJOAUGN"TZX\H2&W!G$?=)A4%9OL9Z0C':?M2J,GG\6?23)Y#-
M*)4UU._:U/.B??Q<7_C;5^96Q&Y2P0KD$X^-Y2T*_"A]EGG+Z'\L?Z2+T: \
M83*,__SRAPKWS==_C*[N+G^D2Z@V/2DV334I_IHM,+.Z7+ .OL!$0QRA9Q&J
M-#2JD(;58+4%[VY^PZ$.A 3\\^:WV^20J>!X\NN?@^G"_3XYR8IU\%/,:5Z>
MRO-;AZI6.'$Y3,*BP[KIJ1]5]08^O[FDP,BRW0_XH9P-. "69W6.7TZG- P,
MOZE#)\B4"#;AASDYYN=H%/EW%/ -1!@,6?*.+!QRB<B-4[3<.>KT$;HSM\0&
M6!.QO0.:S[_R]-W_DM=]:X=[>8=1"PH8Z_P6 B1>9.**7F,9*ZY;HE8DQ<FR
M>))&74OF4.6/'ZAQFS&<1=:F @%5"EN.]2,+/$0)^-ZZH] <WEK5:X^2M#G1
M@1Z^!5IB[+Y4#8KAG^-.W0*K'L',"JHUT WE:ZS&QIP8^4A3/,F5&%F8SA(R
M #:2G;\?4X_P@5+5_'G&M[U6V8!B[+(^^&W^D&\BX>BM[R.X)+>,^O%'O/XM
M$J@M%;.1*K,NI,DC_X?KS>T,%: 1FMC6>C8D72C.3D^>5LF?LIWN3.Z<&L7Q
M(P5=6?S!!-6 R#M*C)#W#C[XB[\P7[D9ZV@JG-8RF69?R^'OEOC[;Y"KNRM[
MP(WV'CVF^<^-CU_3&];SYPD.N@JCE!>B4LW3-UP>Y];+O]DR\#/?EF^>.,$2
M<^%D^@XA;R^&T6W(7NM:[F\W&2@G?-)LM/AWB#HO.&M0AB[*ZA25I;D11U90
M32JW>AY%_1P>GG42;ZV.CH%XS['\4--Z='<.#SBX_UM6D5R$ W_?7,AIHO,C
M^-E I:8[)84;_7Y2WF [9G'M.=].0N+;:O5,&E1/Z(-^KY?W.,+HV1]<%1M@
M3BS<8N0I4J5HIPFP-]&^&?0F%<N%Y'CZ2,,!,.)!D/ 3C=0<X'HOD,2]4[6_
M)X(;L_LRCYWHQ68-B03=HU<?]%<%C$R@?I)YALOK;2^2!^O5C6^3FD*H"9G^
M))#&'/Z,&"^7A!R<P3_%!A1U+J\0>4)PI]PWU_B=4$/?-!]?JL&N3;X/\3O-
M\JMD'<26_^(JW7=K'I"A%-J<FEOXV??Y^>;'<HM)#B!)*')2A5N0-T<$OCLE
M?P/IS0ADIB"E.0RFAJ".;*UG UR^_4AQR,^Y7_YN&X[_+H^6%TNFNTZ%O,74
M<>@6Y*/*M0=_G+NL%.E3 -1 %<(H;"'-KT,V?#Y0R['1O'IW'M5&.P'=8(]\
M2GO-R6VJ"&OO+(.S<VFF!05>Z@_TP\,Y'%#O[MKNSDLDVL)".WOHMCMO/EPK
MY<[ YX."7*7\\-.[;P">\>"DZ52^7,*S3 ,+R7FD'ZL+4YS3! L%"E;K$XZK
MUD^X]#ZW%2]YOWB&G!@I-O1+SMYLF TX@KC&.D+SF"K@-C&?[ET^_\H:U7GK
M-8JE;E/(E2V8_:#ZJ];UY;.))XGR]_B/'0P(4(%Q:P 6K+<BJQ6!$8@+A?-1
MLY*;JE>6(U[3#D1_8 ,*/$L^Y!N7Y;0;Q^7^E@O_PRC899ZH<-L#Y'WT,R$>
M'NHE59/]-T*U8=L+0$9)5&T&2>(M6'R8]9LE_KT?5UJ*$G3IMM;F__S)K]8S
MZO;,W_:Q1YJW99-W?GY1OW7#;3=W4S/)J=S:SCE+H+AX9K[+YI)4JAHQ>XZ1
MI_128<QD-?@4.B)9NHB .MZ>XVSI^<+P4HQYA_C0FX4+6RLP/]_@54*O;DW
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M4;'Z_/V1WRI"F[:'81F0Y_Q!]V\+9K<CG1#"S%*$ XEEGH_0EJ=EWN5RW-%
MEW!4MIYF Q(PU%Z@)7UM:JVQ?3\A,42JM&;__:CUCMNO7U,X70'O+:)B+Y<)
M98MTTP8"ZRLQ/+J!ST6GRV)&YOZLR.L;I3Y-/7'P!4;$DRJBR?= T$B3#_!_
M7RY\W']#%L#KSQWTOBK/;!^YE7"IO!X7O+/VSGY?=OG+#W8L1N>Z%D0.I-.0
M-'2N*U/-P-PHJW!Z&=%)=V3U^@C9#X+_(I5.Q,(OGLZ%:4M(0N9>H999+P<;
M%<#97Z'YBP("6[TU33,C+7"X.&:]1_=J3:"#D&SFN;NLP:G1*#3/Y$/>MS5K
MH2-F%&[)C-(9\&>#UEL985=;_E>?'+(G>_(_53: KS!GO5"O:J7"S7K39HL\
MBN\742 ^<MYBHV88(XO?:FR :,X9F8,:(G?,$7?]XLIQ"W^8221(I&<GT-<5
M.G@CY>V/WK4,WB;)5= GEA#M'!5 *]Q!5@5.NMWQ=K6J:!]/%R2V1D,&-#>'
M0MB ET+TA>NW\'K;EALU<?DH?O@9J%JL7.Z;A%;'L1,B5YPR*J&I_[DV9:E+
M_J7^QSB,AF=QRQ#\W#: 1YVX?U[J;TQ\KLV4WW=Z,Z&VS1#W$AN$F\R$K:O3
MC%G5XFQ 5Y//Y .OY<[:2963V$8^OH2PM57M7S>,- -UF5%\1IJ /=F3_Q_(
M?E7@&Z1D;!V.#R&;U_2S%!>ARR$+C,YQ#EU48;XM%6\XRP8X*M!B8>774?AJ
MU&H821ZD>%8ZAX(.VWA2I/3LSKB+V?8+-B!)BL_(5I:F])^A!0]$XTI"L@%W
MTJ!=9C\G2$;8;5'&%3; EA<U_Z1VVS!G'C3I3I,<9*"1?&P ]@AD0]8V>#]S
MDGFNH7-;THD-&)F(7C_.9P2[CX+MGE16'[:%'K*C^O>PP+H$S;[-<RMJ"QC'
M(>K%U[ZQ;2P:A-)1^PY&DX"]_O!>S: PU:M!DT/DEL)\OQ@G7D,'M=$F)'[+
MQM8]R>K+'()UKD,@\]@:!PXK_)OF,[=>;?;U,PK'AYJR-2*CJ.?( @W,BW-F
M)%860MOQ+X'D/S]YI^Q$WZ#R=X3$PK/5DQ).H^6N.9CWO'V8LIJ/:-#D,W/#
MV&V<!9OZE.L?Y," >3STA5)6L,BY/!,8%@/OQ_K\^,;IDH,Q8V]W?WXT4_M5
M/[&F/DSRRZS\;%E!P.YE7O&RLV,5+'&;4T1O/B5'6K."<XMK-U]F.ZDE<$J3
MS\C3H!<M]T<R(^R2U_>KLK/#^K.<VW(<_W0F'_%0!G$JOGW[?X-C"/ZO)1!.
M E(52'--:V^'%<.PI34/>Q:W"\_8ESDQL&.CND &AZ5_]II_S3HR-$G01]7K
M%@I6/6K", 6L'S1WH17&\;,T]$FY>R+^'Q!WA^/.&?ZFJP+W=<-\QS@<7<F3
M!\0\URR4^L);KDX8TV;6 1&!/)7A99R2';?62:X-$7MCH#<.D6E]OQ4#?J?>
M9*IF>C7FNV-V(ORS=K(I5=!EG#ZDX)JNK.D#.5 K@B?;$9Z'3EU9G>G-[%-K
ML]8 )A6W1NFJL@&#*E1@%!M0Q"RO<P_Q$;T<WBB_**<-%ZDH#[!YN1T"I/04
MFDZ=U5+OU!9HM/ ^*@*5P=[\:CC0O>F&#&DK,=)T/Y,^U]/R99&ZSHEWZ34G
MQ6=(I93'' ;^XVBA[?,@33[CP0Q0 AMP+'&<,U) &<^39ZTXR!IV?M/]@D];
M66<#KF>$21ZWS>7\4ZOFI*8R0PKQQTB37_@G<VQPE&,MSDX8$M1*W5B[N%I4
M[D>D8[D%=V 0),*1OAFO]SL1_XF2A#\YLPV4&;0GM@<XC>.;.$IY N]BY'YP
M@P+J;(7134B%KA)=B9OD1?^W-9@/8O1T^W2;0",B[L_EUKK: X->9,+"7* \
MM*):EOE&9$8LYA9D(&" 'Z05EWEV$^QX@W"OZE(!E"<J)6+NNVXQ,5DRH^P'
M.$E7?XK3X#3,X['G9=NH#[L:U^4-'>2K.1ZH2!*@JI?2!DGK$XV]OC%N<KK2
MXB]'L@M):L7H[06C!U^S19U%1=U2I^3T1">$1P442F$S'K,JH K.+60P'^+>
M $/BX&ARA#\JX7CC+S&*VB]B;#G3$XLB09:/L11(MF\)LD2O$IL']4>[779T
MWS=_/Q_KN,,&^">9O1$[JY^+CR0\RY-IZ&DDN$HVYYM\\I((R-LPQ+?PF8[Y
MZ+$:!TJE5-LH2+S'I?(4-D!=K?)JO&M;X WQK]).+J_^8;8F[E(/M@*J.(@8
MM?'".:/C):=YEAN:6FJ[.+:_Y3.S1_+YYB*.P(GG(A66$1">Q!FH![T8/JL[
MPUJCLP%,_W2OXE$"-J)ARD'0+#D<T\ D1F8DU#;V02;3I1Y_&EN$D=+S/DA-
M5\@>%TYCF7<R&"8F!=RPTVK5O9#6%Q8/HL#?PS$.5Y"Z&!%.U44;W#W(I1^<
M_HXK++L3.9,!"^0HFC$OWJ?(^.L?'D,ZU6]@0H:3+.4^#K/*?1*E-)U@ ?'A
M,T*UZIGI/X3*A<TE1"_^^H+-JW:CB_FZ3_G4)54;$\;TC5D3P;]B'1T]!%^.
M0HX(BL+4R+0:1*9Y?8D+0BC]C'':E$?\ U_]BMO#U(DNCJ,:[RS:4/N^LGV0
MSZP/5\P&+%=.\42ACJTJZ)06/,0WWK]1MG9BGO$F#I47F*+6_F&]0Y&:_]4T
M4HFBL\V84&ZPCWLH)H#4!MFX.HQNNX1UDP^]_N)K9]WG&:FUS_V+N;6NNYK=
MIYCBKYF7I(Q6'Z2"[B@X5S7;W.& \C]P1^)_((5KD^X-=)DP'/\-R-&)4:B;
MPY>2)?$$/*^#U#2<#<A86@;2?%"O^]Q0O$L9=^0^WC!GH'RL2^$GLU:D.B,Z
M?*M O^!'CT?%/G!6Y]_R!N_/J&6@:!(R;]^Q =KDAUA.O/X<*AR/]^UE'2'"
M'SM<8PF156$V=^5%/F<_Y]-=MA<>N-[<&Y??*8=^IWS0^45SGFV1$ZTGK+)@
M?I E/"#CV:[7OEQZ5%>M*MSOA+TN:&$BB..] G.:)H+]H>'9Y+L[]N7-IG0Y
M2_?U-A]>;<X A_PI#(N?,E3K<>Q]:L&RB9NRBV@R*576C[^!G6"@X[\4%A-R
M7HO1W,E';4C#-BU^HDE*Y8IR^)DU:J%A:40JL9TO0-!E@^R9:1D1&QYAC_G"
M&9&.MSBAS()Z_&&!\\1N8J[\VNPK)U:9ZBW9FZ;04.<XIG,O[;_V:;OQ;C=J
M/(@G5LHE7JMTR,% JR6QWVM%D3^[EVJY>TLYW2FP\S#/ZW#\<F:8[#1P<F4+
M+SS8(BK6D]FML*)O$ 6]"0(EN55/[,Q=LC,LN:IG%/YG>[3XW??E\5)_)5V*
M"M(J*<Y(\WG@^?_<U,=_@]CFTI40 F4T,C&E_1#1)%8GZKB*5;?X0\(]UKH2
MQ_P']3;1$9AO_1,-V/V+HN>[-[=+R[^)VE-?6!TXQ+/MP@8LJ4P^K;P4^L;A
M=V=L,]S0]"6>#7CZQ.5%_Y:_,S9I/8W/K(#5S@;LGZ*M$0*ANBD/$_7UK:"0
MMF  RW'MF-_<@I5>SC6_K "_X,<AK=?7&PDV'S,#_JSK@<8ASNBASQ.3_.EO
MX>Z%^GDHYU9Q6,U+[>)6 '5G\'6W84:>J-/I^%GS9W/'A6VYK;L"^W_L$I"!
MSJ*%H9'D803'KV1[\KJHLO;M\A,!J";N4498/PGW9A-USF7A\[R__?!;^K&L
M,PLON2ISX_I\Y'(MXP4-LYU?9$_H)YD\W(JL%@F<Y#DU/B^4T9C\]F-$I_ #
MOQ2(S^S#XS:#,K(W0!JG#O>]_A'G5\BAHS/T&\B.OQF![J>N_6C[8=$#[FR\
MSC4QZY>.V^PH3NT3:^NXAI>OG_%U^5!]M^#PBZ7GJ_C@;AA<GPTX0"BY'4<N
M& U?O'::#0C'AFVF79Z[VX\M6?K%R,L#)4EEL0&%T0.>2_6%[QV38LF7K3"_
M_VZ=:Y=LIKHT"8&ZD7\AQ%*(4'0F:6=,-Z>.ZE.1[GM?6:>+@UVOAD@@&#*9
M,B".^K7R@B?GCS&G@B\)E_EFG.<]GJ9:Q4V7LO*BOA#!N9>7$8J:/D AEJA$
M/3HT>>+-9%6L$1JZ7E>1= #IF"3\PINC1/P:BXL9A&FN/=J%T%)[7A;^U=QJ
M/-RLYUZP0O2!%,@@O?]W]07!WS8&Y&J#> >:OV^J@8-@?UB<=-::%S+TS_;%
ML)I"9]0?_X'LG.UT]S^KE\HH4$;)^C2VR(O#C4L3,!DN FP *6GL>O#0S"EF
M$.2E(WW#I$#(NIJIUT:+E6X9NQ2)D2D9;JF=F$58<(CM[8V62A"> ^H5U^X3
M5SJG7'<Y9X:4>KW!G8>)DQR*HNY_WG:K_E48J)C,50\[3=.O/Y-^:: $W_M,
MIA#<":ADCF+I./DV#G&9P_#S)D>%7+)^*O2&*%2LCYE:96F?Y8R;-J]F(W]U
M.L?ZS;!WH6JBT3';\_\@/UE]/O\Z8/UCGB#\>OB#;N3-?^)"@']/L",?(,1Q
MR)8F4LQLI0U(7@/2,VI1UX>3&!0"KND5&U#.!E#K+24SJCU(_^Z#_B/)4K_B
MS*,'>*N"^?AOYB8"U__/4J":8USTNAW%$,SZ_6Z.'CBQ:2')C-J/+!RG@4$8
M-U2=@@XO0T.B%PK<,;;Q6:DBAS=#N"^3?!@7?WSK;MH9/_=Z6EOBP_V1-\!J
M#73MYNYWD&]F'55LY!>[$(SA/)!_ 5@FL<P&$-RCC'V-&.I2$:BA#)+UT98P
M5/ZI[4"N?"]*[+1YYSBPS2+KFPEM,8LB7A.Y69M'0\WEKJ\&T=T1#[M7+R:L
MF9<,V$62Q7TL$4[V0&IG*[8+^M864DK+F3P.;/SV,<CKL$;)I?)WHPRT:&#J
M*9I9@[\$@V-EA$O,:2,8S&DX\,NL;H*?^'LVX.<Q7Z;K*A9 DS&@Z4^JJ]XI
MB4,Y+I01Y.%_^SU2]O'8Z6VBGV--3Q-#2:,+/5%ZB:6UU7D,=)O,,*2^;)R;
M1B347.Z 2#=)@WN%.51%7AS^"[7A<!W9@>,]@6%^5+O@^XSJQWHZE9:.L0PG
M;D6NL,08C\B0=YY;/ YP^,S(+Q6=:/P,_CS##MO/<\Q2$S4I)3?@V_B^_;'P
M"QZCF8A!-^N[\_5R@= NRG.)-E_8U9^JML:VFTR!;4S"^%%F>NT%A&;/H>R/
MM.>S2U#(XJIXNI)8[+CZ.H(X.BA&F#BTA-P_ +Q'/I$$CO\B;NNDVWN^:1/;
M!>-G#2$!-"L"C';W22_V^6F#O]JG>Y]$C%CYV3$MMIMO'K.W"]OVEU*!#D]0
MDZK-Q9T\K4(HX!XEW_Q,YH3H*VCW]-<<R\P!?[$\"0)BY)1*1?7O".>I3%'7
MX:WU[73]26QP^A5:.(>>!M\ U3RYJQ1CY406=F0EZ]J&!M!%$(^+OBOR3!UQ
MP#.*P];'=2$;#LB@):$YSMA_.A&L-4,(U^^^9B+N/=!";P$*GP<P5OTXGI^&
M8G&+9"PB+^BK6S4HJAC&BJ>;]]FE=LY@J%W:T3N#:G#3.9(4#R:S.54CZ;=O
M1,I!+BWU00;P]UR#T#B'I'G<CX7VEVQOC#2R 19N'L!$<2]#G E2!0$D;>'1
M^[:CKP'=Z9!AS_8'O')OUM\HL;C65F!)0M W7@;0YH<L 7T4R#2=0E?"RS"*
M8]O6EVJ#+SR,R.K/#YPX"C<5ID;J#EC'Y) OL];=#_ON;P1#^FKQ4^U":V85
M:*;C4"8;8,H&V$#FTKPM.9RS@:S1((1(?KOUNK"]&KX=<]19K&)H(TH9M!%0
MA^0C37!LA-3]\75K<<]&*ZK$UE:OPO&\P[3'3O)V/87%+66?3 Z&'#:X_ ;F
M/LP:9$6CU[;!MI#U2W#\:<NL@H.>" .P0@>E6E,[=LKD2]U(*1O02@;KD,H;
M9 1\!^I6-R \+BH%&<I!T^5OU."_5/#FPZRWN30[XXI>!:LC&RMW]B665Z!;
MHP\BRQE2,!Z7=&'P>=+H]>RH&LD^FXP(B:0+44J4[;L@2AZU@PV(C2.G*\UV
ML@$ZF7F?PKQ<]%(B\P-2Y9O-V]9NY+TJ,+AS/2+;C74F'C/N@2)UP'A1Q:QQ
MQ(5 *E1FY=RZ_,R.,8.?KHJX2XO,C#2^36KO[TC6>E(90U 2>^^/KX6.\_@S
M=4CM$6:L@ST%JR=UCPTCX!74]6;7>H8-W<'WZ)1C*/3-A=XUZ?_"W'N'-;5^
M_X(YHJ*BHB B".0H56FB(#VQ(2!"#EA06E1$FAAI$B D"M)+#B"@H,E!FH@0
MZ9V E(BH45JD!A(Z 1)*"*EW^_W^YMYG9NZ=N?>Y<V?FC_U7]O/LO'NM]2GO
MNU8B;=N9TU-T4:ZF!L#U:3SUR"^]U!3-(_<6;CR)A-AE@3U#DPIBVN[>/5'T
MT[QE;6VQ$R<YV"11TI)#F*_T#IF7S98*^JP7X>O;AM_)1[!VRN#;QQ6:^_\Q
M5S\Q?1F=9LUK8#19TETEZ(Y+\EQR/"$F9])XF4^$7%.#D,!<(G=VYH@(M*H:
M44 3@8;#)X%7'5ONQ@E;L:,X_*%8BLO*AQUHFQ/G[5X%?ZE]<YOD-<I3H,0'
MOE;="P%+1@<0[#6KWF1EX:FY+ L*XQDK')9DK1N5#[_?5!LH OT]13@UN*YX
M[1,W[Y=/C?1\0Y*8KI__[P3>+&H3@4:R)>,A9GTHPV+D-9Z2S:;>R*A%R.QE
MN")XTWUG#?$1<9MW&*DMG'S0H,G]QL\R[9F$"=V5LV8M]EC6FJ_)K>*^8OG
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M^<4:0E9(_PAM$H'T*/X\.1'H7RFY^*^4_ '8R_9V)T1T%IQUZ:#-W7]<]CE
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M0HD=9C)YF%\F8H @ZD353D!'\%:<>)H&RI"&W=-9Y,W-2?2:\F[I.RH+E&&
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MNC0KVB5'(J9K>O"%9L@<V@DI/FF8B%8?;4(?^8$PP.L*[I?C=0#-79.&7FY
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M&9,J')\EU0XJ?^L7^M ;7C@>FE2/JZV\HD!Q4OV^L@46&T8/@V494UM-U[/
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M5*#NL-22RY!A5HSJ$RHIY!NAT)01Z")T,3^B9-"SD4EBK# _UE^O_%'E_.@
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MV [?A&V>0#W2E<[2N%<<H+':!IG?V,/S%>XNZ< ?E.298(2CCAW5;"I?&B9
M=$ W@T0@05UQU^*%:4XDE=L<!T,$BD VD.Z:@=PLY\:^W=MHX^.F,6"&U>H?
M(M#;;^A[PE_H R+0\XOTE;CM_ELWAU]A_\(*AS$ >7_&W2545U./[)-DU_\(
MJD%9EG BEIB8V;?6*O%<E6HZE6F/W[U;&W6"AORQ#ZN&/[.YQ02LZ5OJ&L%4
MG/?^9P2YLTZIEOT@]++TDV2O,&?N1TR;<9.*<C7+,3[_/*];N>^?#:5;IZ'"
M)-B7EJZ/_:4KRXB\VL=+WKI# )9C[F"F_R1H"%[P=<'/H)XKDEH=EMJ=1/;S
M5>BU&11?!&H]B[Y.'G+O#$3.MLKC "L5^-<@83966!]*\IS3W&OQWNX: [4B
MU9_IB>VB#[X_/0W';H$EA4,=X.%K74C&P]AI#\5PV781*!%:!<%/@/</>4$E
M@T:6]DCL4JZL1\)G:U=)F8!P_6UM6&ZF/,_?QXOD14] ^MM3YD):3T$G+W%D
ML5M/AS#S)HY^#W(OY_C,SC>=QQ8]F^27#$].WC!Y7&NPONGX -N-/=@3&$)8
M")%_CO%H29NQUODMQ -"JWF[Z5K8;8MNQ*$^S%P#_SF+RL="5 %>228+DS*)
M<#-?$>@X!-#X=X 7NWX[3Z&/'7(9<OQV4WD!E3D%E=?\?_3\)0)E6=Y+@5ZD
MX32$;7DVDA?,-AXP,I8\J,(_M@3_PRK"ZO^D(EK^I2+N_]^KB ?WP4VKE8)N
MS4R<6L$)U1NWMKXHN+_V>-F@;Q2[)V\/WEN;2&9"]8B#E&(.@NW&R:7E6 &.
M.Z+_L=69EE6K)?+4JN-[=*L()/G0S)E>ZNO:?S<E5%]C2?A-(4_@DA;ZZE]6
MY0>^BKBD3I-\%M+@U_)JTK)?^]$_IR%%CQG:>8^1B<\VR4[O!X;Q*@:F@=]/
M=;6?$7[NOO.:USW"Y9$3@ZE#SC1"3*E'73/PU%1UZ)R#Q6.8H#+ERFK]O;03
MJBE6_&) O&;>V!2!VK C158LU.8@VK"VFOGU[S^1!/?4_)J<00A^T;QDECP\
MTDG<CPJA];@&MM86+CJD;X81,CQ5_ 'F-:-N/D4S@TIR;[[/TDK]F3J[Q5@#
M,_BS>T4@D@Q2P%,49Y@R%[B;M*\F7063(\7ZT7VJV63[^H_IC''/5TIGK84$
M#/<+&U ?Y$_9E 0AV.LP=S\VXL-HY_O=JHFV-6FA4E"=JZ\M-[:]1W=B%-8C
M?-NYNNTCX?O.!_M!NJP]ZE/O'?!7%P2MF7R&1C;GT$-(YN )NRC/][Y/#&M3
M7;]KTVW-W4/6]J1!!ZUP,4W<ZI/AX;_X629?UV ;Q?<4U9?^%'Q>KQCAD[\H
M.EL3F0+>KX5,6:=@OI@N(ARA$O"G"%06<&-% FGHPFK>^OCC]YD&(]@F:&W[
MC3FT?C,8"(^<)O+)[M*^#MF_+ \TQ4H>2-E%#_%7>/,\ #H)SW4[R,QZ3O24
MC GPT_-NL'BN%+S$^ ?QB@D-/;8\T[SG)=;S2*,/%_QA]K6WLWK;C^?S<%E[
MBU4V,7!"39 ".:5=-"SY?-?*=$0+]2N@ZS*FA:K,F/J);^=N^0Z[CJ<B+U]P
M(TU'P;W5^8=\+T*.\TPY#EQMR2>07X_H/$L!%ZC(5$VJF?TD3%S8"]]W5^?G
M@HG?.L2O@.%E]EDA124I]84_KMGW",W77G@<$LJJB<BX670-\JGS&OYZ#8!?
M%U?=FJ6O"G!H95\GV\+<NY.:/3F:[WIINY6]8CA4@6N@FQ$S)7="5]:G!=P?
MY]LC\>S1K# ,N[4(+\& ?EH"V?U'FKC)OA0,4U'3Q0)Q[T5F+20KT:BFQN)"
MC+)N59YC_9;G!/CYN#8''\#BN)]O&D01-]*Z4'7IPF%K7L-\DSU/%V7+?(#7
M%A9/'L66D\"OE$>L%6:@GXPUYS$*Z$&E(P+<Q@.F813J='9T67IB>(RLTE7[
MSQ ^:G4UA+KBML4\0X?@6:0V<>>J:E]K*7=$H(?RBI?+$X.D<H.\$B>PYDO_
M0DQ4?J7UG;L*FK6VP5OX=)D')%C3 $*Y\F-D^,A(O%G=OX]/FDO87YCF^&=H
MPP5_[\&9X3Z'2/-SI",=F*;36[&L-#.AP0:"X<<TM&5*MB_"I=R&2>IQU746
M7].A:KO ,U;I/X+*OKS$7?$O]B/7?.60);*FU@.-2-DWM+V66KA;8*5A=#?X
M\$JIQ2A:HB%!;4J_<B0?O]F1AB@3ZQ2"6.)/@\'EG$3+QEX= 'NO/W)?[<!O
M?&D9Y#P#O.D?'YF$1!W]TJ/MR:5#0Z.ACK*E(=/B0.9BCGT+M\UOV2<H%DI_
M2'..*+(FQLUH/M\6;HUAOT[%?ZG#G?P 44&A."1(3T2FKG%KF\/OP&,^\W/?
MUO(C)B7(("39F;DA JV4Z?/BM3NH:WW"[,$=87P*]C34+]<-I_;"MS?D>=[7
MWR-7#R;_6[-Y_WD>E'_Y/[=,HX1WJ\]LS79B$G>(0 C #CVOLK= SD[\3PT!
M6H4Y]"J]^&-/,/0\7 S3=IDX%<XL$B !RYR;P)O^KW5/AQV1W(Q:1TA"IW+S
M@.^!_O=<]WD!^O>\*^070!"^3Q]P8OS39&$DX57'*F$OL2I/2'9 !CN>EY_*
M)N&L?"L?*:_RB=P'@(^][:8G FWO_].6)8F?[!.!V#0LY\3YG9C8.F/38$E!
M+0'WPMW,HZ"<W_/2H^XJ&>OYO*.S(2 <+GP#QSCL)DX4R%Z&CO&AKD+\,""2
MR&[F+ R[CH7OS-E=11R="S-KLO:[W]%MM!YJBI:9K'(L45 U8F"'3KG(I7IL
MY,$E+]X8HZ[M$:0SK97;ABT%41, 9MPC'M5D.[9A5E6\)@+VO]D/*^IV0]]9
M3WI2OD5,6!EKVZ+:C6!2.;/%"Z=]&C(VEDC<D?C[F3">-QPP0VTFVJ7DQ":X
ML0B$3?7<KH?G>M9C5U<7I^0!Q!Z2I+T&2PAUG6W>C4;DV S0Y5&K5I@0)>@
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M,]Z.&BJ6361+U@F#UW7YA\[>/L;1?;M=H:5^%Z9H:): @]X%29(:'[)$("D
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M"@<GO+"W"%]TY_K@V\ 7*SEG1"#5V%8B^Y2W",2U5T3GH\)%H+2C="H/- Z
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MGT_8^^0Y@5,\I BI[H^'OI_$_B?VWCRNJ:5;$X['HS@<19E%($<!41!01H%
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M_"S@9P'_X0NH ?_S9[_B_VN;\+^E@'\U62E2_XSA LH4FCI2E<O!F2PH).-
M_L9>0+1><P-X^#\6$(UW_6K@9XA0W^GB @XHTB3QT32YQJJ$B['2"WYF(-SV
M#+";8.B_ :4 6<+Z')/MYX3E_5Q M0HT+]60\3SNM9)OY%<W=G;HX]?\J5S
ME&89%Y 5*(1N]''E D"K"A$Y^)XA_=)%+J#9?AI&">?\\I@+H&8,H4DZ4>"_
M/2W<;&Y4%LZ;DR-JF@F=_"P^SN$1+N!O)9SG IZ/MW,0H]"3!E+?)$,Y9^<$
MN  U,!7(D//A.5KUJ:R-3[D<P6#EG3E?>P.AX/./^1G1KTU9/[B +^C)3 +K
M'!VV\7T:P[BY3)C+;/$5,E_.'@1/*_DJ;_ \SWV\&?HGHI^(?B+ZB>@GHI^(
M?B+ZB>@GHI^(?B+ZB>@GHI^(?B+ZB>@GHI^(?B+ZB>@GHO]51(+5?__&_._
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MWH[T<;"*K@9GU' =>'V6+XILDW*ZD'6<M,PR,F!@^09Z@ <)3A@1E@$UET&
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M0_FI&T9TGQTW$CIHW6?(AQ[=1W!=DW(X]N"8.4O35R)^W!VV."O !;1?0!:
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M;MW6OY[WG*_R501CV2&DN4DM-.'3M6?97;6ZN;\RP@.N^>^;]-L ]_N@CR1
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MT-R)*@<H2"Z4>8)%L%S]6#;7U;X[=; XP'93=#%Q&Y34IIC23*!\_WSVF,1
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ML_ZQXF 9GA^/IRT.[ ?M\"-4X<-1L&*"P;('Y/)C@1O?RHV&C"9^$F_KK:L
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M3[TA;O^H;KPJK?LKV] JSN#"^A2X?1^;WFRNS7U;$"HSNR-.HM%5X?'W4HH
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M24SDVFRMX$,1"^S0!\PD+/1R_<#.?(SF^?0NUF2T>K3 )N]FI0C&7GX_2 Z
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MZO.$X]].V\0^=D<)]LU=*.TA^?MB]/B(^2\',C0&-#^:,G3G.R'.,![@:FP
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MN$?9S@UJE"_Z@3<OU?*I^U("''-0P#FGRB958EN1ASS5(,\HAU;P(5M,&&,
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M&5*XY=<-3'P\8L=SCH?@N(R16C^#(Y$EC^<Z$;4V6MUPRST]>!TAZ.T_#!N
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MA!LX # N8EZ&WRI02DF']WMI,Y,<.D5U,_:P,"GDIH;^1AXW@+<_D._$J^G
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M6/%:7W%F630RW#K#I,I,C3'.&O<C9'AC"^HG"T]QP<"[?EL392%[EUT#ON4
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M71>^_&&A][Z3XYM%GL-MZVMXX"8!X8\GTA4[1=T16,*?H<93<M3T"(^QI!]
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M4L8X@#]=13EZIP6E'^OPZ!C9SLGEG3CT\-6A0*[OLAX2*GD:6K6RZ5\\%U!
M(GH[M*0XGI[)/=#MT-QVVZ7BQN:^EL[-2Z0TQ5;4 #%(:0?I&ZEY=RLSV<\#
MH>.-$1=KPK/SC#/01!)#B!:#.[H/$3:.N<";#W8JG^3B=F56FL_(^IMJ;O7T
M@/FDA62%YW/EJ!WDW@#_H)D10!]*X@$#2BIG;A.LMYCI\9=Y,QRB^"QVVF>
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MS?OV.<:2#X>ZDX2&LXT8]PZ\*3I4D-LA2@OWKNL9PP6HN1/3T+*5E8,K>N=
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MEGX!/Q91N-AYRK/$^VJH=^?]08Y(>)3V\';) ?X=7^CX+'X/57P9S;=55[J
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MY2"/Q\0O@(O:T1GB%[ 3XPGXOO01.#VD.MW$YEB8J7Z8;&SH.?LHL_57L.$
M,%XGC8&;X^B07A4#F>D+%!KV#[#*6IHE2^P<: +%G$Z"HU&F;KH$614!^->
MZ*3C&LX*"8I*+TPI,/9!A8[PIALE=N;-Q"]G@,6W0]:RDZ"D>Q)Q%I*,4-=<
MU<';F:WG],NR:</!D8YS?)EY1(PD2WPQ-SHTORUO6K*XEI92CEOXF6J'\BHO
M==NO)S4C;> V.60A5O#+J=B5N',$-O2AEDXSJJ""0[K\1<$[Q!5G6H159<@.
M^M,.*##%];W!:$UM2281L205A3,!D\U\\;9BW89!S>R-OS[6/_"P;PA0@54C
M&"WT<DH+:_EH%$78H;\ZYY% 4Y$S6R=AB;ZL&M[T^>AAYK>D/Y2)HY-?0'G?
MIQR=L\,N6%>P7B!?ZX],A]KUA($?>HIQ)8R@N6(^$YF;E/3?LZ!Q^DIWMM@V
MIJC.G5=/^+YWW]+EL+W^EX-!P8/$R+ =K2UA!:Z_!>DN3/I_]5E!5Z&-\ZIO
M=>(:3X'Y[*V4 MT3[_ 2G6NB3]?V57."6()) !Z8!+E/(4U&,V'SK"IE3BB>
M;)GDM\O"[X0Q]*?@-&LUI@MK56(!N4N7Q/9#O-67Q.U2YMLQ323@7Y#24#2B
MG;0: DZ_&3B0E>MA<J?;A%UXV.F!7RV  P,<]WZ0>T-9=6>B+FG54(2LP=JK
M3JA5A#Z0\5#8QYRIH,"5,SS&;5/N#<+G%?'ZLV[%ETE'<R-IU81%]FK(&LT$
MY'::V,O[H=^L]B@PKUJA1Q51Z7?E0^I? ,(H^OH,=ITAOX>L(>Y3V9*DNR\'
M&;"+. VO5KC*X9*0M3#1CJPMH?V0QD#%'57<L,WNG=!#L8GW$G#(ZH#<54P0
M.HDO'B"J=PQP@LG-6=-="$"I .6A\'4[@BNJ?'?S_"6C+&M<O/SLT[;"-I4%
MS7=US[,H,,=A)],W@B+?46Y7U<?RWQR(/-+@5>&AR4E@?09FH#GKL\4V5A7/
MNB6F5W%_L#F<*PP,()^#>PC/GF2+"-_3FKWW]OF*L3'%++[D:+[\13IN/1#E
MQ60XH,S[Y"Y.PN,"!U%K$ZV,<!&HF"X;MIMTP-+@JB$80J'!P(=,/9&P.E9N
M5#A='=*J79+M:_2 Z2=?H@+&K#TLOV/!CE^1(J71^:TZR1,"5Y3+R2N'QD;F
MUK?LT_>9];>I!;6S^EWK"?K&F9V/9>>L=^([YJ+UUI#6/]^AP"0]8"HPSX*J
MX=B2S1*BV*SS%86S^>5Z\=2Z(>A?E<"'ZTLN*##\*P-1_^+^,Y)TD:U<$Q 5
MF0G 86M&A(%=S1(X4W0-99[)&HMECMRB]!7T4*6=,26Y*VE)CCS B^0Y9D#<
M(,6[#3  _H!]68J$L#ZE1O8E[^5VY$LS9?C^$B *ERH1#"*XD26_X@&I0#ED
M\RT$R:YNLWQD\$^+PRH1T[LR 'N#RUZ) ZWD[2+'9)ENQ&HS2@^+M>A/?X+R
MCGHI,)$X^'["\[+W%M]-@1UOKO$G2W>,$]CMT9JHN)P"D_98@?F%"]4PF :C
MH%2;(.]3DMU!9E#'GQ28AC^"_O$>@A9S8$O=D?RV\SDS73ZN*1P"3EB&]*\A
M2_ P;&KL65D3/U>C]?'M9MO--^Y77Y;Y>$L1E#30:,Z]T&<9R9-Y_H[ -6OC
M7&RZ>IBWFM@J;JS>7%BK49PG. 0LK9P/52L%QRWD/"GRN)_QQ0"%A"66".#]
MMUXYC]A*TJ.4GD%/' W@-/(BSK@NO<G"O,GQ?>?8N-VN7(E!T^*\3VUE$K37
M"<UP#LMJ<'I8H_=VX1WM?O&72R[QB;(M8>'*N175YMMME2M"ULH<</+R$K]&
MUBY+);ZZK>SH#^*\F)7TA166;VE?<8DOJLCFX/7DAMB$S5>9FPD9@XY9YE>J
M;Y^T^Q:MHEYSMM4"5Q=9^\E;T*JR<'YAD,K+U>T>TAAWBNS0D0M);Q;Y21!Q
M 9C(".7]@G63/.R>F+ (<>,6RJS<N+]#U\58X4;10 .')3E=RH_?VGB&LGK%
M@QV%3<>B[(F988.7UN?3QX),CCF<Z TR<]A+60EW5=G&5J-+NEF65MK(@)@S
M2-M$C6?$N^ACJ)2SIWT5=7VLQ1.G?\2'LDI=NQ)9V0$V6) U YA8*5_I]O9%
MQ[GX:R/C]45EY#D'-6^_=!1]A7M&G[Y?8)][Q+O5?"#0)L>_-[Z$G(77&^/&
M:6P6[602[EGBLZ>[%9A. ]G[,1H,X7^#APD5WMDBOY=5'K@[\UL8]\)ZOHF=
M!592KG6A6E!P+;X%<;&=<S?&6!SG$5G30-J Q.J>)%63=H:9X) :C/CU%*87
MN-@#UZY5=MA^D>?(<:'I6P3ZJ.E'681, C_)M<6.#0K,UW5<J8W<,5O0W0J7
M&6Q^/Y%B,5.X>)R/@-Y2Y(T'KTV=%*MG5D)Y.5 VN[K?D,3V#RH!9QCR)<9S
M\ *.LV^*3VL<*CQVA6#>;*&2'!2E(Y?;ZJS7@,N^RL\"=D*Y1T*_R8X/+9B;
MM7VP;A&KR_ANY?\&POUK-5%*Z; 1_"KS,VDC7TAH47U;.'8TR,'IP%KIS.HN
ML:WL.9\">R"6X60A E)B+LB-%)A'J_<!T2$D@$@L%+PQR+T0D-^L4\HV--.S
M=PX,'0?^5HJV'L\#YE[P%FYF*B'VE'2 $=AUO(0^,M(1$AR,1+GA$Q2#5;"[
M/C/V2K,KO:E937LW25=,_%6!*0-O 7[U#LZ]),"XX&F QWVR5[5'4V*;80A*
M]B]_GLUP[Z\PP.V8IG%.YQ'5):E1:BD#A\H4F*=4/8,?8EO.:A^Q"9J-S[8_
M</]1E5\LZ6OH0=U!&1#H\22;%Q]%H!K] !B/M<"3(Y[^P!2"WAD)9"6YU3NR
M'LPAJ)".CAW=O; \E!Y/;+^+.!U@>6$E<6 FGM0ENB5Q[&.JD;LUC*5)(0SW
M83>!\PA;_3>GMLEF23K]T(MGTB<U.1,+5GE;-;^"WN?.E\1\B[SG9RU2<&N-
MY)[\U-C&J]R#L"48AGCV3F-FEDBGL6,#CW);>!7[E7_73-JIZO7G6=BU[8YK
M,^>TE=M<Z^T3'WA^$.3&Y)[V:E/C)L :EX ==;BPQQ'TTY0SW<%@O[4N@IQ1
MP@:+-3RJ#/.G"(T%IQ0')65!RBY@26 8@D3DB8%SL[IYWKF'6_3FE+];?HH.
M5C-S [E-XQ/IAM#]V5F>'PB"*[83ZHXN21T/4$VSM:ES2JW C305X4:> V&K
M].:Z N/XK*H^8?V(:8UF L&<3<6M^:O1E_KK]\7><RT\8G/:4T75]/$>:]O0
M#2^MMI9+HT>'L8V'MCMJIR0'*5?655NV3:#U  ;)TAD1[@?HL:5>(&^8O Z_
M>L61')V>Z!Y'0BFN,:K^GG,%[#SNG6BMT>WUH2VF+ 9G8*/T:YVZKVBUH1:X
M<W5-)Z75OBJ6,^))7\GT0J!B70^?-D<?!2AX@.,QD=QQYWGB&LA)^SG3!<'[
ML'N;=X_UX;Z'VITJ_I\5_! R3EUUO&\*2O<KW31<\$E18)JOCSQ&QLBJM%7-
MVS<:/TJ(25-IQ&WVB A_M7[5PSLI""[1C2&L^^O(ETNHL4_[9B]H!C#FW\4>
MOAX1Z4V5K5@&""1NHN*!U@6IYZF" 'Y3YL]7H >6A OMU[@7.VD3D6CB_4QN
ME-%.%PLJS6BD^=4#O:4KQ9VJM5"*I5Z86 ;OZIGU>"G6255C^2[MD^WRJ9(=
M(K$,VA48/((Z# ;FBS5?H&= A^>+<RAOJ'H^4&]B;Z_S5)(T0Z:\VT;5^CI=
M4RJ -]:(%IK6ZZIK]S]^&N%F!Y?U]ZY5<26=[26=H_2YHR($++=4[WJ!';*T
M+AX2!X45K)'/L: KE,KHS=97'90]'$+3#ML?F#X>[J<\49$RL*TU+$B+[)7H
M@)W/26 ZB[GR':$\[KV5(\2KIXZ[B)XE0;[%!4M!+"$]E>#>Y=93:!%U\/J#
MQV>NDII%V?!&Q*UR>6]KOBC,MWH\QA:XDUYG]UFRRFUUH"OW$4"Z?BU6M\"C
MV.[<:[WNVX<'-9N81\BOR9](%T*@[((A+W_O;Q28LU!!+CSK#@CRD)[?S$,!
M'8*5?UT1!/F=8?9:NAO59?[L.O#JL# &NAH'>^#[7%P3FUP2VM^X!3@/:P B
M!XF/J/.E$;Y)->%&0<!JN$?G@V"P4BO!T1!>@O"TG<C4J;\9:W"D-]DN]-2'
M?M/'IRTK^F[&ZA;%__!?H(;UWVS7_ZJ+&?C7&LUBSG_Z(=N_>O#VCYN<Y\^!
MK[N05><EN/:K)9O?^5))B?SN^N=WXL:."IU?<=Y."0^P<]O4KJQEHBD,1FBI
M#]Y_M/.K(:G.*PMLC*%6I&%%H4'@7G_$ MJIA:R!]<5I!G8N#[)W<WUTN^_[
MZGG^PLADXN!&UE;8-*)?T,3)Z"_-G:4=L%5OZ#;>EZ 'S.0M[$M:35XVVLES
M=LF-N+0C3[6T8F63;E:9V:;.@>6[*QU;9:<C?ZY,6.0X^&NCK$YH?IREX(?8
MD*3[)?<>^.@.8O_-1X*#*Q].O[7%]GXWE"^8)?%$29*=(IV&!:Q_YG?O*HG;
M/LQ>#T^=L,[W\F0C40S5*A'=.C 8EON-#JNT,O<RWY&^S[-]ZJ]2NN;LP?;<
MZ6I2?,0AM?S2N]]\WB2*2PH0!],@,ILLUJH%[ZVP-V/75J /]+7M];)1RMS*
M:.>O%B>KO'>7)0E5L.*E@F&T4G/@B=-9RU/NK<EE/G=R]YS[)BO6X/?9?^\2
MW/_?E&Q>_!>;3842)230*A(!$ N<V=)!?BK__[@C^@O"X2*K;\V#6V\G.*?L
MRTC4$?IG><GW0<5F';:.4"^+XSKR#0)G2LK(2PJ,362E)\_%!.X"*B=3HR+5
M,KW+&6V%*-.$I3";)K3"0[(X-B,2\?Y94LTWO75[QJ1H'L/.M*!VUDKG:B(X
MW1:8B?SU@O2;6>YVTIFQFGT:KLEYMD$:X%1N.UT>K <L"*]CW6)ZH3S.Q(0E
MJ[!3D-DYMQ2J9BO?Z0B?=I;!#6B2$I,N'59@= =Z@#FW=\!R4#RJ!/+/8TQ&
M'FRNP+PQ6^Z4[3)5@O;Z>/44[#G3N+=E1_Q)F\R8O]UK*KD%;[K'*]@GGKIE
M>1P)%K-'_,O\F7Z0:0(JS18<2$>?6H%IBQ0K07$JP/J9($(XN0O[V=4%"G<K
MCG04U!D,!OE3IUD*##TP+;8OVV&/<%=^?_R>LR\7ZY5V(Y\.EKYA>TJ5PQ[E
MW!+6;LW5256!#B:M)B)!83:PT!?M1TCX!!?+*FUM\M=>G#<U^A$6="S6L=5M
M *A _1KY /(-MTF>XHNWC5.2_%654K')VI)XHB%>$^;8&682H/)\QLUDC^Z'
MJOZTX^JJ+CX;GZ1998O-Y3L=7C$W2 O&E#8%I'T.O4W,\X)2S>*-3TPL::/)
MS"_072H_>06C<+G>QLCS%(*LCNQ+&#N<DZ#GLSC!8%/>RR2._;!A1.,IL14K
M[UC>3<,<V4GJ,#+DWV)1$:N#:/WY>K97!.?J)8>4]*._G#5PI9C]2$8ZJ^$$
M<P_X2D=,;FV^)EYSM=I?!4U!I%99#;B(3?8B-"MQ]CGNA=G<K:0-$LJRT&+2
MK1*[/A$D>T&4Q^C /S!J0*+2'5#TC.4GO# V@C-W%LW1.9)6.+45KD::CZ2O
MSK/TY3B>@+M;FG3BW56I?$AH,WET+W%=H,4\&[5[3T^AC4G^RCV^SV.+L[FJ
M@3;D)+#!G(SN$.F)KB& *WS;&GYD?PW$A:*0((.UJ)/J_4+F$7&1WT(HSZ-<
M%43(!VTR)+\C013#G\2%\KQOCW(W#D9HOO( 8DR1@/W=U4+=(O0$*<2U[EFK
MJ7.K%OFR,_YM;\D4@5,^/?/NI\=SB6O*,B72#V72*-GQZ7"+'"1J[O5).D5U
M!R?HJ7"A K,O,FQ=2*#1*\&YLPRYN?CSU;MU*D\^!%I]]3RI0V94Y/US;3AD
MLHAJJ$"F)5&\3N&*V).W$".L>!R:&Q&+4N]P9=<Y=KX)P/J,6B(X;K\:<A@4
M8KF\<7K2.]$O[RES4W,'M@5V!)"320'2V[ZB:A[^GJ5CY"^:,N4'K(N=\HH:
M-%\197F49R!X42>$C^7@7KJZBM=8%_NRF#2XQA-=^_XN]&U6!^6GH#RS='6=
MGU+X[G^V@V\_OB19H[1_/#P: 4IMYQ[C7D+[!4VP3@(@/;ER0LXR-FR#4'E<
M2Y8@]\>=O^R.U+.?MS[MW#JVC[]7*]H1W5/"GB8[([/E1P5F? +'FD.=559A
MKP(3"'R&_" WT[^PM%4#Z[LJA@_I 8+DCOL$F?/A0C8PFN4'F_S5)/37BDY(
M8V1?SM1NH$VR0T8#]QB-H8*F0]:&A+7M%NO7DUUT>6GD/'9/SA3^Z[1EX,#*
MPCU:+?<5:Y-4PU&Z^(Y(1/4^GM#]D<Z6$2&(46RE)=62[H W-O)>^.];+"$:
M!U4:4, *.RW6.H[-B),C(0EE;\1 (ZS^ZQC_;'U5V7WZNC^.1GA"%_V4837D
M"-'(S41L<B Q?]!6C;#\MC9$^=O3.7H-TQ/MH><+3KM,' G.?A-)D&]GP $Q
M4",HF63BI;*=?X:[F<=@I /.*C ;U=O+(EE+G4) 'LQ$CP>0WW4X*C#/B?"'
M/NY0DN3[_CI?!EN\^>5ZN"2CHYT@-NL6@OUL+7"Q'UB;<3_#V!2Q=H1M$V1Q
ML.#7V/MAMA_ZDVS#@W:F+-H:.MM.MAJ>79.AY5@O$!O_VRW>2@6XN".!([$#
M!/14E61D('(8^Z31LB"2J_0([W7=-YH]"UD]?)E9G<?* [H_JA1+$.Q#BRXI
M//". J/,NDR_RW>ODYWJQ2-.GG'.=N+]$.H>LA48?DCO^5^HC:Z2'FKI$QW5
M4C?P8G;!"G?.TS]4:<Z]Q"X$?LJ7>7@2UZ<0^RON-&':0[>_76(%L#Y=HR\C
M#YEC;K;^,_QE#ZQ&VL02O4W<$W>R>]DS_5+,J@(3IK-@L&3^SUV;C4:%G^..
M8R]4\7FZ+HW?SY+S20YWCK+NP/H)CBM7_,T/@.-Z@8LLR=?(APK_[1XS=%1M
MET9M</]0^X!:GJ'U,27D_IL9QZ]8F48$V '\5MDG.!Q<&_UDJD.!X9Q=&9@S
M,WO(*ENX9=6J!;Y(F#QBR5B;D:0&Q B39(?:9-]+=_6?4VO%QE6 )@[8@ZO@
M)0KLX8EO +8R34FN$&4EVL$:[I!]%KX]LNP29^5!I@L5[#S!Z@/']8L/1 "^
M*OX2':_].$Z;MWKG"W#TD8IK")D-:R4@D.YY35EL)_HD )0WB7^+%3D4.M"E
M;N2#-138TJ?;)]9Q?682%B@PU@[>YGQ"+'87,GC;W?WWO3EWYC7MT+HW)=BG
MJHKV46"P52N%90WX8@>%@%]G#'9P@-H<.K;%QK%B%N^D-!S)6GR+1/\S#Z^>
M?G\96T;D;@IO\CE6YLT35CA91VQX]_>7E/N;NZQI/ZI$N_T=!??^JUY_N%V"
M+#;[5KC657@^\/_EN_D7_?%?XMJ-)RR:>H(#%L-%?ZUP??=WP=K_%]?GZ5BI
M-+:J<-<_Z#_^7<)) QT7)"I3#G0]70!7Z6-R_]I<*--$FLBCW)'T#UCI#E1
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M=!X#RDF6P8%P%T)H=[BR\VBN O'&U&376<N9U,*2"4D8.\BBYLDDK(DZF\2
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MWN@_>-T7N1J%%SOM;H<Q#]@_*SPHLF[.HSE 7/8N&:_?E'N&8B>TN7LGP\L
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M]W!&^;[4(^DBJ^X;KX/4*RHKEW*23F;%KP'3!O,T?^Y-,&T4Y;WZ(;-7B/8
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M?\'^L#B[C#W_B6J*;TP'5US/):,>U\D&:V3$N_GI!7XM8*L%Q^M(DVLI?4/
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MO'HE2;4IS,.)9?,6AJWCXVT:4'<Q^C-ZE']WU/975Y7R5VX68![9G/_<2H*
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MMN-Z'N_8$HIIR!=UZ\^K@N@+/>3 XIR:>-"9B!6UD\ "MRA&$XK)& NK^)B
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M0V(K1J@"+"7#K*NEZ%U^MO3#98NOHI^ML0585")MQ12VS\,P$TJ MUIFG,>
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M'Z]_ WK'O'[MU^'C9WI2)XU0>WN&4Q7<0KZ.53;;\'Z2971G9K;N6($G([[
M7.B/C4:H-8A2G&0AV4K  37LFJ\-S]V)5%5XD=+6$V<=C/#*X/9#\UAIL4J,
MG\3XJ0S592M#M<G)4&']K=@M=;M*\*\Y.^<J'\S%#=HU5I=Y#N!$>%RZ#*5W
M/JU6\^0-=[N-5BZW.[U="4[.^YX%[9W#@%K5DK\$K8=:8H.E^VI*Y:&U+OTC
MP"<N3RH]6'ZWF\16FAPG-Q*/A8Z&>P6T3;0AY1H?^\TNPUW!MP/NJFX X>BZ
M=DZR3UE*2Y3F"C$5L$_"I(])"SH_,:IX[2T]=3)8_^'>7541MF?<" _S+^ ?
M](^1)0J)L*.XF2CED,9EJ//L:+)H.ZU=H,3KY_N<Z%%_GM@,L+?*4.TF'KNT
M3B<#'XPEPX*Y6TL<5N+H6._2C<S6I^!-H4F@SC:XT^ A=D%#)V #M$_E3KTI
MY.GHGW7VNY7O3:[(F676T=:X>\.-^6*REKA,#DIIS. @A<N!H6/]3>2R^UW-
M8EMPDZ7:/+W'%Z&EM\85T]:"\0511MRJ>\//1Y7<@](R53,UI*;X:3B#F:=_
M'1?/16^&.M&[GE3^:?+IQY@[D;7A'8V)#W)3.I*LV*L=#/.=L1V^=PJT]^>K
M"^U8 987YX$^E]MQAM(RO%+<"?Y@5:X&89&R<4@$3!Y2[IR)Z&:WRE!!V#Z7
M#FRU"R^0RU$%O3&?@7OMH;=5R>,F619G$Z4NLS)4KP7"Q#0Q!_!2H]Z\?)ME
M:^M<Q[P8]:J!A#64$-^TZ8S*@_L6O0_WQFF43$-?]5-AXY=/QS?FL7'O6]5P
M</#WT,7[B>!^POGU&?J?O&M[2CJ^&-!&-8N.A[V \Y?<?XLY_Y==OL;_*0XO
MH)(:L: F/&=O4T_-JI=U4\+8Z>>IQ&6Z8%0Q7NY?2X/W$^+LNY_5P4!IM:[Q
ME4+?X,)WG@'&EQU8@Q;CS1HK&^ TF3;Y"P?]0QFJH8H/0&L0::7X3?O.[K4E
M4UV6K\2-J^ZX?;9P)JM^6G75KT^0__4)W6:K!-DI@ECN;&;IP("E]-XS=C3=
MET[ 'FQ#*/;Z@B4'.0W,E7TT>1GJY>IJA#6FW?S-(D?>/XV%K(4]<65#LSJ!
MKI*G".EH^)AME/_)M[D^?04;3OMV.KM@C>+,\P,X/V%X&L$E_H+WGA*S/F",
M)%FL^D3;T7^J>!"XS&05<1K-/O^)S_C1$%T-7FL^)&A7[$V84ZLN3X'<8<=C
M T/]M/ AB'TOZCAN8+D)S7]@.28ONB["3>,'81NLHR] E [*#?JYFCHM>=ZJ
MQT"#W[BTZ!1#^$4U=@KJ(<,W">DK_MXE:QPI=FS+P$U93.W*_.-Y3POR;>GM
MD!\;74:9Z29_'K<F?*/#U[!/2:,J.'C#0:XR6CI8S86=F,Z(>$==, 7?2U8T
MW3MLW?,DP%NMGZJCP^8?""JAL763H06$Q*2(TML&8H0G*ZM)PC&P-T1#$L?8
M5S(F0PVW:3?<B#9RR%NZ^/R.J4O%]3!C+S]H+9&[UE1_;Y?$^AECY-3HPEYZ
M[3RM4XV\U-Y>)$.5H1EVVUA1C6Z@X6B-6FWO(N[@3*2+@R@9/VLW!.>Y/78K
M%^-7QU-PV0_$&(DB&E('%L1BI@[T$EV'B(5EK2MOZKFO)IPW++$Z['XOV6.Q
M9A);1>+)C^ V19&^ YWX\Y9?"YPKQJ1/9ONEE_$7:)[V%K_PL<0XHQ. X?1:
M_<<%UJ&C\KL#E:"O:J0S*:[1>!<X,0TR'5"C*()=?B-2%Z&PEU>'#E6A)-+8
M:&%8M3<N%4WR44+DVYZ$\\A\(I[U ,[)R; _H,<$RU![77!JDSUW_%L#>S]>
M#6T(5]>^%Q/F_O#DC1'<+J@!V%D)K .).%(3>B/UA+@F?^1P[JL[K6@X+ID"
M1138J?^8";1^^88^XU>%;')GS*,)Y H-GI&@ZN@AK++WQY76'@FS C_/8K<O
M8/MDJ.)$*-W<FPB;T-K*^AZZK]VJ@0#T_+;JWF>Y-3)4*3QE%OQCD_)WEK@/
M1BJ'*QIWI9$&A*8OX#&?*1D%6*,O:X/OFEJ.@(L;]74N+?*^_-E56B!5Q@Y^
M*K^@+X7WX/OI&_) $_$.<'T#29DHS.\DW1I=T*=/Y)$OTBC%=%\PCCPPRD4T
M9;_U")8J>JO_=>5OR]]7_NZ'*&J?S[61Z#Q^QN<7W$@U%Y@55.([^R-8P$S_
ML Z[U;0X,.ASEILZ"7)CC+DPO@G FR)%EA*;OL7IHQ$3C=@-817$?>@E9)T/
M*:5*2T;D3Z<_6KOE)4)K>>,>GS1VKRO;2?=1[F$O=,J/-D]<I[X@7L_H(Y][
M(JUNKR=,F00;=<XC5$<.O5VYBLJI$1=<2K1B#U^)!0C <(9SQO:D6F*C#+5S
M2CBD6=%1U@GHXCV39:C^4]>O6B!53.72!!GJDA<P8CQ-^T)0U]TZ,B<O#XI(
M4M]F>N:8Y3C0<^H#W#+R8G?-"2Z'?88HVKG(%"\7 /.&1D(?:3JD%R4O3" Q
ML@\2&MO>[JU/<:BE/B<N)UN+?Z'7M=+&O;-FV9A$*!ZJKXM_J$P/?069@0G-
M>!5I?9T-C(;\5+7>FC4_&; "QNZ3#AWJ$E&GKT%K"X)'=-8&USD*Y)W>2IQ"
MQ:V8._C+^&!II?1#:FM@EP5L.7LP![!&4F3IR&:+RT>ODWOJ/IY<I^(3>OJ0
MJN*8_6L92I'()+Y;;H$P\#B?\I9L$WR9OZ_PB:4P,_!2?DH'8>C4R,*>-*QH
M8O<]!E0,9;CTX*@41@(HQW_BY=#83L*]O2#>E+6!_E(#L8JJ\(5-]0B%22)$
M"Z(O=BDBI]X*XG,[P4 Q<]$?6TF'\S\;;%>QFT.!RQ;;]A'B_OL!;_,3"B/Y
M[?>+^8!0NX]^R>O+=@994>+_S'I?(9H5Q#N?TE$KQDK*4SI(4IPT='YZVXA<
M(T89_W+(F+]\2R)/"5!>OA&^BZQMO188RR,OM+F.PJ%83$?X($X7+^HTG&'X
M<_7VF "@,*E-$P8U=*<R3[M=#@YCU-%W<ZZ:)TW[*U]DRXE/03W.<%=#:UQ!
MBG75@F%\#(P[RX.N(.JMXQ;CHG(+9-UW@GD#6^;]0GS\8Y^W"5@]:G/>(\L!
M6^G!:H8S6ZP?/ MP]2E2'&X)[X4$-[LT.QZ0L!]&7-6D>-A9]N,&G?L2N62V
M=H]E.=%68$84:O)&">SEF,@5N@C^N'YOK]5]K_4]$4N'BWJ3FRS/]@TF84<*
M7F)VXYL<V> <=X(P%URG?64O8:4!O"=# 7OAYJD!BSW4^$[^Q$A:BF ]US9]
M]-78]EK?,1([?P$8X\"(T .IEZK1&:7OCOM*6FJV-^KB<B.DWA<6Y&A>-]_<
M7"96\/8C8=(14D"A(B<*QR41H/50 V=SG,F(G;Z>K8F>U:D1:DJG].T]0-R6
MWJ+H;VY4K'U]RJ%8(VC+"'Y73UTL_&N_!$DEK=$43S"6*TS%S/+.PVW;#<R_
MQF(^"4':Z- %P(QO"9[)ND S!4^,\/X4J&P 7*K]B38OB-T-3/_9IP68?IC:
M P?D;T:N00KTVWFG8?C.OV=)[V\7&U;#CH:J,[/S\<+Y>=C>G!QO-5O=W/N.
M<2JBK J]=AT8Z6Z[@#U*_U=+3!3F'+CO]'Y6%'LD+D*&FLI-8L%#._>!NK+*
M=1PWMW7!L!T[V$#0I'RSV/#'LM[_WVE5ZD5"QYVQ2]U/)4Y\Q>IF;$+,Q U]
MS(6?JGJ#:)WJ;W'3/L6LOQ'[]X:Z>[[*]F"DDK?(4(VE=?"4/-%2*$-];]_U
MJ62=(957+H ^L\!=L??B>%,D#/FWFH"6 "TQGFY$+YH&D,'5*FC^-&4#\$90
M! PKA O'%.+Q] 6Y_[GM?V[[G]O^Y[8_Y+9PSCHX <G*E@-C1W>IQ,A0SG4"
M[#MZ=- Y(&AW2#1YH0]A=G6QMQPMIE>B[1_17MF;*S8^F7A<"B?F#O\6>1$V
MM.X'.)LD-="%RC(4VS_P'C@I/HR^Q2DO: S>?6G[!+35:WU#;23KZR3,T)!'
M? 96<ALM0^TN??$O/_B1/K  G=)HQ(FW&W"D^PCU3WM3=^L=^4Z@?M*PS$FA
MVC1%J"[-I7,CHU:)E5QK%DQQCQ@*D?MPHG@DHXS$2D)A@.62 +QTH'_ \I>A
M>@JP>,'IFMA<<K2/[D,G&@<W<5:S=]09/GTOHKE(RI/L1($^&M*#)"1[$Q;!
M('GUYV!"GL2AFZ8013[QL/5)@''XS#VT:$+\JN[=A]*'1]4WG [LP4]+-@7T
MXGJ+SCRK_\@;CX\7>[(DQWKQN_UKY1O=-!(\^L*CGEW91S7#D8+&$"(,[!AI
MY;D,%8W3XL!QVPBO-NF,Z+OA[BR^H&QFB#F#UJ%!"+(X/1LXQ61--]%,WL!?
MEH;;M"<-MRW0N-+],N![IU4M)-JA51<I,\8N =,Z'P+G!I2$#_C22OR>"H$G
M:86^TAITV=0"PZ;/(V0(\^KGKA4&1-Y_BS_YKBTR8^P:L'\EF!',(@[;=&1@
M;AFH6'@E:9D^S>\/$P6?3X%JWC=#U1#D4HN'<Z@@\ ?!07L!IZG8.LOHA/'9
M-./P&QW Q:9D:P7R"[BOJW#3:I0-;^A7$/')+]52CH$)7#(O$4[U>E4<CNA>
M <2^L78SZ0*/$2*#2,@@)4KL"ZQSP3U']UD'&;,T)<6AH6IE0#&<HT&S1X!H
MC_-'1NU(J1KO&S<-3X4.TO=.!>UZ62N?0/%]WKWHA;6N25F^:AWHN]NA]:R9
MFN1$%VT[:.(@.$2/%7H9O\8.H4679*C%UTB-.'8GW@#T&_:[_J$_SB)ZS!PJ
M9;$PH*B.!$5;X.0_FNT$X0:OEA-4NO??4D.DB@PFL>$*N"GZ]'W<0K?=2J ,
M-3O=F7\SU6YH!%T;$QZROT#\S'CY+OH=\5@?;3^^BZ8%-@,7@\)>Y3V?S]?8
M+WTR^HE;R',$SKG#T4WG-&[1AY]DV*0VA;0J9LUFP7B6;;)C-G#.[DO0Q!P&
M?8$J<HU"^\D8\_OXLR'FN#62DS(4 0>M"WP\U H5V]>4STLX*_Y!PH#97"^7
MDD.UF+K1[%WO''Y,8P)[%_7I6/KPT^WD ;.O0/\2C]8Q3U%D&<"I"<I'=LQ6
M5N'('/Y9#SH/O3G.H#MH=.&*3Y(0)Q;I50)BJ^<'V/'GLZJF(L>-5NJMY]Z(
MAQKFQ!8VU)IY":728C?-R;VH"OYF5E!)=?JX-/OPR$) [Y_;(R(_%1'=_(]<
M,7/[:U52V65@=$2;]?N O_)PNZ4R9^J%*?+T^4?KSO[U47%$ 2!<11Q5:HK'
MM2A3B/K<FK<7I(,4862&'ISVI(4 )91\FBIXJ)T[]V.8W0;_":F<53F!I05,
M%)"0A:"<G.I"=R>?'<P+H3VYR@[WN2_6B1J%*=([!CC6KN8JU3TI7J3&ZCZA
M#'6.U%:^-3X7BN[O6G0.>_+1.B/[)O51,2/M24&;<L',0?W'?%4&]R^"#^1S
MY7UT*H\RUAW'Q"P[6(Q%>P=+%DD=E$,R5((3>D6+(_H6GI49XA$"+^G<[9OW
MTK(3-I3/Z"[=#U\R6P\;XX\N[,80-%F@/E8-_X2_-.>('(!)FW@MOHG0A8_^
MV>[ Z+<5R=/.R5A]+Y^S*9TU9C"<91H+U^D8/V];PFLI.[Y\D\]OTNF@'<$S
M\?*@#,4%9^HL@CYP/ !&6D$ MCN(SI0L4&QR:G*/'/=\$V&<O^8M4<\\="&A
M">!;TW><",5(]D*8-W,\^AB9/9K,^J2AVBTQAIOVIUU>SB;D76"I2::F#-7G
M>DE@*6:*_35DJ%T4VB6*M=A1L1OWP[@,=?'<2DY"@JE)093==V5=8;&:,P9L
MS;KB0%=ZKX4B+H>PX*NAYS9Y4MOXJQR"]OK_]K4R"W*C<W=G:#N!E\>#Z^R*
M+$+TDE)CG[QO5WP&U,/6LJ/X(QJ,9C;,R%"OY%IVR% 4G6#(DI)KR+F&_US@
M7!Q:-*WZ)7^\K- 6&PT >>QV7;*P^U01^5^MYU+.NQ(4]^YX;7*2G6WPYUZN
MEM56ZECHSUCN!&X]_>.J47G)Y_ ,^Y A1/] KZR^@3>-BO7HJS3Q.G&ZO"M_
MOO1"WUX"1N0W#K0?N5 R]UNYS/7!D*$["]>(7G,IQAQ**0 =3Y1U&Z)!Z4]5
M/><).L25:;2DLC3Z]350,8GPYR:+T53F]W4VQ5.XZGZ>>G"N/S,DB#]]')[/
M],4YV/#49:A21$C.6!C,Q@D]R_MIN]Y%);[,B(LPGKA>(GE:$F2QTJZY@+ F
M3^;AIK%S8_$GN,&?1?F]W.+)X#(W^<=LB,1. ^4SN54+V.D"DD>EM=*<>8^S
MM6 -]^B =A(/DGO-*2/Q5- ,; +]?*\:[)5?G$PZ/ =,CF!%OJ&X;9-T!4/<
M-5P5N@FMZ.I?K5QR-XU>K.+>]S5Y40M35R,/$2@]9'F)+A]W?>G$TX]X^3>5
M\;;'QN*?,&P(+#NQ:'<XGSY#WQ )5'.:3^4E'3F?/.%!. 4[;LH4K^%MOI%#
M@''$X9"S4XT#+U\).9L1G37\-M<HK[G%XJP3KKT;OMN7I*=^,_@@E&&I 4=W
M-YW7L(^AW,1_+6 TS6V6A I\JP>2<L=5#!!^4;44Z078J_9@,<OABX/5,SW\
MJGYWXV> ?*5\5;KI:]W<>3BYYZS4+M*7#%N-WQ8ZWM<J<1NPO>%.W6N<-(E>
M#;U'KS.U&<80:OT8=G(%62KD@;RW<7#GC@[!!MF.D1Z<ESR??BN!$^75FT''
M4C!&IR1B9:$QXSEQHN=#>=K$,GGQ]:G<<=IC>&9[XTH03LAUX9TG/=CTA)7=
M) ?@V7Z/:+R?5)RO7!GH>&>_SI77+[6=/IZ]SV?BIR88T%YP0B GK $G\B[1
MUQNJA#::;>^ACXZL](U;!P]&T^MJ:A!&RMWA4UB^PRM:J]@,O(@]8!E'W\*V
M&&_7F -&6>.TIWSZM3#T%_[T@2%T5YA4F0'%7];+)6C;*409?2NHOQ^!_PI^
M.:;EB.DK7KBUYNQY& U.B]MP[G<"3H;<35[0F2H/&UMKQ7MH,4.7H?8)^!/0
MSU6<%?TZ:VA=$ Q;]\*SLRR;+4-9E@9.']6Q1)1E@DSLRJO+RJJ0ND)J8EO2
M8:06RNE$L^K&-Z;!OBKD6P9>6.^R)+L#)EX.;28/<E.@&&B^[,85JZ&^EH7'
M3(L!SP7<]Y!JE<!OII"[<?L"9!J.7L_P@6&MYX?$=LH=LVW@ D[Z@YG^U)""
MH(I\E'F#ZJ N]OJ)^0!9XPI5XD+EQE+-[LI,/7F;JIY*L4[LKEV78"_JX5KW
M=)0(I3>?C;,?'I1K6;F,L/]Z89'02_807QHC4 L(U0<R:B\Z?5/714BLL'C]
MB0O@5IS6FSH3/>$-('KDJ"=CWM]^P#I8S%SQ5[LG\&3.[/<3.#*4JZH%VUJ&
M]O;Y\H4Y%R!FC_Z5"V*#9$M]W^3#Q)7GN2U[5_I??.24RU -69N$.FQLP@J:
ME8NL&+*CLW%2">4, ;T/JX\=-/\N/R'7]DQC\_3@^S,W]U!/,3<+9Y[A8Z8Y
M\_=?T:?'/ZW0]G_T"BV7&/$?TK1DJ.L9=ALNS8,DZ!IVH$OZ0HHC0=52OY7:
MC\7:2_5T_;3*:)N?%H\F'*JN*\7'!/XO7_,">D__G&IWE[-!C]PH2*1L_FBT
MU<O"?V@$@UF^A^PZ'4ZJ;\/=A+:1FK'\%$ON757<5AGJC9_8&%L-%"-R2Y_*
MPUV\% -U'87W)U9?.<5^VW;8:6;JN*VDF_Y8@)F9$\> =E;\0^E<X%;/4!3@
MWI4CEF=]*$\^^SP)V4)H-VW=G?H2WX-6&9.6&M:OXI(:V#J=#N\Y\44>-7OG
M)0,F2%7A@AJR:WH9Y QC&N=N+;<L-V5O[EJRGA.MI"$4T6SW?KY%H_RZN,/5
M&9Q&596>14W8I[CJZM45JB$^LX^YY9@UJP6[ESRU]/Z(N@[Y,+X76U[/@6&P
MW]SZC]#.EH(2\,![7<O]4MXB'K?R+?*A!Z/)-9B!1N$2_W7B<")VO<0Z8_F[
MWL4H6J/TD5Y>FLDMI-8Q&S>W)YDV6KJK18;Z'$+'6=#$P;=-O\Z=(G$6EO2J
MYX YGJ_=YF)'87BJU, P*MC7P4GS!6X\+E9LA6<EC%S>;O8%>%"_++PH0&G_
M;</,-6-5R7!\-H5!1'Z\%Y_.;2D^QS?N::"9]%),+8J'!JQ5B\-#0\=?Q3&7
MRJ+IHDW5=5OX"2^!3:8#IACN4<S)-+NE9!9L_\B.=B#EV82W_OX[>P.5NQK;
MMMXOT'DOZ0,/"E:Y2*^;80*AS0+JC5'0Q8FTG].L9(]>>0%G+A,%4@-*($@5
M1X$N#OS1C]@-ZG4"W)VE6U#SA:\JDK$5K5_-C2,'Y%<2FFER_ EB&&=F;NNE
M6GR]#]QL"J^.U<BW^)F>P-F$P;.Y=+G)&,-EB=0\2,P1B[VV4:SR:B94;$^=
M*W8DZJH_%I D6V=WZIDZ"K:S[ :M%:GWKP*<UL!%Y1K.1LE1/N/:E2M73+'<
M3O2QFCHXWJ>'O=#DU3%7IL?ZS3V?9W!<"YF!*N_<L2X%K0CIO6?!F=_AH,T_
MZ_K[@1YGWF\45O^8PSG_;XS__[!:K@5.L^1%:C3%7^@?K''F$),^?\Q,&1&7
M> +[? .GGJC<EZJ[!=1*9TCM35A]#.N(Z;N17MW<&L(1+"_?JP>.%:H-?>UV
MU4DM;4.:.=555;^$BXF'X;W:[]_Z6+%WESUN=W<*KGDM<0)]\B3>_$TE7)N@
M#55*]\A#\DMI\S#FVDMIH1-4UPB4&C@*N"ATDZI?9KYGZY@Y4K@>C13?P!U+
M\W027_-DW(:V1QUL6>[R!A->KJC6Q^_V/AOI_B13I8.&DRQ(/X33Y'?PRQZJ
M493 '>?Y@8KJ)@-91Q7LO>/G:CZJ^WO>]#A<6D<W.SP&.[Y8=*:*!?"4[6\<
MU,G[D.U$K;O:JD9?>&U,/3/H[A%PJ)OM[6$1'A2")JDY,,:;U<*M7$#JE\G@
M5HL/F#O0D8^<77A3H,%%@!%[!W_);H7NYEZ"<.DJU9+RQ&6DYCY(C5):B0,U
MYQKDY?W[6!'I7*R"JRN;,<8(#"QPLT#.^@_;Q&^3H38L\RN@VY1K,A3_&!R0
M6Y[^4@PA0WW7CP@M?_5):'GJ+26A4-5"J9T%WR:OFHW>LC:T,'9P)CJXP8Y-
M^9F\(PYX$H4]WAUG$5088.:7NN]Q<+ "\"+)TI@!HQS#"8!_!GNMMG>P/X&F
M$^5P1/VMQ&2L.5;H"O?#[I#V\68X-%_.@['"4;GAB>_K=(K,BSYFR_&'[A9Z
M$ <Y[_P/=5FCI95)VC,Z25F7NDN4_W(W>3#2>"SAX<>VAV,1*T*SLWP+B8(%
M%U\R+ [D;.%X7C+[*LGTO7^(FS4F$VY ,A(H.&T";((SB\(K$Y]E1PV-6CW_
MB8^^Z7NGY8J%I"()=T"3/IV7C)^W$J,=I>EF"M,QE;5W)QIYFSP*L;&Z]//S
M$J;8S_M:SL>8R)L&KRIY:-OJ'MT@>B_;G3%FCI:6EQ*?V1=T3+; H_FGGY:*
MKFHGLP5(/?E8]M/_:$_P3SR7]'LT]X0[DD!VZE]#Y$O<;?Y>CG3I\Z7_!,[J
M_RA3@KQC3OK3B]G?G!5&N:1&'10&\''?TS0#$34_"I;[=>^%FN1QMRMQK^C=
MO@OJTMZ8$D7[E.N^._ROJBL>.>G8]])<X>Q N/X<<B#-[>@;KY)_20CIIO<7
MK_IWOWTAU%-?#(<I1[\W3RNKX3%Z^A<X\RU?_]-_@OS[_SY?_QLI90FKX=?:
M]8C?9^;^SM<_IB_[!\ME.:_T&_[Z+RV]-Y;5%?^,UNF^DZ$834Y4URJL0* 8
M]/M4_;H9%ZR\*W;_M/IW9K7V[]C<_\K+27]TJ_['4'\G0_VG7NL/?3),9[U/
M-!EG?Y<H^DO9?-^S+$?IY;.?6?V.K5VG_'<=L>[?V.JW2D]_A[+_W^MJX%=+
MZ$"_U> SS'J@?1F9G']XF_Z0?OB[1?Y$_1N+PQ\_Y?_1M>'7Q*_O5[:$/]RC
M_K.Y:_[=[?T_2O[]X0[X5T?\:\P,_'L@_<-;]8?TQ-^M\MG?BNC^^&G_#P/]
M/RY+^:,]7,5?+?/\7V'N[Y/=?=K/+@GXE.)^J_![1K;'O\6T^WYKK9_%_"?P
MPK]ZXU_CYJ^A] ]OTQ_2#[\:9>!O@.X?/NO_8:ROE:'NY;"AFC[>.2_@55>0
M#.4Y_<=[U?]6^>?21B%\T]U#&R/AO[+(]EX(3U?^(X3I*SMK->5,#D$K6KX#
M'@W][ X##V0M!C_F@>AYN-@Z?]=ZN&4&?LOHG?=C^#=\\W??JGV!]>[%5_#?
ME5,GZ^%9EVO[F/(M_%9/A'+)#AC.1S\BU2(<8\1C[E[(#L1B[/Z!$H1LK-X<
M'?LG^,9%= K2@A_?PE^/4:I0R4"XVPRV(]Q/WF/SR_![Q19%&DZY2-N-OZP_
MCG";>>0\RT9:>H1D^. J#6%;T[X-O_^$-W,M"'[HB<C(H (/Z]"0$)622F!:
M/<U.6W,JYV'5L7VY+_;E/)<>'%G^GEK_W20+N",Q N(ARDQ5+;4R68;B4 Z\
M6%=XTAZ\=6<4>P/N @>WOZ^.N?ZZ9%;Y1V^/_"?:DCE9O\KFG?W)2YTF9AV>
M7;,_$@Z>O%0QTR#X_^N_7DUX]0\AO'L%.1?3 IU__/=D#XOR9Q"[E?_V-U"F
M_Y$_8BD&&X%7OW&@AAXWB6?_#?A=R>[B]L"PO_W'L^^TKNA*P]^;DM-Y<D;_
M(4(=6?ABQHGT9_AYX\?:X!N*^A\;A_]B@2]^^K5-"\>FX*]1/GK-Z?E_O]5Z
M2B+5/PR[-C#C+ITDS-31TO=9 ";R0ES&$R2FQ!&.1!P5+$.A\A!-J14;P2[(
MDG,;F-D6*D/EY%.:T0F08DI+K:3VK-Q6P.^3BKV-&3-(CPGU4'+:)AV*=UH5
MO1.][RYQ]Z1USN)+\0P9:C=5GDA>E]<7#I2;EPYXM_N$*%9>1+;[\H 7L*E=
M=6;P; 2$T>'@EYT>3:R88_M*U0FL-IVG,E38A60<9#3N\@K+/RVO"OB![&9O
MA63<X-0A>YR'.?SHO3+4,EVTKA8-:F/NRE"1PTPYAH9DL7?V/&S2(0"OTV?)
M51J:S%*.OXASG* 5/  :7T%PFL.LOHGH+]A!)CC?. MP< 2[#F+TT;=='JU4
M54\Q[PXFIJ-7C-)#U:LSQ71QH#K>&6QON!IE)]ZD0URJ34I1S9>A %..C@SU
MM<AI14M A^PI^<@&Z"/@8[OR;/.;_)W=]NZGAAOZB@^_#076IHJ5\7VTP^""
MP,+A39RE*FGC75JB^B+PIZIDK3CF(1;V%\WAF2!'9Z24)LOB3$U20\L0]L#X
ME)OITUP"0C4[_( \[QUW0H8ZW\R$[K-=RH"7I_%:[S]F;^(O_[ H3M\##21[
M9'(0\G#T"MQY<Q,0H5376_E 2ZQQP*O%;QZD,^1XVB8/$UK(H%9$OK0DM"#.
MJ+MDI(Q@IR/V.TOL2+-;F5!"U,NKJ!^<L?PSF+O;2;0+&4M9$MS"='B!1S1.
MM*X^%%H[(3[\T5NWFX+?$Y7=<O2,Q_OX!*OR6F(' 8.17DA==B&8KN(R=WU,
MOL0:NNM7.%G.&).F36&6@"4F%-V74G*CX6VJF6U@=/KQFSJ*=JS0=Z("X7EI
MG<'<'>7>ZINF]@4ON9RMG@"CLJI[G"6T$XW)4*<_%-.K"AASM]"HB_RA7&Y4
M9:'!4>N.JN?B\.KTL??(QBEV(AN8&XS:S>';8F]]$W?J[84WAEZ8DWQIUESZ
MDRF2T=9,,@9R@V8Q(G_%>)S867*@!DP7'P[,"&]IEP;;5A,="*ZY,I1;2#!4
MW0[/RGNB7(C59VA&V?U=M.'I/G*?>@+)[.X.>AF.IU$$O?'>*I 72B+N15VS
MJD_L(+1@]3$5ENA9^J(G=3$<;XO_F;X5R_U<^FBQ7>>V:3%ZB\6^>QK2,!G*
M0PGZCMB.=/%*/;*/?,C(J#I9Y-PG$"5_$C,HO1R_ABM0G>IYW/_]L[(=0"R^
MH(E#9?"*1YC7Z(IV-TR_5B7I1D38M\;J2>GI4(K&G"EEB;S ;*?D8B\2=X#%
M(_(O>4I-0YBD-A5'YP7]Y%VGZIZ.(B<$<.T=\&-31788(9&G(CYF.28B^PN<
MJ6+*2D22)2"\#ZQHTSWQ7X$WVX<37M;CG"JJDG30FR:Q'YWI2Z\Q^IHRU*)7
MA(^F8[ZM0G?OP\/:2]IOLTXN6OP%WT.N*KW&WQ/*E>H/FEJ,C"JEZSTE;>_#
M+;V1H7C&X*B;#/7C3<FEWM*X]G@7NZZ<!6ROJW^7"! I=5*.@D>&CUH(DT"N
M3WZ \MVF:N/.#E(M;,H2*E)G9*F.KY68@FY<NQL9:NYV-PT"CZJR#M=1!LW%
MK=CI//)\-Y7<6P[.MYDR9P_F"0Z+0K6NYBY,<^'/*U0S:M4_A$156'5++)X
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M!AN8W/5FL&$;7]+<TC*SF3%QS0E:14OF(@W\ L'*,MI]=*T1XQGA-/D/.>)
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MASS%46M%*;!9/0+STQHIM!>]1!8Y %%"F$N8+''F&5'3L=0&V"),>2P7$L]
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MG[+T(;!4'1_/]^9.I_(KN4#"NL;AB9-+88OY:SK&Q%4>C-:UTU>59:HN4#
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MH#1C>AJW40'TG5R@EUE4&]_TL@S_Q:GT0MZW%[R*/DCR%H0I(F/^=#/' 7M
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M.PICIC81S%-^7%&"66<82]&O?JY;M4^]LT%K?]ML2FQ E>Y11^_*-35((UF
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M;GH/ ,$PSD-O6Q]W1IN?XQ])56,3.!.QU*NIBBF/XM9#)#-"OAR1ZBI@@G7
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ME)F?I$KP1$IBD! '6*^?ID?^^S'0IN7+$?^ T?G^_^-J9C1;W ?//.TY1H[
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M!^#,9_,/8#(4JY2L8 60+%:316^)><UIUXUJU_$(!]%0F'XLJBA;!NBO:GW
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M]+IOL[\_U?"B_D"&:!B#3PV9RY:N%_.,^$9]:%7^I1X#F9QY30]?KZY6[_!
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M4 YVQYFX9PNK,;]%O5#$+QX7&1""%7JIBLMWY]0P)YJ01=B6&RM#EZTLRCU
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M=E^<^8VO+7AI=!@EQ]K<4DZ5E 1</*V'!-%VFQE-%3$=<9>@9T1V7N;BBKE
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M9]MJ19Y2^P"/=@#UMOJC$!)X!!W&][O%%$+ ;3"J$WI!\))\O:+GSC*"OYP
M+P88)U?&'B!+;(DX.=3U+RN2!_FGY0XS1^H_ZNCAV#L9Y4GRY0D7".%JZ4@N
M24-D:X<0[+L?.0RJOKIQ(_48*^CYG3.C+NNWIT^+1H_ &?GYUMC[ D7+Q<-
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M%;=&]NP[A,OK7M@>6:0"="@8S?S'78/K__\8VF]8W["^87W#^H;USX*U_+_
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M+IK#N_\)2I7\LU[?A<'7-SD*(>0F@&?UMF]6Y+;M\1="D'N$$,;%3+MM(A]
M^FW#GTS#/^22M!"\A$_6A)P&"3WKMO3;*_A6^& F:$Z.A-,%\&1T&>SB>C7
MDIR&2HED=S,&:UZO6)J$NDW\ISK57 BSZI9+^FY;(/P<<B-0;TJ8#&?F"$)$
MB^-U-&]*#_<[_@%A/!.Y9,BQ!JL5A) OS6$')-<B5WPDX9.O1;Z5#QKQ2<O2
M).*< "W.N0[S65AF>B)CD;N]5Z(\CG8S)G@F?):LM_$7MY)D[M:)12@'RK9C
M2C\'7*(_&ZR?.70]Z::Y07JC$&+LOZH]"6=>,=Q[H/H@K=/!;;$0-E$"FY?'
M & ??K^@6CLFUF)B9"KUDQ#B]OY]^4_/@^%T.#L[I _VM$G/+TQ^G:<9>T65
MAE]X5^P9JQ%3.#8=CH@"QC,HVNQBZ=IRZN$TU2M!Q"'OQ9UUR'<'OI#QJ'L<
M$RJ!(DF=B]]9/A1;3@DHL-?<M?4@)H<)!UR0R:L#.2V2LL:_V\WNX63:E'0Q
MCB]E/NP.?K8CHB+N%7,;O/X+FP7*G9>>I6F>K&TQ#V^EKXU]/:N:9Z;%&TH-
M?\K/2PTUJ#@NTD1^UY#TO%Q.Q+BW,<TMM@2_\P9NI?-\Q!.1@7Z%7.JW%\CV
M\*','K8%$\'.[MW??_$7A<K8IMOF5;F&GS4O!UYOXJGXV2]P"X_2WMEMRKTE
MK6-57=LFA.C#/_&;*GL* Q8YG+($,EA)O)ZW0JA#EL(;?>+TL/SCQ93V3>3?
MFX^4E7I!L<%@W?H8/!8EX-T&.UX"C73=:B35_)Q/1ONQ.+ -5K&Q=L.%R**-
M9.E7OCXO3'U+23#5B<"G1*)&Q_NOC\V\@P/ ($2;ML+5UF U2Z)L0KL2ORB:
M<(XPGM8ECSI&?O%%AV]Q1Q;##2Y_:V#+\J+B%NHG:FZ/'MD_8<72* A5%ZPV
M5Y]Z84W"=@Q.7S"56-1]+I<TJKY\\:2^;#)GNMI?UM3A23W/K"="L::2KX=6
MJBOG1GQ.]&=[M7NHNXK&T(HX97DK9]B3#'<K+DN8GP%#3612U=$%GH=T(N$>
MP)/]MC+[X?>Z5P\8#(7>>:K&7D @V;*VF,N\\RA%P8M ^7$?R=E@'4E/*NQK
M_N_/'YR 3V6EW4DHCM-NFS.^YDO]"):=,C#<(95^3%\7:3+3Z=- K--L5LQ*
M=XPWDR(LM]FSD0/]IV ,Q?'F6_&U"_$KQ1^UV2+-L9U)%\W=@[628YZG[!H#
M@_>GKW%=%R[HS-P*@*P.< 1>-.C %Y'C?I&CC%L< >:.-.LXD1O;VCJ/?*%%
MHQ"-G/4VN<]9'FV[]!G[%\,U^HV>BJS2\TUR.YAO(1+@EX@!(:3P;NU.?-]B
M'%?RP=TOWM4F$WV/2R*V4N9U7<_&V9T:A:][]'SU=\0V2E(<J+B6[?54_9UG
M\Y5<CP]=Z2V0OS #7>EH<=:$'YIY_?3GUUGW4?#MOI=1."6D3?WG?(\*__9K
M*35:P7S)CGG5>6!(A^W;#1[)QL2@U+W8AOL98&>XZX$&AU8A1&WRW*"AR5TT
M40@ICLAIKN(M[@Z)TTELK$2E.]I,AMY>FC# A=0QQCKP"/H/;-0,/8!3I9%N
M+O@XDLNFAU/&<I>S"W'^P4*('+O;"2 KSZO<3E!!5<@O9<<1+O'#><:H'P1I
M?-S.@@>\.Q=25T:V?3;X4?+\C'+D<L%VF+B%8.E,I%Q@25FO#7RDRFQWW-=N
MB_;C%4;5:S]_X7 XCYVE)IXWN2['':SR'^4&EV*GT8Z63H06B\=KP!94^%N.
MW[R%ID)'2O#!Z1#H(_^O6^29A<=KE#LMKJ$K'C5;M73E/,U8O!)A<4/PLE;#
M [<)%0P4SI<%Z[R_?$OQ][@N%\W0]#M^ 4)(6>!J>13@0Y (P=CW!+RM/IM/
M5.2S'(@*>;N1Z4@8&&8[$QLPM@,^F2U2EXUGD%Q-O<F"J!SX4X[S4:H:_H=
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M%IPP>\@C52-:S<#0G_Y@Q6=Z$4,%:Z'I/]\Q+E/Y6'),*_AJ"W;\;?D/DNG
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MU4CH6)2D^6)SXSE"OTQ :LP8>1<*#+:*'^2"O* Q^UEUXY9D'^.'J%>_C"6
M@%5WL3*6^BDQ,6PB7)I).&5U!__J)<Z.7+B'G71V6M&Q=G*RD!OJ)M1C[[EM
MR6%S#A#$T,C%UD.VUF'L*;UDPI,@@3KK,9PXY@ ?N)?P!TFW9R(MX2O2@D0)
M: M^$19ZES"T*"G;4(V]*ORPSTI4H7-9(K!TC4\LH5[!&%IK=CCD4BKS.NMF
M[_;<UU):]GMZ$*;KFM*QXV%NV/J%F#3KESM8*9G?PMN4'GHJ/B-<"V1=I>F-
MS ]CHG8\=A \2>Q<R3F<1WM!VDT:3SS2C/2Q*&<DB&WA$'/2E=-7CUUT9[.^
M."@R%51>+\]<#%RDR)A?L)CU=&BW"J9!VE+MU%S]29,H1Q[H>0M$T&6,RK]!
M.4"XJ\_87C9L?B+P;SA2P__]86&5H2I#L 4[AW/>(SWD[CW&@-6F $1%[+'
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M+\R%;Y[^HW5![+G*4M(L=FB[)B*E>%$R:]Z7>XSJ!(2@_;B*'AE, QEJ=!Q
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MBV:T%>H2JY66(4-]2]X&%G 47W!5&F!,0KNZD\N28:+:J9K<,03EIN"E8?"
M2\6^'EVG>#=:^ .GAKHB:\<;J_=F3[NVH<NGN 4_2]<^ @%;.FX3^*QQTC90
MJ[&"(C\O=RR<SRB3'_8'=A1XBE+$E=1,BTD@_VE7IH IP*1Z&87.KHRQE/U%
MTV$NK_V_IFBF38P3:1WX!R.*,M2[;,:Q#LSNN,:'+A3.L8.PNVT0NK\8 $?@
M$S2F^6:I-X_5M+C.@H-9/PSELZ'3]VPE5<'C\GJT+MON:KEOFJQH>PJ^<IYH
MC3I8D4'2O\M5T,D\G.\0^C;6VNJ[#)*>K8).\9:OP9%WT6@.6OK%*KRS_"E?
M.WE'R< 0>F_+)-"%$\TX;[,!%*HV/]I9.)2P0 +'A(>A3"F.X[6%\UD!/Z1I
MZ[V A\?:*HK*^SH\W"R4F+5+/M"@0R15\*IV5B), ,.S0(]Z\]VU?./:)[$<
M_0<&RW.BW4FOY/Z\ YB=N_8LL#R[U4?AS$-GG[:P+G_:C\$,+-@^)YR0H6Y:
M8K?48^KQ)='TEDUL$?Y;N&W);*1<Y.TG'A$'X$]%H#G--\WW>,\*AU7Z+JST
M7\[;11+8;IEL1#^0H>RP$]EZY=HV)OZZYW:Z>.:EA2OS3+@FDHL$"]"*7]_
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M\2QA:7W=B #Z(XNM0< 49D0^P?=/YX;_A.OC]5X(SDXFRR<T?L7M__8JT/_
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MN8M$SJ$%7,7,>&-5[S8TB;G6?&<@LXS>%'W0_5EIHGZ:JM VV*9>O@@Q.Y'
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MX)%J?!8=<?:%%20.]I"IDF?E<=W<A8['GEE,)2E:)9XYJIC4X.[IK8?HL,D
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M<F@--]VOGS$2-A')P(M'H.U>1DY61@[6.](O.+J^0/.<<2*$E_]1F)*<>JH
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M/.#I@]9O%Z >K',[<0A9,/\M-%S<I4U7GF:LS)]2X,9]7PGQ<VQ11\  T*3
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MX&Z4:B</V(!36$;H,8/R1/$^B9ZA(QK(UFGFS@/3DU,*7'SOI(_ 0+AB)7'
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ME$#QPZ>1%ISR-^#2A:#>,BKJBVY&2Y1_%/HOT;YJ>"Y2BR[17A! '[+C#<*
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M1Z6=9R7I8SF-&;FMFNWM%0^+2[QC4>12UCH!CI^<'=HMW)YE)E?^AK*?I3<
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M5WY*<+)17>X]^R&I?.S6!5=U.>X4N3BJINM8SR*.-CVGI\U)J_7/-?JA1__
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M17\C"G6DX1;90;V+TU\1)Z'Q(B^G*^'D@LP0N3;O=P")NJ/QL* OMS+=;,,
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MM]?(4BI0^M:%N6,FY*SPIM1%,R//RP=/^F)>>-0XL+OROSBH=I7QX/KF"S;
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M-X6Y^J6?>W:Q[E"G7/BO8A>+-YZA^EGIW0P??C2GIVA!L??W;)H)S*MH.FI
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MHK<OSY[(XL][PK!KEA"+*':NZJL(%3@U;KPEHZHWK1\0M',>,%^G%6N3K&^
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M!2QWK"GI3T^'V.U/,ODI&VL'2.@W/U%.L&XD0:\X-Q)2=@LGMXY"33>IL)/
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M DMJ-,-G">W0$^.2VCG;;@F.'X'?0<]P5QJT<\RH!^F_RZF<S"#9QP+WI[M
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M;V;T=\YVGZ7JN8#JA@Q"CG6F1$@@Y,$?/V]ITG)2]ON/<]>,/\N/I 7R6BL
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M/6N%?@CQ==-?KG%=T-2"S9B5VRB.. >+X]RK]M);7E1K3K%6<HKZS\'DG%#
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M->FU[_<MZ9OK#_%KZJ7A,X9"^WKF@L0FGXESP<JHY<:+J5H=/#IG/6".L(.
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M KA32@ Y2K#:N%65 +YTMI_NL=X?8C\%Y>V7J>0][!.&>K$ LEI JV'8W0@
M+HV*/IY*\?%VT*R#O@L1X3TMHW+6T,+ [T\B<H2@Y=^/C!9 #JEK@W7"Y="M
M9HKT$EHQH?LX0>>:??\-JB'=IU#S&@THH105GZK/> PL>^_D[]DU\8S?TT\P
M FZ7HBG:S3CPG3W L=^&?/ZAS816XYO.RC ;9DX0*IS@[1FC81LW# CEGPMC
MY3]Y^G,SV)V()Z[[V3*Y<X91-$J3=?=H5=7+5?'WD*SU#' G+$6SZ7L(_2K
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M;[?]:UX@.TFD!?9GQ86IE^01['Y@^NG)P)1UVRC+'[W6)L_F)A,ZL')("O2
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M.9B;Z .S"!%-MXV\!+*ST:X-.O^J&!><[!SSBM\H9+,FE6W5-2'M F@7P<>
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M%U<6%E[4< Q(HNX,'=9QC[FYV-94><=S/KM7BFQHLWSR1V$'PDYK ?/IY3J
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M8]I8Y-<=OH#G%6(74CSY4A6DD&0B J(UYV^@)_L:&)3ZXRZ:-[ZK^ZS%,[<
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M=1@;'[SBH?*E-E+^M5^R)J,@0EMT4QK/%"YI-+ 8\R9[/#&'>J+Z)*.TVC@
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MU&7H59OK\S)70W]BTUU0XY"3.[A33.M^L/C?79RSJ^Z$H<_-SZ"Q1:11,7H
MM,I<,CX^!7<9ZV#_>.2<UG$IK31JP:=\K&P#P<X=WH5((H4>!SY;KW'\,N[
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MJ6C+OQ.E!+2L02>NIW  QOJ.F-5,5Y46E?%#+=A3&UF)[>%NAP]>%R!XS[=
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M%W.L<J]^MM<$RO9&Z)M9JIQS2S29:]GXJ^;T&-,A7HOP/V5B-8E<YUER\.,
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MH('$JV5>NO&UO-:_G9'KNOOTV:76H\GO_41D$#T0B$2!!'#1]C0^<ALG^&?
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M#Q&VV.JS$:9IKI;C)+.(YQ\=3EQY@H"/556U7 9U%3&RLCB UV^@HAQ O9=
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M:U(A [?.0#;F_(GL*>#!EIR'P"9I 2)+IT%6)D?*^:@]>H:+XA&U$58,UQW
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MYHOTW)0]A23@E+ [;1?T/N5!N-3U/JSJ0ENMXFQNS;GT:'A,MQNH;F/Q;5@
MXW6IO.K//70$0IPYG8C\2'D1&-ZGW= Q=5"PB_E67.Q1.?EH8V- ;N,3JDM_
M7N#N+19@M>2T2534!T<SGT3E'G)J0S;9YSNJN=IH0?+6G2]/WBBG^?%&$M%@
M.(R1J*5(3A(QOIQXFWP\YA.VZN;:M=T$4,))4CSM(MV]^M5*-9J+3T[0LFO[
M?E& D .S[ODX-/@Q.S39F;0:R&A#OC:1KSN^R?W2[N8&YM0PK<GK2\$>1;3/
M *DFA9-KAWMC=(FTC;(=N87M9IM)W'Y.C"^;C-T^G)8O+A7K@"K)I1X9K?1'
MW=+ER'.^6I[>@)*YUDT.+/$J?KK< ZZS*;?C1..<4>.>?;.@BJ^K)NYC0C64
M4*#S=OXKO47ZP<^VX.53'T3<;$VB(@UZ;0>OM<W+S*\UW+]B.QABV'E_%CRN
MFD*$GAVGUK1\?X=""J3U'LX8!<YK#S1Q[)9,G90RK?BNOE)GEJ)B7U-'<OI3
M3;<T'%=XU84I5\WL.[+O=#BV'\]6O *\NX169&@%W(BJ"G[M-'JTJK7?IOTP
M97R?J)]KH+R8LK6XVQ/4<P6P8=U9F5<$*A!I/<AWT-*^IV/3&5LGDE!AMSN\
M#1[?FNV"GR1II9U.^S::%UPG']LY><%[9UU@? F\K^T^G'?L+I*27/+8)*JM
MH\Y'>=E;/:KV^V"K14!&YB3(F7J&=@7<A(FP3HE:)&NXE4-MC$Y.G.(4[R)(
M>-YG 139;,/R<*P<KDOUF&,!HD "=0.JM%L^SM=V_YJ'"VL(OY@?K;_'::AH
M;5BY*.^>69LQ)!C36FSGEO*EVEVWY#=< 4D[29UOFH@=Z6OYL\ JKZ'1PFI3
M[C(+@"5>*8:Y4TZ2^2/]ONPI1(JJ)IH"$-L7 I]EZ1UV2(IO8VK_=  HP=;8
MU.U&QRI_Q$]_32KQ]#3O\2);+W&&T:4+8.!;E8,J[OKKOK1'K0]:!'[HB(0]
M?W\][OY1(UV9#QTU_G"MQ:N)'ZPT._8<;O42@MK)P/#*+3Y7-0W[/'?>Q;!A
M)^E/2>P8_U3&B\T-H?)?O#-6.NZ?[0'R4G>8)PCYA!D#[SG(>8-\_$46 "5B
MJ%!Y%Z<G*59+@U E(=&2B0R%UD-;$Q9@2/T9<AGZZ6->Z:]Y=]WKSVFK6@'H
M@9QU[7+W7FD<%M\'_?M/9?T)^J7Z:/. $*2=":U^[4OS@>@ ?E!CG_10>KF@
MRBA*T7;DJF%1 RH.[R10W%E3T]:7!@E@VJ% U )2>@M:0$MCPC)B'3'$\_SR
M&Z)RN8O$N@/BTUBG*-N6;_QF9+?!X73K?%G'B\,>+$ P"X!T^,$"_/3;?W=4
M0+!7QM!O$>(PW$F-5NY(C#N;EST]X;:VD(7_(02F<Q>UFD$$1[3,\\<GV5,T
MOC%CP$D\[;?'V80:WVG&_>,A87=ENK1*<%CB,*Q#"2(Y3Y?&W_^P]HNC2D3J
M0Z"1CVU?Y,[ST;-Q8IC:P\M>/SD,V2);YN.!3Q](GBXY %*B@N9OC<X^K6^8
M#/Y(33ZAIW?GUPY4QHK9"N9J$%'MA%D2+PVM0Q/>3T%<9=EZN',-ZD?\HZD*
M[%^@I'<#D>><!!U//'$QUG@9X.WZ)W;]9/[-B)1MKSI;13[5JH90&A;G\*A<
M[+Z+K&E(222K8D@5%-UZJ@WYS5K;84"$!^%>EL$8[=HX@OPX,5X@J>-7<4B]
MY;"Z8.^-'!Y&PUZ-F6&&4=JHN;@&=GTDK>I#XW5<ZCRN,OS'/I7M62*GW8&_
M2MSA*24W:I0C%87C#V#G):'*I2$RGZG:I%VX##4@!V9+$+EM=#P5U/]T>W^Q
MB]&TA[G%SC[ER_"& I0LXLHC\[<O&1,IJ@V]7FTS(J*2I"5,K@H+X,CLKTR8
M[)[$=<V$*6^--J13'!GISQAHFU;/P]^C4,MM#KYWA*YM>M^ART%?JCV-S4*D
MI:OXS\Y!@)%Y[PI#0TM.3*SU[X!CH?_L<L9F"0MY5AR1(%U+'MT^$ODX<5CH
MX#&BC<"K)6\_UDPX-X@W=)J6-9FQFU!&_A!39[AO:9E4!IT<S70U0\D,[[T0
MUOFX. PJTG4=\J0D&,,Q9>1GR&]'*ZAB2Z/0\X)TRV -HRM%JIB/\>W@Q0SO
MY2,,9M5N05-?N <)-X>-G$OU'*48:XN<:=9;/$A].0T6VB)I2[O>KRP0M1)T
M$MP$J^:M>_LLH=24+*I">82L98[\N :'S&E+M@=I'3I5.9S->:(^>;FQ^9BN
MZ.Q8A[W&GS)OUX")F$08M%5YY=S/&Q6-KVQU6("0+/<-67:2L+E=_+ELT[%N
MYDF243J'64J7W[XVYQM9\&S&X><ZX(3H]:JX7VRJ6A6#DER3"[E$<J"XDM!-
MYH&^M;G848D8O2MY,&49SKO,60KO.O5/=W#S+BY3DZH^(T5B][)*WKHB+T%\
M1EH"W?&H?=17$W+N]YBU4\Y)V_'I5LI.^_RE :H8]L88^'&CSRVRQ 3J58.#
M?,Q'QJ^Z9/T98&[\#M2+&&,:%CADK+,96.?D%]L9."ID;>0[,C;5%U.)_!7<
MBI6JC8-&L !<?B).$\H]268=WCCFA$$S@FL4%\L6I$4V?0*_O^^_V0N&G)Y<
MB?PKKM-(K5;TV<N#URS *"HOQ..U[E%784?8>I^.MX6'4&FQN_7J5.'E"\AW
MHS<41*CF#:ZS=CXM7MX4 S\[4/"E%]R(%@E'M7ERKTPWS@D]/@%Y]=VIYLA:
MCE6(Z:,% %NKR;8?9RLA5-I^,=NXMN3T&-O@+%ZM%EZC,V8G3EASNU9YMJD=
M>]2-;'OEOAQRA'(O\1;C<RXU#6ZTW+YO-BVB\FOVK<1+/91R-YY>R5P,D6:3
M.:F8*2_/W#GO7S'";KHQ);UI"-3G!;0(Z._?0.'=4\'&N@:R5:?,EL97KQ><
MO\F>+/S0!-9S"/<4%S7#&[GA"XST<,S?^ADWNKU).,+XR5:UM(H_DO4]1JI(
M%,L1X7,:&S[B:J#AY2>!G@Y!)37\13OO(J3:^KT@ILJ5#BTQ3+<(QCK<8="1
M7(>C->MC-$4W%@! -RB>[B*JJ]J!F+_N4E@ A^VIG^'[+YV[0>4(O]VZ!\$G
M%2%KW(LO-GEK4U1;33#O2BQV5R=6.V<V1S>VU3'L*3NS"XP"<=?]^0]0+JPM
MJ06YV2NJMB$FVHXU1%/$J6&S&[J+\+_(1XN+Y2'TJMJL ?Q8)Q@\#_7[C^XR
M.5G^KCW0"?G1427O74M/L+3;[* WSC<+WS;AM2XB#D-:UY(Y(\'56I;!?#^]
M)/3B/1@23!JN3G4375'3E(H]#N.S^WOYH;%]H/Q"G9IBVR*)=DSQSR9]=O_A
MNQEK][T7XQ_-B'7OG 1:M#YL!'FZ6^,[@(+()S0%85@6\CS,YA$(."(O0=-I
M/9__6Y2=N^2XF8'H/)_KA#)D:Z.[(RJ">76Z*Y>+]O-B5G L@73"?6/*Y+4U
MGM]<MWN]H"VU0:H]].N.5)%,[L3!KP.9-O0W9+@7G=,A&^:_YSOY6_[NCEN-
M=TB^:WOS26$F[Q;P.%P02=J9FT'-%6WH:ANN&=?PL0!N<6"%[EO-(>JE^SRH
M[1S@+:N')1K?]7<4K4;!P-OJ<//[+@5^"!9@<0$^0GL)VX-+DDQ#;@ ]MB*N
MV$@UK2VBLB _7E<P)TZ.,^) %X#AN&.5HPU0&=.17 _=163=$M=BP9Q C.7[
M52SO"/MJP E];6:Z-_\KNLS'']\CBBT19!9@3(\^^&?S-_7;NCF?3O[U=\V7
M ^EM\8EN=[Q\Q^_%AWL9N<MJ$S2]!=OL][YYI=S$VU%2G_[^%__B_X[WNWG9
MKZ[6'7VW*'!$(M[X:#OES'N]+@NR[M7AF /Y(2_G%R)'Y7@>"OV7+YW]/PV7
M%H2LI?Y.S-8UO[6-_\3K(+P@.G+EKPTC\^[#2!W)[IK@"&F7[-Q_>Q3\BW_Q
M+_[%O_@7_^)?_(M_\3_'WZ:C3X:+>S\E.RUQUJ@@O,8;^B7&&8S,()K9YIZ,
M#0#G7OMN& RY?C.5_AL[\VQZ;<'%Y('.56,^:N\>**DKO?9YSHYDO%@,\D+U
M495T?^X$ZUTYDX?SC=4)4[9X#0%%YC=PAZF-74N 0(+@>?T^\F=BM.*.6!MO
MZM<U:T2DBZ??J5^R'GAZ56V2+CJU8&6B)+G$3?ZYPL6&U[C%DH;LN^"(O!+,
M8VRUBM37\VY\_5-YE35<>"WT2^WY0/I5THW\H9NY'RO--3-OCPXY9VJ]V*)E
M.<RK.HM]0#^9#@#J^% 02OU5,D..KL6/[.Q?)WJ=Z7X)7CCK_D)D+=ZX4,<N
MVT&]8US)4"H[_HF.6I1ZGJ^<GLF]YVG'IVIS\P*>U.?Y@J(>7]"5:I^[OTKA
MJZX]E#[1]LP-(3&X"U2@&3VL_+8#6IY8UJ]A*$?EIE_NT/-Y&A7->(:\5'A6
M<WB:]TNEF;2KS\5A/YYNM*$2LM[<2?X9*,IUY>:"*39%QF383#-X@/[[>U7;
ME\.K26/)HRAAG^[X#LD.@?B#H-KC8EF-M]>>R;&53W-43]WHNNS"=JG\;!1T
MT^#BL>1)FZ'2W.U/#6^L]$AZ%U5DNIX9N6E6Z$;E!'RQ'O_DGOZQ!%]<_D_1
MX[W"^K%;T]H?#Z]F+DXWQH <>UHMR &!S[;;KKE13*<N^'X/VP0OI_U4MG3N
MSWI6HS!PK_?HPSCF1'!X=1SQAB1JJQVX# R[YW79UWS0WW%5NBAFF+N/QZ3^
M)XU+HT[%C7GN.Y3+*:K(/>#,\%/]9P8/=GUO\#H(+GWM\80H!9_-+K2QF[0K
M.N"6J =!IK'>EIPJ538??"E\45]3% 7IL6M+\_Z]U"(!8KJ%__D4I>\B.CRF
M4O_5]7[_XE_\[\#5N,^\W10SO!=XO%142^]*#U%MK\T^^Q58Q<\K LGERP+$
M'3%#MT_PM@J!Z2:F\+LI!N]M;&Q_P@DS;4Q,3S<"FLK$[%=-(F80'"-P/0<2
M?[-U/D:$65;H!AVW%$H9A^- 5H@>P90N%B 9/C99[B+D<X)K=_)V0A\E]4%S
MJ('4BF0]/;+O *B F,!M6X*=6 ":,)$%&(QVVW,E!JZVC;O ]E[,]"9]F"FP
MH9V&,9%"\".#OHR;'\:TE"72SJR_G.]&=8+K@?M;[$M@SP2JT7F\[!O(E^,B
M26MZ'R4B'8.))38Q@?ZC P:+2$*'5A/5TH9$5VO:F@QHS^)[_.TW\IPL/N+Y
M7PN,<O!>$15=J1_2\'VV=(K^@%2SH4E^:8IQ\,F?AKG?>B]:[=_/).,9?HE/
MZ-)#413FX 0R52F35%X08C)-OR;)%,&$L !/[<M8@.Q-=TU*,!7C0;)AGMC(
MA97#VEJ_^_)C=2HR FL4"FWUA)$QH2>'J$^]68!_!K$L0)GR(R!UL0>67)</
M^<("-%V%JVDW()[[JY5/&;  MBQ 9:DX"S#Q)F+0-!UR4"QIEJP&[?(9PIY!
M=)Z#PTC3!:W06/Z4&=DQO]]AB]A4N85D2C7?]NGVLHB(=;WE^V068+VD%-''
MO#C0X$XZ.<,T2FJ,$[%IC@W!CJY."L]WW_C'A\"TMAPB<%3):$/G%-[*KXO>
M>+XX4)P%5ACJO&>!BM-"?H9KD!;;ZXF:OU4RKW+$W9 O4#=7N!CC3!:KFQ$K
MJ%JH;BSVD]4&._:%:$X=1%,V^K=\,SE_H 5]W2UKQAI$ODST>)_#?_3(?8]8
MA=!<(UB C<H/>Y9A<!UG(O+L2MI(]$&RT(?*@.3M(+P8!\>V:BP1P_F;P(\5
M6M6PK=!#9L.B[TN+=#\SN- FBZR/UX9-$+%^C/<@&1:@^10-#.O2(=N^T3::
M"VO;J%I_S )T52*>E:$'_^SU^$$GT] _:H1G(L\L#7*[(.8./(CQW5?D5"I<
MC33813,D(;O4&E,ZDQ48-6!*KV$7V7@_ OP<&3<C33H35Q\XU_=.E/.]]>J@
M:\+!R]4:"1;@:]\G:4D&K72-PDERG *>]H-&6 ^S!W("B/(35 U.%D:L!7)Q
M,@0E&56E=Y@G#@OND:'MC6(+!T'3-9&<$SE)S)VCBTRLHU]M\]4\;.^,LY"/
M9R9S;-9O D_GKI@=Z8U?6$G3S?F\JCB+_^IZ6+FTI+8GZIH IH<_8@'*]ULA
M_%1QXG($\QC\YG!<?4B>#0.G.^:H'EP$G8:'!A$A]+#+(;[3(47$K?,=#!P+
M<%2=E$)Q6'!!"+Y?S;)\CO=Y+<G\9_)IW>]><P>I+AL1WME"0Z6X%-#0ABVX
MA06(%N6CEGA\A<S9V= ,1>0WC626SAGPO)\Z6Y84_]>67=E!+08% JZ^AQ]G
ME"(4?JMMEQ2$-^CDH01^&"+[P%3JRM8R"T#XOE3 Z4K*]'.C70X$WH8AYYW?
M-D#F&5X_)G0K:[*N#N00@I_*+4(E$%N)EXS#&<]#3F@-3X2W*9QQ19_S[3MB
MYP:"1E6=<FZH+*-I89;NIK, @4O/MX<8MAG<$]CCU N.7V"<Q()F2/3WI'<*
M5*N@TA*/0IF.L8WS+$ .9SMDQK(6+E1=3<VCZ</=J6&!+T<G[L<+DK(RX>6!
M2"?V>:[H+QY^>L]V+^.0HNI\7K,@M[B3L!KM7>T+>&!U7S,P_'!J0K=@_OCB
ML-QD5_*%"ZZ>UX$!-Q\@_ AT.6K+'#!F0GI$2[RTJ62R=>E&J%6</G!0/X,C
MAL8%E8-?H6Z0<+.CX2%S"J&($^245EN(;(UU\H>\P"YO!?":XP_0GQWKOR++
MEO)@A"I\VX#?7"3\O)<OU4MBX(KW1\[-1O7E[AWP1HETOVVYP7-SK3M+T5X^
M!,1EYCCX!).7&F7'84.^YUXTR0+@VQH_-*1<F61^/][4%@ ^@Y6#6<X?>\LH
MFY-[>>9IMUJ*9/Q[,C@W0G<7A.?=U@LKP4HR?R*4R<-%I,YEHEX8_4ZQ42'2
MTV5(4*$:[/J4L1#.NX(N#X]!G*>VM"%4A^DG"@BPX#;KI$B_DM]I;SXZQNSM
M:!4G ;5"GUEX1CV<-')X-/:RT!U]AUK0ZF]_CC2#*5U-"-3P3W&5V^A^'2!
MC#V= /S)3;5<2@EG!Q^O>?R&\KS'':).VV9-P9JE1;4][\^ZF^#%5!; '*7
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M)_,72ARZ4"WGK'3+IB;=G&:/-W3-+7JW(X/Q0VGK%*[OMGC.T<M;P?7 >["
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M'(#3/W;"/#":Y[.3IS'SF* .][)E'H?/1'G. $<2;>N%(+\L/CESQ>["7>5
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M2= G,1[A5I?'+OV:LX$^B1P4@HX@%#Y9%B[/7!W0A!7LJN*DK]](1._ZU9A
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M4C87'R)3FI'Q[N=<8]#+@M-%"N@2DM7N$39&"$IOX.<)02O+HLSI1R;_C?A
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MPJBDYRB116.KL9C_^:Y9U\7"@:\FVH=SLLX8:HCPU,N7R<7#1FQP-$/-@OT
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MI EO^"HAXT 9=RC _$#K&&YQ1YCM0G>XN81]B*^3 HG(NP47T?@%V!$M979
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MQU0>1O5BUM%UZ-(U;;(7Q8CD?.?%8G.NZ&8D,B7B57@W,NE*^/LPBD&;S8@
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M;$")QA8X5,L\U!04TLPD!*-WE 2B#'&SH4[U_<[>Z.BH'&<JU[O#D,469 _
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M>\_!*^L8L\S6[7UV(UO;F37UW'J]3>6_8O4[F!-0[;N?JM@L[)(%^,*:W$N
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MWDSEJYCIX/FEQ]V2%^!#>;(#KQQ-*A_K]N-AM*&1*UB]7_^M*'Z&?XMZ?#H
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M$^X6XP$^B(W0IJ_^UCEW< $[B+T[>%/3^>'8#C^5N2A/NQG8>X*]E>^X*ND
M(SX:*\^D519'#E9>),2=<;EL'T$X1:>M%X;0A1RG/-=#;<07C/N+$S^89-+_
M=30*7\K!8$'6GFX)SGMKO^DBVMN*-:?FIC#BH[$54CGL"$XH&6P0Q]0@BUWV
M\SB+R3@C_$)*O#ZHK9"XWRCLG&?8;Q0NWS/</XZ5'<-EQ2#:.A;-Y- HH4D]
M]16[JG![R_^P)RK65?'TQU6ZA!ZH$%XX@ N)$8>X]PEI)A.2B@:)58A$^T5X
MFF=Z[?>LUM[EV>ZG#W6+)1;73P3S#D:4']VYE=X:]=:H9]7>&GU_ERLO)562
MH^AI/@G!'+*&)60\CHHSRJG1B_!E'\@:P7A[:[1R$>_W0!_:T_W2$M>-!N&[
M#TGVAR,? :R@VS2KG3":Y"WPK@&+*]J=W8VCN]#_[,Z$7R_0<;<%NJ:$0_0Q
MDF10A/<@S@!16.8#LI@QRCB3!HO%G<=<V/$:L:6[7SKH*P;<3,31 4/5#>GM
M;5=ONWK;]9"VRP4<(K<$,9IKX&GCD;8^(1RX5PQKF^1"/.C%VBZAMHCN8!&!
M1VB[[K$O?!6#W\>%[KWE;RSA[Z5UY:!IB=0<*CT8C_R?A_",6-7_\1=-B7I6
MY*3]\>E=I*AWFV^ 'K"X^:=?GM G#T?&;IBUE8&ZGIH=IF8OXCU3=HXI-YV:
M]]C:Z,':\C8WIX5SBL$Y1MOI@#3T*KI7*KV*WFAJ]B+>,V7GF'+3J=GWK=J0
MOE6[WL,BC>OBV)[FKN,=V )Y)%K^D9W@NF*7;FTVY3JLXA^BT;'1"5OGD>=1
M(&YB1 :^0T%(HJ)G!GNVD-R0J2IZVVJBQ99BI5N:R^[MMG5%.C<E!Z0W$VM.
MS=Y,K*V94$HP%CV27H"9L$8@$Y)&5A%+L5#<,KJ0-(QEF@F^I44'C]-U13I7
M'<'O?<>.^8[5)'ZSY_'<=D!7%70/&=:<FIN"71\-4@"0$*7E&!%%$CB'3"!P
MSB023E!%)&=*7$8*=W,HLWZ:2QM;<'L/O(55[U1NO&#V%F+-J;DIC/AH+(2)
M06OC3#X4SQ!7X!<:GPQR5@89!7,R76YK?S=?<KD6@FRQOE-@]_S)?B^RB_[D
MUX7@YIS'K3./\GA491GJJHKNL<*:4[/'"FN&%20-U O.P)LT 7&:P.Y[[)&2
MS%,>D@( L/AR;C/(<+I@P+ EL.[QPJ8+9V\EUIR:F\*(C\9*>,M43-$C0PE'
M/%*#3$P>18*)5C92&A;21.J!K 07?;'PSGF5"]ZEI"OU*MFVPFH3O,JVQMH:
M;4AV0R<_#%Z85IMH*7Q]:=!>8STH73>;LQ]BAY,9%@56R 1*$9=4(NVM1Y(Z
M;CQ1RG*U")]T>8%KOL79'2#&=7QWJ7!,+]&]@] ;H\?!NKTQ6JDQHD1[S4)$
MWN+</UE;I'$PH.RU!)_6&>/M(ES?Y1DCM25U;XS6SR'NNV>M>--T&,?%*/5[
MIWU4?'WT3 <8\=% @\ DCRH(Y+"SB MED1&8(,N$5,$:[D1:XM[IF]'0+Q8I
MZ"TJ^I;+&R^@O:58<VIN"B,^&DN1B"/)))K/_X,3&01&UJ:$G(N*.N>24)>;
M)BYN_W09ED+V>ZC=<QG[-E3+=QE?ED,[]+W+V .!U5.S!P)K!@2XT9X++!#3
M+!_>Y!(9&QA2U#BJ!$Z,+*1[<JNDXI)AP%W"RKUHKI=H]C9BS:FY*8SX:&Q$
M-%AZ(A)B44OP&.%_-&$>"<<M=T[@(/$BG,6'L1$$]T:B<W[B@D]P]KFV"\RU
M78,<VXW%!"O.8?I&I_6.=8WL&.47WCKRUK1_-*C$6>D=IH!*M .$(95!SNN(
M4DS*F^B%% OQ7.?RH!:$0!C=4O(.VYHK3X#Z!DMN9BO)#IBV;LAS;^UZ:]=;
MNQ5:.QM)TAI[1(T!:V<$10:3A$@,'FLP?C$NQ =?@K63:WKVY-%9N[X7WWV7
MX^*BH#IZ5)Z@PS*$.-QY^5%3HK&-%$ G9XBGH)!F!M"H#8Z20)0A[NN5O?R0
M)+6W42')E$><)(8<33''Y8B"GZ)+9JD*:F]T=%2.CV)N,Y-+!.=?X*8X]+F3
M\X]O1N-8$/;3&8M=^4_?8&QQ-KQO,-8W&.NIV8MXSY1=9LI-I^8]=GUZ]+@\
MM'8P'OD_#T<#<&7J__@+(%#UK(C_G)3CT[ZA<Z^IUT2W])IZ?:G9BWC/E)UC
MRDVGYNK+W?5%U!<"W]Y6,<6JBIGL .2VBF-;%9_M8!*+LQZ)#YT.:(,B45#D
M-2>(V^B1HS$A&T72(6K#W>5N#G?8>#^;>@-AW]IJOSH8VW$,_YVG_S96!X>V
MBA=W*>#/?#U<5>^GW:-8 5\]'PT&MJJG5Y_O7+QZ\_*&K8MKNEE(J8)R DFL
M8"Z$)N12Q$B&R(04&O,K*E3?82MF]?,'(<-7M;NX9BMG:7S8*KKC")HL3V*K
M6!7G2^^9#0D1YASB/E%D3>#(>48#]HQ0NI!.5Q=7OEFX>G<R/AQ5H+S"A15O
M"%(O@JVI2,YS+) 2(B N24 V^(B4CQI8%V/.E\#6"Y]<[N*%F__O#..VTRCL
MV22?K8J!18C41BX0"SPA'EA$&E8#T1@XL*=56)IE,?"KNIY\]_KFW:^\QAF$
MU'%X_7%FPWP( 06E%>)Y8\QPC!&UA +_)F'%Y0*-"^+=9<X+](T73L)$7((Q
M6@S03'B-J&1&L>2"-G%9Z[4_&==C.\R8:SF3XT)0)AA&W.2JFL& PC&8(T:9
MQ3'Y@-G2%FV!D_M7K$:W437=4D9EP[5MB]=S6G0U"6[S8@C]N9(^&_.[XP8W
M9(8X8@WUTB/0A:!0G<Y%/01#4EF/L0';G_!2G=5F?X$^NW_*1R\#'9:!7AFO
M.34WA1$[K8PYYC+Z#&=]$."2"(R<5A&0JO<X8",%B[TR7F\96/U!US[*OK"4
MUM%P%F)?56 ]L2B=3A)1SR/B1%IDI&9(:,T\I0PGOI#H3#O;CD75HV38&Y5C
MZ<&"9R\UTH%$!%,P($8\8J,7$0U8\>0[%E(_VTPZ"ZZO+#;IA"-2P6(RJ\![
MT5PBIQ1!QI+ I5#:J<L,<#_N?Z#(NF:1.P<S$\#@X)=QA:R0*1_@"1%^PR#V
M"V;MQ8?531]7_\;&4+*:N*"1=WEC2#.&K(?_\81;&X-,!"^D:>VE%;Y3\/FV
M?,L)5EI;A0A3^82UI\@YT,O24A>4<DPSOI19W3TZ>WEJDFQ)1K9 E#K#MSGH
MNB)&52)8D8A 07#P2HAUR"185\J4 )<D.(XO5PA?A"I:*J-:&0B6WB,A<4(\
M@L.E@80H.<U,3GF5;B$["4ME5&&VC%1;FEQ5&:"#>P6%K7-ET=>V\H<%2%A!
M,17-1<^CCT<. ,7T6[Y5P&..(XS]<QR<;G<UGM 'MM:<FGU@:\U.M1-J+0/W
M#GF<P!Q)'4 )*X.X(-@J:SR.B\;\C:>WH*/MDO:5Y#9=%GNCL.;4W!1&?#1&
M@?'DB,(2ALQR60/KD8G@5CL1$M<R@G=-%HSF%VH4^O*BG=MUZ<\V=''791<F
MG>7##HIC6P:83.'M<3FV@Z[JX!X,K#DU>S"P9F  NT UD1Z\/<<0#QJ\/44,
M,KG3(;<$"[N0R/JY+GH+JNC5<*]51 O"!%RK+4 T/3#8=+GL#<2:4W-3&/'1
M& BE"(\B&<0EDX@[RY%./"#.,.:46J7I0G:TEFT@^!96JC<07?,<^WR]3GJ.
MWD^.)H.<N56,QH>Q @$_@N<<QF%=?HY%.83/L:NZN0<):T[-'B2L&4C0G(3
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M(6H\F:CQA"OSH?3^J=T++#7UVG$DHS2(>Y8C3XXM"D0'+IFFP=_KW;U.Y+G
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M) >2.PG+?>"5=RC5;\V.')9&@BS!NL&Z]UM>=N[]['(VLFONFW:$\@8$  0
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M"/E_SMN^GP A "$ (0 AZZ5([=5P[R4=@"& (8 A1X,AWY?MM7^HNDVO $D
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MYA%$+*2-S" 5!4.\1():6XPH9<Q:(S6-81LAY+(KR*\%AW[N8&A;667#P!T
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M.E &$K*PEA&"ZW6#ZZMI6<C87+?[LL1LNE?%COO*#!!8'[@TP47IK8L"W6M
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MU"P6>.<SKHK_-?T0%XO)YW/$H\7:F$=X!)!?7=&I1[9@ ?-KS6\:5]9OC^^
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M_J63R;KG9361;-\WA9>$EUSW)17=[4LNMR.^:]#SX*R%46?]G^^GI4$PFC-
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M")G2=K?OW61^*VUWGR)R/"-2%O(5\I6-_ 1(6<A7R%<V\A,@92%?(5_9R$^
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M7XO6<OQ:2^E24+H4[%Z5V667@I0\]<Q*9+A/B L5X&^$("R$U(HS+E78Z%(
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M.]L#6+>?8^F)O._+@CQ5%:74"2AU OI=)\ PX82V&%&2(\"<,N2,!]TF13#
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M<&I?S=8/Q2(MFL13DU*%1_>G22CJ.=-6(>UE DU"*60U9:!.<*HYV*0DZ(U
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M^.WK-Q^71'H_M-,L%U9/@=T9INZWB^;UM=LA7[+P.)S;*[#WKP>4[35;C<;
MOW#EPBY;F&1M?'P9I6KCU];[\22T1^*6201K20!W\,66 ';_08ZK)+0U 0E#
M\Y$/K)$QVB/EI9*<,N7#9N\D9J5WS"&<.-P3)&AL+F@4",4ZND2(5C<SME<B
MUJO(]F#]B@XH-0,I>+\Q[0[]:@ES-Y0F$*6M+^H(-"6OI,B%JI )VH*FE (H
M/(HAFHQCGF /^M*&D6BPQ#H09(%K$(^&(RL$S09 P@:4^VC)'KP&^NBTH<PF
M_VY',SNYRFS"CLN?(!+'03.///&@(.ODD(U.("\22<%A99C:2-*58 AJC8%!
M' %6411IG*NA*6D53AC+N'%"Y+'D#1EHL.>$>2+R9ND(9R5=9H5^;V>3?$ 9
M)/#7JX5?2II)L^FL3?;+2>&G\5H/:5;4I97P1C[3<YHS\\:PT8\HM^96$LT3
M:V[-JSG.7!:!N79&292T88A[4(8,<6#Q>^.-9512O^&^TDQ)I8)"W.@$0A N
M-\*#YI6L)=(QG"0]:"Z+D G@5P(:T\A!XH*H=I@;%(7F1&CO9=B0TIH$[YWW
M"$<1X,9$D378(1&4!7/$>TYDR66Y=RY+%LMGM.2/7%-M4\"T)MM/]3A[<JN_
M?G@]:-,7EA0\HP79WBTQ7W_98?,%U\R"TE]PS6PLR-)#,?_E.L=_%6X[3\[J
MX,:N/2F6W4?7;I;!BI_E^W%;5@208U3]>1)SZGM.^A_9ZON<&C',"--^'E3_
M>PR(]W_@CP'0P]M9BSX?;?W)CG[XX3J^.YZL0S(0>Y9 @LQ:S_>=:2[YWI\^
M_(K S/D(X%9]J$^'T2,BYMZ*[@&=*R>#7_7KNTU71_7]:/RI6D9[VK3]UG-"
ML/SA;M?)$NMAA!>YWGW1\.Y(B+Z5EP=;LD.N0_PKB0!'$M5(RD@:!!A@AH6L
MKP2PVI-&.AB&G4P\;)Z2M-XS*B1&B4DPNZR-R#D)]KT,6CL1,=5FFZV^NQ01
M<C11BU6CBIY42TOBAGD TQX?C8T #V[:H-_\8.8D*_VSN,UZN)&SR&]NG]G"
MFO!#$%7^QA$">/U<N-W7#JE'E^/AY4(&WKJKY[9(KSCH"&I<':V1)FS$'J0<
M&"]9Z%$*0@\,KB22)U9$9_&&/8.QP4Q(CVQK QG*D%-@W5$G%>.&<!7$08TT
M3Z@!^Y(C9DW,DMPB+4)"D5$NDY61X(T#!T9%($-BR$3F<JX6&'8N)40"V+&*
M8I%4*D;:@XRTG>?XYZN/UTI[[3L:5>]F4]2GL_V'.P%^[RH?/=.A\_GOV2F,
MJ74@KR-]-CJ&<3J';)N9H*OED6'W]47\7(-ZLS '7RR^>-%FIN]IUS^4 ?JP
M!* 8S<ZS10S:W1@VV+6.MC39FU6*7V=S_1;!")T\KN0Z$//><V$_U.<^2_6%
MLMAZ"\;#H77C^3GV<DKIBZ>4L!Y4OUS4,.C:-S?</<OOE_ZA[Q=\N4R'@;&"
M#@'*_GC2G5+Y]]J.3IM9M5B=]V<6= H?9VWW@>J/-MKP,RS4R:#ZRS1<OVU^
MP_)=M[FV6JMI=96W.[L6[]]T<BT.!7SY %1;N.TRGOMZ.CNMOO_I9ZPQZ1XP
M'ODN*0?LQ]9%M;8S;RG>5DJ7];)T&<&E=EFI779+[;)[&,B= 3BO)F97+,!O
MKRCV3#%J(;RWQ>57M=9KU]+2[]:F$/JS&H3[PD6UR'O<ZL):=;L!" S'G_*+
MSF#;55DO&T:0R:=U3H:<9*D%._L.7]P*6BQP 4SN:3U\J,_EQ2TE]"3GC#N=
MG1P&<>\$,B07,O J:&NHUGJC?FM2P@BJ(Z(X%XV6F" MJ$5,:1H5)2+QL.92
MZ-P(5^^ZA0!N?@\C&(?KDX7A_=SSF,]FO,X"[VT]::9OEGCZ >BSZ5P(L\E5
MM).>L%P^\3$7)3?!NS_F0Y4)!HR::=QNA)0)O>I%SJRXSHD/]\PN=F/_?+#K
M+M@^C>Q(':\8!TP,MP!)6""N-4<NY+\)HC3&W##--Z)-.%IB<TT81ACB$62)
M"SF;5%%I-9-)8O=E'^4?8$74E[FWUNZ]E#UBBVU.R<7$]VC<[TF'NV\=2O2;
M=3_"?VT4K%CQVZWXW^S530-^S0)OJ9A#:BM'2++%/<C&]]+L;J_Z@M&=S\RC
M37-Y-,U;;"7'XK;$DVXD#[3$<UC67K1^A)6C)8,J@K:W=LS%KI0][%(WVA==
M?PE_#,/:J9?_^.7/;Z_;V>1,E(7N./:SH9W \YM<OKV]:6[O5PO^_/[#&1#\
MS-8_M/%+7\=\'&73P3&__KJFQ\+3WI&G+8-'1#D\U]<M=UUF=*5TZ8()\E'N
MQ0FS]72GN5J%'*AN=<Y? DOB(DYGUQ58JN]SWM5XUE52698D78;PXP_YXSQ-
M*=LQ<WLF-R09#H'O\[,N)F-X\/0+I\1:^-F^DZX9^DM6EP7%,:"[K:.K+;;1
MK:]>V50/U547<]B6N]RKG76<^J%@CE-- Q(N<,19],@X3Y#!/@3MM8LT;"0:
M&^N\C0$%ES#B3AAD<1#(&Y,#VH2I\!6)QD4_W*=^V/O@S\?Q!*32AZ6(+%KB
MG5HBH3>UQ(Z OXX"C#A7++D1^VE_OD[TO:$7PDO1]<'I:Z"Z3?]KW[6I_W6'
M4+K$X>O1+6"TN^O&RU;3AZ_?NU)"? F?[6.JU.7SK5R;.VO>!9%A,CO==I*Z
ME=#=F.8WPQAGS4I:</8(^C:->?'#1KALD4 ,L-FT]>2NJHO%2>^U4_3O_V_]
MV^N?EL? ER1K1S'7:A=ZP/D8E(!9AEF8V*QM,K2A5L]/EMTRN=4:ZC<6:S#_
MXF8F;5M*JVUPFJ]<Z@F+,:V\&\W/]2\2'U'K88]AF_>V?6#KA/U6]>(+:9#Q
M.@G27<VG!/I^IHE-J1[6'1D>K'_,F;9H'X^A?2B":0H\(8Y3/K<<*2@>H%@0
M[+0T) I.-PZ_*YNBS EW!'Y'H+P$Y+@QR'//E$\<_O5%^_A6[>/'&P&NE9;#
MVR,5F-H@E6D[#CK$#2B!AF.+?-1*)&.))AMUR>[5=C"?F3T;#T&:-;^ ?3V]
M^GT\C3^#M!V.F]DDWM;\I\\.MT?OB*-.'N35?_3QK2[J'$JK;G%[/>Q22OK6
M!3V+PU3]$4_GC=%!PG_(57^6'L#7'W^KWBT*EKWOZL86Q7[M6.#OH#ZV25QD
MV\% 4&FR)RJK7=<T;I8TA@]OL\[Y ;%KU?G#+V^63M!Z7N*QC9^OE",8;*EE
M:"=9U0:].D0'&AGHHI.VE_U@68495C2C9@/:8S6O+'4*:N-IV\;F.(YA>1U)
M\ 9AGFOH1)\#8]RC8+WC03O HHV:O0;T8L<918E;@SAS##E+05TABIB0(G$6
MKZL>]G-]/CMOR\>]2ZW4 R7D9Z#JKR-8Q%FK([^>3<_&$Z!+^#ANBV3LK*KO
ML9S9.JG6V)^O\O\M_)[=LS#3H<U\>UU:VETM&+_S/-YR][R =V;D5C(M2RG.
M*UHO=\TB^MZQ^1&P=306_LTL&G,QSY $LE9%A('574B&"+N10"*5]H81A9C/
M:IE5%KFD#0H.3%01C7+AKO(NNRR.2(ZG%'7V@"^+O*Q(ZJ5K8%7*EB!07X'W
MY]FR!<#T;!)C!6LV/6NJKDYB?RW^=>T@U,=0>PJK+$XB1HI;#H+&):0U!_LO
M2J*MDIR$C://24BF)7$HT0#F/M>Y[9 /R 8+DHHD:^,ZYJY6FUH<,O\X?CT%
M.(#5_%N<OIZ>SQ70W^.TJT@,RA&,\@NUJ?!1NP*R'I?#:, LUV)KO<[P=06A
M+9!X4KWN>;;8C;Z0?1JH/8HJ@C1&[S&62#-J$:<<MIHB%"E/J'0$"RTVSK,R
M;0RE,B"%<[6BF+/&M*5(2Z?@DS/:W-B>H!7,5>$_XGE7+N.-A8F \?_ZTM;#
M[)IJG=?S3;JS @;RA/9ZAZYJ%I,%:2H_ITUE%\2YL5$3_#R$"XY Q2B>DA=_
M6A89K]H]\/P.WSX=U1$TBDGLO.I'(-PI*% J660Q(2#<<])&" $YZ4U05$?-
M-PQ#["03<!.R8 B"[H5S'7U!D BY76)(A)-XTS#<5D3_W6P*MO<H9^9]8_W/
MKZS$@)6#:3F,9,*Y+*DCR%D><__'E)@EW-F-8 2FGB6F)/()Y]:/ M N"H]2
M"LX3HR+#K!>32T[:R*1%*L5<J!>,>YLX1F#E<^)8X-1L!,EVM7+W*MKZM?."
MX6L'S*@4R>=6N$=6NH"D9CX(KA+=;.^PJT7;S;R^KH+&4=78F-<QS@[>\35C
MKY@,-[S%O3]#TDYE>3YZ_BU_KLK2 Q'T !I'YV@LRM*Q*TO_D?M.G ZJ4%_6
M,/=.Q SKO\]RPM)*U<:Y,W4>'%Y\7'-4Y#:5B_:4;? I5'^?P:3;LP#S"$#W
MM$%U,?Z4']/5:<R2*^?RW_:6&[+MJ.LU'H#?NR7NDV1M??'TU2_Y1$FWUNT1
MD*W ML9B\/5PF#N9P'/JZ;!+AWN<([^,2>682X@QDY-BV@9_H-<$+@1HYLJ&
MW232K$9LVH7ZH]TB/1$/\-LQ'->]'$_;;,Q%SV'@F_:X4LM&1Z!4/*+PNE$E
M[?C$UQ^QB9/+[)AI94*?%G,NQQY' &&N3!!,@<0)%'&O*7*4<92BPB& =272
MQA'A;Q% G=O7G\4P&\9E!\C. =Q1_.UX\K8MO+KH0_HQ^SEOR^R;5V<%,^7U
M]&O'WQ;AZ,-*KJ8C3Q8,UQ[\'P^'XT]W0%).25@D\;S\@JS,>W['I4Z^ELK_
MH^K^^;=IZZM>+[B3?;5=19UY=9M,\DPST'SRY6AHKP"=NTLZ\A&,3_!WB^O;
M0E$737S9Q N;*]XNA%"K[W7W78\!!K$L^7-9-[5K'>4O%P]9O1(N#8M+NQ=S
M=4+X=ZL5>1959]J2/#_>=2^YYWV4G2BZYW?N^SXPOA^9KO_VXW2RE0?FQ9?:
M3>"L_]OI))=E1W-9D-I_MLN"[/+I"D"][,I Y2]NXY_U&E"8Y$I/\Z_:#8#A
MB[;GJ+?#.5IV&+I1#VSESLF\;E3[N ,4A'J@4_I?_HE(_&I5/OTX#3?(!^N0
M?_Y?+^B+1R'ELJ+6HMC:Q;1JQL,Z5 L<V$KL+81Y3.(_K)3:AM[T@+(KVU=I
MSRO3[4K,>KPV>]@:>Y,LSX6@1=8<2M9L^.*+N.G3[KBG\N2!:,D_6$_:.K<O
M+33<WV?-::?!_=9NKL87V3)K5CV9]]U%J^,9C;^*WOU75O<%OO=BU_LC\K4\
M>$R"MF]_5";>G@\@I8+G:8D<PS%WF37(>$81H\%*;3 )?*-'B) BT"038M&T
MI>H8TLX29*F405**C;K+$?[&7F0W8>?PN]4;]4UYP=O.- PHU0,B]:VA_[)I
MRZ9]A$U[4,.D\&CAT7X "U?$!Q83$EI)Q /..>HD(:N]ULIJEOA&HIEVWEIF
M.4K,P#TF<&2L\O ']48P;[$*AP86,U"$#+ 2!5?VLF<?Z%<NIM'C;G[89M-)
MW18-71QHRB?4BXU4H.SI0)E7*AHEP"C*<?=@$G(2\$QHKF/$3AI&;D)9L%H*
M+Q6B/!#$,1A7@%X*$1H5)L0I=MT\]E!01@><DH$1O$!9V;/%1"H\6GATK[AB
M.8]8"X]$3( KGD2P=#Q& 7MA'#%&\8TD5*6<\-P"%A%ALXGDD55) ,QPF0!6
M5"2Z![@BV4!B4G"ESR92B1[M*7K4I18N$P]S3N&\Y?TBM;#LBX)EQXUE&'."
M+:'(\_8P,.7(4&<1%A+L'NN$DWK#W4>Y4]$21$.,N8>:1I;E0C68IZ@XE?3.
M$EA[P3(Q8)H.-#4%R\J>+392X='"HWO%E6"<I#YPE%(DB)-<2T/1!&@A(['>
M8*8V*VAPGB0!RR@( 5>J"/IMP@%9XS!U DM!#VXC\0$U@"W\]NI(9<_VP$8J
M8:3]V$COX9:WL[;ZXW]VA9!O' @LNZ$@6-\1[,:!T<*RA66+85!X]!GRZ#YZ
M**K(I9 4><D,XI9;9+B7R'GC?0K2)[=1-S5Z;%@R HGD0U>QS@@:40PF$LJ"
M@/\.;1B0@21D0$G)+^NU85"")_LQ#!:]_ZI)O!C",^9]*+I>*65'%!0[;A0+
MEE@CDD6.*XZX=Q09)B72DIC$.4^8;'0"#K3M*R*0UB87Y[<!V40)8MX9FKNR
M<+-19G3_*(8Q&Q!34@#*GBW64>'1PJ/[Q15/@Q0,6Q1$&UIG"IF<9*:X$%H'
MA5G8",>+8)4P8$PQ++-%%3585)RBI)W"26#)&"ZX\KSV; F;]-HZ^N7\8CB^
MBG%^]N9B-O%GMHFY&_JH%QOBGA59CGG+[!?F'E[RYFD#(<?!2:MY[G/N$1=8
M(6>508H9:XC4-J:-_ %B@B1<Y\,Z*C<[SWG9,H)PTR$IIRVA<J/?P;Z!$-!]
MH)3J)PS>N]1/V?=/0+U].B980:^"7@=%+P:(DQB-*,E\VD<)@9SG"8$!)#@F
MT<FT49V'<05WB8"B9X!>FG*DF77(VH03=YQ(=O#L-Z'8@!%9T*LW^_ZP8;#5
M"OE [OT:?JMELO&)H=^M#0??4:O_((;A_0I ?AS#IN[A]J(G-.^O,)[EPN4%
M5A\!5K^!Q,<%K/?;"=N1-D8BP1;TR"<)=J)E&FG%.&(F.A]8"'RS(<Q]^OWM
M_2PN&4AM!H;T] #3G:SZ=.&V&(M/W%@LN%9PK0^XAJU2(D6/A !PXXSZ7(:/
M(..89<99AO%&@LE]^KWN/1!H!E*H@>*XX%J/Y,&:&0D?<G^A/K5-V7V/L)OD
M*',M<RUS+7/MXUQ_O-%E#KX)]>6?-AO:M=\^*\KD&0-NK3;P^T?K OS\DKY*
MP_@9A7H26P4CM[*;G8]>A;JY&-JKE_G7#17@1 "2Y_?/_:?XA,,7\_Z<BZ&T
MMZ(X"J\NQDW=/GL2A[ TEW&UY=I2E_C\E;H!H??O@/RP[C2[7BE"MJ[2V=(]
M/9])/1K6(QC2U$[F#0G7?P :=U]?V-/8>:J133#1EW;XR5XU\U9VJ\N_KB'F
MY;QFB(V%W>WZ'<2O_*B]<-?VEQ_:ILE+!W<NV@GF_\/G.'EQ<_N)+<0] !D/
M*9T>TE5TH_.L\LEQ:R12\"?B(2IDE8^(*LPE)2:"R?C@SK,KYN#\//_7-I;]
MFN&UC67[NH\>TD3YJ_A#GU0=>:NN+]%_;CD-]17$^;9&T[T@3_NJ;^\QO3Q#
M]L?*&;([J?:(';O7"/G ?MV[YJR_7@!3Y;[(O\7):9P,NC;K*[7<%R?OVL*%
M,53NJEH2]Y-M*I#K(&M"!5?G?9V])?"I'DW'E5W>FS_XO\] G6K?-6_,W!9/
M4*^:M?[+@RK_;>;R^Z>U'0ZOJJ:&2=I)!=A]WBQ>%.JN-1<,X5.$Y]J+"V"1
MMA=R+BH"VL(,)K(RU&XD]G026VYH3JKU'M$MGX3\G,GX<WUNIQ%>_<!.X'O(
M%W'>6:QB/M&<<S\2ILA)HE%02E/J%+%Q(XK%'4\R18=\R-V<@B+(<0Q*$C4B
M<)\$YW1-MJ_LHG=IL8T>7&9/$S&0A-WJS>O#_MC@(&"W>GIV=&P2.-9,N(2B
M8;FH%@G(P%( G&LC. Z6X8V"]LDJBTW,2;&6(BZC0,X:@ZR6U.=ZQ=[81V>3
M+Q__Z 6;O+_Z7#?5NU$>P.G5DEE.>C7( GPK&D)3C5/UV]:&S'T8WR C)>!:
M"V[]ER^$ W9$*5'(U<UY$!E-N$/,$N.,U4[IC=Y/WD4<F31(!YJ;"@(@&4LX
M"B!W8/\[R\EF,=AL2"Z%R[O)'UFU?'>MKCQ0VC#.!U3<GCC1!\ZX1J(U-:U%
MI5$5/\>)K_.!(+#_8N;Q?^X_]RA!0E),(R6% V.3).0,J"92*$.Q4(K1#73:
M&??\,J?8^TRP:]R:_]J0-9;Z*_PUA@]3P'UXT.O6RK8_CX>@GS9M^/-%!:9N
MIC!>Y3OZ!;[3)^3VLI"]8+J+K%+G"0Z.0!I))H.U'#07F8"?<*[Z0PW\+3HK
M+?:8IPUI1'*141LYHHF#(HVU1#;0B+!7D4H2+>C,>Y9&1 UHW_GBZ0DC$KAA
M*2DD76JKSG*D%?5(>1,9E=8PO^DMVQ7S]$$8$7Q";F\0U0NN6TJCUAW0?YZ*
ME#!G _!4L#DG)U<MLQ&P*SI"M4R!V(W2950E%TWN/$8Y !Q6 6D,>I7D8+,I
M@W7<TG/Y<062Y&2@Z.WY-[W@C1N&^I%*(1YDXBH?6PU@M7///'(N'V7E-(;H
MM)-A(XMK9QS3!RDDY8F\_;!K+SAM*85.JE]:MVEJW9M/@P%E\I):DEMU9,>B
M8\!6B3ED91022R]<<!MUJG2BH,='I*RWB%M%D$[2YD97CEFO0L2;U18+ ^X
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M<G_.I?T?'(5B X+Y@*G;>QV5??W$]G4QOIX 19\20SX;H/%,.:&(0C)7^N>
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M*C.@K*<UJYXI^/;7!B4'L4'GS__7-W"SF]3_.FCLJ$%-G-2I&*G%2"T ^=@
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M+HN2%6*Q2^7S__RW:FCZB'%3)I2%@'!<^!SX14%G/,BCN1H5]36JN'_5U[C
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M7(4O2J&T,-=Q03S7OJK<P$/+*R&HS)ZVCJ)Y$U3LF:8TNTE [[:VH" OWSK
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M^HOK=&V$EV^JLY9)W-PA,:TX ;KN>?AD!G[+19&ZCE.X?!.2QC@V5 -O^FV
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M%FP?GG)'$3?[N75C*._QE5=?/AOO7SU!&AZ_6X5>*V:P=\G";/9-*6%L'!7
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M!LR@O%G+J;8O75GEX7=.;^1VN$XL&-:J+=C[N<W6:9FXYJZ+.!D,,P#Y1I6
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M?O7G%\Z+@Q"X->@;7V]6B68'S637+L$:<AVGF_?Q%N4^TV7S>AUYC;C$:N:
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M C+7X/!Q@9](B$=9$UJ.E"0K:UZ!  ,$N6Q"^#S 7394Z1G,]NGQ_]FU5!F
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MC/_HO3H&V]B)KV0B5C*CU2X=-U"(00Z[/HRLCZ'1 <L(>QK-L./:#4WG]T)
MVU&R+\H)&AJTK$3;GQOXM6F(!./&?G8("Z3@T(&C!ZK=)'E=*K_7I(";'RO)
M)UK>I\C"5NO]2_)[G41)Q;M5OB,SE!WE"RWSN@B?UF+GX&,_K=0.3/?_@RH3
M CJ-E),1^U>AL+(W)(6ON6HK)WE1J<#[TY[(E+P#EV;WFHP2]N&RFO[IT3@P
MPJZ2."B$D30OT?S MQD]%<TN5GXP-V/#VS6C:9\,="=A6$]K;B=$-$["A'<5
M,SVKZU&[AX[ E\,JGS+EU_R&=^[D!#480>,D!1H2H/^U,!Q96UJ@+.__F2$/
M3)6OJJG<)M6$<</7#^]:#9&49<U,)2 _X.\T%Y8:-@BF,2T0CL4'MZ0 JZHJ
MT4(+*J6D85V(]&SFMW".K;,$?JMG3 ' 2E]?P]#0*F-<9&M=P[NQLC IJYD5
M[R2W=CJH9D"GI$Q+T#CF'(<FI)@75TL;[N85ZIC1J!"0J@E5@0&^TVJD #7>
M?OL(/^&9K&6Q:-3:TJD$H<0I\(G]H(-T=9W[X/-R F-B7(]=L?J4?$ :0(Z=
MGFC!A07%1HPXB)!@URC$^1N2I*S-5 V<ST<$XU5BGB(_EZ*RB*KH.8456XK6
MB8)E:YL-EG50H@^1D!3,%=[A.N/-9+F8X)UY=IWC*A!D,L'H8)^ WP_(5<!]
MO 4OB6ZXK['0JYIW/</' "=A5T18S"Q*(NZ?]#M"<I85K;.9%SC-:]ZZ%V^/
M8<7QFP)50T$Y_M\"M\ S8&81BCC09XZ\4.4%.RLA"C$.MFU:O^DHO'^JIB"N
M*DW9[-@89KV^HX+S6.P%V-CP7BYV^EUBXK4M?5D?VC>,755\8_D:/5'L1+O"
MV-T$4&;<E\.Q^D$WVH;N>H[E&Z9KN8;]LI\J\YW2&8PS;:DC6NTR(MU#%0PD
M>X;AM)'D7L_=MC7=RZ6G#D786>=K;$H*S)2'";,HF 3W6[OSP$'7MKWY?)W(
MKFVLW@79L6VN^%<RL63B_3$QW%$CA-<%LS.BHKYN5 <WK-@G0G&%5/*JY-63
M\6K/6&%V,BU;RY<?S80AM-C*P+?YH]\)N[.KWBB29R7/'I9G^XQ:L=!EQXG@
M2>8%#ZLP Y^6W(:XG>13[J?A;@R+7T;,5YP2YC7@<^*:03;[%F.<.1K@P*LA
M>!TPL)'"&O$&.?=&.91O; Y/8(C<Q)<B(47B&'8S9T@!Z,#_@ITQ@$$+L*?3
MY ]N,_>]X*[4?^/<=M8+XWD>5F&_8N!$&# 8DTF"NN(;ER!&Z+8*O;'B)7-K
M' @"8G*+(9V08JBG?;+"10P&*T5%BLHA1079D_"NZAA$PN!<!?_Q0%]=% C<
MG!GI _ N@HI"YG*%EI@&D903)8-Q+2@*A05;KZ4RD!Q^3&609#=Y>D,CD7N!
M,?Y*(#KG^L;NIQG <\A4 *F8Z=+69<&-WC2EH S X(>' !N"Y/ M NF<2D8^
M"B.#6=%CV1%N Q >2!=>:X7A?K1YZDT<.P.?(,[3))=,*YGV*"'L!4N\H->X
M0YX7\]:Z>(.72&:4S'@X9FQS)T=*2J]%^([K]1Y#8J96FK X=']_%8$3-S@)
M6+C*K ;3-N1)7=E\O-:$'<I6]?'HNWIF0]) TH!ER:-$_"]%Z</%'XP6=Z^-
M-PQ?HJ3@20JO 1[J:;:(V\NG#\9VDK'WBYH+VMB"#]8"%\VB-[.\3-BS60)W
M<D/?!/D=SAOGTAYCN-OR6()N[+XX3^O]NN^5,O2UJS0IEO2IT Y,![PF=96_
M6?P":,P_GI%KRE6,2F*8Z&N2WI)Y^>;%C\O+OW@X!9>S8XB5A=WO^ITD"_Z@
M.2<+\B6,)701FNO93_B[9RDUU+;7$/?%<%#K5.3]+:N25"GK<()F*U@,2:S0
M&UJPW+80QL=KBE0+^59MI+> 2[,:P\FW;<(6V!!QDO%\1-Q,9/8$VS:I)D5>
M7T_ KN@G<H"9C&E1U;Q-W&NR$_EC^ >+.S CA:4&TFLP3L"Z8U8,C\CUHM;]
M6#5N^+3[.0MQN;'RC6>JPQ)A#*2:D(H%JTE28F)8Q'@&YAR*'.UF%OV,PF8"
MF#68L7-EF.>WDF(Y9P2Y!8*6DV369=.S5+  ;DC2NL+M*>9%X"8M+:;-;A>F
MO+7/$KM7+!<2)H:YY*299[M]"]2DC#!L3B2"@8%]/U<(2[KDHVFR/DN^*FW&
MXR1/ 6S&RON%A1".=Y-4*J;=?LVXI\US'(E!LFA4;UN,#Z<9?)@#"V%**DQC
MFG!W'NU47+O.N^_%;BOR'2@!K);$N/IAPQ#(PH2U,*X+EO[96SM<"1S.=YX+
M",/F4 #WT>R:7./'2=;_!JZFQ370D:UI/Z@+C)>5W6LIL!\?<\=?;,1E23'/
M5KRTX1YF:L.XZH+EW-((B-+<(G)TFSN C0@[<]'+&2]$ZBQ> !B8 %Q%Y7BP
M.8+/'5U_CM="">:#=G"X#;2Q_>I'(EN3+)X44;,ESG :I9+MAH,P%>CO(]-/
ME!N2UBP]64 "^H+ E!4-)QF0[YK=+K86!>[C4"F9,D86VR7M]DB^9C^0[;M?
M8P)ZM]F"$L50CJ$"CBW+*P3#F-P 37! ,)(:<)H3DQ280-U\_@!I.UQ>4BC*
M[81F2D9!_J*6* %M,G3%R4<PRT<<EIBHUJC2"C9<5%YT8=.SOT>4%YOW8-L\
MA882';G%(WIZ;$WB<:.?;O,Z%5[]+=* H_*&Q\!  :@ 1\X *@Z""V=VKO,=
MGB/Z*<UO3W80[%P.="X=#!^2YX)' F+ ]OP6D9D=ED=Y1J6-9@K P)1# AZN
M*:+&"F!GR&)<^_;@"IC021[AZ4R V0S3HZ]8YE)>ER#DY:O!'A)@=0+XS-<$
MKIDG+;Q:'!D^&J06+U<!>O-:7-(&7,?:R^9ZIC1G)7U=4M!M (P-7_#R"^R^
M%RN5*V_ NN.6Y.OF >M*4O(7VOK8,5[V/?#&RV0N^(^;[M-WN >/YOG]_[E'
M>K$^=KW+FN,32I:NDY'=ZICV"A0]N;31$,J([+NRRV)49Z&H"[P8O_KS"^?%
M_DG[Z,+*BY5V&D(=<C&>%CG=L7PL.UO\,6=GBS\LGBU^7/F=0ZW.IC([0UF?
MPY4!NT0\&\22G1[A#(EPQUH./*\MD>RT2';!UM*!B281XR2(\<A^\!(Q!F#[
M/*FKYV%[3PS;D=MJK7ZE%0]0U25/,!?;NPLE-AXM-8?L;SL$HF]/WT>6I#UX
M6>6S*S2[95U98V2;C[<')9_>7QOVI'QZ>5:?Y$*)EH- 2VWDZH_LCB/Y='"]
MU:1QNZUQ*W9I6:GN*V'IOA*)6-+4/6KO$(G9NS4TMD?>4M*[Y,[SY$YIUYXM
M'<^?^2X0&J]T;V3YGF3/TYNS,E9[='.V=Y1C($;L+MM/$LL/O:MW*6B/Q_AU
MX\3&R&Y[>Y+)ST.-7H"U+#%88O#A,-AV1[9^XF#$\X)@&5H>>@(\&N=736NU
M5UU7$^QCLKF55',LFO*&4T,2J:U:UPYA)9^P:"??;]R-Y.>E4G9L%>R,7/WQ
M^7JG[Q-\YB(A$T$NT@60:"[1_(1HKGLC4S,'+!##0O/]^@RKC=TW3V/XW9?9
MDW?HK-WF-;]=B9,/<\2R\$Z/&.]9$XOM^N;R=ML/9K7S[MJ&,;:[CKF\M07V
MLT]*=,I$(XRF[^[ZKKN$OV^"A7H4T8.@]T)6-XI=F":\[%4B^O=:8Z=[-:OH
MPUI?YG$,M^#F#I!$9?. AQ?7XBZS>SUO4_G05>L;@<,5SD*S5"Q6I6+%8-:7
M#PO($EXXZP=M\<J(8BNI1+1$X,TQ8>Q-/1Q1>W;4F\</?9*Q:GV\(@\)P4MN
MBL9%21EBD\V2=\_$.C=D3=4U,>?'4WPM%?K-T&$T_/TS,F=OQI$;74O9$1MO
MC772FOJZ72'>KNE$]T8^<W.!65C9(39E5LV?SDC2>Q[>H8W]]HYNO#VJ];I]
M =EN0 2P-A.93]NP0DF+FP3+3 %-L"P)C?KW]_NH+G5;/(-R0A( 'P) ZW$
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MDP'-__6-;C<),[XYWC_X[8>?L;]R+[GBDV=5E^O;V5S^QJUN%RZ[A N!72#
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MU!L67PX_/?PP64^>(<-73WDS>/G8K!YZ<7VQQQ_PM*)#FQCVS]9]1TT#BNO
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M!_E"[+7=!ID3"U_B&([+$X'\Z,@#4_WU"O^?U.T(AL#P#3_)*OHVR/4<N:B
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MG2:FE^U,:F@<Y%(5C;/%H:KB-7XFBBI3;ZNBL\/O!ZVFV[$<L(H1B'@@:(X
MTW-'YES?_LIU5YA+#X?135^[;&]MMIL8MZ8TJAX">SRC-MRJ:[L/30NC*4RL
MJ2P0H1K@]UT-2QV^K<,TBG:XMKG <MC[Q*IZ OMZ+R)(\&5S0W8!+_A2(STT
M/QR^K2_?:.H/"=M(-797C_A8(H)DA&)&JTSF+A<0Z:5#4^6\(MXD3N5@TL2G
ML.##6<G(7"T>!<(MP]<LZUM=:=PLN!N%3?T&!9/6?W-3D!SMS+!$&"",*J*-
M5D0+ME,;AWPT"2L%W*QYS2C>1B5[II60CO?BR:4I@%:DD$,7=,/R4$,51%JJ
M52QJ,)-J5V0I_@>.T@[3B1TM\;4J,_EL[32?-H^-#G()/=188>$U?=&I) [A
MAT+&CRDK,292UR2N,/H=W+=F!/B4E\+U3U3ZC0+BZF+7,A0EF%;.HHBYI-#-
M+C/5590:Q+//X"_ATJS_X&7*IHV,3410V14E['GI63N:4'8U.H@U3!G9)OSP
M"VQ'(HLT6LQ\WFF^'S&YJ]8UDJ0MYE8!Q'.XFR):&/8"/'(-\+>O&*:$*UC[
MQAR/2L4-4+II( !%04ST2Q([P>1QUC00Z/4M.U@0,)A=':>!/79<+K.3%1B+
M!J/& 9=8]M6MK$OY9]KF:(^E09@Y8Z%(*G(_8&5J J$RV1&J>_OR 79FRL08
MJ>V+^HJ;6W:82RGBTKK6N\@CP,B!3DH6+Z=0A&L^*SRS-]3YB;L 64KTP"*H
MK<[(S,8G0 X:Z%*QOC?@L1<8<Q8[>/7[!Z5*U>^QBP2/3C@+J;&=['0*U:<A
M">)#>_&"]ST)M4HM$X$EZ!3A?REP83@HK'I:#'I@<?^\(TA+=IF!$[$2!=Q!
MIB(#CX]#9O0=-G)26H=/:DOL%NFQI3D[[[F)HX:'34EW7^!E]^?,&UJ6/QW4
M]HJA6;.'>3.K'B .P'I^JB_=;@6;WN.'C[].K<$?6RPSN<IYK>S7DY<ZG@90
MIRU>)11B^&8?T5FC!3?,6_F$UB"S'=:I+E'V&G<"K:!N;>F!O'8AQX]&:7AY
M+_1Q\F ;A_68#UCJW+1HX?UA4<-(.%#VSQ6B4X^U&+W!*PZ^,2-:>IMRZVN>
M@E-X&)*"T6RL!=&?@Y!!QL $/.FQV"DP.!-KML%#)YZHH?R'".]=C$<.'@'N
M>P)KP#2FXP[/RH05"-0K"T?!R@#2SY[-Y#!8?38V90+GJZR@QGX^&]0$,)0=
M:*27Q8^A]PNBDP57XV#.ST-_:NK7]>0I)0\?'IP"1_!HR&Q8>'=@'E@W"$;Z
MU*0$-)NQCU^Y#H#M%D9A+L9GSC7Q30AC?-Z7?2Y.\&:"K2ARTP&YV]6XY];Y
M.PJERQ[YQ#H7WVIQNNZ-TW4^@*T:9,]E7?I2T_/S)S\GK\%+QT* AO'GK_^[
M>'G^@_^]38,I_)5<=<Q2D4&2KX\J<[!FJ0>H]'W+W.83ZJK%WGDG4%*W@LY:
MO*-[XQV]LKN-*KKBB4!U1GGG<PPQ$M5-J1%'.>9TU*,QRR>SZE7*D!E>K$PV
M-C--PL,:CU&-5P'>=;@$DB]P8>A/[9=1+]2Q!>:_<E>+*'8LQ8<#-[(F3)MU
M.OH*BW@5.W'#TD$T]I"0L)WT4D-@UZRIX7C#4F+N.1LX)X<G%/D"E\X"'. +
M2+'!)S<<=_6:SB)*Y[ /YKL=2(SZ&,]"*N4F+"O/-/$JHK<9NG&AF^V(-?HJ
M5#0C@5J)N@XUHV(5)T*6J97"RF2"BD"'=2>]'S!U5^IE6,H!34?10Z@X%3M3
M8_.^\HJ\*#4^-$7+OR1FYZ-7;YR"-*FNSYW>#($B0N?2Z GO303$8[[%O:ZX
MU>&X\O,D@&:RW5O>K'PA32)83J0_3$4.W$#@XUI7).-LY^@Y)O$X'SQ%)^M?
M+=C1$\6./EJPHPMV]"AV])ZXJ'=!!9)1$HE);PC!I: HRSSC@CZ]<26(^&#G
MJE KM@PZEC* X5[Z%SI=B668TPY;2H4@29;T%'";-)_4$^<X;*+DNF'79ZL=
M[4/O5(IE!\W8*'15W8K +\9E,MR9^XY8C0JB5_"%N.@"T7D*6P)YX#Q3A,OR
M+;525XKR+7*-):B[5T'=*.[!VBFQI#@&-Z@]DNM+5<<I$*DLDE#([SN/\]F!
M%U3LJ8UQR%''#%:MN$J2$PSW8*LFGYJ6%945?6L.I:3-HK0!%_51-<FVK%=H
MKJ/6J- ]17M"L:;))7(X7OZP;IY<@%?W8%/GY,O[;YPE;]'>LZ;!9#;O$(%?
MG!A@:.*"TVEV(,$V,GABATQFC"+!;. 69S@PL 5*K;5;,Y1=DO"#TG28]%&C
M$G<<'J;#8><C\Y"V-G[YE7!OQO/M=FF,B3T@)*8ID'],&$\*5U)LU]-.TT)P
MF_M:>)@89!?9NU^*+0),?3]CY;9UQU$I&#=\&<L,^^S TTQ VOJ0E6!8&^15
M]..6:WJ8/M/S, F>QR$3@IG,6'JI#0AH B)F9EELD0(Z0NU@B,K('9]VT$A"
MQP2;]*LX*3+[T=9:2V18]""<;]' 3/COQ*@0>?SHN^_E-F)E4]F7B=S*)*2O
M#?CIT$).;>82QVE_ZJ I/?, )=^*F>U\7<F<L7@V"BC>'AS\J$ITA%<SH,A@
M"Q@+BP7H+!)]V^E&4O?ME+DKBC:BJ%AKGDLWO1KAH&WOC ;#E(U2'DQ:A_-L
M7W22+:RF#7J<O((A4;:@YK7L,3I*%*&LI&7QSI7%1<WIJB5Q?=]\'%/IT]H7
M0;G<>I(%E0XQ;XZI9X?9(7L*0^&WX+VL75XP;6Q&-BOF0X@VG^(9F:&W;8U#
MF* ]$!K1GPL>*/4X])42GR&XFQN)Y";UY+H0<Y;<;0!]\AI@<);G2Z#C/=#O
M>N_>.Q1\@NETD&\C]?(P 4."UNE5>5G0:K,W\21=C5V/VAM@'S]B (;/[AT"
MTKB_9@([.B)4"1E@(M5%AVYFIZ!Y1@=.AN$O'F<#;P8PO6&2%*>8 ,;"0"%9
M=)OJUSI .K<5!B?=>\UH!G@+K.5:H[%&H:'>@5PV@07*"X(9EI?F.6,DGRO]
M#H:R J&)O7:)3!D2%1H9[RDS2T#EHYN\#T:Q6%YA*^5%0O<AMD+<0P5PE4VP
M ?AJ3Y3M'62"A>1/W(G([T+T:M8Z@]^$97D5TN<4B3#R$GM+$6]!;03>+40A
M%PQFZC+V)"=9R,SCJ$LTZ+-8O)O[XMT@V;S8N*E,8(?>GHI%"!N>0FIYHJN"
M&D11$\>[_!6L[3(*GW?UFB304VF;\_?R,0;16.GV$8<;PHC6V-6PX2Z_><N[
MCR_[8[_;9T*=.EG )G Z XSX##[:BT7OBK%IOK?1B.3LJ9E*.GBH6Q2V"VP2
M4EA3BNSL97>1<XKS@+*"F<I"^5![1YD#3@S@87HX2UY.&I^UN!%,A,^HN.SL
M00#R!9-R'(&XBW;"@JF6F^470WI:[OV;F%_AA9.3@R\XWO=I_P2GK$;V)NE!
MHWTZ9L0C-CRL1ZO6NO>:$,C6(=<5U\JIMM[Q-\O# ^XXFW+OSI*?ZDF>=DIP
M:18X[JD;=CYSPG=B_@=>+*<,0L\:[1CTE(A$Q .U,T>1#=B]]@*J+4RR$MC7
MQZ"'02($R_Z>[55(F..$NNWS"%1UQE.<5AGJJTCPGN0@$&%J>&%'V:\-BU?,
M^2QH7$C],&*&S<GK;:.1Y!?([$1 ;IX\FU!T\#WN=M UA3T5=56YTJ P*:,2
M'%)I9B1H)7>R:.*<Z!VIVSEKV6OR-T_QJ;!AM=F3VQ(/?=!^JIQ%*>=60O\W
M)C+A'\*AUJ)S#0Z4CI$4M"0,T79/<-BC)!+M3J,M*;KKXI:<ZDD5=<O)1C''
ML#S'GSP@20V$NQ&O<AR^S;(LG\*D+!9B)N/ER-F8I\B-DM"I>"4</8EM_?%D
MW_.B;_F!<[KH6XXM2UPHB9@X=9V[8M]I!20<I].!OO?_VD6/>['6N[!64CV*
MZG,$8%;N JHF-H7-=-E/><)UMUX,=C'8.S#8#V'B64QS,<T[,$U#)T,AO6>:
MX=U5<?01T<&-&)H6^UWL]P[LUQ(Q(N8AH^^UB4*-N3,8_03DZR,G5BFQ5P=E
M.DH-6<E-"8\6^U[L^P[L6]'P:-"7KBK\3DWD6KA+K^'K!<$XC%[>LATOYOHI
MS!73:O#!2@"4EC>-LW*T%V,WZ\[!5KINQR:\6.IBJ7<1DPVTI[0>K54Q!E,1
M[FBQR,4B[\ BA6#%LT]Z%NDMPN J#[6R^O*$D@ GH=BM>HC3\#.+M2[6>B>)
M@R(W-0-%(:0&_TB 5HFHI/N_[.#Z[-#ZNC[LKVC64U:[=&R?:,?VXZ5C>^G8
MGNK87LZ9Y9RY7:_('"%!&3,<)I[8'QZ)<B2V.>"(X&['=.@*. L$])J 08:A
M-@UMXHHX%%I^[)</HSB;/,Y^Z_B<%S.=NZR'9=LXL>-&L@9,FC@%VE/VVA'Y
M3Q";^O@$0"<+"KIOQG577!E,]2V-4A9H"Z91-]JM- %%G6QI2$6>&[<&0R(>
M:\%&<..?WT?C>%*,>%Z!-?12J;"HZM-Z<1REZGTA:K":]YC@LC>WT4V3;^.'
MK[T JDE%>YY7I D:<M23=51?>>DVO2^;]@WL]Z:"VR/%ZW#(&C'IP]&UX-GH
MA">1:8MO=G\J& 8!YS&?=22D5GST%4.-'-,+IAJ(2T^.+836W%/"],A53Y3;
M-MTNN]T,L38S6+^SVI&^J84_H?(,@ZD4#FROG3XAXUPW#K-5:60GD98140#7
M$.150L;=4AN9T-Q=9LVA(/%QT7@SAW!69>6A=6(WNU@QVC*J$%'C>HX%H\4V
M!^Q!(47NKF@9[UOP*7%3+29<,W #FBFZ+;HLTB#"5'U3JE.>:C$TH+Z:D M0
MNT*6F1WWHZ[<@ )))>-49V+J]#G"H?YSX 4@+20ED6Q4<N=F<NHW%/(>4-7@
MA*Z*VC"SB*ZW9YNZ5ME[\G&Q#R"A!((XCM3F4H&;V&3;8EJ"6UXR]P71"K6W
MB6CO[:W8]32$Z1,-U)/^Y/L(]YS"_G^O#\/;UP6A]G%IC0R-V=B:8GK)0D.8
M;V8SB\,(!DQLXJ-#D_VNX9;AI;U4 4^TPC!O^.N:FA9WZRZ7V]\FV5\]*?3P
MM<]VY8J0(ZM#Z66(ZT+P(V1TJ+$0FG6#)P'GQ):.9%O!]S)[G79'>O^?>O\\
MSV] 5GT L&I$,56@"< ;@J. ^"PN:N[>D2<8#W4SH0F*<PJQ$BZI3E1:E3,%
M86->3+(MZRNB&9'+2W=A"'24&#KT=0[<QE8\))$DV(,+0-L!DRB*8-S4:YQC
M^>%\E!=^M/FL;"ZE!?^@5Q(4(8)V!,X?B_5UJBX.#^ZG42UJ:@91$1/9K,#M
M8:XT>0<3KO%X!I36:ZK/^/58.V7BFNBM!!$_-K2H92LTMR[-6Q\[0_YIBQA+
M>GP&QF( VS;KS62ND5#ZYP4,6,SQ),U1E8&KK OQ[H0V\&*,BS'>MC&R2R.2
MN[!)8J3NRX.<Z (GXY\];I&+12X6>?L6*=[P1 " S#G:F,+T.<212,VK>^3*
M(_!?DG4=:ND2Y8_%4M7!OY><>F$PK9\9@G6Q[5.T;5)I+-!^"2G!.5X%2Z@?
M, I4V4_%'.PA$I>*R:'B:KY1S$:R,9%3K!NSO/P26BQ_L?Q;]S,82,!,L3GZ
M&\36R5Q"1S,:BW4NUGGK^[+$7HW;N(9%*-"#R!FSLO@(BRW>G2VN^F;M*B*J
M5G=UW7L-D#:O]YP]**K+#-DIM8_05Q:,IC5[#@-H _R]J^$)VY"'#W*-A-+P
M?;0$\?P]<32"WX [.!8GEE6PK();AS2'VM:NKK V8J(W:?I"D9.^4=(MAC1X
M>/%BI(N1WGY_5_T+%DB9ZG6(PA]LNUR9E2*FUY!5HU[,=3'76^?)0/UGQH8R
MGFT"%4DR'K*KMGGC7"6B"1RCH7OAB^1$#]H@+VS?,6X'J^2(7%#4IK!M^%SR
M8N6+E=^FE4=F3#FNV@.(D3$\WI&I*QP!+_A)VIAK,+S I;VI4=3O0;^?;[Y=
M3'<QW8]CNG4,Z((O]PC8(?6C"]&'1Q?"PVE;KZ73::0V,/"EP6Y._702BUI4
M9OZCS.0< C!"TTWB4"-Q#;C596!E5]0??&HH5S6AD\"=E/PQEK=DD8=L!7_!
M4Y8U$DD,8E@WR\JNWI+RXEGR+*1:Y<K3$%I18-(1%14J)^"SQ/CNMCL"KXS%
MLU@" N<!U9PB^!_I8: Z,@Z"LQL$/$P&BT*:!HQ:L\#$J^WIPL$7?H83Y6?X
M:N%G6/@9IO@9[ML)>>O-!Y/-OU8!$J:H+1BXCIMW7V$0V*)67D2*"P<%([P)
MC\R*CMSD 6= 3D5IT<NA*%4[U_$(0NV>B1:C5!0T0R,'?71*2"J5,X4N-:-5
M.'T$5V[K^25;.'VQ767ISKT_'M]?C7E&]DC6RPCY20O/C>,RW8A!O1=XJC7]
MWAHC&>W(#S,^G-I9QBZ;UTM'X75DX4V4H4.O""^-C'1&A<YCHU#V?J*U9*Z/
MY)PZ!@AWA9!HYJJN<FXX7#?]UNN,D2+RP<O3-Z$=Y!CO-:.L>I1]?V,Z_?HF
M[LG"M8L]CYR7XCU$>"SHK2F"FUL /1VWESKRSVD'0TTG+ Q74=LCO*'1G:EG
ME'18N<T%A1/ J>Q06TM;KV4F;]R>(Y=FR7CVTW-"G&L?ZJ#]E%_OW.N<U>=1
M*3G\#P0I++1*@!_?_7*6O*5NS<CJ:7"F2<24O_.F+SCY(?9G\MGC#*#-K@2\
M:+2/CF5ZRT*O"8=UL9.FTO F<Q;"S:5GWG2/&LX2_$E82Q;*DL]Z\W[.2R8=
M[::\R\'F(C#ZOBN(%B?#%K!]&7#UP0)'"/NSY&^X266^SVTBMO?1* :_?:"0
M=K^ \TA^18,-A%X98+ ASJY>-.ZZXJYU+*]?4BOW%8_'N!\E\K(W*%@Y,3@:
MA% R36$'%[L^5;M^(7W-HF^9=3-F0D)3EV[:IXW."5$$]GDEX9_PK:']C!N4
M\B'"JX5SWE135SSI)5F:'&FX.VM>YUC::M)G7AH./W8>_Y,;]9+*'UO6C%.(
M&SYN[^LFNY*C:];ALYLY\I@X/-G,+S^O0NIBQ2=HQ:'?WR,+.U2ZSBG6B.TS
MO\BJ+1OH57:(_HK]Z*)=X.0:GR?F93'B$S1B4RKR*18,_A3JNF/W60IT@8W*
M]^0JF9BU=OZHUF?QXZ)1[P*SJOFXDCW!."M)G=2;S\OV%SC!J1F^86OI5_\0
M)I(-9DFPA>P?$'!Z/3 T5UH(A8:V>7%94!XG;U#TED3OX?\_/TFOQ6Y/S6Z/
M^,X*?*"TI.SK3+,HJG4M]I01M70J:5_LD*3)>/C]JLSR=\FJ_H5^?O2]RN#1
M#DW<44T6$J>+F2]F?O?.-6)L"*BX<VJ(R;;'5$W==YC^Y*Y=:1X&TV]'R?T-
MX7#1TUGU]/W/UM]>C/H$C=K4U-R:,I(7KEQ3S4=HTX@"5 JOBVTNMGFW[3H4
MD_'.2RS-1$VL_'L(_UF0WHLIW@'2NW'[GFF[R1J9R?GSP&O?$9WPNB;^5]4^
MD>+9/YCSTN(KMC718G*&!V'=FR;#6Q,_:57W7BSX%T0",&F\%5J9T@SV"20E
M$AYSB>*GVZZ&F -5X-C=$X#S AV[-U7:YTV](Z/1GH 4[0;)T':9@EXP1>(S
MAH'R=HU"/(B.*=H+!?I<9DU1]VW24B<!UDH#KB&-P$35.J DZ= :F;1'USMJ
MX^_H&8G @OH"P$0+.-TZ>+J6F.Q;9WXC3+5()>2"Q<-24.Q/W,!W4\)_!4RU
M_6I7M*U\VSS7AMJR6A$GH"4T1(SMLX.(5.'<1RT:9\GT^\ K[?M56>2$$I)%
M3>5U6M3H:OJWI)P'W6!*SI+SLISZ0Z+P#FIXA!'[IHZJAUT"WR<\0[_;"^(*
MQ4 P,XS38FUC_ )0R"%9PW:4$>5_>8B$('$'44NCK!T/'7%Z'.=A1P;F\%;N
M4*.]4#=%U35U>99$F^3.N6[BL=KQI,$NAOF0#@%EO(<1JK;WX2I3/Q/!L\[M
M!VZ9<)\*\3*ZA=_E)KKLF7<L,H4O;@.WCC BWN\&8Z'%SCN>PD\?;.J<\;F1
M"@;A]F*I#-Q+,4W(B$TT&L'Y&34+6KSL9PGM.[4Z"X01$8Q>*:\\+"?TO3FA
M?R:0=#@;&60]L1<QW1V9#%H4V!+9CM^>BI; Q[()2SQXEOS->0,1;!X>XHXA
ML3L4J:@RJ3#"50>&&31>"!X(^R5K]PUMVG^.]K\KARV';6(^L')HR_*<N%5V
M25\5"-#B_'CP%[#O(FO +T >^J+KY5!Z-<6T[Z^7TADG/TI2G-O[^5=3O/N"
MGY6ZIYDS 9%/H=G.DB?F<_:-&''*X):07J37+,I*^,P:YP(%;)0(M%84C>2;
M&#4>!!8XE4JO8@=3IEP=U0%.GRM[6[H1=:B96C"]?Q%+4NJ$".86()EJ1R1:
M11!FA&XR U/4L1)\'TI!!&/%<Y@Y1$H5CQ#UNM10\FIW.M;I%./,_H#W!TG(
MH9&>RKD7R([*M7MK$!VRW).D=*5M N#MM0Z;6MF,<K@ ^#^N84,_),@RN<9F
MVLNZ)+4A?T>Y:H>O+SH.:+F )T-&OZ$_P_/B)TN45>AYX6+[D/8$U'M<E>A0
MV:LSN'R,JJ17>67EHGC=&WE-<5=&AAW>+9M(1$8;V9;_;73A=?QJ%S_F5$\6
MT<;,KC(F:2=T=[2I>YT]LW/F*+P*+@;N-G5L&.=/GZCXEX\(S G1.-KY'^3P
MC4Y,A5QBY,2D^F1+5?P>U@SK?UE?2B.QH*@4=AK=42FB^*5H.]GB11IS$&-%
M2BW#449G84]Y%>D:8<88C6M5?B[;LMYLAQT[03$X0/'KTFQZ1,+A%70*5OP;
M!ID6?*PP8]2EHQ["8<NX^\7E?>>B-I%D7V;5Z:Z[I6'\1!O&OUX:QI>&\<^A
M8?PV^L-5 9;"!MK#R:%=.VRM5&UQLS&K8RK>6T<0M1 0F,.5&F2Q+SQ-]N0+
MTU>HJXL348'2?* 8&KJ\:](!#?Y_-%I"8<#W.)IP92$-H)@G&%\[# S'!#XO
MC<\G#RB!1F5%/(FKE@.=3,H/]@&O7)B$9B#N_NO4"!>W\#8;M^8:^JA'FB-1
MZIDFVQKD#AK"R0^R$<,@E!39"XKFP?V)>H6;B?!CI"=+7JL(8.1-#:;HZPY>
MA]U>5>*1<3S'X4QC@='X&^/MQHO"[?9E??!J ^#O,E.Q\84/'+EG^85TG\-8
MGKM5TV/D]OCAXV]2:2Z_PO^CS_ZB\K[??O.0?.C(*63FATGYV:NZ*=?P"G%-
M*L<Q\P^U" +X1\TMY8T;I5<FHVV=1/7P;9?UN<>9EP=] MHB)&:@#D[>>4B/
M.KPL&.0[<L<K?X.Y^>)A10D &@H8 .:AL.=U8 38XUU4&':'L'/0>XXO*=J6
MAF\LCOQ3\*([*BIH3VQ7I\GY:O5_"@>10WZ&/^2T3<M/</V?[?7?GJ=8:4'!
M-7B<'XJ:@H;<)><_P!]:C/"S%F6YFUWF+])"]/-_7>7R#)SW/$V>P*?@0(ZN
MK!]^FA7PIHOD;5:].]24<8+UD28_=FOXZ[,>1X?WW<LM,C+X8EV@"<*,P)_R
M S)F0?CS)X>@?9=?Z,7_5)0H[OB6Q\SWA-^6V2_U6YB/B_]$%R_E0?YXN(2+
MV%O]!+N:G9S7&]B<X AY?5&4>,/D[=G^[!S^\!).@G?)6_C:WB5/ZXN=2[YX
M^?;IE_1VWF3O>I0&?\FI+;[8LD5'D3L5&VQ&"?Y'^5>,39DI8930XE]KW6I2
M$]R2FSU[^L/_>OY3RJ6+P1NT:5S.RSHXW$E>&W9@42Y^YPZ14JEDN+!1Q8SL
MS>]?)G_^Z>V3)V=H%;U*A+;)LS\]?T/V\..?WGPC@\<OK(J\K"LL+</#UZW;
M==DN6[';] /<K,FB2_S^YS\]?[!R719=8B,= FA>,&6PRC9]"XY*N<F2+WYX
M<O[HX:,O.=U7U<S18;/+_A@+EQPWW\</C)R'DS/.WEZ+L%C?RE\>HN1'=\'R
MK_6\%#EN()W;'J;7R2V$/Q]E22P>W*V$*UYL6>T5DV1R6'*F3!9I,%^_=[1N
MRZZ:=AC\^?7_^5^\0-.DRH@U\L]U_:[8AV6&)OSZZ5L\"? L\;^_S/*\J#1M
MO(TN^U-6U9B<+W[Q'V^R=5&[ZH+]#UICDJ2F,JG+FK)@GS'V7;3__BP1,@V,
M6*R70H].X )RKW0(;[.\Z/I_];![)-OZ$EX/K#8] OVH?G[SZO6#Q][9XR/-
M__4GC(JJ!U^;J81/IHFK2$T"+PV^"2UTOVE8]V[@I](\,ZZ8,J 7]56%_A_'
M;,W!Y$&1KS/+#R13#3-S8.=7DHC68XM2_.L#O$-XS=S1ZD$+7DR+2P!3H^OW
M7!=3;YJ,K*37"_L<#]R_D^'1@RP/M#FV,HP,]F,Z6/9NMVIJB GI-<C%_],=
M8-MU#[[]PW\HNWR_A>%B^<D0GO1[>#3>?-%VMCN8L&+##C^.A/[DP.GD:KFA
MH^?B4+A2@6@@'+@OIV(N=9N\>*5#4NM3<=W6=1U!?3A1*]E9/05D%66^V!.L
M-;^H27A'KHO'GUQK\7',)J9EA$D)]9@^9DMM)4V$.O-E8A/0\?1G>\[2#*O1
M>A5/L91RI8U=T*@?-@T!8YJT6:GU[WZ_+XE5%@9-VDJ-*5=XU?AU'9>)(P#1
M+GOGJ,+F?VO2*+!*:R*C8@83A(AYLXJ7 -V[PHC7WR?E))"NR&R]AH&VY-KP
MTRBW_14M5^3K\1 SJ4^:P'@(0Z 0;[HD3@Q=]A4:@BZIK7#EAJ)KY]KT!B60
M$H<B-$5(LM@ZCXVYW]61.U_WIY3''H(1!J]S6,V6S!/A."0-"TMZAU5U/IZZ
M"]RB%UJ>I>GBM]!T\>'5!Y_=YW,LVR@&=EP>^'YI'EKL^,[LN*BJ^C+3^L)1
MH-5BF(MAWK;(KZ<09@<U@O^#QTOM'I8,2N% \&*IFENKFKLGWR0T9Z+%]I*1
M=4W==QQ6Z]6:A;5AL?$[L7%IZ2$_@+18IQBY Q%4&^+7Q3H7Z[S]%O<B=X/.
M*P-1H"ZV"R?Y;RQ-2U5:)54Y;R!ZPL5NU3<MMP12FMCC-!G5?N&RLJ-&@[[!
MG#1E#A8S7\S\+CU@3_M='>#7,"^7W$L:J%7!F;@@7"5:^F*;BVW>[A9<NFJ+
M_4\;[E.^XA+;%G9(-$M));M?\K)OBTLT8I5Q&&_75]KQRLD*RDD8E!GWRHY[
MV61[SK#>2']JDQ_Y*\GY?E\JL]07/_QX_N79U(*X;[65.Q% \OEQK%L5V.P>
M81!(7#?T@069"P9><,LI6D)?T1$:Y.R,M& X2O5T%B8[[%7E5@V61+HDEC"1
MQK#"&)*J4L#M)U;&6%IA[[@ZP#WY:%PK9\4AK*6.A5B83ZZH$! 0\*!1TV+G
M6H__C+EOCSJ;&ONDN "T9_,L>3VC!2/V/=+T&K)1#&]E"YCP5]AL45>&.1"H
M*,+PQP!C#>.BY17=W8@S523]4U27^/1;VTJL0F7$'*/98=H>!K0'(CET431K
M@L4?K+1KP$F$3EJ\(OQ92K J51H-G9[/P."E=U3)N8?$"ZH+VCK&EQ+V0J@^
MLIQW@@!'(%RG K1$N%2;;2U:+72<SNN;*#0%*>Q)9(DI01K/@\]L]QHTHT;4
M-FO6I<PC]^\V!3\#F0)V?M9]AYVSZ=A\/(XGO,.U"\JE.YK;6*Y4^'"Y6S:F
M9DI%X)3J!1LGN2K*19&#J2:!$-(U-V.S?7#?&\ZO?[_D"V@%UE? 4X*>=AF#
M+':PN*F#%5L.URW7KUFX1EKB*IZ)2)LF\[JIHN1J"#,&S7R3I,!A$F.QVMQC
M]&[2-BA-BA6WI5GMKP'>V%LE TA(7NO\R<_):YA5>#4[920^?_W?Q<OS'_SO
M!^"E@92WV6O, X7CM&BYW1IO*5JV\$],E6N3!H'1 _-(F*IP7F.3T/R)3;WA
M3,DB>$A"-9YL;75I,SS1-L-OEC;#>PK/N*LVP]^",ZM5>637VF9(9I*4-5.-
M>-7..4G!6#[V$\1*MPTNGS+ZNWLU____]^C;A]^_Y[/^"LO\=?OSK<>@;RAZ
M>B-N(?@);T(YZ$<K\'1NE=H8A/XC^+LEH1W!AM&+>)EU\*SM$G3?VUS1SQ=N
M7!#LA4+0:WR%>$_B' PT XO3S:5F,:7$*4=L/(11XU#:WA<I-:HG+B*8"@C@
M.A7J3H^EI4+$.:U2-HBC;&=4!"?5%FL3Z<!8L"'N5W8Y+W9^USQK%,1:P0(Q
ME:!<9R7MC SUAQ@VA&RQP6+C:7?8"U-FE[VC]HSJD!Q<UK1&N7+,9[J99"IE
M4"S<9F^Y/#$U P'ML$/#!NH0!D$(:;-!<_+:4?@=*76:^E1=8C#9>@)8*\P#
M#RP[QZ[N!X]"32(0<2-,G?,7V_FW@=&LR+2M.7''TX057D+2C!>R3UY,]KLH
MN1"1F#*H^!]PX78M&EM$G4;>%W8+LZ7X @CM3I/CG*V&2!Z=*B#@'K<%;5>*
M@O;YB:GM:.:*K4;YK7/O+"ITP+U&.QASE8[VQLF'6-#S)QF>O9K,4W*8H&2@
M(K<[>?J)6?SU[.T9F2EM/D+".]PN_&ZT@.N7LO=OH>R-QSP5JXLVVS;.^11P
M@JK36\KZC[L(HWYM/IH7_-!BK'<CO15"GK4#_X4I JCJ0O6]KF@W7 6Q,1IY
M'%9-)B( FJ:I6DQZ,>G;%4WTJ<EAG(.F;B4 0F,HJB6BSTR:#AX>D)L SP1P
M&^O>+N:\F/,GW:&9A_L&\6K(.ZQ<Y38$).@[2APE^(. . C_LECU8M6?QDE&
M)YAXD&  P34V%" 3ZCOUXC<O]GNG]DOVB)@?%E1B=::!MS&+!50WA.H 'CQ#
ME 7$S#JA&I4E/_QXKMXX+ARL-]!>;C_77%.Q,#F;98$L"^2N-OA-0?4%-O2<
M>#YIIV]\HE$PE:(U8@&UIC381$C0S2R,M+5=MR3#BW(!L (W]IR(.6F8C@<;
MPQ?-TV5MW$5CS*CBE9"(W=;R0=I%%+-82?$*"UQH^Q5I'6&CBU(KQ74Q!&;Z
M@R8*7S\/F=6/7]_%SB(&$MA7Q9M1)$MUX6QEEH%7\.H4%APC<S4W@2\TH++Q
M?>%.*#1=<H!/PB8(>$M-4S-H ]GUJ(P3FPQIC<?0KDD4UR3B:P#M(D(\M,R+
MK)TK!HNS,3%[=!J AX]L!?#(5Q>.8?#2BSOYX J<\*736<3%6?+L$B[(8(Y
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M]%6S1PXEC$S&3L+[Q?VQ*K)A&A+BHVFQ9,Z%"_LVO/8Z+RA&H6A_9G1#-9T
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MDA.G(,]+,W_X93EA/$&T80C^9X\EJD!K']\)9UOUJBKGUFU4C G"@E-G\[4
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M5:--%PY.I4B16&A &HDHOLHTR!SJ/AGWZJK?@I'.MG$N[NS@Q+BH81-Z2/K
M(C85:BR=/A7P+]3S,0&/;. \BP&2.%YTXZ;<W\W\(?U$3S,^7@=',[RCMZ(0
M/#FQ<.57%5K:]B#M/>0<M:F>S;;$F)QO.13N.]S[UAP@%]4EE?48.<4ZI:3P
MFM*LR3#!9C>N:71^(%K5.\ 0(-9;USNPX[7UG57NU4(G?:).73Y2'.=V'G1
MI W]0;^72(J2]N #;@@H<"199GSQH<?*9A&_@51Z6M'&,--?XNAUK$Z4\+C#
MT[OJ_)ISE'&!Y]LZ29%>%*@EJ.XR<@25[@')OG*:D$IK2A4CY1/?D,P(!FK&
MQ9FO*X2N87=OSXW \![X]7)O8D4,,'1;<JG$;:*+4'U62GB*8,!L0*10O!Z+
M$]]X[8<*8MU92<^;=,>E\^UQ!+ZK)/V+4QQZ-)=FR FA6;5$GECJ\OOQG/*
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M"=LP\.XB[D+$ U%48.@#KR,W$:^ (^(2*>U@,:*/A-A(\%:Y_(P)[2!D*)A
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M.=30T8 -J?SS>S>F]>_LQ!R\LRL"05"QAJ!.HZPL[+>93@B"F=):U]9MH,3
MBH$N,-</2I1[+$\*O O\1_&P:K"3_3-R\@#G4]ST$/-0R-S*GI7#8]^5FH#"
MCI,F('Q*+.' /_Q>:!S]T\A9DU2X\B'RVP_C)\21C%7[+5",6E*N=([0E%);
M#33(3RZ5GPH#N;U8O::+&#GQ9CRLB<J$:$9[:ES?&HWS:]8X1X_FBK[E3992
M4^E.2-C?]'LQ!5Q)5T'0%M5,26<9R#AXX8.2]S-DMRH,KQ4!B[?,9M4X,#1E
M=WH6@4R5RXV$Z#>".GV&98)'>C62.FJ8;Y;HE3FKVZC_KGBX[.K&9"^\":)1
MT/< 9E#O+ML''=7 +PWL0YCXAMT)U<Z3G,T'3)/"&E H8.@ ^^MWSQ_I-2(+
M%X&68Q4 W&Q@>H0$+Z=F?;'ZZZ2% EEBN2IR6]-[,ZZYX'V5)9_@@K)9,CUC
MRDQX8CZOG+M,,+$XUG?58PE=+^7$2&ZJ_CWM8X5E)BJ,-7/KL5,'PU"[4YU0
M0+<4M4YM'8^1SZCS@Y)LD$"";:>#WJ1W@VI<9$89&#C-;<N)'EG(]^A8"$',
MF@!**G+ETK/ ']QC,]C.P;VW-"O7$$-2"V:FO>:D3CB)K0V0(,104V$%AOR[
M,L-[S3%Q(%]!["S3$6,&30ZY,Z=8QBF+?3P-J&*'LT27<I=<K3))"["Y/._H
M8Q ^-7/OB]7?P5IQ1J$Y-UJ88-.>N'4'AL$7*WV7E+@I<O0U9QSH+'PJ#29)
M?B+83DX\XGE+YRR>CD %>46[CKK-)+=:F'[BV]A\7OSA\*E/H9'6RFD@4L:O
M. R)L6;<[H!@.6UG)@@W".%>K)YK<1' E09S?\;) 3_"U3OR[[JH4U9>.[C)
M?DI*WC#[MC]60QDE:AV)>LBL!,9=OC/HW+"H#^T^V=N&@;TSW>I^]]#Q;L]'
M1J<O9]9=/;.T,9NSHYBF!P(GO[.P)^%&_&2Y[MH2H0:;\DB9&<RB1E@.B*M"
M6IU.@#C>&\3)Q#:T:%^>,5ZP.KVG;I7JK5-54,L(95=-98-P'%<87.K9I]O?
M#^^\LX=!J!):$%G 34'*Q)B3%VP5680V0#$5 N'A)GDN.R!@@D+8UHF>=S_X
M^(0;X65@WC 34G)P@5(1O'^,*Y2;+ H:FFG#!&8"M! 1LB[]8+I38GX(UL'A
M;JV9X#/NA$A-(4\!1A\R#_*FCN#,,+Q'H'RX@HYCM]E['SJ3>H" "^\XR64D
MY:8?9[GN8"/Y1Z]ABMC@&@6<3-Q&\V"G%PLJF4W%XDXF:M6UT@H +%R%)Y>G
MG;RYT.DA^G39]6Z/$2R9G]4\D/X;W$5Q+$NE*YG50J.P;5O$&U9VDSFF8N^*
MO#+IOB$7 <"IAARZ1ZH4)M9#!RN4/(UND'AO@,H&OZN?RVW-];$>6S"+V#L$
M]!VS;4?+<79'CS-#1Q,@:[3C<Q1!-V;9( N$^'A=B, ,A+!B29$)D0C::68)
M>3&%\-?NLNKKP-@?)]N\U0*,<@AN2FW$5" V(%N43@;[*"?\/V24B2 (#EKB
M?<%#05U>8W']*=9#149)4PKUWIFB!OKBX?&%&$?/*J-.0Q\@[Y'FF#N[8SJ>
M^-HL*L*4D&L_.9#S30R2:5BE?+P=/_B6G.X1@3;64&U:2BYB5ID#Z).^)TXO
M@LU)PD=$?]/P(ECO?+HUR/DE\:*_V3&-"Q>C<6\*HDVIW*N\?6W=/-G)BBO
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MXG__$*0O^[2Q3,APP@,*=;Q2_TOU$(,4+*[D6%Q$NU#9=(R!3-CXL_-L:XK
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M^%TA_@F(^6TR\?$0M! JTDI.4EM@7/ V&O2;>;/BZ2;@-Y%]C+K QX$= 23
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M3>H/[$WP7RA-]KH\^!D"[IS&E=@%[ZTQ??ZO2A4UO=:/E%T#)U>O%J@JS#G
M!PIF4.1H2+T:4X&XZ3!9#:X\4#%!JLV0X8?/M)URE#LY/ AP@%[Y1QP/XX@Q
M<T2X$$(LFXZWW5B?2PH>JZ,#HT/Y8G\>#Y4A&D)T;P0[3X$D F-(X2#G<H^
MDA;^SO3OBP[-G=W7P#W@ADJ9$8-3%]:O()6B ETQ4[/SOQV,"$D%^!C$R$*A
MWTD)'BN>D+<G*1MF[+#<5T!$[<UN3QE0O_+?5G4=D+]=!7@,:6_&R@DLS:!7
MRXBBQE%8O ?&+M.G;'8G(HB)(S/>#E&_'E$B7NMVLOLC0M'\&F# :Z>B]7,1
MW' R0X$=N@$"'?J6ZPZL:^B_5]>)U //(B(HD-0+'S%<#%%N&WZ]"!K*\GJ5
MB$WB,LB>^""M[+T W+RGWF/ABVDED\_Z%S?6E\AF&83$-,<=J8G%U*+A2A42
M/@!9$==>P%!>-_PG;8!IQ^$X#HM%N3>IC!]CG)LA-N#SR&(S#>(1FERJ7E"D
M 4PGB,NPZ6Q,6#'-#E!R";^$']XCPW?"'&D9X3;:G8$Q8<ETW)N#C),* !;L
MR>1K?Q@:F'9V%2+GI7=]UB.9R9L6):('QYI[C1)LIS]Y?@B+EFK7O5/<KI+(
M(JLM'HIT(*&.U=L:.[:P)NCGV"';C2[_F'=O; P#L0&6(ML&/3)A.5W/_*X!
MO2F,@E!O1[B5$3J0_9+\?@K\2:05Z!Z SV0:)N*29&^3N/3\X3:".F;,2=D*
M4XG<:P%9QNN:8%W,Z PP;0)Y*[X^] _2>9X!%X? A9)(R1N-=H/?!ZLJ:%!A
M=@)=L8IOP;3^S#WL #Q^B-9\W'$5PI\(PUXH]0*P/I6LTN=]%*3E!!T0!YQ6
MW 4@(1 @X7BG63>+>$&8=Y ;7Y#F<VP ]-R0B!D%6ENT"KC/:G0P"66N)%KP
M+6X2B.0UJ^;*]4,@CM?^S8W^ O;$"!R;_> .!VTR*\\0+\M.:KM5U&[S:H<A
M%0%D-J$Y4W3'8"D$*5!NMQ3!.!,F^@<##")KKX'T5GU%CPQ(Z4YQ)T3!5O#F
MECNF3#\83QXD'8) .0-@4VJ7I!DR-A[I%1 A7@1X.!4=(HRFP8ES_VU!Q)3@
M97(WIF6GT@]-<-U$B^WO:INRL_Q#)AM.X!\WI27B+M0,-='JU[T34BEX(\KT
MG7\Q\BJCUXW+TJXYPZLSTU1K9YK.I9U"F%!QEM((4%ML9/Y-^F%FL<CHRDAX
MG5F TT'>:^O]*3KZ@KPF&O:F999Y! OV9<UB]NJ44$.L]SK\SR,R-U&@#<A6
M/^\E,M_2UL) ._HDPKX&;$/7C^S&)M"C1>Q0F[)#E+Y=5V0LT:U8W.'[Y#;\
MEG6V*8^!]$%PZ/F<7P6G7$4:8;F4"1YA^:^*4]B?R;7TC%T$OKEK=I71K6=Y
M4EWY 'B'AV&"/W["J&.+#UOE0<4$TE QGS40H+';.C\7='!K/G1V4D#)$PTO
M$F (9R61%%*VH]4-Z6[8CIB89AE8VH5,%26I*$#_;]&I"+,!XP*')S<GT1.1
MH*Y#X@A_XZX#7".U,&8(.P!QZ#KPVMG\"S^M'V24B!**>7/M2-K3'R:=L_<Q
M9.7I^DR79Q'-.OJ$H^:T"(*+:FH\.]*R29=EO:<6SOOFI*O+D&6]&6,=4O"Z
M)],"$](X#@I![,C=*ED>M6<JF69+WH[12!G[*#EGDJ.X F)/BF8ZDVV4B^-9
M?X#N7%QZU8%CLT!,HK%Q_-S\E+ MVR'0*%B"XOA+;=#U@I8%?Y^&8UGC1VDP
M""YRQ!(JSI1M_2+.&73%[%O@USV%I4#DH=Z9O]6:.6"(3MFXJ0;"FSZ$TE'H
MA= '=9>WZZ7X7$X70B<1];NL.;/AN;74OK5,:CMDMHN991R\9;*FQOS.;.$P
ML&D89"] F<',)0HY7Q@=P[&C-D3$*L5*(2L5PR3"18F<N"@F5@L;>_H1NLTS
M9#FVHS$4+2A<E0:$:\.0J:"M#%.FC5J*G&*/[76\4Q2K=VS5K^ZT^_OC&*OC
MF"I<?X)\1,_5EI8X"3B8HP(WJPL%_J47/_T(,;9EBRU",6>&IKB=]*FSL49Q
M3:!80&_.1-ZS',)],:<14U!_-I]((<!G7X>W@7<;$G*US**^D^]Q"6.F"J\H
M^@.YGE@\/EBU:U6R*H+@/#7>M61\I2A91,5(_I!JV,R("6>5?QY,- 3,7Q\2
MB3D."3)25+,"!1G2BNG=IL,^,R8YT9JI.AZ1WN5U0^ZKI#:UXAW2>:S#14?/
M4AZ]JROZ.P=<(T[RH*37H1'#1(ZC8%C#.;M. 7.4]Y'D>ALVBS90-EL+UOE-
MACYS8,05LUS._R0Q8] ;1T_M:JR!,I)]/B:HQ+RY4!T=G'^2;5RQ. &02G7;
MAJ'<O%7"#^1SZ#H^@>J=GTLH_%KB?)E$S =P=CZBI>(:70'Q$SRH/$QSV5-5
M:P1W]ZKJ1G3)DG(<J:L. ZA6)D&;C:HAK\I*-(AS:?65CJAFXJU7[9C$TCN*
M '3Q9H-M%Z2WRZ9O#]<PBSH%_J_^CX_:W2.9;OW3<<^9PC R^4PX+T% &S@Q
MZ1 %_LT.W4985 /.:M4?_$R5Y+<.T+!L>Y\)H@-VKXLF%QO?,52&5_?(>]2N
M!#*J9MMORB,K0CA5C.!!XPJY[-IKYBK5-GX_]!:>9["W)921"G7!=Y&>L@J"
MQ/Z? #JWK914:$JDYB3Y!2.FS)&_+RG2&B8D^]KOK,E=H.5W%%K^]0(M7Z#E
MGSVT7 \_R8_WWH\84'Q!3L,\$7'KUWBCR1YOP%H?,/X/"9E6-;(6;O:F3EZN
M_ ZZ=(-%0H;\%92[-M61F:7[R.H3]YAHJPFI*Z,2*&,J#EO,96>@JNJLB(\2
MZ*PZ=Z##A$XBMV7>:<JI;PF,6[7;)1MC*URH&G[-\!A]/6Z;T;03Q3QFU2!<
MB93<T_>"'DBG#']-"T@)H2.6=/GT'C:W0I](G-TBU YF(3%"]Q/A60PP19=R
M76<65)0!B1.!,[02N% [J(2APXWP [D<]47 MKH"3E!-(NE]85SM!AEF&S<@
M"9,1HCLXV+7>5[2/FY$;Y"K& RD!1#/RD-^N?Z^7'7,O2RW"FTN(BHHP,AX%
ML\;M3ST[H!M-'9%_3Y**LTNBL- CP*$<(..<62<V92U&@:@YKA@=R!>2M6!)
M_V7<5CR,)"3;A0,W86EBQBXE[[]VA*5J 5#(Z@#@K-OYU?J.I>ZIAFGB\5S2
M<%KAM85JYD#2ZE6&=-^$?E L !EO['O@%),)N^26VVZ\S-T%0[N:%8(I]3FE
M^3%Z$?K'*6[-2DB6 M&R=)BPQ@X-:K[;*IU2U1!IK<99H:: 75284LLG;Y,>
MAG@'"-PL!%YP.33'NZ$@:"_F-A#,-XVW6Q5)0&8[.-?CUB96,0W\:U8Z0G,&
M6,P)68,)H+&(.  M7:ND%WJDOY)W+NI_;'_=WE\[UECF51!WGQA,+\)]'#/>
M8UD: F^_GQZ1OG-%>N8 6M^>+E9O0(^!,;Z)Z,0,231!Q2*M0,$HVXHLB^H2
M#?. O+,  [5M.S:'I><2P18PD0IFW<?=95"M!_XS I02BVZ4@LW4"O"@TDL'
M!VL;A!;YC7E3L97<5?2.+)EO(NV(QPVVH6RE]%MM5N2;^T_OJZ-?PU:DG+4]
MVKINKU$\A<%[7:#D*-,I$0P?<S-.RQBT \:>Z?Z2BN ,TD\%$:B:!WV(=$7\
M?(9(3EH><YM$NX>@7@]*P\UEFR3\DJ[!\)+G0#^QW9TU9D0E#;>PVC8)8Y[P
M.[9!-; 57X6PM"*.QD\ZL*HOL'D%6F!6W:%DGD0;,9E7J?.$$]-VMIHE@NC@
MGF B<M.UR*01BFM*E.>O)0G-?D -&;BF 4PM9[XY\W_5$$U[_ :*IZA63?B5
M9R0:>TJ@N;'I/")K.'X:Z_3ZA<@ST-V$AW#NE->K/N.,;"XG3Q*UM'+/".ZF
MLLTDP"M2K$K_B;C=Y*/&(B]+QBZ9#! -]J'UZKJ)*197,K/A"1Y)]0C,3HP=
MJX?CZ[<:ZW%O3M3N2#H"6M^+C[<@DVH[EQ)>US-="&3(=Y2XGH HWZ.#6X>!
M9IEEE^WP9OBV,VJNHID5BXSC!A#1$I:L$,Y.4:]J!*F?E22&+;(L^ GB0U(3
M:C-FHE(56'*BI82]-T&'B'IA(!L0&E>D R7LH<+&J\EF"A$QG<.0I> V@0,4
MO9.&%2/Q"UQ ?NDA(>L::6^_"[T1*^BIP9"F[+8U"_X"A- O;OB#KE$6LC/-
M#I842WH>TA@$GF\JX02S!_S-DAX<E=J6_1\0%_/OPOL!&W1BP1]IFWSG]N\O
M#2W%^$\&H@H(C B+*R^;"*"9 \'&X$'B!+':9=^W&](7(=M'_7&PH@W&PUB]
M>L&8)AT,L!=[Y]YF4QVH4"F1PCPS22**TR!_P9L!64E6SS<;A!9= E4-L4#@
MV^:<9(9\W<#4Z#6;.*]5%ANCRV6TD4B3G0K' _+7BXR.*N&$IXJZVO]\9VO+
MIN3E[W]X5%?]\,A1*A['<#15+UY\4,B#E?STVS_$=>9D'6<+RE@%?88K]A'<
ML?_SVL>!4 >=\DSK \"V^>9ND4Q_>?'-5T^??//MUU_^Z>D7WWSYS=.O_O#L
MVB]&JM_^^:US1S_46B>(:[TX3V<F!AA6OWWZ]&NE6#5%7[KQD\>/_Y!<]:YL
M>4!ED/B6V?!15HI2&]5A#<@W/-9!9^I 8/[)EGL6EBJ4:/F_RY)=ENP'6[*&
MZMVTE?CG\DNY%[#G&MLJ.PKP-XY)C+BH+3*->8TTN_J7Y;PLYX^\G,7)]9Y*
M^9:@U99:9U<'VB;U@I&20+J\F%R6<_PJ3DJ7C1H2E^6\+.>/O9S3_--0OA-E
M%^82/ARJRRZDVA#"3(0<D"$))"9U=<7E#V_2KQQRBY",YK*,EV7\D9>Q.K8(
MX=^<5KL:8/Z)EG)27PN*,R$N34J$4!_;2D>B=.%2]Z.I^OH+83(;H=)MDK_P
MWY%F 7"Z3\MN6';#QS;J0;>/@"Q2M+,,0-(-,&G 4J(CI!T@F0/,QP!T;YJT
MP5002^P*4P&W; TB2CQW#R&AZ\N#5J7*7D4NEZVR;)6/O%4X'PK>3;]O.T(=
M!"TSK?$@JJXW2G1=>1U@<4"00LKGH4UL0B<BSA!LCF5=+^OZHZ[KN("B",ID
M95^Z]E&(4LLI%UWH8>.VMHOLTOW<*S$O0F(+64$GY7HL=-7G"F.:5U#2"6%=
M5'EYK5\3W $QC9 ]*V*K4TRIHA 1(?QU1,8CQ_<U(OFO+1F6,JK:4M\9'L#0
M9!Y >ED:C3,L&BN90@:#(-!C,YU6ZTK[X0L9#641HP*_E3$%@J1-P"+J7&^A
MD@\M;Q6VB#?)6\.K$L@?[V_PH/L2-M/&B3IMB\0-\,+Z>":1:QES0TCI"*^'
M<Y]P/X%[\/BY^\'NP!=[/X]^#)(OU;$K=Z0)2M(),]-RDCX! C64_1 0!G>V
M=K;T9=[1OLQOEK[,I2_SL^_+C.%._HRY)"7KP8^63W8VT6M#PJ:'%Q.I\Q$P
M;3KHQ60KGS'@I9!)8GJL1+<-+7?AB.$3K-WVVL=/5+\^P.A0/C,@:'WD@;2\
M?!#"CT.'TG@/KIFU-[@OCYAVI1_]A1YM.[\2FH="$L93%*%*V*])CG+Q,,BO
M0%(!/+U<<U5U;4.$F3]&[D9=O76,).=K=<<VB) +Z,V*Q\L)R8F'Q&_(86"B
MCI P6L-M$Z%/Z8U;T(N6.C/.A>%Z1.]A>KH_%-9%'C@NB1B7B* ;\<NX94)2
M*'Q%C$T56TKTYM3$"2!>^/!EW:ZA18(^'O@&12^&^2)"9U!AT8F_CU[M%NQJ
M=V&[OZ^H]F\^+SZ(F5OPD.VGP$-^9_H32:6'5"/@'V]>OC#.N8D>O+?3;(+-
MVU=(Y$DR/H8-5/AD&\##UR$6$SY<M.]4VT .,-DV*?L7QT,(X3.5$&E6#%;#
M?FGA@+LW?@@$J+)L@G()]6Q<5?Z":+J)R-._]>O 4LL=_)8@ML0>+$>7VI43
M)0RSC/TZW&)$:]8LR8@%#2]068Z%_HCEE,/0DZCSC;W? 8&*'_H?0&WF-$F4
M<#3+Y^'%ZKD?#O2?\*,..(N\$W&?<>0K%4'LD.?8?75R)9 -A%,M@;Y/'U9]
M!#A<WQ"Z7V ;+P6Q]*(]'*J^1PX\;P0>%C>8 =W&<<^5V;>IM@Q676!(0?:+
MM$9,YB?T>,4X;?(>).NG9( T B3(!\< $QA^TBKJ=!D;OX:WU0;I:>_!L?R9
MFH+\<626GZXY96#IZ_::G&%_5P.YWJ',TC6VVZ/#O)9-1LU/?X1H1-B!UR?S
MS<P2CREYSZ81DS[<9+/&<*O5T\=/OL6G\__X4Q%VIAE"OQ^A0 F,[^X*NZG8
M1IC@R]H8'3$Q*O31)/*Q#A2KZ-SOQJXFWN..]U,LZ]/[Y17^9E400;X&-E_=
M-J"XDPP8QXOD#9:3(6GQ#:Y^WOK#<V+?C1X"O-G3AF)O'-A>)6")]W/N36#)
M,7'FJ53B*[@<5E:=J8[V0J$@6#A:PM0:$%;:ICQ6U/.WPFP.<Y60&B/_D<BP
MMRKC_B&Y;A=;]G$YU&^[0R"CL),8EKEF_87\]O;KS<H#P\[0,H+=]<250>V9
MU-FOS4@BKWF)B,VJ08P#[17:6GV1OZ:57_PM6_BF@?XKMOC=WRV?*('[Z1[S
M/__CR=>/G_TKG_5?E'GXW^ONCY_N)7^($LMGPJ3_$S;V_11RG)"7_8X9?S;8
M^?LSDI2])I*R^WRJ??3))$4.Z!E/V3#R>B^0[^8.R")1#@J*BR:M?)WE"?&A
MMX@ FE;SNF6.L'G$'I)&=&F@P(%GQ7K"AI!OINNT"]P)>%/UQ!48>-D!?4*/
M7B!B<I>,U+UQW5AKN&1:<V3LP)<X$;=ZO?.W]@'#7ZJV5Z45+L* (\(NT0OO
ML927;>&C@JX?2\):*R<5(.'X^D!/*GV0AG1F9^H?<ZW0,Q>'S7.+JR<J-GK5
MGJI60BZ?F0<IM<RH@#&\I$AYZ3-7:F<OTB>*8R5>X"WXCL"@Q7<0]B631BJF
M'"E%2/SY9>)\B-OX[W;MR;O=)V#L0V5F8)/7S8L?5@J)@N<1)@L(,@(INJ7=
MHPS#%&WO/SNJD!%SU$2ZFQ$C'U/>H9A UJ[Q-&X#A449LY:K-MWM#"FR:>$U
M$0YZ"A4[-&WHM+L.A%Q9XT!M>;Y+8029P0J%>E4!@%Y/)$K 3#!U'9*[:JJ1
M:X22-.:&T0I&SD.\?DD\*$,U$-<P,)(8^OV9"URL?F@[!_<A%B"9 <HSL4:4
MB*[E7P0.%W!51"[BFO35^"<LX@ID>",FO4E\*BD;"@5QS(<B] 4D%[R#0CKW
M+@7*0=(&Y_A/GT<UW.B<2M+%U\*XZW<_DKPH$@Q%H/U+=Y'B'(5ZO'.B10[<
M"E*_3E=;*]J%D*"/K X$FJA;5)C;J""<"3T)U!:&862XLJ,!F@=B=(2[*^,_
MK9WY3H)KMR+2T6117KM8N8P7](22R<GSL-#C#H4'()IGKHC;7<5,3Y;7>K.O
M_%<)OETAX 6^X4\TCLGO0=![3_R,3Z$>#.\7RZ9(O^3>QL)9D3H=?$(I+,N:
M&B$GPI]&7DX.LUBZ+\(!J3!YT(&.;EK,W7+FXE.IOCDQ0)/OY$U*N5,#%6&+
M,W%2%M?Z/KG6)(-HL6?1>L^L+Q"/=^!P_*/U:QIX7P>A9)]NB?=:^SDE7#;Q
M:U>C7<73@YA2J=KKX]/QDOXYWH:33UA.4S5<*]ITW@-_;O=CQ%7+-58\82,^
M6?\2'G50W^TDJ%6,=7?)W$.!8;5QW"D!R>I'<-8S$V<UD&Y2U?>C4J2'OKFJ
M'@<72PQZ?WKS=N\WD^M$WU>YCRU;&U >WY^L[.>[6W>@@!RS$Y-_76'# >Y9
M7&*&+3-LX= 3(,%%XR[;@8F+)=G/9(6@.HT[!=8Z2%\)_K3J$S;L@C?D.Z9:
M8=YLZ\;'ATRL%(L+EG=E)*Y=9H;NMYG)3-4,@DRUHW>LF#S-%1FAJ9-X;UL(
M:[=<E89"=^M'44+5#PC+B3XX80^F'$ DXLPDM#2SUH3)@V-5)3^J$K&8$A^@
M!>E!MB["96[=P<\XSHCWV7<.XF/\ ,AS'5F:#5X B&T)GR=7.8,JN9"?>3NF
M]AA (9'9B&2W@^YYN2'3UG8J64VY14;,"EFY2> !*RDZ]O"1\NA\?+[1HI%&
MM&6CI2(IY2;Z&1#=@ZG^S:#/I07D#K> ?+NT@"PM(&=;0#[3(U\Q,)2BR'O3
MLVE: @UECE#+?#F7O\['A7Y/85 (Y]3:-<X/EYQA!!)&;D)&M3Y*L:C,$%SL
M$*I40>XT@!?9ES]"+ Q"DBA,8G.<2*1-BD: 8A">[)"".PL3^^W'"S#G(_*-
MLW3K4'T"I[Q@K0IF5M9W86;*O(I":5 EC43N &G80T@&)!K^= ?M)8@90'H$
M?7]:MA0*X#)![O/0F*(WDU"OZOH!1)TVC@*:H ^!:XP0<2 ZXA?MN42']<O,
MRK,\K6<8T.FMP8!^!YEZ%?J2+AV(!QSW0HPNOP?-E$U,X'/-@!6(=3^HHW$7
MS,:]#IL^15X/@-"4V(J2#6U4!<DN-]HNPLJ.&'<KNFREG1E B+HH!%1'.VC9
M/J1'/5G2.ZPTL4 CN_!21*+=@+@R@^U"XTBRSM)?-@/THN.50HW.X2.?Q'RB
M\&)9=2F2LFJJH>)2N\C4Q/I))$M3R&"S C.*\>7GCO/J"O^5!/N21[PW;HK?
M4<S:%*I4$-@5T&X$?_+GFC]L&A-$%EQ&M3KJN"B$YN8TV8Z8OO(+;3V2'*@L
MOB(LPVA5K?X)]7=:]1"^@]1;/ZY]^("X(A9_X^66:M*$6'AJ ;(&Y*2,6+&^
M>]ZJN* \!J==K DEMT0JH(I53H4MO0W@8_3'IN.(;T]^&,#>(4N1W9BSZ1*\
M,;]9#-1U\TOY%94G$LAIK"N9C@>G@RMCJI@QI3K:2#HCXCT"'])U5Y(G=;%,
MO;\6CH$'5^@O@J0H7!%_ZYVE;6@FXIK@>172V;>6Z!=%[X[\.78-48P0R#V4
M28>9/D#(S5OEGGJD3CIP+G3+VXYD,J @'TX5Y#I&[X9ZJA/=/663!9"5?Y!>
M95351;Z-'L*W7SP]9]'>+Z3EG['Z_>>G%U_]Z8L/S@7UY2>U]_=M=CXD\- R
M$1,70.<POI"F/"/2%AL$ :E0;M$FMTU*E;DT;?ZVT_)[*1MKU8R'M</M%#:Y
M&8>%)P[E6_BFO9^!4D#[DB HW7"KO?'9G/:(]X@MMJT=E+D8+6H:E :H,YZJ
MM"$ 8P$:TD[8K.W2.?B)61V<#X:-V%L\LHF@ 0)?+UL W;0= -18L?@4=3QX
M'Q5&3G)S/4:T#)Q9G^8\:]LX9*&WMG/"^Q[;LMN:CK 77'3\OFVWJQ^BL;]F
M*;W5@\WW/[Q^B  AC.^Y!84EU[*[*H<!QEM&$T(1AO2&@\J3A>HHBDVJG/ ;
M/IH*V",IT$F:9U"1FWD,2<74KR>^'Q4+0@#D=W1[0,YGVL+"=T:G(_DFW+@"
MDD\1[@81?MO4PR*T@@98(%Y17\'9"-=2**;!4QD'!PG-K,>!ZI:L?UBD%6V+
MK"3-P285&M<^^7P^S=\;&3Y2-2N *I&:%;ST'A(]F[)GN70"3*'KT;_U[@6]
MQP"BLB"O&P/:@&&J_DE9)BN@QRDDO\2]<?+WB^);5JW3,@XHBL ) +X[Y)QV
MC@K>N.ZR(\5)G$P9H5-7H E<H:=CZGPRA^B?H]O6.VDMYZ1.5$SW2Y<HR0'I
M-F+1R3P!OEU;KY=@6[.C0:D]^J+=ZUS"FC[&+9()KS1+:E\:MWXG.YJ5_FBQ
MA%QA@NKS#CDH;J)UH!+O=3QT\;Y[H]4>;-\VZ,1;TR$.J1HP>OFXYB%?&<PO
M6SM-VUZ.U982L@04Y$QC*M@%0\6A<Z*.:J^3P4_8)DPVU\2- M^;S1B6TNU&
M@%SL(?##\']9C]M+-RSIO+OJ??S+0N&,X*E(6$NR(#T@"$64<&K>A'D*.SM"
MR:+3FV0KY> F0'),(S]9XLCTU0]Z5J4$WC,Z.%.^")/<3R)NYG7BR-E:MU #
M8@MK ;+Y-X;,LG.OHV#7Q9^?/1ZA(>V358><.7UG4;YYPV'K5]2*@?ZN&;]B
MNB5#C#+*T)?@!--P@W]JK2ZX?5AO\;Z157B)OG0+-E5:#B$X@F+X(GBW\%A_
M7CS6)10"9ZL:?) D%8U9E#,W4)K4WZ(PL*S@CRW9B&4ZP'D" \- X@&16FL=
MZMP8VX"KDWPJ*)ZJ+'6ZN)>EO"SEC[R400!=C.NFC>@&_> "!DBA^ &%TG;+
M^ES6YT=>GYRNIJAG-CP)"10.5&;_'D/V#/'/?$)Y6>7+*O_(JSP*)"&?@GE3
MA5DP/!&3*QO(\ZW+8;,G.$4V0EX4B99E^PF6+4&'3"B70,ER^2)BO(B_AJ5#
M QC:.C^.+:7:,>>O6+1%JFB^?31J@#?M6PD[BSU&7WSWPX_])(=GX"R8MKM8
MO0SM^<@!<^--^,*VZH/H<@>91I#]#F=P!\132Q9LL9V?E^U,M@;N&#1XP0GE
MALXJ1LQ9'-WBFB[K]!.<\<>V)P0 4S-QOB IIRD$@SF)8$4O"W19H)]R@1ZJ
M/O3<Q^U*BJ6I@)'LP+1G,=J<!'QZM^F$GOIMTUX_VK?7\Q'5TLU\1[N9_[1T
M,R_=S+ENYN7X68Z?CW/\" LD)^S\%SO7N.O TI5UDA!BREAW@#.!WFS;#Z0^
M#NW%C0^_*Z$[&9<LR%P6!$%@;5.?%,5L,:X,A;6Y"F %A*:$+ W53/**,& 1
M>(R1RPA)V\9Y,,%?(]%EQ1!BD']D#B\DMV2H WV4>MF9X@65$-\B1XX"J0%#
M=!R[S1ZQM8A^]>:D DJLA$C3(JH#B14,KAI@=J8(N)NFP)!FZ8@$7R: OD!R
M<PL\7T#901M9DE2RN.Y=W%-H,;T$?[6)K:5/))$2PWP<O20F(II2#:: -XL@
MOK&UV58P")+'R#O*+NZ=(O'8(^<,87+C&0!S2J ;A+*)1Y?5NHE'V#KUNK>
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M,7^:VLW(@25HC'><A(4J<W 0>X+T.E)'0-MM0Q,@^,"7KD&0<]5<0:* U%K
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ME8:;VQ"M<0XVG_1MQ^$XPL:&;@:$"L*>:U<U]B&KRS6QJ.@IZ8K6WL:(C-/
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MD/CW1N7/)\EBJ=*R6RS-"]Q=55$L!;RCI!(4;$A 74#1R[5/(<H!XN$^+81
MYI8$)VDTLXMVVWRPQ]CKB^!8JR16$8Y62!UFX ; /RT"JL>^/6_RI'(87(Z?
MP4R&.RTSE<,W_TI0MT(LCKW21$>"J([*\FHS5BIS)>2K 2^P/-!&C;L"0YC
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M?2NAQOEGT#4PNU%2Q(WS59L<[?=7.E/G*$[P_T0(I-O1I_TUZ .2[6:[S?6
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M>W0R7 F&8AC]3C7?GIJT3KZOI[@ /*(6O(Q0S*N*.3+F'JLH;-C<8_.^<A^
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ME07 8MX#E5%RI+8B./A2D7Y4E -S+GW!;4FAV2^@P^]/4-P5B);!WF9U2G-
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M_7=]$>[]^ P3&"8P3.!.3V"P@'?% FY#0(Z&!P8$\MO<&>/1_C98;QMG_7I
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M7AB!IZK:B,VAZ_*TP^W>C<-V)#P\/&NV\;=,;=,;=IP#=W1!N>N*V:H<W5?
M 7"#K^*ZLO/K(\)#;>UC;+=AP;Z(()=!] JN<_;/+'LW7%3 ^7=>:KW)#E\9
MW1@@SC]D/-C 5L@KG!SADTQS2+ 2<;7RL3"Q&J&PPVM.B__@HX7S76"J-6JV
M_?DA"]"TUF,='=PM+SG/A>;1O\9$:/'(<%\>3X'A.3%B#7?K:=7ES4%WV )H
M4N:Z%*!*^3_H\$KH:RN['Z## _;XX'@C$ 7B-8,-^[%#)DQ7+/(XQO0Q\)^\
MK 2.&=T"P7/!+CJ+S3Q-'M91>.G'20J;'G@DO0#L\JKMLC_1T;C;6@[CVL?'
ME__?Z*AJ>\NXOS!+0?S/R _37]D_-VW.S9U>M?.=",\7UJ3OTLUME]>'M\^F
M2V%)>L%M)!"!VNSO#J\.=Y^[G3:N_NSWX5$%^-=W7=^EJ>I)BXZVFC:QW.QJ
M<Z0UOSQL*$O$,O&F*[?OIH!3Y?/C#7KVSWT9+NO&0F5[*DK24RQ)3U\CBEX"
M/V1F"'*];BMJWX6"TSO(_3,-@K9\WMQ#3MF;>6]7"V@S(AM1M]R7ZIX?N/*\
MS;>;?VA0*WVR3&ELQ52OI>QT18FR3W4G!>-C4SR+6A\_V$0*D0\"GIN.Z0N-
M->B..3E$C+;KEFQ=(Z2'C'84O ^27<CO.MLD*3,SX[HDCGVI.-HQ9'_@K$;\
MDOVE:K.H>W),WBVX-SZS70P^)2T9O+MGJH[ X?4^@@J?>B.U-]F1N,2;2J:K
MGART1T/=-MF+U( M,IA)1_5D-/AH\%:+VUK=H=K^WIAVE.ZN:N64END_7^)H
MLX8C#P)BV+J;+EI;?SME84ALB[WRYG=_WW6OM+9,9F9E!QZ_#XN_[)%7/2@K
MH\)OKP>'J'MZN!)=[^V,'49^>N;%\989N0A6U=1CO>D-5V!#D"G"[-6S:%$)
M,*3_;/A3.Z?KF+(+M.C%JD,PU/NAVE\: W9E,TJ?P4;<-:J=/#W%]"DKW\N\
M&^P"YFVYJ7&&!\83H#?[ 3MQHI#*S%UFCMRP2YH73-;K.&*'3]54F!_$:0:)
ML+_6$HQ3I+/F*IFSK(I9=$JSAXN9&?WI#1=WB9^\4'Q! $<>!?Y"?EW,P$[8
M3 E4%!774K&N-I^@&=J.=L)K1B.X?68+M-8_6WID))>D4MG]#HE#HVCX/6&;
MQ )@DOT7+<_YX@VL78Y:#2;01JZ68M)!FWO*&/GA%+3@*:IL^7G^XBH\\]9^
M6MJ6VYXV?,J(?9^I";JH,SMRNE1]Z&2#DZJ#H]-[8RDC+95]\C^PPVNO4M+N
MY(9/_A:G52-$6\W#PS/?L:JG[O%!\0Y\[I3D#4*X^33?*4-Z)QK6;,^BP==L
M1):>'G *:M(V&G-HVMX:KB)0,",\<EBC=5/;J:/NZ=&4415Z./,+(*]!1&37
MCN54K62&SX3*%P WWRE;7K)S\LO+C7!HJZ--X5IF?0*KFTWW)#;\*:-.O490
MMMK'#4^+2C#*Q1AJ<KNZO#&@$09-8.A"FN(M77<K'Q[N<B9.L%DDVDC60C77
MW=.Z$Q@>-*8'"'>G.DH+ SD.O6?M=7@*3D/LO?2HX1WBU(^@6$ND-DV8[87.
MEGI_:_,+-BJ]Q>9>ZJ+#_@#+O^KO%_ZZ].>JOTU#[+DS@?]6/]VPK2.E-&QN
MZC,6UD90)]W3F](-'-?((.--3FX+W4E;9U!0IMV8&/XD:CX7\"!X"*-'R+B
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MO;!0D# !ROGF@$B<3&9?K4*B6!*O5/<IQ$1_2*Y9X ;%]-(5?EZVJT%-RUD
M!]&$].M*AMA-$7Y)X=;(9I>LX^@I]E8U54.6NT(",'KJ/P;T-J9LV%@DN7$C
MEVMG+]3%4C]/-1" 5?"1A#X$>K=8#ICU:[N[IRVIQ4>M2ZM&$!\W'T-^XU9Q
M.RT+6U\?5S_7+RYP2O,Y[-.E.M+9![KT4W"YX@; 8P#)+&(Z2J+ 7T"&45\7
M>WYPWB%$6A1\? ''R'<)R01W]F9L#.!6'T9M^2BT0JW144=D$D0L<L#2"(L$
MKOTE)?=SG\*Z$UPYP.C(8"O[0C$#^MXX&?Z9,QS2)U#X0;!<G1KGB&7-ECC?
MP-G-,]7X%JME124R>6G?)#:3O:XD+UAU8Q>5TYV>2L4<J@N1S(Y;.*O#MBAM
M]0=:;DJE*(_6D:N;(:;S894:<ITA^1^_:868VRWRYJJ[C6)([56'^G+7%&<N
M+D2N  !+;@/U[._*[:<UYM"G6GT!%=0A'P9\6X<C7\DQB00Y"*D@>3"R5+LA
MRP(YJM/NVU50G#UPC1DZ<EP\#X&GT4>'3:FQ>CNK4@GQ4O(5<[-_/#DBGS]]
M_FG0;'-#E9:-F?4N*E]-2QAT$\T9>)L%$6L+!L[M%PSP G-KB0F:+6K60)&)
M";JQ>W?_8+FV>/S:,G>,=$Q TB? NL4\?OT7 2-0OV6(!>+EYR'1GEN+>?#X
M/*AV@]D\1-D\1'(>XOP\.&K74:A'[P4$5:Q%=X;]9$2(IJIZF[VT[F 9]41K
M84L2PLU>D(,!LJW^GMSGG5^5(EB.-2E,/G/XS3G(3B<(SL;$"!HD<).W8$R4
M4CQ7"VB_VD9REKO2%QI"W@JS,R>+E1_Z4(P*51?]:IP$530O\W2E)7U@<NE?
MCRZ<ER-^:$)ISI'V&7/D(C$L8_[JRDL(GVHG4'GMK'LP>&R5F8*0[Q8^">FN
MPF44KW!#@-X!I\Q<6*R@;OCB+86F>X\!O0C9IA'C(_N>Q*)03PU^I*ZWVO@$
MFQ<PH_%L>O[U2-1B9VP0C0\WH"&/[;;X8\D6?UO[G,?![SF*$Y?N_B%TEDLQ
M!X+P44G9'?1:O& 6V@J<\N#EG46WHHA(U$ O9%?8GJ>U&@53RG+52J(X?@%9
M:#B4W=0K2_+*ZY*2$\BS(X#( 615^8+((0Y1S-R%:H<YM8[%[27/\/_ADO?B
M!11[-\@J./B!'9#Y/VA/]H1. 6I''/U9(PI.&%6&QQ^! [3P1_T-AQ K@Z@K
M[U$MYJC-4478&YYJ.@&=Z?6,[/=?'+3N$]EF/=H;%1H?L_\,-@O>MBKFAV&A
MT!J*!Z(P970"#G7 :U['*VS.!^PHS:D'MYKUGDMS#"VSSEM&0#D2GH=!-7"L
M,"GANW@*_7_V2SO21N,7Y"IG)U4YC7+( ]= 4!:>@^E66*+2@K_[5H0O]N#9
M;P58]Y_4)X#W;+"FYW@?N<V4,2=34!1'M#G)I4 =CCCZEMLLDR-G2;YL3]SB
M>IU[A5J](QDG<I?RTTN4H"B%**J\=21%J1K*9/)MOA@*\O45/"4DT^FIN0<G
M9U E8KZSCK/$6^/"%5L=E@OW2AG5[A#8\>K4OV3[+G^G.0C^@Q+KXNIKM^@:
M+:A).GNF7[WX[]!4C5<GWO*JQ?[Q/2B!5,WV!-6#$D9,S"0EC"[AA$L2N0GW
MF1:M8-<R$6$C7W$159VJ*&"U;KXVUE/D^J5)A]LM&\I.WS]>M4S%H%EE+_?
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M@A22FV^AQ^:"+DZW#PF _?(-F-VI)O/4?\&R41/5J(HL\13=PY=0+, ;"*Q
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M6= BU) 'HKXT363_:1_:^%FOW!Y<I6#N'0N#=J18X*VU@@?W)N0F_AHQ4:#
M=0O8=U_]T%]M5@8N[^WQR-.J>&1UWWKN:L=4RHQ?<H>9,(+EWZ_R<UB#4DTO
MBO(161VPALY]@"T-%W?[0_.Z6)6235R3OSM%5Z[ A53)UJ>!]5;'V94<X_PW
M4:BP_GA,YW0+RHI"I@M#W<"T%KBE/K+?A+A%UP.[O/+<$'TXU3B7?4%J2(>!
M3R@/%M[W[<7;'',J;[S5WIN%($4D+0+$QLY\+JSO5 *\K5R\L8N$#XZ2+)U<
M9I/WVTLX75AY:T9Y62@VL W/:%RXH)-<!R-.P1<PD%C%;O>3.<<Z@C,1_AE3
M>AZM/#_<<[94#WN-\!&1I,EOG+C=L /")J&J W3[EDY_D:W0L[^E'&.PR)!5
M88.RG'5%DK93GJS*6>SHN<.\6L]<N&=<(3.B5+AO-VY5]^RT';<I(7(>K)PD
MUL,:6AQXYKV)'*=$6K734&598?X$H&09L9;94A-QNP3C=KEX-&!4"60JZZ>%
M P7(V(0N(F26R;$ #2]3B]Y>6.+(V5:"NA!FK9)[9TUJ=V6-JM,@I%&Q]&6L
MR?:5>D#7:D5-[PN_2!OYP@M'18+[7RB@,M#%Y(5=X9XH_@A=?I36AO.SJ'J#
M+Z(2-53X]9)K(MCFCV![(LT]\SN?B5SZIR!^[ F%+4%+V+ ;.PD+8-PG&-3^
M3C-RQ>4K]TNJ0R4=(^;UH%J$9 \OGD/ Z9R^T"!:HYXR+4+O&DB"FD5,4>Q\
M75U&,?ILDAFCW^L:),=&AY<V>CX]3S* Z&2<!3SG.1-'!-BP?F4:5%T%; M#
M.K.,,1 MV047P80AELE6]"9(/<QSZ-<66*?,(YF*-N1J.&H0;$&^$A1&0<YY
M)N>2#6(; L.X?'F,B&;AK)\=F\>$_F/#M'WQPOY//P1\18L@,7?!6Q-"Y,NW
M\I+8$B")T[]]]=X@@MA+\X*&=87WYE=7\L$PG3=@!*FAF\3N7:I9U?SVT(0I
MPVT&!;E<PF]**56+-4R;Y_A\RX<$(L)TWPS\K!^>P&M!LL?1\AA27I'R08F5
M2Y93LG$8G5B*MH%::!>BW<9T[?D+X0ON!^ O:$GOMC/P?B,R%&"K4) &X'Z<
M'.NVB1G)M*VB;HI<5)]R\(+I\MS;)EIE T<<@QYCJI7I/IVF"R9SAI2P8,/E
M2SL$ AEV%:.J?2K<O^T:TG85(#["3' 8)E_-(>#E8"B2]8VUV8/;@=S5B#N[
MS+K=7&L_^3L<^0_AG,8IN_'# 6TP-1GIXP:5&^'@9 H:Q7&9BFQ-Q&)QP_"B
MJO+20D/'<XYFW.>DJ6IF*<@Z:L1D2*B@59X#$22W4=;!5)-C"65M,ROM@JUT
MR$G#XA-,>>F%5,7),:.&9 0MPT>9E"*7E.9>E(HK:O^K]8B9;;PZNVKZ,WME
M!\%V&E)5V0]&RJU Q+73XRG%,4D44D+%J,(V4DB\3IL]V=*!6(VYGD]\+(1_
MD:,)HUB.-TSS)ULZR/> ^GS2*+7U*K;,Z/\U G<'NE#V3LK2KC1'A!/D3B'[
MY7AF!*F 7A"MXKT-^UICS.7YX(LCV7Z#>$-BY;W$NF#DA<]2[&265)Q>SZ)1
M?_P/G\80-=WVBE=KN3J*(-KR-Y-?G46@K0I:DYE4DM8Z^A)ZVGJV%D4:[KJ)
M]F&Y;)ZX]3FRJP$4!-_&$518+4ZW#PF@XO$B)/813\!QTL=*A+L'EAS+(2!M
MZP.,0OSP>Z(&(ME(ARNS/IL@^!P$7^N";Z3@OA+<<R:XYHC3>S[PRI<;^HH_
M[8VVI3L=<STMCA1^+1N#/W&@HN;2D"4P3A%+R'8ED5T1\\?ZO>9,'6U:'_Z?
M7_G7Q'5P,ES:*?X/$=PXNLL/J;E2FS"5QRCWM[4CU\RE']#XS$OI4Q3OW1R5
M.V20%)&T1LYZA4/)#?^MY0^BZ.&6AEX@P#/[%G\H6@=0_6%(?+$T&TL_%-)P
MIA]'91_E<G$1;=X7BC&7,8%1>%]4A8<T_>7@Q)%F<+G,G7P0I+]W #@)>XVX
MHESZR=P+_DJ]^")<](@]"W*$TR- D%Q ;K+%(*M),7)^F0%D*=WK^45R$BXT
M=[>XZR^FX1W4XH.9QQY@JRF6_\D.=3^Y]D-ZE=)5+XLVCTS"6,%+OYY!)[F!
MS5?QPUT#&D<$62*_ 5,$N7+G&QE"AR4GT='!Z8_=A=GNE&[!/YPRY4":(E87
M&,Q=D&.H/,PU+UD(7>2]V1$OR$MVA/[UM"C@</AJU1>#WB9^1='W84A2<<VK
M P9'UXVK9B5FIDES/E5V:6J0T%&21M_*/:W?[568LKTR\>>]BQLGJA^IHBFW
M<8?MSD>C&G.N$%6!J_%V5%3R[T:OW W"C,J=EMT1F*'<)@AL(K./5%WWJ1>G
M.RKLE#[Y8>A09W5MA$^W^B\]@$DD1*@R%#/$4$PAM I4PE'J/<"'$]CT$%]D
MZCWSUM[<9X+)'B4/X8+&S!9ZBKV=@2>+0/T>QXB3Z/QB2#(78Q)/#DH &"J&
M( L,:QFKW[86Y-[K<7!^B<HOI9=C96UA"(Y&Q'"'+7R^V+GKC-MWSMZQ_02\
M,V': PM0.&8S6M:Q $TP7^%:=B2!W%LS-$SN-+NAZ605L7WOGZ);'\"R0$\>
M=JN[9?N$WP_S%IRF%,T<J"H0I)U<41T(*I9B"6 4XK(I]C92PV%%B1@0CQTQ
MY#>@!?V:U$<5CJY,LISFCJX93[#_W=.GWGV\L]*96-$EB2!\."(%16DRDN3>
MD3309PMD>:'A'O=0;3%BTS&4 4DY6E^]V _RG,><RLA5GDO'=,MX!K7<>L]*
MZBY:B(9L 'ZYRP4_:;SA"V1FAQV/'6LMY_C4FF;A$*1-=:?;W(.#J*Y83-37
MTUVNBW(*QF=,G&)UU+6LCI+IYD#=0371BL9/3* O<?2:/L-2\L*>J2N2).$T
MB2!Z(+)4%4>Y%4@N-<V1TRMU7._WY"I3O#?O^C1HQ*QG4L_1RF:3?0_>/&AK
M^K"&FNW/GT[^>/)C_]J8R?T# 5K')S\>I"R!NJ4*VD01)YRZ%,\9%M77**1;
MWL 9 .#[0;PA,<*I$21W8'+D\)Y0F!47!O#KK9N7!2A+><_B&<&:CQSR"^9]
MKBHE -7L!L8'*WCD83Q']QFK.@CV%_^@Y:["@B42T)27K972X*-L3'),'EWH
MX-(/(=Z#N$TR[68+D>[^($&<=(;=I!41HWL0Q1=)9.""<'!:&I8VT 6E$GY+
M$>8I W8KJGA;5-'6_([]W]B']D\<$A^[G/??E25YDM$7<18^@H#HL)@W;$O*
M8E=8*6B<"<J_3 \'L1LJLR!?T'$"G:%P*K<$!_7[2M/G:)&YE'LG%.K>&CX$
MX6-H/<+<I@G:$[G.U3(2N1TT;.0PFR/N2UCNEND&&72\RF_OENE&0UI%/[?W
M)@I8P CJ@C!J,ZH')% ]^H*P6SUG4MUO'M%XY*'&GH69@I8HCADWZT&!9T=]
M+7OQK*^;4T1K1=.>;R\)P.O'=$X!5#!B,T,2*1M[S_KW?A=MO:!OVVE.PYFU
MU(OG7&J08/S.<LP.S5C1S7#V&AFQR04Y F!%3K"'^O*?N_AGS(^:YZ#$KAM=
M?XFC)+F-HSFEBP2 3B5"P!6[3?I><,NV"'\^72XI%/GTF0D<"1+@<"@.<NIK
M< 0^'Y"L<43V%S[D 4L?Z(+?Y@17. QB(,)'(M/#E[JP>S1.>\V<V[WEVQ4_
M;_&,;-&7*@^OPO6&78"A,<])KXU+KR/D1(\(DB4GSDYK@U+I&Y<0PT&O)MWI
MA(+P>P2'2[FAZ70Y\][^XJ?/T#,!4@HZB_4S%RO$4@19S &E]Z\9M?_+WKLV
M-ZY;"Z)_194[57>GJCOI[CQ.]LS<#_)KCS-NR^.6=RIS/J1H";)Y0I$*2;E;
M^?47"P\2) $0%$$"$OTAV6X1K[4 +*SW*OE$[JN/^470$F<HSR,JC1.WHT*#
M):K.3QH]C4)?%1W=!WZPF4C)T@7=4P4Z8%&<]!P0H4H9I-C[PIB05T^4^[J0
M2M<JDZIZO)SW P9YR(@TO<-:MZ*010ERLN@)XU]J_9-CB2%VI&11S^U*P>?V
M.+4:JLK@%E9*;Q]$2RS4?_$MD+*Q%4*@4+GTV7($A<0)[(;V$*LQ-VH,<-V]
MT6+RA8J3XZ#>C0,!PVZ3+#'_^/D5B/!S&Z]24/E=(?K?VUAJD1_(Z^ 406-[
MR$>?\>&QF#/C?@<4T&**4P2S)K;[ "Z_E+^@&%,\*.PY7V\QQ8-(/JB,P])
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M."]Q*BR)&Z/?<3A,F5X)JCVHV7M*NU+72A"D$\\#>!O*W0EJNY,)#5DU\UE
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M806.J K"'06A&.XD8! -8"I QBB<<[3+.',,?T2%#I3[A/<YEJ7=JZCT(,S
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M](3@@'XJ!5L"'%7"*5_"(YX>U)1'V\6+O;O>[J+D@##^T[=PA>1A6O<)R7R
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M^C)RM2A]\?"IPVSB?/6O?9B%Q(?!Z+EL&<2+O08_8H0*OI!D9,^DBAZS'EX
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M_>D[/A 7;&E8J +B(,3D-DZ6[0G<HXQ[,8GUB!M@RQJY7_HR^'&Y)QS;7[$
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MB%#-GE#8Y2@_70]V-26]UB=V3[L[^?UZZ]9;&HDJ,0]J\B1MZ 4(!:FAJ@M
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MJ;,,'3&,%^#+TF$^?GM2LV':#NYOV$.*;O8QYHFY4;(I2#2NG$$?3_9*7JU
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M[?!/<<X(>./ R!IY@>^B]#(FCO@!43Q7$98:V&/_6)2FI,\1T=9IZ;3E*;Q
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M.UHVB?;!-.%/;6\?'=1AB2*,;*!4)'P+KY5H:?#55ST[RO;N$G<+*[E*MOA
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MZ^LG:,> Y)I**S@61</3I!"M1\[&V,Y04ZY2 9_0P+<B!>^U%KQA&HI;$+_
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MF2.CW9V_S(9CZF9_UK=,ZJ#/ST[E6)UKQMKV.( JY6XZWI_U >G@O/^>4]K
M45Z"*Y,7[EP19N;M7\&61<YL$C?7.!:A>!HE00&3P)35X(("F^T>_!-!;E?7
M?]6[>^XTL35A0'&TE#$)$SE1]J(:A,R-VMB!22"V)>Y O)<&C\NY7U/C=&V=
MXB(F(JA;39YA2<4FON63N.]#*SO-'_YS+[K1_J3KXY F4O!A@'==C*&:!!8[
M/TNM,5R30-NPM%!J=9M$R8;6D+I*+3")^IYCZ7?G_1:WOQ!M,8"3.$Z#O!$#
M1"].8C.&I9D:RC&)FA7M%*$EWG026/*5($A#92>Q(P-3!;6%;8@R(:<E1+:$
M-$^BCLH@!,$X&GL2*![FAM=<4H:HJ'):MUD54#^)6C.VK[%AK/\D<#OL"ZWU
M&!JB4,UIW>JV7 Z3*.4SU.TV2R\Q"10/>\F5IN(A2A[Y=,$'82^/2S,R7G6I
MLSW&=G:3;<1?SGHC!CGX\IPT[_CL]00J$N8PK/[\CM5^6&4)"+A5]&S]FX9Y
MZ8P2$7'<GK?)>1 $'Y\]B2/]O&U6PSQCW=,[<6R?MRU@(&Y9E8:*(_6\U:^#
M(-5"'BV._?-6GGF ?75^+[X%YZW:&$\&+U..<<R>M[0]'F;%=&D<M^\"7V?<
M=DCTQK%L50 \K] "-9Z[I*;COE_G[; XI+=VF;R.X_)=$NSAQ-3,"<C1^B[K
M':,,:N8JY/A\E^:.5EB89ESDJ'Z7\3JC6IX<DB/T76SK[A8FSW#),?HNA1U#
M717I-SE2WP6PSL>T1_Y0CO5WT>R8HSQ2XE*^2>^F/3L4W#!3*O?F?Y?S;% D
M"XE<^88,&T;^/W_?V H,Z#^%!M+O# 65?<&X"#-\[Y,H>3G\;I5L?\]SWOX^
M#WXD<;(]T$4P0#$)(<SQ:Q)A2+/K?^TQB//U.J2@W<: ?AKNB_(@C$K$ASE,
M6U_3;RH'" &6U_AD.RN_:)SR,Z([UZ&CN[+Q9492Z=K+[^[+7M(#A:6P'2:&
MD(_-H/2EM(\S4&JKT9X:>5L?2D5I#TRSG=TE9VDN+!?_JURJ(N<L6V#]ZZC+
MJN6[;2RL^GU\C$FN4O6;N]M?>%C2"_$5Y:_ 9;YAGHBH"Y>2HC8=.SNF!_6\
MDE)"4#1RMQ-MV4/KR%>V]_<P-7C"K@>J', 9D%4+T$.0+E+R'%(#$.:"B5%(
M :!A9]L%@O+E*_H:I/]$F+_&\V/9\B%-7M) 3C'-^GBR =0$-]_C@Y)*:E@8
M=G((#(A"Z"$*5NJBKBV-O=H);85.30?;-1=3=+,'>>9O 0BK>:8^Z:JF#CGR
MP@1RM2<7CZA^*+KNT7?R2<V:&W6V74Z[?((>$7#2>.++8!>LX&E]P\(H, )/
M&,DI(R*RC>@^B _L>L<7P*2GNY,GW$A,;%9MP*C;V[_.F\H=K<[)?E7<;I.>
MEM?[2YID&3ZE*X36&=@QN:O.;1R"J_ #"0'E#ZMLW1U'</@&' =D]_ZVZS8"
M(?F>AI#&!31LR1[T%]1O.\S 2UY>R]&@FVWBRDDZX$97W4W>T"OV8+'/LSR(
MU[H#H>_E \TW9#IU/?P!X[1JJLOH!82S5#GC#L1&TGEH7K3)GAGQI9)N_IRB
M]HNM[>(#(+\F0-0?PY?71N7<MM:V:TQ3?27A"KEF!RQPS_EMG.7IGNA"2F*R
M3,C1D!VB(T?R8CLDM9Z5S0:09[(YI'?+RH>]C%M422^Z+K97*++>^Q1H6;Y,
M!*W-/-\R,>D>5#CEFJ2+/WXTV[JJ-Y1B= $V=1*(ONU8W'P1:4F#*#MP\=6>
M[E[3,F>AFN]M:>R'IX*7%2.]\^<P,O:*"%*85,^]O(?6DJQ(#3")@_1>>%2&
MC,G7T>QF1I8F>I93I'-'G-Q$+2]]J$?MN6/JO;JF[3MYI_->-C5SG_5K=QQS
M:6ASGUAEE<X/0VNN[[,M&&7SYC95U=,X=T>)@RIOC"$*>GC$QQY_6>5INZWB
MZ;PO9BT_WWF'9!_QC"K]>"963:/SZ]GAI Z!RO.YM:;>6$-@\13?""DRCW42
MFUA%C6/.IY$KVL0J&QQUS]6^;Q-+&=_Y8IMZYTTL9WEG/';U&APB5?;9/#E'
M."A.(DEVC_-IY#(Y2&KLLSF5.H?.01)?GPWFC+U*IY'*VAK3J%803ERV[H;
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M,"BIJ$W\*<J[5T&NDSUM;+_/;"W?@XE22?R_CCS5J4A2.ZM>\E,7GPY\GXY
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M6X1V"6'#S!!0C'2%$$<6#]"U-" )&F_WY/F[TB!2=L$)\RS#59*@GA_TPL4
MU)TB%,H!JC-(,VV^H!TZTG=BO:_#2N[06UJ'EK (3VF>W>K:-]T@(IZ9@#W8
M(!-H1(B]XHL9K])CW^FG.@O0U2TUV&?O/$KS+>=!>W08+__%%AI'U683ZK)%
M,X=W+J,1<U5I]>'Y :%!+!@3TW7-S AKX]E"!JYB#=R*##^3>U=U)&0"Q1YK
M_:1>$*TXL(G:$?L$T4-X_NCEW+RU[%9(^+^#;$<[ZVT/7OB.7C N[O=[9,8J
M-GP3L)ZV&#^\GWWOS0]R;:$0(NN+4O\VY.4;LJSUZU>Q./S"X0VF9Y+RD.(]
MDW,^,;24$0O8[+<1YTIP0P,FK=:27#S)=:FCGQV3W,1T%+R((Q>S:?%O2YJ*
M13#E\]QDF15?PB=VBA(O^!1'V8ET2R<G&.*;B>]M<4DC;CW82;< B%VVI8>2
MA?&:DJG/AZ89,)P%%WL;)C<_46WR/CF=1EF8ZMFZ2[/WJ*((CA'2U*"IT,B)
M892\V*H)B2W<8JY%+*Q$U+[-DC0ZHG@X<Q"OLD0:@XD/U)GB-=CYXSABAL?/
MM +HE )3'$?1^+BJ)JJ:H2Z.(T1K0$RKX*U:.(GCZ!L?6=+#%2]4PW$,Z8K?
MJ+,F#$1*.(YCDZ$0[8ASE<@!QY$Y/HJ@(E%MWGO7(_DOD=2$/-1QQ.B6U-0"
M(!Q'FA[9S0RO=!RUQJ3 ;KB*XWBZ3-P;$#WC.)ZF$DAX#ES'T:=9!.'%#CG>
M=N BZ4*(2\<18\H.5,5H.8X?/8+$D, OQQ%FU$AT05R9XVC58SP:')#F.-:F
MDBTXD6^.8^\RT>+RT#K'^]JHR1Q3!]XYCE0#\LJ@P#O'T6?H&1&$ZSF.L*E>
MD+'!@8ZC5],3(P\NO(H>8=-&)#J.4MTO"3<FT7$\Z7DRA@0X.HZPJ9Z,(03L
M.$JG\+,VPE0=;Z(XCK,-"XIU'$5ZY(XA8;97T8OR\@ >Q]&D6ZB01#3/NH>G
M9HNR2Y4>7_#__%I?CQLO\1/:IRS!,'E%)-77['CTXO-Z_]5_#_V]OR6Z=^Y^
M(5UAHL#?$OY5]4%Y#/=1?"P"LE+/#Y*Q12$Y&167;+-' <U\"ST+:\X?N613
MK+*2FA:U6&VDW9V[T<"]:!S2 7C 1/N%0&\#+TD4&AQPQ]M+4VSL1-C0@#'0
MWJ9Y=<Z%_0!DLZR!L\%KK_>K7?[B"&%@#K69LUQP&4S9X<Z+=\GKB90;_NE/
M/_[EQ_\20J(V%T)-N(<H?D+?&APUQF]Q%N:1M8G@N@];PU7RL]_'Y (>9G_S
MG09BS'VWQT"\[C_]^*>_CKWNC;F0LO6)9'6(XG2#XJ.\XL* !4">WY_^])?1
MYU?/M9?M>SQY?DSPN]Y_CHA7]@/M\FCU372#<J<%VJWW'/#4YVO6$YXR@KCU
MOFE(8XG^S''VGHQV_YT\D6J=I0FA#4PCO.=#-LW>_:>1$%6 (GVA_7#KGP+$
MI7SZ#')+DURRHGMH(%8#_&_=N"B7=0HACU@=3U'L>X&XG)6.I9VK-Z#?%%1Y
M)S287!Q-.#2#U"&F&\B(DS:*TFNP8];+Z!N((&-,)9";JW.UC/,R0XWC6!"I
MSIWX+15#"6AL*'7G&V4V:6**C5%'$"/JT6<$,VYTZE-L["@SIK<8"X/].(("
M82/'RW!@EAPF2%LT*\AT3&V0<6119AG(J"!C<9H7O&G[=#2GQ^R]&V)<=12!
M.LFI88IU-'[?+#D-L/4Z&MAJT$C"MC<[&J]IEL[D1FY'PQ$-<_M+3.F.ABP"
MQ6AEE3>!UK]>(UK[MGV7 D?KF-$'_(+2NIE?\ . _YM*7Q5.BVAL$A2:I'%&
M?R35-GW\SJ;5U'7X0NH!8)R]TS.Z,&ST8E]-M;%<%L!$TLC-+>#<-3:-!SQ%
M8=R"H4<P':>-WF]8<VOI $/4_%S?^O91='-NW)&'&/T[0^'V+ C[4ID) :SJ
MG__71UC,V1[.G]$'"M0@$TVV#UR3J_5W*HP1&[;&]8!J/U*NPU08;(3RC=<P
M>DM03*N,/X:G+"V3+/-JLS=G.IT:3]6PH_MSUA#X)0K1.:\42 K&)L* +\Y@
M^Z=/D9Q0;O.C$ +1#+N]U'O%S*NMUA*:(,Y0;;[]DV*]?H,94G?F/,$"Q%V;
M'$M-%NB,MP^"VP\$(%IH"@855&I,5S35&F"O7S<QW=>Y+F4G!$<PP?[I--ZU
MGP:_A#_9!D-<7)#; 'SP=%#G),Z)$LW0WGJ]F1(MES\4)]FC)LJ#U>4H_GCG
M0FJ-VK^:!E.-5B/(L3K2V MC5C0FLD7V)\AH5(OZ&F:/8B)(S0+B"*I$T6$3
MX<J1H$)Y,(9I?:")89YM92XH'&)F9%(>RVPS%^28>G '&(M HW+H2R!SN,A8
M6\\LXPAV%)F_9O0XPN^'$A';BB609S6^#XX@4I'>[&'2$=(<]XYRC,=2N:UG
MB(,<@@U.F1)*SI Q"4S@%9E2YX)&G4+O3W-#CBFA5]TN##E7 !S?ZS[BD)%G
MZXX:3<2U@1S==U35=>!HWLIT/([OK9A1/+&)XK+ZO'+B(U41E'I'S'/GZ?R4
M?7?FY= HA0[K^HR](EFQ%R;>ENX$?T802\,:"6';PO"7_CCWM@PHU&:)QQX0
M4 0O'OMKACD1,>>D]Q_X?R07GC<:TO:%I\(?[SX(]IE"7J6B[G] /D*D8SY!
MB69  T-X*N(Y\P'%/I%UZ%\8F,8>:_]=@1A9]QF]1[<'=/SL;TF?W]5[C.CY
M,_>G,F.>,7435=?&VFK98B>_CT7[92&UR&;9)_R9)B7./V,D:1J*AD?2,V9;
M Z^AH*OS",DD4&=%VFKU3 Q)V\;PTC'Z%<VWV*VW!YRT_F]K?N;N\%<^\#8^
MZKY_Z_T>/P"DJV6"B%)&NL.2AS:BS9X+%LILX31^,?-050)<HR["<Y10R^8]
M,:,FI+SI?9@=B^:W3U%:4#3:/01>MQBZN>^X'[ENP";+]/EH,V&"#DM1BI@2
M6"E;Q9#Z)C9'8!<%.8T%WI&XI"4"WYR[7K,7I%4UG&=+A(Q!Q2*_8C.I! LN
M4))JI5\-B)@3%U(P>79ZX8KL<8[@0T0@.A'B"*$HM 26V?@%]V9N22?.!#Y-
MV8^!YPBN@I=DUEG'$3"5)G5Q !-8#"IY>EI5Y64F9M (65*SX"1VL$S#D*/%
M02E-UO+E;<3>&^;N,LL^Y/!H4$0I%.(A8Q$0,4[DF8$<L@Z*IIDV4\C8 T#+
MEWK,(/>Q $6<-A,])V@,8IM>-?A"W<QOR2N[$!2VDQ"KDOGU@/I'FFWG[TG5
M_*3*:MQ'<>*19>RFP7S='M N"TBS(FZ^98\TNE&!@]8 T!L^[]F0K,.RE2T6
M!FA;%U%"BO)T,)44VR2Z.D9QZO^.=K=1DE*.P O?&[J,_6"=I5;MU18SGT4I
M5\F5JQMM?XJC!)\.!B @=_ 31OT->4HPZ_D^[CHKKNT<:DAO3U.H::\-!C43
M5LYU(YYLE'##;C$H$QD<-U]?C*GAL@=DC"GKLD-E2HM%.69:<'/J^D-+'3OW
M_"6FN9NJ?.:XI=\:&CNRG.-&9NUHO+0R%C0CV]=<#FS\@='DLS2*OR!*,9MH
M<T"?_3WZNO51N*W6L&U>R[?Q@DY$  K?*U8;OI/CQ0>X+F-&GN-H[Z>$U!\P
MN103-]%M%"91X).FHSNI(<[0UZQI..V7:;T7;S]I[U]DS-.PL%ZD)'':0 C^
MKQH9^#]^Q=O:9=MT'7_%#[>_9=64X ZSL5%2*ZO8 ]L@)1YKC> ^H1 30H!W
MM-H=,;]+TIAZ/@INLWHC?]BF'*I2G0T5O'%@34M@]47$%Y>R)RY]<8=:PW_%
M9DK&(K14\D;K;@$4G;T@/;^@#Q1FB-Y&CT@GY=_]]P-GHX.G6WQ(!(YUR:U6
MFPL3M#$@V;[/G+>-,] UYF._X,M%LH_TKNA8VQIJZEURX&L,@%:#:*D*9?%&
MY6\?]U(4/VM^N(DQG;RWU24K=6+.)56<9*\G,MX:EAMR;'%PV1ZC&Z%XB+_U
M@D(QN?7"'>5, NE'-L7L#K]X8;;'9Y9QJ\BHSM*\SV<4)U$8HJ PSY1$=O]]
M&V0[(M*FT?:W&R\A+J$C^8U>9#X(ERVH&;JAFY]R;]S[O8E2+QC$$?(9VBNK
MG&*TS>4#HE'FGD$) N63X%46XS P_GC=5Q"+*BA)J+67- _#@A86.[TP?4 B
MAJ8RS1ZR49KC3""BM<=H1NHZ/:"8C[SFS^Y&39BU63<]&3KLN^XZ>66&78(I
MB4T5-/!R5]A <VN3=*2F3$=1HV)F:.*!:U)T&'ZI$Z'N03+$=NDH1D;9,-M<
M5F@A!(T6*0,5VP]+%LJ_48Y SRH1<SGXLRD(H]6FV;P[38L@9!PI1RSJ<ZE;
M37!>JE+9BQ6>4C\H#:N.XFR8G;;5\[MM#'44_D'&_DJJD]IA(<>C6N+$?&42
M,K)@L!O56^HX)B^ZA$Q7 ^2 9HOWD">40T87C)LX4-=U'*'#+N2%/C77H^:G
M(SYEJZ3C*!U&?M-3UX2%5*P+&85WUG$T#J,H!5>P"7S\>59DI>"'=AR) U])
M%;>W"8S\99YDU?:X.XZX8:34<O:;@/Q_9DDRFFSQ;N8N=NN))ZO=SL^W_1CN
MH_B8$YSEM$2V>K6*8R]\I]O&1T*/81-AK8-LFQ (N0[28F!:EK;7#+7*S;T
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MT@4'6385$2)*XTW:>L$V"SR#CO8J9@"+_#O"27;X'TD4^#OR2-]X <FF^7I
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M-"/]F\A)YD.;<9K@ 64E:S%=GLUAC@ W1'N2Q?:]AC'R O]WM/N$E0ZGT,#
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MZMUCT1"PUY-I^L=G\\O!WQX8]^L%;:/WD$3N"IT'BBN $;CD^G3_>#NBM6
M2))NI("7&=]%*GC':"X=!Q*\PC571^[G2FMMT-D5>:G)ZPD_N_L4Q0]^G*3D
M&(G<[ 7$Q==Q %Z\6I/@H=2G(#VWL?3ED\(RI)]%%"990!ZK!X0Z-*XT%"0Y
M-(+MFS8,*ES_G+?E)@78JB;-]66F-1':?0C[@=^:5G6('Q9!BJLPS+R@N!Z$
M"FI%C?<[&"#E]K(]?J9B<0J8> S(NZ#2,[J?]\<;Z<YQ,C,7^UF* XNJJ"T
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M7!@(I8HUH#OE\LI@#.T?(^&7<V<() ,Z86[FRI4C\>R<):#R [\D#*0!LG.
M" K\("RM"B2%P61%]Y+@W]@PMM U,C\B$*U'N6R%.R8B/K>8_K'>5R( <89L
M-C9HA\DE!!(<&>(G9&@*=F'P'Z7PW)5.0/JKLY,/*BT>,@RX6!18*5I=J$K=
MZE,PQXAP#*: 6,O"J(C:4/PGKW#.BR"IR'FAM'EEC B,T+K4/&/8KY:;,M$+
M 4H;>:/X&A6F]ZLW *GF<@R,9L)W;3X"SZW' [ /DP>J4(<YV$%*+&:GL;<1
MG_@TH!_OMH&,@.D-R$5<L+/YLF^?!XH+>)R(GF5U6V*/HQ>HF8+P,'9"+W\\
M?PH>\ZMAQ^WMSO;V]DL7\KP\VQ+:F]1_[)?ADUY:YDJ"=**T9K/QPJK55[89
M]])^IX@W8'P?=WZA= N>76)OYU5319Z_>PV+=A^%1>_*=ZMV[]XQMV*5]XG)
MU87^?S]<ENN\3VRN;)>Y/V06D@$^H "MGUY<7_//=XR5.G;8/ &#KTF+/GY:
M=/M9I471I?N72=.P(XH(U+J(OU85^XZ'[R$& ^%C>#:=<%-Q"=XTY0OR0">E
M;='?E3B";SQH$Y 1>3B&7B[&+6(F.#S%&[(R@ C.-.6W*/V#^:W5>9\K)Z:\
M6(NGQ9AK/\!6 XRH3X0-\PE6K(<"^4ZN:$81"2H;Y137%_Z*68&:)85D"%"$
M0"Q,CM&A+"ESU'F"F:("B1NM+9X(N:U77<RYV8S,D0(\%EGRW9TM&T:CL(=3
M6[@J*+E"F*Y1ZU1:.W<[;]'5^+YLI2=2S:,$$U^]#*6_!X34?RR"/UPBZ8)
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M:'1M[5M;<]NV$G[/KT#=24\R(\J2;/E"N9E)$V?&#Z=I,WGH*T@N)1R#  N
MNO37=Q<@95I6$]EQ4BN'>I!$<(%=+/;#7@A>S%PA7SUC%S/@&?ZR"R><A%>7
M?T1'P_[HXC!<(L%A37&1Z&S%K%M)^/F@Y%DFU#0^*Y>3@INI4#&OG/Y!%*4V
MCBLW^2L2*H-E/)B4V@HGM(H-2.[$'"8'GF$FYLUP#?%H4@@5S4!,9RX>],="
M;>U]<8A]UV.DDEO[\T'!L6NJE0/E_"]>@SG89#'>/F+9T.78,[+B+XB'@]+5
MDXN<+G$F_E[."R%7\4=1@&6_PH)]T 57#6&BG=,%TCI8NHA+,44^-!UB0OT;
M/JF6VL0_#OQGLI@)!Y$M>0IQ:2!:&%X&=HN@C$3+;+(AVZ?$\?>NP2A:):45
M>,TN1.9F<2Y<HRB4ZG(Y$XEP+"P[]4/]ECMI9'CV&2D^H904N8-YLEIY<_GA
MX]6[JS>O/UZ]__6>:GFPH4C('VPGCZV JQ[[C1>($/9&*P5<KGHL!>-$OF)N
MQEW<5DH+ABA?$4EA7002"L(BR5BVD%@K@"8;'_?'H[/GDTS84O)5G$M8MC5Y
M@M/Y7V6):2.:IXFLX\9-O-8BXFCCA%N0@B:TH=^;"2*SH]/G;8778_][.C_N
MGXY'P].SD^/ST='I\>EH_'RRT":+$@/\.KX&*%%4N5:04#3'R.OI$XHY>#7L
M-^O3VF8#S^%@\'QCP"=C=&S&Y\ ,S 4L($-#$Y;]7N&4P,@5^P#D79A6[)TV
M!1L.HM^9SMEOJR62O5<D]13-]$JE_<G:/,E5U-^=F3XU,QWMI9G^@HN8D1D6
M*W:M]$)"-H5>L%83;#33.+;2CM61".-JQ2KE3 4H/7?>YLAX.2OPR@@N6<Y3
M;#),%^B.G0YT=P@4I& M-RLB*?@U(-_6F!;;,A0&64KRD<2#"%)ATJI ,H7=
M49(,#$.-I3-F*_JZZ;\  _4@-(%"6(D1("J%+82;X01M":D7D,9%R B=X33G
MV"UCR:JMA@Z%>X'"H^\+A<!RH=#."3(W=MU#""(YWC:M^T+EZ$HXY0/X/Y55
MAF,B=EI&W$/<"7(_.!U+J"4T2WD#RQH1=H,U2IKY1*-'%)5$ L2B1NOV[*R7
M)^5VQG*I%[8!JH$I L)@#L4X-0:Y4<I>"V^V$>:.M!WD]@)RQWL)N8^W[/,_
MMH93G1>0B]!Y+O#2V^P5XP8\.M#:12*!K)@!JB!! YP1.9%1XDXNDJYQVJG4
MML)^Q-5H&6!2&IU"ALV6O4!49( P"Z9_N4QG7$V!O4:?]*&22#$\XM%P_ )>
M^J[#<1:NPJ6@M%,%>-+XC!Q7"[4!123+SHSR6XQR9$3SW,0R4E!P&S\J/L_[
M@Y/Q_S4^S\_.1Z=G@_'X='P\')P_$CSY7L+S+5A<%317'])]'DL]BC937MG=
MNU#8EP#BHN84 DE=&1P C70NK'=X2 7*CT.U@AM7V7:WH?R&0*LCR1NP]&I7
M3#<%NDV4Q6HI,NZ\H(D5F>!&T 1$B'=] *!HI,I2#.KW)>L#5N\>M044R*$[
MIDXE+K)(*\G)J^.TO! WL2SV")%Q.Z#'?PD0(2XA]H?L<1UM!^2O ^3D.P#R
MSB[K#IYW=W8[PQJW@KG("*W<:L7)JZ.Y5X;R2H(P-UD#)P2XX(F0PJTHN-W&
MEC87CSP/JK OW")MY:4^>%C6$RHK4R*HK0_&TQ1-Q0O@,]0I*(RQ)6(;[T!)
MFP:18/8=\(N;BRC1?W<(W@<$IWN)X,LYEY7W5V3>D.>8((HY&J;=DNAA(+V#
MYPV7V[,^#U7LB%[3AMPRT97[9]Z[Q 9\30V4..>?+_>PI$G)_>X#00<HSX0&
M[]"V!VC+]A)M;X,YWX4%55WKM,W?V4#=/?PCA;$Z32M#9M^*&6^-5VCKL(6>
M;>(H-L4A_@Q/+]B+.\0Y8A:]U09=+6:*5NG+PU0Y5M5:EI=!DAFWZZ":_)S'
M.&0^ /"SKYWSBDEQ#;*N%6_0][Y (8^/Z*[4])5*3>.]A/1]2TW^P6'6[ .]
M&U=$GK&-RQNO1/BZ1VQ])TU%H3@FJ4X;NPYD?0,.5A3".8"MOC[1&"33G4R@
M3+[["\0M L.2Z\9?2I*;#0;^K 2*[+>42J6^=/RRJR+M@S/=SRK2:XEI%ZZ+
M0'A1Y9)JH*D Q$,=A*ZK.0M4#T65(0WS<:5/(/U#S.8YQ[U05A=>0MUXBP_C
M&7:TL'9A6Q!9)YQ(C.#"5>R%H-9B1&NK NT2U>6G48<(6Y\%=0'KOF!L/PL\
MKS$NS0TZBQY:/'C/AICQC]MK</5J* @UUW(.%.XI/JV/#9C:&T)12KT"O+N8
MZ> "^2WL(M:^,/+M;T/!TSX$-WJT96*M0V[/&!V2]06O+?"FTZ^3! T:C)>,
MAL9I$7F$YH?)>"!96V8?;;.FQ]E)7EJ(;2B"K9'M#XZ&?O[(+ E@&NY4DPM[
M7=P,T% A678;"L?C_O%X2!R7I"22KCDJBTW^2*W+_JGSN#\8GS^P[U%_</30
MOL<G.PN-_\P=#=7GB+UE)CR]GAI=J2RJC2GWG^W&U-J9_'=$#=NT6Y^##A;?
M'PSIP'+=Y,UB@ US"EDQQ:OM&TG7-(W]M[J9^NRS'^LK'TS^$JCMEI>C,<?L
MOWS%AN,>&PU&X_:IT:U+WVETYQVI4^ #%/C+*OZ&*JQW^+IE6.*<Z$$F:R;S
M7:KXIQ^')X-)^_O0'FZ>)M^Z"-TV_B07M-MT.@5^-07>>96GT^BW,,EN.][;
MI>MLOU-@MQWOC49W>]]T)B!G[];UM_>MAUOAWOM04%?3YMZGMVS\0\6G;Z^6
M;U=$#;G%+36TWPN_\VZYKQN'9V[T^C>N7U6HC8K\YNOG6VO/H++/O)<^6[O+
M6GMU/=M7K4-%[_8-'#(TEWP*P4E&/'=@8BX7?&6]F[PXI'?P7SV[./1O[_\-
M4$L#!!0    ( #<]KUI(8O;2K04  %,F   /    <'EX<RUE>#,R7S$N:'1M
M[5IM;]HZ%/Z^7^';J=,FD9#PTI>$56*4ZE;:2E>8M/O1) [QK>/DVDXA^_7W
MV$D8I:RKNK:778%0(/:Q??R<Y]C'+[U8)>SD%>K%!(?PBWJ**D9.AE^M=LMV
M>\WR%02:E41OFH8%DJI@Y/U>AL.0\IEWE"W\!(L9Y1[.5?H'3;)4*,R5_\VB
M/"0+S_&S5%)%4^X)PK"B-\3?,PV&]*:NKA9N^0GE5DSH+%:>8W<IWUBZUX2R
MRSH"AJ5\OY=@*!JD7!&NS"^\$[&WWD1W<XU9+1=!24O2;\1SG4Q5G;-4FD%/
M3%Z$$\H*;T(3(M$%F:.K-,&\%IRF2J4)R"JR4!9F= ;MZ.[H1G3YNIT@9:GP
M7COFX\]CJH@E,QP0+Q/$F@N<E<W-2S"F*0O]-=WN4\?D71/!M95XRHE!=DY#
M%7L15350H-5P$=,I5:@TNRX'^&;/BT@ 31.Q#LF/07CJ/K]Y[1XX_G_;VZTA
MP&!X-3D_.Q_T)^>C"W3YY6K\I7\Q09/1#A^#CWN$OMAC>V"C\7!@,'+;7:>!
M^F/4/QU=3H:G.]#N@%9#=>P<H-$9FOPY1./^U8?^Q7!LC;Y^'/Z%^H.)SFDY
M3FLC9J:O>LSFRNO8W79[?UW3%1@/?J+X/4#^G4M%H^*Q2#XU<.<<P0LG@9ZB
MT)RJ&*F8H,\Y%F!O5J KHJ=8E$;HLEA0B49<JSHK&NB<!S9ZJZ7?O%ZT'#?P
M!VF285Z4KZ'_#D&59ZE(D.M8GU&4"E-W1@1-0T0 ZQ!]PB*(4=MM@&5:W0;"
M$D640<92E3$)<@$S*'00\Q -%T&,^8P@:"RA4FJUX:LE0ZP(BHD@H.PMO<H^
M+-4"U5% A#9# V6YD#E$$$BEZ+OKZ1'[T*\\#W3"89HIT&I5NI+1E(,&C:I8
M3#$GTAHM&"E0/S"X:<HU(!\K;Y5Y*[$$&#NQ&)7*(HPD.J#0!L]6PHF*4(Q$
MAIVMHWT_I#)CN/ B1A;KW*Q(5MO9R%A2@4U]PT)+MRB]*9:$4<V.-;Y^9XMV
MA</]K2)PQS[LMMS#HX/.<:M]V#EL=??]>2I":RH(OO:N"<E 5;8$B'+=1\O@
M= \P,/+:M7U68L6R3==Q]M<JW!8/G@#Q*B>-<@8>&X 7,NTN2Q<2Y)^<"L,L
MJ1DI*W=WVV\Q.*E ;O=M^&[)XN\.MW2VBLKN<;OC:S=<$EE'QM5S1^AM(W3K
MMR4TY3!;)-BPM%Y<A9!J"%JS'5,]08$R4A.[H;,!)@3%8(;!#&@O,V"Z;)A2
M$>68!SH=*@S-DLQ,*""5,\/N% AJFI2U*U03FKV)[L\9;6FW^#5SM)[,'&AE
MTH(U,*S<\92137ZLE^3^%(A+A-%,5PW=TN(6T"S-*Y$E VW@8"4/O6,XD\23
M),-@A:4+F]5L6<ZLX[4"HF[]ADI83#*J"J^NH)8"L? VY3M=N]-U=8L+#9+6
MKEZ_0Y)9YZOP1X6[MM,]?F39MNVT'UNV<_!@I>&?N(-0M;EAF#G%P?5,I#D/
MK8I,D?EL)M/*"&2>ED[8A&ZU.5,RWG9<O8M2)1E:.)!PH\.M +.*WR"ZE*GY
MOU),5!LRIJYGWBWY%5=[D/^< ID]B',+F&7+*'<U"MQH^AVB#QZ1=@ ^ L /
MA?>"$%8C?)7B9M"GE-$0U9WY7T)<;OF5SZ9LHH\PJ:$QQ.?T!O,:_!?VD-T$
ML954V0UG.P"?#< [.Z\[1%^"DK>&^P;Z9)_:NR'Y]S'?CO\[ '=#\F^#Z(,
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M>M\3>M<(W?EI"4TY9(L,6Y;65XX86BU!:[9C:A(4&*,,L5NF&V!", PR#&9
M>Y4#TU7+CDHHQSPR[3!A;"\J-J& U()9=@L@J%6IZE"H$IJ[C>[/>=PR8?%]
M[OC6">7Q[D!K20MNAG"?Q3-&ML6QN:B&,R ND=8R,S4LRX@[0#.QJ$0:!KK
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M4Y;-.9Z3,H,Z.-%$!I@M<:%LNARTS6,S[UX,VO:!F[\!4$L! A0#%     @
M-SVO6C$(R^8E[@< T2,* !$              ( !     &EM9S,S,S0R-S,Q
M7S N:G!G4$L! A0#%     @ -SVO6NF'##H9B@( .!P? !$
M ( !5.X' '!Y>',M,C R-3 S,S$N:'1M4$L! A0#%     @ -SVO6G#LI>32
M5 $ P*T4 !$              ( !G'@* '!Y>',M,C R-3 S,S$N>'-D4$L!
M A0#%     @ -SVO6O]HJB^J%@  #K\   \              ( !G<T+ '!Y
M>',M97@Q,%\Q+FAT;5!+ 0(4 Q0    ( #<]KUHDRJP\M @  -8_   /
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) 0  J@$,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>pyxs-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pyxs="http://pyxisoncology.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pyxs-20250331.xsd" xlink:type="simple"/>
    <context id="C_80d25345-2134-4fdf-8b7a-dc5dcc526082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_80ea7a33-ca44-4b1a-9d84-3b098b016750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_81dccbcc-0e5d-42f2-a90b-5d7a220cc416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_824b7ea1-2dee-4608-a3e0-704fe74262da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_837677d7-498f-48bb-95c8-9faa16b30f62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_88407054-4ac6-407e-bd60-882ac0345a83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="C_89abcaed-dbf0-4b59-a0d5-c994ebb137d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:MabwellAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8bcaa3a4-f396-49d4-9a7c-9a2c953ca07d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c771a10-e6fd-417a-b90f-987505443224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8d18d1ea-08eb-44d4-af0c-63d65768614d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_90baed6e-d409-47ed-8fce-1c10ef7e5899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9785fcb7-9dea-48db-b586-d63e6e45e9ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_97ecf8f3-9e3b-4ebb-bbff-1d5047205f7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9ac06ca8-b7a6-46a3-8c25-6237c2d2084e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9b6f4f8e-a104-4456-901f-a188c4f57515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9c3347c8-7c90-48dd-9028-f27b924409e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9cae4734-8e55-4f7a-9b85-7922cacc7b3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9dce6431-1c01-4d1f-a411-889976d95f6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9e825b7d-73d0-4c61-872f-ab5440ba67fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9eedb432-f4a9-43b3-ba2d-11719dfe1ba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="C_a0ea1ad7-9313-4e2a-bd73-2726a836f60b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:SimcereLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a41389f4-c186-43d0-9794-403390ddc786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5dc214b-639f-4fb3-8b7c-2568718e0614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:SaleOfRoyaltyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a6cf378c-872f-4a4d-8695-c15519d97e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_acc32560-f36b-4aae-bb63-26d88b5e0289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b3932593-36a9-4778-8638-9db8cecfbe4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4d6bc39-6741-4f87-ba31-c08c44f3521e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b53bcca6-85b4-46ee-be42-becc61d48b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bbca090c-3069-4f5a-8956-acdcd6237047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_bbf42254-df44-4f1b-9c73-8807bc61e7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="C_bc5c6809-e7d5-4c1f-a9d6-81bcb2d63dcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="C_bd63dfaf-0acf-4759-9e38-63e3f7d254fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bd8b966a-b09c-4ecf-99e4-4af048f4ca8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bf458c23-24e3-416a-b060-7beb4e11b9d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="C_c06d934d-2ece-4e58-aff2-9571ee296c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:DepreciationAndAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_c59ed3d1-dcfa-490f-9209-32cb9b6920ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_c5ab9c1f-a895-4812-ad9e-35f1af6217e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_cdf070fa-6052-434b-970a-be0e009d0f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cf0a40a2-d12e-452a-8754-687353eafcbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d20dc9b5-8895-44ad-af21-3cb92effe49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d297973c-6ba2-4ed6-8a31-917d0510d880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d48085d6-bea7-4f85-a614-7273694f7fc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d8f2f73e-7aca-4a71-8f6a-4c1b3ac7de0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="C_da865c67-24d1-400e-a077-12e7011b7389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_df592aff-6947-440e-aa39-c1fea2a3aa9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e7c0ee51-b9d9-4edc-98ee-3e53a89d2eef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_eb99ab08-0e63-41ea-bc44-35b639d19208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ec093f95-5fcd-47b1-952e-ed9e123d523d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ec1ee2ec-2bfc-4df3-8172-db225ac82cb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ed227005-05eb-4b2e-b46b-86ab51890c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_f563861b-f2d5-448b-b5cd-ada4a71faae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f759528e-20d8-4601-852a-3782e7215f4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:SimcereLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fcbfab1e-0b3b-450f-9242-753a06599476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:TwothousandtwentytwoequityinducementplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_fe614f09-8f0b-41ae-9225-979a71f0c648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0090356c-a2e4-4923-b76e-2b67349147d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:BiosionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_02c3f376-cf08-485b-be5c-ffdbc197e303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_044f61dc-d55f-47ed-bf0d-a9b02b506528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_06f49316-3dfe-4d13-b37e-04d9737a5946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_088e0ae4-1139-4dc9-a66c-b53dac8ce75b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0964fba2-c28f-4b10-aca6-474fe77b4e30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0b635d7f-a221-440b-8651-5dc1b8df141e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0c364169-e051-40a7-a92d-d1015992ee48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0c8f0bca-3bcd-4650-a38f-74cace0f746e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="C_10a1478c-a269-4056-ab01-10627d5bbfdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_12af53c6-9378-49ea-91fd-c3d3ea22941c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_150aa5b2-9b4d-462c-adf9-5645140d7e33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_1659b880-a5b1-4e72-804b-476a70f006ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_186c4ea3-09e7-46f6-8773-3f7d43d03df6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_189a9dd8-c9d5-41ca-b297-364c9a96704a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_18c2f871-fdac-46c2-8c4b-4a534962e9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_19b0546a-3406-4376-b2bf-06e6e947abae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_19d61487-1275-421e-96ed-c8df7b8a1263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1d4aedb6-5a72-4040-a006-c27215f1acae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_1e12a232-a571-45f6-9670-3ee553d3dba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_25fe5748-df27-4969-8126-fe2fae43fe71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_27edf172-17df-4f47-b122-520ad30120e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_27fbe99f-b243-407d-805e-643897908e7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pyxs:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_290608d1-a120-4e94-a552-45ef09566ea1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_2967ce11-ebdd-4b1d-826e-9763f4ccb671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2b13fbbe-afbd-4ba7-8372-4ec974d6de0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pyxs:SharesReservedForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2d47bb13-07cb-4ad3-9049-3c989f5e965b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2dc476af-db9c-4877-bce2-5597b5ff0528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pyxs:SeriesBConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_2e03161b-ec31-4f96-ba1e-2d45184ac84f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2e0c1cd2-1b21-4b47-bbed-f7f5df307193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_33284524-71cb-4060-be6e-5f4b5bb7ea1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_347129ce-fb5c-4096-80fe-ffcae8c2d8cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3478df5d-ec35-4824-83ab-aaf0f4b41638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3899226d-7062-4ed7-98a2-86b74edb9890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_38f8afe4-2256-4b92-a723-49f29459a24f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:RoyaltyRevenuesAndSaleOfRoyaltyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_40a96fb2-dbbb-44c6-a5a1-b2efcc758b42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pyxs:ApexigenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_47a74493-ee6e-4c87-8e18-0799e2bce42e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4ac8c464-a9ee-4f4c-9cbd-ba23e9e145ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4acf36bb-505b-45ee-99cd-5d1d91b303d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_4b4f6feb-cd93-4d71-b40e-b295d4cf5442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pyxs:ApexigenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="C_4d7cc448-0612-40c7-9727-ba960bd2bcad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5032b180-a6c9-4ff7-8f03-2d4bd35aeef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_51fc16e6-9e11-4e1d-9846-6d3d5c32f0b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5254b7a9-eb08-4cba-9a41-271a24160c2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_54406d8b-7256-474a-b20f-863ecd5c0745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_565d2f6f-3e93-4e23-8ba1-a266d622097c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_57742700-4cba-41b8-9f39-b740f3f99b64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pyxs:RoyaltyRevenuesAndSaleOfRoyaltyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5ba8496a-b732-4e27-8494-8cc671bac84a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:DepreciationAndAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5d1a4394-6692-49e3-a78c-53add9ce8cdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_5da75939-3069-4ae8-9442-f8b70f506330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:ApexigenReplacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5e3e027d-5bca-4423-870c-4ca85780f63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6027eb9f-48b8-4d75-8321-038710d6afd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_610571ac-f3e0-4db3-951b-cc88505cd8c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_61d130af-cc4f-4a22-b82e-c45279feb48c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_63a6cb3b-0f48-4d6e-abd8-d1208ebf1187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="C_63ba58e4-c1b8-480d-a574-db0f42fe8744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pyxs:UniversityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_64ad9aed-64e7-4300-99be-13fdf0483d74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_668a1b98-824d-41d1-8593-7b9e8f0d78b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_678c9317-3c78-4a7a-bf89-db2215e97bda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pyxs:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-14</instant>
        </period>
    </context>
    <context id="C_68b75572-7f9e-4d54-be03-9c22d10c8355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6d1b9939-fd67-4211-8cf2-48609643426e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_6fc6795c-50db-425e-91fd-5a73256a6dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_70a309a0-7032-4844-baa7-96b76069261c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74975660-2e58-4083-b25a-adbe25ac8127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_77b5c4a5-315a-49dc-a7f5-2446f1b77e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7afe6a9e-11e5-428d-b499-c4c37cf4f4fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pyxs:ToraySublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7e808a75-bd9f-4f76-9117-82cd0f5be7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pyxs:ClinicalProductManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7f2bf259-5d8f-4d8c-a46e-c559de6ac9a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pyxs:Segment</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_a26e425e-3944-4a16-a6e2-cb252d7eeff7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_80c67580-8bb2-49f5-a6e5-90496bccc23d">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_55a25125-49a7-44c4-af71-84be795231a1">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_29449aad-d243-4379-853d-8e8039b4a2d0">0001782223</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      id="F_82180ae2-8643-4fd7-839f-aadb21d1791b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      id="F_8f68cae7-637c-41f3-b2fe-4981768cebf9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      id="F_b1a92c6c-dbc2-4b80-aa53-67ac009de2f0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      id="F_4046ec04-3cd5-4350-b87e-ffcc0d09653e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_40e1fafa-fcae-43cf-bb09-058d3cf2faa5">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_18387c80-8f46-4fb9-a403-2e1db91eb8aa">http://fasb.org/us-gaap/2024#NetIncomeLoss</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_919eb334-f6d5-488e-b6a4-883e2e2b54ae">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_50f475fe-5818-4777-9b17-da883f47b671">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_f3825054-684d-4b50-bda0-823c939b41eb">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_e5c2db27-63e3-4ce8-8341-03a838a0716f">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_9ca34646-0d13-45cc-8954-5844971bc5f8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_4f152e14-7c66-4403-beda-d645932f71e7">001-40881</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_2793e371-ce17-40a4-af88-14e7b13f0074">Pyxis Oncology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_956826d8-808d-4039-a422-6ce76c954d0e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_b7473420-1fed-4592-8109-0f167451df87">83-1160910</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_20405245-7517-4a03-b3b3-c6da5617b984">321 Harrison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_5f71b9fc-c999-4256-835f-ff6fc5fd75f3">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_75bcf2f1-dd71-494e-8817-8f4e642940ca">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_e27fcedf-dc02-4a77-a0d5-5de7742c749e">02118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_ad82d445-dddf-4a94-ae88-c495fad9152c">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_9efd3aa3-f9ef-4a1f-b5fe-b1f98df5e379">453-3596</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_6ed3a3ff-d6f0-41d3-ac0f-14b192ca0e9f">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_ef4e754d-5cba-43f3-b5a3-ef36ccbc3930">PYXS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_af3a92ea-a67f-4645-a807-d791838b1f9c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_b7b64659-2aab-4e9e-9146-47cf2d0224db">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_c4cb0a8d-fa1f-408d-b91a-fd4abea238b4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_e9675749-0556-47f2-bcaa-1516b3adec5f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_a7f42600-038f-412d-afaa-5bcdf726f85f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_cc0da0c5-1f01-48e8-98b7-f752b70d5c62">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_cfa4ee56-7679-4ad5-bb69-45f24681954d">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_81e07264-96d4-41b8-89f5-c48092f9075a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_bbf42254-df44-4f1b-9c73-8807bc61e7ce"
      decimals="INF"
      id="F_4aa0b68a-de3d-45f1-a021-778d1503bbd9"
      unitRef="U_shares">61947665</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_7d534628-5646-4884-8435-680f3732141f"
      unitRef="U_USD">12759000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_42ad59c8-6da8-4bfa-bb5c-e149045dc96d"
      unitRef="U_USD">19473000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_d7c2981d-8a61-45fb-96c0-1426eba93010"
      unitRef="U_USD">92673000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_a835e633-03b6-41d4-8b60-623f56bb58eb"
      unitRef="U_USD">107458000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_b105eeeb-b55e-4f10-b590-2ff04a1fdf5d"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_04ec80d7-7964-465d-882d-95ffdaf38e66"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_e461d880-d4c1-4b15-a6c4-abeaa373ed36"
      unitRef="U_USD">4967000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_5a17dc9b-7220-4f39-b82b-2946f22b61f0"
      unitRef="U_USD">4037000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_992da8fa-5da5-4042-8293-efb49dd1e8ff"
      unitRef="U_USD">111871000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_f9f64ee9-472d-43e1-ae95-4e7559d289a1"
      unitRef="U_USD">132440000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_34bc78f4-1f2d-4cdb-b66a-10f8e535fedf"
      unitRef="U_USD">9403000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_d0e5bdda-32f7-4a3a-afa1-b37d68414ba1"
      unitRef="U_USD">9899000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_36a7a0e4-325f-4b9b-bb51-0feb8ac5912d"
      unitRef="U_USD">2544000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_67b0b10f-f909-4029-a0b8-4843ef9b95cd"
      unitRef="U_USD">2600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_255c5bb8-f31b-4ccf-836f-672d607de18c"
      unitRef="U_USD">12049000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_7c662764-ec25-403b-a93f-9c0e74324298"
      unitRef="U_USD">12242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_5ecee1f9-eace-435b-a3cd-a03323436905"
      unitRef="U_USD">135867000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_bd0de4a1-32c1-489c-8acf-0d4c7308af68"
      unitRef="U_USD">157181000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_b98f0abc-c4e5-49ee-9b98-d5617ec390c3"
      unitRef="U_USD">2846000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_b77533ec-6c55-4a95-9df8-a71a20574a32"
      unitRef="U_USD">4859000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_3ece6a40-171f-4435-8466-5b5271643752"
      unitRef="U_USD">10076000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_9ed889b9-ec23-475b-9cf9-ba6d6e53b6f6"
      unitRef="U_USD">11371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_62d2c543-179d-42fb-bc0c-763c24df7ffd"
      unitRef="U_USD">1508000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_ca37efec-9214-4e29-9efc-e10187ae22d1"
      unitRef="U_USD">1450000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_3393e507-9d22-4626-8cac-62b49c177a47"
      unitRef="U_USD">14430000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_218c83de-ca07-4a8a-80d9-de8685bb99ca"
      unitRef="U_USD">17680000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_d364e7d5-b0ba-457a-9501-a3567da94b5f"
      unitRef="U_USD">18254000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_f1b1f9f2-49e7-4d50-aaff-bbe72bbbf57c"
      unitRef="U_USD">18650000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_498c4505-383f-4446-9ad3-729b2750f31c"
      unitRef="U_USD">80000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_e906c15f-3e86-4986-813c-5b4a4bb50d60"
      unitRef="U_USD">100000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_ba6cb02f-38b8-4679-bc8e-fef7c9ec565c"
      unitRef="U_USD">32764000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_ae1f880c-2998-4952-901f-1edc08679ee0"
      unitRef="U_USD">36430000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_ead71e52-c841-4aec-b2ef-ae5f8de894b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_9667d7b5-6071-412f-bfe0-6de3565804fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_e6cc3adf-13bb-4cf2-a9d4-bc32d0c31222"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_25fbc405-755d-461d-adce-7ce8f370044d"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_5de2ae45-3d4f-4d3e-8efe-2ed4221a7069"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_f193cddd-d787-437c-9400-2a127cef5a57"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_6ccc5b60-2bf8-4a0d-b5c8-263973fbd89e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_45523530-4922-4d9d-a904-323a0efcd037"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_f3e6b8f6-2c4e-416a-9683-5883c2230f49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_e630c97f-bfda-4868-8d1e-df19bac4e098"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_b5b16776-3a72-4846-b771-9a1d46578b78"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_83e4bb76-5c97-4b47-a56f-901de3e40e6b"
      unitRef="U_shares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_efa81bd8-cbbb-4833-ac33-c14aaed6f10d"
      unitRef="U_shares">61631376</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_410788a7-1378-46c2-bb68-6a2bd77b3834"
      unitRef="U_shares">61631376</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_75da5f15-d545-41ab-9fc2-2375965db40f"
      unitRef="U_shares">59967814</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_a6d106cc-560f-4ed5-8000-fb83982176b7"
      unitRef="U_shares">59967814</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_12aa39ba-c0f5-468d-be79-4510a7a9c0e8"
      unitRef="U_USD">62000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_34fb1706-fa3e-49ac-9ebb-b5df486e8331"
      unitRef="U_USD">60000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_0bd2816c-a2b3-4d8b-8719-964e74a105ad"
      unitRef="U_USD">487706000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_7714e5f9-4636-4ba4-8f4d-4300422a782f"
      unitRef="U_USD">484077000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_841dd3c7-bb6f-45c6-98fc-50509cff33d3"
      unitRef="U_USD">49000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_505ba08a-a50f-4fab-bc33-701ce2d8f7c5"
      unitRef="U_USD">170000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_a877ff9a-2021-4207-8a37-1b28398f5bef"
      unitRef="U_USD">-384714000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_12424634-7251-4250-b980-509163a92667"
      unitRef="U_USD">-363556000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_888f76a7-9089-44ad-bc4d-25ad8f02b02f"
      unitRef="U_USD">103103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_693ed0dd-a527-4200-a996-f91f94e005ed"
      unitRef="U_USD">120751000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_7d32026e-aba8-43fc-ad7a-7fb89bc61495"
      unitRef="U_USD">135867000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_a3c5f7e5-3735-4a4e-b0b6-d6f3f5ca7b18"
      unitRef="U_USD">157181000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_2e0c1cd2-1b21-4b47-bbed-f7f5df307193"
      decimals="-3"
      id="F_fa86b21d-3786-4f75-98ea-75782c0377ea"
      unitRef="U_USD">8146000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_a5dc214b-639f-4fb3-8b7c-2568718e0614"
      decimals="-3"
      id="F_4297952a-0186-4115-98a7-e1104252a2af"
      unitRef="U_USD">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_30eb0429-0ff0-44eb-8d86-850f81f1b382"
      unitRef="U_USD">16146000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_6938749a-10b7-4b24-915c-cda36ef022ee"
      unitRef="U_USD">475000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_713135df-8ece-4450-af8c-7a988272ba4d"
      unitRef="U_USD">17044000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_5cf1df99-5e94-42bd-b75e-54f7f6caec16"
      unitRef="U_USD">13029000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_56e6c1f1-3aa5-487b-9dbe-1313081c8356"
      unitRef="U_USD">5870000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_ddbb548e-9aa5-4a2f-bc5f-b779559e3a9b"
      unitRef="U_USD">8247000</us-gaap:GeneralAndAdministrativeExpense>
    <pyxs:CostsAndOperatingExpensesTotal
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_1a73e057-6189-4a49-bfc4-5faf7abe2b36"
      unitRef="U_USD">22914000</pyxs:CostsAndOperatingExpensesTotal>
    <pyxs:CostsAndOperatingExpensesTotal
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_ea32e04a-0d23-44cc-88c9-df5d3aa3b434"
      unitRef="U_USD">21751000</pyxs:CostsAndOperatingExpensesTotal>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_045f3b6e-e323-42ed-87c3-ef7ea78c4814"
      unitRef="U_USD">-22914000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_28fa5319-eac8-4199-af6f-2419e8dbaa1b"
      unitRef="U_USD">-5605000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_3e5f3d6c-003a-4459-933a-8041ca9fca14"
      unitRef="U_USD">1241000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_74049cbd-960d-4fe4-8e5a-f7dfc5421b02"
      unitRef="U_USD">1550000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SubleaseIncome
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_0682c8b4-6e69-4c39-940a-d18d46382dce"
      unitRef="U_USD">515000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_8c316f53-78ab-4aae-b3c4-73de6d7016d1"
      unitRef="U_USD">799000</us-gaap:SubleaseIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_102411e8-ad19-49cf-9322-92c0c2dbbf88"
      unitRef="U_USD">1756000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_f35b5fd0-fd9a-4234-90e2-65dd50601588"
      unitRef="U_USD">2349000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_8fea8274-25a6-4373-9442-b2c27fd91d8f"
      unitRef="U_USD">-21158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_959e1cb2-4e42-47b7-ade4-bac7b1958dbc"
      unitRef="U_USD">-3256000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_5363a8f5-a0fb-4c81-b755-75a2858b712b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_03b6d12f-fdf8-4648-b7a8-82b2a60dea0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="2"
      id="F_62f0a93a-9b57-4116-9a2d-ae7691610b73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="2"
      id="F_5155d6c4-628a-494a-938d-78f58c2e3b1e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="0"
      id="F_08bd7c79-cd46-4949-8552-9d7406fac424"
      unitRef="U_shares">61048948</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="0"
      id="F_2191922a-d948-40d6-8b6f-1629b7a80e19"
      unitRef="U_shares">61048948</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="0"
      id="F_178d925c-a38b-4dcc-ba97-fa148f2f0639"
      unitRef="U_shares">51289284</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="0"
      id="F_267956e3-9c12-411b-afa2-21f49f6fa25b"
      unitRef="U_shares">51289284</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_1b922ecb-2c44-466f-bf6d-85eb4e4c7a8b"
      unitRef="U_USD">-121000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_0bfa32fa-64eb-4b91-a82f-0da2d43badb8"
      unitRef="U_USD">-123000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_af1b43b9-7770-46ed-93d9-ad84516e7ba6"
      unitRef="U_USD">-121000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_5b41a0fb-93f6-480d-81f9-9124194d9456"
      unitRef="U_USD">-123000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_333f8242-c93e-451d-abd5-3d410e3dc6f0"
      unitRef="U_USD">-21279000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_dca78208-3eff-4666-b308-11574308b4cc"
      unitRef="U_USD">-3379000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa"
      decimals="INF"
      id="F_cc2b7173-fa93-4758-8ca7-873166b44106"
      unitRef="U_shares">59967814</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_12112377-78bc-49d7-ac8b-d2dd2254fcaa"
      decimals="-3"
      id="F_8eeb34d9-31c1-45b8-925d-f81f1c9658a6"
      unitRef="U_USD">60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a6cf378c-872f-4a4d-8695-c15519d97e1d"
      decimals="-3"
      id="F_9aa411a6-4d92-4a3b-b43d-78628a1b7fdb"
      unitRef="U_USD">484077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06f49316-3dfe-4d13-b37e-04d9737a5946"
      decimals="-3"
      id="F_42fdc434-ad92-4521-9895-acd470c7cbf9"
      unitRef="U_USD">170000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_80d25345-2134-4fdf-8b7a-dc5dcc526082"
      decimals="-3"
      id="F_63fc028e-bd8d-4507-9f6f-edbfbd33c1f2"
      unitRef="U_USD">-363556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_1b89b4f0-2732-4730-83ec-93491eb58315"
      unitRef="U_USD">120751000</us-gaap:StockholdersEquity>
    <pyxs:ExerciseOfPre-FundedWarrants
      contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"
      decimals="INF"
      id="F_e486d116-e751-4f18-850d-8b3bdc30e67f"
      unitRef="U_shares">1611215</pyxs:ExerciseOfPre-FundedWarrants>
    <pyxs:ExerciseOfPre-FundedWarrantsValue
      contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"
      decimals="-3"
      id="F_63dba521-a127-4325-bbf7-83c975108b5f"
      unitRef="U_USD">2000</pyxs:ExerciseOfPre-FundedWarrantsValue>
    <pyxs:ExerciseOfPre-FundedWarrantsValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_a2d19092-7741-417e-99fe-dc3db79d58cc"
      unitRef="U_USD">2000</pyxs:ExerciseOfPre-FundedWarrantsValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"
      decimals="INF"
      id="F_28f013ab-cbf5-4b42-85c9-21c8db8a4ed8"
      unitRef="U_shares">22728</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0964fba2-c28f-4b10-aca6-474fe77b4e30"
      decimals="-3"
      id="F_767afd1b-b9c1-4a13-87b1-8cc20d4b1556"
      unitRef="U_USD">-2000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_0bc18980-d907-4712-b3ef-221da1e20a0d"
      unitRef="U_USD">-2000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"
      decimals="INF"
      id="F_42121ed8-8dd3-4a82-b208-5e5208823805"
      unitRef="U_shares">29619</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0964fba2-c28f-4b10-aca6-474fe77b4e30"
      decimals="-3"
      id="F_762e3cc4-a369-4a9d-9df9-6aade6b26fe1"
      unitRef="U_USD">3631000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_c81cde43-3957-4eef-be44-ca00f130e92c"
      unitRef="U_USD">3631000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_27edf172-17df-4f47-b122-520ad30120e0"
      decimals="-3"
      id="F_2da76f21-c8e2-4f64-81b7-7a9922385727"
      unitRef="U_USD">-121000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_ba866c89-e183-4a48-bbb4-5621cfb4b22c"
      unitRef="U_USD">-121000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_33284524-71cb-4060-be6e-5f4b5bb7ea1b"
      decimals="-3"
      id="F_24971b87-4a83-4b0b-ac99-2f1d62de5a83"
      unitRef="U_USD">-21158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_6165e690-ba49-48b1-8353-28d9fd203793"
      unitRef="U_USD">-21158000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0c364169-e051-40a7-a92d-d1015992ee48"
      decimals="INF"
      id="F_a98b0736-952a-40eb-ab7a-fcac0bb3dc7b"
      unitRef="U_shares">61631376</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0c364169-e051-40a7-a92d-d1015992ee48"
      decimals="-3"
      id="F_398da536-4f1e-490a-a42e-61abede1425a"
      unitRef="U_USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fe614f09-8f0b-41ae-9225-979a71f0c648"
      decimals="-3"
      id="F_8dc471dd-7455-4473-82ab-b95652dbc677"
      unitRef="U_USD">487706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b4d6bc39-6741-4f87-ba31-c08c44f3521e"
      decimals="-3"
      id="F_e78065d0-237e-444c-baf6-8b374bf9563f"
      unitRef="U_USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5254b7a9-eb08-4cba-9a41-271a24160c2d"
      decimals="-3"
      id="F_14b759f1-6678-4959-955c-31d9f5217425"
      unitRef="U_USD">-384714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_94917acf-5c95-46a8-9a03-e3776ed39f0a"
      unitRef="U_USD">103103000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_b3932593-36a9-4778-8638-9db8cecfbe4e"
      decimals="INF"
      id="F_f7c94256-c9fe-44ff-b164-bfbb1473885e"
      unitRef="U_shares">44754853</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b3932593-36a9-4778-8638-9db8cecfbe4e"
      decimals="-3"
      id="F_bcf9b75d-c76e-41c4-96ab-142df94ef271"
      unitRef="U_USD">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_64ad9aed-64e7-4300-99be-13fdf0483d74"
      decimals="-3"
      id="F_457aebe1-07e0-4259-8a5b-07d3b2ec98aa"
      unitRef="U_USD">411821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_10a1478c-a269-4056-ab01-10627d5bbfdc"
      decimals="-3"
      id="F_56377afd-0aa5-4914-8af6-6c2290ea3c48"
      unitRef="U_USD">63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf0a40a2-d12e-452a-8754-687353eafcbf"
      decimals="-3"
      id="F_f6484dea-2e85-42ec-9b88-2963334f29dd"
      unitRef="U_USD">-286225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70a309a0-7032-4844-baa7-96b76069261c"
      decimals="-3"
      id="F_959768f3-83f0-4beb-9fc2-5cb46f025629"
      unitRef="U_USD">125704000</us-gaap:StockholdersEquity>
    <pyxs:IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="INF"
      id="F_9545a8ad-68b7-4965-bf99-cebd8d7dd8de"
      unitRef="U_shares">8849371</pyxs:IssuanceOfCommonStockInPrivatePlacementNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="-3"
      id="F_7c04dba8-a130-4459-8700-2fba72898fb5"
      unitRef="U_USD">9000</pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_d34a39a3-5eb9-4a36-86c5-636ff9b2d74e"
      unitRef="U_USD">39163000</pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_4c18ee2e-a38f-45d7-9d12-a8506fef4091"
      unitRef="U_USD">39172000</pyxs:IssuanceOfCommonStockInPrivatePlacementValueNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="INF"
      id="F_2a882db8-de60-4768-a8ee-58fa428644e8"
      unitRef="U_shares">3600000</pyxs:IssuanceOfCommonStockSharesPursuantToAtTheMarketProgramNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="-3"
      id="F_34ec0489-0d98-4f95-a5d7-5d260394d5cc"
      unitRef="U_USD">4000</pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_b933aaa6-2fd1-4519-b4f1-bf8e471f44d4"
      unitRef="U_USD">10586000</pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts>
    <pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_b5955663-630c-4474-863c-c1baae3ec23e"
      unitRef="U_USD">10590000</pyxs:IssuanceOfCommonStockPursuantToAtTheMarketProgramValueNetOfOfferingCosts>
    <pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_94164628-ec4f-43d2-9a04-6ddb6a1c6346"
      unitRef="U_USD">7700000</pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts>
    <pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_e0adf6de-0174-4287-bcc2-4d104f1b6a02"
      unitRef="U_USD">7700000</pyxs:IssuanceOfPreFundedWarrantsInPrivatePlacementNetOfOfferingCosts>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="INF"
      id="F_1628123a-01de-433e-b0f7-19d3b1e4c863"
      unitRef="U_shares">1497921</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="-3"
      id="F_755960e9-99a9-4578-8f9e-b030f645dc5e"
      unitRef="U_USD">1000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_ee2c6fec-3c89-4115-b804-a38c5527707c"
      unitRef="U_USD">-197000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_44edfb31-389f-409d-8f05-ee1a24744741"
      unitRef="U_USD">-196000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e1f5b95f-326e-4fb7-9c59-75208e76ac28"
      decimals="INF"
      id="F_8cfd3630-ba5f-449d-a1a5-228eccb06e84"
      unitRef="U_shares">100981</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_48559947-4ad0-4622-bc6e-dd5e00633cdd"
      unitRef="U_USD">245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_2961843f-99e3-44a3-9e3f-647c0288adfe"
      unitRef="U_USD">245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_43f54a7e-d7f4-45bd-aa13-e2954ede0cae"
      decimals="-3"
      id="F_30bf45c1-ceba-479b-ba58-99a1f457fba7"
      unitRef="U_USD">4320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_99443c53-435e-41d4-8c65-5413c0523395"
      unitRef="U_USD">4320000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_68b75572-7f9e-4d54-be03-9c22d10c8355"
      decimals="-3"
      id="F_bb3bf106-ddd3-4539-8cc1-dc38ddd59007"
      unitRef="U_USD">-123000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_162485fc-572f-47a8-b3a5-0512f10a71ac"
      unitRef="U_USD">-123000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_610571ac-f3e0-4db3-951b-cc88505cd8c7"
      decimals="-3"
      id="F_8b69ccbe-5456-4155-9ab6-58609f126855"
      unitRef="U_USD">-3256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_c7797d3d-4e0c-4d8d-ad54-9f95d82eefd9"
      unitRef="U_USD">-3256000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7"
      decimals="INF"
      id="F_f164a1d5-ead3-4994-abce-6cd96fcc01f0"
      unitRef="U_shares">58803126</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e7da0ddb-86a7-451b-b9fa-d78fc74e0df7"
      decimals="-3"
      id="F_f81cc628-a2e2-4dc2-9e6d-379ef6e1519e"
      unitRef="U_USD">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_54406d8b-7256-474a-b20f-863ecd5c0745"
      decimals="-3"
      id="F_4e8688b9-7726-4b3c-bb6e-37c6b2ce3979"
      unitRef="U_USD">473638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2e03161b-ec31-4f96-ba1e-2d45184ac84f"
      decimals="-3"
      id="F_9a500dff-7b6e-4a08-8ae9-e0a72f72ea2f"
      unitRef="U_USD">-60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5ab9c1f-a895-4812-ad9e-35f1af6217e1"
      decimals="-3"
      id="F_b718cb25-6ff5-4e35-8e06-8df290c12d3b"
      unitRef="U_USD">-289481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f"
      decimals="-3"
      id="F_fc167666-5a16-44e4-a2a7-410c84d74ea8"
      unitRef="U_USD">184156000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_b241c64b-0628-4e33-9a43-78f51eb27704"
      unitRef="U_USD">-21158000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_7f3cadfe-4774-425f-8260-a7079cb54670"
      unitRef="U_USD">-3256000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_db09f815-52c6-424c-b4cd-9140be2a0b64"
      unitRef="U_USD">552000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_dfee8321-45e0-4bb0-b216-a68d761d0315"
      unitRef="U_USD">1116000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_4ddf106d-7f8c-4c3a-9a4d-3b3a1df004fb"
      unitRef="U_USD">3631000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_21ae49bb-4404-49ec-90ae-65c54ffdd57f"
      unitRef="U_USD">4320000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_e056ae39-7e53-41fd-88a0-2233aa9682ed"
      unitRef="U_USD">193000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_3570f6a1-75d9-4551-ad96-37996d244c02"
      unitRef="U_USD">164000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_9c5ad98d-93a0-4fa3-9fb2-f90f1c77fae1"
      unitRef="U_USD">1157000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_257e5968-3356-4542-b197-1cff2d5076d9"
      unitRef="U_USD">1288000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_df6c0e4a-7578-4df2-99ed-8367ed11777a"
      unitRef="U_USD">8000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_32fba8b0-c193-48cd-a7b1-5f97fa5bd061"
      unitRef="U_USD">930000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_1af43cf4-6bd7-44fd-8435-b80d93754337"
      unitRef="U_USD">2046000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_a46ae99d-aad0-4e3c-bcbc-f2203f390ffc"
      unitRef="U_USD">-2013000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_3cc98d8d-1bda-49b2-a69b-d724b6bcb4af"
      unitRef="U_USD">-1365000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_bfab11e1-82f4-4d9e-94d0-0eeefffcfc2b"
      unitRef="U_USD">-1315000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_6b7ced05-692d-4166-ae98-1a8e57a16974"
      unitRef="U_USD">-2143000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_10e9431a-b96c-412f-ba24-ae1daa2d270d"
      unitRef="U_USD">-338000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_0eae169a-b7ab-4e5e-b41d-0c506f973aca"
      unitRef="U_USD">-552000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_67da2b34-1330-4300-b33b-8de1643faab2"
      unitRef="U_USD">-7660000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_de24db5b-7d2d-4c07-8e61-2f8813e41271"
      unitRef="U_USD">-22535000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_47171c76-b2e0-43f4-a358-ecc6266fecbd"
      unitRef="U_USD">-20710000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <pyxs:RedemptionOfMarketableDebtSecurities
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_1249d671-82f3-40d7-8963-26f9069e11fd"
      unitRef="U_USD">67173000</pyxs:RedemptionOfMarketableDebtSecurities>
    <pyxs:RedemptionOfMarketableDebtSecurities
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_b0a65138-2c88-4a4f-8cb8-20d0e2431230"
      unitRef="U_USD">74532000</pyxs:RedemptionOfMarketableDebtSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_89846476-fe54-45e3-bee4-af1e6236ce0c"
      unitRef="U_USD">51352000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_1e5270e0-e029-47bb-a09b-f3653858e872"
      unitRef="U_USD">92793000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_950d48f2-6194-40e6-84dc-0cea46f59699"
      unitRef="U_USD">237000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_a9ab73fe-77bb-4683-a10a-26f7f3499fc4"
      unitRef="U_USD">15821000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_dde87236-c11c-4807-aab9-cd8f62cb5037"
      unitRef="U_USD">-18498000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_249264bd-6a5a-4a16-9c47-a0247fa5d2ed"
      unitRef="U_USD">2000</pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_bf454984-4dc6-4ac6-b96a-50616a99bca5"
      unitRef="U_USD">46872000</pyxs:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement>
    <pyxs:ProceedsFromStockIssuedUnderAtmNet
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_c219da51-495b-40d0-8f92-20e85d061011"
      unitRef="U_USD">10590000</pyxs:ProceedsFromStockIssuedUnderAtmNet>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_c698a52e-efb8-4a86-a978-12eb1e81429e"
      unitRef="U_USD">2000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_60c50b47-519d-40fd-a665-b34388744d7b"
      unitRef="U_USD">196000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_380d1b83-0910-4ca0-8c56-7a8c720762ba"
      unitRef="U_USD">245000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_aabf1f41-c5ab-4947-bb3e-2799d7801293"
      unitRef="U_USD">57511000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_0d4f9dd3-0800-4cb8-915a-b74f5bd86793"
      unitRef="U_USD">-6714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_f4cd90f2-725a-4c3d-aa49-b0d4b7f3ca37"
      unitRef="U_USD">18303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_aea171e3-8b46-4498-b681-a9532b3cf89f"
      unitRef="U_USD">20945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_70a309a0-7032-4844-baa7-96b76069261c"
      decimals="-3"
      id="F_413a2d5f-b9da-4246-a9f8-074553328fa1"
      unitRef="U_USD">11136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_a409cc90-1d28-495b-b395-1c2eca52f58d"
      unitRef="U_USD">14231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f"
      decimals="-3"
      id="F_b66d9a4c-e596-4e74-98f8-3153cc9e5655"
      unitRef="U_USD">29439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_50e5be57-71ec-44d7-8560-32d5fdec44e1"
      unitRef="U_USD">12759000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f"
      decimals="-3"
      id="F_839130ac-1894-4756-ba44-f29b15c134c9"
      unitRef="U_USD">27967000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_53a61e6a-3f3b-4e69-8f55-dfd9085584c6"
      unitRef="U_USD">1472000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f"
      decimals="-3"
      id="F_096dc4b1-65b6-4cc3-bad6-141f855ab811"
      unitRef="U_USD">1472000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_9104b223-d6e2-442d-a4b2-9db25b81ceda"
      unitRef="U_USD">14231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5e3e027d-5bca-4423-870c-4ca85780f63f"
      decimals="-3"
      id="F_fd963eb7-b0b4-40a1-bb14-79a7173178ff"
      unitRef="U_USD">29439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_28aca06a-3a7d-4ed8-801f-392421ee01c2">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Description &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with a specific focus on head and neck squamous cell carcinoma (HNSCC) tumors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <pyxs:NatureOfBusinessPolicyTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_58d3ff14-87a8-4781-9c8f-cb531fb2a98e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pyxis Oncology, Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, was founded in June 2018 and launched its operations in July 2019. The Company is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with a specific focus on head and neck squamous cell carcinoma (HNSCC) tumors.&lt;/span&gt;&lt;/p&gt;</pyxs:NatureOfBusinessPolicyTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_276e4bf2-a8b9-4bcc-8770-41b319a2c522">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three fiscal quarters end on March 31, June 30 and September 30. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the three months ended March 31, 2025 are not necessarily indicative of those expected for the year ending December 31, 2025 or for any future period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 18, 2025 (Fiscal 2024 10-K).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;384.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The C&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ompany has incurred losses and negative cash flows from operations since inception, including net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not generated any revenues from product sales to date and does not anticipate generating any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company currently expects that its existing cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of March 31, 2025 will fund its operating expenses and capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, marketable debt securities, fair value of intangible assets and research and development costs, including clinical trial accruals. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks common to early clinical stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third party service providers such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collabo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ration or supply agreements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Con&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;centration of Credit Risks&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents, restricted cash and short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its excess cash primarily in money market funds and highly liquid United States (U.S.) Treasury securities. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no significant changes to the Company&#x2019;s significant accounting policies disclosed in &#x201c;Note 2 &#x2013; Basis of Presentation and Summary of Significant Accounting Policies&#x201d; of the Company&#x2019;s Fiscal 2024 10-K.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures. The amendment requires (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendment requires disaggregated disclosure of (i) certain costs and expenses, (ii) certain already required disclosures must be included in the same disclosure as the new disaggregation requirements and (iii) a qualitative description of the amounts not separately disaggregated. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_14e9f0fb-941f-4257-a003-1aff6ea28c35">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s fiscal year ends on December 31 and its first three fiscal quarters end on March 31, June 30 and September 30. The accompanying condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and follow the requirements of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the three months ended March 31, 2025 are not necessarily indicative of those expected for the year ending December 31, 2025 or for any future period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 18, 2025 (Fiscal 2024 10-K).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <pyxs:LiquidityPolicyTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_2aa17f1d-0472-45f1-ac78-8f54d6806d68">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;384.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The C&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ompany has incurred losses and negative cash flows from operations since inception, including net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not generated any revenues from product sales to date and does not anticipate generating any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for its current or any future product candidates. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to expand its research and development programs and develop its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company currently expects that its existing cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of March 31, 2025 will fund its operating expenses and capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements are issued. Additional funding may be necessary to fund future clinical and preclinical activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity, convertible or debt financing or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/p&gt;</pyxs:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-5"
      id="F_a13f8ccd-e7a2-4790-8f96-b1b01b6c4201"
      unitRef="U_USD">-384700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-5"
      id="F_0d8656e2-ee42-4eed-be49-0a3ef479e1fe"
      unitRef="U_USD">-21200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_9d6cc82f-bc26-4975-a4b6-5531c6c99323"
      unitRef="U_USD">-3300000</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-5"
      id="F_c9faad99-d89b-4b9b-9ee1-e6bc315688d3"
      unitRef="U_USD">105400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:UseOfEstimates
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_1f71ca36-c7a6-4426-91bd-25366c559b24">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense and related disclosures. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, operating leases, assessment of the useful lives of property and equipment, marketable debt securities, fair value of intangible assets and research and development costs, including clinical trial accruals. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Actual results could differ from those estimates and there may be changes to management&#x2019;s estimates in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pyxs:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_b2aac487-879f-4739-935d-0704bcc0702d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks common to early clinical stage companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key suppliers for active ingredients and third party service providers such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), protection of intellectual property rights and the ability to make milestone, royalty or other payments due under any license, collabo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ration or supply agreements.&lt;/span&gt;&lt;/p&gt;</pyxs:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_70455f4d-fb41-46f9-ac51-06bbc3bdfb53">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Con&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;centration of Credit Risks&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents, restricted cash and short-term investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its excess cash primarily in money market funds and highly liquid United States (U.S.) Treasury securities. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_a7c5527f-cf01-4a58-b65e-cfeb320f8b4d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures. The amendment requires (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendment requires disaggregated disclosure of (i) certain costs and expenses, (ii) certain already required disclosures must be included in the same disclosure as the new disaggregation requirements and (iii) a qualitative description of the amounts not separately disaggregated. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company's consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_2d8e2f00-b98b-4b2c-9a2f-94b903c587b3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.586%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.723%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;116,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;116,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents represent deposits in a short-term money market fund quoted in an active market and are classified as Level 1 assets. Marketable debt securities include investments in United States Treasury securities and are classified as Level 1 assets as they are valued using quoted prices in active markets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_3b46831b-d2bf-43d7-aa60-09c0da1d250a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the financial instruments carried at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024, respectively, in accordance with the FASB ASC 820 hierarchy (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.586%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.723%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;116,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;116,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_25fe5748-df27-4969-8126-fe2fae43fe71"
      decimals="-3"
      id="F_41312c2f-7f24-4ec6-8212-e2f7f4caf03e"
      unitRef="U_USD">8242000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d48085d6-bea7-4f85-a614-7273694f7fc3"
      decimals="-3"
      id="F_5fd66e30-764c-478e-bdd7-40a18540d6cc"
      unitRef="U_USD">8242000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bbca090c-3069-4f5a-8956-acdcd6237047"
      decimals="-3"
      id="F_ecae893d-05da-48d1-ac31-a0eedb179936"
      unitRef="U_USD">92673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8c771a10-e6fd-417a-b90f-987505443224"
      decimals="-3"
      id="F_08d33412-da34-466f-9b45-8b16c47f9be5"
      unitRef="U_USD">92673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_47a74493-ee6e-4c87-8e18-0799e2bce42e"
      decimals="-3"
      id="F_13d648af-f7ea-44cd-8f7a-d3c025cf4289"
      unitRef="U_USD">100915000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ec1ee2ec-2bfc-4df3-8172-db225ac82cb8"
      decimals="-3"
      id="F_0a7dd369-6769-4874-bb6a-6ac327a38f02"
      unitRef="U_USD">100915000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_90baed6e-d409-47ed-8fce-1c10ef7e5899"
      decimals="-3"
      id="F_85ceeee2-d88d-48ad-9919-b7af25e7807f"
      unitRef="U_USD">9491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_df592aff-6947-440e-aa39-c1fea2a3aa9f"
      decimals="-3"
      id="F_649c1561-a6e2-4804-8803-cf44ef6608a1"
      unitRef="U_USD">9491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_51fc16e6-9e11-4e1d-9846-6d3d5c32f0b5"
      decimals="-3"
      id="F_5689062a-aac4-4414-84f8-dfc9f56deda4"
      unitRef="U_USD">107458000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_189a9dd8-c9d5-41ca-b297-364c9a96704a"
      decimals="-3"
      id="F_fbf747ee-a6b4-4e04-ad29-813c1aaad1ae"
      unitRef="U_USD">107458000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2d47bb13-07cb-4ad3-9049-3c989f5e965b"
      decimals="-3"
      id="F_6883ad28-919f-45c2-8ae6-8baf4ed10adf"
      unitRef="U_USD">116949000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8d18d1ea-08eb-44d4-af0c-63d65768614d"
      decimals="-3"
      id="F_9458bb1e-0f32-470d-8b50-82d19a17a4d0"
      unitRef="U_USD">116949000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_1a2e4af5-9922-4023-8751-d3c4f357eabf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Marketable Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities, all of which were classified as available-for-sale, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:28.446%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.562000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;107,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the remaining contractual terms of the U.S. Treasury securities were less than 12 months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has not recognized any allowances for credit losses or impairments in relation to its marketable securities as these securities are comprised of high credit quality, investment grade securities that the Company does not intend or expect to be required to sell prior to their anticipated recovery, and the decline in fair value of these securities is attributable to factors other than credit losses.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest and investment income consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.991%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.823999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.823999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion of discount, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total interest and investment income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_9834cc27-21cd-491a-a921-fa8032f06bc3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities, all of which were classified as available-for-sale, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:28.446%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.562000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.383000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;107,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;107,458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07"
      decimals="-3"
      id="F_071d1d2d-d06e-4857-a9d4-0239ffca47a1"
      unitRef="U_USD">92624000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07"
      decimals="-3"
      id="F_c8567d34-a9d5-40fe-9f7b-a14a590b39dd"
      unitRef="U_USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07"
      decimals="-3"
      id="F_8e07af3f-1983-4592-b0b3-e3dd182f5aa7"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_40cd098b-1dd0-4773-b7a8-0ec29e588f07"
      decimals="-3"
      id="F_9c847836-51f6-4a5f-81d3-2d2b1bdeec58"
      unitRef="U_USD">92673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_00982888-e946-4583-8cbe-17ef85af9b9a"
      unitRef="U_USD">92624000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_23b674dd-066d-487c-bc94-c35fedd94f2f"
      unitRef="U_USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_c393ff8f-a8fe-4e20-9b74-d48d05409199"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_ceb653ab-954d-4e37-9ced-d2add18f6d70"
      unitRef="U_USD">92673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a41389f4-c186-43d0-9794-403390ddc786"
      decimals="-3"
      id="F_3f3eb36d-25d6-4bf3-92b1-0c1ac222196c"
      unitRef="U_USD">107288000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a41389f4-c186-43d0-9794-403390ddc786"
      decimals="-3"
      id="F_7af2ea60-af64-4b2d-aed0-ebb274a692a7"
      unitRef="U_USD">170000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a41389f4-c186-43d0-9794-403390ddc786"
      decimals="-3"
      id="F_922ecba4-7326-4e4b-b80b-686baa18eee2"
      unitRef="U_USD">107458000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_ffc2c3a6-94cf-457d-9411-05568743467d"
      unitRef="U_USD">107288000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_d1142024-284c-403f-a342-0588f193dd4e"
      unitRef="U_USD">170000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_800bafc7-a396-4810-a75b-b1a382ecaf6d"
      unitRef="U_USD">107458000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_18db2034-dc6c-4cb7-8bf9-7dfd7e2e3ff4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest and investment income consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.991%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.823999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.823999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion of discount, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total interest and investment income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_e962e1d3-7c3d-4e3b-9f98-a2c45320aa24"
      unitRef="U_USD">84000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_f03627ca-5847-4560-bf5f-4254001d575d"
      unitRef="U_USD">262000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_042f2084-8a11-4ad7-bae6-b3a5cdc9710e"
      unitRef="U_USD">1157000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_95956429-9dac-4b2f-97e6-f4d744a04e48"
      unitRef="U_USD">1288000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_935b58a0-213d-4423-b9cc-4fe971c533fa"
      unitRef="U_USD">1241000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_0b4c0cc4-d985-420e-b816-2eab198bdd25"
      unitRef="U_USD">1550000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_633f879f-abfd-4536-892d-74a4616b7260">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Segment disclosure&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment related to the development of clinical and preclinical product candidates focused on addressing unmet medical needs in patients with solid tumors with a specific focus on HNSCC tumors. The Company&#x2019;s chief operating decision maker (CODM) is the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_40e1fafa-fcae-43cf-bb09-058d3cf2faa5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of the single segment are the same as those described in the Company&#x2019;s significant accounting policies disclosed in &#x201c;Note 2 &#x2013; Basis of Presentation and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&#x201d; of the Company&#x2019;s Fiscal 2024 10-K. The CODM assesses performance for the segment based on net loss, which is reported on the condensed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_18387c80-8f46-4fb9-a403-2e1db91eb8aa;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consolidated&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the product candidate through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As such, the CODM uses cash forecast models in deciding how allocate resources. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management&#x2019;s compensation, along with cash forecast models.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes segment net loss, including significant expenses for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Royalty revenue and sale of royalty rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Costs and operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical product candidates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical product manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other (i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional and consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other (ii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total costs and operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment income (iii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustments and reconciling items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development segment items include facilities expenses, lab services, professional services and technology costs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment income for the three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest and investment income and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of sublease income, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_d62568e2-aa77-4d7b-880c-71b29743c159">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_9eff11b0-e574-4b17-b4a5-ae999582e7c6"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_631756e5-d4e4-41eb-8d81-78753f852943">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes segment net loss, including significant expenses for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Royalty revenue and sale of royalty rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Costs and operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical product candidates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical product manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other (i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional and consultant fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other (ii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total costs and operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment income (iii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustments and reconciling items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development segment items include facilities expenses, lab services, professional services and technology costs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment income for the three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest and investment income and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of sublease income, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="C_38f8afe4-2256-4b92-a723-49f29459a24f"
      decimals="-3"
      id="F_f4ea9f04-769d-41ed-9e95-fd1448a6f252"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_57742700-4cba-41b8-9f39-b740f3f99b64"
      decimals="-3"
      id="F_008f3d62-2f0e-468f-bb3c-74886d363547"
      unitRef="U_USD">16146000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_614cdb46-8d92-475f-ae40-ee91d120d24d"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_af61aaf8-0501-4060-afbc-e548309a67ab"
      unitRef="U_USD">475000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6d1b9939-fd67-4211-8cf2-48609643426e"
      decimals="-3"
      id="F_2a2ceb53-d4d1-4412-9a6c-8b0c4d45f05d"
      unitRef="U_USD">5146000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5032b180-a6c9-4ff7-8f03-2d4bd35aeef6"
      decimals="-3"
      id="F_3319c881-77fd-495a-8a71-609db9c1dd14"
      unitRef="U_USD">3974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_150aa5b2-9b4d-462c-adf9-5645140d7e33"
      decimals="-3"
      id="F_c4c6d138-3e56-4cc0-b51a-6513f93891b6"
      unitRef="U_USD">3384000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7e808a75-bd9f-4f76-9117-82cd0f5be7ca"
      decimals="-3"
      id="F_cccc7b32-2b33-4c97-bfc7-3919148e8749"
      unitRef="U_USD">2563000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd"
      decimals="-3"
      id="F_c923affb-e570-4c6d-a31a-c3eab3c9e93e"
      unitRef="U_USD">4739000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9dce6431-1c01-4d1f-a411-889976d95f6a"
      decimals="-3"
      id="F_91a1cab4-e687-49e2-971d-b5b5d2c931b7"
      unitRef="U_USD">3504000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1e12a232-a571-45f6-9670-3ee553d3dba3"
      decimals="-3"
      id="F_72c438a7-8c6f-4977-a823-974284b3c1d8"
      unitRef="U_USD">1122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c"
      decimals="-3"
      id="F_1b211396-9969-4ec9-aa83-77c66df1cb30"
      unitRef="U_USD">678000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c06d934d-2ece-4e58-aff2-9571ee296c3f"
      decimals="-3"
      id="F_236c9424-e023-4315-9bdc-39d9c9888fef"
      unitRef="U_USD">473000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5ba8496a-b732-4e27-8494-8cc671bac84a"
      decimals="-3"
      id="F_23c637e1-6d14-4c60-a1df-c92552e94d49"
      unitRef="U_USD">315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_80ea7a33-ca44-4b1a-9d84-3b098b016750"
      decimals="-3"
      id="F_68eea835-d0ae-43a3-a5db-839ff48d87d0"
      unitRef="U_USD">2180000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6"
      decimals="-3"
      id="F_b3bdf2c0-420d-47fe-b921-53b2cd1e0dba"
      unitRef="U_USD">1995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_ba0cc46b-8ba8-42ff-a656-48de9e8f2a92"
      unitRef="U_USD">17044000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_2b473f73-bcc1-4e2b-ade6-722cb88153ba"
      unitRef="U_USD">13029000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_bb2a91f0-2d78-47dc-a1cc-d3b8a122b9bd"
      decimals="-3"
      id="F_efe256dc-b6bc-40d2-8e7b-a1ae4f772638"
      unitRef="U_USD">1491000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9dce6431-1c01-4d1f-a411-889976d95f6a"
      decimals="-3"
      id="F_3654a86d-1ad6-4c8d-92d1-7577ad621e8b"
      unitRef="U_USD">1918000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1e12a232-a571-45f6-9670-3ee553d3dba3"
      decimals="-3"
      id="F_b5e7870c-0e7c-4385-9088-fb0dbe749e4c"
      unitRef="U_USD">2509000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fc251bec-86ea-4416-bd83-7c3b3e71a24c"
      decimals="-3"
      id="F_9a027b66-afec-442a-9f14-17ba764aba13"
      unitRef="U_USD">3643000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9cae4734-8e55-4f7a-9b85-7922cacc7b3e"
      decimals="-3"
      id="F_60d9c90f-e6a4-40d9-8a73-0c7ce41622c7"
      unitRef="U_USD">814000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2967ce11-ebdd-4b1d-826e-9763f4ccb671"
      decimals="-3"
      id="F_cb9bf7ae-fe09-4c22-84cf-24211b5f44d3"
      unitRef="U_USD">1080000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_80ea7a33-ca44-4b1a-9d84-3b098b016750"
      decimals="-3"
      id="F_12eb3a19-56ed-45bb-bcc4-78e43ce2212d"
      unitRef="U_USD">1056000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_531df0bf-e1f8-4c7c-97a5-efbdec85fef6"
      decimals="-3"
      id="F_4181f35f-78ef-4941-bf4e-98d542eac641"
      unitRef="U_USD">1606000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_b13f8e24-d3a7-4499-a24b-ba62b7b79219"
      unitRef="U_USD">5870000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_b5a9e764-cf3f-4703-8c60-fa14b092bc38"
      unitRef="U_USD">8247000</us-gaap:GeneralAndAdministrativeExpense>
    <pyxs:CostsAndOperatingExpensesTotal
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_4d742b61-9db6-4980-b51c-0133eba2a573"
      unitRef="U_USD">22914000</pyxs:CostsAndOperatingExpensesTotal>
    <pyxs:CostsAndOperatingExpensesTotal
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_2739259a-0ca7-4991-883c-832abf86d01d"
      unitRef="U_USD">21751000</pyxs:CostsAndOperatingExpensesTotal>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_89cf541d-996b-4e65-8c2f-7c43a84e23de"
      unitRef="U_USD">1756000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_48fd381f-259b-4b6d-af6d-72a27e10d70a"
      unitRef="U_USD">2349000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_14d128bb-baeb-49b4-b6cf-114fdbaf22e1"
      decimals="-3"
      id="F_bee292ae-fec0-4a5e-8b1a-b5d013942930"
      unitRef="U_USD">-21158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_61d130af-cc4f-4a22-b82e-c45279feb48c"
      decimals="-3"
      id="F_f01cd46c-bef8-47d8-acef-6630fb7564e9"
      unitRef="U_USD">-3256000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_3ed43711-744b-4f32-8a18-65759efc820b"
      unitRef="U_USD">-21158000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_20dd5430-0c42-4052-aaee-266a4d3f6368"
      unitRef="U_USD">-3256000</us-gaap:ProfitLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-5"
      id="F_00dbc6de-14d8-47b4-b0c2-cff74c1088c8"
      unitRef="U_USD">1200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_2f9d4130-9ed8-436f-b8f7-00c066674653"
      unitRef="U_USD">1600000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SubleaseIncome
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-5"
      id="F_51c59098-0422-4693-b21e-71cbf4bd2c6b"
      unitRef="U_USD">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_d7b8d8b1-61db-4492-bfef-c3f688696652"
      unitRef="U_USD">800000</us-gaap:SubleaseIncome>
    <pyxs:LicensingAgreementsTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_85018afc-cddb-4596-8220-04c87977eeea">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Licensing Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The University of Chicago Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2020, the Company entered into a license agreement (the &#x201c;University License Agreement&#x201d;), as well as a sponsored research agreement, with the University of Chicago (the &#x201c;University&#x201d;). Under the terms of the license, the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent, incorporate or use the licensed know-how and materials or are known to assess, modulate or utilize the activity of certain specified biological targets. In partial consideration for the license from the University, the Company issued to the University &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,919&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock in 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the University License Agreement, the Company is obligated to pay potential development and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the University License Agreement as of  March 31, 2025 and 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pfizer Inc. Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2020, the Company entered into a license agreement (as amended, the &#x201c;Pfizer License Agreement&#x201d;) with Pfizer Inc. (&#x201c;Pfizer&#x201d;) for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. The Company&#x2019;s rights are exclusive with respect to certain patents owned or controlled by Pfizer covering the licensed ADCs. The initial licensed targets include CD123 and Extradomain-B Fibronectin (&#x201c;EDB+FN&#x201d;) and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program. The Pfizer License Agreement became effective in March 2021 and the Company paid a combined $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the license fee, consisting of an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,152,145&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series B convertible preferred stock, which was converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911,015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock upon the initial public offering (&#x201c;IPO&#x201d;) in October 2021, with a value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Pfizer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 6, 2022, the Company entered into an amended and restated license agreement (the &#x201c;A&amp;amp;R License Agreement&#x201d;) with Pfizer, which amends and restates the Pfizer License Agreement. Pursuant to the A&amp;amp;R License Agreement, Pfizer granted to the Company exclusive worldwide rights under Pfizer&#x2019;s Flexible Antibody Conjugation Technology Flexible Antibody Conjugation Technology (&#x201c;FACT&#x201d;) Platform technology to develop and commercialize ADC product candidates directed to certain licensed targets, including micvotabart pelidotin and PYX-203, and products containing the ADC product candidates. Additional ADC targets may be licensed for a nominal upfront payment and milestones. In accordance with the terms of the A&amp;amp;R License Agreement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,229,654&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock to Pfizer in October 2022, paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Pfizer in January 2023 and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,811,594&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock to Pfizer in March 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further, pursuant to the A&amp;amp;R License Agreement, the Company is obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products at varying rates. The Company assessed the milestone and royalty events under the A&amp;amp;R License Agreement as of March 31, 2025 and 2024, and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;/p&gt;&lt;h2 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement with Biosion USA, Inc.&lt;/span&gt;&lt;/h2&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 28, 2022, the Company entered into a license agreement (the &#x201c;Biosion License Agreement&#x201d;) with Biosion USA, Inc. (&#x201c;Biosion&#x201d;), pursuant to which the Company obtained an exclusive, worldwide (other than Greater China (mainland China, Hong Kong, Macau and Taiwan)) license for development, manufacturing and commercialization rights for BSI-060T, a Siglec-15 targeting antibody, an IO product candidate (now referred to as PYX-106), and products containing the licensed compound.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Biosion License Agreement, the Company paid an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in March 2022. Further, the Company is also obligated to pay future contingent payments including development, regulatory and commercial milestones as well as running royalties on net sales of licensed products and sublicensing revenues at varying rates. In December 2024, the Company paused the clinical development of PYX-106. The Company assessed the milestone and royalty events involving the Biosion License Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acquired Out-Licensing Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2023, the Company completed the acquisition of Apexigen, Inc. ("Apexigen") and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;assumed all out-licensing agreements of Apexigen upon the Merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Simcere License and Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2008, Epitomics, Inc. (&#x201c;Epitomics&#x201d;) (Apexigen&#x2019;s predecessor) and Jiangsu Simcere Pharmaceutical R&amp;amp;D Co., Ltd. (&#x201c;Simcere&#x201d;) entered into a license and collaboration agreement (the &#x201c;Simcere Agreement&#x201d;) for the development and commercialization of suvemcitug (BD0801) for oncology in China.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Simcere is obligated to pay the Company milestone payments for achievement of certain clinical development milestones and low to high single-digit percentage royalties on net sales of suvemcitug in China until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years after the first commercial sale of suvemcitug. The Company assessed the milestone and royalty events involving Simcere as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;T-Mab/Mabwell Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2008, Epitomics and Jiangsu T-Mab Biotechnology Ltd., Co. (&#x201c;T-Mab&#x201d;) entered into a license, co-development and contract manufacture agreement (the &#x201c;T-Mab Agreement&#x201d;) for the development and commercialization of therapeutic candidates, each directed to a specified target for specified fields, including VEGF for the treatment of ocular diseases, in China. Mabwell (Shanghai) Bioscience Co., Ltd. (&#x201c;Mabwell&#x201d;) acquired T-Mab in 2015.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the agreement, Mabwell was granted an exclusive, royalty-bearing, perpetual license (without the right to sublicense) to rights in certain intellectual property to develop and commercialize such therapeutic candidates. Mabwell is obligated to pay the Company a mid-single-digit percentage royalty on net sales of such therapeutic candidates in China. The Company assessed the milestone and royalty events involving Mabwell as of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Toray Sublicense Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2012, Epitomics and Toray Industries, Inc. (&#x201c;Toray&#x201d;), entered into a non-exclusive sublicense agreement (the &#x201c;Toray Agreement&#x201d;) under which Epitomics granted Toray a non-exclusive, worldwide sublicense, with the right to grant further sublicenses, to develop and commercialize drug product candidates that Toray developed using antibodies created using Apexigen&#x2019;s antibody-discovery platform (the &#x201c;APXiMAB Platform&#x201d;) that target certain molecules to use in the development of its drug product candidates. Under the Toray Agreement, Toray paid an upfront fee, and agreed to pay certain development- and regulatory-related milestone payments and a low single-digit percentage royalty on net sales of licensed products and sublicense revenues by Toray or its affiliates.  The Company assessed the milestone and royalty events involving Toray as of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such amounts were receivable.&lt;/span&gt;&lt;/p&gt;</pyxs:LicensingAgreementsTextBlock>
    <pyxs:CommonStockIssuedToUniversity
      contextRef="C_5d1a4394-6692-49e3-a78c-53add9ce8cdb"
      decimals="INF"
      id="F_694fde81-6e33-41cd-8adf-44d58570ea5a"
      unitRef="U_shares">48919</pyxs:CommonStockIssuedToUniversity>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_9785fcb7-9dea-48db-b586-d63e6e45e9ce"
      decimals="INF"
      id="F_00a6f56b-887f-4fd7-96e4-179f2314203e"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_63ba58e4-c1b8-480d-a574-db0f42fe8744"
      decimals="INF"
      id="F_296eb025-24bf-4618-92cd-c08ffbad9d30"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:PaymentForLicenseFee
      contextRef="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec"
      decimals="-5"
      id="F_94ae6472-502c-4508-ae87-0edfb369d96f"
      unitRef="U_USD">25000000</pyxs:PaymentForLicenseFee>
    <pyxs:UpfrontPayments
      contextRef="C_f457fd30-0a38-4eba-9ed6-486f8bf622ec"
      decimals="-5"
      id="F_5627afd9-8d53-4901-a044-c709fc6d3fb3"
      unitRef="U_USD">5000000</pyxs:UpfrontPayments>
    <pyxs:IssuanceOfConvertiblePreferredStockShares
      contextRef="C_2dc476af-db9c-4877-bce2-5597b5ff0528"
      decimals="INF"
      id="F_6a47b622-6f23-4422-a08f-a606c7efbe3e"
      unitRef="U_shares">12152145</pyxs:IssuanceOfConvertiblePreferredStockShares>
    <pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock
      contextRef="C_74975660-2e58-4083-b25a-adbe25ac8127"
      decimals="INF"
      id="F_1729a777-3db7-45ee-adc8-1af59bbfd483"
      unitRef="U_shares">1911015</pyxs:NumberOfCommonSharesIssuedUponConversionOfPreferredStock>
    <pyxs:ConvertiblePreferredStockSharesIssuedValue
      contextRef="C_ed227005-05eb-4b2e-b46b-86ab51890c85"
      decimals="-5"
      id="F_02b5cb00-4d07-44ab-ba0c-5f56bc84203c"
      unitRef="U_USD">20000000</pyxs:ConvertiblePreferredStockSharesIssuedValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_63a6cb3b-0f48-4d6e-abd8-d1208ebf1187"
      decimals="INF"
      id="F_47f58a9d-5928-4308-998c-7c6764237cd9"
      unitRef="U_shares">2229654</us-gaap:CommonStockSharesIssued>
    <pyxs:UpfrontPayments
      contextRef="C_290608d1-a120-4e94-a552-45ef09566ea1"
      decimals="-5"
      id="F_c7653ed4-9d8a-44fd-8673-2f9b3c10c6bc"
      unitRef="U_USD">8000000</pyxs:UpfrontPayments>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1659b880-a5b1-4e72-804b-476a70f006ea"
      decimals="INF"
      id="F_5f40d83c-c1cb-48fb-aeb5-c5f1fdb07937"
      unitRef="U_shares">1811594</us-gaap:CommonStockSharesIssued>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_837677d7-498f-48bb-95c8-9faa16b30f62"
      decimals="INF"
      id="F_5048b976-f893-4c6e-91bb-8c9c9a3262c3"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_81dccbcc-0e5d-42f2-a90b-5d7a220cc416"
      decimals="INF"
      id="F_56fea162-42e4-4ecb-b049-e584158cc6d7"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:UpfrontFee
      contextRef="C_acc32560-f36b-4aae-bb63-26d88b5e0289"
      decimals="-5"
      id="F_f7962d5c-c93d-4c6d-9df8-8d930b6f4dea"
      unitRef="U_USD">10000000</pyxs:UpfrontFee>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_0090356c-a2e4-4923-b76e-2b67349147d5"
      decimals="INF"
      id="F_55ae0cf8-158d-4c22-9dc8-f5fc1a5eba07"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:MilestoneAndRoyaltiesIncurred
      contextRef="C_97ecf8f3-9e3b-4ebb-bbff-1d5047205f7f"
      decimals="INF"
      id="F_c1293264-3a9e-4c6a-85df-e3246fa6e100"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesIncurred>
    <pyxs:RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale
      contextRef="C_f759528e-20d8-4601-852a-3782e7215f4d"
      id="F_864434b8-2b69-4cb5-9118-9c7d8a928882">P15Y</pyxs:RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale>
    <pyxs:MilestoneAndRoyaltiesReceivable
      contextRef="C_a0ea1ad7-9313-4e2a-bd73-2726a836f60b"
      decimals="INF"
      id="F_00d0194a-0405-4884-bd05-451780049384"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesReceivable>
    <pyxs:MilestoneAndRoyaltiesReceivable
      contextRef="C_89abcaed-dbf0-4b59-a0d5-c994ebb137d6"
      decimals="INF"
      id="F_53b4282d-5bd4-43ec-9bc1-90cdd8c8be2d"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesReceivable>
    <pyxs:MilestoneAndRoyaltiesReceivable
      contextRef="C_7afe6a9e-11e5-428d-b499-c4c37cf4f4fc"
      decimals="INF"
      id="F_7102fd4f-40fa-44e2-90ed-10b8691e5429"
      unitRef="U_USD">0</pyxs:MilestoneAndRoyaltiesReceivable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_02ad6792-469b-4959-940a-ce875f9a181e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Shelf Registration Statement and ATM Offering Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 1, 2022, the Company filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On November 14, 2022, the registration statement was declared effective by the SEC. The registration statement includes an ATM offering program for the sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t sell any shares of common stock under the ATM offering program. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025, the Company h&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ad $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of remaining capacity available under the ATM facility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; issued and outstanding shares of preferred stock as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Each holder of outstanding shares of common stock shall be entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote in respect of each share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reserved Shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:23.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:24.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,463,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,382,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,295,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-Funded Warrant Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Apexigen replacement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,689,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19,657,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <pyxs:MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue
      contextRef="C_9eedb432-f4a9-43b3-ba2d-11719dfe1ba0"
      decimals="-5"
      id="F_fc8e1dc9-0448-4ec4-bd4c-dacb4d8b941f"
      unitRef="U_USD">250000000</pyxs:MaximumValueOfStockAndDebtInstrumentsAuthorizedToIssue>
    <us-gaap:CommonStockValue
      contextRef="C_678c9317-3c78-4a7a-bf89-db2215e97bda"
      decimals="-5"
      id="F_e9a9a932-feb7-4df5-aa7e-0dc9bdf915a2"
      unitRef="U_USD">125000000</us-gaap:CommonStockValue>
    <pyxs:SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission
      contextRef="C_f563861b-f2d5-448b-b5cd-ada4a71faae0"
      decimals="0"
      id="F_0715e9e0-74a4-4abf-884d-ce618a7641da"
      unitRef="U_shares">0</pyxs:SharesIssuedPursuantToAtTheMarketAtmProgramNetOfCommission>
    <pyxs:SaleOfStockRemainingCapacityAvailableUnderProgram
      contextRef="C_3899226d-7062-4ed7-98a2-86b74edb9890"
      decimals="-5"
      id="F_2eecc006-832a-424b-b712-7c126b105850"
      unitRef="U_USD">106200000</pyxs:SaleOfStockRemainingCapacityAvailableUnderProgram>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_22f2d7fa-a011-4259-addd-b6c9d728e842"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_07ba01b0-6f0b-47b1-ba4e-92cff3a14bae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_fb6ae36a-7fe0-4e32-af40-93241b3d4299"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_f2418b11-7718-464c-a6bd-683cd547f23c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockVotingRights
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_3367b3bf-3398-4922-a05b-d4559d77ad1e">one</us-gaap:CommonStockVotingRights>
    <pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_0479d537-d4d2-4c82-b234-fe70dde5c5f4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock for issuance:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:23.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:24.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,463,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,382,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,295,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-Funded Warrant Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Apexigen replacement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,689,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19,657,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pyxs:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_565d2f6f-3e93-4e23-8ba1-a266d622097c"
      decimals="0"
      id="F_667ace86-b30e-4e79-9c32-32da68901d47"
      unitRef="U_shares">12228168</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8bcaa3a4-f396-49d4-9a7c-9a2c953ca07d"
      decimals="0"
      id="F_471cd3ef-5876-4d07-981f-a8c887a83f4c"
      unitRef="U_shares">9711075</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_da865c67-24d1-400e-a077-12e7011b7389"
      decimals="0"
      id="F_4c77e975-3278-4d9f-b607-5848ee0b6931"
      unitRef="U_shares">2421954</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_77b5c4a5-315a-49dc-a7f5-2446f1b77e18"
      decimals="0"
      id="F_a44e085c-5ef8-4c1e-9ac0-d0c59b19974e"
      unitRef="U_shares">2463601</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_824b7ea1-2dee-4608-a3e0-704fe74262da"
      decimals="0"
      id="F_00410a12-c40b-4724-92ba-056a07ab5b68"
      unitRef="U_shares">5382829</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_044f61dc-d55f-47ed-bf0d-a9b02b506528"
      decimals="0"
      id="F_d9b62cd4-ffe1-41fa-a72f-466e1ac90372"
      unitRef="U_shares">4295342</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ec093f95-5fcd-47b1-952e-ed9e123d523d"
      decimals="0"
      id="F_57e46562-c639-4a4a-94c6-bc9ccfd6cfb0"
      unitRef="U_shares">1611215</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d20dc9b5-8895-44ad-af21-3cb92effe49e"
      decimals="0"
      id="F_da1a95fa-b474-4cb2-9366-8619f444f01d"
      unitRef="U_shares">1003191</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5da75939-3069-4ae8-9442-f8b70f506330"
      decimals="0"
      id="F_c2d6530a-d5ee-4637-9ef8-745588d703d8"
      unitRef="U_shares">1003191</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_19d61487-1275-421e-96ed-c8df7b8a1263"
      decimals="0"
      id="F_40db6a84-44ec-4507-ba79-739a9168aef2"
      unitRef="U_shares">653777</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3478df5d-ec35-4824-83ab-aaf0f4b41638"
      decimals="0"
      id="F_38dff32e-f65a-4755-bc4f-1915401eb6f7"
      unitRef="U_shares">573316</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="0"
      id="F_ee16aefc-cf6c-4a38-8734-39ebcd3dd41e"
      unitRef="U_shares">21689919</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="0"
      id="F_0a775fec-55fc-432c-9811-9b3a39ba300d"
      unitRef="U_shares">19657740</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pyxs:CommonStockWarrantTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_7cfb4a96-74a9-4de7-a7ce-27046219e0a7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Apexigen Replacement Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the Merger, each outstanding warrant issued by Apexigen was assumed and converted into a warrant to acquire the Company&#x2019;s common stock, on substantially similar terms and conditions as were applicable under such Apexigen warrant agreements. The Company replaced approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,815,613&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Apexigen warrants with approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Pyxis Oncology warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344,259&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants outstanding with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,212&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants outstanding with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;641,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Each of the warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share will expire on the fifth anniversary of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 29, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or earlier upon redemption or liquidation. Each of the warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 30, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Private Placement Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company received gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million via private placement with certain institutional and accredited investors by issuing (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,849,371&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and (ii) pre-funded warrants (&#x2018;Pre-Funded Warrant&#x2019;) to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019; common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.779&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Pre-Funded Warrant.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2025, the pre-funded warrant holder exercised their right to convert the Pre-Funded Warrants to common stock and accordingly, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to the warrant holder.&lt;/span&gt;</pyxs:CommonStockWarrantTextBlock>
    <pyxs:ReplacementOfWarrants
      contextRef="C_4b4f6feb-cd93-4d71-b40e-b295d4cf5442"
      decimals="0"
      id="F_bcba07ee-ed35-4f02-b618-d77822b71aee"
      unitRef="U_shares">5815613</pyxs:ReplacementOfWarrants>
    <pyxs:ReplacementOfWarrants
      contextRef="C_fa7a09e7-12a2-46e5-ba99-a862cc59bc9a"
      decimals="0"
      id="F_d40835bf-e931-411d-9dec-c389540da301"
      unitRef="U_shares">1003191</pyxs:ReplacementOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a"
      decimals="0"
      id="F_14295e66-d85c-4d5e-b24b-3a19b9a8b78c"
      unitRef="U_shares">344259</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a"
      decimals="2"
      id="F_751df738-765b-491f-b993-657920577321"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6"
      decimals="0"
      id="F_636daa47-16fb-40b1-929b-4eba6a0c04fc"
      unitRef="U_shares">17212</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6"
      decimals="2"
      id="F_1d493ff7-6bff-4664-872c-7c9e326a93c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_27fbe99f-b243-407d-805e-643897908e7c"
      decimals="0"
      id="F_e213bad7-6dac-43c6-bae9-8eb1286fd1a0"
      unitRef="U_shares">641720</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_27fbe99f-b243-407d-805e-643897908e7c"
      decimals="2"
      id="F_4d6f4779-7dbf-4c3c-bb07-b42edeb8b6dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">66.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d8f2f73e-7aca-4a71-8f6a-4c1b3ac7de0d"
      decimals="2"
      id="F_6fc62a11-2d35-4b3f-bf3b-a6e5606c5bdb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">66.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_27fbe99f-b243-407d-805e-643897908e7c"
      id="F_efa64eb7-220f-481c-9878-20c934e9f16e">2022-07-29</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a"
      decimals="2"
      id="F_da80a861-01e2-48a2-8db5-87970a9e7f50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6"
      decimals="2"
      id="F_37969291-8280-48f3-9cbe-e59aca703477"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_1a72fae4-2f45-4086-ad2e-0c7e261ea4f6"
      id="F_52372c30-e9bf-4183-a3a2-ec9b1ca557f4">2028-07-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_cbe0e369-8d23-4eeb-9a14-da7adecba41a"
      id="F_73e49186-d144-4aad-b475-992a6f849bb7">2028-07-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_bf458c23-24e3-416a-b060-7beb4e11b9d0"
      decimals="-6"
      id="F_e71a41f3-f672-4be6-8e7e-711d0bc88404"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3"
      decimals="0"
      id="F_b88e0d9d-e1cd-47a1-bc09-dc28090885e5"
      unitRef="U_shares">8849371</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_88407054-4ac6-407e-bd60-882ac0345a83"
      decimals="3"
      id="F_564cde6a-5968-47ec-be21-dccb4112d666"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ef169058-b0f3-4f8f-b821-c8446fa6b6d3"
      decimals="2"
      id="F_9609a530-0339-400d-ad44-fb0a247802b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.78</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_18c2f871-fdac-46c2-8c4b-4a534962e9f8"
      decimals="0"
      id="F_82201f5b-f8b0-40ac-bf65-506381d814d0"
      unitRef="U_shares">1611215</us-gaap:ClassOfWarrantOrRightOutstanding>
    <pyxs:PrefundedWarrantsIssuedPricePerWarrant
      contextRef="C_0c8f0bca-3bcd-4650-a38f-74cace0f746e"
      decimals="3"
      id="F_31c4da06-cf50-4b7d-8333-3e92d8a6dca6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.779</pyxs:PrefundedWarrantsIssuedPricePerWarrant>
    <pyxs:PreFundedWarrantsIssuedDuringPeriod
      contextRef="C_bc5c6809-e7d5-4c1f-a9d6-81bcb2d63dcd"
      decimals="INF"
      id="F_9ddf16be-1625-476f-9af9-02c70bf713d0"
      unitRef="U_shares">1611215</pyxs:PreFundedWarrantsIssuedDuringPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_901b211c-3fc1-415a-aba2-d2d602a08c7f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company grants stock-based incentive awards pursuant to the 2021 Equity and Incentive Plan (the &#x2018;2021 Plan&#x2019;), 2019 Equity Incentive Plan (the &#x2018;2019 Plan&#x2019;), Apexigen Equity Incentive Plans (the &#x2018;Apexigen Plan&#x2019;) and the 2022 Equity Inducement Plan (the &#x2018;2022 Inducement Plan&#x2019;). As of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,072,703&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,435&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764,154&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;413,537&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future issuance under the 2021 Plan, 2019 Plan, Apexigen Plan and 2022 Inducement Plan, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.200000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,104,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options exercisable March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,379,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable stock options and the fair value of the Company&#x2019;s common stock o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;r share as of March 31, 2025. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock options were exercised during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an aggregate $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of gross unrecognized stock-based compensation expense as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant-date fair value of options granted during the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2024, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively, and was calculated using the following key input assumptions in the Black-Scholes option-pricing model:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.569%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.076%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.076%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.910&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes restricted stock units activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,533,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361,263&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs which are vested but not settled at  March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,728&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock from the settlement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,892&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; restricted common units, with the remaining shares withheld for taxes. The Company has an aggregate $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of gross unrecognized restricted stock-based compensation expense as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, remaining to be amortized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the total stock-based compensation expense for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.368%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.276999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.276999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan (&#x201c;2021 ESPP&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the 2021 ESPP in force. The Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,619&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares under the 2021 ESPP during the three months ended March 31, 2025. The company did not issue any shares during the three months ended March 31, 2024. As of March 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653,777&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are available for issuance under the 2021 ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b53bcca6-85b4-46ee-be42-becc61d48b23"
      decimals="INF"
      id="F_90c6338e-6586-4845-a3b5-c220482cb708"
      unitRef="U_shares">4072703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_c59ed3d1-dcfa-490f-9209-32cb9b6920ef"
      decimals="INF"
      id="F_e5683581-dac1-4bcd-8167-0ac41130660a"
      unitRef="U_shares">132435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_40a96fb2-dbbb-44c6-a5a1-b2efcc758b42"
      decimals="INF"
      id="F_9bede5f5-5e3b-47e8-8f71-ef95eb5ea4e2"
      unitRef="U_shares">764154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_fcbfab1e-0b3b-450f-9242-753a06599476"
      decimals="INF"
      id="F_0872dc92-dc7f-48a3-bff7-aec1f9e5cb3c"
      unitRef="U_shares">413537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_69c68630-2296-4453-b7a1-16329e9d989c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.200000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,711,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,104,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options exercisable March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,379,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_5ebb6338-c9dd-4b05-bf34-9e6f94f56313"
      unitRef="U_shares">9711075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="2"
      id="F_5265a503-06a9-47ce-8e59-2380ec79c99c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_eb99ab08-0e63-41ea-bc44-35b639d19208"
      id="F_10714c8e-bed0-4682-b419-42da9649cded">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="-3"
      id="F_5224e73c-bca0-45fc-a616-b1d568e9fcaa"
      unitRef="U_USD">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_780c0e93-e63d-4ffb-8ffc-bc718430adf3"
      unitRef="U_shares">3104372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_c37b5717-607e-44ff-9856-deeb23356079"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_984068ff-beff-4f77-b3d1-ddc4871a9e42"
      unitRef="U_shares">587279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_7f3f4d3f-0637-4fa5-b070-606f29cf387a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_a73ce622-4953-4f1e-8705-0bbf5b94dd44"
      unitRef="U_shares">12228168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="2"
      id="F_2c1e9288-98a7-40dd-852e-1a5c7c73bc77"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_29a69e71-f328-4493-af9c-0f1f6e0cc78a">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_ea86d72f-d4e2-4656-a4d4-a55cc6ffd8b2"
      unitRef="U_USD">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_f8a8f018-b8c5-4054-9f2c-0249fa865bff"
      unitRef="U_shares">4379232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="2"
      id="F_7961af5b-c794-41bd-a333-64e386db1af5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_8a1fef11-361e-4e30-bea1-74cfe0c65622">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-3"
      id="F_bf22de3e-9efb-41fc-a75c-9480c12bb90b"
      unitRef="U_USD">21000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <pyxs:FairValueOfCommonStockPerShare
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="2"
      id="F_61602945-0a0e-4189-b643-8c81189c190d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.98</pyxs:FairValueOfCommonStockPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-6"
      id="F_bdbee86c-77ea-4cd6-afca-dc3b8518f0d3"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_2c66c621-252b-4c37-9c7f-be9611609475"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_650df13c-4872-4cfa-a20c-0b213c6c6bd7"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="-5"
      id="F_911b63eb-0497-46c5-896d-a0aea8aff795"
      unitRef="U_USD">11000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_10d8adcf-c5bb-4868-9fa2-455e7366fd0a">P1Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_0a2f12ee-3ab5-4797-be87-966edacf13f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="2"
      id="F_4d82f20b-32d7-4e02-910a-7079833ecc33"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_e799a3ba-3cf4-418c-89f2-c0306ed5d3e9">
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.569%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.076%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.076%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.910&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="5"
      id="F_6b046986-938a-4858-866b-7b98c64be04d"
      unitRef="U_pure">0.9392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="5"
      id="F_41b19c66-488b-47f2-a968-b5ebcd1f5b49"
      unitRef="U_pure">0.9991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="4"
      id="F_e251b728-7607-4e4d-8026-7b0851407173"
      unitRef="U_pure">0.9941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="4"
      id="F_851f3c48-1ca2-4567-b694-8891f8c9a24d"
      unitRef="U_pure">1.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="5"
      id="F_a2740dea-f054-45f8-97c8-c78bf0abc7e5"
      unitRef="U_pure">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="5"
      id="F_0125b84b-7bc4-4952-950a-609a56b1c3ee"
      unitRef="U_pure">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="4"
      id="F_9d6dbcda-e38d-41e8-b541-d16a5b774785"
      unitRef="U_pure">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="4"
      id="F_8e027856-7557-431e-8601-abd99533c341"
      unitRef="U_pure">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="4"
      id="F_188c03f5-28e3-478a-9a1b-9d43bdebb780"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="4"
      id="F_74fa6589-1835-4a0e-89de-1c952cf8267a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9b6f4f8e-a104-4456-901f-a188c4f57515"
      id="F_47bddac4-a3c5-4b6d-9d67-9111b824f2bb">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bd8b966a-b09c-4ecf-99e4-4af048f4ca8a"
      id="F_410ce99c-d2f6-4e22-84a8-66114feef5c8">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_668a1b98-824d-41d1-8593-7b9e8f0d78b9"
      id="F_61e296a1-aceb-44a9-9620-521dacbb61f0">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_19b0546a-3406-4376-b2bf-06e6e947abae"
      id="F_b3d267fe-438c-47c3-aab6-3190600b2b38">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_5a4d8d3a-18c0-41ff-8fc7-d6bb0b475189">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes restricted stock units activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,533,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and settled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361,263&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs which are vested but not settled at  March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="INF"
      id="F_9b232a63-9709-4743-b8f4-5f46dfbd935f"
      unitRef="U_shares">2533650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_02c3f376-cf08-485b-be5c-ffdbc197e303"
      decimals="2"
      id="F_de4fe867-5c27-4c0e-a690-9d5af383f74e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_d6d83514-ff73-438c-9686-da4b69ef4524"
      unitRef="U_shares">80804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_03259449-2071-4257-93d5-21290948d7fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_72b9d8fe-578b-463e-8878-ee24c92029d9"
      unitRef="U_shares">-30892</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_60a07a97-3899-43cf-879f-36eb3e4f4d45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.73</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_eb048427-93e9-455f-a767-147bad79de92"
      unitRef="U_shares">2421954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="2"
      id="F_28d88699-f2c8-4f89-b409-94995d0a617e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod
      contextRef="C_da865c67-24d1-400e-a077-12e7011b7389"
      decimals="INF"
      id="F_efada5f0-6733-4e25-b4bf-210267137194"
      unitRef="U_shares">361263</pyxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButUnsettledInPeriod>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae"
      decimals="INF"
      id="F_dfce2efa-7245-4298-8671-a7bc9411684d"
      unitRef="U_shares">22728</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae"
      decimals="INF"
      id="F_5aae43ba-2435-4c46-9e5a-cae5fc9a530d"
      unitRef="U_shares">30892</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_da865c67-24d1-400e-a077-12e7011b7389"
      decimals="-4"
      id="F_2a6850ef-198a-4d47-a1f2-e09eefd186bf"
      unitRef="U_USD">5040000.00</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_1d4aedb6-5a72-4040-a006-c27215f1acae"
      id="F_6de3de73-c3db-4af0-b4bd-c89665e6f677">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_03ef56e1-7f14-41b6-89d4-95acfb27afb5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the total stock-based compensation expense for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.368%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.276999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.276999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d297973c-6ba2-4ed6-8a31-917d0510d880"
      decimals="-3"
      id="F_0a28f99d-6a29-40ca-a2fc-3c80bd98cb5a"
      unitRef="U_USD">2509000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4d7cc448-0612-40c7-9727-ba960bd2bcad"
      decimals="-3"
      id="F_52f9e4c3-e8f7-4e5e-af8c-5e501f50ae7c"
      unitRef="U_USD">3642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6fc6795c-50db-425e-91fd-5a73256a6dfc"
      decimals="-3"
      id="F_2b2a5278-1047-4cc5-975d-12f074a2054f"
      unitRef="U_USD">1122000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_088e0ae4-1139-4dc9-a66c-b53dac8ce75b"
      decimals="-3"
      id="F_5ee893c7-8fbc-4630-a1cd-c960f0ec2a5c"
      unitRef="U_USD">678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_148daaa4-8f72-4670-b574-56fea47aa111"
      unitRef="U_USD">3631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_b9131ad9-3aa7-46ca-9456-437cc0d7c6c9"
      unitRef="U_USD">4320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_9c3347c8-7c90-48dd-9028-f27b924409e6"
      decimals="INF"
      id="F_0744c2e7-4587-4d2b-a71e-31ac6e0f2d77"
      unitRef="U_shares">29619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9e825b7d-73d0-4c61-872f-ab5440ba67fa"
      decimals="INF"
      id="F_ae9351ff-53f0-427d-a9d8-dc1e11bf5919"
      unitRef="U_shares">653777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_a7a5b322-5d86-4028-a59c-b11e11ff5142">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Operating L&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;eases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases its office and facilities in Boston, Massachusetts under a non-cancellable operating lease agreement that continues through December 31, 2032. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash paid for operating lease liabilities were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025 and 2024, respectively, which is included in operating cash flows within the accompanying unaudited condensed consolidated statements of cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The component of operating lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company subleases approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,729&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office and laboratory space in the building located at 321 Harrison Avenue, Boston, Massachusetts. The Company remains jointly and severally liable under the head lease and accounts for the sublease as an operating lease. The lease term commenced on March 24, 2023 and is expected to end in March 2026. The Company recognized sublease income of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-5"
      id="F_fa9432c1-0783-4d86-ac98-4369663b20bf"
      unitRef="U_USD">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_0c0e3fde-33ab-4efe-b29e-ffdb1d974886"
      unitRef="U_USD">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_dc19ee83-3bc8-4556-bc13-e86db6bde817">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The component of operating lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_006b0c7c-0846-47f6-a75c-5e2f6d045827"
      unitRef="U_USD">672000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_89fa099b-6ea3-4219-a8b2-c0149f65285a"
      unitRef="U_USD">663000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_81b422a3-157f-4a50-9292-1a42df69e37c"
      unitRef="U_USD">55000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_3bb47fae-a509-4313-b338-e8b9c1a8ce3a"
      unitRef="U_USD">539000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-3"
      id="F_5a1148b1-f223-460a-92b5-044e92c46dd9"
      unitRef="U_USD">727000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-3"
      id="F_0cc536b8-e238-4f10-b7fc-98f9cb1a4284"
      unitRef="U_USD">1202000</us-gaap:LeaseCost>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0b635d7f-a221-440b-8651-5dc1b8df141e"
      decimals="INF"
      id="F_dc280d88-407f-4e4c-9a6a-2dc60da48669"
      unitRef="U_sqft">17729</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:SubleaseIncome
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="-5"
      id="F_9a78009a-214d-4a4d-ae3f-0622928635b8"
      unitRef="U_USD">500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="-5"
      id="F_a5065d81-d10d-4af1-9519-829542cc33d1"
      unitRef="U_USD">800000</us-gaap:SubleaseIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_64a3e4f0-851a-4548-a36a-21b63fefc356">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s effective tax rate from continuing operations was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for the three months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded a federal income tax provision for the three months ended March 31, 2025 and 2024. The Company recorded a nominal state and local income tax provision for the three months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company assesses the realizability of the deferred tax assets at each reporting date. The Company continues to maintain a full valuation allowance for its U.S. federal and state deferred tax assets, which significantly consists of net operating losses and tax credits. If&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;certain &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;substantial changes in the entity&#x2019;s ownership occur, there may be an annual limitation on the amount of the carryforwards that can be utilized. The Company will continue to assess the need for a valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="2"
      id="F_8a2cc4c6-321b-44d7-b43c-3aa63cebcf68"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="2"
      id="F_bc0172a2-4f17-4bd9-9f2f-a4a5bab95552"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="INF"
      id="F_f053d39c-054d-45ca-9c08-a5c72c2d26a1"
      unitRef="U_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="INF"
      id="F_655e9779-eb83-4753-89d3-0941f5614f1d"
      unitRef="U_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_b50f2cd4-44f7-4d9f-9b49-92ba058fbf41">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Net Loss per Common Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:23.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:24.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,892,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,110,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,382,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,649,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Apexigen replacement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;675,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,689,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;13,331,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Pre-Funded Warrant Shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_bf384460-e0fe-4ae5-ae46-2783b6a4ad7b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:23.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:24.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,228,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,892,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,110,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,382,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,649,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Apexigen replacement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,003,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;653,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;675,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,689,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;13,331,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Pre-Funded Warrant Shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,611,215&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.&lt;/span&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6027eb9f-48b8-4d75-8321-038710d6afd6"
      decimals="0"
      id="F_0cfd4810-8b28-4663-b856-5c12b80c2b70"
      unitRef="U_shares">12228168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4ac8c464-a9ee-4f4c-9cbd-ba23e9e145ef"
      decimals="0"
      id="F_d1d8664d-050f-4246-bfa5-47f505e0d65a"
      unitRef="U_shares">6892951</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bd63dfaf-0acf-4759-9e38-63e3f7d254fe"
      decimals="0"
      id="F_dd48a018-ad53-48e9-bda9-621b91f19a91"
      unitRef="U_shares">2421954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7f2bf259-5d8f-4d8c-a46e-c559de6ac9a7"
      decimals="0"
      id="F_57026c0c-953d-45c8-a725-c876a37453f2"
      unitRef="U_shares">3110597</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e7c0ee51-b9d9-4edc-98ee-3e53a89d2eef"
      decimals="0"
      id="F_d11126c9-e372-48a4-95bc-3774a69095a2"
      unitRef="U_shares">5382829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2b13fbbe-afbd-4ba7-8372-4ec974d6de0c"
      decimals="0"
      id="F_9a6bfe8a-cb5a-4c4d-8467-e5d8c171d2e4"
      unitRef="U_shares">1649038</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cdf070fa-6052-434b-970a-be0e009d0f61"
      decimals="0"
      id="F_f2c5c620-7a3a-40fb-866b-5aa740a60863"
      unitRef="U_shares">1003191</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9ac06ca8-b7a6-46a3-8c25-6237c2d2084e"
      decimals="0"
      id="F_385bced4-797a-454b-b689-8e36d249b45d"
      unitRef="U_shares">1003191</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4acf36bb-505b-45ee-99cd-5d1d91b303d4"
      decimals="0"
      id="F_b2f9f12b-d707-4b10-a375-c6e6509e954e"
      unitRef="U_shares">653777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_186c4ea3-09e7-46f6-8773-3f7d43d03df6"
      decimals="0"
      id="F_1cca1161-2c9a-4966-9786-1b4ea21837b7"
      unitRef="U_shares">675485</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      decimals="0"
      id="F_9beeda0a-f17a-415f-a86d-aa80e77056d7"
      unitRef="U_shares">21689919</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_afdb8a34-8cc7-4257-b07c-3f54fdf6dc6a"
      decimals="0"
      id="F_5b96c0d7-aa06-42fc-8570-d7aeafabe65c"
      unitRef="U_shares">13331262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_347129ce-fb5c-4096-80fe-ffcae8c2d8cb"
      decimals="0"
      id="F_5691690c-0ccf-47bf-8700-6f82933e7f07"
      unitRef="U_shares">1611215</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_f6d142dd-9b5c-4bf1-beba-1c2a2abe5141">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Commit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of business. The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that the Company believes could have an adverse effect on its business, operating results or financial condition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into agreements with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes, which are generally cancellable by the Company at any time, subject to payment of remaining obligations under binding purchase orders and, in certain cases, nominal early-termination fees. These commitments are not deemed significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_5c5c6533-cdac-4758-bdaf-09a23f583036">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_8bb09e40-1dc3-4aa6-b893-e64f6c517dcf">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_fd2c7b21-38ce-4b1b-b872-c14d503d4f76">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_12af53c6-9378-49ea-91fd-c3d3ea22941c"
      id="F_cb037122-fe58-44e3-b806-da9b639546a3">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
